APPLICATION_ID,ACTIVITY,ADMINISTERING_IC,APPLICATION_TYPE,ARRA_FUNDED,AWARD_NOTICE_DATE,BUDGET_START,BUDGET_END,CFDA_CODE,CORE_PROJECT_NUM,ED_INST_TYPE,FOA_NUMBER,FULL_PROJECT_NUM,FUNDING_ICs,FUNDING_MECHANISM,FY,IC_NAME,NIH_SPENDING_CATS,ORG_CITY,ORG_COUNTRY,ORG_DEPT,ORG_DISTRICT,ORG_DUNS,ORG_FIPS,ORG_IPF_CODE,ORG_NAME,ORG_STATE,ORG_ZIPCODE,PHR,PI_IDS,PI_NAMEs,PROGRAM_OFFICER_NAME,PROJECT_START,PROJECT_END,PROJECT_TERMS,PROJECT_TITLE,SERIAL_NUMBER,STUDY_SECTION,STUDY_SECTION_NAME,SUBPROJECT_ID,SUFFIX,SUPPORT_YEAR,DIRECT_COST_AMT,INDIRECT_COST_AMT,TOTAL_COST,TOTAL_COST_SUB_PROJECT
9527704,N01,MH,,N,,,,,N01MH000000,,,271201300028C-9-0-1,NIMH:874304\NINDS:0\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,,,,,4146619,,,,,,,12627838; ,"MASH, DEBORAH ;",,7/5/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ","NIMH, NICHD, AND NINDS BRAIN AND TISSUE REPOSITORY",,,,,,,,,874304,
9528359,N01,AI,,N,,,,,N01AI000000,,,272201400030C-7-0-2,NIAID:1895089\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,14175030; ,"ROOS, DAVID ;",,9/30/2017,9/29/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human Resources; pathogen; Protozoa; Research; Resources; Services; tool; Update; user-friendly; ,BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,1895089,
9529331,N01,HL,,N,,,,,N01HB000000,,,268201200013C-11-0-1,NHLBI:26455\NICHD:15056\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WASHINGTON,UNITED STATES,,98,56282296,US,3499801,HOWARD UNIVERSITY,DC,200590005,,11301131; ,"RANA, SOHAIL ;",,1/10/2012,7/31/2017,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BABY HUG FOLLOW-UP STUDY II ,,,,,,,,,41511,
9536539,N01,AI,,N,,,,,N01AI000000,,,272201400054C-6-0-1,NIAID:1511799\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,12441610; ,"STAATS, HERMAN ;",,9/30/2014,9/29/2018,Adjuvant; Animal Model; Cells; Contractor; Contracts; Emerging Communicable Diseases; Formulation; high throughput screening; Human; human disease; In Vitro; in vivo; Influenza; Lead; Libraries; mast cell; National Institute of Allergy and Infectious Disease; novel; pathogen; Pharmaceutical Chemistry; programs; receptor; Research; Signal Pathway; Structure-Activity Relationship; Study models; Testing; Vaccine Adjuvant; vaccine candidate; vaccine discovery; Vaccines; Validation; West Nile virus; Work; ,Adjuvant discovery for vaccines against West Nile Virus and Influenza,,,,,,,,,1511799,
9536614,N01,HL,,N,,,,,N01HB000000,,,268201200018C-11-0-1,NHLBI:38900\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BROOKLYN,UNITED STATES,,9,40796328,US,5992616,SUNY DOWNSTATE MEDICAL CENTER,NY,112032012,,11301125; ,"MILLER, SCOTT ;",,1/10/2012,4/30/2018,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; clinical research site; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BABY HUG FOLLOW-UP STUDY II: SUNY CLINICAL SITE,,,,,,,,,38900,
9537835,N01,AI,,N,,,,,N01AI000000,,,272201700032I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BOSTON,UNITED STATES,,7,39318308,US,8422704,TUFTS UNIVERSITY BOSTON,MA,21111901,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537841,N01,AI,,N,,,,,N01AI000000,,,272201700024I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALBUQUERQUE,UNITED STATES,,1,45911138,US,679302,LOVELACE BIOMEDICAL & ENVIRONMENTAL RES,NM,871085129,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537843,N01,AI,,N,,,,,N01AI000000,,,272201700025I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537875,N01,AI,,N,,,,,N01AI000000,,,272201700021I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,Tacoma,UNITED STATES,,6,959131194,US,4276901,GENEVA FOUNDATION,WA,984024446,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537889,N01,AI,,N,,,,,N01AI000000,,,272201700018I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FORT COLLINS,UNITED STATES,,2,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805231062,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT ,,,,,,,,,3500,
9537903,N01,AI,,N,,,,,N01AI000000,,,272201700012I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537907,N01,AI,,N,,,,,N01AI000000,,,272201700011I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9538107,N01,AI,,N,,,,,N01AI000000,,,272201400050C-4-0-1,NIAID:2796602\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MISSOULA,UNITED STATES,,0,10379790,US,1381006,UNIVERSITY OF MONTANA,MT,598124104,,12441650; ,"EVANS, JAY ;",,9/30/2014,9/29/2018,Address; Adjuvant; Adjuvanticity; Agonist; Animal Model; C Type Lectin Receptors; Cells; Contractor; Emerging Communicable Diseases; Evaluation; Formulation; high throughput screening; Human; human disease; Immunologic Receptors; In Vitro; in vivo; insight; Interleukin-17; Lead; Ligand Binding; Ligands; Mycobacterium tuberculosis; nanoparticle; National Institute of Allergy and Infectious Disease; novel; novel vaccines; pathogen; Phagocytosis; Pharmaceutical Chemistry; programs; Proteins; receptor; Research; Signal Pathway; Signal Transduction; small molecule libraries; Structure-Activity Relationship; Study models; System; Technology; Testing; trafficking; Vaccine Adjuvant; Vaccines; Validation; Work; ,Identification of novel Th17 inducing CTLR agonists for vaccines against mycobacterium tuberculosis ,,,,,,,,,2796602,
9538541,N02,DA,,N,,,,,N02DA000000,,,271201400007I-1-27100003-1,NIMH:333\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILLOW GROVE,UNITED STATES,,,64341449,US,,,PA,190900433,,14638876; ,"NA, NA ;",,5/20/2016,5/19/2017,Autopsy; Award; Biological Assay; Blood; Brain; brain tissue; Contractor; Cost Savings; drug of abuse; Funding; Hair; Human; Laboratories; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; nervous system disorder; Neurodevelopmental Disorder; Performance; Pharmaceutical Preparations; programs; Psychotropic Drugs; repository; Research; Research Personnel; Resources; Sampling; Services; Standardization; Testing; Therapeutic; Tissues; Toxicology; United States National Institutes of Health; Urine; ,IGF::OT::IGF NEUROBIOBANK: TOXICOLOGY TESTING (NIMH/OD/OTDC) ADDITIONAL FUNDING FOR TASK ORDER #HHSN271201400007I,,,,,,,,,333,
9538920,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500024-1,NICHD:359\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,; ,",  ;",,9/23/2014,9/22/2024,Child health care; Collection; Contractor; Ethnic Origin; Fetal Growth; Genetic; Human; Human Development; Laboratories; Minnesota; National Institute of Child Health and Human Development; Population; Sampling; Ships; Specimen; trait; Universities; Variant; ,REPLACEMENT SAMPLES FOR GENETICS OF FETAL GROWTH AND RELATED TRAITS IN MULTI-ETHNIC US POPULATION,,,,,,,,,359,
9544507,N01,AI,,N,,,,,N01AI000000,,,272201700010I-0-27200001-1,NIAID:1737288\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15089747; ,"VANCOTT, THOMAS ;",,6/10/2017,6/9/2024,Antigens; Area; Award; Clinical Trials; Contractor; Contracts; Databases; Development; Documentation; efficacy study; Equipment; Equipment and supply inventories; HIV vaccine; HIV-1; Human; Human Resources; immunogenicity; In Vitro; Information Systems; Investigational Drugs; Laboratories; Laboratory Animals; meetings; National Institute of Allergy and Infectious Disease; Phase; plasmid DNA; preclinical development; Preclinical Testing; Preventive vaccine; product development; Production; Proteins; Protocols documentation; prototype; quality assurance; Quality Control; Reagent; Reporting; research clinical testing; Secure; Ships; Specimen; System; Temperature; Testing; Time; TimeLine; Toxicology; Vaccines; Viral Vector; ,"ESSENTIAL CORE ACTIVITIES, NIAID PRECLIN DEVELOPMENT SUPPORT",,,,,,,,,1737288,
9545118,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200006-1,NIAID:498099\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15017489; ,"SWARTZ, GLEN ;",,5/1/2017,4/30/2018,Acquired Immunodeficiency Syndrome; Adoption; AIDS prevention; Clinical Trials; Contracts; Development; Devices; HIV; HIV Infections; Investigation; Investigational Drugs; Licensure; microbicide; National Institute of Allergy and Infectious Disease; novel therapeutics; Pathway interactions; peri-urban; Play; Positioning Attribute; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; product development; research clinical testing; Resources; Role; Services; sexual HIV transmission; South African; Technology; United States Food and Drug Administration; United States National Institutes of Health; Woman; Work; ,"DEVELOPMENT OF HIV NON-VACCINE BIOMEDICAL PREVENTION PRODUCTS: PRODUCT ATTRIBUTES, POSITIONING, AND MESSAGING TO DRIVE ADOPTION AND USE OF NEW PERSONAL USE PRODUCTS",,,,,,,,,498099,
9545135,N01,AI,,N,,,,,N01AI000000,,,272201600010I-0-27200001-1,NIAID:27304\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15061433; ,"SHANKAR, GITA ;",,6/1/2017,5/31/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Area; Clinical Research; Clinical Trials; Development; HIV; HIV Infections; Licensure; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; preclinical study; prevent; Prevention; Prevention strategy; Preventive vaccine; quality assurance; Quality Control; research clinical testing; Resources; Role; sexual HIV transmission; Technology; United States Food and Drug Administration; United States National Institutes of Health; Work; ,DEVELOP A QUALITY ASSURANCE/QUALITY CONTROL (QA/QC) PLAN FOR ACTIVITIES CONDUCTED UNDER TASK AREA D.,,,,,,,,,27304,
9545616,N01,AI,,N,,,,,N01AI000000,,,272201300002I-3-27200013-1,NIAID:129321\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14264428; ,"PAL, RANAJIT ;",,9/18/2015,7/14/2018,Advanced Development; African; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Development; Evaluation; Evaluation Studies; Funding; Grant; HIV vaccine; HIV-1; Immune; Immune response; Investigator-Initiated Research; Local Microbicides; Modality; National Institute of Allergy and Infectious Disease; Newcastle disease virus; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Proteins; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates,,,,,,,,,129321,
9547681,N01,DA,,N,,,,,N01DA000000,,,271201500050C-5-0-1,NCCAM:77873\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14256069; ,"HERR, KEELA ;",,9/1/2015,8/31/2018,Accreditation; addiction; Affordable Care Act; Americas; Analgesics; Attention; Caring; Dental Assistants; Dental Schools; Development; Diagnosis; Distress; Education; education planning; education research; Educational Curriculum; Educational process of instructing; Educational workshop; Epidemic; Funding; Future; Goals; Guidelines; Health Occupations; Health Personnel; Health Professional; Health Resources; Health Services Administration; Healthcare; high risk; Hour; improved; innovation; Institute of Medicine (U.S.); Institutes; Institution; interactive teaching; interest; Lead; Learning Module; Measures; Medical; medical schools; Medical Students; Mental Health; National Institute of Drug Abuse; Nursing Schools; Online Systems; Pain; Pain management; Pain Research; Patients; Persistent pain; Pharmaceutical Preparations; Pharmacy facility; Pharmacy Schools; Physical therapy; Prevention; programs; Provider; Recommendation; Reporting; repository; research data dissemination; Resources; risk minimization; Schools; Students; success; Teaching Hospitals; tool; Training; Training Programs; undergraduate student; United States; United States Centers for Medicare and Medicaid Services; United States National Institutes of Health; Universities; web site; ,NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION,,,,,,,,,77873,
9547707,N01,AI,,N,,,,,N01AI000000,,,272201400029C-5-0-3,NIAID:417450\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NOTRE DAME,UNITED STATES,,2,824910376,US,6169301,UNIVERSITY OF NOTRE DAME,IN,465565708,,14207859; ,"COLLINS, FRANK ;",,9/16/2014,9/15/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Culex (Genus); Data; Equipment; Human; Human Resources; Invertebrates; pathogen; Research; Resources; Services; tool; Update; user-friendly; vector; ,Bioinformatics Resource Centers for Infectious Diseases - Invertebrate Vectors of Human Pathogens.,,,,,,,,,417450,
9547712,N01,DA,,N,,,,,N01DA000000,,,271201500051C-3-0-1,NICHD:52500\NINDS:77870\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SEATTLE,UNITED STATES,,,42803536,US,,UNIVERSITY OF WASHINGTON:,WA,981056692,,14264241; ,"TAUBEN, DAVID ;",,9/15/2015,9/14/2018,case-based; Dental Assistants; Development; Education; Educational Curriculum; Evaluation; Health Professional; improved; Medical; Pain; Pain management; Pharmacy facility; Public Health Schools; Resources; Social Work; United States National Institutes of Health; ,NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION,,,,,,,,,130370,
9547973,N01,AI,,N,,,,,N01AI000000,,,272201400010I-0-27200028-1,NIAID:319626\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15178921; ,"PTAK, ROGER ;",,8/15/2017,8/14/2018,Academia; analog; base; Biochemical; Biological Assay; Cell Line; Cells; Characteristics; Contracts; cytotoxicity; Data; Development; Exhibits; Funding; high throughput screening; HIV; Intervention; Investigational New Drug Application; Lead; Local Microbicides; Location; National Institute of Allergy and Infectious Disease; novel therapeutics; phase I trial; preclinical development; Primates; Private Sector; product development; prospective; Public Health; public health priorities; Research Personnel; service utilization; Services; SIV; Source; Structure; Structure-Activity Relationship; Therapeutic; Virus; Virus Replication; ,IDENTIFICATION OF ANTI-HIV LEAD COMPOUNDS,,,,,,,,,319626,
9551473,N01,AI,,N,,,,,N01AI000000,,,272201300018I-2-27200010-1,NIAID:399062\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14369236; ,"MULLIGAN, ROBERT ;",,11/2/2015,11/30/2019,chikungunya; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase I Clinical Trials; Population; programs; Resources; Vaccines; ,Vaccine Treatment and Evaluation Unit: Phase I Clinical Trial for a Chikungunya Vaccine ,,,,,,,,,399062,
9552662,N01,CA,,N,,,,,N01CA000000,,,261201200033I-2-26100006-1,NCI:251615\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,14162336; ,"BAILEY, HOWARD ;",,7/1/2015,6/30/2019,Address; Antigens; base; Breast Cancer Prevention; Clinical; Clinical Trials; Disease remission; DNA; Dose; Epitopes; ERBB2 gene; Image; immunogenicity; Insulin-Like Growth-Factor-Binding Proteins; malignant breast neoplasm; Mammographic Density; Myelogenous; No Evidence of Disease; Operative Surgical Procedures; Patients; Phase; phase I trial; Plasmids; Positive Lymph Node; Regulatory T-Lymphocyte; response; Safety; Suppressor-Effector T-Lymphocytes; T memory cell; Vaccination; Vaccines; ,"A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT",,,,,,,,,251615,
9553006,N01,HD,,N,,,,,N01HD000000,,,275201400003I-2-27500006-1,NICHD:14911\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15190105; ,"MANDACI, OGUZ ;",,9/9/2016,9/8/2017,Best Pharmaceuticals for Children Act; Blood; Clinical; Feces; Freezing; Human; Monitor; National Institute of Child Health and Human Development; Plasma; repository; Saliva; Services; Specimen; Temperature; Urine; ,REPOSITORY SERVICES FOR THE BEST PHARMACEUTICALS FOR CHILDREN'S ACT,,,,,,,,,14911,
9554386,N01,AI,,N,,,,,N01AI000000,,,272201300015I-0-27200012-1,NIAID:303349\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14922147; ,"EL SAHLY, HANA ;",,11/7/2016,11/6/2019,Antimicrobial Resistance; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Gram-Negative Bacteria; Individual; named group; Population; programs; protocol development; Resources; therapeutic development; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,303349,
9554729,N01,CA,,N,,,,,N01CA000000,,,261201200035I-2-26100004-1,NCI:461777\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,12446129; ,"BERGAN, RAYMOND ;",,8/26/2014,8/28/2019,Address; Aftercare; aptamer; base; Biological Markers; Biopsy; Breathing; Bronchoscopy; Chemoprevention; Chronic Obstructive Airway Disease; Clinical Trials; Colorado; Dose; Dysplasia; Gene Expression; gene panel; Goals; Histology; Iloprost; Lesion; lung cancer prevention; lung carcinogenesis; Malignant neoplasm of lung; Measures; Medical center; Oral; Participant; Pathway interactions; phase I trial; Placebos; Prostaglandins I; Protocols documentation; Pulmonary function tests; Quality of life; Questionnaires; Randomized; Regimen; respiratory; Schedule; Serum Proteins; Smoker; Testing; Time; Tissues; Toxic effect; Universities; Walking; ,PROTOCOL NWU2013-02-01A PHASE I TRIAL OF INHALED ILOPROST FOR THE PREVENTION OF LUNG CANCER IN FORMER SMOKERS,,,,,,,,,461777,
9554734,N02,CA,,N,,,,,N02CM000000,,,261201300028I-8-26100001-1,NCI:16220358\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,12446334; ,"RIORDAN, STEVE ;",,8/31/2013,8/30/2018,Area; Cancer Trials Support Unit; Clinical Trials; Complement; cost effective; Information Technology; Logistics; programs; Services; Site; Standardization; ,IGF::OT::IGF Cancer Trials Support Unit,,,,,,,,,16220358,
9559803,N01,AI,,N,,,,,N01AI000000,,,272201300003I-0-27200014-1,NIAID:149505\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,15195792; ,"ANDERSEN, HANNE ;",,9/1/2017,8/31/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; in vivo; Investigator-Initiated Research; Local Microbicides; Macaca mulatta; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; Route; simian human immunodeficiency virus; SIV; Titrations; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; Virus; ,In Vivo SHIV/SIV Titration via Mucosal Route in Indian-origin Rhesus Macaques,,,,,,,,,149505,
9560666,N01,AI,,N,,,,,N01AI000000,,,272201300029C-7-0-1,NIAID:763534\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,833063154,US,,SCIENCE APPLICATIONS INTE,VA,221023703,,12338792; ,"KOONTZ, CASEY ;",,9/30/2013,9/29/2018,Adjuvant; Agonist; Anthrax disease; anthrax protective factor; Anthrax Vaccines; Antigens; base; Biotechnology; Cell Line; clinical candidate; Communicable Diseases; Contracts; Development; Emerging Communicable Diseases; Formulation; Hawaii; HIV; Human; immunogenicity; Immunologics; improved; Infection; Insecta; Investigation; Lead; Licensure; Lipid A; Liposomes; Modeling; Names; National Institute of Allergy and Infectious Disease; National Security; pathogen; Program Development; Pseudomonas fluorescens; Public Health; QS21; Recombinant Vaccines; Recombinants; Saponins; Technology; Testing; TLR4 gene; Vaccine Adjuvant; vaccine candidate; Vaccines; West Nile virus; ,"Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)",,,,,,,,,763534,
9562005,N01,AI,,N,,,,,N01AI000000,,,272201600009C-4-0-1,NIAID:283967\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALACHUA,UNITED STATES,,3,73438462,US,4146401,"NANOTHERAPEUTICS, INC.",FL,326159403,,14642070; ,"HOUSE, ROBERT ;",,9/30/2011,12/30/2017,Advanced Development; base; biodefense; Botulism; Clinical; Development; Monoclonal Antibodies; monoclonal antibody production; pre-clinical; product development; research and development; Support Contracts; Therapeutic; therapeutic candidate; ,Production of monoclonal antibody-based therapeutics for botulism,,,,,,,,,283967,
9564740,N02,HD,,N,,,,,N02HD000000,,,275201600260U-3-0-1,NICHD:357534\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14752417; ,"ROGERS, LYDIA ;",,9/8/2016,1/31/2018,Advisory Committees; Allografting; animal data; Applications Grants; Area; Atlases; base; Big Data; biobank; Brain; Cataloging; Catalogs; Communication; Contracts; Data; Data Set; Databases; digital; drug development; Extramural Activities; fetal; Fetal Death; Fetal Growth Retardation; Fetus; Foundations; Funding Opportunities; Future; Gases; Generations; Goals; Grant; Grant Review; Health; Hormones; human data; Immune system; Immunologics; improved; Institutes; Internet; Intervention; Investments; Journals; Kidney; Knowledge; Lead; Link; Lung; Malignant Neoplasms; member; Methods; model building; Molecular; Morphology; Mothers; National Institute of Child Health and Human Development; Nutrient; online resource; Online Systems; Organ; Peer Review; Periodicity; Physiology; Placenta; Placentation; Policies; potential biomarker; Pregnancy; Pregnancy Maintenance; Pregnancy Outcome; Procedures; Production; programs; Regulatory Pathway; Research; Research Institute; Research Training; Resources; Schedule; Science; Societies; Source; Standardization; Systems Biology; therapeutic target; tool; Training; United States National Institutes of Health; Update; Waste Products; ,PLACENTAL CURATED RESEARCH DATASET,,,,,,,,,357534,
9564749,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-4,NIAID:2046973\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human Resources; Influenza A virus; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,2046973,
9564750,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-5,NIAID:409394\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Ebola virus; Equipment; Filoviridae; Filovirus; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,409394,
9566068,N01,AI,,N,,,,,N01AI000000,,,272201600029C-2-0-1,NIAID:9174369\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MALVERN,UNITED STATES,,6,962754037,US,10026839,"VENATORX PHARMACEUTICALS, INC.",PA,193551200,,14759402; ,"HENKEL, TIMOTHY ;",,9/23/2016,1/12/2020,Advanced Development; Bacterial Drug Resistance; Bacterial Infections; bacterial resistance; biodefense; Emerging Communicable Diseases; Gram-Negative Bacteria; product development; therapeutic development; ,Development of Therapeutics for Biodefense and Emerging Infectious Diseases,,,,,,,,,9174369,
9566414,N01,HL,,N,,,,,N01HL000000,,,268201700006I-0-26800004-1,NICHD:92000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15213136; ,"DOHENY, KIM ;",,9/8/2017,9/7/2019,Award; Contracts; Data; Disease; DNA sequencing; gene discovery; Genetic Research; Genetic study; genome wide association study; Genotype; Health; High-Throughput Nucleotide Sequencing; Human; insight; next generation sequencing; Peer Review; Phenotype; Principal Investigator; Production; programs; Publications; Quality Control; Research Design; Research Personnel; Resources; Sampling; Services; Site; United States National Institutes of Health; Universities; ,CIDR HIGH THROUGHPUT SEQUENCING AND GENOTYPING RESOURCE ACCESS - GWAS,,,,,,,,,92000,
9566425,N02,CA,,N,,,,,N02CO000000,,,261201200005I-0-26100018-1,NCI:69643\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,,,,143986672,,,,,,,15326804; ,"RATEL, RACHEL ;",,3/27/2017,3/26/2018,design; Maintenance; web site; ,IGF::OT::IGF ITCR Website Re-Design & Maintenance,,,,,,,,,69643,
9566491,N01,AI,,N,,,,,N01AI000000,,,272201200003I-0-27200025-1,NIAID:294930\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15266183; ,"HORNBACK, RANDI ;",,9/6/2017,12/31/2019,Antimicrobial Resistance; assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; National Institute of Allergy and Infectious Disease; neurovirulence; novel vaccines; pathogen; Phase; product development; Readiness; reproductive; safety testing; Sampling; Services; Testing; Toxicity Tests; Toxicology; vaccine development; Vaccines; ,TASK X25: Preparedness for Testing NIAID Priority Vaccines in Neurovirulence and Reproductive Toxicology Studies,,,,,,,,,294930,
9566960,N01,CA,,N,,,,,N01CA000000,,,26120140002B26100007-7-0-1,NCI:2254726\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FAIRFAX,UNITED STATES,,11,66783721,US,10030448,"ICF MACRO, INC.",VA,220316050,,; ,",  ;",,9/15/2015,9/14/2018,Cancer Control; Contractor; Country; design; International; Libraries; mHealth; Office of Assistant Secretary of Health; Resources; social media; Text; Tobacco Use Cessation; United States Dept. of Health and Human Services; web site; , Core Support for NCI Tobacco Cessation and Cancer Control Resources,,,,,,,,,2254726,
9567373,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500027-1,NICHD:87576\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15238137; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,Adolescent; AIDS/HIV problem; antiretroviral therapy; Brazil; Child; Child health care; Childhood; Clinical Trials; Clinical Trials Network; Collection; combat; Communicable Diseases; Data; data management; Dose; Drug Kinetics; Foundations; frontier; Goals; HIV; HIV Infections; HIV prevention trials network; HIV therapy; Human; Human Development; IMPAACT; Infant; Infection; International Maternal Pediatric Adolescent AIDS Clinical Trials; Intervention; National Institute of Child Health and Human Development; operation; Population; Pregnant Women; prevent; Prevention; Public Health Schools; repository; Research; Research Activity; Safety; safety testing; Science; Services; Specimen; Symptoms; System; Technology; therapy design; transmission process; Treatment Efficacy; Vertical Disease Transmission; young woman; ,REPOSITORY SERVICES FOR BRAZILLIAN HPTN SPECIMENS FOR THE MPIDB,,,,,,,,,87576,
9568095,N01,HD,,N,,,,,N01HD000000,,,275201500001I-0-27500003-1,NICHD:894011\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15226133; ,"WILCOX, WILLIAM ;",,9/18/2017,3/17/2019,2 year old; Accounting; Adolescence; Adolescent; Adult; Advisory Committees; Affect; Age; Age of Onset; Age-Months; American; Anterior; Anterior Horn Cells; Antisense Oligonucleotides; Birth; Brain Stem; Cell Nucleus; Cessation of life; Child; Child health care; Childhood; Clinic; Clinical; Contractor; Data; data resource; Deposition; Development; Developmental Disabilities; Diagnosis; Diagnostic tests; Disease; Early Diagnosis; Early treatment; Evaluation; Exhibits; FDA approved; Flaccid Muscle Tone; follow-up; Genes; Goals; Guidelines; Health Personnel; Heritability; Horns; independent ambulation; Individual; infancy; Infant; Inherited; Intellectual functioning disability; Kugelberg-Welander Disease; Laboratories; Left; Leg; Longevity; Lung diseases; Medical Genetics; medical schools; medical specialties; Messenger RNA; Motor Neurons; Muscle hypotonia; Muscle Weakness; Mutation; Myopathy; National Institute of Child Health and Human Development; Neonatal Screening; Nervous System Trauma; new technology; Newborn Infant; Performance; Pharmaceutical Preparations; Physically Handicapped; Pilot Projects; programs; Proteins; Randomized; Rare Diseases; Recommendation; Reporting; Resources; Respiratory Muscles; RNA Splicing; scoliosis; screening; Severities; Spinal Cord; Spinal Muscular Atrophy; technology validation; Testing; Type II Spinal Muscular Atrophy; Variant; Werdnig-Hoffmann Disease; young adult; ,NEWBORN SCREENINGS FOR PILOT STUDY FOR SPINAL MUSCULAR ATROPHY (SMA),,,,,,,,,894011,
9568097,N01,HD,,N,,,,,N01HD000000,,,275201500010I-0-27500003-1,NICHD:561121\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,15226158; ,"BAILEY, DONALD ;",,9/18/2017,3/17/2019,2 year old; Accounting; Adolescence; Adolescent; Adult; Advisory Committees; Affect; Age; Age of Onset; Age-Months; American; Anterior; Anterior Horn Cells; Antisense Oligonucleotides; Birth; Brain Stem; Cell Nucleus; Cessation of life; Child; Child health care; Childhood; Clinic; Clinical; Contractor; Data; data resource; Deposition; Development; Developmental Disabilities; Diagnosis; Diagnostic tests; Disease; Early Diagnosis; Early treatment; Evaluation; Exhibits; FDA approved; Flaccid Muscle Tone; follow-up; Genes; Goals; Guidelines; Health Personnel; Heritability; Horns; independent ambulation; Individual; infancy; Infant; Inherited; Intellectual functioning disability; Kugelberg-Welander Disease; Laboratories; Left; Leg; Longevity; Lung diseases; Medical Genetics; medical schools; medical specialties; Messenger RNA; Motor Neurons; Muscle hypotonia; Muscle Weakness; Mutation; Myopathy; National Institute of Child Health and Human Development; Neonatal Screening; Nervous System Trauma; new technology; Newborn Infant; Performance; Pharmaceutical Preparations; Physically Handicapped; Pilot Projects; programs; Proteins; Randomized; Rare Diseases; Recommendation; Reporting; Resources; Respiratory Muscles; RNA Splicing; scoliosis; screening; Severities; Spinal Cord; Spinal Muscular Atrophy; technology validation; Testing; Type II Spinal Muscular Atrophy; Variant; Werdnig-Hoffmann Disease; young adult; ,NEWBORN SCREENING FOR PILOT STUDY FOR SPINAL MUSCULAR ATROPHY (SMA),,,,,,,,,561121,
9568112,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100019-1,NCI:239627\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326886; ,"GIANNINI, ROBERT ;",,2/13/2017,8/13/2018,capsule; Clinical; Contractor; Gelatin; Label; Life; Pharmacologic Substance; repository; seal; Testing; , Z-Endoxifen HCl Capsules ,,,,,,,,,239627,
9568944,N43,AI,,N,,,,,N43AI000000,,,272201700072C-0-0-1,NIAID:225000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN DIEGO,UNITED STATES,,52,78391520,US,10031193,"QOOLABS, INC.",CA,921211414,,15327611; ,"HONG, QI ;",,8/1/2017,7/31/2018,Antibodies; cost effective; Cytomegalovirus; Detection; Development; Diagnostic; Immunoassay; Individual; Infection; Lateral; point of care; Serological; Simplexvirus; Virus Diseases; ,Rapid Point-of-Care Detection for Serologic Status of Individuals for CMV and HSV Infection,,,,,,,,,225000,
9568974,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100024-1,NCI:80834\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326901; ,"GIANNINI, ROBERT ;",,9/6/2017,9/5/2018,capsule; Clinical; Contractor; Cyclic GMP; Gelatin; Label; Life; Pharmacologic Substance; repository; seal; Testing; ,"IPdR Capsules, 600mg Strength",,,,,,,,,80834,
9569246,N01,AI,,N,,,,,N01AI000000,,,272201300020I-0-27200013-1,NIAID:1356867\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14922189; ,"WINOKUR, PATRICIA ;",,9/16/2013,1/15/2020,Antimicrobial Resistance; Bacterial Infections; bacterial resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Gram-Negative Bacterial Infections; Individual; named group; Phase IV Clinical Trials; phase IV trial; Population; programs; Resources; Therapeutic; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS: PHASE IV TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS ,,,,,,,,,1356867,
9569767,N01,HL,,N,,,,,N01HL000000,,,268201700003I-0-26800001-1,NHLBI:821233\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,14921901; ,"FOLSOM, AARON ;",,11/15/2016,11/21/2021,Abdomen; Adult; African American; aged; Ancillary Study; Ankle; Atherosclerosis; Atherosclerosis Risk in Communities; base; Behavioral; Behavioral Genetics; Carotid Arteries; caucasian American; Characteristics; Clinical; clinical development; clinical predictors; cognitive function; cohort; Cohort Studies; Collaborations; Communities; Contracts; Coronary heart disease; County; Data; Data Collection; Data Set; Event; follow-up; Fostering; Funding; Genetic; Geographic Locations; Goals; Grant; Heart failure; Hemostatic Agents; indexing; Laboratories; Measurement; middle age; Monitor; mortality; Myocardial Infarction; Natural History; operation; Participant; Photography; Policies; Process; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Recruitment Activity; Research Personnel; Retinal; Risk Factors; Risk Marker; rural setting; sharing data; socioeconomics; Structure of popliteal artery; Subgroup; suburb; Testing; trend; Ultrasonography; United States National Institutes of Health; Washington; ,IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - CORE STUDY OPERATIONS,,,,,,,,,821233,
9569858,N01,AI,,N,,,,,N01AI000000,,,272201700040I-0-27200001-2,NIAID:627668\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,15213147; ,"BEASLEY, DAVID ;",,7/14/2017,7/13/2024,Animal Model; Antimicrobial Resistance; Contracts; Development; drug resistant bacteria; efficacy testing; Escherichia coli; Infection; infectious disease model; Licensure; mouse model; Pathogenicity; Standardization; therapeutic development; ,Task 2: Murine models of Ascending UTI Infection caused by Drug-Resistant Bacteria,,,,,,,,,627668,
9570101,N01,AI,,N,,,,,N01AI000000,,,272201500013I-0-27200006-1,OD:530940\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14922246; ,"CHANG, POLLY ;",,2/6/2017,2/5/2020,animal efficacy; authority; Award; Clinical; Contract Services; Contracts; Documentation; efficacy study; Evaluation; Formulation; good laboratory practice; Human; Medical; Medical Licensure; National Institute of Allergy and Infectious Disease; Nuclear; Pharmacology Study; product development; Radiation; Radiation Injuries; Radiology Specialty; Research; research and development; Safety; Services; stability testing; Strategic Planning; United States Dept. of Health and Human Services; United States Food and Drug Administration; United States National Institutes of Health; ,RADIATION/NUCLEAR MEDICAL COUNTERMEASURE (MCM) PRODUCT DEVELOPMENT SUPPORT,,,,,,,,,530940,
9570305,N01,AI,,N,,,,,N01AI000000,,,272201700046I-0-27200001-2,NIAID:801951\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,YEMASSEE,UNITED STATES,,,199145954,US,,ALPHA GENESIS INC,SC,299457115,,15190096; ,"WESTERGAARD, DR. GREG ;",,9/30/2017,9/29/2018,biodefense; Breeding; Contractor; Contracts; cooperative study; germ free condition; Immune Tolerance; Macaca; Macaca fascicularis; Macaca mulatta; Maintenance; Modeling; National Institute of Allergy and Infectious Disease; nonhuman primate; novel; preclinical efficacy; preclinical safety; Primates; Regimen; Research Support; Transplantation; Transplantation Tolerance; ,MAINTENANCE OF NIAID SPECIFIC PATHOGEN-FREE MACAQUE BREEDING COLONIES for Biodefense,,,,,,,,,801951,
9570355,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-15,NIAID:2546186\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,15032410; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; Tuberculosis; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,2546186,
9570367,N01,AI,,N,,,,,N01AI000000,,,272201700071C-1-0-1,NIAID:2616817\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,5,79917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,,15266237; ,"CROWE, JAMES ;",,9/30/2014,6/30/2019,Affinity; Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; Biochemistry; Bioterrorism; Computer software; Contracts; Crystallization; Data; Databases; Emerging Communicable Diseases; Epitopes; Evaluation; Genetic; Human; human monoclonal antibodies; Humoral Immunities; Immune; Immunoglobulin Variable Region; In Vitro; Influenza; influenzavirus; Monoclonal Antibodies; multidisciplinary; nanoparticle; neutralizing monoclonal antibodies; novel; Pathogenesis; Point Mutation; programs; Protein Fragment; Proteins; Recombinant Proteins; Recombinants; Resources; Sampling; Structure; Toxin; Validation; Variant; Viral Antibodies; Virus; Zika Virus; ,GENETIC & STRUCTURAL BASIS FOR INFLUENZA VIRUS NEUTRALIZATION,,,,,,,,,2616817,
9570535,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-2,NIAID:40753\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Borrelia burgdorferi; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,40753,
9570538,N43,CA,,N,,,,,N43CA000000,,,261201700022C-0-0-1,NCI:299250\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,54460865,US,4204801,"AETHLON MEDICAL, INC.",CA,921095757,,15231005; ,"MARLEAU, ANNETTE ;",,9/15/2017,6/14/2018,Affinity; Agglutinins; base; Chondroitin Sulfate Proteoglycan; Clinical; clinical care; Complex; Devices; Epitopes; exosome; Fiber; Galanthus nivalis; Hemofiltration; Lectin; Magnetism; Mannose; Medical; melanoma; Membrane Glycoproteins; Methods; Non-Malignant; Phase; Plasma; Population; Price; Recovery; Research; Research Personnel; Small Business Innovation Research Grant; Standardization; Techniques; Technology; Tissues; tumor; Tumor-Derived; Vesicle; Virus; Work; ,IGF::OT::IGF Phase I SBIR Topic 359 Title: Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes09/15/2017 - 06/14/2018Firm Fixed Price,,,,,,,,,299250,
9570552,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-6,NIAID:40753\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Trypanosoma brucei brucei; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,40753,
9571002,N01,DA,,N,,,,,N01DA000000,,,271201500018C-8-0-1,NIDA:74732\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LENEXA,UNITED STATES,,3,945491256,US,10000978,"XENOTECH, LLC",KS,662199603,,14174726; ,"BUCKLEY, DAVID ;",,7/6/2015,7/5/2020,addiction; Affect; Contracts; cost; Data; design; Development; drug development; drug efficacy; drug metabolism; Enzymes; Evaluation; Excretory function; Funding; Genetic Polymorphism; In Vitro; Individual Differences; metabolic abnormality assessment; Metabolic Pathway; metabolic rate; Metabolism; Methods; National Institute of Drug Abuse; Performance; Permeability; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology and Toxicology; pre-clinical; Program Development; research and development; research clinical testing; Research Personnel; Research Support; Safety; Toxic effect; United States Food and Drug Administration; ,IGF::OT::IGF PURPOSE: TO FULLY FUND THE PERFORMANCE UNDER TASK ORDER 2 PERIOD OF PERFORMANCE: 09/03/2015 - 09/02/2016,,,,,,,,,74732,
9571106,N01,HD,,N,,,,,N01HD000000,,,275201300014I-2-27500002-1,NICHD:56867\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CINCINNATI,UNITED STATES,,1,41064767,US,1523902,UNIVERSITY OF CINCINNATI,OH,452210001,,15231740; ,"KUES, KIM ;",,7/16/2013,12/31/2018,Acetates; Adherence; Age; Amenorrhea; arm; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Dose; emergency contraception; Estrogens; Hemorrhage; In Vitro; Interruption; malignant breast neoplasm; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Obesity; Oral; Oral Contraceptives; Ovulation; pill; Population; progesterone receptor A; Progesterone Receptors; Progestins; Public Health; Randomized; Regimen; reproductive; Risk; Safety; Thromboembolism; Time; United States Food and Drug Administration; Uterine Fibroids; Venous; Woman; ,CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE,,,,,,,,,56867,
9571107,N01,HD,,N,,,,,N01HD000000,,,275201300019I-2-27500002-2,NICHD:267496\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,NORFOLK,UNITED STATES,,3,58625146,US,471501,EASTERN VIRGINIA MEDICAL SCHOOL,VA,235011980,,12062832; ,"ALLEN, ERIN ;",,7/16/2013,12/31/2018,Acetates; Adherence; Adverse effects; Age; Amenorrhea; arm; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Dose; Drug Kinetics; emergency contraception; Estrogens; Hemorrhage; In Vitro; Interruption; malignant breast neoplasm; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Pharmacodynamics; pill; Population; progesterone receptor A; Progesterone Receptors; Progestins; Public Health; Randomized; Regimen; reproductive; Risk; Safety; Thromboembolism; Time; United States Food and Drug Administration; Uterine Fibroids; Venous; Woman; ,CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE,,,,,,,,,267496,
9571109,N01,CA,,N,,,,,N01CA000000,,,261201500003I-3-26100016-1,NCI:1348291\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14274957; ,"ROBILLARD, CRAIG ;",,9/26/2015,10/31/2018,,BLDG. 538 INFRASTRUCTURE PROJECT,,,,,,,,,1348291,
9571427,N01,AI,,N,,,,,N01AI000000,,,272201300020I-0-27200014-1,NIAID:393914\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,15151972; ,"WINOKUR, PATRICIA ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNITS (VTEUS): CLINICAL OPERATIONS SUPPORT,,,,,,,,,393914,
9571438,N01,AI,,N,,,,,N01AI000000,,,272201300020I-0-27200012-1,NIAID:609231\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14922186; ,"WINOKUR, PATRICIA ;",,11/7/2016,5/25/2019,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Drug Kinetics; Evaluation; Gram-Positive Bacteria; Individual; named group; Population; programs; Resources; therapeutic development; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS (VTEU): POPULATION PHARMACOKINETICS STUDY ,,,,,,,,,609231,
9571444,N01,AI,,N,,,,,N01AI000000,,,272201300021I-0-27200019-1,NIAID:247821\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,15151975; ,"HOFT, DANIEL ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: CLINICAL OPERATIONS SUPPORT,,,,,,,,,247821,
9571729,N43,CA,,N,,,,,N43CA000000,,,261201700027C-0-0-1,NCI:249946\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LITTLETON,UNITED STATES,,4,832528678,US,10025150,"VITAN-BIOTECH, LLC",CO,801257965,,15232961; ,"ZHOU, XICHUN ;",,9/18/2017,6/17/2018,Affinity; analytical tool; Animals; Antibodies; Binding; Biotin; C-terminal; Cells; Coupling; cyanine dye 5; Cysteine; Data Set; Detection; Development; Dyes; Engineering; Epigenetic Process; Epitopes; Fluorescent Dyes; Genetic Transcription; Goals; Haptens; human disease; Image; Immune; Immunoblotting; In Vitro; in vivo; Label; Link; Maps; Methods; Modification; Monitor; nanobodies; nanomolar; Nucleosides; Nucleotides; Organism; Phage Display; Phase; Play; Protocols documentation; Pseudouridine; Research; Resolution; Ribonucleosides; RNA; RNA Instability; Role; Scientist; Site; Specificity; Technology; tool; ,IGF::OT::IGF Single domain antibodies for detection and imaging of modified RNA nucleosides,,,,,,,,,249946,
9571751,N01,AI,,N,,,,,N01AI000000,,,272201300022I-0-27200017-1,NIAID:1397685\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,14922204; ,"KOTLOFF, KAREN ;",,11/7/2016,8/6/2020,Antimicrobial Resistance; Biological Assay; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Drug Kinetics; Evaluation; Gram-Negative Bacteria; Individual; named group; Population; programs; protocol development; Resources; Therapeutic; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: POPULATION PHARMACOKINETIC ANALYSES ,,,,,,,,,1397685,
9572053,N01,AI,,N,,,,,N01AI000000,,,272201600011I-0-27200005-1,NIAID:135934\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,10,20790895,US,10019434,INTERNATIONAL AIDS VACCINE INITIATIVE,NY,100042400,,15266216; ,"DEY, ANTU ;",,9/20/2017,9/19/2018,assay development; Basic Science; Chemistry; Clinic; clinical development; Clinical Trials; Contracts; Development; Development Plans; HIV; HIV Infections; HIV vaccine; Immunology; Investigational New Drug Application; manufacturing process development; Molecular Biology; National Institute of Allergy and Infectious Disease; novel vaccines; Phase; Preparation; prevent; Process; product development; Proteins; Technology Transfer; vaccine development; Vaccines; ,Product Development Plans to Support HIV Vaccine Manufacturing Efforts,,,,,,,,,135934,
9572078,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200023-1,NIAID:276846\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,15151978; ,"CREECH, BUDDY ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: CLINICAL OPERATIONS SUPPORT,,,,,,,,,276846,
9572238,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-11,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572246,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-16,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Zika Virus; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9573327,N01,ES,,N,,,,,N01ES000000,,,273201300010C-8-0-3,NIEHS:400000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15043498; ,"HEBERT, CHARLES ;",,9/23/2013,5/19/2018,Address; Adult; Adverse effects; Algal Blooms; Animals; Birth; Chemicals; Congenital Abnormality; cyanoginosin LR; design; Development; developmental toxicity; disorder prevention; early life exposure; Excision; Exposure to; Fetal Development; Goals; Hazard Identification; Hazardous Chemicals; Health; Human; Infertility; Laboratory mice; Laboratory Rat; Life; Materials Testing; microcystin; National Toxicology Program; Ovary; Plants; prenatal exposure; programs; Puberty; public health research; reproductive organ; reproductive toxicity; Research; Surface; Testis; Toxic effect; Toxicity Tests; Toxin; tumor; Water; water treatment; ,"Other Projects, Microcystin Subproject 3",,,,,,,,,400000,
9573615,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200023-2,NIAID:768693\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,15151978; ,"CREECH, BUDDY ;",,7/12/2017,7/11/2018,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Diagnostic; Evaluation; Gram-Positive Bacteria; Individual; named group; Population; programs; protocol development; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT:CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,768693,
9573644,N01,HD,,N,,,,,N01HD000000,,,275201300020I-2-27500002-1,NICHD:15133\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PHILADELPHIA,UNITED STATES,,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,15238013; ,"BARNHART, KURT ;",,7/16/2013,12/31/2018,Acetates; Adherence; Adverse effects; Aftercare; Age; Amenorrhea; arm; Attitude; base; Biopsy; birth control; Blood specimen; Breast; Cervix Mucus; Chlamydia; Clinic; Clinical; Clinical Chemistry; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive History; Contraceptive methods; Counseling; Data; data exchange; demographics; diaries; Dose; Drug Kinetics; Eligibility Determination; Endometrial; Endometrium; Estradiol; Estrogens; follow-up; Future; Gonorrhea; Guidelines; Gynecology; Height; Hematology; Hemorrhage; In Vitro; Informed Consent; Interruption; Luteal Phase; malignant breast neoplasm; Measurement; Measures; Medical; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Ovulation; Pap smear; Pattern; Pharmaceutical Preparations; Pharmacodynamics; Phase; Physiologic pulse; pill; Population; Positioning Attribute; Pregnancy; Pregnancy Tests; Procedures; Progesterone; Progesterone Receptors; Progestins; Protocols documentation; Public Health; Randomized; Recording of previous events; Recovery; Recruitment Activity; Regimen; reproductive; Reproductive History; Rest; Risk; Rupture; Safety; Sampling; screening; Serum; SHBG gene; Specific qualifier value; Thick; Thromboembolism; Time; Transvaginal Ultrasound; treatment duration; United States Food and Drug Administration; Urine; Venous; Visit; Weight; Woman; ,"CCTN - A MULTI-CENTER, RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE, CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE",,,,,,,,,15133,
9573716,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-12,NIAID:344050\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Zika Virus; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,344050,
9573738,N01,HD,,N,,,,,N01HD000000,,,275201300026I-0-27500018-1,NICHD:184148\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,15242164; ,"CLEMONS, TRACI ;",,9/11/2013,9/10/2018,Address; Contracts; Controlled Clinical Trials; Couples; Data; Data Collection; Data Coordinating Center; data management; Data Set; diet and exercise; Documentation; Double-Blind Method; Ensure; Epidemiology; Female; Fertility; Fertility Study; Folic Acid; follow-up; infertility treatment; Life Style; male; Monitor; National Institute of Child Health and Human Development; Online Systems; Participant; Placebo Control; Preparation; Process; Randomized; Recruitment Activity; Research; Seminal fluid; Site; Supplementation; Support Contracts; System; TimeLine; Treatment outcome; Universities; Utah; Woman; Work; Zinc Sulfate; Zinc supplementation; ,DATA COORDINATING CENTER FOR THE IDEAL FERTILITY STUDY ,,,,,,,,,184148,
9574095,N01,HL,,N,,,,,N01HL000000,,,268201600010C-4-0-1,NHLBI:698365\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WATERTOWN,UNITED STATES,,5,153914080,US,2034501,"NEW ENGLAND RESEARCH INSTITUTES, INC.",MA,24722463,,14368971; ,"ASSMANN, SUSAN ;",,9/29/2016,6/30/2018,"2 year old; Age; Award; Benefits and Risks; Blood Chemical Analysis; Blood specimen; Brain; Chemistry; Child; Chronic; Clinical; clinical research site; cohort; Contracts; Cytogenetics; Data; Data Analyses; Data Collection; Data Coordinating Center; Databases; Development; double-blind placebo controlled trial; drug distribution; Early treatment; Enrollment; follow-up; Follow-Up Studies; Growth and Development function; Hematology; hydroxyurea; Kidney; Laboratories; Lung; Medical; Monitor; National Heart, Lung, and Blood Institute; Organ; Patients; Performance; Pharmaceutical Preparations; prevent; Protocols documentation; Randomized; Reading; Recruitment Activity; Risk; Sickle Cell Anemia; Site Visit; Structure; Surrogate Markers; Testing; Toxic effect; Transcranial Doppler Ultrasonography; ",BABY HUG FOLLOW-UP STUDY II:  DATA COORDINATING CENTER,,,,,,,,,698365,
9574416,N43,AI,,N,,,,,N43AI000000,,,272201700019C-0-0-1,NIAID:224960\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KATY,UNITED STATES,,22,57606011,US,10043171,"TECHWAVE INTERNATIONAL, INC.",TX,774501231,,15239941; ,"WU, CANGLIN ;",,8/1/2017,7/31/2018,base; Bioinformatics; Contractor; Data; Data Discovery; data integration; Data Reporting; Data Set; Data Storage and Retrieval; Databases; Immune system; Immunology; indexing; information organization; Ingestion; interest; Knowledge; Maps; Metadata; Modeling; Natural Language Processing; Ontology; prototype; Research; Resources; System; Techniques; Technology; Terminology; tool; user-friendly; ,An Integrated Biomedical Dataset Discovery System for Immunological Research Databases ,,,,,,,,,224960,
9575051,N02,CA,,N,,,,,N02CA000000,,,261201500047I-2-26100001-1,NCI:30253\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ISSAQUAH,UNITED STATES,,,63080705,US,,,WA,98029,,15241091; ,"MUCCI, NEIL ;",,9/29/2015,9/28/2018,actionable mutation; cancer type; Center for Translational Science Activities; Clinical; Clinical Data; Clinical Trials; Collection; Colorectal Cancer; Communities; Country; Data Analyses; Data Collection; Funding; genome analysis; insight; Investments; malignant breast neoplasm; Malignant neoplasm of ovary; Malignant Neoplasms; Modification; Molecular; National Cancer Institute; Normal tissue morphology; open source; Operative Surgical Procedures; Pathway interactions; peripheral blood; Post-Translational Protein Processing; precision oncology; prospective; Proteins; proteogenomics; Proteome; Proteomics; Protocols documentation; Quality Control; Resected; Resistance; Resources; screening; Site; Source; Tissue Preservation; tissue processing; Tissue Procurements; Tissues; Toxic effect; Training; tumor; ,"IGF::OT::IGF Tissue Source Site (TSS) for NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC)The purpose of this modification is to add and fully fund line item 0003, and extend the Period of",,,,,,,,,30253,
9575441,N01,ES,,N,,,,,N01ES000000,,,273201400027C-9-0-2,NIEHS:429864\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15059066; ,"BURBACK, BRIAN ;",,7/25/2014,5/24/2018,Adverse effects; Animals; Anthracenes; Aromatic Compounds; Benzo(a)pyrene; Chemicals; Chemistry; Chrysenes; Complex Mixtures; Contracts; Development; disorder prevention; Dose; Ensure; Environmental Exposure; Evaluation; Exposure to; Formulation; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; Human; Human Cell Line; Immunotoxicology; in vitro testing; Methods; National Toxicology Program; Outcome; phenanthrene; programs; Public Health; public health research; Pyrenes; Risk Assessment; Risk Factors; screening; Solubility; sound; Specific qualifier value; Testing; Toxic effect; Toxicity Tests; Toxicology; Validation; ,Polycyclic Aromatic Compound Mixture Assessment Program (PAC-MAP),,,,,,,,,429864,
9575740,N01,CA,,N,,,,,N01CA000000,,,261201200033I-0-26100011-1,NCI:277191\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,15213133; ,"BAILEY, HOWARD ;",,9/15/2017,9/14/2018,Atypical Endometrial Hyperplasias; Atypical hyperplasia; cancer cell; Complex; Contractor; Diagnosis; Endometrial; Endometrial Carcinoma; Endometrial Hyperplasia; Endometrial Intraepithelial Neoplasia; Exemestane; Intraepithelial Neoplasia; Measures; Operative Surgical Procedures; Pilot Projects; Postmenopause; S-Phase Fraction; Tissues; Woman; ,IGF::OT::IGF  PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER,,,,,,,,,277191,
9576431,N01,CA,,N,,,,,N01CA000000,,,261201700012I-0-26100001-1,NCI:20739852\OD:200000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,COSTA RICA,,,853088008,CS,10011285,FUNDACION INCIENSA,,,,15157190; ,"GONZALEZ, PAULA ;",,8/1/2017,7/31/2020,Antibody Response; Antibody titer measurement; cohort; Contracts; Costa Rica; Dose; Enrollment; follow-up; HPV-16/18 Vaccine; Human Papilloma Virus Vaccine; Immunization; Participant; prophylactic; Public Health; Regimen; vaccine efficacy; vaccine trial; Woman; ,"IGF::OT::IGF TASK ORDER 1: ONE-DOSE TRIAL SETUP, ENROLLMENT AND IMMUNIZATION",,,,,,,,,20939852,
9576593,N43,DA,,N,,,,,N43DA000000,,,271201700029C-1-0-1,NCATS:225000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BURLINGAME,UNITED STATES,,,80421815,US,,,CA,940104062,,15243811; ,"GANAPATHI, S.K. ;",,6/15/2017,3/14/2018,Automation; Computer software; Contractor; design; Dimensions; Environment; Equipment; Failure; high throughput screening; Human; Human Resources; innovation; Intervention; Laboratories; Laboratory Research; Location; Logistics; Measurement; Mechanics; Movement; operation; Productivity; Robot; Robotics; Safety; sensor; Translational Research; ,IGF::OT::IGF Fully Adaptive and Autonomous Drone for Laboratory Automation Projects,,,,,,,,,225000,
9576638,N43,DA,,N,,,,,N43DA000000,,,271201700054C-0-0-1,NIDA:225000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SAN JOSE,UNITED STATES,,18,848536975,US,10037108,"BCL TECHNOLOGIES, INC.",CA,951282541,,15243910; ,"KUMAR, AMAN  ;",,9/15/2017,3/14/2018,Award; BCL1 Oncogene; Bibliometrics; Data; Effectiveness; Evaluation; Feasibility Studies; Government; Health Care Research; improved; Internet; Machine Learning; Medical; Methods; Modeling; Performance; Procedures; Publications; Research; Semantics; System; Text; ,"IGF::OT::IGF Semantic Bibliometric System for Improving Healthcare Research (Topic 162) (Period of Performance: September 15, 2017 - March 14, 2018). BASE AWARD N43DA-17-1217",,,,,,,,,225000,
9576702,N44,DA,,N,,,,,N44DA000000,,,271201700044C-0-0-1,NCATS:1499740\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,HUNTSVILLE,UNITED STATES,,5,185169620,US,2805101,CFD RESEARCH CORPORATION,AL,358062922,,15244027; ,"PANT, KAPIL ;",,9/15/2017,9/14/2019,assay development; base; Basic Science; Biological Assay; Biotechnology; Cells; Collaborations; Communication; Complex; cost; design; Development; Disease; drug development; Electronics; Elements; Environment; In Vitro; instrumentation; Microfluidic Microchips; Modeling; next generation; novel; Organ; personalized medicine; Pharmaceutical Preparations; Phase; Process; Research; Research Personnel; Ships; Technology; Testing; Time; United States National Institutes of Health; Universities; ,IGF::OT::IGF SmartPlate Technology for Advanced Cellular (STAC-M),,,,,,,,,1499740,
9578131,N02,CA,,N,,,,,N02CA000000,,,261201700014I-0-26100001-1,NCI:895\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15327012; ,"WANG, JENNIE ;",,8/1/2017,9/30/2017,Chemicals; Contracts; cost; Formulation; Malignant Neoplasms; meetings; Pharmacologic Substance; Teleconferences; ,"IGF::OT::IGF Admin Costs - Contract Orientation & Kick Off Mtg, DTP-17-039, 08/01/17 - 09/30/17, HHSN261201700014I, Analysis of Anti-Cancer Chemical & Pharmaceutical Formulations PRB",,,,,,,,,895,
9580494,N02,HL,,N,,,,,N02HL000000,,,268201500060U-4-0-1,NIDCR:1325612\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCKVILLE,UNITED STATES,,,876875154,US,,IQ SOLUTIONS INC,MD,208523046,,15327230; ,"PANZER, JULIANNA ;",,11/2/2016,5/2/2017,Caring; Communication; Communication Research; Contractor; Contracts; craniofacial; Databases; Dental; Development; Disease; Institutes; Logistics; Maintenance; meetings; Mission; National Institute of Dental and Craniofacial Research; operation; Oral; Oral health; outreach; Patients; Prevention strategy; Research; Resources; response; Services; symposium; web site; ,IGF::OT::IGF NOHIC Services,,,,,,,,,1325612,
9581078,N01,HD,,N,,,,,N01HD000000,,,275201400001I-0-27500008-1,NIAAA:5625497\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,GAITHERSBURG,UNITED STATES,,,143526247,US,,FAST TRACK DRUGS AND BIOL,MD,208784276,,15143651; ,"RANSOM, JANET ;",,7/12/2017,7/11/2019,alcohol abuse therapy; Alcohol consumption; alcohol use disorder; Clinical Trials; Oxytocin; ,IGF::OT::IGF COORDINATING CENTER CLINICAL TRIALS'OXYTOCIN FOR ALCOHOL USE DISORDER'TASK ORDER NO. 8 - HHSN275201400001I/HHSN27500008TITLE: OXYTOCIN FOR ALCOHOL USE DISORDERPERIOD OF PERFORMANC,,,,,,,,,5625497,
9581105,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100059-1,NCI:574966\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,1/1/2017,12/31/2017,Consult; Contracts; Division of Cancer Control and Population Sciences; ,Scientific Consulting Group Contract No.: HHSN26120140011I  Task order #59 ,,,,,,,,,574966,
9581155,N02,CA,,N,,,,,N02CA000000,,,261201700015I-0-26100002-1,NCI:1160202\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,COLUMBUS,UNITED STATES,,3,147212963,US,1495302,RESEARCH INST NATIONWIDE CHILDREN'S HOSP,OH,432052664,,15250727; ,"GASTIER-FOSTER, JULIE ;",,9/22/2017,3/21/2020,Academia; Address; Biological Products; Cancer Center; cancer genomics; cancer initiation; Cancer Model; Cells; Clinical; Communities; Contractor; Data; Development; Ensure; Formulation; Genomic Data Commons; Genomics; Goals; Human; In Vitro; indexing; Industry; Institution; Intake; Intellectual Property; International; Libraries; Methods; model development; Modeling; Molecular; National Cancer Institute; next generation; novel; Office of Cancer Genomics; Organoids; Play; programs; Protocols documentation; Reagent; Research Personnel; Resources; response; Services; Standardization; Techniques; tool; tumor; ,Biospecimen Core Resource Services for Cancer Models Development Centers (CMDCs) POP:  09/22/2017-03/21/2020,,,,,,,,,1160202,
9581232,N01,HL,,N,,,,,N01HV000000,,,268201200005I-0-26800010-1,NHLBI:243277\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,INDIANAPOLIS,UNITED STATES,,7,603007902,US,577806,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,IN,462022915,,14975956; ,"CORNETTE, KENNETH ;",,2/21/2017,5/31/2017,"Animal Model; Clinical; Clinical Research; Contractor; Contracts; Dose; Funding; gene therapy; Gene Transfer; Laboratories; Lentivirus Vector; National Heart, Lung, and Blood Institute; Pharmacology and Toxicology; Production; programs; Regulation; Research Personnel; Resources; Safety; Testing; United States Food and Drug Administration; vector; ","IGF::OT::IGF GENE THERAPY RESOURCE PROGRAM (GTRP) LENTIVIRUS VECTOR PRODUCTION CORE LABORATORY FOR DR. YUPO MA RSA 1285, FEBRUARY 16, 2017 THROUGH MAY 31, 2017.",,,,,,,,,243277,
9581235,N01,HL,,N,,,,,N01HL000000,,,268201600011I-0-26800004-1,NHLBI:1740024\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DUARTE,UNITED STATES,,32,27176833,US,3058203,BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,910103012,,15266103; ,"GOLD, JOSEPH ;",,9/29/2017,9/28/2019,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - Production Assistance For Cellular Therapies (PACT)- Cell Processing Facilities,,,,,,,,,1740024,
9581254,N01,HL,,N,,,,,N01HL000000,,,268201700020C-0-0-1,NHLBI:300000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,Burnsville,UNITED STATES,,2,787489140,US,10011981,"IMRICOR MEDICAL SYSTEMS, INC.",MN,553372559,,15266127; ,"LLOYD, TOM ;",,9/26/2017,7/25/2018,"Ablation; Acetic Acids; Animals; aortic valve; Award; Cardiac; Cardiac ablation; cardiovascular imaging; Cardiovascular system; Catheters; Caustics; Cells; Charge; Clinical; clinical development; Contractor; Contracts; Contrast Media; Coupled; design; Development; Development Plans; Devices; direct application; Disease; Electrodes; Electromagnetics; Elements; experience; Family; Family suidae; Feedback; femoral artery; Funding; Goals; Heating; Human Resources; Hypertrophic Cardiomyopathy; Image; Imagery; in vivo; Injection of therapeutic agent; Investigation; Laboratories; Left ventricular structure; Magnetic Resonance Imaging; Maryland; meetings; Myocardial; Myocardium; National Heart, Lung, and Blood Institute; Needles; operation; Penetration; Phase; Positioning Attribute; pre-clinical; programs; prototype; Publications; Publishing; PubMed; Radial; radiofrequency; Radiologic Health; Reporting; research and development; research clinical testing; Right ventricular structure; Risk; Roentgen Rays; Side; Site; Small Business Innovation Research Grant; structural heart disease; success; Surface; System; Techniques; Technology; Test Result; Testing; Torque; transmission process; Travel; United States Food and Drug Administration; United States National Institutes of Health; Venous; Ventricular Tachycardia; ","IGF::OT::IGF SBIR Topic 100, Phase I of Fast-track, MRI Myocardial Needle Chemoablation Catheter IGF::OT::IGF ",,,,,,,,,300000,
9581309,N01,HD,,N,,,,,N01HD000000,,,275201500006I-0-27500003-1,NIAAA:122391\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,LA JOLLA,UNITED STATES,,49,781613492,US,7375802,SCRIPPS RESEARCH INSTITUTE,CA,920371000,,15266305; ,"JANDA, KIM ;",,9/21/2017,9/20/2018,alcohol abuse therapy; Alcohols; ghrelin; Hormones; Investigation; Production; Rattus; Research Institute; Vaccines; ,IGF::OT::IGF:The Scripps Research Institute. Task Order 3 (HHSN275201500006I/HHSN27500003).'Production and Distribution of Investigational Ghrelin Vaccines--Ghrelin Vaccine Against Rat Hormone. 09/21/,,,,,,,,,122391,
9581310,N43,HD,,N,,,,,N43HD000000,,,275201700001C-0-0-1,NIAAA:224656\,SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,GAITHERSBURG,UNITED STATES,,6,963268094,US,10026936,"CODEX BIOSOLUTIONS, INC.",MD,208793467,,15327839; ,"LU, JIMMY ;",,6/15/2017,6/14/2018,alcohol use disorder; Alcohols; Development; inhibitor/antagonist; novel; PDE4B; Phase; Small Business Innovation Research Grant; ,IGF::OT::IGF 'Development of Novel PDE4B Inhibitors to Treat Alcohol Use Disorder' (SBIR Phase I),,,,,,,,,224656,
9581368,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100081-1,NCI:28792\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,8/15/2017,8/14/2018,Consult; symposium; ,IGF::OT::IGF SCIENTIFIC CONSULTING GROUP INC:1108176 [17-064277],,,,,,,,,28792,
9581373,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100057-1,NCI:23823\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,10/7/2016,12/2/2016,Cancer Intervention and Surveillance Modeling Network; meetings; ,IGF::OT::IGF FHHSN261201400011I Cancer Intervention and Surveillance Modeling Network (CISNET) November 2016 Meeting. POP 10/7/2016-12/2/2016. Labor-$13526.88 ODCs $10293.63 TOTAL $23822.51 Eric Feuer,,,,,,,,,23823,
9581375,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100061-1,NCI:46870\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,2/17/2017,12/31/2017,Ambulatory Monitoring; International; meetings; Movement; Physical activity; symposium; ,Task Order No.61 - 5th International Conference on Ambulatory Monitoring of Physical Activity and Movement (ICAMPAM 2017) - Meeting Support,,,,,,,,,46870,
9581389,N02,CA,,N,,,,,N02CA000000,,,261201700515P-0-0-1,NCI:24500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ANN ARBOR,UNITED STATES,,,789525941,US,,,MI,481038856,,15327158; ,"BANERJEE, MOUSUMI ;",,9/15/2017,9/14/2018,learning strategy; Machine Learning; Malignant neoplasm of urinary bladder; ,IGF::OT::IGF Machine Learning Methods to Identify Bladder Cancer Cases Missed by Routine Surveillance,,,,,,,,,24500,
9581580,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-158,NCI:203102\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,analog; Antibodies; Area; Biological; Cell Line; Characteristics; Chemicals; Child; Childhood; Chimeric Proteins; clinical candidate; clinical translation; Clinical Trials; Cryoelectron Microscopy; design; Drug Kinetics; efficacy study; flexibility; Funding Opportunities; Fusion Oncogene Proteins; Goals; Immunotherapy; in vivo; inhibitor/antagonist; Laboratories; Libraries; Malignant Childhood Neoplasm; Malignant Neoplasms; meetings; Phage Display; Pharmaceutical Preparations; Pharmacodynamics; pre-clinical; preclinical efficacy; Procedures; Process; Production; Proteins; Reagent; Recommendation; Research; Research Activity; research clinical testing; Resolution; Resources; response; Safety; safety study; scale up; Testing; Translational Research; Work; ,MS PEDIATRIC MOONSHOT CORE,,,,,,,,,203102,
9581731,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-160,NCI:7498297\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,analytical tool; anticancer research; Authorization documentation; cancer genomics; Data; data modeling; Data Science; design; Ecosystem; Elements; Environment; experience; genomic data; Genomic Data Commons; genomics cloud; Image; knowledge base; Malignant Neoplasms; repository; Research Infrastructure; Secure; sharing data; tool; Validation; Vision; Vocabulary; working group; ,MS Expand Data Commons and Data Sharing,,,,,,,,,7498297,
9581860,N01,HL,,N,,,,,N01HL000000,,,268201700006I-0-26800009-1,NIDCR:96800\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15252382; ,"HU, JAN CHING CHUN ;",,9/19/2017,9/18/2019,Address; Affect; ameloblastin; Ameloblasts; Amelogenesis Imperfecta; Appearance; Biological; Blindness; Body part; Bulla; calcification; Calcified; Candidate Disease Gene; Cells; Chemicals; Child; Clinical; clinical phenotype; Collection; Conscious; County; Defect; Dental; Dental Enamel; dental genetics; Dentists; Diagnosis; Disease; DNA sequencing; Enamel Formation; Etiology; Exhibits; exome; Food; Future; Gene Mutation; General Population; Genes; Genetic; genetic disorder diagnosis; genetic linkage analysis; genetic pedigree; Genetic Predisposition to Disease; Genetic screening method; Genetic study; Genomic DNA; Genotype; Grant; Health; Human Cell Line; human disease; Ice Cream; Immunologic Deficiency Syndromes; improved; Individual; Inferior; Inheritance Patterns; Inherited; Kidney; kindred; Knockout Mice; LAMC2 gene; loss of function; malformation; Medical; Medical Genetics; Membrane Proteins; Michigan; Mission; Molecular Chaperones; mutant; Mutation; National Institute of Dental and Craniofacial Research; novel; Oral; Oral cavity; Organ; outcome forecast; Pain; Pathologic; Pathology; Patients; Persons; Phenotype; Physical Examination; Pigments; premature; prevent; Prevention; proband; Procedures; prospective; protein misfolding; Proteins; Quality of life; reconstruction; Recording of previous events; Recruitment Activity; Rehabilitation therapy; Reporting; Research Proposals; Research Support; Running; segregation; self esteem; Skin; STIM1 gene; Stress; Surveys; Syndrome; Tissues; Tooth structure; Translations; United States National Institutes of Health; Validation; Variant; vector; ,IGF::OT::IGF Sequencing - Whole Exome plus UTR (95% at 20X) for NIDCR (Hu) FY 2017 CAN 8469539,,,,,,,,,96800,
9581942,N01,HL,,N,,,,,N01HL000000,,,268201700006I-0-26800008-1,NIDCR:563850\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15252534; ,"SHAFFER, JOHN ;",,9/14/2017,9/13/2019,genome wide association study; Genomics; Mouth Diseases; National Institute of Dental and Craniofacial Research; Oral health; ,IGF::OT::IGF:  GWAS Multi-Ethnic Global for NIDCR (Shaffer 2) FY 2017 CAN 8469539,,,,,,,,,563850,
9584032,N44,DA,,N,,,,,N44DA000000,,,271201700045C-0-0-1,NIDA:1000000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WASHINGTON,UNITED STATES,,98,787027762,US,10030638,"MEDIA REZ, LLC",DC,200094310,,15255739; ,"GREENBERG, DANIEL ;",,9/15/2017,9/14/2019,Adult; base; Chronic; chronic pain; Clinical; Contractor; Feedback; Focus Groups; Intervention; Modality; Pain; Pain management; patient population; Patients; Phase; Pilot Projects; Population Heterogeneity; prototype; Randomized Clinical Trials; Small Business Innovation Research Grant; Testing; Therapeutic; tool; treatment planning; treatment program; virtual reality; ,IGF::OT::IGF: BASE AWARD. Virtual Reality for Mobile Pain Control. PoP: 09/15/2017 - 09/14/2019. N44DA-17-4435.,,,,,,,,,1000000,
9587918,N02,DA,,N,,,,,N02DA000000,,,271201400017I-0-27100004-1,NINDS:19500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LYME,UNITED STATES,,,967593588,US,,,CT,63713307,,15327374; ,"MARTIN, WILLIAM ;",,9/29/2014,9/28/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,IGF::CL::IGF WHM CONSULTING LLC:1197753 [17-004930],,,,,,,,,19500,
9589182,N01,DA,,N,,,,,N01DA000000,,,271201400015I-0-27100004-1,NINDS:28500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BOULDER,UNITED STATES,,,45377676,US,,,CO,"80,303,296",,; ,",  ;",,9/28/2014,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"IGF::OT::IGF FRANKLIN ADME CONSULT, LLC:1239158 [17-004902]",,,,,,,,,28500,
9591574,R01,GM,7,N,12/27/2017,9/1/2017,1/31/2018,859,R01GM089933,SCHOOLS OF MEDICINE,PA-13-302,7R01GM089933-08,NIGMS:153629\,Non-SBIR/STTR RPGs,2017,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,,SAN FRANCISCO,UNITED STATES,OPHTHALMOLOGY,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,9387542; ,"NACHURY, MAXENCE V;","GINDHART, JOSEPH G",4/1/2010,1/31/2020,Agonist; Back; Bardet-Biedl Syndrome; Binding; Biochemical; Biochemistry; Biological Assay; Cells; Cilia; ciliopathy; cilium biogenesis; Clinical; cohesion; Complex; Coupled; Cystic kidney; Data; desensitization; Development; Disease; Ensure; Erinaceidae; Etiology; Excision; Exhibits; extracellular; G-Protein-Coupled Receptors; Genetic Transcription; Goals; GTPase-Activating Proteins; Guanine Nucleotide Exchange Factors; Guanosine Triphosphate; Hydrolysis; Image; In Vitro; innovation; insight; Light; Location; Mediating; Membrane; Modality; Modeling; Molecular; molecular modeling; Molecular Models; Monomeric GTP-Binding Proteins; morphogens; Movement; novel; Nuclear; Nucleotides; Obesity; Pathway interactions; polymerization; Process; programs; Property; protein complex; protein transport; Proteins; public health relevance; receptor; Receptor Signaling; receptor-mediated signaling; reconstitution; Regulation; Research; Retinal Degeneration; Role; Signal Pathway; Signal Transduction; Signaling Molecule; single molecule; skeletal abnormality; Smell Perception; SSTR3 gene; Stimulus; Testing; Therapeutic Intervention; tool; trafficking; Training; UBD protein; Ubiquitin; Vision; Work; ,MOLECULAR STUDIES OF PRIMARY CILIUM BIOGENESIS,89933,MBPP,Membrane Biology and Protein Processing Study Section ,,,8,96927,56702,153629,
9594184,N01,DA,,N,,,,,N01DA000000,,,271201700015C-0-0-1,NIA:406116\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15014129; ,"HOWARD, VIRGINIA ;",,4/24/2017,7/23/2018,,IGF::OT::IGF OBJECTIVE MEASUREMENT OF ACTIVITY AFTER RETIREMENT IN REGARDS STUDY PARTICIPANTS,,,,,,,,,406116,
9594206,N01,DA,,N,,,,,N01DA000000,,,271201300026C-8-0-2,NIA:105694\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,15124112; ,"KEMNITZ, JOSEPH ;",,9/1/2013,8/31/2018,,IGF::OT::IGF MANAGEMENT OF THE PRIMATE AGING DATABASE (PAD),,,,,,,,,105694,
9594226,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300126-1,NIA:110873\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15201018; ,"MOLYE, ELIZABETH ;",,9/1/2017,8/31/2018,,IGF::OT::IGF: LEVERAGING RARELY-INVESTIGATED POPULATIONS FOR RESEARCH ON BEHAVIORAL AND SOCIAL PROCESSES IN AN AGING CONTEXT: AN EXPERT MEETING,,,,,,,,,110873,
9392553,R01,DK,5,N,12/26/2017,12/1/2017,11/30/2018,847,R01DK103854,,PAS-13-031,5R01DK103854-03,NIDDK:356494\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,,SEATTLE,UNITED STATES,,7,78200995,US,861001,FRED HUTCHINSON CANCER RESEARCH CENTER,WA,981094433,,11105415; ,"BRADLEY, ROBERT K;","BISHOP, TERRY ROGERS",12/1/2015,11/30/2019,3' Splice Site; Address; Affect; Aging; base; Biological Models; Biology; Blood Cells; Blood groups; cell killing; Cell Line; cell type; Cells; Data; Development; Diagnosis; Disease; Disease Pathway; Disease remission; DNA; Dysmyelopoietic Syndromes; effective therapy; Epigenetic Process; experience; Failure; Frequencies; Gene Targeting; Genes; Genetic; genome-wide; Goals; Health; Hematological Disease; Hematopoiesis; Hypermethylation; improved; Incidence; Individual; insight; Killings; knockout gene; Knowledge; Lead; Molecular; Molecular Abnormality; Morbidity - disease rate; mortality; mutant; Mutate; Mutation; new therapeutic target; novel therapeutic intervention; novel therapeutics; Pathway interactions; Patient Care; Patients; Phenocopy; Physicians; Population; prevent; Protein Isoforms; Proteins; Proteome; Public Health; public health relevance; Research; response; Ribosomal RNA; RNA Degradation; RNA Splicing; Role; Scientist; Signal Transduction; small molecule; Spliced Genes; Testing; Therapeutic; Transgenic Organisms; Translating; United States; Work; ,U2AF1 mutations in myelodysplastic syndromes: from mechanism to therapy,103854,ZRG1,Special Emphasis Panel ,,,3,209760,146734,356494,
9430033,N01,AI,,N,,,,,N01AI000000,,,272201000022I-5-27200005-1,NIAID:356367\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,12446851; ,"MURRAY, MICHAEL ;",,2/26/2014,1/31/2018,Animal Model; animal model development; Contracts; Coxsackie Viruses; Development; efficacy testing; Human poliovirus; infectious disease model; mouse model; Standardization; therapeutic development; ,Task A60: Mouse Models for Polio and Coxsackie Viruses,,,,,,,,,356367,
9430080,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-41,NCI:10000000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Address; Algorithms; application programming interface; Bioinformatics; Biomedical Research; cancer Biomedical Informatics Grid; Code; Collaborations; Communication; Complex; computer program; Computers; computing resources; Consultations; Contractor; cyber infrastructure; Data; data management; data visualization; Databases; Development; Discipline; Emerging Technologies; Engineering; Environment; Funding; Genomics; Government; Image; Information Resources Management; Information Systems; Joints; Laboratories; Laws; Local Area Networks; Maintenance; Manuals; member; Molecular Biology; Nanotechnology; Network Infrastructure; operation; Policies; programs; Proteomics; Protocols documentation; Regulation; Research; Scientist; Security; Services; sharing data; software systems; Specialist; structural biology; support network; symposium; System; Technology; Training; United States National Institutes of Health; ,Information Systems Program (ISP),,,,,,,,,10000000,
9430090,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-50,NCI:660000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Acquired Immunodeficiency Syndrome; base; Basic Science; Biological; cancer cell; cancer genome; Chromosomes; clinically relevant; Complex; cost; Data; Development; Disease; DNA Sequence Alteration; Environment; epidemiologic data; epigenome; Etiology; factor C; Genome; genome sequencing; HIV; HIV Infections; Immunologic Deficiency Syndromes; Incidence; Informatics; Joints; Kaposi Sarcoma; Laboratories; malignant breast neoplasm; Malignant Neoplasms; Molecular; novel; Office of Cancer Genomics; Oncogenic Viruses; Pathogenesis; Pathway interactions; Patients; permissiveness; Persons; phenotypic data; Play; Research Support; Risk Factors; tool; transcriptome; tumor; tumor heterogeneity; Tumor Subtype; tumorigenesis; Viral; whole genome; ,Molecular Characterization of HIV-Associated Tumors by Sequencing,,,,,,,,,660000,
9430122,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-89,NCI:0\NIA:0\NIAID:0\NIDDK:85000\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Affect; Cell Line; Charge; Chronic; Cryopreserved Cell; Databases; Diabetes Mellitus; Diabetic Nephropathy; Disease; Eligibility Determination; End stage renal failure; ENG gene; Family; Genes; Genetic Predisposition to Disease; genetic technology; Goals; Hyperglycemia; Hypertension; Individual; Institution; Insulin-Dependent Diabetes Mellitus; Intervention; Investigation; Kidney Diseases; Link; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Patients; Phenotype; Plasma; Predisposition; Prognostic Factor; repository; Research Personnel; sample collection; Sampling; Secure; Urine; ,Repository for the Family Investigation of Nephropathy & Diabetes (FIND),,,,,,,,,85000,
9430155,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-121,NCI:46400\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Blood; Breast Cancer Prevention Trial; Clinical Trials; cost; Freezing; Leukocytes; Maintenance; National Surgical Adjuvant Breast and Bowel Project; Plasma; repository; Specimen; Study of Tamoxifen and Raloxifene; Woman; ,DCP - COPTRG Support [National Surgical Adjuvant Breast and Bowel Project (NSABP),,,,,,,,,46400,
9430184,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-152,NCI:500000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14368683; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Antibodies; base; Benign; Biological Assay; Capsid Proteins; Cells; Cervarix; Communities; Development; Dose; Evaluation; Gardasil; Genotype; Goals; high risk; Human; Human papilloma virus infection; Human Papilloma Virus Vaccine; Human Papillomavirus; Human papillomavirus 16; Human papillomavirus 18; Insecta; L1 viral capsid protein; Laboratories; Malignant neoplasm of cervix uteri; Oncogenic; reagent standard; Recombinants; Regimen; Resources; Serologic tests; Serological; Serum; Standardization; Testing; vaccine development; vaccine-induced immunity; Vaccines; virtual; Virus-like particle; Work; Yeasts; ,HPV Serology,,,,,,,,,500000,
9430200,N01,ES,,N,,,,,N01ES000000,,,273201500010C-10-0-3,NIEHS:34210\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE PARK,UNITED STATES,,4,130427701,US,1933801,"INTEGRATED LABORATORY SYSTEMS, INC.",NC,277093501,,14082068; ,"ALLEN, DAVID ;",,5/5/2015,5/4/2017,Animals; base; Chemicals; Computer Simulation; Contractor; Contracts; Data; Databases; Development; Drug Kinetics; Educational workshop; Evaluation; Exposure to; Hazard Identification; Health; high throughput screening; Human; In Vitro; in vivo; Interagency Coordinating Committee on the Validation of Alternative Methods; interest; International; Knowledge; Literature; meetings; member; Methods; Modeling; National Toxicology Program; novel; outreach; pharmacodynamic model; Physiological; Production; Publishing; Quantitative Structure-Activity Relationship; Reporting; research and development; Research Methodology; Research Support; Risk Assessment; safety testing; screening; Support Contracts; System; Testing; Toxicokinetics; Toxicology; Travel; Work; ,NICEATM Support Contract: Contractor Travel,,,,,,,,,34210,
9430202,N02,CA,,N,,,,,N02CM000000,,,261201200020C-25-0-1,NCI:381725\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALACHUA,UNITED STATES,,3,12852344,US,10020711,ALCHEM LABORATORIES CORPORATION,FL,326156687,,14195670; ,"DENYSENKO, SERGIY ;",,8/1/2012,7/31/2017,Chemicals; Pharmacologic Substance; pre-clinical; preclinical trial; ,MANUFACTURE OF BULK CHEMICALS AND BULK PHARMACEUTICAL INGREDIENTS FOR PRECLINICAL,,,,,,,,,381725,
9430204,N01,HL,,N,,,,,N01HL000000,,,268201600003C-2-0-1,NCI:0\NHLBI:1101046\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,STANFORD,UNITED STATES,,18,9214214,US,8046501,STANFORD UNIVERSITY,CA,943041222,,14368955; ,"MULKEY, KAREN ;",,10/15/2015,10/14/2017,Cardiovascular Diseases; Communities; Contracts; follow-up; Knowledge; Mentors; older women; Research Personnel; Resources; Women's Health; ,IGF::CT::IGF WOMEN HEALTH INITIATIVE - REGIONAL CENTER,,,,,,,,,1101046,
9430222,N01,HL,,N,,,,,N01HV000000,,,268201300029C-8-0-1,NHLBI:795571\NIA:0\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,OAKLAND,UNITED STATES,,13,150829349,US,3497005,KAISER FOUNDATION RESEARCH INSTITUTE,CA,946123466,,12576629; ,"SIDNEY, STEVE ;",,7/1/2013,6/30/2017,acquired factor; Address; Adult; Affect; Age; Ancillary Study; Atrial Fibrillation; base; Blood; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; cardiovascular risk factor; Cardiovascular system; Chicago; Clinical; cohort; Communities; Coronary artery; Coronary Artery Risk Development in Young Adults Study; Coronary heart disease; Data; Development; Disease; Education; emerging adult; Event; Evolution; follow-up; Heart Abnormalities; Heart failure; high school; Institutes; Lung; Measures; middle age; Myocardial dysfunction; novel; Participant; Phenotype; Race; racial disparity; Research Personnel; Risk; Risk Factors; Sampling; sex; sharing data; stomach cardia; stroke; Structure; Subgroup; Time; Training; Update; young adult; ,IGF::OT::IGF,,,,,,,,,795571,
9430249,N01,HD,,N,,,,,N01HD000000,,,275201500002C-6-0-1,NICHD:891211\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14261295; ,"LEE, WESLEY ;",,9/15/2015,1/31/2018,Abdomen; adverse outcome; African American; Amniotic Sac; Area; arm; Asians; base; Biometry; Birth; Blood flow; Body Composition; bone; Brain; Budgets; Caucasians; Cerebellum; Characteristics; Chest; Chorionic Sac; Clinical; clinical practice; cohort; Complement; Computer software; Computers; Contractor; cost; Data; Data Collection; Data Coordinating Center; Deposition; design; Dimensions; Discrimination; disorder control; Documentation; epidemiology study; Ethnic Origin; Etiology; Evaluation; Face; Fatty acid glycerol esters; fetal; Fetal Growth; Fetal Growth Retardation; Fetus; follow-up; Future; Gestational Age; Gestational Diabetes; Goals; Government; Growth; Head; Healthcare; Heart; high risk; Hispanics; Image; Imaging technology; improved; Individual; Intervention; Kidney; Knowledge; Limb structure; Liver; malformation; Measurement; Measures; Monitor; National Institute of Child Health and Human Development; neonatal morbidity; Non obese; Obesity; open label; Organ Size; Participant; Pathologic; Patients; Pelvis; Picture Archiving and Communication System; Population; Pregnancy; Pregnancy Complications; Pregnant Women; Prenatal Diagnosis; programs; prospective; Prospective cohort study; Protocols documentation; Race; racial difference; Randomized; Reading; Recruitment Activity; Reporting; Research; Rest; Risk; Scanning; Schedule; Severities; Side; Signal Transduction; Site; Small for Gestational Age Infant; soft tissue; Specific qualifier value; Study Subject; subcutaneous; System; Taiwan; Technology; Testing; Thigh structure; Thinness; Three-Dimensional Image; Time; Twin Multiple Birth; Ultrasonography; Uterus; Visceral; Visit; Woman; Work; ,FETAL BODY COMPOSITION AND VOLUMES STUDY,,,,,,,,,891211,
9430276,N01,HD,,N,,,,,N01HD000000,,,275201300002C-8-0-1,NIAAA:1606757\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BETHESDA,UNITED STATES,,8,177159456,US,3020801,"CDM GROUP, INC.",MD,208146133,,12576989; ,"URBAN, ROSE ;",,1/1/2016,12/31/2016,Address; Affect; Alcohol consumption; alcohol policy information system; Alcoholic Beverages; Alcohols; Area; Behavior; Consumption; County; design; Effectiveness; Government; Health; Laws; Marketing; Measures; Municipalities; National Institute on Alcohol Abuse and Alcoholism; online resource; Outcome; Policies; Preventive service; Principles of law and justice; Process; Production; Public Policy; public policy on alcohol; Regulation; Research; Research Personnel; Sales; social; Taxation; tool; Transportation; United States; web site; ,ALCOHOL POLICY INFORMATION SYSTEM (APIS),,,,,,,,,1606757,
9430291,N01,AI,,N,,,,,N01AI000000,,,272201200004C-14-0-1,NIAID:2434475\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WILMINGTON,UNITED STATES,,7,362574527,US,4079901,"PPD, INC.",NC,284013331,,12576901; ,"GLESSNER, MARY ;",,1/1/2012,12/31/2021,Clinical Research; clinical research site; Clinical Trials; Conduct Clinical Trials; Contracts; Ensure; Immune Tolerance; International; Monitor; Regulation; Research Personnel; research study; Services; symposium; , DAIT CLINICAL SITE MONITORING CENTER,,,,,,,,,2434475,
9430294,N01,LM,,N,,,,,N01LM000000,,,276201300007C-9-0-1,NIDDK:911985\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,12627804; ,"GIFFEN, CAROL ;",,7/1/2013,12/31/2017,Communities; Contracts; cost effective; Data; Data Set; Databases; Equipment and supply inventories; Genetic; Grant; Individual; Informed Consent; International; Label; Metadata; National Institute of Diabetes and Digestive and Kidney Diseases; Online Systems; Reporting; repository; Research; Research Personnel; response; Sampling; Secure; Structure; System; Testing; Time; web site; ,NIDDK DATA REPOSITORY,,,,,,,,,911985,
9430298,N01,DA,,N,,,,,N01DA000000,,,271201500007C-9-0-1,NIDA:1051567\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,12576621; ,"THOMAS, BRIAN ;",,1/15/2015,1/14/2020,Chemicals; Cigarette; Contractor; Contracts; Dosage Forms; Drug abuse; Drug Addiction; Drug or Chemical; Equipment and supply inventories; interest; Marijuana; Methods; National Institute of Drug Abuse; Nicotine; Pharmaceutical Preparations; Preparation; Research; Ships; Source; Tobacco; ,IGF::OT::IGF PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS PERIOD OF PERFORMANCE 9/1/2015 - 2/29/2016: TASK ORDER 3 AWARD,,,,,,,,,1051567,
9430310,N01,AI,,N,,,,,N01AI000000,,,N01AI40074-32-0-3,NIAID:2564303\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN FRANCISCO,UNITED STATES,,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,14270711; ,"LINDA, GIUDICE ;",,9/29/2004,4/30/2018,Adolescent; Area; Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; Contractor; Developing Countries; experience; Hepatitis C Vaccine; High Prevalence; Human Resources; Incidence; Laboratories; Leadership; Population; Prevalence; protocol development; Research Infrastructure; sample collection; Sexually Transmitted Diseases; Training; vaccine candidate; Woman; ,Sexually Transmitted Infections Clinical Trials Group,,,,,,,,,2564303,
9430315,N01,MH,,N,,,,,N01MH000000,,,271201100006I-7-27100005-1,NIMH:288473\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,BOSTON,UNITED STATES,,8,73130411,US,4907701,MASSACHUSETTS GENERAL HOSPITAL,MA,21142696,,1882325; ,"FAVA, MAURIZIO ;",,9/12/2013,2/28/2017,Adult; Age; antidepressant effect; Area; Authorization documentation; Budgets; Clinical; Clinical Trials; cohort; Contractor; Contracts; cost; Development; Diagnosis; efficacy trial; Government; Government Programs; Hour; Human; Intervention; Intramural Research Program; member; Mental Depression; National Institute of Mental Health; Pharmacology; Procedures; Randomized Clinical Trials; response; Site; Sleep Deprivation; Testing; treatment-resistant depression; ,RAPIDLY-ACTING TREATMENTS FOR SEVERE TREATMENT RESISTANT DEPRESSION (RAPID),,,,,,,,,288473,
9430324,N01,AI,,N,,,,,N01AI000000,,,272201300020I-2-27200009-2,NIAID:101856\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14652698; ,"BUSH, DAVID ;",,7/12/2016,7/1/2019,Clinical; Clinical Trials; Clinical Trials Unit; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,Vaccine and Treatment Evaluation Unit - Clinical Trial Operations Support,,,,,,,,,101856,
9430359,N01,DA,,N,,,,,N01DA000000,,,271201400013I-1-27100003-1,NINDS:1200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ANN ARBOR,UNITED STATES,,,16763403,US,,INTEGRATED NONCLINICAL DE,MI,481032122,,14608921; ,"DUDDY, STEVEN ;",,9/28/2016,9/27/2017,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"IGF::OT::IGFINTEGRATED NONCLINICAL DEVELOPMENT SOLUTIONS, INC.:1212619 [16-004097]",,,,,,,,,1200,
9431313,K08,HL,1,N,12/21/2017,12/24/2017,11/30/2018,838,K08HL140190,SCHOOLS OF MEDICINE,PA-16-191,1K08HL140190-01,NHLBI:168264\,OTHER RESEARCH-RELATED,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BIRMINGHAM,UNITED STATES,INTERNAL MEDICINE/MEDICINE,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,9809728; ,"HARRIS, WILLIAM THOMAS;","TIGNO, XENIA",12/24/2017,11/30/2020,Address; Affect; airway epithelium; Animal Model; Award; base; Binding; Biochemical; Biological Assay; Biological Preservation; career; Child; Childhood; Clinical; Clinical Investigator Award; Cystic Fibrosis; cystic fibrosis patients; Cystic Fibrosis Transmembrane Conductance Regulator; Data; Development; Disease; Disease Progression; disease-causing mutation; Down-Regulation; Environment; Epithelial Cells; Epithelium; experimental study; FDA approved; Foundations; Genetic; Goals; improved; In Vitro; in vivo; innovation; Interruption; learning strategy; Lung diseases; Measures; Mediating; Mentors; Messenger RNA; MicroRNAs; Modification; Molecular; mutant; Mutation; next generation; Nose; novel; Pathway interactions; Patients; Pharmacologic Substance; pre-clinical; promoter; Proteins; Pulmonary Cystic Fibrosis; Pulmonary Fibrosis; Rattus; Recovery; Regulation; Reporting; Research; Research Personnel; Resources; response; Role; Signal Transduction; small molecule; targeted treatment; Therapeutic; therapeutic development; Therapeutic Studies; therapeutic target; Training; Transcript; Transforming Growth Factor beta; Translating; Translational Research; Translations; treatment response; ,Overcoming barriers to F508del CFTR correction,140190,MCBS,NHLBI Mentored Clinical and Basic Science Review Committee ,,,1,155800,12464,168264,
9440304,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300002-1,NIEHS:968248\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14576287; ,"WAGNER, DAVID ;",,6/1/2016,5/31/2017,Clinical; Clinical Research; Clinical Trials; Code; Collection; computer program; Computers; Contractor; Contracts; Data; Data Analytics; Data Collection; data management; Databases; Ensure; Human; human subject protection; Maintenance; member; multidisciplinary; National Institute of Environmental Health Sciences; Participant; Patients; Preparation; Procedures; quality assurance; Quality Control; Reporting; Research; Research Project Grants; Running; Sampling; Services; Site; System; Training; Work; ,IGF::OT::IGF Task Order 2 to Clinical Support Services for NIEHS,,,,,,,,,968248,
9446862,N01,AI,,N,,,,,N01AI000000,,,272201200005I-7-27200001-1,NIAID:2114\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12577149; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; novel vaccines; Office of Administrative Management; pathogen; Phase; product development; Services; Toxicology; United States Food and Drug Administration; Vaccines; ,Task X1: Manufacture and Characterization Services for Vaccines and Biologics,,,,,,,,,2114,
9446863,N01,AI,,N,,,,,N01AI000000,,,272201600002C-5-0-1,NIAID:2086921\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SALT LAKE CITY,UNITED STATES,,2,556915205,US,3190601,"BIOFIRE DEFENSE, LLC.",UT,84107,,14369300; ,"PHILLIPS, CYNTHIA ;",,11/10/2015,3/14/2018,Advanced Development; Anthrax disease; Bacteria; Categories; Communicable Diseases; Development; Diagnostic; Ebola virus; Francisella tularensis; next generation; Parasites; Translational Research; Virus; ,Advanced Development of Multiplex Diagnostic Platforms for Infectious Diseases ,,,,,,,,,2086921,
9451482,N01,HD,,N,,,,,N01HD000000,,,275201300026I-0-27500014-1,NICHD:202862\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14959299; ,"GORE-LANGTON, ROBERT ;",,3/6/2017,11/5/2017,3-Dimensional; Biometry; Body Composition; body volume; Catalogs; cohort; Data; Data Coordinating Center; Database Management Systems; Discipline of obstetrics; Disease; Fatty acid glycerol esters; fetal; Fetal Growth; Gravid; Gravidity; Healthcare; Image; Measurement; National Institute of Child Health and Human Development; Online Systems; population health; Pregnancy; Pregnant Women; Research; research study; Services; subcutaneous; Technology; Thinness; Twin Multiple Birth; two-dimensional; Ultrasonography; Visceral; ,DATA COORDINATING CENTER FOR THE 3-D FETAL GROWTH STUDY,,,,,,,,,202862,
9451981,N01,HD,,N,,,,,N01HD000000,,,275201400003I-1-27500015-1,NICHD:60674\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14438413; ,"MANDACI, OGUZ ;",,2/26/2017,2/25/2018,Biochemical Markers; Birth; Blood; Body Weight; Cardiovascular Diseases; cohort; Complications of Diabetes Mellitus; Denmark; Development; Diabetes Mellitus; diet and exercise; Genetic; Gestational Diabetes; Life Style; lifestyle factors; Medical; Non-Insulin-Dependent Diabetes Mellitus; Nurses' Health Study; Participant; Pregnancy Complications; Pregnancy Histories; repository; Risk; Saliva; Services; Sleep; Specimen; Structure of nail of toe; Urine; Woman; Women's Health; ,REPOSITORY SERVICES FOR DIABETES AND WOMEN'S HEALTH STUDY (DWH) SPECIMENS ,,,,,,,,,60674,
9452856,N01,DA,,N,,,,,N01DA000000,,,271201500023C-4-0-2,NIDA:1767905\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,UNIVERSITY,UNITED STATES,,1,67713560,US,5390301,UNIVERSITY OF MISSISSIPPI,MS,386770907,,14463710; ,"MAHMOUD A., ELSOHLY ;",,3/23/2015,3/22/2018,Authorization documentation; Cannabidiol; Cannabinoids; Cannabis; Cigarette; Contracts; Harvest; Marijuana; Methods; National Institute of Drug Abuse; Pharmaceutical Preparations; Plants; Process; Production; programs; Research; Research Personnel; Research Support; Standardization; Tetrahydrocannabinol; ,"IGF::OT::IGF : Production, Analysis, and Distribution of Cannabis and Related Materials. March 23, 2015 - March 22, 2018. N01DA-15-7793. ",,,,,,,,,1767905,
9457275,N01,AI,,N,,,,,N01AI000000,,,272201000039I-1-27200019-1,NIAID:4926\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14708071; ,"MORREY, JOHN ;",,9/15/2016,9/14/2017,Animal Model; Avian Influenza; Contracts; Development; efficacy testing; Human; infectious disease model; Influenza; Influenza A virus; Influenza B Virus; Influenza Therapeutic; mouse model; pandemic disease; Research; seasonal influenza; Standardization; therapeutic evaluation; ,Task A99: Mouse Models for Evaluation of Therapeutics against Human Seasonal Influenza and Avian Influenza Strains with Pandemic Potential,,,,,,,,,4926,
9459269,N01,ES,,N,,,,,N01ES000000,,,273201600015U-2-0-2,NIEHS:791829\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,14505712; ,"BURCH, DAVID ;",,4/21/2016,4/20/2017,Address; base; Carcinogens; Contractor; Data; Educational workshop; Epidemiology; Evaluation; hazard; Health Hazards; Information Management; interest; Literature; Logistics; Malignant Neoplasms; meetings; National Toxicology Program; Public Health; Reporting; Research; Source; symposium; systematic review; Technical Expertise; Toxicology; United States; webinar; ,Scientific Information Management and Literature-Based Evaluations for the National Toxicology Program (NTP) ? Support for the DNTP Office of the Report on Carcinogens,,,,,,,,,791829,
9459805,N01,DA,,N,,,,,N01DA000000,,,271201400035C-8-0-2,NIDA:960399\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,RICHMOND,UNITED STATES,,3,105300446,US,353201,VIRGINIA COMMONWEALTH UNIVERSITY,VA,232980568,,14498598; ,"BEARDSLEY, PATRICK ;",,8/29/2014,7/9/2018,addiction; Clinical Trials; cocaine relapse prevention; Contracts; Data; Development; drug of abuse; Evaluation; in vivo; method development; Modeling; National Institute of Drug Abuse; Pharmaceutical Preparations; Pharmacotherapy; preclinical safety; programs; protocol development; Rattus; Relapse; Rodent; Testing; ,IGF::OT::IGF Medication Discovery Using Rat Models of Relapse; POP 8/29/2014-7/9/2017; FY16 N01DA-14-8917,,,,,,,,,960399,
9459806,N01,AI,,N,,,,,N01AI000000,,,272201400007C-7-0-1,NIAID:2787937\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,12651358; ,"ROTHMAN, RICHARD ;",,4/1/2014,3/31/2021,Basic Science; Clinical; Development; Government; improved; Influenza; influenza outbreak; influenza surveillance; Institution; Link; Medical; pandemic disease; pandemic influenza; Pathway interactions; Public Health; Public Health Practice; Research; seasonal influenza; Virus; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,2787937,
9460333,N01,AI,,N,,,,,N01AI000000,,,272201300019C-12-0-1,NIAID:2034475\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MALVERN,UNITED STATES,,6,962754037,US,10026839,"VENATORX PHARMACEUTICALS, INC.",PA,193551200,,12577025; ,"XERRI, LUIGI ;",,9/16/2013,6/30/2018,Advanced Development; Bacterial Drug Resistance; Development; Gram-Negative Bacteria; Klebsiella pneumonia bacterium; Medical; pre-clinical; product development; research and development; Support Contracts; therapeutic candidate; therapeutic development; ,Development of Therapeutic Medical Countermeasures ,,,,,,,,,2034475,
9460334,N01,AI,,N,,,,,N01AI000000,,,272201300019C-12-0-2,NIAID:1017237\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MALVERN,UNITED STATES,,6,962754037,US,10026839,"VENATORX PHARMACEUTICALS, INC.",PA,193551200,,14588796; ,"XERRI, LUIGI ;",,9/16/2013,6/30/2018,Advanced Development; Bacterial Drug Resistance; Burkholderia pseudomallei; Development; Gram-Negative Bacteria; Medical; pre-clinical; product development; research and development; Support Contracts; therapeutic candidate; therapeutic development; ,Development of Therapeutic Medical Countermeasures,,,,,,,,,1017237,
9463402,N01,AI,,N,,,,,N01AI000000,,,272201200005I-2-27200007-1,NIAID:137529\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12445111; ,"RICHARDSON, JAMES ;",,5/6/2014,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Malaria Vaccines; novel vaccines; pathogen; Phase; product development; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X7: Malaria Vaccines Stability Study,,,,,,,,,137529,
9463404,N01,AI,,N,,,,,N01AI000000,,,272201100019I-1-27200018-1,NIAID:9782\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14751002; ,"SMEE, DONALD ;",,9/16/2016,9/15/2017,antimicrobial; Antiviral Agents; In Vitro; meetings; programs; screening; Support Contracts; Testing; Viral; ,TASK B24: Comprehensive Viral Screening Panel,,,,,,,,,9782,
9463737,N01,AI,,N,,,,,N01AI000000,,,272201400008C-12-0-2,NIAID:4138539\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,13,78861598,US,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NY,100296574,,14476472; ,"GARCIA-SASTRE, ADOLFO ;",,4/1/2014,3/31/2021,Animals; Avian Influenza; Environmental Risk Factor; Evolution; Immune; Immune response; improved; Influenza; influenzavirus; Molecular; pandemic disease; Pathogenicity; Research; transmission process; Vaccine Research; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,4138539,
9463738,N01,HD,,N,,,,,N01HD000000,,,275201400013C-6-0-1,NICHD:873466\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,STONY BROOK,UNITED STATES,,1,804878247,US,5992612,STATE UNIVERSITY NEW YORK STONY BROOK,NY,117943362,,12644423; ,"BELL, ERIN ;",,9/15/2015,1/14/2018,6 year old; 8 year old; abdominal fat; Adolescence; Affect; Age; Assisted Reproductive Technology; Award; Biolectric Impedance; Blood; Blood Pressure; cardiometabolic risk; cardiovascular risk factor; Cause of Death; Charge; Child; Child health care; Childhood; Clinic; Clinic Visits; Clinical; cohort; computerized data processing; Conceptions; Conflict (Psychology); Contracts; Data; Data Coordinating Center; Databases; Dehydroepiandrosterone Sulfate; Diastolic blood pressure; DNA Methylation; early childhood; Epigenetic Process; epigenome; Exposure to; Fertilization in Vitro; follow-up; Generations; Growth; health difference; Height; High Density Lipoproteins; Home environment; In Vitro; Infant Development; infertility treatment; interest; Intracytoplasmic Sperm Injections; Journals; Laboratories; Lipids; Measurement; Measures; Monitor; Mothers; New York; Newborn Infant; Obesity; Ovarian; Ovulation; Ovulation Induction; Parents; Participant; pediatrician; Physicians; Process; programs; Puberty; Public Health; Questionnaires; Recruitment Activity; Reporting; Risk; Risk Assessment; Risk Factors; Saliva; Salivary; Sampling; screening; Site; Specimen; Spottings; Standardization; Subgroup; Testing; Time; Training; treatment effect; Triceps Brachii Muscle; Twin Multiple Birth; Visit; waist circumference; Weights and Measures; ,CARDIOVASCULAR RISK IN CHILDREN CONCEIVED BY ART,,,,,,,,,873466,
9467407,N01,AI,,N,,,,,N01AI000000,,,272201600016C-2-0-1,NIAID:1446838\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,14620060; ,"ISON, MICHAEL ;",,7/1/2016,6/30/2021,Address; Adult; Advanced Development; Caliciviridae; Calicivirus; Clinical Course of Disease; Clinical Research; Medical; Norovirus; patient population; Research; Therapeutic; therapeutic development; Transplant Recipients; Virus Diseases; ,TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS,,,,,,,,,1446838,
9471297,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-13,NIEHS:421167\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Address; Breathing; carcinogenicity; Data; Dermal; design; drinking water; Exposure to; feeding; Future; Goals; Health; Life; Phase; Play; Poisons; Public Health; Research Personnel; Route; Rubber; Toxic effect; Toxicology; Work; ,Conduct of benchtop and in life studies to evaluate systemic exposure and feasibility of conducting toxicity studies by multiple routes  ,,,,,,,,,421167,
9471636,R13,HD,2,N,12/28/2017,12/1/2017,11/30/2018,865,R13HD038685,SCHOOLS OF ARTS AND SCIENCES,PA-16-294,2R13HD038685-14,NICHD:10794\NIDCD:3000\,OTHER RESEARCH-RELATED,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MADISON,UNITED STATES,ZOOLOGY,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,1926458; ,"HALLORAN, MARY C;","TOYAMA, REIKO",4/18/2000,11/30/2022,3-Dimensional; Alleles; Animal Model; base; Biological Models; body system; Cancer Model; career; Cells; Chemicals; Collaborations; Communication; Communities; Congenital Abnormality; CRISPR/Cas technology; Data; Development; developmental disease/disorder; Developmental Process; Disease; Disease model; Dissection; Embryo; Epitopes; Etiology; Faculty; Failure; Financial Support; forging; Fostering; Future; Gender; Generations; Genes; Genetic; genetic analysis; genome editing; Goals; Grant; Growth; Human; human disease; Image; Imagery; imaging modality; Inflammatory; insertion/deletion mutation; interest; International; Investigation; Malignant Neoplasms; meetings; Mental disorders; Metabolic Diseases; Metabolism; Methodology; Methods; Microscopic; model development; Modeling; Molecular; Mutation; Natural regeneration; Nerve Degeneration; neural circuit; new technology; novel; Optics; optogenetics; Organ; Organism; originality; Pathway interactions; Physiology; Postdoctoral Fellow; Process; Proteins; Race; Research; Research Personnel; research study; Resolution; Resources; reverse genetics; Science; screening; senior faculty; Series; Students; success; symposium; Technology; Therapeutic Agents; Time; Tissues; tool; transcription activator-like effector nucleases; Transgenic Organisms; Vertebrates; virtual; Walkers; Zebrafish; zebrafish development; zebrafish genome; zinc finger nuclease; ,Zebrafish Development and Genetics Conference,38685,CHHD,Biobehavioral and Behavioral Sciences Subcommittee ,,,14,13794,0,13794,
9474076,N01,AI,,N,,,,,N01AI000000,,,272201300002I-6-27200002-1,NIAID:307005\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12445107; ,"PAL, RANAJIT ;",,5/1/2013,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Caring; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; vaccine trial; Vaccines; ,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,,,,,,,,,307005,
9475640,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200005-3,NIAID:87209\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,4/21/2017,11/30/2017,Categories; Communicable Diseases; Contracts; Development; Intervention; National Institute of Allergy and Infectious Disease; Organism; pre-clinical; programs; Services; therapeutic evaluation; therapy development; Translational Research; ,Task Order 5: The Interventional Agent Development Services Program,,,,,,,,,87209,
9476858,N01,ES,,N,,,,,N01ES000000,,,273201600011C-1-0-1,NIEHS:385391\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,15232079; ,"SMITH, MARJO ;",,4/25/2016,4/24/2018,Animal Experiments; Area; computer program; Contractor; Contracts; Data; Data Analyses; Development; Experimental Designs; Intramural Research; Laboratories; laboratory experiment; mathematical model; Molecular; National Institute of Environmental Health Sciences; programs; Research; Research Design; Research Personnel; Sample Size; Services; Statistical Methods; Statistical Models; Surveys; Writing; ,"Statistical Support Services for NIEHS within DIR and DNTP, Subproject: Support for DIR",,,,,,,,,385391,
9478002,N01,HD,,N,,,,,N01HD000000,,,275201300016C-11-0-1,NIAAA:1282365\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ARLINGTON,UNITED STATES,,8,96356431,US,1379501,"CSR, INC.",VA,222013091,,14270615; ,"CASTLE, I-JEN ;",,9/27/2013,4/30/2018,Acute; Alcohol abuse; Alcohol consumption; alcohol effect; alcohol related problem; Alcoholism; Alcohols; Area; Area Analyses; Behavior; Behavioral; Benefits and Risks; Characteristics; Charts and Tables; Chronic; Contractor; Contracts; Country; Data; Data Analyses; Data Collection; data collection methodology; Data Set; Databases; Descriptor; Directories; disability-adjusted life years; driving under influence; epidemiologic data; Epidemiology; follow-up; Funding; Genetic; Graph; Health; health disparity; Health Personnel; Health Status; Information Systems; Institution; International; Lead; Leadership; Link; Manuals; Methods; Morbidity - disease rate; mortality; National Institute on Alcohol Abuse and Alcoholism; Nature; Neurosciences; Phase; Preparation; Prevention; Process; Production; program dissemination; programs; Publications; Recommendation; Reporting; Research; research data dissemination; Research Institute; Research Personnel; Research Support; Review Literature; Risk; Risk Factors; Sampling; secondary analysis; Surveys; Translating; trend; United States Dept. of Health and Human Services; United States National Institutes of Health; Validity and Reliability; web site; Work; ,Alcohol Epidemiologic Data System (AEDS),,,,,,,,,1282365,
9478635,N01,CA,,N,,,,,N01CA000000,,,261201300017I-4-26100005-3,NCI:30500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,14512953; ,"SWEENEY, CAROL ;",,5/1/2015,4/30/2018,cost effective; Data; Ensure; Goals; Insurance; Laws; Malignant Neoplasms; Medical; Modification; Newly Diagnosed; oncology; Recruitment Activity; Research Infrastructure; SEER Program; System; Testing; ,"IGF::OT::IGF  CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)",,,,,,,,,30500,
9478641,N01,CA,,N,,,,,N01CA000000,,,261201300015I-4-26100006-2,NCI:30500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12684309; ,"WARD, KEVIN ;",,5/1/2015,4/30/2018,Cancer Patient; Data; design; Goals; Incidence; Malignant Neoplasms; Medical; Medical Oncology; Pilot Projects; Process; Registries; Reporting; Research Infrastructure; SEER Program; ,IGF::OT::IGF SEER CORE INFRASTRUCTURE: CANCER SURVEILLANCE INCIDENCE AND TREATMENT REPORTING FROM MEDICAL CLAIMS; GEORGIA PILOT,,,,,,,,,30500,
9478642,N01,CA,,N,,,,,N01CA000000,,,261201300015I-4-26100006-3,NCI:2226115\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14512945; ,"WARD, KEVIN ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF  CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) POP MAY 1, 2015 THROUGH APRIL 30, 2017",,,,,,,,,2226115,
9478659,N01,AI,,N,,,,,N01AI000000,,,272201500005C-8-0-1,OD:1380245\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,78829605,US,10034379,"LIGNAMED, LLC",PA,191042853,,14083437; ,"HARRIS, JIM ;",,6/1/2015,5/31/2018,Animal Model; Animals; Chemicals; Chest; Clinical; Contracts; Development; Drug Kinetics; Exposure to; Goals; Hour; in vivo; Inflammatory; Injury; Ionizing radiation; Lung; lung injury; Medical; Morbidity - disease rate; Nuclear; Nuclear Radiology; Oral; Pharmacodynamics; Pre-Clinical Model; Preclinical Testing; Process; Property; Radiation; Radiology Specialty; Research Support; Structure of parenchyma of lung; Therapeutic; Tissues; ,DEVELOPMENT OF MEDICAL COUNTERMEASURES TO MITIGATE AND/OR TREAT RADIATION-INDUCED LUNG INJURY AFTER A RADIOLOGICAL/NUCLEAR INCIDENT,,,,,,,,,1380245,
9478663,N01,AI,,N,,,,,N01AI000000,,,272201500006C-2-0-1,NIAID:1437196\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,AMHERST,UNITED STATES,,26,38633251,US,5992614,STATE UNIVERSITY OF NEW YORK AT BUFFALO,NY,14228,,14134188; ,"MORSE, EUGENE ;",,5/30/2015,5/29/2018,Award; Biological Assay; Clinical Pharmacology; Clinical Research; clinical research site; Clinical Trials Network; computerized; Data; Development; Enrollment; Ensure; Future; HIV; Laboratories; Measures; Methods; Monitor; National Institute of Allergy and Infectious Disease; Performance; Pharmaceutical Preparations; Pharmacology; Pharmacology Study; Preventive measure; programs; quality assurance; Quality Control; Reagent; Sampling; Specific qualifier value; Specimen; System; Testing; Validation; ,CLINICAL PHARMACOLOGY QUALITY ASSURANCE,,,,,,,,,1437196,
9478816,N01,HL,,N,,,,,N01HL000000,,,268201300049C-7-0-1,NCMHD:750000\NHLBI:220140\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,JACKSON,UNITED STATES,,2,44507085,US,692401,JACKSON STATE UNIVERSITY,MS,39217,,12255149; ,"GATES, MICHAEL ;",,8/16/2013,8/12/2018,Abdomen; African American; Ancillary Study; Aorta; Area; Back; Biochemical; Biological; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; career; Clinical; cohort; Cohort Studies; Collection; Communities; Community Health Education; Community Outreach; Contracts; Data; Data Analyses; Disease; disorder risk; Echocardiography; Epidemiology; Event; follow-up; Funding; graduate student; Health Professional; Health Promotion; healthy lifestyle; heart imaging; High School Student; Hospitalization; improved; Institution; interest; Interview; Investigation; Jackson Heart Study; Magnetic Resonance Imaging; Manuscripts; Measures; Minority; minority student; Mississippi; Morbidity - disease rate; mortality; Outpatients; Participant; Prevention; Public Health; public health research; Publications; Recruitment Activity; Research Personnel; Resources; Risk; Risk Factors; Sampling; Services; Site; socioeconomics; Testing; Time; Training; Training and Education; Training Programs; undergraduate student; Validation; Visit; X-Ray Computed Tomography; ,IGF::OT::IGF Jackson Heart Study Renewal Graduate Training and Education Center a,,,,,,,,,970140,
9480906,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500023-1,NICHD:2159\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15025273; ,"MANDACI, OGUZ ;",,3/23/2017,3/22/2018,Asthma; Cells; Collection; Knowledge; Predictive Factor; Pregnancy; pregnancy immunology; repository; RNA; Sampling; Ships; Testing; ,REPOSITORY PULL FOR ASTHMA RNA,,,,,,,,,2159,
9483241,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-11,NIAID:1157325\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; , MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,1157325,
9483243,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-13,NIAID:462930\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Ebola virus; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; , MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,462930,
9487082,N01,AI,,N,,,,,N01AI000000,,,272201500011C-5-0-2,NIAID:239962\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,809832558,US,10018550,"KINETA, INC.",WA,981095230,,14524137; ,"IADONATO, SHAWN ;",,6/30/2015,7/31/2017,Clinical; clinical development; Communicable Diseases; Dengue; drug candidate; Future; In Vitro; in vivo; infectious disease treatment; Lead; novel; Pharmaceutical Chemistry; pre-clinical; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases ,,,,,,,,,239962,
9492480,N01,AI,,N,,,,,N01AI000000,,,272201400055C-9-0-1,NIAID:2513447\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PORTLAND,UNITED STATES,,3,96997515,US,6297007,OREGON HEALTH & SCIENCE UNIVERSITY,OR,972393098,,12440432; ,"NELSON, JAY ;",,9/30/2016,9/29/2018,adaptive immune response; Adjuvant; Animal Model; Antiviral Agents; Cells; Computer Simulation; Contractor; Dendritic Cells; Dengue Virus; dimer; Dimerization; Emerging Communicable Diseases; Formulation; high throughput screening; Human; human disease; immunogenicity; Immunologic Adjuvants; Immunologic Factors; in vivo; Interferons; IRF1 gene; IRF3 gene; Japanese encephalitis virus; Lead; Libraries; National Institute of Allergy and Infectious Disease; novel; pathogen; Pharmaceutical Chemistry; programs; receptor; Research; RNA Viruses; Signal Pathway; Signaling Molecule; small molecule; small molecule libraries; Structure-Activity Relationship; Study models; Testing; Therapeutic; Vaccine Adjuvant; vaccine candidate; Vaccines; Validation; West Nile virus; Work; Zika Virus; ,"Targeting IRFs for Immune Adjuvant Enhancement of Vaccine Immunogenicity in West Nile Virus, Dengue Virus, Zika and Japanese Encephalitis Virus vaccines",,,,,,,,,2513447,
9495650,N01,ES,,N,,,,,N01ES000000,,,273201300009C-6-0-1,NIEHS:966181\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE PARK,UNITED STATES,,4,130427701,US,1933801,"INTEGRATED LABORATORY SYSTEMS, INC.",NC,277093501,,12386542; ,"RECIO, LES ;",,9/19/2013,6/5/2018,Anabolism; Animal Model; Animal Testing; Animals; base; Biological Assay; Biological Monitoring; Blood specimen; Brain; cancer risk; carcinogenicity; Cells; Chemicals; Clinical; Clinical Research; Collaborations; Comet Assay; Contracts; cost; Data; Data Set; Databases; Disease; DNA Damage; Environmental Exposure; Environmental Hazards; Erythrocytes; Event; exposed human population; Exposure to; Family suidae; Frequencies; Future; Genes; Genetic; genetic profiling; genotoxicity; Goals; Guidelines; Health; Heritability; Human; human study; In Vitro; in vivo; innovation; interest; International; Kidney; Laboratories; Leadership; Liver; Lung; Methods; micronucleus; Micronucleus Tests; Mission; Mitochondrial Diseases; Modeling; Molecular; Mouse Strains; Mus; Mutagenicity Tests; Mutation; National Institute of Environmental Health Sciences; Neurodegenerative Disorders; Outcome; peripheral blood; PI-Glycan; Population; Protocols documentation; Rattus; reproductive; Research Design; Research Personnel; response; Rodent; Sampling; Services; Source; Sprague-Dawley Rats; Stomach; Study models; Study Subject; System; Testing; Tissues; Toxic effect; Toxicity Tests; Toxicogenetics; Toxicology; Translating; Translations; Update; ,Genetic Toxicity Testing Services for the NTP,,,,,,,,,966181,
9509880,N01,AI,,N,,,,,N01AI000000,,,272201000037I-0-27200002-1,NIAID:775399\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALBUQUERQUE,UNITED STATES,,1,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,,14972585; ,"WU, TERRY ;",,3/22/2010,3/20/2018,Animal Model; animal model development; Contracts; Development; efficacy testing; Francisella tularensis; infectious disease model; Pulmonary tularemia; Rattus; Standardization; Therapeutic; ,TASK A110: DEVELOPMENT OF THE RAT ANIMAL MODEL FOR PNEUMONIC TULAREMIA,,,,,,,,,775399,
9509956,N01,AI,,N,,,,,N01AI000000,,,272201000039I-0-27200020-1,NIAID:813138\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14922072; ,"MORREY, JOHN ;",,1/11/2017,1/10/2018,Alphavirus; Animal Model; animal model development; Arenaviridae; Arenavirus; biodefense; Bunyaviridae; Contracts; Development; efficacy testing; Flavivirus; infectious disease model; Orthobunyavirus; Standardization; Therapeutic; Vaccines; Virus; ,TASK A105: SMALL ANIMAL MODELS FOR BIODEFENSE VIRUSES,,,,,,,,,813138,
9511680,N01,LM,,N,,,,,N01LM000000,,,276201400009C-6-0-1,NCATS:0\NCCAM:4994\NCI:0\NCMHD:12499\NEI:29175\NHGRI:18207\NHLBI:131983\NIA:0\NIAAA:18328\NIAID:0\NIAMS:0\NIBIB:0\NICHD:0\NIDA:0\NIDCD:17228\NIDCR:15303\NIDDK:83772\NIEHS:0\NIGMS:108697\NIMH:0\NINDS:71635\NINR:0\OD:0\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,LOS ANGELES,UNITED STATES,,,78547071,US,,,CA,900141790,,12348570; ,"SHUKLA, ROHIT ;",,7/8/2017,7/7/2018,commercialization; programs; ,IGF::OT::IGF- Commercialization Assistance Program,,,,,,,,,511821,
9511959,N01,HL,,N,,,,,N01HL000000,,,268201700009C-0-0-1,NHLBI:405821\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BRANFORD,UNITED STATES,,3,79635309,US,10038300,"VASCUMAB, LLC",CT,64052904,,14921928; ,"DA SILVA JARDIN, PAUL ;",,11/15/2016,5/14/2018,Aortic Aneurysm; Area; clinical candidate; Coronary Arteriosclerosis; Development; Disease; Dissection; Drug Kinetics; HDAC4 gene; Heart; Heart failure; Histone Deacetylase Inhibitor; Hypertension; Hypoxia; inhibitor/antagonist; interest; intracranial artery; Lead; Lymphatic Diseases; Lymphatic System; Modeling; Monocrotaline; Oral; Peripheral arterial disease; product development; programs; pulmonary arterial hypertension; Pulmonary artery structure; Pulmonary Hypertension; pulmonary vascular disorder; Rattus; Side; Smooth Muscle Myocytes; SU 5416; Thrombosis; Toxicology; Vascular Diseases; Venous; Work; ,IGF::OT::IGF HDAC INHIBITORS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - VITA 2,,,,,,,,,405821,
9513369,N01,DA,,N,,,,,N01DA000000,,,271201600004I-1-27100001-1,NINDS:43951\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14628373; ,"KRYSTAL, ANDREW ;",,7/1/2017,6/30/2018,Area; Clinical; Development; operation; Phase I Clinical Trials; ,IGF::OT::IGF TASK ORDER #001 - PERFORMANCE AREA A - ADMINISTRATIVE AND OVERALL CLINICAL OPERATIONS SUPPORT,,,,,,,,,43951,
9515631,N01,HD,,N,,,,,N01HD000000,,,275201300020I-4-27500001-1,NICHD:10303\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PHILADELPHIA,UNITED STATES,,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,2086069; ,"BARNHART, KURT T;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,10303,
9519627,N01,AI,,N,,,,,N01AI000000,,,272201600008I-1-27200001-1,NIAID:763839\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14636867; ,"PAL, RANAJIT ;",,7/15/2016,7/14/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Clinical Trials; Contracts; Development; HIV; HIV Infections; Licensure; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; quality assurance; Quality Control; research clinical testing; Resources; Role; sexual HIV transmission; Technology; United States National Institutes of Health; Work; ,QUALITY ASSURANCE/ QUALITY CONTROL (QA/QC),,,,,,,,,763839,
9520749,N01,AI,,N,,,,,N01AI000000,,,272201200003I-0-27200021-1,NIAID:274639\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15078151; ,"HORNBACK, RANDI ;",,7/1/2017,6/30/2019,antimicrobial; Antimicrobial Resistance; assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; National Institute of Allergy and Infectious Disease; novel vaccines; pathogen; Phase; product development; Readiness; Safety; safety testing; Sampling; Services; Testing; Toxicity Tests; Toxicology; vaccine development; Vaccines; ,Task X21: Preparedness for Testing NIAID Priority Vaccines in General Safety and Toxicology Studies,,,,,,,,,274639,
9521486,N02,CA,,N,,,,,N02CA000000,,,261201100046C-15-0-2,NCI:4744035\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,14197415; ,"WHITE, JONATHAN ;",,9/1/2011,7/31/2018,Chemistry; Chemopreventive Agent; Human; Human Papilloma Virus Vaccine; Performance; Pharmaceutical Preparations; repository; stability testing; Vaccines; ,IGF::OT::IGF Centralized Chemopreventive Agent Repository and Drug Chemistry SupportPeriod of Performance 09/01/2011 - 03/28/2016.,,,,,,,,,4744035,
9521674,N01,DA,,N,,,,,N01DA000000,,,316201200037W-0-0-1,NIAMS:0\NICHD:179004\NIEHS:0\NIMH:6797446\NINDS:0\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,,,,,,,,"OMNITEC SOLUTIONS, INC",,,,14162707; ,"HALL, DAN ;",,7/1/2017,6/30/2018,Affect; Archives; autism spectrum disorder; Autistic Disorder; biomedical informatics; Brain Diseases; Data; Data Collection; Databases; Diagnosis; flexibility; Genetic; interest; operation; Persons; Prevention; repository; Research; Retrieval; Series; System; United States National Institutes of Health; ,SUPPORT THE ONGOING OPERATIONS OF THE NATIONAL DATABASE FOR AUTISM RESEARCH - NDAR,,,,,,,,,6976450,
9521689,N01,HL,,N,,,,,N01HL000000,,,268201600011I-1-26800001-1,NHLBI:173320\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DUARTE,UNITED STATES,,32,27176833,US,3058203,BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,910103012,,14658125; ,"SHAW, MICHAEL ;",,8/1/2016,6/30/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities,,,,,,,,,173320,
9522277,N01,AI,,N,,,,,N01AI000000,,,272201100009I-0-27200005-1,NIAID:638080\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,809846819,US,3125901,INFECTIOUS DISEASE RESEARCH INSTITUTE,WA,981023788,,14922081; ,"PARISH, TANYA ;",,11/4/2016,10/31/2017,antimicrobial; Biological Assay; Contracts; Growth; In Vitro; in vitro testing; mycobacterial; Mycobacterium tuberculosis; screening; Services; Testing; therapeutic evaluation; ,TASK A27: In Vitro Characterization Of Antimicrobial Activity,,,,,,,,,638080,
9523040,N01,HL,,N,,,,,N01HL000000,,,268201700006C-0-0-1,NHLBI:318434\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHICAGO,UNITED STATES,,7,98987217,US,577703,UNIVERSITY OF ILLINOIS AT CHICAGO,IL,606127224,,14921919; ,"MACHADO, ROBERTO ;",,11/15/2016,11/14/2019,Adverse effects; Aortic Aneurysm; Area; Clinical; clinical effect; Coronary Arteriosclerosis; design; Development; Disease; Dissection; inhibitor/antagonist; interest; intracranial artery; Lymphatic Diseases; Lymphatic System; nicotinamide phosphoribosyltransferase; Peripheral arterial disease; Pharmaceutical Preparations; product development; programs; pulmonary arterial hypertension; Pulmonary Hypertension; pulmonary vascular disorder; Research; targeted agent; Thrombosis; Vascular Diseases; Venous; ,IGF::OT::IGF - DEVELOPMENT OF NAMPT INHIBITORS TO TREAT PULMONARY ARTERIAL HYPERTENSION,,,,,,,,,318434,
9525657,N01,HD,,N,,,,,N01HD000000,,,275201300003I-4-27500001-1,NICHD:8636\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,AURORA,UNITED STATES,,6,41096314,US,1199905,UNIVERSITY OF COLORADO DENVER,CO,800452571,,12445701; ,"TEAL, STEPHANIE ;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,8636,
9525753,N01,HD,,N,,,,,N01HD000000,,,275201300002I-5-27500001-1,NICHD:12760\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,NEW YORK,UNITED STATES,,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,100101710,,12445703; ,"WAN, LIVIA ;",,6/26/2017,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; Contraceptive methods; Contracts; Devices; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Lead; Leiomyoma; Methods; Mission; National Institute of Child Health and Human Development; Obesity; Pharmaceutical Preparations; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; Protocols documentation; Reproductive Health; Risk; Safety; synthetic peptide; Testing; Thromboembolism; unintended pregnancy; United States National Institutes of Health; Venous; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,12760,
9594387,N01,DA,,N,,,,,N01DA000000,,,271201200002I-0-27100008-1,NIA:160968\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,8,556875508,US,2768901,"KAI RESEARCH, INC",MD,208523003,,15198411; ,"SZENTENDREI, TIBOR ;",,8/30/2017,12/31/2017,,'IGF::OT::IGF',,,,,,,,,160968,
8929925,H79,HH,5,N,9/14/2015,9/30/2015,9/29/2016,239,H79AE000100,,RFA-HS-11-023,5H79AE000100-05,,OTHERS,2015,DEPARTMENT OF HEALTH & HUMAN SERVICES,,DAVIS,UNITED STATES,,3,47120084,US,577503,UNIVERSITY OF CALIFORNIA AT DAVIS,CA,956186153,,11105069; ,"STEVENS, ANN ;",,9/30/2011,9/29/2016,,"University of California, Davis Poverty Research Center",100,SRC,Special Emphasis Panel ,,,5,,,,
9412468,R13,EY,5,N,12/25/2017,12/1/2017,11/30/2018,867,R13EY026323,,PA-13-347,5R13EY026323-03,NEI:12499\,OTHER RESEARCH-RELATED,2018,NATIONAL EYE INSTITUTE,,WEST KINGSTON,UNITED STATES,,2,75712877,US,2988701,GORDON RESEARCH CONFERENCES,RI,28921502,,1923376; ,"FOREST, KATRINA T;","ARAJ, HOUMAM H",12/1/2015,11/30/2018,Area; Asia; Bacteria; Behavior Disorders; Biological Neural Networks; Biological Process; Biology; Biomedical Research; Biotechnology; career development; Clinical; Collaborations; Communities; Development; Din Nation; Discipline; Engineering; Ensure; Europe; Faculty; frontier; fungus; Gene Expression; graduate student; interest; International; Italy; Laboratory Organism; Mammals; man; meetings; Mentors; Methodology; Microbe; Molecular; multidisciplinary; Nature; neurotransmission; new technology; Oceania; Operating System; Optics; optogenetics; Oral; Participant; Pathogenicity; Photobiology; Photoreceptors; photosystem; plant growth/development; Plants; Postdoctoral Fellow; posters; programs; public health relevance; Receptor Signaling; Renaissance; Research; Research Personnel; Resort; Science; Scientist; Senior Scientist; Sensory; Series; Signal Transduction; Site; social; Socialization; South America; Students; symposium; System; Talents; Techniques; Technology; Texas; Time; tool; Vision; ,2016/2018 Photosensory Receptors & Signal Transduction Gordon Research Conference & Gordon Research Seminar,26323,ZEY1,Special Emphasis Panel ,,,3,12499,,12499,
9430031,N01,AI,,N,,,,,N01AI000000,,,272201000013I-3-27200002-1,NIAID:100000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SALISBURY,UNITED KINGDOM,,,233388961,UK,10007041,PUBLIC HEALTH ENGLAND,,,,14922054; ,"CARROLL, MILES ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,Animal Models for Infectious Diseases Support,,,,,,,,,100000,
9430041,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-6,NIAID:214457\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Chemistry; Communicable Diseases; Development; drug candidate; drug development; Intervention; Lead; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Services; therapeutic development; therapy development; Translational Research; Yellow fever virus; ,Task Order 2: The Interventional Agent Development Services Program,,,,,,,,,214457,
9430054,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-8,NCI:4174882\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Antineoplastic Agents; Biological Assay; Biology; cancer cell; Cancer cell line; Chemicals; Crude Extracts; Developmental Therapeutics Program; drug development; drug discovery; Extramural Activities; in vivo; interest; Laboratories; Lead; Location; Malignant Neoplasms; Marine Invertebrates; Microbe; Molecular Target; Natural Products; Plants; Preparation; Process; Production; Quality Control; Ramp; Sampling; small molecule; Source; Structure; Work; ,DCTD Natural Products Extraction,,,,,,,,,4174882,
9430059,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-15,NCI:16789928\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Academia; Address; analog; Antineoplastic Agents; Area; Award; Biological; Biological Assay; Biology; Biotechnology; bone; Businesses; cancer diagnosis; cancer therapy; Charge; Chemicals; Chemistry; Clinic; Clinical; clinical application; clinical candidate; Clinical Research; Clinical Trials; Complex; Contracts; Data; design; Development; Developmental Therapeutics Program; drug development; drug discovery; Drug Discovery Groups; Ensure; Evaluation; experience; flexibility; Funding; Generations; Goals; Government; Grant; high throughput screening; Human; innovation; Investigation; Investments; Joint Ventures; Joints; Lead; Malignant Neoplasms; Medicine; Mission; Molecular; molecular oncology; Monitor; NCI Center for Cancer Research; New Agents; novel; Office Management; Oncologist; oncology; Oncology Group; Patient Care; personalized therapeutic; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Phenotype; Private Sector; Process; programs; Research; Research Activity; research clinical testing; Research Infrastructure; Research Support; Resource Development; screening; Signal Pathway; Site; small molecule; Structure; Structure-Activity Relationship; Synthesis Chemistry; targeted treatment; Technology; Testing; Therapeutic; therapeutic development; Therapeutic Human Experimentation; tool; Vision; Work; ,DCTD Drug Development Project Management,,,,,,,,,16789928,
9430113,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-76,NCI:5323870\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Back; Bioinformatics; Clinical; Databases; Foundations; Funding; Informatics; open source; Research; Research Infrastructure; Resources; Software Tools; Speed; tool; Translational Research; ,Informatics Support at SAIC Frederick,,,,,,,,,5323870,
9430149,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-115,NCI:10438590\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,,NCI Cancer Genomics Commons,,,,,,,,,10438590,
9430160,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-128,NCI:1400000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Advanced Development; Area; Data; design; Explosion; Generations; Genomics; Institutes; Marshal; Methods; Mission; Nanotechnology; Proteomics; Resources; targeted imaging; Technology; ,Strategic Scientific Pilot Support ,,,,,,,,,1400000,
9430167,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-135,NCI:275000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Affective; Behavioral; Behavioral Medicine; Behavioral Research; cancer palliative treatment; Chronic; Clinical Trials; Data Analyses; Diet and Nutrition; Division of Cancer Control and Population Sciences; experimental study; Frequencies; Health Psychology; Hypertension; Intervention; Late Effects; Malignant Neoplasms; Measures; Mental Depression; Methodology; Morbidity - disease rate; Obesity; Palliative Care; Participant; Pilot Projects; prospective; Research; Science; Scientist; sedentary lifestyle; social; Systems Biology; ,DCCPS Behavioral Research ,,,,,,,,,275000,
9430173,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-141,NCI:85436\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Antineoplastic Protocols; Area; Behavior Therapy; Cancer Control; Cancer Patient; cancer prevention; Cancer Survivor; Clinical; Clinical Trials; cohort; community setting; Coupled; Development; digital media; Effectiveness; Ensure; Frequencies; Funding; Guidelines; healthy volunteer; Human; human subject; human subject protection; Institutional Review Boards; Intervention; Investigational New Drug Application; Laws; Malignant Neoplasms; Nature; Office for Human Research Protections; operation; Participant; Phase; Placebo Control; Police; Population; Preventive vaccine; Procedures; Program Effectiveness; programs; Protocols documentation; Quality of life; Regulation; Research; Research Design; Risk; Risk-Benefit Assessment; social media; symptom management; Training; treatment trial; United States Food and Drug Administration; Vulnerable Populations; ,DCP Thought Leaders Program Human Subject Consultant,,,,,,,,,85436,
9430174,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-142,NCI:525000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Acquired Immunodeficiency Syndrome; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Automobile Driving; base; Bioinformatics; Biology; burden of illness; Burkitt Lymphoma; cancer diagnosis; cancer genome; cancer genomics; cancer therapy; Child; Chromosomes; Clinical; cohort; Collaborations; Communities; Data; data access; Data Coordinating Center; Data Display; data portal; Data Set; Detection; Development; diagnostic biomarker; DNA Sequence; DNA Sequence Alteration; effective therapy; Ethics; Event; exome; Face; Family; functional genomics; Future; Gene Expression Profile; Genes; Genetic; genetic profiling; Genome; genome sequencing; Genomic approach; Genomics; Goals; high risk; high throughput screening; HIV; HIV Seropositivity; Human; human tissue; Incidence; Informatics; innovation; insight; Kidney Neoplasms; Lead; Maintenance; Malignant Childhood Neoplasm; Malignant neoplasm of lung; Malignant Neoplasms; medulloblastoma; Methodology; Methods; Methylation; MicroRNAs; Molecular; Molecular Abnormality; Molecular Target; Mutation; Nephroblastoma; Neuroblastoma; new technology; next generation sequencing; Non-Hodgkin's Lymphoma; novel; novel strategies; novel therapeutic intervention; novel therapeutics; operation; osteosarcoma; Pathway interactions; Patients; precision medicine; Prevalence; Prevention; Prognostic Marker; programs; Refractory; Research; Research Infrastructure; Research Personnel; Resolution; Resources; RNA Interference; Role; Sampling; sharing data; small molecule; System; Techniques; Therapeutic; therapeutic target; Time; Tissue Banks; transcriptome sequencing; Translating; Translations; tumor; Tumor Biology; Validation; whole genome; ,OCG Data Coordinating Center,,,,,,,,,525000,
9430193,N02,CA,,N,,,,,N02CM000000,,,261201200012C-24-0-1,NCI:412782\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALACHUA,UNITED STATES,,3,12852344,US,10020711,ALCHEM LABORATORIES CORPORATION,FL,326156687,,14368715; ,"RUDCHENKO, VLADIMIR ;",,5/21/2012,5/20/2017,analog; Analytical Chemistry; Biological; Chemistry; combinatorial; Contracts; Development; drug development; drug discovery; Evaluation; falls; Funding; improved; Lead; Libraries; Literature; Methods; Pharmacodynamics; Procedures; Program Development; programs; Property; Publishing; Recommendation; Route; Work; ,Synthesis support for early stages of drug discovery and development program,,,,,,,,,412782,
9430197,N01,HD,,N,,,,,N01HD000000,,,275201400003I-1-27500010-1,NICHD:203172\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14369384; ,"MANDACI, OGUZ ;",,10/28/2015,10/27/2017,Clinical; Collection; Data Coordinating Center; Equipment and supply inventories; Freezing; Human; Maternal-Fetal Medicine Units Network; Monitor; National Institute of Child Health and Human Development; repository; Services; Ships; Specimen; System; Temperature; United States; ,REPOSITORY SERVICES FOR THE MATERNAL-FETAL MEDICINE UNITS NETWORK (MFMU),,,,,,,,,203172,
9430239,N01,AI,,N,,,,,N01AI000000,,,272201300017I-1-27200013-1,NIAID:896652\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14369232; ,"WALTER, EMMANUEL ;",,12/1/2015,9/30/2018,Clostridium botulinum; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Individual; named group; Phase I Clinical Trials; Population; programs; Resources; Therapeutic; therapeutic development; ,VTEU: PHASE I Clinical Trial for Clostridium Botulinum Therapeutics ,,,,,,,,,896652,
9430241,N01,AI,,N,,,,,N01AI000000,,,272201400040C-4-0-1,NIAID:4028420\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ANNAPOLIS,UNITED STATES,,3,82804936,US,10002813,"PHARMATHENE, INC.",MD,214013475,,12430470; ,"TROYER, JOHN ;",,9/10/2014,1/5/2024,Advanced Development; Anthrax Vaccines; Categories; Cold Chains; Communicable Diseases; Development; Disease Outbreaks; Event; Formulation; National Institute of Allergy and Infectious Disease; pathogen; response; Technology; vaccine development; Vaccines; ,DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS ,,,,,,,,,4028420,
9430281,N01,AI,,N,,,,,N01AI000000,,,272201200005C-17-0-5,NIAID:2222145\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,12627966; ,"TOPHAM, DAVID ;",,12/13/2011,12/12/2018,"Avian Influenza; Basic Science; Clinical Research; Development; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza virus vaccine; Measures; pathogen; Research; respiratory; Translational Research; Vaccine Research; Viral; ",RESPIRATORY PATHOGENS RESEARCH CENTERS (RPRC),,,,,,,,,2222145,
9430283,N01,AI,,N,,,,,N01AI000000,,,272201200005C-17-0-7,NIAID:1074037\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,12627962; ,"TOPHAM, DAVID ;",,12/13/2011,12/12/2018,Basic Science; Clinical Research; Communicable Diseases; Development; Measures; pathogen; Research; respiratory; Streptococcus pneumoniae; Translational Research; Viral; ,RESPIRATORY PATHOGENS RESEARCH CENTERS (RPRC),,,,,,,,,1074037,
9430296,N01,NS,,N,,,,,N01NS000000,,,271201500006I-2-27100001-1,NINDS:52075\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,12576597; ,"CARTER, ALAN ;",,1/15/2015,1/14/2025,analytical method; Clinical Trials; Contractor; Contracts; Data; Development; Documentation; Dosage Forms; drug candidate; drug development; drug distribution; efficacy study; Formulation; good laboratory practice; Grant; Investigational Drugs; Investigational New Drug Application; Label; method development; novel therapeutics; Pharmaceutical Preparations; Pharmacologic Substance; preclinical efficacy; Preparation; Process; programs; Regulation; small molecule; support network; United States Food and Drug Administration; United States National Institutes of Health; Validation; Work; ,IGF::OT::IGF DRUG MANUFACTURING AND FORMULATION PROGRAM (DMFP) TASK ORDER #01:  PERFORMANCE ACTIVITY 1  TECHNICAL SUPPORT (1/15/15  1/14/16),,,,,,,,,52075,
9430301,N01,HL,,N,,,,,N01HL000000,,,268201300028U-10-0-3,NIA:0\NIAMS:1873259\NICHD:0\NIDCR:0\NIDDK:0\OD:0\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCKVILLE,UNITED STATES,,,876875154,US,,IQ SOLUTIONS INC,MD,208523046,,12576541; ,"HOLMES, KIM ;",,2/15/2013,1/14/2018,Affect; American; Arthritis; Awareness; Basic Science; bone; Bone Diseases; Chronic; Clinical Research; Communication; Communities; Contracts; cost; Databases; Development; disability; Disease; Event; Exhibits; Goals; Health Care Costs; Health Personnel; Healthcare; Human; improved; Information Dissemination; Institutes; Joints; Language; Learning; Life; Logistics; Medical Research; meetings; Mission; Muscle; Musculoskeletal Diseases; Musculoskeletal System; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nature; operation; Oral; Osteoporosis; outreach; Pain; Patients; Population Heterogeneity; Press Releases; Productivity; Professional Organizations; programs; Public Health; Publications; Research; Research Support; Research Training; Resources; response; Services; Skin; skin disorder; Structure; Translational Research; United States Dept. of Health and Human Services; United States National Institutes of Health; Visual Aid; Work; ,NIAMS Information Clearinghouse ,,,,,,,,,1873259,
9430312,N02,NS,,N,,,,,N02NS000000,,,271201300222P-9-0-1,NINDS:57000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,,,,,57726183,,,,,,,12674789; ,"YOUNG, STEVEN ;",,2/28/2017,2/27/2018,Address; Biological; Biological Assay; Biology; Contracts; design; Development; Development Plans; Disease; drug development; Drug Industry; Drug Modelings; experience; Funding; Future; indexing; Industry; innovation; Institutes; Lead; Leadership; Modeling; nervous system disorder; Neurosciences; Neurosciences Research; Peer Review; Pharmaceutical Preparations; Principal Investigator; Process; Program Development; programs; Research; Research Contracts; Research Personnel; Seasons; Shapes; Therapeutic; United States National Institutes of Health; virtual; Work; ,STEVEN A YOUNG:CONV001654 [13-005393],,,,,,,,,57000,
9430317,N02,NS,,N,,,,,N02NS000000,,,271201300223P-10-0-1,NINDS:28500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,,,,,78684915,,,,,,,12674793; ,"MOSS, NEIL ;",,2/28/2017,2/27/2018,Address; Biological; Biological Assay; Biology; Contracts; design; Development; Development Plans; Disease; drug development; Drug Industry; Drug Modelings; experience; Funding; Future; indexing; Industry; innovation; Institutes; Lead; Leadership; Modeling; Mosses; nervous system disorder; Neurosciences; Neurosciences Research; Peer Review; Pharmaceutical Preparations; Principal Investigator; Process; Program Development; programs; Research; Research Contracts; Research Personnel; Seasons; Shapes; Therapeutic; United States National Institutes of Health; virtual; Work; ,"MOSS, NEIL:1223715 [13-005395]",,,,,,,,,28500,
9430329,N01,HD,,N,,,,,N01HD000000,,,275201200002I-10-27500001-1,NICHD:498698\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DURHAM,UNITED STATES,,,803902113,US,,HEALTH DECISIONS INC,NC,277132260,,14636812; ,"DART, CLINT ;",,9/20/2012,9/19/2017,Clinical; Clinical Trials; Contraceptive Agents; Contractor; Contracts; Development; Devices; drug candidate; Equipment; Female Contraceptive Agents; Goals; Gynecologic; Gynecology; Human Resources; Investigation; Investigational New Drug Application; Male Contraceptive Agents; Monitoring Clinical Trials; National Institute of Child Health and Human Development; Notification; novel therapeutics; Pharmaceutical Preparations; Phase; protocol development; research and development; research clinical testing; Safety; Services; Site; Statistical Data Interpretation; United States Food and Drug Administration; ,STATISTICAL AND CLINICAL COORDINATING CENTER FOR CCTN (SCCC),,,,,,,,,498698,
9430336,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300011-1,NIEHS:312093\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14770515; ,"WAGNER, DAVID ;",,9/27/2016,9/26/2017,Agreement; Argentina; Argentine; Aspirate substance; Child; Clinical Data; Clinical Research; Consent; Contractor; Contracts; Data; Databases; design; Disease; Enrollment; Ensure; Exclusion Criteria; Family; follow-up; Goals; Hospitals; Human Resources; inclusion criteria; Infant; Informed Consent; Injury; Location; Low Birth Weight Infant; Monitor; National Institute of Environmental Health Sciences; Neonatal; Neonatology; Oxidants; Parents; Participant; Perinatal; Procedures; Process; prospective; Protocols documentation; Questionnaires; Records; Recruitment Activity; Research; Research Activity; Research Personnel; Research Support; Role; Safety; Saliva; Sampling; screening; Secure; Services; Severities; Site; Susceptibility Gene; Telephone; Time; Training; ,Clinical Research Support Services for NIEHS Contract Task Order 11 Role of oxidant susceptibility genes in severity on neonatal diseases associated with hyperoxic injury (Argentina Study),,,,,,,,,312093,
9430351,N01,AI,,N,,,,,N01AI000000,,,272201500005I-1-27200003-1,NIAID:1530675\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,6,14130053,US,10001472,"DYNPORT VACCINE COMPANY, LLC",MD,217024734,,14721635; ,"SHUMWAY, DAVID ;",,8/23/2016,4/30/2017,Communicable Diseases; immunoregulation; infectious disease treatment; Investigation; Middle East Respiratory Syndrome Coronavirus; novel therapeutics; Phase I Clinical Trials; Therapeutic; therapeutic evaluation; ,Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV,,,,,,,,,1530675,
9430353,N01,AI,,N,,,,,N01AI000000,,,272201300017I-3-27200009-1,NIAID:128378\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14214555; ,"NAGGIE, SUSANNA ;",,7/13/2015,4/1/2018,Antimicrobial Resistance; Clinical; Conduct Clinical Trials; Contracts; design; Evaluation; Gram-Negative Bacteria; Individual; infectious disease treatment; Investigation; named group; novel; operation; Population; protocol development; Resources; Route; System; Vaccines; ,Vaccine and Treatment Evaluation Units: Concept and Protocol Development,,,,,,,,,128378,
9430358,N01,DA,,N,,,,,N01DA000000,,,271201400009I-1-27100003-1,NINDS:37500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CARY,UNITED STATES,,,36513535,US,,,NC,275191564,,14608917; ,"SISCO, JAY ;",,9/28/2016,9/27/2017,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"JM SISCO PHARMA CONSULTING, LLC:1238758 [16-004028]IGF::OT::IGF",,,,,,,,,37500,
9434827,R03,HD,1,N,12/27/2017,12/27/2017,11/30/2018,865,R03HD094117,SCHOOLS OF PUBLIC HEALTH,PA-16-162,1R03HD094117-01,NICHD:82291\,Non-SBIR/STTR RPGs,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BOSTON,UNITED STATES,PUBLIC HEALTH & PREV MEDICINE,7,604483045,US,894901,BOSTON UNIVERSITY MEDICAL CAMPUS,MA,21182340,,8035062; ,"WISE, LAUREN A;","EISENBERG, ESTHER",12/27/2017,11/30/2019,Ablation; adverse outcome; adverse pregnancy outcome; Affect; base; Biological Response Modifiers; Canada; Cervical; Cervical dysplasia; Cervical Intraepithelial Neoplasia; Cervix Mucus; Cervix Uteri; Child; child bearing; Clinical Medicine; Cold Therapy; Conceptions; Cone; Conization; coping; cost; cost effective; Counseling; Country; Couples; Cryosurgery; Data; Data Analyses; Data Reporting; Denmark; design; Diagnosis; Distant; Dysplasia; Ecosystem; Emotional; Excision; Female; Fertility; Fertility Study; Funding; Future; Goals; Gravid; Gravidity; healing; Healthcare; Human papilloma virus infection; Human Papilloma Virus Vaccination; Human Papillomavirus; Immunologic Factors; Impairment; Infection; Infertility; infertility treatment; Investigation; Lasers; Lead; Lesion; Link; Loop electrosurgical excision procedure; Measurable; Measures; Medical; Medical Records; Methodology; Methods; modifiable risk; Mothers; Mucous body substance; National Institute of Child Health and Human Development; North America; Online Systems; Operative Surgical Procedures; Outcome; Pap smear; Participant; pathogen; Pathology; Patient Self-Report; Play; Pregnancy; Pregnancy Outcome; Premalignant; Production; prospective; Prospective cohort; Prospective cohort study; Prospective Studies; Public Health; Recommendation; Recording of previous events; Recurrence; Registries; reproductive; Reproductive Health; Reproductive Medicine; reproductive tract; Reproductive Tract Infections; Research; Research Design; Research Infrastructure; Risk; Risk Factors; Role; Selection Bias; Sexually Transmitted Diseases; Smoking Status; sperm cell; Sperm Transport; Stenosis; Stress; success; Time; United States; Uterus; Validation; Woman; ,"A prospective study of cervical dysplasia, cervical surgery, and fertility",94117,CHHD,Biobehavioral and Behavioral Sciences Subcommittee ,,,1,50000,32291,82291,
9435820,R21,CA,1,N,12/26/2017,12/27/2017,11/30/2018,393,R21CA216660,,PAR-16-176,1R21CA216660-01A1,NCI:195756\,Non-SBIR/STTR RPGs,2018,NATIONAL CANCER INSTITUTE,,BETHESDA,UNITED STATES,,8,144676566,US,1809301,HENRY M. JACKSON FDN FOR THE ADV MIL/MED,MD,208171888,,1893021; ,"GIAM, CHOU-ZEN ;","READ-CONNOLE, ELIZABETH LEE",12/27/2017,11/30/2019,"Adult T-Cell Leukemia/Lymphoma; Affect; Agreement; Antigen Receptors; B lymphoid malignancy; Caspase; CD28 gene; CDKN1A gene; Cell Aging; Cell Line; Cells; chemokine receptor; Clonal Expansion; Clone Cells; cohort; Complex; CREB1 gene; CTLA4 gene; Cyclin-Dependent Kinase Inhibitor; Data; Development; Diagnosis; DNA; Ectopic Expression; Evolution; Family; Family member; FOXP3 gene; FRAP1 gene; FYN gene; Gene Rearrangement; Genes; Genetic Transcription; genome analysis; genome sequencing; Goals; Guanine Nucleotide Exchange Factors; HTLV-1 Infection; Human; Human T-lymphotropic virus 1; IL2RA gene; Individual; Infection; Interferons; Knowledge; leukemia treatment; Leukemic Cell; Longitudinal Studies; Malignant - descriptor; Malignant Neoplasms; MAP Kinase Gene; Mediating; Mediator of activation protein; Mutation; notch protein; nuclear factors of activated T-cells; Oncogenes; Oncogenic; Onset of illness; Pathway interactions; Patients; Phosphotransferases; Platelet Factor 4; Play; PLC gamma1; Point Mutation; precision medicine; Premalignant; prevent; Process; Proliferating; protein kinase C beta; Proto-Oncogene Proteins c-fyn; Proviruses; public health relevance; Receptor Signaling; Receptors, Antigen, B-Cell; Recruitment Activity; Recurrence; Regulatory T-Lymphocyte; response; Retroviridae; Role; senescence; Signal Pathway; Signal Transduction; Somatic Mutation; Specific qualifier value; Stat3 protein; Surface; synergism; T-Cell Activation; T-Cell and NK-Cell Neoplasm; T-Cell Proliferation; T-Cell Receptor; T-Cell Transformation; T-Lymphocyte; Taxes; Testing; Transcript; transcription factor; VAV1 gene; Viral; Viral Regulatory Proteins; whole genome; ",Clonal Expansion of HTLV-1-Infected Cells and Adult T Cell Leukemia,216660,ZCA1,Special Emphasis Panel ,,A1,1,130500,65256,195756,
9442390,R15,HL,1,N,12/22/2017,12/26/2017,11/30/2020,837,R15HL140528,SCHOOLS OF VETERINARY MEDICINE,PA-16-200,1R15HL140528-01,NHLBI:483000\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BLACKSBURG,UNITED STATES,VETERINARY SCIENCES,9,3137015,US,8968001,VIRGINIA POLYTECHNIC INST AND ST UNIV,VA,240616100,,8492518; ,"HE, JIA-QIANG ;","REID, DIANE M",12/26/2017,11/30/2020,Adult; Affect; aged; American; Amino Acids; Amputation; Anatomy; angiogenesis; Antibodies; Arteries; Attenuated; base; Biological Assay; Blood; Blood flow; Blood Vessels; Caliber; Cardiac Myocytes; Cardiovascular Diseases; Cardiovascular system; Clinical; Data; Development; Disease; Distal; drug discovery; Drug Targeting; Dyes; Economic Burden; Economics; Embryo; Embryonic Development; Endothelial Cells; Eukaryota; EVI1 gene; foot; Genes; Goals; Growth; Heart; Hindlimb; Homeobox; Homeobox Genes; Homeostasis; Image; improved; In Vitro; inhibitor/antagonist; insight; Intervention; Ischemia; Knock-out; Knockout Mice; Lasers; Leg; Ligation; Limb Bud; Limb structure; Low-Density Lipoproteins; Lower Extremity; Medical; MEIS1 gene; Mesenchyme; Morbidity - disease rate; Morphogenesis; mortality; mouse model; Mus; Muscle; Muscle Cells; Myelogenous; Natural regeneration; Necrosis; Neonatal; new therapeutic target; novel therapeutics; Operative Surgical Procedures; Organ; Pathology; Pattern; Peripheral; Peripheral arterial disease; Peripheral Vascular Diseases; Pharmacotherapy; Physical therapy; Pilot Projects; Play; Pre-B-Cell Leukemia; protective effect; relating to nervous system; response; Role; Skeletal Muscle; Skin; Staining method; Stains; Symptoms; Techniques; Testing; Therapeutic; Therapeutic Effect; Tissues; Toes; Transcript; transcription factor; Transgenic Mice; Tube; tumorigenesis; uptake; Vascular Endothelial Cell; Vascular remodeling; Vascular Smooth Muscle; Wild Type Mouse; ,Meis1 Negatively Regulates Blood Flow in Hindlimb Ischemia,140528,ZRG1,Special Emphasis Panel ,,,1,300000,183000,483000,
9444397,N01,HL,,N,,,,,N01HL000000,,,268201600011C-1-0-1,NHLBI:984538\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,14444998; ,"BOWN, ALICIA ;",,3/1/2016,2/28/2018,"Address; base; clinical practice; community organizations; Disease; Family health status; Fostering; Government Agencies; Health; Health Professional; Heart Diseases; Hematological Disease; Individual; Industry; Institutes; Institution; International; Leadership; Lung diseases; Mentors; National Heart, Lung, and Blood Institute; patient advocacy group; Patients; Physicians; Prevention; Privatization; Professional Organizations; programs; Public Health; Research; Research Infrastructure; Research Training; Resources; Scientist; Training; Training and Education; Translations; ","IGF::OT::IGF SMARTT COORDINATING CENTER; BASE PERIOD; FY16; AMT $ 1,094,824; CAN 8470205",,,,,,,,,984538,
9446100,U19,AI,1,N,12/28/2017,12/1/2017,11/30/2018,,U19AI135817,,RFA-AI-16-027,1U19AI135817-01,NIAID:412840\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,76647908,US,8961401,BENAROYA RESEARCH INST AT VIRGINIA MASON,WA,981012795,,10231365; ,"WAMBRE, ERIC ;",,,,Address; Adverse event; Adverse reactions; Agreement; Allergen Immunotherapy; Allergens; Allergic; Allergy to peanuts; Biological Assay; Biological Markers; CD4 Positive T Lymphocytes; Cells; Clinical; Clinical Trials; clinically actionable; cohort; desensitization; design; Disease; Epitopes; Food; food challenge; Food Hypersensitivity; Funding; Future; Genetic Transcription; Heterogeneity; Hypersensitivity; Immune; Immune Tolerance; Immunotherapy; insight; interest; Intervention; Investigation; Investigational Therapies; Label; Lead; Molecular Profiling; Monitor; oral immunotherapy; Oral Stage; Outcome; Patients; Peptides; Phenotype; precision medicine; predictive marker; Regulatory T-Lymphocyte; response; Risk; Sampling; Severity of illness; Staining method; Stains; T cell response; T-Lymphocyte; T-Lymphocyte Epitopes; T-Lymphocyte Subsets; Technology; Testing; Therapeutic Intervention; TNFSF5 gene; transcriptome; transcriptomics; treatment response; vaccine development; Vaccines; Work; ,Allergen T cell epitopes and phenotypes during peanut immunotherapy,135817,ZAI1,Special Emphasis Panel ,8610,,1,242847,169993,,412840
9446869,N01,AI,,N,,,,,N01AI000000,,,272200800005C-25-0-6,NIAID:3039\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12245158; ,"MULLIGAN, MARK ;",,11/1/2007,6/30/2017,Conduct Clinical Trials; Contracts; design; Evaluation; Human Papilloma Virus Vaccine; Individual; infectious disease treatment; Investigation; named group; novel; Papillomaviridae; Papillomavirus; Phase I Clinical Trials; Population; Resources; Route; System; vaccine candidate; Vaccines; ,VACCINE AND EVALUTION TREATMENT UNITS:PHASE I CLINICAL TRIAL OF A HPV VACCINE CANDIDATE ,,,,,,,,,3039,
9446874,N01,AI,,N,,,,,N01AI000000,,,272201300018I-2-27200014-1,NIAID:277704\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14759382; ,"MULLIGAN, ROBERT ;",,9/16/2016,2/28/2019,"Birds; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Individual; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza virus vaccine; named group; Phase I Clinical Trials; Population; programs; Resources; Vaccines; ",VTEU: Phase I Clinical Trial of an Influenza Vaccine,,,,,,,,,277704,
9448408,R01,CA,1,N,12/26/2017,12/27/2017,11/30/2018,395,R01CA215651,SCHOOLS OF MEDICINE,PA-16-160,1R01CA215651-01A1,NCI:509469\,Non-SBIR/STTR RPGs,2018,NATIONAL CANCER INSTITUTE,,LA JOLLA,UNITED STATES,PEDIATRICS,49,804355790,US,577507,UNIVERSITY OF CALIFORNIA SAN DIEGO,CA,920930934,,1882337; ,"DURDEN, DONALD ;","FORRY, SUZANNE L",12/27/2017,11/30/2022,1-Phosphatidylinositol 3-Kinase; Academia; Active Sites; adaptive immune response; Adult; Alcohols; analog; Automobile Driving; base; BAY 54-9085; Binding; Binding Sites; Bromodomain; c-myc Genes; Cancer Biology; cancer cell; cancer therapy; Catalytic Domain; CD47 gene; cell transformation; Chemicals; Childhood; Childhood Solid Neoplasm; clinical application; clinical candidate; clinical development; Clinical Trials; Collaborations; Combined Modality Therapy; Computer Simulation; Consensus; Crystallization; Data; design; Development; Diagnostic; Digit structure; disability; drug candidate; Epigenetic Process; Evaluation; Formulation; Funding; Generations; Genetic Transcription; Goals; Grant; Growth; Head and Neck Squamous Cell Carcinoma; Human; Immune; immunoregulation; improved; in vitro testing; in vivo; Industry; inhibitor/antagonist; innovation; insight; Laboratories; Lead; Legal patent; Lysine; Malignant Childhood Neoplasm; Malignant Epithelial Cell; Malignant Neoplasms; MAP Kinase Gene; medulloblastoma; Mission; Modeling; Molecular; molecular modeling; Molecular Models; Morbidity - disease rate; mortality; Mus; Mutation; MYCN gene; neoplastic cell; Neuroblastoma; novel; novel therapeutics; Oncogenes; oncology; Oncoproteins; Oral; overexpression; Pathway interactions; Patients; PDCD1LG1 gene; Phase; Phase I Clinical Trials; Phosphotransferases; PIK3CA gene; Play; preclinical development; preclinical study; predictive marker; Preparation; Primary carcinoma of the liver cells; prognostic significance; Property; Proteins; Public Health; Receptor Cell; Receptor Signaling; Regulation; Reporting; Research; Resistance; Role; Safety; scaffold; Signal Pathway; single molecule; small molecule; small molecule inhibitor; Specificity; Structure; Structure-Activity Relationship; Study models; Subgroup; success; Technology; technology development; Therapeutic; therapeutic evaluation; Therapeutic Studies; Toxic effect; transcription factor; transcriptome; tumor; tumor growth; Tumor Immunity; tumorigenesis; tumorigenic; Tumorigenicity; United States National Institutes of Health; Validation; Viral; ,Dual PI3K/BRD4 inhibitory chemotype for maximum inhibition of Myc and cancer,215651,DMP,Drug Discovery and Molecular Pharmacology Study Section ,,A1,1,355376,154093,509469,
9451484,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500022-1,NICHD:180213\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14958952; ,"MANDACI, OGUZ ;",,2/23/2017,2/22/2018,Affect; Clinical; Couples; DNA; Embryo; Fertilization; Folic Acid; implantation; infertility treatment; Pregnancy Rate; Process; repository; Seminal fluid; Services; Specimen; Treatment outcome; Zinc; Zinc supplementation; ,REPOSITORY SERVICES FOR FAZST SPECIMENS,,,,,,,,,180213,
9451982,N01,HD,,N,,,,,N01HD000000,,,275201400003I-1-27500014-1,NICHD:56471\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14438409; ,"MANDACI, OGUZ ;",,2/26/2016,2/25/2018,Biopsy; Blood; Fetal Growth; Fetal Growth Retardation; Gestational Age; Membrane; National Institute of Child Health and Human Development; Non obese; Obesity; Observational Study; Placenta; pregnant; Pregnant Women; prospective; Recruitment Activity; repository; Risk; Services; Specimen; Umbilical Cord Blood; Umbilical cord structure; Woman; ,REPOSITORY SERVICES FOR FETAL GROWTH STUDY (NFGS) SPECIMENS,,,,,,,,,56471,
9455560,N01,ES,,N,,,,,N01ES000000,,,273201400020C-5-0-1,NIEHS:3249000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,12634490; ,"ALGAIER, CLARK ;",,7/18/2014,3/17/2018,Adverse effects; Amniotic Fluid; Analytical Chemistry; bisphenol A; Chemicals; Chemistry; Contracts; Coumarins; Development; disorder prevention; Dose; Ensure; Environmental Exposure; Ethers; Ethinyl Estradiol; Evaluation; Exposure to; fetal; Formulation; Furans; Generations; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; Hexachlorobenzene; Human; Immunotoxicology; inorganic phosphate; Measurement; Methods; National Toxicology Program; Outcome; Plasma; Preparation; Procedures; programs; public health research; pulegone; Rattus; Risk Assessment; Risk Factors; Rodent; sample collection; Sampling; Services; Ships; sound; Specific qualifier value; Testing; tetrabromobisphenol A; Tissue Sample; Toxic effect; Toxicity Tests; Toxicology; Triclosan; Tris-A; ,Chemistry Support Services for the NTP,,,,,,,,,3249000,
9460331,N01,AI,,N,,,,,N01AI000000,,,272201400005C-9-0-1,NIAID:2789358\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,12651382; ,"TREANOR, JOHN J ;",,4/1/2014,3/31/2021,Animals; Avian Influenza; Basic Science; Environmental Risk Factor; Evolution; Immune; Immune response; improved; Influenza; influenzavirus; Molecular; pandemic disease; Pathogenicity; Research; transmission process; Vaccination; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,2789358,
9463729,N01,DA,,N,,,,,N01DA000000,,,271201300007C-11-0-1,NIDA:2300866\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,12246540; ,"CARROLL, IVY ;",,6/9/2013,6/8/2018,Area; Chemicals; Communities; Contracts; Data; Databases; Deuterium; Development; Drug abuse; Drug Controls; drug distribution; drug of abuse; Equipment and supply inventories; Institution; Label; Pharmaceutical Preparations; programs; Radio; Research; Research Personnel; Sampling; Standardization; System; Update; ,IGF::OT::IGF: SYNTHESIS AND DISTRIBUTION OF DRUGS OF ABUSE AND RELATED COMPOUNDS.,,,,,,,,,2300866,
9463733,N01,AI,,N,,,,,N01AI000000,,,272201400006C-10-0-2,NIAID:6052826\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MEMPHIS,UNITED STATES,,9,67717892,US,7893501,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,TN,381053678,,14443113; ,"WEBBY, RICHARD ;",,4/1/2014,3/31/2021,Animals; Area; base; Biological; Birds; Control Animal; Development; Disease; Domestic Animals; Effectiveness; Environmental Risk Factor; Epidemiology; Evolution; Human; Immune; Immune response; improved; Influenza; Influenza A virus; Influenza virus vaccine; influenzavirus; interest; International; Maintenance; Measures; migratory bird; Molecular; pandemic disease; Pathogenicity; Research; Role; Serological; Surveillance Program; transmission process; Vaccination; Vaccine Research; virology; wild bird; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,6052826,
9466334,R43,GM,1,N,12/27/2017,12/28/2017,12/27/2018,859,R43GM126770,,PA-16-302,1R43GM126770-01,NIGMS:224889\,SBIR-STTR RPGs,2018,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,,Framingham,UNITED STATES,,5,829359145,US,10021476,"BRIDGE 12 TECHNOLOGIES, INC.",MA,17028768,,8876421; ,"MALY, THORSTEN ;","KREPKIY, DMITRIY",12/28/2017,12/27/2018,Alzheimer's Disease; Area; base; biophysical techniques; Cell Nucleus; Cell physiology; cost effective; Defect; design; Detection; Development; Disease; electron diffraction; Electron Spin Resonance Spectroscopy; Electrons; Equipment; Evaluation; experimental study; Frequencies; Funding; Health; Heart; Heating; Home environment; Hydration status; improved; instrumentation; interest; irradiation; Journals; Laboratories; Liquid substance; macromolecule; Maps; Mechanics; Membrane; Membrane Lipids; Membrane Proteins; Methods; microwave electromagnetic radiation; NMR Spectroscopy; Non-Insulin-Dependent Diabetes Mellitus; Nuclear; Parkinson Disease; Performance; Phase; Physiologic pulse; Physiological Processes; Play; programs; Proliferating; Protein Dynamics; protein structure; Proteins; prototype; Research; Research Activity; Research Personnel; Resolution; Resources; Role; Sampling; Signal Transduction; Site; Small Business Innovation Research Grant; solid solution; solid state nuclear magnetic resonance; Spectrum Analysis; Spin Labels; structural biology; Structure; success; Surface; Techniques; Technology; technology development; three dimensional structure; Time; United States National Institutes of Health; Water; X-Ray Crystallography; ,A Resonator for Pulsed ODNP Spectroscopy to Study Surface Hydration Dynamics,126770,ZRG1,Special Emphasis Panel ,,,1,,,224889,
9469394,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200011-1,NIAID:107963\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12577129; ,"RICHARDSON, JAMES ;",,11/6/2014,5/1/2020,APBA1 gene; Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; novel vaccines; pathogen; Phase; product development; Respiratory Syncytial Virus Vaccines; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X11: Product Development Plans and Feasibility Assessments,,,,,,,,,107963,
9471287,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-3,NIEHS:724853\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Alaska; Animals; carcinogenicity; Chemicals; Chronic; Development; drinking water; Goals; ground water; hazard; Human; immunotoxicity; Laboratory Animals; Mus; National Toxicology Program; Pathology Report; Phase; Rattus; Risk; Toxic effect; Toxicity Tests; Writing; ,Conduct of studies to evaluate the toxic and carcinogenic potential of sulfolane in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,724853,
9472158,R01,AG,1,N,12/26/2017,1/1/2017,12/31/2018,866,R01AG057197,SCHOOLS OF MEDICINE,PA-16-160,1R01AG057197-01A1,NIA:402500\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE ON AGING,,PHILADELPHIA,UNITED STATES,PHARMACOLOGY,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,6244533; ,"AXELSEN, PAUL H;","YANG, AUSTIN JYAN-YU",1/1/2017,12/31/2022,abeta accumulation; Affect; age related; Alzheimer's Disease; Amyloid; Amyloid beta-Protein; amyloid formation; Animal Model; Apolipoprotein E; Apolipoproteins; base; Biochemical; Biological Assay; Brain; Brain Diseases; brain tissue; Cause of Death; Chemicals; Clinical; Data; Deposition; Disease; DNA Sequence Alteration; early onset; fatty acid oxidation; Heritability; Human; human disease; Impaired cognition; In Vitro; in vivo; Intervention; Ions; Link; link protein; lipid peroxidation inhibitor; lipid transport; Lipids; Lipoproteins; Mediating; Membrane; method development; Modification; Nature; Neurofibrillary Tangles; neuron loss; neurotoxic; novel; oxidation; Oxidative Stress; particle; Pathogenesis; Pathogenicity; Pathology; Peptides; Pharmacology; Plant Roots; Post-Translational Protein Processing; Preparation; Process; protein E; Protein Isoforms; protein transport; Proteins; Radiolabeled; Risk; Sampling; Senile Plaques; Severities; tau Proteins; Testing; Transition Elements; ,Posttranslational Protein Modification in Alzheimer Pathology,57197,ZRG1,Special Emphasis Panel ,,A1,1,250000,152500,402500,
9474074,N02,CA,,N,,,,,N02CA000000,,,261201200008C-15-0-1,NCI:416632\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,12674675; ,"MITTL, BETH ;",,4/16/2012,4/15/2018,Administrator; Adult; Cellular Phone; Child; Computer Security; Computer software; Contracts; Databases; Devices; Diet; Documentation; Food; Hour; Image; Instruction; Intuition; Modification; Monitor; Nutrient; Output; Recipe; Reporting; Research Personnel; Respondent; Running; Self-Administered; System; Time; Update; user-friendly; web site; ,Enhancements & support of the ASA24 System,,,,,,,,,416632,
9474299,N01,HD,,N,,,,,N01HD000000,,,275201300023I-0-27500010-1,NICHD:43785\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,14994182; ,"TSAI, MICHAEL ;",,9/9/2013,9/8/2018,Asthma; Cells; Collection; Knowledge; Nose; peripheral blood; population health; Predictive Factor; Pregnancy; pregnancy immunology; Research; RNA; Sampling; Specimen; T-Lymphocyte; Testing; ,PILOT EXTRACTION OF RNA FROM B WELL MOM SAMPLES IN RNALATER SOLUTION,,,,,,,,,43785,
9474533,N01,AI,,N,,,,,N01AI000000,,,272201300003I-5-27200001-1,NIAID:632260\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,12445027; ,"LEWIS, MARK ;",,5/1/2014,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Data; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; Occupational activity of managing finances; pre-clinical; preclinical evaluation; preclinical study; Preparation; Prevention; Prevention strategy; programs; Reporting; Research Personnel; Research Project Grants; Resources; Ships; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,,,,,,,,,632260,
9474804,N01,HD,,N,,,,,N01HD000000,,,275201600003I-0-27500002-1,NICHD:1505717\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BOSTON,UNITED STATES,,7,149617367,US,3212904,HARVARD SCHOOL OF PUBLIC HEALTH,MA,21156028,,14952070; ,"CHAVARRO, JORGE ;",,9/29/2016,9/28/2023,Adolescent Behavior; adolescent health; Adult; Age; Asthma; Basal metabolic rate; Behavioral; Bioinformatics; Biological; biomarker evaluation; Biometry; Blood; Blood Pressure; Blood Vessels; Body Composition; Bone Density; Cardiovascular Diseases; Categories; Characteristics; Childhood; Chronic Disease; Clinical; cohort; Collection; Comorbidity; Complement; Custom; Data; Data Collection; design; Development; developmental disease/disorder; Diagnosis; Diet; disorder risk; Dual-Energy X-Ray Absorptiometry; Economic Factors; Enrollment; Epidemiology; epigenetic marker; Exercise stress test; Fathers; Fatty acid glycerol esters; fetal; follow-up; Gender; Genetic Markers; Gestational Diabetes; Goals; Health; Health behavior; Heart Rate; Human; Hybrids; Hypersensitivity; in utero; indexing; interest; intergenerational; Intramural Research; Lead; Life; Life Style; lifestyle factors; male; maternal obesity; Measures; Medical; Medical History; Metabolic; Mission; Molecular; Mothers; named group; National Institute of Child Health and Human Development; Non-Insulin-Dependent Diabetes Mellitus; Obesity; offspring; Overweight; Participant; Pathway interactions; population health; Pregnancy; Pregnancy Complications; Pregnancy Histories; prospective; Public Health; Questionnaires; Recording of previous events; Recruitment Activity; Reproduction; Reproductive Health; Reproductive History; reproductive hormone; Research; Research Methodology; Respiratory physiology; Saliva; Scanning; Seminal fluid; Siblings; socioeconomics; Standardization; Subgroup; Technology; Thinness; Time; Urine; Weight; ,PILOT RECRUITMENT AND FOLLOW-UP FOR THE INTERGENERATIONAL HEALTH STUDY ,,,,,,,,,1505717,
9475696,N02,CA,,N,,,,,N02CM000000,,,261201000017C-22-0-1,NCI:510800\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,PRINCETON,UNITED STATES,,12,61814323,US,1721601,"THERADEX SYSTEMS, INC.",NJ,85405748,,14272677; ,"ANDERSON, BARRY ;",,5/1/2010,4/30/2017,Adherence; anticancer research; Cancer Center; cancer diagnosis; cancer therapy; Cancer Therapy Evaluation Program; Cancer Trials Support Unit; Clinical Investigator; Clinical Trials; Community Clinical Oncology Program; Contract Services; Data; data management; Funding; Funding Agency; Good Clinical Practice; Guidelines; Institution; International; Monitor; Monitoring Clinical Trials; Patients; Phase; Phase II Clinical Trials; Policies; Procedures; Protocol Compliance; Regulation; Research; Resources; Services; Site; Site Visit; symposium; United States Food and Drug Administration; , CLINICAL TRIALS MONITORING SERVICE,,,,,,,,,510800,
9477391,N01,CA,,N,,,,,N01CA000000,,,261201300019I-3-26100005-2,NCI:2737144\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HARTFORD,UNITED STATES,,1,807853791,US,1854401,CONNECTICUT STATE DEPT OF PUBLIC HEALTH,CT,61061367,,14511287; ,"MUELLER, LLOYD ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER). PERIOD OF PERFORMANCE 05/01/2016 - 04/30/2017",,,,,,,,,2737144,
9478637,N01,CA,,N,,,,,N01CA000000,,,261201300010I-6-26100005-2,NCI:2949393\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALBUQUERQUE,UNITED STATES,,1,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,,14503037; ,"WIGGINS, PHD, CHARLES L. ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SEER; 5/1/15-4/30/17,,,,,,,,,2949393,
9478638,N01,CA,,N,,,,,N01CA000000,,,261201300010I-6-26100005-3,NCI:30500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALBUQUERQUE,UNITED STATES,,1,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,,14503037; ,"WIGGINS, PHD, CHARLES L. ;",,5/1/2015,4/30/2018,cost effective; Data; Ensure; Goals; Insurance; Laws; Malignant Neoplasms; Medical; Modification; Newly Diagnosed; oncology; Recruitment Activity; Research Infrastructure; System; Testing; ,IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SEER; 5/1/15-4/30/17,,,,,,,,,30500,
9478639,N01,CA,,N,,,,,N01CA000000,,,261201300010I-6-26100005-4,NCI:44966\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALBUQUERQUE,UNITED STATES,,1,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,,14503037; ,"WIGGINS, PHD, CHARLES L. ;",,5/1/2015,4/30/2018,Alaska Native; Data Reporting; Development; Methods; Modification; Native Americans; Online Systems; Research Infrastructure; Testing; ,IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SEER; 5/1/15-4/30/17,,,,,,,,,44966,
9478808,N01,AI,,N,,,,,N01AI000000,,,272201600007C-3-0-1,NIAID:1006453\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,14548669; ,"KULOW, RACHEL ;",,6/1/2017,9/30/2018,Alleles; Communicable Diseases; Communities; Contracts; Databases; design; experimental study; Frequencies; gene discovery; Genetic; genetic variant; Genotype; Goals; Haplotypes; immunoglobulin receptor; Immunoglobulins; Immunology; Killer Cells; knowledge base; Length; Major Histocompatibility Complex; Major Histocompatibility Complex Gene; Methods; Molecular; nonhuman primate; Program Development; receptor; Receptor Gene; Resources; Technology; technology development; Transcript; Transplantation; ,NHP MHC ALLELE DISCOVERY AND TYPING TECHNOLOGY AND DEVELOPMENT for transplantation studies,,,,,,,,,1006453,
9478809,N01,HL,,N,,,,,N01HL000000,,,268201300047C-6-0-1,NHLBI:2584510\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,JACKSON,UNITED STATES,,3,928824473,US,5390304,UNIVERSITY OF MISSISSIPPI MED CTR,MS,392164500,,12685959; ,"CORREA, ADOLFO ;",,8/16/2013,8/12/2018,Abdomen; African American; Ancillary Study; Aorta; Area; Back; Biochemical; Biological; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; career; Clinical; cohort; Cohort Studies; Collection; Communities; Community Health Education; Community Outreach; Contracts; Data; Data Analyses; Disease; disorder risk; Echocardiography; Epidemiology; Event; follow-up; graduate student; Health Professional; Health Promotion; healthy lifestyle; heart imaging; High School Student; Hospitalization; improved; Institution; interest; Interview; Investigation; Jackson Heart Study; Magnetic Resonance Imaging; Manuscripts; Measures; Minority; minority student; Mississippi; Morbidity - disease rate; mortality; Outpatients; Participant; Prevention; Public Health; public health research; Publications; Recruitment Activity; Research Personnel; Resources; Risk; Risk Factors; Sampling; Services; Site; socioeconomics; Testing; Time; Training; Training Programs; undergraduate student; Validation; Visit; X-Ray Computed Tomography; ,IGF::OT::IGF Jackson Heart Study Renewal Field Center,,,,,,,,,2584510,
9483233,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-3,NIAID:102117\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Leishmania; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; , MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,102117,
9483236,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-6,NIAID:102118\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; , MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,102118,
9483395,N01,AI,,N,,,,,N01AI000000,,,272201100019I-0-27200019-1,NIAID:80586\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,15019558; ,"SMEE, DONALD ;",,5/1/2017,4/30/2018,Advanced Development; antimicrobial; Biological Assay; Cell Line; Contracts; In Vitro; in vitro testing; Influenza Therapeutic; Maintenance; respiratory virus; Viral; virus development; ,Task B26: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses ,,,,,,,,,80586,
9484172,N01,CA,,N,,,,,N01CA000000,,,26120150003B26100001-6-0-1,NCI:14112182\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,; ,",  ;",,8/15/2015,8/14/2017,Area; arm; Biomedical Computing; Cancer Control Research; Contracts; data management; design; Development; Division of Cancer Control and Population Sciences; effective intervention; Ensure; Internet; Knowledge; Maintenance; Malignant Neoplasms; Methodology; Monitor; National Cancer Institute; Population; Publications; Research Infrastructure; Research Support; Services; Systems Analysis; trend; United States National Institutes of Health; , Biomedical Computing Support Services for DCCPS;,,,,,,,,,14112182,
9490249,N01,HL,,N,,,,,N01HB000000,,,268201200021C-9-0-1,NHLBI:24105\NICHD:65991\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MEMPHIS,UNITED STATES,,9,67717892,US,7893501,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,TN,381053678,,11301083; ,"WANG, WINFRED C ;",,1/10/2012,7/31/2017,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BABY HUG FOLLOW-UP STUDY II,,,,,,,,,90096,
9492897,N01,AI,,N,,,,,N01AI000000,,,272201100019I-0-27200019-2,NIAID:28315\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,15019558; ,"SMEE, DONALD ;",,5/1/2017,4/30/2018,antimicrobial; Biological Assay; Cell Line; Contracts; Coronaviridae; Coronavirus; In Vitro; in vitro testing; Maintenance; Middle East Respiratory Syndrome Coronavirus; respiratory virus; SARS coronavirus; Severe Acute Respiratory Syndrome; therapeutic evaluation; Viral; virus development; ,Task B26: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses ,,,,,,,,,28315,
9493585,N01,AI,,N,,,,,N01AI000000,,,272201000005I-0-27200002-1,NIAID:523459\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,76137314,US,838205,BIOMEDICAL RESEARCH INSTITUTE,MD,208521707,,14972573; ,"HSIEH, MICHAEL ;",,3/21/2017,3/20/2018,Animal Model; Biological Assay; Contracts; Development; infectious disease model; Maintenance; Parasites; Production; Reagent; Schistosomiasis; Standardization; ,"TASK D16: MAINTENANCE, DEVELOPMENT AND PRODUCTION OF SCHISTOSOMIASIS PARASITES, REAGENTS AND ASSAYS",,,,,,,,,523459,
9509793,N01,AI,,N,,,,,N01AI000000,,,272201000034I-0-27200002-1,NIAID:50000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WORCESTER,UNITED STATES,,2,603847393,US,850903,UNIV OF MASSACHUSETTS MED SCH WORCESTER,MA,16550002,,14973664; ,"GREINER, DALE ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,50000,
9510623,N01,AI,,N,,,,,N01AI000000,,,272201200005I-0-27200021-1,NIAID:174745\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14968390; ,"SANDALON, ZIV ;",,3/20/2017,3/19/2018,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; novel vaccines; Office of Administrative Management; pathogen; Phase; product development; Services; Toxicology; United States Food and Drug Administration; Vaccines; ,TASK X21: ADMINISTRATIVE - MANUFACTURING AND CHARACTERIZATION SERVICES FOR VACCINES AND OTHER BIOLOGICS,,,,,,,,,174745,
9511678,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300006-1,NIEHS:101932\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14633178; ,"WAGNER, DAVID ;",,9/1/2016,6/30/2018,Affect; Allergens; Back; Biometry; Clinical Research; Contractor; Contracts; Data; Data Analyses; data management; Data Set; design; Development; Endotoxins; Epidemiology; experience; Health; Hypersensitivity; Manuscripts; National Institute of Environmental Health Sciences; NHANES; Nutritional; programs; Quality Control; Research Support; Secure; Services; Statistical Data Interpretation; Statistical Methods; Statistical Models; statistics; Surveys; System; ,Clinical Research Support Services for NIEHS Contract Task Order 6 - National Health and Nutritional Examination Survey,,,,,,,,,101932,
9515629,N01,AI,,N,,,,,N01AI000000,,,272201400027C-9-0-1,NIAID:4490357\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,,,,,85341774,,,,,,,12426198; ,"STEVENS, RICK ;",,9/15/2017,9/14/2018,Antimicrobial Resistance; Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Gram-Negative Bacteria; Gram-Positive Bacteria; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; ,BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,4490357,
9517628,N01,HD,,N,,,,,N01HD000000,,,275201300006I-4-27500001-1,NICHD:9935\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SAN FRANCISCO,UNITED STATES,,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,12445699; ,"DARNEY, PHILIP ;",,6/26/2017,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,9935,
9518508,N01,AI,,N,,,,,N01AI000000,,,272201500018C-3-0-1,NIAID:3360169\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BETHESDA,UNITED STATES,,,57052391,US,,TECHNICAL RESOURCES INC,MD,208171197,,14164963; ,"BUTLER, SANDRA ;",,7/1/2015,6/30/2018,Agreement; Clinical Research; design; Educational Activities; Preparation; programs; Regulatory Affairs; Reporting; Research Infrastructure; Support Contracts; Training Activity; ,DMID REGULATORY AFFAIRS SUPPORT,,,,,,,,,3360169,
9519625,N01,DA,,N,,,,,N01DA000000,,,271201600005I-2-27100001-1,NINDS:48656\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILMINGTON,UNITED STATES,,,109359435,US,,"PPD DEVELOPMENT, LP",NC,284013331,,14628195; ,"GOLD, MICHAEL ;",,7/1/2016,6/30/2017,Area; Clinical; Development; operation; Phase I Clinical Trials; ,IGF::OT::IGF PHASE I CLINICAL TRIALS FOR DEVELOPMENT OF NEUROTHERAPEUTICS TASK ORDER #001 - PERFORMANCE AREA A - ADMINISTRATIVE AND OVERALL CLINICAL OPERATIONS SUPPORT,,,,,,,,,48656,
9565898,N01,CA,,N,,,,,N01CA000000,,,261201500037I-0-26100006-1,NCI:800994\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MILWAUKEE,UNITED STATES,,5,937639060,US,46001,MEDICAL COLLEGE OF WISCONSIN,WI,532263548,,15078142; ,"YOU, MING ;",,6/2/2017,11/30/2019,Animals; Antigen Targeting; Antigens; Autoantigens; Automobile Driving; BRCA2 Mutation; cancer risk; CDKN2A gene; Characteristics; chronic pancreatitis; cigarette smoking; clinical translation; clinically relevant; Collaborations; Diabetes Mellitus; Diagnosis; Disease; Early Diagnosis; effective intervention; efficacy testing; Excision; Familial Atypical Multiple Mole Melanoma; Family history of; Genes; Genetic; Genetically Engineered Mouse; Goals; Hereditary Nonpolyposis Colorectal Neoplasms; high risk; Human; Immune; Immune checkpoint inhibitor; immune function; Immune response; Immune system; immunogenic; immunogenicity; Immunosuppressive Agents; improved; Individual; KRAS2 gene; Lesion; lung tumorigenesis; Malignant neoplasm of pancreas; Malignant Neoplasms; medical schools; men; Modality; Monitor; Morbidity - disease rate; mortality; Mus; mutant; mutant mouse model; Mutate; Mutation; Natural immunosuppression; novel; Obesity; Oncogenic; Oncoproteins; Operative Surgical Procedures; overexpression; Pancreas; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraepithelial Neoplasia; pancreatic tumorigenesis; Patient-Focused Outcomes; Peptides; Peutz-Jeghers Syndrome; Pre-Clinical Model; prevent; Prevention; Preventive; Preventive Intervention; Preventive measure; Process; programs; Risk; Risk Factors; screening; small molecule; Survival Rate; Syndrome; targeted agent; Therapeutic; Treatment outcome; tumor; Tumor Antigens; tumor growth; Tumor Immunity; Tumor-Derived; tumorigenic; Tumorigenicity; Vaccinated; Vaccination; Vaccine Adjuvant; Vaccines; virtual; Von Hippel-Lindau Syndrome; Wisconsin; Woman; , EFFECT OF A MULTIPEPTIDE KRAS VACCINE IN THE PREVENTION OF PANCREATIC CANCER DRIVEN BY KRAS ONCOPROTEIN HHSN2612015000371  TORFP: 2017-E02,,,,,,,,,800994,
9566069,N02,HL,,N,,,,,N02HL000000,,,268201600294A-1-0-1,NHLBI:15000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,HYATTSVILLE,UNITED STATES,,4,189030067,US,4046605,MEDSTAR HEALTH RESEARCH INSTITUTE,MD,207822031,,14763385; ,"ASCH, FREDERICO ;",,9/30/2016,9/29/2018,Affect; bicuspid aortic valve; Blood Vessels; Cardiovascular system; Cessation of life; Clinical Management; Clinical Research; Communities; Connective Tissue Diseases; Data; Databases; Diagnosis; Eligibility Determination; Enrollment; fundamental research; Genetic study; Goals; Hereditary Disease; Image; improved; Individual; Medical; Morbidity - disease rate; patient registry; Patients; Persons; premature; programs; Registries; repository; Research; Research Personnel; Resources; Specimen; Support Contracts; Syndrome; Thoracic Aortic Aneurysm; Turner's Syndrome; ,IGF::OT::IGF Storage of the GenTAC images,,,,,,,,,15000,
9567049,N01,AI,,N,,,,,N01AI000000,,,272200800026C-28-0-4,NIAID:312440\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HINCKLEY,UNITED STATES,,16,966783706,US,10023022,"CLINICAL RESEARCH MANAGEMENT, INC.",OH,442339801,,1902032; ,"GRIFFISS, JOHN MCLEOD;",,5/30/2008,1/31/2018,Antimicrobial Resistance; biodefense; Clostridium difficile; Communicable Diseases; Contracts; Disease; HIV; immunoregulation; Individual; infectious disease treatment; Investigation; National Institute of Allergy and Infectious Disease; novel therapeutics; Parasitic Diseases; pathogen; Phase; Phase I Clinical Trials; phase I trial; Resource Development; Therapeutic; Therapeutic Agents; Viral; ,Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases,,,,,,,,,312440,
9567336,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500025-1,NICHD:23646\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15223564; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,Age; Blood; Child health care; Collection; Defect; design; DNA; Event; Genomics; Hospitals; Human; Human Development; Immune; maternal serum; National Institute of Child Health and Human Development; neurodevelopment; Neurologic; offspring; Perinatal; Pilot Projects; Pregnancy; repository; Research Activity; Sampling; Specimen; United States National Institutes of Health; Woman; Work; ,"COLLABORATIVE PERINATAL PROJECT (CPP), SAMPLES FOR TWO DIPHR PROJECTS 2017",,,,,,,,,23646,
9567904,N01,CA,,N,,,,,N01CA000000,,,26120150002B26100009-1-0-1,NCI:2384179\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,; ,",  ;",,9/22/2016,9/21/2018,Division of Cancer Prevention; Informatics; Information Technology; Performance; ,"Division of Cancer Prevention, Information Technology and Informatics SupportPeriod of Performance 09/22/2016 - 09/21/2017",,,,,,,,,2384179,
9568124,N01,AI,,N,,,,,N01AI000000,,,272201300012I-0-27200014-1,NIAID:538961\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15200720; ,"HOOK, EDWARD ;",,9/1/2017,5/31/2018,Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; experience; Human Resources; Laboratories; Leadership; Phase III Clinical Trials; protocol development; Research Infrastructure; sample collection; Sexually Transmitted Diseases; Syphilis; Therapeutic; Training; ,Sexually Transmitted Infections Clinical Trials Group: Phase III Clinical Trial for Syphilis Therapeutics,,,,,,,,,538961,
9568146,N01,AI,,N,,,,,N01AI000000,,,272201700082C-0-0-1,NIAID:2639002\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,1,53284659,US,4050801,THOMAS JEFFERSON UNIVERSITY,PA,191075125,,15266239; ,"SCHAILEY, TIMOTHY ;",,8/31/2017,12/31/2017,Advanced Development; Contracts; Development; Dose; Ebola virus; efficacy testing; Filoviridae; Filovirus; Formulation; Frankfurt-Marburg Syndrome Virus; immunogenicity; Individual; Lassa Fever; nonhuman primate; research clinical testing; stability testing; Toxicology; vaccine candidate; Vaccines; ,Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever,,,,,,,,,2639002,
9568703,N01,ES,,N,,,,,N01ES000000,,,273201600003I-1-27300003-1,NIEHS:461490\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14661975; ,"BAKER, SUSAN ;",,6/30/2016,6/29/2018,Air; Aliquot; Archives; Biological; Biological Assay; Blinded; Body Fluids; Cell Count; Cell Separation; Collection; Contractor; Contracts; cost; Cryopreservation; Data; Data Base Management; Databases; Development; DNA; Dust; environmental transport; Epidemiology; Equipment; Equipment and supply inventories; field study; Freezing; Guidelines; Inherited; Institution; Laboratories; Liquid substance; Maintenance; Maryland; meetings; Monitor; Movement; National Institute of Environmental Health Sciences; Nitrogen; operation; Phase; Preventive; Procedures; Process; Protocols documentation; quality assurance; Regulation; repaired; Reporting; Research; Research Personnel; Safety; sample collection; Sampling; Services; Ships; Silver; Soil; Specimen; Testing; Tissues; Training; Urinalysis; vapor; Water; web portal; ,IGF::OT::IGF SUPPORT SERVICES FOR EPIDEMIOLOGY - TASK ORDER 3 - SPECIMENS,,,,,,,,,461490,
9568926,N43,CA,,N,,,,,N43CA000000,,,261201700042C-0-0-1,NCI:211535\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHAMPAIGN,UNITED STATES,,13,80409441,US,10043333,"SIMBIOSYS, INC.",IL,61820,,15228066; ,"PETERSON, JOSEPH ;",,9/11/2017,6/10/2018,Behavior; Behavioral; cancer cell; Cancer Model; Cancerous; Cells; Characteristics; Chemicals; Complex; Computer Simulation; Computer software; computerized tools; Cues; Data; Data Set; Diffusion; Environment; Epigenetic Process; Genetic; Genotype; Growth; Histology; Image; Individual; insight; malignant breast neoplasm; Malignant Neoplasms; Mechanics; Metabolic; metabolic profile; Metabolism; metabolomics; Microscope; Modeling; novel; Oncogenic; Pathogenicity; Pharmacotherapy; Phenotype; Predisposition; Property; Radiation therapy; Reaction; Research; Research Personnel; Role; stem; System; Techniques; Technology; transcriptomics; tumor metabolism; tumor microenvironment; ,SimBioSys Environment: A computation Microscope for Cancer Microenvironments,,,,,,,,,211535,
9568966,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100023-1,NCI:8280\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326898; ,"GIANNINI, ROBERT ;",,8/15/2017,2/15/2018,base; Biological Assay; capsule; Contractor; Cyclic GMP; Decitabine; Methods; Pharmacy facility; Testing; ,"Conducting Assay, Purity profile, and Dissolution rate for Decitabine Capsules",,,,,,,,,8280,
9568983,N02,CA,,N,,,,,N02CA000000,,,261201500010I-0-26100006-1,NCI:6117\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SOUTH SAN FRANCISCO,UNITED STATES,,,930243360,US,,,CA,940801934,,15326910; ,"JOHNSON, CHARLES ;",,5/19/2017,7/18/2017,Archives; Biology; cancer diagnosis; cancer therapy; Chemicals; Collection; Contractor; Databases; Destinations; Dimethyl Sulfoxide; drug development; drug discovery; Dry Ice; Electronic Mail; follow-up; Government; high throughput screening; Informatics; Information Distribution; Investigational Therapies; Libraries; Library Services; Maps; Medical center; multidisciplinary; Names; NCI Center for Cancer Research; oncology; planetary Atmosphere; Privatization; programs; repository; Research Infrastructure; Resources; Sampling; screening; seal; Services; Shipping; Ships; small molecule; Solvents; Specific qualifier value; Therapeutic; Time; United States National Institutes of Health; ,IGF::OT::IGF HTS Cherry Pick Compounds - Paul Shinn - NCATS,,,,,,,,,6117,
9569563,N02,ES,,N,,,,,N02ES000000,,,273201600020C-1-0-1,NIEHS:652451\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,GERMANTOWN,UNITED STATES,,19,41722133,US,9620201,"TACONIC FARMS, INC.",NY,125265320,,14752409; ,"LOHMILLER, JEFFREY ;",,9/30/2017,9/29/2018,Animal Diseases; Animals; base; carcinogenicity; Chemicals; Contracts; design; Evaluation; Genetic; Hybrids; Laboratories; Mission; Modeling; Modernization; Molecular Biology; Mouse Strains; Mus; National Institute of Environmental Health Sciences; National Toxicology Program; Production; programs; Public Health; Rattus; Rodent; Science; Support Contracts; tool; Toxicology; ,BASE CONTRACT (12 MONTHS),,,,,,,,,652451,
9569764,N01,HL,,N,,,,,N01HL000000,,,268201700001I-0-26800001-1,NHLBI:2695715\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,14921886; ,"COUPER, DAVID ;",,11/15/2016,11/14/2021,Abdomen; Address; Adult; African American; aged; Ancillary Study; Ankle; Atherosclerosis; Atherosclerosis Risk in Communities; base; Behavioral; Behavioral Genetics; Carotid Arteries; caucasian American; Characteristics; Clinical; clinical development; clinical predictors; cognitive function; cohort; Cohort Studies; Collaborations; Communities; Contracts; Coronary heart disease; County; Data; Data Collection; Data Set; Development; Disease; Electronic Health Record; Event; follow-up; Fostering; Functional disorder; Funding; Genetic; Geographic Locations; Goals; Grant; Heart failure; Hemostatic Agents; indexing; Laboratories; Measurement; middle age; Monitor; mortality; Myocardial Infarction; Natural History; operation; Participant; Photography; Policies; Process; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Recruitment Activity; Research Personnel; Retinal; Risk Factors; Risk Marker; rural setting; Sampling; sharing data; socioeconomics; Structure of popliteal artery; Subgroup; suburb; Technology; Testing; trend; Ultrasonography; United States National Institutes of Health; Washington; ,IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - COORDINATING CENTER - CORE STUDY OPERATIONS,,,,,,,,,2695715,
9569843,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500030-1,NICHD:24922\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15232029; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,adverse pregnancy outcome; Age; Aspirin; base; Biological Assay; Biological Markers; Blood specimen; Conceptions; Data; Data Sources; double-blind placebo controlled trial; Eligibility Determination; Endocrine disruption; environmental chemical; Equipment and supply inventories; Exposure to; Fertility; follow-up; Funding; Gestational Age; Impairment; Measurement; Measures; Medical center; Menstrual cycle; novel; Ovulation; Participant; Placebos; Pregnancy; Pregnancy loss; pregnant; Property; Randomized; randomized trial; Research; Residual state; Risk; sample collection; Sampling; Serum; Ships; Specimen; Spontaneous abortion; Spottings; Time; Urine; Visit; Woman; ,RESOSITORY PULL FOR THE MEASUREMENT OF BIOSPECIMENS FROM THE EAGeR TRIAL 2017,,,,,,,,,24922,
9569856,N01,HD,,N,,,,,N01HD000000,,,275201600001I-0-27500004-1,NICHD:677277\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENANDS,UNITED STATES,,20,2436061,US,5966001,"NYSDOH/HEALTH RESEARCH, INC.",NY,122042719,,15232726; ,"KANNAN, KURUNTHACHALAM ;",,9/22/2017,3/21/2019,Accounting; Adult; adverse pregnancy outcome; Area; Aromatic Polycyclic Hydrocarbons; Aspirin; Benzophenones; Biological Assay; Biological Markers; Chemicals; Contractor; cost; Data; Data Sources; Detection; Dose; Endocrine disruption; Endocrine Disruptors; environmental chemical; environmental chemical exposure; Evaluation; Exposure to; falls; Fertility; Folic Acid; follow-up; General Population; Gold; Impairment; Individual; Laboratories; Live Birth; Measurement; Measures; Methods; novel; Occupational Exposure; Outcome; Ovulation; Oxidative Stress; Parabens; Phenols; phthalates; Pregnancy; Pregnancy loss; Pregnancy Outcome; pregnant; Property; prospective; Prospective Studies; Randomized Controlled Trials; Recording of previous events; repository; Reproduction; reproductive; Reproductive Health; Research; Risk; Role; sample collection; Sampling; Serum; Site; Spottings; Testing; Time; trial design; Urine; Visit; Woman; Work; ,MEASUREMENT OF ENVRIRONMENTAL CHEMICALS IN THE EAGeR TRIAL,,,,,,,,,677277,
9570554,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-8,NIAID:624606\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Influenza; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,624606,
9571160,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200016-1,NIAID:2927513\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15190084; ,"FRENCK, ROBERT ;",,8/28/2017,9/15/2019,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Ebola Vaccines; Evaluation; Individual; named group; Phase; Phase I Clinical Trials; Population; programs; Resources; vaccine candidate; vaccine trial; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: PHASE I EBOLA VACCINE TRIAL,,,,,,,,,2927513,
9571419,N01,AI,,N,,,,,N01AI000000,,,272201300020I-2-27200009-3,NIAID:105346\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14922183; ,"BUSH, DAVID ;",,7/12/2016,7/1/2019,Antimicrobial Resistance; Clinical Research; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Population; programs; protocol development; Resources; Staphylococcus aureus; Therapeutic; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,105346,
9571743,N01,AI,,N,,,,,N01AI000000,,,272201300022I-0-27200018-1,NIAID:217479\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,14974800; ,"KOTLOFF, KAREN ;",,3/7/2017,12/31/2017,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Multiple drug resistant Mycobacteria Tuberculosis; named group; Phase; Population; programs; Resources; Therapeutic Trials; Tuberculosis; Vaccines; ,Vaccine Treatment and Evaluation Unit: Phase IV Tuberculosis Therapeutics Trial,,,,,,,,,217479,
9571744,N01,AI,,N,,,,,N01AI000000,,,272201300022I-0-27200022-1,NIAID:2862677\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,15266201; ,"MEDEIROS, MICHELLE ;",,9/11/2017,9/11/2019,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Pertussis Vaccine; Phase; Population; programs; Resources; vaccine trial; Vaccines; ,Vaccine and Treatment Evaluation Unit:Phase II Pertussis Vaccine Trial,,,,,,,,,2862677,
9572204,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200020-1,NIAID:133497\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,15190090; ,"NIXON, JENNIFER ;",,7/12/2016,1/31/2018,Biological Assay; Bordetella pertussis Bacterium; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Population; programs; protocol development; Resources; vaccine development; Vaccines; ,Vaccine and Treatment Evaluation Unit - Concept and Protocol Development,,,,,,,,,133497,
9572822,N01,AI,,N,,,,,N01AI000000,,,272201700010I-0-27200007-1,NIAID:1200124\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15266234; ,"MACK, FRED ;",,9/22/2017,3/17/2020,Antigens; Bioinformatics; Clinical Trials; Computer Analysis; Contractor; Contracts; Databases; Development; Documentation; efficacy study; Equipment and supply inventories; HIV vaccine; HIV-1; Human; immunogenicity; In Vitro; Investigational Drugs; Laboratories; Laboratory Animals; Macaca; Measurement; National Institute of Allergy and Infectious Disease; Phase; plasmid DNA; preclinical development; Preclinical Testing; Preventive vaccine; product development; Production; Proteins; Protocols documentation; prototype; quality assurance; Quality Control; research clinical testing; SIV; Testing; Toxicology; transcriptomics; Vaccinated; Vaccines; vector; Viral Vector; ,NIAID Preclinical Development Support,,,,,,,,,1200124,
9572894,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200020-1,NIAID:6618\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15143632; ,"WALKER, EMMANUEL ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,Vaccine and Treatment Evaluation Unit - Clinical Operations Support,,,,,,,,,6618,
9572912,N43,AI,,N,,,,,N43AI000000,,,272201700076C-0-0-1,NIAID:222693\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,4,80123728,US,10042923,ZYMERON CORPORATION,NC,277090002,,15327623; ,"LIU, MICHAEL ;",,8/1/2017,7/31/2018,Antibodies; Bedside Testings; Blood; Cytomegalovirus Infections; Development; Diagnostic; Human; Immunoglobulin G; Immunoglobulin M; Measures; point-of-care diagnostics; tool; ,Rapid point of Care Diagnostics to Determine Cytomegalovirus Infection ,,,,,,,,,222693,
9572988,N01,HD,,N,,,,,N01HD000000,,,275201300011C-10-0-1,NICHD:2475061\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BETHESDA,UNITED STATES,,8,7511046,US,10000350,AMERICAN COLLEGE OF MEDICAL GENETICS,MD,208144812,,12403196; ,"WATSON, MICHAEL ;",,9/26/2013,9/25/2018,Address; Advisory Committees; American; assay development; Authorization documentation; Biological; Biological Markers; Blood; Centers for Disease Control and Prevention (U.S.); Child; Child health care; Clinical; Clinical Data; Collaborations; Collection; Common Data Element; Confidentiality of Patient Information; Congenital Disorders; Congresses; Consent; Contracts; Cytomegalovirus Infections; Data; Data Collection; Data Set; Databases; Development; Diagnosis; Disease; Disease Management; disorder prevention; dissemination research; Early identification; Early Intervention; Early treatment; Effectiveness; epidemiology study; ethical legal social implication; Ethics; Evaluation; follow-up; Funding; Future; Genetic; genetic resource; genomic data; Genomics; Goals; Guidelines; Health Resources; Health Services Administration; Heritability; Hormonal; Immunologic Deficiency Syndromes; improved; Inborn Errors of Metabolism; Incidence; Individual; Infant; Information Dissemination; Institutes; Intellectual functioning disability; interest; Intervention; Laboratories; Language; Medical Genetics; medical schools; member; Metabolic; Metadata; Methods; Morbidity - disease rate; mortality; National Institute of Child Health and Human Development; Natural History; Neonatal Screening; Newborn Infant; Online Systems; Other Genetics; Outcome; Patients; Performance; permissiveness; Phase; phenotypic data; Policies; Predictive Value; Privacy; privacy protection; Procedures; programs; Public Health; Rare Diseases; Recommendation; Regulation; Reporting; repository; Research; research data dissemination; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Residual state; Resources; Risk; Safety; Scientist; screening; Secure; Sensitivity and Specificity; Severe Combined Immunodeficiency; Severities; sex development disorder; sharing data; Site; Specificity; Specimen; Spinal Muscular Atrophy; Spottings; Standardization; System; Technology; Testing; Time; tool; Translational Research; Treatment Effectiveness; United States National Institutes of Health; United States National Library of Medicine; virtual; web-based tool; Work; ,NEWBORN SCREENING TRANSLATIONAL RESEARCH NETWORK (NBSTRN),,,,,,,,,2475061,
9572989,N01,NS,,N,,,,,N01NS000000,,,271201500005I-3-27100005-1,NINDS:477919\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,ALBANY,UNITED STATES,,20,787793900,US,3294801,"ALBANY MOLECULAR RESEARCH, INC.",NY,122035121,,14412432; ,"COSTELLO, CARRIE ;",,2/5/2016,1/31/2019,analytical method; Clinical Trials; Contractor; Contracts; Data; Development; Documentation; Dosage Forms; drug candidate; drug development; drug distribution; efficacy study; Formulation; good laboratory practice; Grant; Investigational Drugs; Investigational New Drug Application; Label; method development; novel therapeutics; Pharmaceutical Preparations; Pharmacologic Substance; preclinical efficacy; Preparation; Process; programs; Regulation; small molecule; support network; United States Food and Drug Administration; United States National Institutes of Health; Validation; Work; ,IGF::OT::IGF  DMFP TASK ORDER NO. 5 BUCKPITT BPN 19186,,,,,,,,,477919,
9573085,N43,AI,,N,,,,,N43AI000000,,,272201700074C-0-0-1,NIAID:224887\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN DIEGO,UNITED STATES,,52,159070825,US,10005283,"NANOCOMPOSIX, INC.",CA,921111806,,15327617; ,"BALDWIN, RICHARD ;",,8/1/2017,7/31/2018,Antibodies; Cytomegalovirus; Development; Diagnostic; Human; Immunoglobulin G; Immunoglobulin M; point-of-care diagnostics; Serological; ,Rapid Diagnostic for HCMV Serological Status,,,,,,,,,224887,
9573290,N01,AI,,N,,,,,N01AI000000,,,272201300022I-2-27200016-1,NIAID:80427\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,14767768; ,"KOTLOFF, KAREN ;",,9/16/2016,3/31/2020,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza; Influenza A virus; Influenza virus vaccine; named group; Phase; Phase I Clinical Trials; Population; programs; Resources; Vaccine Clinical Trial; Vaccines; , VACCINE AND TREATMENT EVALUATION UNITS: PHASE I INFLUENZA VACCINE CLINICAL TRIAL,,,,,,,,,80427,
9573292,N01,HL,,N,,,,,N01HO000000,,,268201400073C-5-0-1,NIDCR:3507957\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,362726007,US,3709001,"RHO FEDERAL SYSTEMS DIVISION, INC.",NC,275178079,,12441870; ,"YOVETICH, NANCY ;",,9/30/2014,9/29/2018,base; Clinical; Clinical Research; clinical research site; Clinical Trials; Collection; Computers; Consult; Contractor; Contracts; Data; Data Analyses; Data Collection; data management; Data Reporting; Databases; design; Development; Devices; experience; Extramural Activities; Human Resources; Intramural Research; Investigation; Investigational Drugs; Investigational New Drug Application; Knowledge; Laboratory Research; Management Information Systems; Monitor; National Institute of Dental and Craniofacial Research; Operations Research; Phase; Preparation; Procedures; programs; protocol development; Protocols documentation; Quality Control; Reporting; Research; Research Design; Research Personnel; research study; Resources; Role; Safety; Secure; Serious Adverse Event; Services; Site; sound; Statistical Data Interpretation; System; tool; Training; Update; web site; Work; ,IGF::OT::IGF CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT (CROMS),,,,,,,,,3507957,
9573326,N01,ES,,N,,,,,N01ES000000,,,273201300010C-8-0-2,NIEHS:1549000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15043498; ,"HEBERT, CHARLES ;",,9/23/2013,5/19/2018,absorption; Acquired Immunodeficiency Syndrome; Adult; Adverse effects; AIDS therapy; Animals; Birth; body system; Chemicals; Congenital Abnormality; design; Development; dietary supplements; disorder prevention; Drug Kinetics; early life exposure; Environmental Pollution; Exposure to; Fetal Development; Flame Retardants; Goals; Hazard Identification; Hazardous Chemicals; Health; HIV; Human; Industrialization; Infertility; Laboratory mice; Laboratory Rat; Life; Materials Testing; Mus; National Institute of Environmental Health Sciences; National Toxicology Program; Ovary; personal care products; Pharmaceutical Preparations; preclinical toxicity; prenatal exposure; programs; Puberty; public health research; Rattus; Reproduction; reproductive organ; reproductive toxicity; Resveratrol; Rodent; Safety; Testis; Therapeutic; Toxic effect; Toxicity Tests; trans-resveratrol; tumor; ,AIDS Resveratrol Subproject 2,,,,,,,,,1549000,
9573430,N43,CA,,N,,,,,N43CA000000,,,261201700029C-0-0-1,NCI:224819\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BETHESDA,UNITED STATES,,8,832700087,US,10025086,"CARE PROGRESS, LLC",MD,208142914,,15237360; ,"ISENSTEIN, HOWARD ;",,9/18/2017,6/17/2018,Cancer Patient; Caregivers; caregiving; Caring; Cellular Phone; Comprehensive Health Care; Computer software; Consensus; Contracts; design; digital; Electronic Health Record; Environment; Goals; improved; Industry Standard; informal support; innovation; insight; Interview; Malignant Neoplasms; Medical Records; meetings; Participant; Patient Care Planning; Patients; peer support; Persons; Phase; Research Project Grants; Secure; Small Business Innovation Research Grant; Symptoms; System; Testing; Time; usability; ,IGF::OT::IGF: Phase I SBIR Contract - FY17 - Topic 363 - Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving,,,,,,,,,224819,
9573645,N01,HD,,N,,,,,N01HD000000,,,275201300003I-2-27500002-1,NICHD:312861\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,AURORA,UNITED STATES,,6,41096314,US,1199905,UNIVERSITY OF COLORADO DENVER,CO,800452571,,15239068; ,"TEAL, STEPHANIE ;",,7/16/2013,12/31/2018,Acetates; Adherence; Adverse effects; Age; Amenorrhea; arm; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Dose; Drug Kinetics; emergency contraception; Estrogens; Hemorrhage; In Vitro; Interruption; malignant breast neoplasm; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Pharmacodynamics; pill; Population; progesterone receptor A; Progesterone Receptors; Progestins; Public Health; Randomized; Regimen; reproductive; Risk; Safety; Thromboembolism; Time; United States Food and Drug Administration; Uterine Fibroids; Venous; Woman; ,"A MULTI-CENTER, RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE, CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL LOW DOSE ULIPRISTAL ACETATE",,,,,,,,,312861,
9573730,N01,HD,,N,,,,,N01HD000000,,,275201300023I-1-27500012-1,NICHD:501569\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15238260; ,"TSAI, MICHAEL  ;",,9/15/2013,2/14/2019,Adverse event; adverse outcome; Age; Anti-inflammatory; Anti-Inflammatory Agents; Biological Assay; Biological Markers; Blood; Brain-Derived Neurotrophic Factor; Child; cytokine; Defect; design; Development; Event; Exposure to; Hospitals; Human; IL8 gene; Immune; Immune response; Immunologic Markers; Immunology procedure; Individual; Infection; Investigation; Link; maternal serum; Measurement; Mothers; National Institute of Child Health and Human Development; Neurocognitive; neurodevelopment; Neurologic; neuropsychiatric disorder; offspring; Perinatal; population health; Pregnancy; Pregnancy Complications; Pregnancy Trimesters; prenatal; prenatal exposure; repository; Research; Risk; Sampling; Serum; Specimen; stressor; United States National Institutes of Health; Woman; ,MATERNAL IMMUNE ACTIVITY DURING PREGNANCY AND OFFSPRING NEURODEVELOPMENT,,,,,,,,,501569,
9574384,N01,AI,,N,,,,,N01AI000000,,,272201200004C-14-0-2,NIAID:77821\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WILMINGTON,UNITED STATES,,7,362574527,US,4079901,"PPD, INC.",NC,284013331,,14922117; ,"GLESSNER, MARY ;",,1/1/2012,12/31/2021,biodefense; Clinical Research; clinical research site; Clinical Trials; Conduct Clinical Trials; Contracts; Ensure; Immune Tolerance; International; Monitor; National Institute of Allergy and Infectious Disease; Regulation; Research Personnel; research study; Services; symposium; ,NIAID DAIT CLINICAL SITE MONITORING CENTER for Biodefense,,,,,,,,,77821,
9574403,N01,AI,,N,,,,,N01AI000000,,,316201200036W-0-0-1,NIAID:2500000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,; ,",  ;",,9/30/2017,9/29/2022,analytical tool; biodefense; Bioinformatics; Clinical Data; Contracts; data access; Data Collection; data integration; Data Storage and Retrieval; Databases; Development; Environment; Funding; Immunology; Information Technology; interoperability; Methods; novel; Production; quality assurance; Research; Research Infrastructure; Services; tool; ,The Immunology Database and Analysis Portal (ImmPort) for Biodefense,,,,,,,,,2500000,
9574505,N43,CA,,N,,,,,N43CA000000,,,261201700045C-0-0-1,NCI:297604\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BOULDER,UNITED STATES,,2,963360719,US,10005513,"SUVICA, INC.",CO,803073131,,15240064; ,"FREDERICK, BARBARA ;",,9/18/2017,6/17/2018,Academia; Aftercare; base; Biological Assay; Cancer cell line; Cell Count; Cell Line; Cells; chemotherapy; Cisplatin; commercial application; Data; Data Analyses; Dose; efficacy testing; Enzymes; imaging software; imaging system; Industry; Laboratories; Libraries; Literature; live cell imaging; Measures; miniaturize; Modification; Nuclear; oncology; Pharmaceutical Preparations; Preclinical Drug Evaluation; Procedures; Process; programs; Proliferating; Protocols documentation; Radiation; radiation response; Radiation therapy; screening; Side; Statistical Data Interpretation; System; therapeutic development; Time; tool; tumor; Work; ,Clonogenic High-Throughput Asssay for Screening Radiation Modulators,,,,,,,,,297604,
9520978,N01,AI,,N,,,,,N01AI000000,,,272201100018I-0-27200013-1,NIAID:218716\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,15027967; ,"PATTERSON, THOMAS ;",,5/16/2017,5/15/2018,Advanced Development; Anti-Bacterial Agents; Antifungal Agents; Antimicrobial Resistance; Biological Assay; Contracts; Development; Enterobacter; Enterococcus; Escherichia coli; in vitro testing; Klebsiella; Maintenance; Pseudomonas aeruginosa; Staphylococcus aureus; therapeutic development; ,TASK A29: In vitro testing for Antimicrobial Resistant-related antibacterial activity,,,,,,,,,218716,
9521481,N01,AI,,N,,,,,N01AI000000,,,272201300010C-6-0-1,NIAID:2796093\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,14617371; ,"GALE, MICHAEL ;",,7/1/2013,6/30/2018,AIDS Vaccines; Algorithms; biocomputing; Bioinformatics; Biological Assay; Combined Vaccines; Contracts; cross reactivity; Data; design; Enrollment; functional genomics; genetic signature; Genomics; Grant; Immune response; Immunization; Immunologic Tests; Infection; Infection prevention; Laboratories; Methods; Modeling; Molecular Profiling; National Institute of Allergy and Infectious Disease; neutralizing antibody; nonhuman primate; Pathway Analysis; programs; Protocols documentation; Research Personnel; Risk; RNA; Route; Sampling; Services; Testing; tool; transcriptomics; vaccine delivery; vaccine efficacy; vaccine evaluation; Vaccine Research; Vaccines; Virus; Virus Replication; ,Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a,,,,,,,,,2796093,
9521759,N01,CA,,N,,,,,N01CA000000,,,261201300012I-0-26100011-1,NCI:75367\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SEATTLE,UNITED STATES,,7,78200995,US,861001,FRED HUTCHINSON CANCER RESEARCH CENTER,WA,981094433,,15109130; ,"SCHWARTZ, STEPHEN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY (POC):  DIAGNOSIS YEAR 2016 7/31/2017-7/30/2018,,,,,,,,,75367,
9524972,N01,AI,,N,,,,,N01AI000000,,,272201000039I-1-27200018-2,NIAID:6576\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14972591; ,"MORREY, JOHN ;",,3/21/2017,7/20/2017,Animal Model; Antiviral Agents; Communicable Diseases; Flavivirus; meetings; programs; Support Contracts; Testing; Zika Virus; ,Task A103: Small animal models for Zika and other flaviviruses,,,,,,,,,6576,
9527459,R21,AI,1,N,12/26/2017,12/26/2017,11/30/2018,855,R21AI133522,SCHOOLS OF ARTS AND SCIENCES,PA-16-161,1R21AI133522-01A1,NIAID:224550\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,BIOLOGY,5,965717143,US,8721001,VANDERBILT UNIVERSITY,TN,372407749,,8027875; ,"BORDENSTEIN, SETH R;","COSTERO-SAINT DENIS, ADRIANA",12/26/2017,11/30/2019,Adult; Affect; Alleles; Animals; Arachnida; Arthropod Vectors; Arthropods; Bacteria; Bacterial Genes; Bacterial Infections; Bacteriophages; Benchmarking; Brothers; Candidate Disease Gene; Cause of Death; Centrosome; Cessation of life; Code; Complement; Complex; Culex pipiens; Culicidae; Cytology; Databases; Defect; Dengue; density; Deposition; Development; Diptera; Disease; Disease Vectors; Dosage Compensation (Genetics); Drosophila genus; Drosophila melanogaster; Ecology; egg; Embryo; Evolution; experience; Fathers; Female; fitness; Fluorescence Microscopy; fly; Future; Genes; Genetic; Genetic study; Genetic Variation; Hour; Infection; Inherited; Insecta; interest; Killings; Knock-out; Knowledge; Lepidoptera; Link; male; Mediating; microbial; Microbial Genetics; Modeling; Modification; Mothers; Mutation; Nematoda; offspring; Order Coleoptera; Ovary; Parasites; parasitism; Partner in relationship; Pathway interactions; Phenotype; Planets; Population; Population Sizes; Process; programs; Prophages; protein complex; Proteomics; Reproduction; reproductive; Reproductive Biology; Research; Resources; response; sex; Son; Specific qualifier value; Speed; Spiroplasma; Sterility; Target Populations; Techniques; Testing; Time; tool; transcriptomics; Transgenes; Transgenic Organisms; transmission process; Ursidae Family; Validation; vector control; vector transmission; Vector-transmitted infectious disease; Virus; Wages; Wolbachia; Zoonoses; ,Wolbachia Genes that Mediate Male Killing,133522,GVE,Genetic Variation and Evolution Study Section ,,A1,1,150000,74550,224550,
9529451,N01,AI,,N,,,,,N01AI000000,,,272201300015I-1-27200004-1,NIAID:96260\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14369216; ,"KEITEL, WENDY ;",,10/19/2015,9/30/2018,"combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Individual; Influenza; Influenza A Virus, H5N1 Subtype; Influenza virus vaccine; named group; Phase; Population; programs; Resources; Vaccine Clinical Trial; ",VTEU: Influenza Phase I Vaccine Clinical Trial,,,,,,,,,96260,
9532450,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200018-4,NIAID:250000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14972594; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Human; Influenza A virus; novel vaccines; pathogen; Phase; Process; product development; Reagent; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X18: Process Development and Early Reagent Manufacturing for Vaccines and Other Biologics,,,,,,,,,250000,
9532454,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200018-5,NIAID:265405\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14972594; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Hepatitis B Vaccines; novel vaccines; pathogen; Phase; Process; product development; Reagent; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X18: Process Development and Early Reagent Manufacturing for Vaccines and Other Biologics,,,,,,,,,265405,
9533349,N01,AI,,N,,,,,N01AI000000,,,272201300014I-2-27200009-1,NIAID:1055787\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14754121; ,"JEFFREY, KLAUSNER ;",,9/15/2016,9/14/2018,Antimicrobial Resistance; Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; Communicable Diseases; Diagnostic; experience; Human Resources; Laboratories; Leadership; Neisseria gonorrhoeae; Procedures; protocol development; Research Infrastructure; sample collection; Sex Behavior; Sexually Transmitted Diseases; Therapeutic; Training; ,Sexually Transmitted Infections Clinical Trials Group,,,,,,,,,1055787,
9536612,N01,HL,,N,,,,,N01HB000000,,,268201200020C-11-0-1,NHLBI:21000\NICHD:3373\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,11466924; ,"EVA, BUREN ;",,1/10/2012,4/30/2018,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BABY HUG FOLLOW-UP STUDY II,,,,,,,,,24373,
9536613,N01,HL,,N,,,,,N01HB000000,,,268201200016C-13-0-1,NHLBI:59757\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WASHINGTON,UNITED STATES,,98,143983562,US,1518602,CHILDREN'S RESEARCH INSTITUTE,DC,200102916,,11301101; ,"LUCHTMAN-JONES, LORI ;",,1/10/2012,4/30/2018,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BABYHUG FOLLOW-UP STUDY II,,,,,,,,,59757,
9537833,N01,AI,,N,,,,,N01AI000000,,,272201700033I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,1,53785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537840,N01,AI,,N,,,,,N01AI000000,,,272201700026I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,100101710,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537844,N01,AI,,N,,,,,N01AI000000,,,272201700030I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SYRACUSE,UNITED STATES,,24,58889106,US,5992619,UPSTATE MEDICAL UNIVERSITY,NY,132102306,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9538105,N01,HL,,N,,,,,N01HB000000,,,268201200037C-11-0-1,NHLBI:35933\NICHD:550\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CORAL GABLES,UNITED STATES,,27,52780918,US,5221250,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,FL,331462926,,11301050; ,"ALVAREZ, OFELIA ;",,1/10/2012,4/30/2018,"2 year old; Age; Award; base; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BASE FUNDING NHLBI  (1/10/2012 - 12/31/2016)  BABY HUG FOLLOW-UP STUDY II - CLIN,,,,,,,,,36483,
9538106,N01,HL,,N,,,,,N01HB000000,,,268201200022C-11-0-1,NHLBI:22308\NICHD:8338\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,JACKSON,UNITED STATES,,3,928824473,US,5390304,UNIVERSITY OF MISSISSIPPI MED CTR,MS,392164500,,11301080; ,"MAJUMDAR, SUVANKAR ;",,1/10/2012,4/30/2018,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",BABY HUG FOLLOW-UP STUDY II,,,,,,,,,30646,
9542467,N01,AI,,N,,,,,N01AI000000,,,272201300003I-0-27200013-1,NIAID:746628\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,15151969; ,"ANDERSEN, HANNE ;",,8/1/2017,5/31/2019,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Development; DNA/MVA vaccine; Evaluation Studies; Funding; Grant; HIV Envelope Protein gp120; HIV vaccine; Immune; immunogenicity; Investigator-Initiated Research; Local Microbicides; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Proteins; Research Personnel; Research Project Grants; Resources; simian human immunodeficiency virus; vaccine candidate; Vaccine Design; vaccine efficacy; vaccine evaluation; Vaccine Research; Vaccines; ,Immunogenicity and Efficacy of a Bivalent Clade B gp120 Protein Boost for aDNA/MVA Vaccine,,,,,,,,,746628,
9543911,N01,AI,,N,,,,,N01AI000000,,,272201300015I-3-27200010-1,NIAID:13469\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14652682; ,"GILMORE, DANIELLE ;",,7/12/2016,12/1/2017,Biological Assay; Clinical; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Vaccine Research; Vaccines; ,Vaccine and Treatment Evaluation Unit Clinical Operations,,,,,,,,,13469,
9545128,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200003-1,NIAID:88357\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14922267; ,"SWARTZ, GLENN ;",,12/1/2016,11/30/2017,Acquired Immunodeficiency Syndrome; AIDS prevention; Biological; Biological Assay; Cells; Clinical Trials; Contractor; Contracts; Development; Equipment and supply inventories; Formulation; HIV; HIV Infections; Licensure; Liquid substance; microbicide; National Institute of Allergy and Infectious Disease; pathogen; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; Reagent; research clinical testing; Resources; Role; Services; sexual HIV transmission; Shipping; SIV; Specimen; Technology; Tissues; United States National Institutes of Health; Work; ,"MATERIAL RECEIPT, STORAGE, SHIPPING AND INVENTORY",,,,,,,,,88357,
9546355,N01,AI,,N,,,,,N01AI000000,,,272201400004I-0-27200004-1,NIAID:76840\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HIGHLAND HEIGHTS,UNITED STATES,,,184227809,US,,,KY,410769167,,14947854; ,"KIRKBY, MATTHEW ;",,1/13/2017,12/29/2017,Clinical; Clinical Research; Communicable Diseases; Laboratories; National Institute of Allergy and Infectious Disease; research study; Research Support; Services; ,CLINICAL CENTRAL LABORATORY SERVICES,,,,,,,,,76840,
9547190,N01,HD,,N,,,,,N01HD000000,,,275201400005C-5-0-1,NIAAA:368492\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BLOOMINGTON,UNITED STATES,,9,6046700,US,577805,INDIANA UNIVERSITY BLOOMINGTON,IN,474013654,,12453254; ,"BELL, PH.D., RICHARD L. ;",,9/29/2014,9/28/2018,Address; Alcohol consumption; Alcohol dependence; Alcoholism; Alcohols; Behavior; blind; clinical toxicology; Contracts; Data; Data Display; Development; Drug Industry; efficacy testing; Future; Genetic Models; Genetic Screening; Human Resources; Intellectual Property; interest; Modeling; National Institute on Alcohol Abuse and Alcoholism; Neurosciences; Pharmaceutical Preparations; pre-clinical; preference; Program Development; programs; Provider; Rattus; Reporting; Standardization; Testing; Work; ,PRECLINICAL MEDICATIONS SCREENING FOR GENETIC MODELS OF ALCOHOLISM,,,,,,,,,368492,
9547577,N01,AI,,N,,,,,N01AI000000,,,272201700041I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9547687,N01,DA,,N,,,,,N01DA000000,,,271201400011C-7-0-2,NIDA:465902\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,NORTH BETHESDA,UNITED STATES,,8,161157631,US,1968001,"JOHNSON, BASSIN AND SHAW, INC.",MD,208525032,,14600460; ,"HAYASHI, SUSAN ;",,9/8/2014,9/7/2018,Address; Adolescent; Alcohol or Other Drugs use; Americas; Continuing Education; continuing medical education; Contracts; Dentists; design; drug abuse prevention; Early Intervention; Education and Outreach; Exercise; Health Personnel; Healthcare; Intervention; knowledge of results; Medical; National Institute of Drug Abuse; Nurse Practitioners; Nurses; Patients; pediatrician; Pharmacists; Physician Assistants; Physicians; Positioning Attribute; preference; Primary Health Care; Psychiatrist; Research Infrastructure; Specialist; Substance Use Disorder; Training; ,IGF::OT::IGF; FY16; Purpose: To exercise Option 1 Contract Year 3; N01DA-14-1152; POP: 09/08/2014 - 09/07/2016.,,,,,,,,,465902,
9547688,N01,AI,,N,,,,,N01AI000000,,,272201300017I-5-27200011-1,NIAID:659393\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14262966; ,"WALTER, EMMANUEL ;",,9/15/2015,5/31/2018,antimicrobial; Antimicrobial Resistance; Child; Communities; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; phase IV trial; Pneumonia; Population; Resources; Route; System; Vaccines; ,A Phase IV Trial to Evaluate Antimicrobial Therapy of Community Acquired Pneumonia in Children - VTEU,,,,,,,,,659393,
9548958,N01,AI,,N,,,,,N01AI000000,,,272201600028C-2-0-2,NIAID:4676851\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BETHESDA,UNITED STATES,,8,79454826,US,10036940,"ABVIRO, LLC",MD,208142934,,14759398; ,"RAMSTEDT, URBAN ;",,9/23/2016,3/21/2019,Advanced Development; Categories; Communicable Diseases; Disease Outbreaks; Event; Flavivirus Infections; National Institute of Allergy and Infectious Disease; pathogen; product development; response; Therapeutic antibodies; therapeutic development; Zika Virus; , A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.,,,,,,,,,4676851,
9548959,N01,DA,,N,,,,,N01DA000000,,,271201600030C-1-0-1,NIDA:420280\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SILVER SPRING,UNITED STATES,,,961728586,US,,,MD,209103447,,14734728; ,"NEUMANN, AARON ;",,9/1/2016,8/31/2018,Acquired Immunodeficiency Syndrome; addiction; Consult; Contracts; data management; Databases; Drug abuse; Ensure; Event; expectation; Fees; HIV; Logistics; Maintenance; meetings; National Institute of Drug Abuse; Office of Administrative Management; payment; Preparation; programs; Publications; Reporting; Research; Research Personnel; Research Support; Resources; Services; Update; web site; ,IGF::OT::IGF: Research Support Services for NIDA AIDS Research Program,,,,,,,,,420280,
9549183,N01,AI,,N,,,,,N01AI000000,,,272201100019I-0-27200020-1,NIAID:654046\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,15185401; ,"SMEE, DONALD ;",,9/16/2017,9/15/2018,Advanced Development; Biological Assay; Cell Line; Contracts; in vitro testing; Maintenance; screening; Therapeutic; Viral; virus development; ,TASK B27: COMPREHENSIVE VIRAL SCREENING PANEL,,,,,,,,,654046,
9555909,N01,AI,,N,,,,,N01AI000000,,,272201500013I-3-27200001-1,OD:1710738\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14256257; ,"CHANG, POLLY ;",,9/1/2016,8/31/2017,animal efficacy; authority; Award; Clinical; Contract Services; Contracts; Documentation; efficacy study; Evaluation; Formulation; good laboratory practice; Human; Medical; Medical Licensure; National Institute of Allergy and Infectious Disease; Nuclear; Pharmacology Study; product development; Radiation; Radiation Injuries; Radiology Specialty; Research; research and development; Safety; Services; stability testing; Strategic Planning; United States Dept. of Health and Human Services; United States Food and Drug Administration; United States National Institutes of Health; , RADIATION/NUCLEAR MEDICAL COUNTERMEASURE (MCM) PRODUCT DEVELOPMENT SUPPORT SERVICES. TASK ORDER A-1 ADMINISTRATIVE AND TECHNICAL SUPPORT,,,,,,,,,1710738,
9555915,N01,HD,,N,,,,,N01HD000000,,,275201300017C-4-0-1,NICHD:1653982\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,12418412; ,"PIOSKE, GREGG ;",,9/30/2013,9/29/2018,Agonist; Ants; Area; Catalogs; Chemical Agents; Chemicals; Chemistry; Contraceptive Agents; Contraceptive methods; contraceptive target; Contractor; Contracts; cost; Data; Data Analytics; design; Development; drug discovery; Female Contraceptive Agents; female reproductive system; Fertility; Fertility Agents; Goals; Government; Human Resources; instrumentation; interest; Label; Laboratories; Laws; male; Male Contraceptive Agents; Mass Spectrum Analysis; men; milligram; novel; Nuclear Magnetic Resonance; Optical Rotation; Peptide Synthesis; Pharmaceutical Chemistry; Pharmaceutical Preparations; pre-clinical; Pregnancy; Process; programs; Proteins; Radioactivity; Radiolabeled; Regulation; reproductive; Research; Research Personnel; Research Support; Resources; Roentgen Rays; Role; Route; Services; small molecule; Structure; Synthesis Chemistry; Testing; United States; Woman; Work; Writing; ,MEDICINAL CHEMISTRY FACILITY,,,,,,,,,1653982,
9559776,N01,AI,,N,,,,,N01AI000000,,,272201100021I-0-27200039-1,NIAID:654933\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15190358; ,"VANCOTT, THOMAS ;",,8/29/2017,8/28/2018,AIDS prevention; Contractor; Development; Documentation; flexibility; HIV vaccine; Investigational Drugs; Investigator-Initiated Research; microbicide; Modality; National Institute of Allergy and Infectious Disease; Phase; preclinical development; Preclinical Testing; Process; Production; research clinical testing; research study; Support Contracts; ,Essential Core Activities: NIAID Preclinical Development Support ,,,,,,,,,654933,
9563040,N01,CA,,N,,,,,N01CA000000,,,261201500032I-1-26100002-1,NCI:350383\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,PHILADELPHIA,UNITED STATES,,13,64367329,US,1190002,RESEARCH INST OF FOX CHASE CAN CTR,PA,191112434,,14757474; ,"MENGES, CRAIG ;",,9/20/2016,9/19/2019,aggressive therapy; anakinra; arm; Asbestos; Asbestos-Related Malignant Mesothelioma; Biological Response Modifiers; Cancer Etiology; cancer prevention; CDKN2A gene; Cessation of life; Chemoprevention; Chemopreventive Agent; chemotherapeutic agent; Chronic; cytokine; Data; Deletion Mutation; Deposition; Developing Countries; Development; Disease; Disease Management; Early Intervention; Exhibits; Exposure to; Fiber; Genetic study; Genetically Engineered Mouse; Genomics; Greater sac of peritoneum; Human; Immune Targeting; In Vitro; in vivo; Incidence; Inflammation; Inflammatory; Interleukin-1 beta; Interleukin-6; Kineret; macrophage; Malignant mesothelioma; Malignant neoplasm of lung; Malignant Neoplasms; Mesothelial Cell; Mesothelioma; Mesothelium; Mineral Fibers; Molecular Genetics; mouse model; Mus; novel; novel strategies; Operative Surgical Procedures; Pathogenesis; Patients; Physiological; Pleural cavity; preclinical study; Prevention approach; Recruitment Activity; Recurrence; Refractory; Regimen; response; Role; Signal Pathway; Site; Sulindac; Testing; therapy resistant; TNF gene; Tumor Suppressor Genes; tumorigenesis; , TARGETING THE IL SIGNAL PATHWAY,,,,,,,,,350383,
9563042,N01,AI,,N,,,,,N01AI000000,,,272201300022I-2-27200012-1,NIAID:592553\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,14256249; ,"SZTEIN, MARCELO ;",,9/1/2015,12/3/2020,Biological Assay; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; Population; Resources; Route; System; Vaccines; Work; Yellow Fever Vaccine; ,Vaccine and Treatment Evaluation Unit: Yellow Fever Vaccines Assay Support,,,,,,,,,592553,
9564340,N01,HD,,N,,,,,N01HD000000,,,275201700074U-0-0-1,NCCAM:119989\NIDCD:40012\NIDDK:1279364\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,15017495; ,"NA, NA ;",,4/17/2017,4/16/2018,Area; base; Collaborations; combat; Communities; cost; Data; Data Set; Data Sources; Digestive System Disorders; Disease; Epidemiology; epidemiology study; Federal Government; Frequencies; Government Programs; Health; Health Care Research; Individual; Knowledge; Lead; Leadership; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; nutrition; Obesity; programs; Public Domains; Publishing; Reporting; Research; Research Personnel; Resources; Science; Scientist; Services; Surveys; United States; United States Centers for Medicare and Medicaid Services; United States National Center for Health Statistics; United States National Institutes of Health; Update; ,Support services for the NIDDK Epidemiology Coordinating Committee,,,,,,,,,1439365,
9564747,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-2,NIAID:136465\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Herpesviridae; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,136465,
9565462,N44,CA,,N,,,,,N44CA000000,,,261201500019C-5-0-1,NIGMS:693710\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHAPEL HILL,UNITED STATES,,4,78778864,US,10034629,"GLYCAN THERAPEUTICS, LLC",NC,275990001,,14274969; ,"PAGADALA, VIJAYAKANTH ;",,9/18/2015,9/17/2018,Aldehydes; Anions; Bacterial Infections; base; Biological Process; Blood coagulation; Cell surface; chemical synthesis; Chemicals; chromophore; Collection; Communities; Contractor; Contracts; cost effective; Detection; Disaccharides; Elements; Embryonic Development; Exhibits; Extracellular Matrix; Family; Glucosamine; Glucuronic Acids; Glycosaminoglycans; Goals; good laboratory practice; Heparitin Sulfate; High Pressure Liquid Chromatography; Iduronic Acid; innovation; Knowledge; Libraries; Link; Location; Mass Spectrum Analysis; member; Methods; Nucleic Acids; Oligosaccharides; Pattern; Phase; Play; Polymers; Polysaccharides; Preparation; Proteins; Research; response; Role; Sampling; Small Business Innovation Research Grant; Structure; sugar; sulfation; United States National Institutes of Health; Unspecified or Sulfate Ion Sulfates; Virus Diseases; ,IGF::OT::IGF CHEMOENZYMATIC SYNTHESIS OF HEPARAN SULFATE OLIGOSACCHARIDES,,,,,,,,,693710,
9565465,N01,OD,,N,,,,,N01OD000000,,,263201200074I-1-26300102-1,NCCAM:10000\NEI:10000\NIDDK:15000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14745796; ,"WESTBROOK, DAVID ;",,9/16/2016,9/15/2018,Academy; Healthcare; Leadership; Medicine; Science; ,IGF::OT::IGF: LEADERSHIP CONSORTIUM FOR VALUE & SCIENCE-DRIVEN HEALTH CARE,,,,,,,,,35000,
9574614,N44,CA,,N,,,,,N44CA000000,,,261201700013C-0-0-1,NCI:1999931\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HACKENSACK,UNITED STATES,,5,153632369,US,10033074,"CHAMPIONS ONCOLOGY, INC.",NJ,76016201,,15240332; ,"KIPP, PETER ;",,9/19/2017,9/18/2019,Address; Adoption; African American; Businesses; Cancer Patient; Cell model; Clinical; Clinical Trials; cohort; Development; Ethnic group; Goals; Growth; high risk; Industrialization; liquid biopsy; Logistics; Malignant neoplasm of prostate; men; Metastatic Prostate Cancer; Methods; model development; Molecular; Mus; Neoplasm Circulating Cells; novel; oncology; Patients; Process; Prostate; Quality Control; Research; Services; Techniques; Technology; Tissues; tool; translational study; Work; Xenograft Model; Xenograft procedure; ,"IGF::OT::IGF (CHAMPIONS ONCOLOGY)To address the slow growth rate of prostate PDXs by eliminating logistical barriers through development of CDX (i.e., PDX from circulating tumor cells) models. PERIOD ",,,,,,,,,1999931,
9575250,N02,CA,,N,,,,,N02CA000000,,,261201700175U-0-0-1,NCI:1199777\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,807935080,US,10023248,"ESAC, INC.",MD,208500389,,15241472; ,"BASU, ANAND ;",,9/15/2017,9/14/2018,Adherence; anticancer research; application programming interface; Bioinformatics; cancer proteomics; Clinical Data; Collaborations; Collection; Communities; Data; data access; Data Analyses; data modeling; Data Set; data visualization; Development; digital; Ecosystem; Environment; Extramural Activities; Fostering; Genomics; Goals; Guidelines; Image; improved; Informatics; informatics infrastructure; Information Systems; interdisciplinary approach; interoperability; knowledge base; Laboratories; Malignant Neoplasms; Molecular; multidisciplinary; National Cancer Institute; Nature; Performance; Pilot Projects; Proteomics; Reproducibility; Research; Research Personnel; Resource Informatics; Resources; Scientist; Security; sharing data; tool; Training; Validation; ,Proteomics Data Commons (PDC).  Period of Performance 09/15/2017 - 09/14/2018,,,,,,,,,1199777,
9575811,N01,CA,,N,,,,,N01CA000000,,,261201200035I-0-26100014-1,NCI:347069\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15242423; ,"KHAN, SEEMA ;",,9/15/2017,9/14/2019,Address; base; Breast; breast surgery; Clinical Trials; cohort; Common Terminology Criteria for Adverse Events; Dermal; Dose; Gel; phase I trial; Placebos; Safety; Woman; ,Phase I trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery,,,,,,,,,347069,
9576501,N44,DA,,N,,,,,N44DA000000,,,271201600035C-3-0-2,NCATS:749955\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,FORT WORTH,UNITED STATES,,12,14005016,US,10001488,"UHV TECHNOLOGIES, INC.",TX,761043503,,15243670; ,"KUMAR, NALIN ;",,9/15/2017,9/14/2018,Contracts; Development; Drug Industry; Equipment; Excision; Exercise; Funding; instrument; Measures; Metals; Monitor; operation; Performance; Phase; Reaction; Small Business Innovation Research Grant; ,"IGF::OT::IGF PURPOSE: To exercise Option Period, extending the period of performance and obligating additional fund.",,,,,,,,,749955,
9576594,N02,CA,,N,,,,,N02CA000000,,,261201600024I-0-26100002-2,NCI:167190\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,15326958; ,"REID, JOEL ;",,4/28/2017,4/27/2022,Antineoplastic Agents; base; Biological Availability; Drug Kinetics; Mus; Performance; Plasma; Sampling; small molecule; tumor; ,Title: Pharmacokinetic and Bioavailability Studies and Analytical Support with Selected Anticancer Compounds in Mice.Period of Performance: 6/27/17 - 4/27/2022,,,,,,,,,167190,
9576691,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100039-1,NCI:12889396\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15244003; ,"PHUNG, QUY ;",,9/28/2017,9/27/2020,Address; Archives; Clinical Data; Clinical Trials; Community Clinical Oncology Program; Data; Data Analyses; data archive; Deposition; Genomic Data Commons; Laboratories; Molecular; Molecular Analysis; Molecular Profiling; multidisciplinary; National Clinical Trials Network; Normal tissue morphology; operation; Outcome; Patients; Plasma; predicting response; predictive modeling; Process; programs; Recommendation; repository; Research; Research Personnel; Research Project Grants; sharing data; Specimen; statistical center; Summary Reports; treatment response; tumor; Tumor Tissue; Whole Blood; ,IGF::OT::IGF Retrospective Tumor Characterization Analysis ,,,,,,,,,12889396,
9578256,N01,CA,,N,,,,,N01CA000000,,,261201600016I-0-26100002-1,NCI:255996\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,15246437; ,"LYNCH, MARYELLEN ;",,1/26/2017,6/30/2018,2-hydroxypyridine; acute toxicity; anti-cancer therapeutic; anticancer activity; Award; Biological; Biological Availability; Body Weight; Cardiovascular system; Clinical; Clinical Chemistry; Contracts; Data; Development; Dose; drug candidate; Drug Kinetics; Evaluation; Hematology; Histopathology; Investigation; Liquid substance; Malignant Neoplasms; Measures; Metabolic Clearance Rate; Methodology; neurotoxicity; Oral; Organ; Pharmaceutical Preparations; Plasma; Process; Rat-1; Reporting; research clinical testing; Rodent; Specific qualifier value; Testing; Time; Tissues; Toxic effect; ,"IGF::OT::IGF NExT Project IDH1_2-Pyridinone TO#2 Characterization of Tox of Potential Anticancer Compounds Following Multiple Dose Admin to Rats, 1/26/17-6/30/18, Pre-clin Tox Study of Drug Dev for Ca",,,,,,,,,255996,
9578314,N02,CA,,N,,,,,N02CA000000,,,261201700038C-0-0-1,NCI:299466\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BALTIMORE,UNITED STATES,,3,80200015,US,10041619,"RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC",MD,212312607,,15246578; ,"GHALY, MICKEL ;",,9/18/2017,6/17/2018,"Clinical; Clinical Data; Clinical Research; Clinical Trials; commercialization; Computer software; Data; design; Devices; Documentation; Dose; Dose-Rate; dosimetry; External Beam Radiation Therapy; Feedback; Goals; Grant; Investigation; Label; Legal patent; Malignant Neoplasms; Manuals; Maps; Methods; osteosarcoma; Patients; Phase; Preparation; Process; prospective; quantitative imaging; Radiation therapy; Radiopharmaceuticals; Samarium 153; System; Testing; Time; Tomography, Emission-Computed, Single-Photon; tool; Toxic effect; treatment planning; tumor; United States National Institutes of Health; Validation; X-Ray Computed Tomography; ",SOFTWARE FOR OPTIMAL COMBINATION OF EXTERNAL BEAM RADIOTHERAPY (XRT) AND RADIOPHARMACEUTICAL THERAPY (RPT),,,,,,,,,299466,
9579471,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100047-1,NCI:6624683\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266028; ,"LEAMAN, K. ADAM ;",,9/20/2017,4/30/2019,Floor; Wing; ,"IGF::OT::IGF Bldg. 560, Wing 2, Floor 1 Refurbishment",,,,,,,,,6624683,
9579704,N02,CA,,N,,,,,N02CA000000,,,261201700007C-0-0-1,NCI:1823000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,RESTON,UNITED STATES,,11,43690788,US,10022495,"EDJ ASSOCIATES, INC.",VA,201911244,,15248468; ,"GRAY, ARIE  ;",,5/1/2017,5/31/2019,cancer diagnosis; cancer therapy; Cancer Therapy Evaluation Program; Contracts; Databases; Division of Cancer Prevention; drug distribution; Maintenance; National Cancer Institute; Pamphlets; Pharmacologic Substance; Process; Recovery; Research Personnel; Services; treatment trial; ,IGF::OT::IGF Support Services for the CTEP Pharmaceutical Management Branch (PMB),,,,,,,,,1823000,
9580247,N02,CA,,N,,,,,N02CA000000,,,261201700006C-2-0-1,OD:150000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,15249178; ,"BROTZMAN, MICHELLE ;",,3/20/2017,3/19/2018,Biological; Cancer Etiology; cancer risk; Clinical Data; Collaborations; Contractor; Contracts; Discipline; Division of Cancer Epidemiology and Genetics; epidemiologic data; field study; Immunity; Infection; Inflammation; interest; Malignant Neoplasms; Mission; Molecular; novel; Oncogenic; Outcome; Research; Research Personnel; Role; sample collection; Services; Testing; ,"IGF::OT::IGF Support Services for Studies of Infection, Immunity, and Cancer",,,,,,,,,150000,
9581081,N44,HD,,N,,,,,N44HD000000,,,275201300008C-7-0-1,NIAAA:9168\,SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DURHAM,UNITED STATES,,4,23317253,US,4529501,"INNOVATION RESEARCH AND TRAINING, INC.",NC,277136628,,15327786; ,"PARKER, ALISON ;",,8/1/2013,9/20/2016,Adolescent; alcohol abuse therapy; base; Fees; Fetal Alcohol Spectrum Disorder; Phase; Prevention program; Small Business Innovation Research Grant; substance abuse prevention; ,"IGF::CL::IGFMindfulness-Based Substance Abuse Prevention Program for Adolescents with FASD. August 1, 2013 - September 20, 2016Cost Plus Fixed Fee - Completion (SBIR Phase II)",,,,,,,,,9168,
9581099,N01,DA,,N,,,,,N01DA000000,,,271201700173U-0-0-1,NIDA:1253696\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ALEXANDRIA,UNITED STATES,,8,555498187,US,10040457,"CALIBRE SYSTEMS, INC.",VA,223103252,,15250555; ,"KEILMAN, ROBERT ;",,9/23/2017,9/22/2018,Accelerometer; addiction; Address; Affect; Agreement; Architecture; Authorization documentation; base; Businesses; Code; Communication; Computer Security; Computer software; Consult; Contractor; Databases; design; Development; Engineering; Ensure; Future; Human Resources; Informatics; Information Systems; instructor; Java; Knowledge; Life Cycle Stages; Maintenance; Management Audit; Management Information Systems; member; migration; Modernization; Modification; National Institute of Drug Abuse; navigation aid; Occupations; operation; Output; Performance; Policies; Process; processing speed; Production; Recommendation; Reporting; Resolution; response; Risk Assessment; Risk Management; Security; Serious Adverse Event; Services; software systems; System; Testing; therapy development; Training; United States National Institutes of Health; Update; Work; ,"IGF::OT::IGF: Informatics Support for NIDA. September 23, 2017 - September 22, 2018. N01DA-17-8940.",,,,,,,,,1253696,
9581160,N02,DA,,N,,,,,N02DA000000,,,271201700181U-0-0-1,NHGRI:110000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,15327498; ,"BABIN, MARVA ;",,9/30/2017,7/29/2018,Advocacy; Clinical Research; Communities; Disease; experience; Family; genetic counselor; Hand; Health Professional; Hereditary Disease; Information Centers; Information Specialists; member; National Human Genome Research Institute; Nurses; Occupational Therapist; Patients; physical therapist; Physicians; Rare Diseases; Research; Resources; Scientist; Social Workers; teacher; United States National Institutes of Health; virtual; Work; Writing; ,The Genetic and Rare Diseases (GARD) Information Center,,,,,,,,,110000,
9581231,N02,HL,,N,,,,,N02HL000000,,,268201600034I-0-26800003-1,NHLBI:22203889\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CAMBRIDGE,UNITED STATES,,7,623544785,US,10021177,"BROAD INSTITUTE, INC.",MA,21421401,,15327251; ,"GABRIEL, STACEY ;",,9/28/2017,9/27/2018,"base; Behavioral; Blood; Caring; Clinical; Clinical Data; Clinical Trials; Communities; Coupling; Data; Diagnosis; Disease; disorder subtype; DNA Methylation; Drug Targeting; Electronic Health Record; Ensure; Environment; Environmental Risk Factor; epigenomics; Genes; Genetic Markers; Genetic Transcription; genome sequencing; Health; Heart; heart disease risk; Heart Diseases; Hematological Disease; Image; improved; Institutes; Lung; Lung diseases; Medicine; metabolomics; Methylation; mHealth; Molecular; molecular marker; Molecular Profiling; National Heart, Lung, and Blood Institute; Organ; Outcome; Patients; personalized intervention; PMI cohort; Population Heterogeneity; precision medicine; Precision Medicine Initiative; prevent; programs; Proteomics; repository; Research; Sample Size; Services; Sleep; Sleep Disorders; System; Testing; Tissues; Trans-Omics for Precision Medicine; transcriptome sequencing; Translating; United States National Institutes of Health; whole genome; ",IGF::OT::IGF - Sequencing Services,,,,,,,,,22203889,
9581234,N01,HL,,N,,,,,N01HB000000,,,268201100004I-0-26800003-1,NHLBI:499439\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,PITTSBURGH,UNITED STATES,,14,791981202,US,10005667,INSTITUTE FOR TRANSFUSION MEDICINE,PA,152203608,,15266082; ,"TRZYNA, LYNNE ;",,9/30/2017,3/31/2019,"Adult; Affect; Allogenic; Amendment; Area; base; Basic Science; Biological Sciences; Blood; Blood Donations; Blood Transfusion; Cancer Center; Cardiac Surgery procedures; Clinical Research; Clinical Sciences; Collection; Community Hospitals; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; data hub; data management; Data Security; Development; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; Evaluation Studies; evidence base; evidence based guidelines; Grant; Health Insurance Portability and Accountability Act; Health Personnel; HIV; Hospitals; improved; Institutional Review Boards; Intensive Care Units; International; K-Series Research Career Programs; Knowledge; Laboratories; Laboratory Study; Leadership; Manuals; Medical; Medicine; meetings; member; Mentors; National Heart, Lung, and Blood Institute; oncology; operation; Orthopedic Surgery procedures; Outpatients; Participant; Pathologic; Patient Care; Patient Education; Patients; Performance; Phase; Policy Developments; Population; population based; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; Risk; Safety; Series; Services; Ships; Site; Surveys; symposium; System; tertiary care; Training; Training and Education; Transfusion; Translational Research; Trauma; Voting; Work; ",IGF::OT::IGF Recipient Epidemiology and Donor Evaluation Study III (REDS-III)  Phase 3 - Domestic Site - ITXM,,,,,,,,,499439,
9581240,N01,HL,,N,,,,,N01HB000000,,,268201100001I-0-26800004-1,NHLBI:733554\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SAN FRANCISCO,UNITED STATES,,12,6902498,US,10004326,BLOOD SYSTEMS RESEARCH INSTITUTE,CA,941184417,,15266073; ,"BUSCH, MICHAEL ;",,9/30/2017,3/31/2019,"Adult; Affect; Antibodies; Antigens; Apoptotic; Area; Basic Science; biobank; Biological Assay; Blood; Blood Tests; Blood Transfusion; chemokine; Clinical Research; Collection; Communicable Diseases; Communities; Contractor; cost; Country; cytokine; Data; Data Coordinating Center; dopamine D5 receptor; Ensure; Epidemic; Epidemiology; Genetic screening method; Genotype; HIV; human leukocyte antigen testing; Immunologic Tests; immunoregulation; improved; Infectious Agent; Inflammatory; International; Journals; Laboratories; Laboratory Procedures; Laboratory Study; Leukocytes; Manuals; Medical; Medicine; meetings; member; Molecular Genetics; National Heart, Lung, and Blood Institute; Nucleic Acids; operation; Participant; Patient Education; Peer Review; Phase; phenotypic data; Population; Principal Investigator; Procedures; programs; Property; Protocols documentation; Public Health; Publications; Quality Control; repository; Research; Research Activity; Research Personnel; Risk; Safety; Shipping; Ships; Site; Specific qualifier value; Specimen; Surveys; symposium; Test Result; Testing; Training; Training and Education; Transfusion; Translational Research; Voting; ",IGF::OT::IGF DBDR REDS-III Central Lab Phase 3,,,,,,,,,733554,
9581241,N01,HL,,N,,,,,N01HB000000,,,268201100008I-0-26800003-1,NHLBI:708835\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15266094; ,"CARSON, DARYL ;",,9/30/2017,3/31/2019,"Acquired Immunodeficiency Syndrome; Address; Adult; Affect; AIDS/HIV problem; Alloimmunization; Amendment; Area; base; Basic Science; Behavior; Biological; Biological Sciences; Blood; Blood Banks; Blood Donations; Blood donor; Blood donor screening; Blood Transfusion; Books; Budgets; Catalogs; Characteristics; Clinical Research; Clinical Sciences; Code; Collaborations; Collection; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; Data Set; Databases; Development; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; Evaluation Studies; evidence base; evidence based guidelines; Geography; Goals; Government; Health Insurance Portability and Accountability Act; Health Personnel; HIV; HIV-1; HIV-2; improved; Incidence; Income; Infection; Infectious Agent; Informed Consent; Institution; Institutional Review Boards; interest; International; Knowledge; Laboratories; Laboratory Study; Language; Leadership; Location; Manuals; Medical; Medicine; meetings; member; Methodology; Monitor; National Heart, Lung, and Blood Institute; Office Management; operation; Participant; Pathologic; Patient Care; Patient Education; Performance; Phase; Policy Developments; population based; Prevalence; prevent; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; Questionnaires; Reporting; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; response; Risk; Risk Factors; Safety; sample collection; Sampling; Ships; Site; Specimen; Surveys; symposium; Technical Expertise; Test Result; Testing; Training; Training and Education; Transfusion; Translating; Translational Research; transmission process; Vascular blood supply; work-study; Writing; ",IGF::OT::IGF Recipient Epidemiology and Donor Evaluation Study III (REDS-III) - International Sites - Phase 3,,,,,,,,,708835,
9581246,N01,HL,,N,,,,,N01HL000000,,,268201600010I-0-26800003-1,NHLBI:1551404\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,FREDERICK,UNITED STATES,,6,78706021,US,10034768,"PRECISION BIOSERVICES, INC.",MD,217014765,,14983373; ,"PHIPPARD, DEBORAH ;",,4/1/2017,3/31/2018,"Aliquot; biobank; Biocompatible Materials; Collection; Contractor; Contracts; Databases; Equipment and supply inventories; Guidelines; National Heart, Lung, and Blood Institute; programs; quality assurance; Quality Control; repository; Research; Resources; Retrieval; Sampling; Site; Specimen; ",IGF::CT::IGF NHLBI BIOREPOSITORY,,,,,,,,,1551404,
9581248,N01,HL,,N,,,,,N01HL000000,,,268201600012I-2-26800001-2,NHLBI:130918\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CORAL GABLES,UNITED STATES,,27,52780918,US,5221250,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,FL,331462926,,15115359; ,"JOSHUA, HARE ;",,8/1/2016,6/30/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES,,,,,,,,,130918,
9581251,N01,HL,,N,,,,,N01HB000000,,,268201100006I-0-26800003-1,NHLBI:780708\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,NEW HAVEN,UNITED STATES,,3,43207562,US,9420201,YALE UNIVERSITY,CT,65208327,,15266088; ,"MANEESHA, JOSHI ;",,9/30/2017,3/31/2019,"Adult; Affect; Allogenic; Amendment; Area; base; Basic Science; Biological Sciences; Blood; Blood Donations; Blood Transfusion; Cancer Center; Cardiac Surgery procedures; Clinical Research; Clinical Sciences; Collection; Community Hospitals; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; data hub; data management; Data Security; Development; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; Evaluation Studies; evidence base; evidence based guidelines; Grant; Health Insurance Portability and Accountability Act; Health Personnel; HIV; Hospitals; improved; Institutional Review Boards; Intensive Care Units; International; K-Series Research Career Programs; Knowledge; Laboratories; Laboratory Study; Leadership; Manuals; Medical; Medicine; meetings; member; Mentors; National Heart, Lung, and Blood Institute; oncology; operation; Orthopedic Surgery procedures; Outpatients; Participant; Pathologic; Patient Care; Patient Education; Patients; Performance; Phase; Policy Developments; Population; population based; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; Risk; Safety; Series; Services; Ships; Site; Surveys; symposium; System; tertiary care; Training; Training and Education; Transfusion; Translational Research; Trauma; Voting; Work; ",Recipient Epidemiology and Donor Evaluation Study III (REDS-III) - Domestic Site - Phase 3 ,,,,,,,,,780708,
9581258,N02,HL,,N,,,,,N02HL000000,,,268201600032I-0-26800003-1,NHLBI:3195915\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,15327248; ,"NICKERSON, DEBBIE ;",,9/28/2016,9/27/2018,"base; Behavioral; Blood; Caring; Clinical; Clinical Data; Clinical Trials; Communities; Coupling; Data; Diagnosis; Disease; disorder subtype; DNA Methylation; Drug Targeting; Electronic Health Record; Ensure; Environment; Environmental Risk Factor; epigenomics; Genes; Genetic Markers; Genetic Transcription; genome sequencing; Health; Heart; heart disease risk; Heart Diseases; Hematological Disease; Image; improved; Institutes; Lung; Lung diseases; Medicine; metabolomics; Methylation; mHealth; Molecular; molecular marker; Molecular Profiling; National Heart, Lung, and Blood Institute; Organ; Outcome; Patients; personalized intervention; PMI cohort; Population Heterogeneity; precision medicine; Precision Medicine Initiative; prevent; programs; Proteomics; repository; Research; Sample Size; Services; Sleep; Sleep Disorders; System; Testing; Tissues; Trans-Omics for Precision Medicine; transcriptome sequencing; Translating; United States National Institutes of Health; whole genome; ",IGF::OT::IGF - Sequencing Services,,,,,,,,,3195915,
9581350,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100067-1,NCI:11066\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,3/27/2017,7/31/2017,Communication; Contracts; health care delivery; Parents; Performance; programs; Research; Strategic Planning; ,SCG PARENT CONTRACT HHSN26120140011I - Task Order No.67TITLE: 'Strategic Planning and Communications Support for the Healthcare Delivery Research Program (Program Support).' Period of Performance: M,,,,,,,,,11066,
9581354,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100070-1,NCI:46711\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,5/9/2017,10/31/2017,meetings; ,IGF::OT::IGF Task Order 70: 2017 NCORP Annual Meeting Support ,,,,,,,,,46711,
9581357,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100069-1,NCI:16542\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,3/27/2017,4/30/2017,Decision Making; Educational workshop; Emotions; Palliative Care; Research; ,Task Order No.69 - Emotion and Decision Making in Palliative Care Research Network Workshop.,,,,,,,,,16542,
9581381,N02,CA,,N,,,,,N02CA000000,,,261201700183P-0-0-1,NCI:16500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WASHINGTON,UNITED STATES,,,126551290,US,,WOODS & POOLE ECONOMICS I,DC,200092808,,15327146; ,"HOLDRICH, MARTIN ;",,4/14/2017,7/13/2017,base; Censuses; County; Economics; Population; Wood material; ,IGF::OT::IGF WOODS & POOLE ECONOMICS INC:1107927 - Obtaining Annual Population Estimates for Counties and Census Tracts Based on the Counts Produced by the US Census Bureau,,,,,,,,,16500,
9581382,N01,CA,,N,,,,,N01CA000000,,,261201700342P-0-0-1,NCI:20977\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SHAKER HEIGHTS,UNITED STATES,,,79765138,US,,,OH,441223077,,15093316; ,"MERGLER, PATRICK ;",,6/14/2017,12/13/2017,,IGF::OT::IGF SEER*DMS IMPLEMENTATION PLANNING,,,,,,,,,20977,
9581386,N02,CA,,N,,,,,N02CA000000,,,261201700511P-0-0-1,NCI:15000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,,,,827379046,,,,,,,15327155; ,"LI, YAN ;",,9/1/2017,8/31/2018,Algorithms; base; Complex; health disparity; Measures; Surveys; ,IGF::OT::IGF Algorithms for Inference of Health Disparity Summary Measures Based on Complex Surveys,,,,,,,,,15000,
9581391,N01,CA,,N,,,,,N01CA000000,,,261201700401P-0-0-1,NCI:20862\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CORAL SPRINGS,UNITED STATES,,,79764766,US,,,FL,330716200,,; ,",  ;",,9/12/2017,3/11/2018,Area; Contracts; dashboard; Evaluation; Human; improved; Leadership; Procedures; Signal Recognition Particle; System; ,IGF::OT::IGF SEER DMS Change Implementation: Gary Levin,,,,,,,,,20862,
9581396,N02,CA,,N,,,,,N02CA000000,,,261201700469P-0-0-1,NCI:135000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW YORK,UNITED STATES,,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323702,,15327152; ,"HRIPCSAK, GEORGE ;",,8/30/2017,8/29/2018,Cancer Patient; Clinical Data; Feasibility Studies; Malignant Neoplasms; Observational Study; Outcome; Pathway interactions; Research; Variant; ,IGF::OT::IGF  Efficient Conduct of Large-Scale Observational Studies in Cancer,,,,,,,,,135000,
9581398,N02,CA,,N,,,,,N02CA000000,,,261201700086A-0-0-1,NCI:40000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HANOVER,UNITED STATES,,2,41027822,US,2021601,DARTMOUTH COLLEGE,NH,37551421,,15327137; ,"AYERS, DONNA ;",,9/18/2017,9/17/2018,cohort; Division of Cancer Epidemiology and Genetics; population based; Relative Risks; Risk Estimate; Services; Smoking Status; Source; ,IGF::OT::IGF Services for a Project Titled 'Population-Based vs. Self-Selected Cohorts as the Source of Relative Risk Estimates by Smoking Status' in Support of the NCI/DCEG,,,,,,,,,40000,
9581400,N01,CA,,N,,,,,N01CA000000,,,261201700393P-0-0-1,NCI:20823\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MOORESTOWN,UNITED STATES,,,194318775,US,,,NJ,80573652,,; ,",  ;",,9/18/2017,3/17/2018,,IGF::OT::IGF SEER DMS Change Implementation: Frank Manion,,,,,,,,,20823,
9581410,N02,CA,,N,,,,,N02CA000000,,,261201700718P-0-0-1,NCI:30000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FAIRFAX,UNITED STATES,,,79769475,US,,,VA,220303400,,15327179; ,"WONG, DAVID ;",,9/30/2017,9/29/2018,Classification; Data; Maps; Methods; ,IGF::OT::IGF Stand-Alone Application for the Class Seperability Classification Method to Map SEER Data in a Chorolopeth Map ,,,,,,,,,30000,
9582479,N44,DA,,N,,,,,N44DA000000,,,271201700021C-0-0-1,NIDA:954231\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,AUSTIN,UNITED STATES,,21,834870490,US,10026929,"RINGFUL, LLC",TX,787495206,,15253501; ,"JOHNSON, KIM ;",,9/25/2017,9/24/2019,Algorithms; Awareness; base; Clinical; Clip; Competence; Computer software; Consent; Contractor; Cost Analysis; Custom; data exchange; Data Reporting; Data Security; design; Development; Effectiveness; Elements; Environment; Evaluation; flexibility; Focus Groups; handheld mobile device; Health Insurance Portability and Accountability Act; Hospitals; improved; Infant; Institutional Review Boards; Internet; Interview; Knowledge; Learning; Licensing; Measurement; meetings; Methods; Mothers; multimodality; Narration; Neonatal Abstinence Syndrome; Nurses; Nursing Students; Participant; Patients; pediatrician; Phase; Physicians; Pilot Projects; Population Heterogeneity; Procedures; programs; prototype; Provider; Recommendation; Recruitment Activity; Registered nurse; Reporting; Resources; response; Role; Sampling; satisfaction; Secure; Security; simulation; software development; statistics; Structure; support tools; Surveys; Symptoms; System; Target Populations; Technology; Testing; Text; Time and Motion Studies; tool; Training; treatment as usual; usability; Weaning; ,"IGF::OT::IGF: Neonatal Abstinence Syndrome Primer Reference and Decision Support Tool. September 25, 2017 - September 24, 2019. N44DA-17-1210.",,,,,,,,,954231,
9582496,N43,DA,,N,,,,,N43DA000000,,,271201700022C-0-0-1,NIDA:149987\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CAMBRIDGE,UNITED STATES,,5,115243701,US,3785301,"CHARLES RIVER ANALYTICS, INC.",MA,21384555,,15253520; ,"BRACKAN, BETHANY  ;",,9/22/2017,3/21/2018,Abstinence; Algorithms; base; commercialization; computer based statistical methods; Contractor; Cues; Data; design; Effectiveness; Elements; Ensure; Environment; Evaluation; Exposure to; Feedback; Fostering; Future; General Hospitals; graphical user interface; Health Insurance Portability and Accountability Act; Immersion Investigative Technique; individual patient; Intervention; Learning; lens; Machine Learning; Massachusetts; Mathematics; Measures; Medical center; Motivation; Output; Patients; Performance; Phase; prototype; psychologic; Quick Test for Liver Function; Recommendation; Regulation; relating to nervous system; Reporting; Research; response; Rivers; Secure; sensor; simulation; smoking cessation; Statistical Models; Stimulus; Summary Reports; System; Techniques; Testing; Therapeutic; therapy design; Trust; virtual reality; Visit; Work; ,"IGF::OT::IGF Constructed Environments for Successfully Sustaining Abstinence Through Immersive and On-Demand Treatment. Period of Performance: September 22, 2017 - March 21, 2018. N43DA-17-5583.  ",,,,,,,,,149987,
9584247,N01,DA,,N,,,,,N01DA000000,,,271201700056C-0-0-1,OD:724343\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,OVERLAND PARK,UNITED STATES,,,102335952,US,,,KS,662121758,,15256062; ,"KELSH, DEBRA ;",,9/20/2017,9/19/2022,Biological Products; Cannabis; Clinical Pharmacology; Clinical Research; Cocaine; Contractor; Development; Disease; Drug Kinetics; Enzymes; Methamphetamine; Molecular; Monoclonal Antibodies; novel therapeutics; Opiates; Pharmaceutical Preparations; Pharmacodynamics; stem; therapy development; Tobacco; United States Food and Drug Administration; Vaccines; ,IGF::OT::IGF: Pharmacokinetic and Pharmacodynamic Studies for Medications Development. PoP: 9/20/2017-9/19/2022. N01DA-17-8935.,,,,,,,,,724343,
9587849,N01,NS,,N,,,,,N01NS000000,,,26320090024B26500010-0-0-1,NINDS:146676\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,HERNDON,UNITED STATES,,,789995933,US,,,VA,201703838,,; ,",  ;",,4/17/2017,12/29/2017,meetings; Services; symposium; ,IGF::CL::IGF:INFINITY CONFERENCE GROUP INC:1108883 [17-007500]Conference planning and administrative services for the PDBP Consortium Meeting 2017,,,,,,,,,146676,
9587917,N02,DA,,N,,,,,N02DA000000,,,271201700006C-0-0-1,NINDS:44500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,AMBLER,UNITED STATES,,,78493484,US,,,PA,190022810,,15327435; ,"LIN, JIUNN ;",,6/8/2017,6/7/2018,Award; base; Categories; Consult; cost; drug development; Drug Kinetics; drug metabolism; Elements; Employee; Fees; Formulation; Funding; Government; Hour; Information Technology; National Institute of Drug Abuse; National Institute of Neurological Disorders and Stroke; Positioning Attribute; Travel; United States National Institutes of Health; ,NINDS BPN DMPK Consulting - Jiunn Lin IGF::CL::IGF,,,,,,,,,44500,
9588372,R00,AA,4,N,12/29/2017,12/25/2017,11/30/2018,273,R00AA024499,SCHOOLS OF MEDICINE,PA-15-083,4R00AA024499-03,NIAAA:248987\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM,,PHILADELPHIA,UNITED STATES,PHARMACOLOGY,2,2604817,US,2205901,DREXEL UNIVERSITY,PA,191021119,,10436551; ,"BARKER, JACQUELINE M;","CUI, CHANGHAI",8/1/2016,11/30/2020,Agonist; Alcohol consumption; Alcohol dependence; alcohol exposure; alcohol seeking behavior; alcohol use disorder; Alcohols; Amygdaloid structure; Arbitration; awake; Award; base; Behavior; Behavioral; behavioral impairment; Brain region; career; career development; Career Mobility; Chronic; Cognitive; cognitive control; Consumption; Corpus striatum structure; Data; Dependence; design; Development; drinking; drinking behavior; drug seeking behavior; Ethanol; experimental study; extracellular; flexibility; Food; Generations; glutamatergic signaling; Glutamates; Goals; Habits; Hippocampus (Brain); Impaired cognition; Individual; insight; Investigation; Knowledge; Laboratories; Lead; Literature; Mediating; Mentors; metabotropic glutamate receptor 2; Microinjections; Modeling; multi-electrode arrays; Mus; Neurobiology; Neurons; novel; Nucleus Accumbens; optogenetics; Outcome; Performance; Pharmaceutical Preparations; Pharmacogenetics; Phase; Prefrontal Cortex; premature; presynaptic; Prevention strategy; Procedures; Process; reduced alcohol use; Regulation; reinforcer; Relapse; Research; response; Rewards; Rodent Model; Role; Scientist; skills; Stimulus; Structure; Sucrose; Techniques; Testing; Time; Training; Treatment Efficacy; treatment strategy; Work; ,Arbitration Between Goal-directed and Habitual Ethanol Seeking by the Nucleus Accumbens Shell.,24499,NSS,Special Emphasis Panel ,,,3,159097,89890,248987,
9589164,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300118-1,NINDS:25000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15056783; ,"WESTBROOK, DAVID ;",,5/26/2017,8/25/2018,improved; low and middle-income countries; Quality of Care; ,IGF::OT::IGF: IMPROVING QUALITY OF CARE IN LOW-AND MIDDLE-INCOME COUNTRIES,,,,,,,,,25000,
9589198,N01,DA,,N,,,,,N01DA000000,,,271201600006I-0-27100003-1,NINDS:218286\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15266155; ,"GREEN, CAROL ;",,9/30/2017,9/29/2018,Drug Kinetics; Rodent; ,"IGF::OT::IGF Task Order #3, 'Continuous Rodent and Non-Rodent Pharmacokinetic Assessments'",,,,,,,,,218286,
9591716,N01,OD,,N,,,,,N01OD000000,,,26320170082B26300001-0-0-1,NEI:10000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,NORTHAMPTON,UNITED STATES,,,825136117,US,,,MA,10603267,,; ,",  ;",,9/1/2017,9/30/2017,Academy; Agreement; Anniversary; Area; Calendar; Communication; Communities; Contractor; digital; digital media; Education; Eye; Hand; Health; Health Communication; Language; Measures; meetings; Mission; National Eye Institute; outreach; population health; Privacy; Records; Reporting; Research; Research Support; Resource Sharing; Resources; Science; Security; Services; Site; social media; Strategic Planning; tool; Training; United States National Institutes of Health; Vision; ,IGF::OT::IGF - NEI Communications and Outreach Support Services--Transition Support,,,,,,,,,10000,
9591728,N01,OD,,N,,,,,N01OD000000,,,263201700001C-1-0-1,NEI:6718044\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14921832; ,"HAMMEL, KERI ;",,11/1/2016,10/31/2017,Acquired Immunodeficiency Syndrome; active method; adaptive optics; Adrenal Cortex Hormones; age related; Age related macular degeneration; Antigens; Area Analyses; Behcet Syndrome; biobank; Case-Control Studies; Cell Line; central retinal vein occlusion; Ciliary Neurotrophic Factor; Clinical; Clinical Research; Clinical Trials; Collection; Coloboma; Cone; Contractor; Contracts; cost effectiveness; Cyst; Dark Adaptation; Data Analyses; data management; Databases; design; Diabetic Retinopathy; Diagnosis; Disease; disorder of macula of retina; DNA Repository; Early treatment; Economics; Electrooculogram; Enrollment; Epidemiology; Epigenetic Process; Evaluation; Evaluation Studies; exome; Extramural Activities; Eye; Eye diseases; Family; follow-up; Follow-Up Studies; gene therapy; Gene Transfer; Generations; Genes; Genetic; Genetic Markers; Genetic study; genome sequencing; Genotype; geographic atrophy; Healthcare; Image; Immune response; Immunogenetics; Immunology; induced pluripotent stem cell; Inflammation Mediators; Inflammatory; Inherited; inhibitor/antagonist; Interferon gamma 1b; Intramural Research; Investigation; Laboratories; macula; macular edema; Mediating; Medicare; microbiome; Microglia; Minocycline; Molecular; Molecular Genetics; National Eye Institute; Natural History; Oral; Outcome; Outcomes Research; Participant; Pathogenesis; patient expectation; Patient Monitoring; patient safety; Patients; Phase; Phase I/II Trial; Phenotype; Pilot Projects; Platelet-Derived Growth Factor; preclinical study; Proteome; Quality-of-Life Assessment; Randomized Clinical Trials; ranibizumab; repository; Research; Retinal; Retinal Diseases; Retinal Vein Occlusion; Retinitis Pigmentosa; screening; Somatic Cell; Specific qualifier value; Syndrome; Telangiectasis; Toxic effect; Type 7 Spinocerebellar Ataxia; Uveitis; Vertebrate Photoreceptors; Vision; Vision Disorders; Visual Motor Coordinations; Von Hippel-Lindau Syndrome; whole genome; Work; X-Linked Retinoschisis; ,IGF::OT::IGFEMMES NEIS-V,,,,,,,,,6718044,
9594195,N01,AG,,N,,,,,N01AG000000,,,271201000011I-3-27100005-1,NIA:625\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON AGING,,NORTH BETHESDA,UNITED STATES,,8,161157631,US,1968001,"JOHNSON, BASSIN AND SHAW, INC.",MD,208525032,,15040785; ,"BURTON, DAVID ;",,9/22/2010,9/21/2012,,NIA INFORMATION RESOURCE CENTER-HHSN-271-2010-00011I-JBS-CAN#8469736,,,,,,,,,625,
9594202,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300127-1,NIA:99677\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15211107; ,"MOLYE, ELIZABETH ;",,9/6/2017,9/5/2018,,IGF::OT::IGF: USING LONGITUDINAL STUDIES OF YOUNGER COHORTS FOR AGING RESEARCH,,,,,,,,,99677,
9594221,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300125-1,NIA:98932\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15201015; ,"MOLYE, ELIZABETH ;",,9/1/2017,8/31/2018,,IGF::OT::IGF:  IMPROVING PATIENT OUTCOMES THROUGH EFFECTIVE CAREGIVER-CLINICIAN COMMUNICATIONS AND RELATIONSHIPS EXPERT MEETING,,,,,,,,,98932,
9594236,N01,HL,,N,,,,,N01HL000000,,,268201300028C-9-0-2,NIA:16951\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,14921841; ,"SHREINER, PAMELA ;",,7/1/2013,6/30/2017,,IGF::OT::IGF CORRECT PAYMENT OFFICE FROM NCI INV-BR-A TO NHLBI INV-BR-A,,,,,,,,,16951,
9594244,N01,LM,,N,,,,,N01LM000000,,,276201400009C-6-0-2,NIA:86463\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,LOS ANGELES,UNITED STATES,,,78547071,US,,,CA,900141790,,; ,",  ;",,7/8/2017,7/7/2018,,IGF::OT::IGF - MODIFICATION 08:  The purpose of this modification is to fund support services for Technical Assistance to the SBIR Phase II Awardees (Under option year 3).  The period of performance i,,,,,,,,,86463,
9594245,N01,OD,,N,,,,,N01OD000000,,,263201600278U-3-0-2,NIA:6000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,,,,,88365767,,,,,,,; ,",  ;",,9/19/2017,,,Part no. 29-ACE-BAS-1Acquia Cloud Enterprise Basic (1 Codebase) IGF::OT::IGF,,,,,,,,,6000,
9594364,N01,DA,,N,,,,,N01DA000000,,,271201600004C-1-0-2,NIA:185452\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SAN DIEGO,UNITED STATES,,52,78531542,US,10033936,"REVEAL BIOSCIENCES, INC.",CA,92121,,14966606; ,"WESTON, CLAIRE ;",,5/1/2016,4/30/2021,,IGF::OT::IGF DEVELOPMENT AND MAINTENANCE OF AN AGED RODENT TISSUE BANK,,,,,,,,,185452,
9594404,N01,HL,,N,,,,,N01HC000000,,,268200900040C-28-0-2,NIA:297000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WINSTON-SALEM,UNITED STATES,,5,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,,14983364; ,"REBOUSSIN, DAVID ;",,9/14/2009,3/31/2018,,"OTHER FUNCTIONS R&D, SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL (SPRINT) COORDINATING CENTER",,,,,,,,,297000,
9600196,R33,AI,4,N,12/29/2017,1/2/2017,12/31/2018,855,R33AI122384,SCHOOLS OF MEDICINE,PAR-15-041,4R33AI122384-03,NIAID:497886\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW HAVEN,UNITED STATES,INTERNAL MEDICINE/MEDICINE,3,43207562,US,9420201,YALE UNIVERSITY,CT,65208327,,9678952 (contact); 7676442; ,"KUMAR, PRITI  (contact); SUTTON, RICHARD ;","SANDERS, BRIGITTE E",12/1/2015,12/31/2020,adeno-associated viral vector; Animal Model; Anti-Retroviral Agents; Antibodies; antiretroviral therapy; Binding; Biological Assay; Capsid; Carrying Capacities; CCR5 gene; CD4 Positive T Lymphocytes; Cell Count; Cells; Code; Collaborations; college; Complement; complement system; Coupled; Dinitrophenols; Disease; Disease remission; DNA; Dose; Elements; Epitopes; expectation; Frequencies; Generations; Genomic DNA; Glycoproteins; gp160; Grant; gutless adenoviral vector; HIV; HIV Infections; Human; humanized mouse; Immune; Individual; Injection of therapeutic agent; interest; Intramuscular; Investigation; Knowledge; Leukocytes; Life; Light; man; Measurement; Medicine; Modeling; Monitor; mouse model; Mouse Strains; Mus; Muscle; Natural Killer Cells; neutralizing antibody; nonhuman primate; novel; novel strategies; Patients; peptidomimetics; Peripheral; peripheral blood; Persons; Pharmaceutical Preparations; Phase; Plasma; Population; prevent; Prevention; Production; promoter; prophylactic; Proviruses; public health relevance; Recombinants; Recruitment Activity; Role; Serotyping; simian human immunodeficiency virus; Skeletal Muscle; small molecule; success; Surface; System; T memory cell; Testing; Tetanus Helper Peptide; Tetracyclines; Therapeutic; Therapeutic Effect; therapeutic evaluation; Time; transgene expression; Treatment Efficacy; vector; Viral; Viral Load result; viral rebound; Viral reservoir; Viremia; virology; Virus Latency; ,Exploring antibody-Fc effector function in humanized mouse models of HIV latency,122384,ZRG1,Special Emphasis Panel ,,,3,299999,197887,497886,
9354394,H79,HH,5,N,8/31/2017,9/30/2017,9/29/2018,239,H79AE000103,,RFA-HS-16-001,5H79AE000103-02,,OTHERS,2017,DEPARTMENT OF HEALTH & HUMAN SERVICES,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,7255653; ,"BERGER, LAWRENCE M;",,9/30/2016,9/29/2021,,Poverty Research Center,103,ZAE1,Special Emphasis Panel ,,,2,,,,
9388364,R01,EY,5,N,12/26/2017,12/1/2017,11/30/2018,867,R01EY016454,SCHOOLS OF ARTS AND SCIENCES,PA-13-302,5R01EY016454-13,NEI:313875\,Non-SBIR/STTR RPGs,2018,NATIONAL EYE INSTITUTE,,AUSTIN,UNITED STATES,PSYCHOLOGY,25,170230239,US,578403,"UNIVERSITY OF TEXAS, AUSTIN",TX,787595316,,8040915; ,"SEIDEMANN, EYAL J;","FLANDERS, MARTHA C",5/1/2005,11/30/2018,Address; Area; area striata; Attention; Behavioral; Code; Complex; Computer Simulation; Discrimination; Elements; Employee Strikes; experimental study; Goals; Grouping; Image; Individual; insight; Joints; Lateral; Link; Location; luminance; Maps; Masks; Measures; Mediating; millimeter; Monitor; Monkeys; Nature; neuromechanism; Neurons; Noise; novel; orientation columns; Pattern; Perception; Play; Population; Primates; Process; Property; public health relevance; relating to nervous system; Research; response; retinotopic; Role; Sensory; sensory neuroscience; Signal Transduction; spatiotemporal; Stimulus; Testing; Time; V1 neuron; Variant; Visual; Visual Perception; visual stimulus; voltage sensitive dye; ,Linking Neural Population Activity and Visual Perception,16454,SPC,"Mechanisms of Sensory, Perceptual, and Cognitive Processes Study Section ",,,13,202500,111375,313875,
9388971,R00,CA,5,N,12/25/2017,12/1/2017,11/30/2018,393,R00CA181500,SCHOOLS OF MEDICINE,PA-11-197,5R00CA181500-05,NCI:248999\,Non-SBIR/STTR RPGs,2018,NATIONAL CANCER INSTITUTE,,LEXINGTON,UNITED STATES,BIOCHEMISTRY,6,939017877,US,2793601,UNIVERSITY OF KENTUCKY,KY,405260001,,10310607; ,"BLACKBURN, JESSICA S.;","JHAPPAN, CHAMELLI",12/15/2015,11/30/2018,Acute; Acute T Cell Leukemia; Adult; Adverse effects; Animals; Award; B-Cell Acute Leukemia; base; Behavior; cancer imaging; Cancer Model; cancer type; Cell Line; Cells; chemotherapy; Chemotherapy-Oncologic Procedure; Child; Childhood; Chronic Myeloid Leukemia; Clinical; Clinical Treatment; Communities; Coupled; Data; defined contribution; Development; Drug Targeting; Environment; experimental study; Foundations; gain of function; General Hospitals; Genes; Genetic Epistasis; Goals; Hand; Human; improved; In Vitro; in vivo; Induction of Apoptosis; inhibitor/antagonist; innovation; inorganic phosphate; International; knock-down; Knowledge; Learning; leukemia; loss of function; Malignant Neoplasms; Massachusetts; medical schools; Mentors; Mentorship; Modeling; Molecular; Molecular Target; molecular targeted therapies; mortality; mouse model; Multiple Myeloma; Mus; Nature; new therapeutic target; novel; Oncogenes; Outcome; outcome forecast; overexpression; Pathway interactions; Patients; Phase; phosphoproteomics; Phosphorylation; Play; pre-clinical trial; Protein Tyrosine Phosphatase; Proteins; public health relevance; Relapse; Research; Research Personnel; Role; Sampling; small molecule; small molecule inhibitor; Solid Neoplasm; success; Survival Rate; Techniques; Testing; Therapeutic; Therapeutic Uses; Thymus Gland; Time; Transgenic Animals; tumor progression; Tumor stage; Tyrosine; Work; Xenograft Model; Xenograft procedure; Zebrafish; ,The Role of Protein Tyrosine Phosphate PRL3 in Leukemia Development,181500,NSS,Special Emphasis Panel ,,,5,165448,83551,248999,
9430034,N01,AI,,N,,,,,N01AI000000,,,272201200005I-1-27200008-1,NIAID:73281\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12445494; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Falciparum Malaria; Malaria Vaccines; novel vaccines; pathogen; Phase; product development; Services; stability testing; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X8: Stability Testing of a Malaria Vaccine,,,,,,,,,73281,
9430043,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-8,NIAID:197958\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Antimicrobial Resistance; Bacterial Drug Resistance; Chemistry; Communicable Diseases; Development; Intervention; Lead; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Services; Staphylococcus aureus; therapeutic development; therapy development; Translational Research; ,Task Order 2: The Interventional Agent Development Services Program,,,,,,,,,197958,
9430053,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-7,NCI:813796\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Address; analog; Antineoplastic Agents; base; Biological Availability; Biology; Biotechnology; cancer therapy; CCR; Characteristics; Chemical Structure; Chemicals; Chemistry; Clinic; clinical candidate; Communities; Complex; Contractor; design; Development; Developmental Therapeutics Program; drug development; drug discovery; Drug Discovery Groups; Drug Industry; Extramural Activities; Funding; Goals; improved; Joints; Laboratories; Lead; Malignant Neoplasms; Methodology; Molecular; molecular oncology; NCI Center for Cancer Research; New Agents; novel; novel therapeutics; oncology; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; pre-clinical; Private Sector; Process; programs; Property; Proteins; repository; Research; scaffold; screening; Signal Pathway; Solubility; Synthesis Chemistry; Testing; Therapeutic; tumor; Work; ,DCTD Synthetic Chemistry,,,,,,,,,813796,
9430089,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-54,NCI:131483648\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Computers; Contract Services; Contractor; Contracts; data management; Development; Funding; Information Services; International; Libraries; National Cancer Institute; National Institute of General Medical Sciences; operation; programs; Science; Services; statistical service; Support Contracts; Wages; ,NCI-Frederick Operations and Technical Support II,,,,,,,,,131483648,
9430154,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-120,NCI:47805000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Acquired Immunodeficiency Syndrome; Area; Biomedical Research; Budgets; Computers; Contract Services; Contractor; data management; Development; Diagnosis; Environmental Health; Funding; HIV Infections; Human Herpesvirus 8; improved; In Vitro; in vivo; International; Laboratory Animal Science; Libraries; Maintenance; Malignant Neoplasms; Modeling; Molecular Virology; multidisciplinary; nonhuman primate; Office of Administrative Management; operation; Prevention; Principal Investigator; programs; repaired; repository; Research; Safety; Satellite Viruses; Services; statistical service; Support Contracts; Technology; tumor; Viral Epidemiology; Virus; Work; ,Support for AIDS Research,,,,,,,,,47805000,
9430156,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-123,NCI:60000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,,DCP - Early Detection Research Network (EDRN) Repository,,,,,,,,,60000,
9430164,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-132,NCI:3953948\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,actionable mutation; Address; analytical tool; Biopsy; Biopsy Specimen; Cancer cell line; Cancer Center; cancer genome; cancer genomics; Cancer Model; Cancer Patient; Catalogs; Clinical Data; Clinical Trials; cohort; Collection; Colon Carcinoma; Contractor; Data; Data Set; Databases; Deposition; Derivation procedure; Development; DNA; DNA Sequence Alteration; Enrollment; falls; Genes; Genomics; Goals; Histology; Human; improved; In Vitro; Institution; Lead; Legal; Lung Adenocarcinoma; Malignant Neoplasms; material transfer agreement; Mission; Modeling; Molecular; Mutate; National Cancer Institute; Office of Cancer Genomics; Oncogenic; Ovarian Carcinoma; Pathogenesis; Patients; payment; prevent; Process; programs; Proteins; Recurrence; repository; Research Project Grants; RNA; Sampling; Science; Site; Source; Specimen; Structure; The Cancer Genome Atlas; therapy resistant; Tissue Sample; Tissues; treatment response; tumor; Xenograft procedure; ,GCC Genomic Characterization Centers,,,,,,,,,3953948,
9430180,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-148,NCI:1200000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14368683; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Contractor; Laboratories; Malignant Neoplasms; Methods; preclinical development; Standardization; Work; ,DCP- Cancer Immunoprevention Laboratory Support,,,,,,,,,1200000,
9430181,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-149,NCI:25000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14368683; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,biobank; cancer prevention; clinical research site; Contracts; Phase; prevention clinical trial; programs; repository; Specimen; ,DCP - Cancer Prevention Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia) BioRepository,,,,,,,,,25000,
9430183,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-151,NCI:100000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14368683; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Adoption; anticancer research; Area; Biological Assay; Biopsy; Blood; Bone Marrow; Cells; Development; Genomics; Immune system; Immunotherapy; Laboratories; Measures; metastatic process; Morphology; Pathology; Proteomics; Technology; Tissues; tool; ,High Content Pathology,,,,,,,,,100000,
9430190,N01,AI,,N,,,,,N01AI000000,,,272201300004C-5-0-1,NIAID:2442692\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,12576977; ,"MILLER, ROBERT ;",,11/15/2012,11/14/2017,Accreditation; Acquired Immunodeficiency Syndrome; Address; Amendment; base; Clinical; Clinical trial protocol document; Clinical Trials; Code; computerized; Contracts; Data; data management; Diagnosis; Diagnostic; Disease; Ensure; Funding; Immune; Immunology; International; Laboratories; Libraries; Mediating; Medical; Microbiology; Monitor; National Institute of Allergy and Infectious Disease; patient safety; Performance; prevent; Prevention; programs; Protocols documentation; Provider; Readiness; Recurrence; Research Support; Safety; Sampling; Specific qualifier value; System; Testing; therapeutic development; Training; United States Dept. of Health and Human Services; United States National Institutes of Health; vaccine development; ,PATIENT SAFETY MONITORING IN INTERNATIONAL LABORATORIES (SMILE),,,,,,,,,2442692,
9430192,N02,CA,,N,,,,,N02CM000000,,,261201300007C-11-0-1,NCI:310000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,12576815; ,"WHITE, PHD, JONATHAN ;",,2/1/2013,1/31/2018,Academia; Biological Markers; cancer diagnosis; cancer imaging; cancer therapy; Clinical Trials; Diagnosis; Dosage Forms; drug discovery; Evaluation; Funding; image guided; image guided therapy; Imaging Techniques; Industry; Investigation; Life; member; National Cancer Institute; novel diagnostics; novel therapeutics; Play; Retinoblastoma Protein; Role; Running; Support Contracts; Therapeutic; ,"INITIAL FUNDING, RFP #N02-CM-37002-05, DTP-13-015,   02/01/2013 - 01/31/2014, SHE",,,,,,,,,310000,
9430203,N01,CA,,N,,,,,N01CA000000,,,261201500022C-2-0-1,NCI:453713\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BRONX,UNITED STATES,,14,79783367,US,10039582,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",NY,104611975,,14275164; ,"GUHA, CHANDAN ;",,9/30/2015,12/29/2017,Carbon ion; carbon ion therapy; Clinical Trials Network; clinically relevant; Conformal Radiotherapy; Contractor; Malignant neoplasm of pancreas; Malignant Neoplasms; member; National Cancer Institute; oncology; Outcome; Phase III Clinical Trials; phase III trial; Radiation therapy; Randomized; Unresectable; ,PHASE III TRIAL OF CARBON ION THERAPY,,,,,,,,,453713,
9430223,N01,HL,,N,,,,,N01HV000000,,,268201400001C-3-0-1,NHLBI:524527\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MOUNTAIN VIEW,UNITED STATES,,18,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,940430816,,12576809; ,"HANSEN, KAREN ;",,11/15/2013,11/14/2017,"Advisory Committees; Blood Vessels; Development; Diagnostic; Disease; innovation; Instruction; Intervention; Logistics; medically underserved; meetings; Modality; National Heart, Lung, and Blood Institute; product development; programs; Pulmonary Hypertension; Research; research and development; Research Personnel; Resource Development; Secure; Services; Site; Site Visit; Support Contracts; Teleconferences; Therapeutic; Training; Vascular Diseases; ","IGF::OT::IGF, R&D - VASCULAR INTERVENTION/INNOVATIONS THERAPEUTIC ADVANCES",,,,,,,,,524527,
9430237,N01,ES,,N,,,,,N01ES000000,,,N01ES75564-25-0-1,NIEHS:51181\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,14270733; ,"FENNELL, TIMOTHY ;",,5/1/2007,12/15/2017,Adolescent; Adult; Affect; Birth; body system; Breeding; Chemicals; Chemistry; Congenital Abnormality; Contracts; critical period; design; Development; Diet; Dose; drinking water; environmental chemical; Epididymis; Evaluation; Exposure to; fetal; Fetal Development; Fetal Weight; Generations; Growth; Hazard Identification; Health; in utero; Infertility; innovation; Laboratory Animals; Mus; offspring; Organ; Ovary; Perinatal; Pregnancy; prenatal exposure; Production; programs; Protocols documentation; Puberty; Rattus; reproductive; reproductive organ; reproductive toxicity; Research; Research Design; response; Testing; Testis; Toxic effect; Toxicology; Uterus; ,REPRODUCTIVE ASSESSMENTS BY CONTINUOIUS BREEDING (RACB),,,,,,,,,51181,
9430240,N01,AI,,N,,,,,N01AI000000,,,272201200002C-15-0-1,NIAID:2067893\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WILMINGTON,UNITED STATES,,7,362574527,US,4079901,"PPD, INC.",NC,284013331,,12577101; ,"SCHULLER, CHARITY-ANNE ;",,11/1/2011,10/31/2017,Clinical; Clinical Research; clinical research site; Clinical Trials; Conduct Clinical Trials; Contractor; Contracts; Funding; Future; Grant; Individual; Industry Collaboration; Principal Investigator; programs; Regulatory Affairs; Research Personnel; Services; U-Series Cooperative Agreements; ,REGULATORY MANAGEMENT CENTER,,,,,,,,,2067893,
9430244,N01,HL,,N,,,,,N01HB000000,,,268201400008C-3-0-1,NHLBI:59626\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,PITTSBURGH,UNITED STATES,,14,33098401,US,1329103,ALLEGHENY-SINGER RESEARCH INSTITUTE,PA,152124756,,12576719; ,"PFEIFER, REBECCA ;",,12/1/2013,5/31/2017,"Blood Vessels; Clinical; Clinical assessments; Computer software; Contracts; Development; Devices; Diagnostic; Disease; Disease Progression; Future; Goals; hemodynamics; Imaging technology; improved; innovation; Intervention; Learning; medically underserved; Modality; Monitor; National Heart, Lung, and Blood Institute; novel; Patients; product development; prognostic; prognostic tool; programs; pulmonary arterial hypertension; Pulmonary Hypertension; Risk; safety testing; Support Contracts; Testing; Therapeutic; Vascular Diseases; ",IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances (VITA): A Study to Explore the Feasibility of using Combined Modalities to Test the Safety of CaridMEMS Device in PAH Patients,,,,,,,,,59626,
9472862,N02,HD,,N,,,,,N02HD000000,,,275201600088U-2-0-1,NICHD:2226914\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ARLINGTON,UNITED STATES,,,622383052,US,,,VA,222093199,,14614867; ,"BRYANT, CHRISTINA ;",,4/22/2016,4/21/2018,Age; Automobile Driving; Blood Pressure; Code; Contracts; cost; Data; Data Collection; data management; Data Set; Databases; Environment; fast food; Food; Gender; Geography; Height; Internet; Link; Metabolic syndrome; Neighborhoods; Nutritional; population health; Publishing; Reporting; Research; Restaurants; socioeconomics; Speed; Statistical Data Interpretation; Transportation; walkability; ,DATA ANALYSIS AND STATISTICAL PROGRAMMING SUPPORT FOR DIPHR ,,,,,,,,,2226914,
9472864,N01,MH,,N,,,,,N01MH000000,,,271201100004I-1-27100024-1,NINDS:21669\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14745957; ,"BAUGHMAN, KATHRYN ;",,9/30/2016,9/29/2017,"analog; Chemicals; Clinical Research; Clinical Trials; Contracts; Data; Drug Kinetics; Evaluation; Human; Image; Investigational Drugs; Investigational New Drug Application; Magnetic Resonance Imaging; novel; Pharmaceutical Preparations; Pharmacology and Toxicology; Positron-Emission Tomography; Process; programs; Psychotropic Drugs; Radiopharmaceuticals; Research; Research Personnel; Resources; Safety; Testing; Therapeutic; Tomography, Emission-Computed, Single-Photon; Toxic effect; Toxicology; United States Food and Drug Administration; ",Pharmacology and Toxicology for Neurotherapeutics Program-KENNY LDT,,,,,,,,,21669,
9472865,N02,CA,,N,,,,,N02CA000000,,,261201400002I-3-26100002-1,NCI:1850000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BETHESDA,UNITED STATES,,,57052391,US,,TECHNICAL RESOURCES INC,MD,208171197,,14090654; ,"MOLINA, DANIEL ;",,5/30/2014,5/29/2017,cancer prevention; Cancer Prevention Trial; cancer type; Chemopreventive Agent; Clinical; clinical research site; Clinical Trials; Conduct Clinical Trials; Contractor; Contracts; Data; data management; Data Reporting; Databases; Division of Cancer Prevention; Documentation; Ensure; Evaluation; Extramural Activities; Good Clinical Practice; Informatics; International; Intervention; Malignant Neoplasms; Monitor; National Cancer Institute; New Agents; Persons; Pharmacy facility; Phase; phase II trial; Policies; Practice Guidelines; preclinical study; Prevention; prevention clinical trial; Procedures; Process; programs; Protocols documentation; Research Personnel; Research Support; Risk; Role; safety study; Services; Site; Support Contracts; Testing; Training and Education; Work; ,CANCER PREVENTION CLINICAL TRIALS AUDITING & INFORMATICS SUPPORT,,,,,,,,,1850000,
9474075,N01,AI,,N,,,,,N01AI000000,,,272201300002I-5-27200004-1,NIAID:2265914\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12445103; ,"PAL, RANAJIT ;",,5/1/2013,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Breeding; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; germ free condition; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Macaca mulatta; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; operation; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; research study; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY,,,,,,,,,2265914,
9478006,N01,CA,,N,,,,,N01CA000000,,,261201300013I-4-26100005-3,NCI:30500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LEXINGTON,UNITED STATES,,6,939017877,US,2793601,UNIVERSITY OF KENTUCKY,KY,405260001,,14511283; ,"TUCKER, THOMAS ;",,5/1/2015,4/30/2018,cost effective; Data; Ensure; Goals; Insurance; Laws; Malignant Neoplasms; Medical; Modification; Newly Diagnosed; oncology; Recruitment Activity; Research Infrastructure; SEER Program; System; Testing; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,30500,
9478634,N01,CA,,N,,,,,N01CA000000,,,261201300017I-4-26100005-2,NCI:1896986\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,14512953; ,"SWEENEY, CAROL ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF  CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)",,,,,,,,,1896986,
9478643,N01,DA,,N,,,,,N01DA000000,,,271201400020C-9-0-1,NIDA:4999812\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,PISCATAWAY,UNITED STATES,,6,1912864,US,1196203,"RUTGERS, THE STATE UNIV OF N.J.",NJ,88543925,,12247962; ,"TISCHFIELD, JAY ;",,4/30/2014,4/29/2019,addiction; Biocompatible Materials; Blood specimen; Brain; Cell Line; clinical diagnostics; Communities; Computer software; Contracts; cost effective; cyber infrastructure; Data; Data Storage and Retrieval; database of Genotypes and Phenotypes; Databases; Development; distributed data; DNA; Environmental Exposure; epigenomics; Funding; Genetic; genetic pedigree; Genetic study; Genomics; Genotype; Grant; High-Throughput Nucleotide Sequencing; Human Genetics; induced pluripotent stem cell; Information Sciences; interoperability; Link; Molecular; National Institute of Drug Abuse; Phenotype; phenotypic data; Process; repository; Research; Research Personnel; Research Support; Resources; RNA; Serum; Support Contracts; System; United States National Institutes of Health; ,OTHER FUNCTIONS: N01DA-14-7789 NIDA CENTER FOR GENETIC STUDIES TASK ORDER 2; FY14- POP 4/30/2014 - 4/29/2015.,,,,,,,,,4999812,
9480652,N01,AI,,N,,,,,N01AI000000,,,272201200005I-1-27200020-1,NIAID:275146\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14533141; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; cell bank; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; novel vaccines; pathogen; Phase; product development; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; Zika virus vaccine; ,Task X20:Master Cell Banks,,,,,,,,,275146,
9481781,N01,HL,,N,,,,,N01HV000000,,,268201300001I-2-26800003-1,NHLBI:138827\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,14174691; ,"CAI, JIANWEN ;",,7/9/2015,5/31/2016,"Acculturation; aged; Area; Cardiovascular Diseases; Central American; Chicago; Chronic Disease; college; Communities; Cuban; cultural values; design; Diabetes Mellitus; Digestive System Disorders; Disease; Dominican; Echocardiography; Enrollment; epidemiology study; Event; Funding; Gestational Diabetes; Health; Health Services Accessibility; Hispanic Community Health Study; Hispanic Community Health Study/Study of Latinos; Hispanics; Hospitals; Illinois; Incidence; Institutes; interest; Journals; Kidney Diseases; Laboratories; Latino; Left Ventricular Hypertrophy; Length; Logistics; Lung diseases; Medical; Medicine; Mexican; migration; mortality; National Heart, Lung, and Blood Institute; New York; North Carolina; Outcome; Participant; Prevalence; Publications; Puerto Rican; Reading; Recruitment Activity; Research; Risk; Risk Behaviors; Role; Services; Socioeconomic Factors; South American; Time; Universities; Woman; ", HISPANIC COMMUNITY HEALTH STUDY - STUDY OF LATINOS,,,,,,,,,138827,
9483244,N01,CA,,N,,,,,N01CA000000,,,316201200124W-6-0-1,NCI:14167703\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,606270015,US,10002607,"CTIS, INC.",MD,208503236,,14261299; ,"KONOPELSK, PAUL ;",,9/15/2015,8/31/2017,Cancer Therapy Evaluation Program; Contracts; Development; Maintenance; Support System; System; Telecommunications; Work; ,IT AND TELECOM- OTHER IT AND TELECOMMUNICATIONS,,,,,,,,,14167703,
9492900,N01,AI,,N,,,,,N01AI000000,,,272201100019I-0-27200019-3,NIAID:12100\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,15019558; ,"SMEE, DONALD ;",,5/1/2017,4/30/2018,antimicrobial; Biological Assay; Cell Line; Common Cold Virus; Contracts; In Vitro; in vitro testing; Maintenance; respiratory virus; therapeutic evaluation; Viral; virus development; ,Task B26: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses ,,,,,,,,,12100,
9495651,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300004-1,NIEHS:507408\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14617387; ,"WAGNER, DAVID ;",,6/18/2016,6/17/2017,Adverse event; Advertising; Autoantibodies; Autoimmune Process; Autoimmunity; Biopsy; Calcinosis; Clinical; Clinical Research; Collaborations; Conflict of Interest; Connective Tissue Diseases; Consent; Contractor; Contracts; Data; Data Analyses; Data Reporting; Databases; demographics; Department of Defense; Dermatomyositis; Development; Diagnosis; Enrollment; Ensure; Environmental Risk Factor; Evaluation; Health; Hobbies; Human; Laboratories; Ligase; material transfer agreement; Military Personnel; Monitor; Myositis; National Institute of Environmental Health Sciences; Natural History; Nursing Research; Occupations; Pathogenesis; patient subsets; Patients; Periodicity; Physicians; Process; Protocols documentation; Questionnaires; Regulation; Reporting; repository; Research Assistant; Research Support; response; rituximab; sample collection; Sampling; screening; Services; Signs and Symptoms; Site; sodium thiosulfate; Spottings; Surveys; Syndrome; Test Result; Time; Treatment Protocols; Twin Multiple Birth; United States Food and Drug Administration; United States National Institutes of Health; Update; Veterans; Visit; ,Clinical Research Support Services for NIEHS Contract Task Order 4 - Environmental Autoimmunity Group,,,,,,,,,507408,
9497596,N01,HD,,N,,,,,N01HD000000,,,275201500002I-3-27500001-1,NICHD:682698\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14256337; ,"BAUGHMAN, KATHRYN ;",,9/4/2015,9/3/2017,Archives; Biological; Biological Products; Biological Testing; Communication; Computer software; Contraceptive Agents; Contraceptive methods; Contractor; Contracts; Data; Data Analyses; data archive; Data Storage and Retrieval; Databases; Documentation; Equipment; Equipment and supply inventories; Government; Histopathology; Maintenance; Manuals; men; National Institute of Child Health and Human Development; new product development; Office of Administrative Management; preclinical development; Principal Investigator; product development; programs; Property; Reagent; Sampling Studies; Scanning; Ships; Site Visit; Specimen; Teleconferences; Woman; ,"BIOLOGICAL TESTING FACILITY - MANAGEMENT, ADMINISTRATION AND DATABASE",,,,,,,,,682698,
9503676,N01,AI,,N,,,,,N01AI000000,,,272201300011C-7-0-1,NIAID:6965269\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14666565; ,"NEERAJA, PUTTA ;",,6/16/2013,6/15/2018,Acquired Immunodeficiency Syndrome; AIDS/HIV problem; Clinical Research; clinical research site; Cognitive; Comorbidity; Contracts; Cyclic GMP; Databases; design; Equipment and supply inventories; expiration; Hepatitis C; International; Label; Location; manufacturing facility; Monitor; National Institute of Allergy and Infectious Disease; operation; Pharmaceutical Preparations; Pharmaceutical Services; Pharmacists; Pharmacy facility; Procedures; Process; programs; Protocols documentation; Reporting; Research; Ships; Site; Technical Expertise; Training; Tuberculosis; United States; United States National Institutes of Health; ,Clinical Research Products Management Center (CRPMC),,,,,,,,,6965269,
9503677,N01,AI,,N,,,,,N01AI000000,,,272201200022C-10-0-1,NIAID:3292436\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14612930; ,"BROWN, BRUCE ;",,7/15/2012,7/14/2018,Acquired Immunodeficiency Syndrome; AIDS/HIV problem; Biotechnology; Communication; Contracts; cost; Development; Educational workshop; Enhancement Technology; Methods; Pharmacologic Substance; programs; Protocols documentation; Publications; Reagent; reagent standard; reagent standardization; Research; Research Personnel; Resources; Technology; Technology Transfer; ,AIDS REAGENT PROGRAM (ARP),,,,,,,,,3292436,
9503678,N02,HD,,N,,,,,N02HD000000,,,275201400090U-6-0-1,NICHD:292173\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,GAITHERSBURG,UNITED STATES,,,114394778,US,,,MD,208793328,,12441486; ,"MILLER, VANESSA ;",,9/30/2014,9/29/2017,Advocate; Clinical Data; Collection; Common Data Element; Communication; Contractor; Custom; Data; Data Set; Databases; Development; Disease; Down Syndrome; Environment; Funding; Individual; individual patient; Language; Legal; Link; Maintenance; Marketing; Minor; mobile application; National Institute of Child Health and Human Development; operation; Parents; patient registry; Patients; programs; Registries; Research; Services; Support System; System; Translating; Translations; United States National Institutes of Health; ,RESEARCH DATA PATIENT REGISTRY ENVIRONMENT AND DS-CONNECT: THE DOWN SYNDROME REGISTRY,,,,,,,,,292173,
9509684,N01,AI,,N,,,,,N01AI000000,,,272201000010I-0-27200002-1,NIAID:50007\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14973643; ,"FROTHINGHAM, RICHARD ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,50007,
9514440,N01,HL,,N,,,,,N01HL000000,,,268201600005I-0-26800002-1,NHLBI:219521\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,PHILADELPHIA,UNITED STATES,,1,57123192,US,8240301,TEMPLE UNIV OF THE COMMONWEALTH,PA,191226003,,14949871; ,"CRINER, GERARD ;",,3/1/2017,2/28/2018,Chronic Obstructive Airway Disease; Clinical; Clinical Data; Contractor; Data; Enrollment; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Link; Lung diseases; Operative Surgical Procedures; Pathogenesis; Phenotype; Process; programs; Research; Research Personnel; sample collection; Specimen; Structure of parenchyma of lung; Tissues; wasting; ,IGF::OT::IGF LTRC CLINICAL CENTER - TASK ORDER 2 - 03/01/2017 - 02/28/2018 - CAN 17-8470204,,,,,,,,,219521,
9514712,N01,AI,,N,,,,,N01AI000000,,,272201100018I-1-27200010-1,NIAID:74331\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,14608929; ,"PATTERSON, THOMAS ;",,8/1/2017,7/31/2018,Anti-Bacterial Agents; Antifungal Agents; Basic Science; Biological Assay; Contracts; Development; in vitro testing; Maintenance; Pneumocystis; scale up; System; ,Task A22: Development of a new system for scaled-up culture and propagation of Pneumocystis,,,,,,,,,74331,
9518509,N01,AI,,N,,,,,N01AI000000,,,272201300019I-6-27200005-1,NIAID:3218382\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,78198520,US,3080503,KAISER FOUNDATION HEALTH PLAN OF WASHINGTON,WA,981011466,,8449685; ,"JACKSON, LISA A;",,9/4/2015,9/1/2017,Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; Malaria Vaccines; named group; novel; Phase; Phase I Clinical Trials; Population; Resources; Route; System; vaccine trial; Vaccines; ,Vaccine and Treatment Evaluation Unit: Phase I Malaria Vaccine Study ,,,,,,,,,3218382,
9521000,N01,AI,,N,,,,,N01AI000000,,,272201100018I-4-27200009-2,NIAID:4456\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,14922087; ,"PATTERSON, THOMAS ;",,2/1/2016,1/31/2017,Antifungal Agents; Biological Assay; Contracts; Development; Histoplasma capsulatum; in vitro testing; Maintenance; pathogen; therapeutic development; Translational Research; ,Task A21: In vitro testing against fungal pathogens,,,,,,,,,4456,
9521673,N01,HD,,N,,,,,N01HD000000,,,275201400004C-5-0-1,NIAAA:722967\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CHARLESTON,UNITED STATES,,6,183710748,US,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,294035120,,12367044; ,"BECKER, HOWARD C. PH.D. ;",,8/1/2014,7/31/2019,Address; Alcohol consumption; Alcohol dependence; Alcoholism; Alcohols; Animal Model; Animals; Behavior; blind; clinical toxicology; Consumption; Contractor; Contracts; Darkness; Data; Data Display; Dependence; deprivation; Development; drinking; Drug Industry; Drug Kinetics; efficacy testing; Ensure; Ethanol; experience; Future; Guidelines; Human Resources; indexing; Intake; Intellectual Property; interest; Liquid substance; Locomotion; member; Methodology; Modeling; mouse model; Mus; National Institute on Alcohol Abuse and Alcoholism; Nature; Neurosciences; Outcome; Pharmaceutical Preparations; pre-clinical; preference; Program Development; programs; Protocols documentation; Provider; Quinine; Reflex action; Reporting; Respondent; response; screening; Standardization; Statistical Data Interpretation; Sucrose; Taste Perception; Testing; vapor; Withdrawal; ,Preclinical Medications Screening in Dependence Models of Alcoholism.,,,,,,,,,722967,
9521675,N01,DA,,N,,,,,N01DA000000,,,316201200037W-0-0-2,NIAMS:0\NICHD:0\NIEHS:0\NIMH:0\NINDS:227005\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,,,,,,,,"OMNITEC SOLUTIONS, INC",,,,14588800; ,"HALL, DAN ;",,7/1/2017,6/30/2018,Affect; Archives; autism spectrum disorder; Autistic Disorder; biomedical informatics; Brain Diseases; Data; Data Collection; Databases; Diagnosis; flexibility; Genetic; interest; operation; Persons; Prevention; repository; Research; Retrieval; Series; System; United States National Institutes of Health; ,IGF::OT::IGF  Management and Operations Support for the National Database for Autism Research,,,,,,,,,227005,
9521680,N01,AI,,N,,,,,N01AI000000,,,272201000051C-22-0-1,NIAID:376160\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,YEMASSEE,UNITED STATES,,,199145954,US,,ALPHA GENESIS INC,SC,299457115,,7696259; ,"WESTERGAARD, GREG ;",,9/30/2016,9/29/2017,Breeding; Contractor; Contracts; cooperative study; germ free condition; Immune Tolerance; Macaca fascicularis; Macaca mulatta; Maintenance; Modeling; nonhuman primate; novel; preclinical efficacy; preclinical safety; Primates; Regimen; Research Support; Transplantation; Transplantation Tolerance; ,Nonhuman Primate Breeding Colony,,,,,,,,,376160,
9521687,N02,DA,,N,,,,,N02DA000000,,,271201600036C-1-0-1,NINDS:7280\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CHAPEL HILL,UNITED STATES,,4,362726007,US,3709001,"RHO FEDERAL SYSTEMS DIVISION, INC.",NC,275178079,,14769110; ,"PATTERSON, BRYAN ;",,9/7/2017,9/6/2018,Achievement; Address; Adherence; Affect; Agreement; Animals; Area; authority; Award; Bachelor's Degree; base; Basic Science; Behavior; Biologic Development; Biotechnology; Brain; Businesses; Cell Therapy; Characteristics; Chemistry; Client; clinical development; clinical investigation; Clinical Investigator; Clinical Protocols; Clinical Research; Clinical Trials; clinically relevant; Code; Collaborations; Color; Communities; Comprehension; Computers; Conduct Clinical Trials; Confidential Information; Consent; Consult; Contractor; Contracts; cost; Data; Data Analyses; Data Files; Decision Making; design; Development; Development Plans; Disabled Persons; Discipline; Disclosure; Disease; Documentation; Drug Evaluation; Drug Industry; Educational workshop; Electronic Mail; Elements; Employee; encryption; Evaluation; Evaluation Research; experience; experimental study; Extramural Activities; federal policy; Feedback; Food; Funding; gene therapy; Government; Grant; Guidelines; Health; health data; Home environment; Hour; Human; Human Resources; indexing; Individual; Industry; Information Technology; Institutes; Institution; Internet; Intramural Research Program; Investigation; Investigational Drugs; Joints; Knowledge; Lead; Licensing; Life; Mediation; meetings; member; Mission; Modality; Monitor; multidisciplinary; Multimedia; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; novel; novel therapeutic intervention; Oligonucleotides; Oral; Outcome; Ownership; Participant; Peptide antibodies; Performance; Performance at work; Personnel Management; Persons; Pharmacology and Toxicology; Phase; Preparation; Prevention; Price; Principal Investigator; Privacy; Privacy Act; Process; product development; Production; programs; Progress Reports; Property; Protocols documentation; Recombinant Proteins; Recommendation; Regulation; Regulatory Affairs; Rehabilitation therapy; Reporting; Research; Research Activity; Research Design; Research Personnel; Research Project Grants; research study; Resolution; Resources; response; Rights; Risk; Role; scale up; Scanning; Schedule; Secure; Security; Services; Site; Site Visit; skills; Specific qualifier value; Speech; stroke; Supervision; symposium; Telephone; Testing; Theft; Therapeutic; therapy development; Time; Time Management; Training; Training Programs; Translational Research; Translations; Travel; U-Series Cooperative Agreements; United States; United States Food and Drug Administration; United States National Institutes of Health; Virus; Visit; Visual; web site; webinar; Weight; Work; Writing; ,NINDS RHOFED BPN REGULATORY AFFAIRS CONSULTING IGF::CL::IGF,,,,,,,,,7280,
9521690,N01,HL,,N,,,,,N01HL000000,,,268201600014I-2-26800001-1,NHLBI:132980\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,14658137; ,"MCKENNA, DAVID ;",,8/1/2016,6/30/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities,,,,,,,,,132980,
9521762,N01,CA,,N,,,,,N01CA000000,,,261201300010I-0-26100010-1,NCI:31400\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALBUQUERQUE,UNITED STATES,,1,829868723,US,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,NM,871310001,,15115064; ,"WIGGINS, PH.D., CHARLES ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF HHSN261201300010I-HHSN26100010. PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016 (POC/QOC SEER STUDY) POP 07/31/2017-07/30/2018.,,,,,,,,,31400,
9521764,N01,CA,,N,,,,,N01CA000000,,,261201300021I-0-26100010-1,NCI:165637\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW BRUNSWICK,UNITED STATES,,6,78728091,US,10034166,RBHS -CANCER INSTITUTE OF NEW JERSEY,NJ,89011914,,15111717; ,"ANTOINETTE, STROUP ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016  PERIOD OF PERFORMANCE:  07/31/2017 - 07/30/2018,,,,,,,,,165637,
9523022,N01,HL,,N,,,,,N01HL000000,,,268201700001C-0-0-1,NHLBI:535149\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14921883; ,"RAJAGOPAL, SUDARSHAN ;",,11/15/2016,11/14/2019,Aortic Aneurysm; Area; Breathing; clinical translation; Coronary Arteriosclerosis; Devices; Diagnosis; Diagnostic; Diagnostic tests; Disease; Dissection; Heart Diseases; human subject; imaging probe; interest; intracranial artery; Lung; Lung diseases; Lymphatic Diseases; Lymphatic System; Magnetic Resonance Imaging; noninvasive diagnosis; Peripheral arterial disease; Pharmaceutical Preparations; product development; programs; Pulmonary Hypertension; pulmonary vascular disorder; Research; research clinical testing; Sensitivity and Specificity; Symptoms; Technology; Thrombosis; Vascular Diseases; Venous; ,IGF::OT::IGF NON-INVASIVE DIAGNOSIS OF PULMONARY VASCULAR DISEASE USING INHALED 129XE MRI,,,,,,,,,535149,
9525656,N01,HD,,N,,,,,N01HD000000,,,275201300016I-5-27500001-1,NICHD:12930\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,12447340; ,"TUROK, DAVID ;",,6/26/2013,6/25/2018,Basic Science; Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; Contraceptive methods; Contracts; Development; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Health education; Lead; Male Contraceptive Agents; Methods; Mission; National Institute of Child Health and Human Development; Obesity; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; Protocols documentation; Reproductive Health; Risk; Site; Social Welfare; synthetic peptide; Testing; Thromboembolism; unintended pregnancy; United States National Institutes of Health; Venous; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES,,,,,,,,,12930,
9525756,N02,DA,,N,,,,,N02DA000000,,,271201600040C-1-0-1,NINDS:8000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CHAPEL HILL,UNITED STATES,,,122466548,US,,,NC,275168376,,14772086; ,"BURGER, SCOTT ;",,9/21/2017,9/20/2018,Academia; Achievement; Address; Affect; Agreement; analytical method; Area; authority; Award; base; Basic Science; Behavior; Biochemistry; Biologic Development; Biological Assay; Biological Products; Biological Sciences; Biotechnology; Brain; Businesses; Cell Therapy; Cells; Characteristics; Chemicals; Client; Clinical; clinical development; clinical investigation; Clinical Protocols; Clinical Research; Clinical Trials; Code; Collaborations; Color; Communities; Complex; Comprehension; Computers; Confidential Information; Consent; Consult; Contractor; Contracts; cost; Data; Data Analyses; Data Files; Decision Making; design; Development; Development Plans; Disabled Persons; Disclosure; Disease; Doctor of Philosophy; Documentation; Educational workshop; Electronic Mail; Elements; Employee; encryption; Evaluation; experience; experimental study; Extramural Activities; federal policy; Feedback; Food; Formulation; Funding; gene therapy; Government; Grant; Guidelines; Health; health data; Home environment; Hour; Human; Human Resources; indexing; Individual; Industry; Information Technology; Institutes; Institution; Internet; Intramural Research Program; Investigational Drugs; Joints; Knowledge; Lead; Licensing; Life; Liposomes; Mediation; member; method development; Methods; Mission; Modality; Monitor; multidisciplinary; Multimedia; Names; nanoparticle; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; novel therapeutic intervention; Oligonucleotides; Oral; Ownership; Participant; Peptide antibodies; Performance; Performance at work; Personnel Management; Persons; Phase; Polymers; Preparation; Prevention; Price; Principal Investigator; Privacy; Privacy Act; Process; Production; programs; Progress Reports; Property; Published Comment; Recombinant Proteins; Recommendation; Regulation; Rehabilitation therapy; Reporting; Research; Research Activity; Research Design; Research Personnel; Research Project Grants; Resolution; Resources; response; Rights; Risk; Role; scale up; Scanning; Schedule; Security; Services; Site; Site Visit; skills; Specific qualifier value; Speech; stability testing; stroke; Supervision; symposium; Telephone; Testing; Theft; Therapeutic; therapy development; Time; Time Management; Training; Training Programs; Translational Research; Translations; Travel; U-Series Cooperative Agreements; United States; United States National Institutes of Health; Viral; Virus; Visit; Visual; web site; webinar; Weight; Work; Writing; ,NINDS ADVANCED CELL AND GENE THERAPY CMC CONSULTING IGF::CL::IGF,,,,,,,,,8000,
9526060,N01,CA,,N,,,,,N01CA000000,,,261201300004I-0-26100011-1,NCI:134318\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LOS ANGELES,UNITED STATES,,37,72933393,US,7636101,UNIVERSITY OF SOUTHERN CALIFORNIA,CA,900339263,,15124106; ,"HAMILTON, ANN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnostic; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/ QUALITY OF CARE STUDY/ DIAGNOSTIC YEAR 2016POP: 07/31/2017 - 07/30/2018,,,,,,,,,134318,
9528360,N01,AI,,N,,,,,N01AI000000,,,272201400030C-7-0-3,NIAID:1895091\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,14175030; ,"ROOS, DAVID ;",,9/30/2017,9/29/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; fungus; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; ,BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES ,,,,,,,,,1895091,
9528361,N01,AI,,N,,,,,N01AI000000,,,272201400014C-3-0-1,NIAID:1220827\NICHD:294388\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,1870526; ,"DENNY, THOMAS ;",,9/30/2014,9/29/2018,base; CD8-Positive T-Lymphocytes; CD8B1 gene; Clinical Trials Network; computerized; cost; Data; data management; Diagnosis; Disease; Ensure; Freezing; Future; Immunologic Tests; Immunology; instrument; Laboratories; Laboratory Procedures; Libraries; Lymphocyte Count; Measures; Monitor; National Institute of Allergy and Infectious Disease; new technology; novel; Online Systems; Performance; Peripheral Blood Mononuclear Cell; Procedures; programs; Records; Reporting; repository; Resolution; Resources; Site; Specific qualifier value; System; technology validation; Testing; Training; ,IMMUNOLOGY QUALITY ASSESSMENT PROGRAM,,,,,,,,,1515215,
9529452,N01,AI,,N,,,,,N01AI000000,,,272201400018C-5-0-1,NIAID:1219812\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,68552207,US,9083901,WASHINGTON UNIVERSITY,MO,631304862,,12441804; ,"FREMONT, DAVED ;",,7/1/2017,6/30/2019,Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; Bioterrorism; Computer software; Contracts; Data; Databases; Emerging Communicable Diseases; Epitope Mapping; Epitopes; Evaluation; Goals; Human; Humoral Immunities; Immune; In Vitro; multidisciplinary; neutralizing antibody; novel; Pathogenesis; programs; Resources; Sampling; therapeutic development; Toxin; vaccine development; Validation; Zika Virus; ,B Cell Epitope Mapping of Zika,,,,,,,,,1219812,
9531998,N01,AI,,N,,,,,N01AI000000,,,272201100021I-1-27200032-1,NIAID:81463\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14721631; ,"ISHIKAWA, PHILLIP ;",,8/30/2016,1/30/2020,Adenovirus Vector; AIDS prevention; authority; Contracts; Development; Documentation; flexibility; Guidelines; HIV; HIV vaccine; immunogenicity; Investigational Drugs; Investigational New Drug Application; Investigator-Initiated Research; microbicide; Modality; National Institute of Allergy and Infectious Disease; Pamphlets; Phase; preclinical development; Preclinical Testing; Process; Production; Protocols documentation; research clinical testing; Research Personnel; research study; Safety; Testing; vector vaccine; ,NIAID PRECLINICAL DEVELOPMENT SUPPORT - SUPPORT FOR PRODUCTION AND TESTING OF ADC6-HIV GP140 AND ADC7-HIV GP140,,,,,,,,,81463,
9430245,N01,AI,,N,,,,,N01AI000000,,,272201200009C-8-0-1,NIAID:11271499\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,12577171; ,"BREWER, BRENDA ;",,11/15/2011,11/14/2017,AIDS/HIV problem; Area; Biometry; Clinical; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Communicable Diseases; Contracts; data management; Ensure; Funding; Good Clinical Practice; HIV; Laboratories; Medical; Monitor; National Institute of Allergy and Infectious Disease; operation; Participant; Practice Guidelines; programs; Regulation; Research Support; Safety; Services; Site; Social Welfare; Training; Translations; Writing; ,NIAID HIV AND OTHER INFECTIOUS DISEASES CLINICAL RESEARCH SUPPORT SERVICES (CRSS),,,,,,,,,11271499,
9430293,N01,HL,,N,,,,,N01HL000000,,,268201600001C-2-0-1,NCI:0\NHLBI:1246650\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,AMHERST,UNITED STATES,,26,38633251,US,5992614,STATE UNIVERSITY OF NEW YORK AT BUFFALO,NY,14228,,14368939; ,"CASEY, MARLENE ;",,10/15/2015,10/14/2017,Cardiovascular Diseases; Communities; Contracts; follow-up; Knowledge; Mentors; older women; Research Personnel; Resources; Women's Health; ,IGF::CT::IGF - WOMEN HEALTH INITIATIVE - REGIONAL CENTER,,,,,,,,,1246650,
9430295,N01,AI,,N,,,,,N01AI000000,,,N01AI40096-25-0-1,NIAID:9797\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,1,5447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,,14650806; ,"LINNELL, REBECCA ;",,9/30/2004,12/19/2017,Animal Model; Animals; biodefense; Cellular Immunity; Contracts; Development; Disease; efficacy testing; Humoral Immunities; immunogenicity; In Vitro; Influenza; Licensure; Modeling; nonhuman primate; Pharmacology; safety testing; Standardization; Testing; Therapeutic; therapeutic evaluation; Toxicology; vaccine evaluation; Vaccines; ,Task Order 2/E04: H1N5 Influenza Toxicology Studies,,,,,,,,,9797,
9430299,N01,AI,,N,,,,,N01AI000000,,,272201000040I-7-27200009-1,NIAID:633348\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,12576287; ,"BARRETT, ALAN ;",,12/1/2014,4/27/2017,Animal Model; Contracts; Dengue Virus; Development; efficacy testing; infectious disease model; mouse model; Standardization; therapeutic evaluation; Therapeutic Human Experimentation; Translational Research; vaccine evaluation; Vaccine Research; ,Task A71: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus,,,,,,,,,633348,
9430302,N01,AI,,N,,,,,N01AI000000,,,272201200003I-3-27200013-1,NIAID:280945\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14223657; ,"BRUCE, MARY ;",,8/10/2015,6/30/2017,Antimicrobial Resistance; assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; Escherichia coli Vaccines; Evaluation; evaluation/testing; Feasibility Studies; immunogenicity; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; vaccine candidate; Vaccines; ,Task X13: Evaluation of an E. coli Vaccine Candidate - Immunogenicity Testing,,,,,,,,,280945,
9430325,N01,AI,,N,,,,,N01AI000000,,,272201300021I-2-27200015-1,NIAID:27849\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,14652702; ,"SILER, WILLIAM ;",,7/12/2016,3/31/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,Vaccine and Treatment Evaluation Unit - Clinical Operations Support,,,,,,,,,27849,
9430327,N01,AI,,N,,,,,N01AI000000,,,272201200003I-1-27200017-1,NIAID:790279\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14636697; ,"HORNBACK, RANDI ;",,7/6/2016,7/5/2018,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Falciparum Malaria; Feasibility Studies; immunogenicity; Malaria Vaccines; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; Toxicology; vaccine development; vaccine safety; Vaccines; ,Task X17: Malaria Vaccine Safety and Toxicology Studies,,,,,,,,,790279,
9430330,N43,CA,,N,,,,,N43CA000000,,,261201500073C-3-0-1,NCI:1999999\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BROOKFIELD,UNITED STATES,,5,966566465,US,3461901,"SIBTECH, INC.",CT,68043400,,14278140; ,"BACKER, JOSEPH ;",,9/30/2015,10/31/2018,Affinity; Binding; Cancer Patient; Chelating Agents; chemotherapy; clinical development; Contracts; cost effective; Data; Development; dosimetry; Engineering; Goals; Growth; improved; KDR gene; Lead; malignant breast neoplasm; Mediating; Metastatic breast cancer; Modeling; mouse model; Neoplasm Metastasis; Patients; Phase; phase I trial; Physicians; preclinical development; Preparation; Primary Neoplasm; Production; Radionuclide therapy; Radiopharmaceuticals; receptor; Recombinants; Site; targeted treatment; Testing; Therapeutic; Toxicology; tumor; Universities; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors; vessel regression; ,IGF::OT::IGF SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE,,,,,,,,,1999999,
9430338,N01,LM,,N,,,,,N01LM000000,,,276201100016C-18-0-1,NIDDK:680556\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,PISCATAWAY,UNITED STATES,,6,1912864,US,1196203,"RUTGERS, THE STATE UNIV OF N.J.",NJ,88543925,,12387810; ,"TISCHFIELD, JAY ;",,9/24/2016,3/31/2017,Blood specimen; Cell Line; Clinical; Collection; Communities; Contracts; cost effective; Custom; Data; Disease; DNA; Ensure; Ethics; Funding; Genes; Genetic; Genetic Determinism; Genetic Materials; genetic pedigree; genetic variant; Grant; immortalized cell; Individual; Institutes; Lymphocyte; Maintenance; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; Participant; Population; Population Control; Process; Quality Control; repository; Research; Research Personnel; Resource Sharing; Resources; RNA; Sample Size; Sampling; United States National Institutes of Health; Work; ,NIDDK Genetics Repository,,,,,,,,,680556,
9430341,N01,AI,,N,,,,,N01AI000000,,,272201300015I-2-27200009-1,NIAID:203024\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14605359; ,"EL SAHLY, HANA ;",,6/15/2016,3/15/2019,Antimicrobial Resistance; Bacterial Drug Resistance; Clinical Research; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Diagnostics Research; Individual; Lower Respiratory Tract Infection; named group; pathogen; Population; programs; Resources; Therapeutic Human Experimentation; Translational Research; ,VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI),,,,,,,,,203024,
9430355,N01,DA,,N,,,,,N01DA000000,,,271201400028C-12-0-1,NIDA:3733019\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,12319702; ,"VANVELDHUISEN, PAUL ;",,6/19/2014,7/9/2019,base; Behavior Therapy; Clinical Research; Clinical Trials; community setting; Conduct Clinical Trials; Consultations; Contractor; Country; Data; Drug abuse; Effectiveness; Funding Mechanisms; Goals; Grant; National Institute of Drug Abuse; Performance; Pharmaceutical Preparations; Phase; Resources; Science; Site; statistics; Testing; Therapy trial; U-Series Cooperative Agreements; ,"IGF::OT::IGF: DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT FOR NIDA (DSC4). N01DA-14-2237. PERIOD OF PERFORMANCE: JUNE 19, 2014 TO JUNE 18, 2019. ",,,,,,,,,3733019,
9430362,N01,AI,,N,,,,,N01AI000000,,,272201400033C-5-0-1,OD:26544\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,73757627,US,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PA,191044318,,12404524; ,"LAMBERT, MICHELE ;",,9/1/2014,8/31/2017,Advanced Development; Biological Products; Calcium; Complex; Contracts; Data; drug candidate; Formulation; Heparin; Investigational Drugs; Investigational New Drug Application; Laboratories; Lead; Licensure; Medical; Osmolalities; Pharmacologic Substance; product development; programs; Proteins; Radiation; Radiation Toxicity; research and development; subcutaneous; Subcutaneous Injections; Thrombocytopenia; Translational Research; ,"2-O, 3-O desulfated heparin as a Countermeasure for Radiation-Induced Thrombocytopenia",,,,,,,,,26544,
9430367,N01,HL,,N,,,,,N01HL000000,,,268201600020C-1-0-1,NHLBI:791702\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14628163; ,"LINDBLAD, ROBERT ;",,1/1/2017,10/31/2017,Animals; Area; Cell Therapy; Disease; effective therapy; Monitor; Natural regeneration; Organ; Production; programs; Research Personnel; Services; System; Therapeutic Studies; Tissues; Translational Research; working group; ,Production Assistance for Cellular Therapies (PACT) - Coordinating Center (CC),,,,,,,,,791702,
9430378,N02,CA,,N,,,,,N02CP000000,,,261201300002C-9-0-1,OD:103203\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,,,,683523359,,,,,,,12377190; ,"ROZHKO, ALEXANDER ;",,2/15/2013,2/14/2018,Accidents; Affect; Age; Area; Belarus; cohort; Dose; follow-up; in utero; Life; Malignant neoplasm of thyroid; Measures; nuclear power; Pathology; Persons; prospective; Radiation; Thyroid Diseases; Thyroid Gland; Time; ,Support For Thyroid Cancer & Other Thyroid Diseases in Belarus,,,,,,,,,103203,
9434266,R21,AG,1,N,12/26/2017,1/1/2017,12/31/2018,866,R21AG058005,SCHOOLS OF MEDICINE,PA-16-161,1R21AG058005-01,NIA:191933\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE ON AGING,,AURORA,UNITED STATES,PHARMACOLOGY,6,41096314,US,1199905,UNIVERSITY OF COLORADO DENVER,CO,800452571,,10814407; ,"KENNEDY, MATTHEW J;","WISE, BRADLEY C",1/1/2017,12/31/2019,abeta oligomer; Aftercare; age related; Alzheimer's Disease; Amino Acids; Amyloid beta-Protein; Amyloid beta-Protein Precursor; amyloid peptide; Amyloid Proteins; Anatomy; base; Binding; Biochemical; Biological Assay; Brain; Cell Death; cellular pathology; Cerebrospinal Fluid; cognitive function; Coupled; Coupling; Cyclic AMP-Dependent Protein Kinases; Data; Dementia; Development; Disease; Dose; Electrophysiology (science); Excision; Excitatory Synapse; Exposure to; Functional disorder; Genetic; Glutamate Receptor; Goals; Image; Impairment; Individual; insight; Knockout Mice; Learning; light microscopy; Link; Measures; Mediating; Molecular; N-Methyl-D-Aspartate Receptors; N-Methylaspartate; Neuraxis; Neurodegenerative Disorders; neuron loss; neurotoxic; neurotransmission; novel; Pathologic; Peptides; Permeability; Pharmacology; Phosphorylation; Phosphorylation Site; Play; postsynaptic; Process; Proteins; receptor; Receptor Activation; receptor function; Regulation; Reporting; Resolution; response; Role; Second Messenger Systems; sequential proteolysis; Signal Pathway; Signal Transduction; Signaling Molecule; Site; stem; Surface; Synapses; synaptic function; Synaptic plasticity; tau phosphorylation; tau Proteins; Techniques; Testing; Work; ,Mechanisms of beta-amyloid induced synaptic dysfunction,58005,CMND,Cellular and Molecular Biology of Neurodegeneration Study Section ,,,1,125000,66933,191933,
9437001,R21,AI,1,N,12/26/2017,12/26/2017,11/30/2018,855,R21AI135711,SCHOOLS OF MEDICINE,PA-16-161,1R21AI135711-01,NIAID:263440\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,INTERNAL MEDICINE/MEDICINE,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,6864303; ,"MORENO, ALBERTO ;","MCGUGAN, GLEN C",12/26/2017,11/30/2019,Address; Adult; Animal Model; Aotus primate; Area; atovaquone; B-Lymphocytes; base; Bile Acids; Biological; Biological Markers; Biology; biomarker identification; Blood; Bone Marrow; Bone Marrow Stem Cell; CD14 gene; CD3 Antigens; CD34 gene; Cebidae; Cells; Chimerism; Clinical; cohort; Detection; Development; Disease; Drug resistance; effective intervention; Engraftment; Ensure; Enzyme-Linked Immunosorbent Assay; Erythrocytes; experience; Experimental Animal Model; Experimental Models; Flow Cytometry; Generations; Genetic; Glucosephosphate Dehydrogenase Deficiency; Goals; Growth; Health; Hematopoietic; Hematopoietic stem cells; Hematopoietic System; Hepatic; Hepatocyte; Histology; Human; Immune; Immune response; Immunity; Immunological Models; In Vitro; in vivo; Inbred NOD Mice; Individual; Infection; insight; Integration Host Factors; Intervention; Intervention Studies; Investigation; Life Cycle Stages; Liver; Macaca; Macaca mulatta; macrophage; Malaria; Measures; metabolomics; Methods; Modeling; Molecular; Monkeys; monocyte; mouse model; MS4A1 gene; Mus; nonhuman primate; novel; novel marker; Parasites; Pattern; peripheral blood; Phylogenetic Analysis; Plasmodium; Plasmodium cynomolgi; Plasmodium falciparum; Plasmodium ovale; Plasmodium vivax; Primaquine; Primary Infection; Primates; Production; Property; PTPRC gene; Relapse; Reporting; Reproducibility; Research; Research Priority; Reticulocytes; Sampling; specific biomarkers; Spleen; Sporozoites; T-Lymphocyte; Testing; TFRC gene; Time; Tissue Sample; tool; transmission process; Transplantation; Vaccination; Woman; Xenograft procedure; ,Development of simianized mice to study the biology of relapsing malaria parasites,135711,PTHE,Pathogenic Eukaryotes Study Section ,,,1,150000,113440,263440,
9440305,N01,ES,,N,,,,,N01ES000000,,,273201600002I-2-27300001-1,NIEHS:769312\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14576283; ,"WAGNER, DAVID ;",,6/1/2016,5/31/2017,Advertising; Agreement; base; Clinic; Clinical Research; Clinics and Hospitals; Collaborations; Contractor; Contracts; cost; cost effective; Data; Data Collection; Equipment; Generations; Health; Health Services; Healthcare; Internet; Interview; Location; Logistics; Maintenance; Management Information Systems; Medical center; National Institute of Environmental Health Sciences; Office of Administrative Management; Personal Communication; Personally Identifiable Information; Principal Investigator; Printing; Procedures; Provider; Radio; Recruitment Activity; Reporting; Research; Research Infrastructure; Research Institute; Research Support; Resources; Sampling; Secure; Security; Services; Specimen Handling; System; Telephone; Television; Training; Universities; Visit; Work; ,Clinical Research Support Services for NIEHS Contract Task Order 1 - Core Function Activities,,,,,,,,,769312,
9443551,N01,CA,,N,,,,,N01CA000000,,,261201500039I-2-26100003-1,NCI:151260\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW YORK,UNITED STATES,,12,60217502,US,1514803,WEILL MEDICAL COLL OF CORNELL UNIV,NY,100654805,,1873540; ,"LIPKIN, STEVEN M;",,9/24/2015,9/23/2017,Chemoprevention; Clinical; Development; Hereditary Nonpolyposis Colorectal Neoplasms; Immunotherapy; Malignant neoplasm of gastrointestinal tract; mutant; novel vaccines; Peptide Vaccines; Pre-Clinical Model; small molecule; Testing; Vaccines; ,IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER,,,,,,,,,151260,
9443552,N01,ES,,N,,,,,N01ES000000,,,273201400022C-7-0-1,NIEHS:4824449\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,12627956; ,"FERNANDO, RESHAN ;",,7/30/2014,2/28/2018,Acrylamides; Adverse effects; Amniotic Fluid; Blood specimen; Brain; Chemicals; Chemistry; Colon; Contracts; Cyclophosphamide; deoxynivalenol; Development; disorder prevention; Dose; drinking water; Duodenum; Ensure; Environmental Exposure; Evaluation; Exposure to; feeding; Fetus; Formulation; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; Human; immunotoxicity; Laboratories; Mammary gland; Measures; Methods; Milk thistle extract; Mus; National Toxicology Program; Oryctolagus cuniculus; Outcome; Oxides; Performance; phthalates; Plasma; pregnant; prenatal; public health research; Rattus; Reporting; Research; Risk Assessment; Risk Factors; Services; Sodium Chloride; sound; Specific qualifier value; Technology; Testing; Thallium; Tissue Sample; Tissues; Toxic effect; Toxicity Tests; Toxicology; Tungsten; Unspecified or Sulfate Ion Sulfates; Vanadium; Whole Blood; ,"CHEMISTRY SERVICES FOR THE NATIONAL TOXICOLOGY PROGRAM, Sub 1",,,,,,,,,4824449,
9444398,N01,HL,,N,,,,,N01HL000000,,,268201600014C-1-0-1,NHLBI:1406438\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14445006; ,"BAUGHMAN, KATHRYN ;",,3/1/2016,2/28/2018,"Address; base; clinical practice; community organizations; Disease; Family health status; Fostering; Government Agencies; Health; Health Professional; Heart Diseases; Hematological Disease; Individual; Industry; Institutes; Institution; International; Leadership; Lung diseases; Mentors; National Heart, Lung, and Blood Institute; patient advocacy group; Patients; Pharmacology and Toxicology; Physicians; Prevention; Privatization; Professional Organizations; programs; Public Health; Research; Research Infrastructure; Research Training; Resources; Scientist; Training; Training and Education; Translations; ","IGF::OT::IGF SMARTT PHARMACOLOGY AND TOXICOLOGY CENTER (PTC); BASE PERIOD; FY16; AMT $1,653,316; CAN 8470205",,,,,,,,,1406438,
9453385,R03,HD,1,N,12/26/2017,12/26/2017,11/30/2018,865,R03HD088806,SCHOOLS OF ARTS AND SCIENCES,PA-16-162,1R03HD088806-01A1,NICHD:88507\,Non-SBIR/STTR RPGs,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,UNIVERSITY PARK,UNITED STATES,NONE,5,3403953,US,1524202,PENNSYLVANIA STATE UNIVERSITY-UNIV PARK,PA,168027000,,11317242 (contact); 9120235; ,"DAMASKE, SARAH  (contact); FRECH, ADRIANNE ;","BURES, REGINA M",12/26/2017,11/30/2019,Acute; adverse outcome; Age; American; Arthritis; base; career; Cause of Death; Cessation of life; Characteristics; Child Care; Chronic; Chronic Disease; Cicatrix; cohort; County; Data; Development; Diagnosis; Disadvantaged; economic cost; Economics; Employment; experience; Family; Future; Gender; Health; Health behavior; Health Benefit; Health Care Costs; health disparity; high risk; Hospitalization; Hypertension; improved; indexing; Individual; Inequality; innovation; Lead; Life; Life Cycle Stages; male health; men; Mental Health; middle age; Modeling; mortality; National Longitudinal Survey of Youth; Occupations; Outcome; Pathway interactions; Patient Self-Report; Pattern; Persons; physical conditioning; Policies; policy implication; Population; population health; prospective; Public Health; Reporting; Research; Research Personnel; Risk; Risk Factors; Role; SF-12; socioeconomics; statistics; stroke; Structure; Testing; theories; Time; Translating; Unemployment; United States; Variant; Woman; Women's Health; Work; ,Economic Context and Health over the Lifecourse,88806,CHHD,Biobehavioral and Behavioral Sciences Subcommittee ,,A1,1,56302,32205,88507,
9454665,N01,HD,,N,,,,,N01HD000000,,,275201600001I-0-27500003-1,NICHD:363661\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENANDS,UNITED STATES,,20,2436061,US,5966001,"NYSDOH/HEALTH RESEARCH, INC.",NY,122042719,,14947860; ,"KANNAN, KURUNTHACHALAM ;",,3/1/2017,2/29/2020,Adult; Affect; Area; Birth; Blood; Blood specimen; case control; Child; Contractor; Cretinism; Data; Diagnosis; ethnic diversity; Etiology; Excretory function; fetal; Fetus; Goals; Goiter; Hypothyroidism; Impairment; Intake; Iodine; iodine deficiency syndrome; Kidney; Lactation; Measures; Mothers; Newborn Infant; Nutrient; Paper; Population; Pregnancy; Pregnancy loss; pregnant; Pregnant Women; Production; programs; racial diversity; Sampling; screening; Spottings; Testing; Thyroid Gland; Thyroid Hormones; United States; urinary; virtual; Woman; ,IODINE STATUS AND CONGENITAL HYPOTHYROIDISM IN THE USA ,,,,,,,,,363661,
9457208,N01,HL,,N,,,,,N01HB000000,,,268201100002I-7-26800002-1,NHLBI:474935\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,12446065; ,"BRAMBILLA, DONALD ;",,3/15/2013,3/14/2019,Address; Adult; Affect; Area; Basic Science; Biometry; Blood; Clinical Research; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; data management; Data Set; Databases; Development; Documentation; Ensure; Epidemic; Epidemiology; Evaluation Studies; expiration; HIV; improved; International; international center; Laboratories; Laboratory Study; Link; Manuals; Medical; Medicine; member; Monitor; Observational Study; Online Systems; operation; Patient Education; Patients; Privatization; Procedures; programs; protocol development; Protocols documentation; Public Health; Publications; Research; Research Activity; Research Personnel; Resources; Retrieval; Risk; Safety; Secure; Site; Site Visit; Surveys; System; Training; Training and Education; Transfusion; Translational Research; transmission process; web site; ,Recipient Epidemiology and Donor Evaluation Study III (REDS-III)- Data Coordinating Center,,,,,,,,,474935,
9457276,N01,AI,,N,,,,,N01AI000000,,,272201000039I-1-27200013-1,NIAID:145141\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14256145; ,"SWEETEN, UNA ;",,8/30/2015,8/29/2017,Animal Model; Contracts; Development; efficacy testing; Enterovirus 68; Enterovirus 71; infectious disease model; mouse model; Standardization; therapeutic development; ,TASK A79: MOUSE MODEL FOR ENTEROVIRUS D68 (EV-D68) AND ENTEROVIRUS 71 (EV71),,,,,,,,,145141,
9458644,N01,AI,,N,,,,,N01AI000000,,,272201000039I-1-27200017-1,NIAID:45657\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14644224; ,"MORREY, JOHN ;",,8/15/2016,8/14/2017,Animal Model; Contracts; Development; efficacy testing; Hepatitis B; Hepatitis B Therapy; Human; infectious disease model; mouse model; Standardization; Testing; Therapeutic; therapeutic development; Virus; ,Task A89: Human Hepatitis B Virus (HBV) Mouse Models for Testing HBV Therapeutics,,,,,,,,,45657,
9459271,N01,ES,,N,,,,,N01ES000000,,,273201600015U-2-0-4,NIEHS:791829\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,14505712; ,"BURCH, DAVID ;",,4/21/2016,4/20/2017,Address; Analgesics; base; Chemicals; Communication; Contractor; Data; Development; Epidemiology; Evaluation; Health Hazards; Information Management; Literature; Logistics; Malignant Neoplasms; meetings; National Toxicology Program; Process; Professional counselor; Public Health; reproductive; Research; Source; systematic review; Technical Expertise; Toxicology; ,Scientific Information Management and Literature-Based Evaluations for the National Toxicology Program (NTP) ? Support for the DNTP Office of Nomination and Selection,,,,,,,,,791829,
9460281,N01,AI,,N,,,,,N01AI000000,,,272201300018I-1-27200013-1,NIAID:119054\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14652690; ,"KLEINHENZ, DEAN ;",,7/12/2016,7/11/2017,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,Vaccine and Treatment Evaluation Unit - Clinical Operations Support,,,,,,,,,119054,
9460332,N01,AI,,N,,,,,N01AI000000,,,272201400005C-9-0-2,NIAID:1909929\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,14462347; ,"TREANOR, JOHN J ;",,4/1/2014,3/31/2021,Animals; Environmental Risk Factor; Evolution; Immune; Immune response; improved; Influenza; influenzavirus; Molecular; pandemic disease; Pathogenicity; Research; transmission process; Vaccination; Vaccine Research; , CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,1909929,
9460335,N01,AI,,N,,,,,N01AI000000,,,272201300019C-12-0-3,NIAID:1017238\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MALVERN,UNITED STATES,,6,962754037,US,10026839,"VENATORX PHARMACEUTICALS, INC.",PA,193551200,,14588796; ,"XERRI, LUIGI ;",,9/16/2013,6/30/2018,Advanced Development; Bacterial Drug Resistance; Burkholderia mallei; Development; Gram-Negative Bacteria; Medical; pre-clinical; product development; research and development; Support Contracts; therapeutic candidate; therapeutic development; ,Development of Therapeutic Medical Countermeasures ,,,,,,,,,1017238,
9469455,N01,OD,,N,,,,,N01OD000000,,,263201200074I-1-26300093-1,NCATS:0\NIMH:0\NINDS:50000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14501462; ,"WESTBROOK, DAVID ;",,4/15/2016,4/14/2018,Academy; Development; drug discovery; Educational workshop; Lead; meetings; Neurosciences; Paper; Policies; Reporting; Research; symposium; Translations; ,"IGF::OT::IGF: NAS TASK ORDER: FORUM ON DRUG DISCOVERY, DEVELOPMENT AND TRANSLATION",,,,,,,,,50000,
9471286,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-2,NIEHS:1098195\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Breathing; carcinogenicity; Chemicals; Chronic; Fertility; Flavoring; follow-up; Goals; hazard; Human; Inhalation Exposure; Laboratory Animals; male; Mus; National Toxicology Program; Pathology Report; Phase; Rattus; reproductive; Risk; Self Care; Sperm Count Procedure; Sperm Motility; Toxic effect; Toxicity Tests; Toxicokinetics; Turpentine; Writing; ,Conduct of studies to evaluate the toxic and carcinogenic potential of alpha-pinene in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,1098195,
9471290,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-6,NIEHS:1237721\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Autopsy; Breathing; Carbon Nanotubes; carcinogenicity; Chemicals; Chronic; Evaluation; Goals; hazard; Human; immunotoxicity; Industrialization; Laboratory Animals; Life; Nanotechnology; National Toxicology Program; Phase; Risk; Toxic effect; Toxicity Tests; ,Conduct of studies to evaluate the toxicity and carcinogenicity of multiwalled carbon nanotubes in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,1237721,
9471293,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-9,NIEHS:1670261\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Breathing; carcinogenicity; Chemicals; Chronic; Data; design; Goals; hazard; Human; Laboratory Animals; National Toxicology Program; neurotoxicity; Pathology Report; Phase; reproductive; Risk; Toxic effect; Toxicity Tests; Vanadium; ,Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,1670261,
9471296,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-12,NIEHS:1327965\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Chemicals; Data; Data Analyses; Databases; Development; Dose; Evaluation; feeding; Goals; hazard; Human; Laboratory Animals; National Toxicology Program; neurobehavioral; Pathology; Phase; Plasticizers; Production; Reporting; reproductive; Risk; Toxic effect; Toxicity Tests; ,Conduct of studies to evaluate the toxic potential of N-BUTYLBENZENE SULFONAMIDE (NBBS) in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,1327965,
9567752,N01,AI,,N,,,,,N01AI000000,,,272201500006I-0-27200006-1,NIAID:1281164\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15266204; ,"CAUDLE, ROB ;",,9/6/2017,6/30/2019,Antimicrobial Resistance; Bacterial Infections; bacterial resistance; biodefense; Communicable Diseases; Contracts; Disease; Gram-Negative Bacteria; HIV; immunoregulation; Individual; infectious disease treatment; Investigation; National Institute of Allergy and Infectious Disease; novel therapeutics; Parasitic Diseases; pathogen; Phase; Phase I Clinical Trials; phase I trial; Resource Development; Therapeutic; Therapeutic Agents; therapeutic evaluation; Viral; ,Phase 1 Clinical Trial Units for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for Resistant Bacterial Infections,,,,,,,,,1281164,
9567903,N01,AI,,N,,,,,N01AI000000,,,272201300016I-2-27200011-1,NIAID:289680\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,14759374; ,"BERNSTEIN, DAVID ;",,9/16/2016,12/31/2018,"combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza virus vaccine; named group; Phase; Phase I Clinical Trials; Population; programs; Resources; Vaccine Clinical Trial; Vaccines; ",Vaccine and Treatment Evaluation Unit: Phase I Influenza Vaccine Clinical Trial,,,,,,,,,289680,
9567905,N02,CA,,N,,,,,N02CA000000,,,261201500132U-2-0-1,NCI:162490\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,14275188; ,"THOMPSON, GEISELLE ;",,9/29/2017,9/28/2018,Contractor; Data; Health Personnel; Healthcare Systems; Malignant Neoplasms; Medicare claim; Respondent; Surveys; System; United States Centers for Medicare and Medicaid Services; ,PROGRAMMING AND ANALYTICAL SUPPORT TO ENHANCE SEER DATA WITH DATA FROM THE CENTER FOR MEDICARE AND MEDICAID SERVICES CONSUMER ASSESSMENT OF HEALTHCARE PROVIDERS AND SYSTEMS SURVEY.,,,,,,,,,162490,
9568127,N01,AI,,N,,,,,N01AI000000,,,272201300012I-0-27200013-1,NIAID:976630\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15200717; ,"HOOK, EDWARD ;",,9/1/2017,2/28/2019,Biological; Chlamydia; Chlamydia trachomatis; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; experience; Human Resources; Laboratories; Leadership; Phase; protocol development; Research Infrastructure; sample collection; Sexually Transmitted Diseases; therapeutic development; Training; , Sexually Transmitted Infections Clinical Trials Group: Phase IV Chlamydia Clinical Trial,,,,,,,,,976630,
9568157,N01,AI,,N,,,,,N01AI000000,,,272201700085C-0-0-1,NIAID:4099878\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15266242; ,"KUDRICK, JOHN ;",,9/22/2017,9/21/2018,Adherence; Clinical; clinical material; Clinical Research; Clinical Trials; Communicable Diseases; Contracts; Ensure; Good Clinical Practice; good laboratory practice; Microbiology; programs; Services; Shipping; Specimen; ,Division of Microbiology and Infectious Diseases (DMID) Clinical Materials Services,,,,,,,,,4099878,
9568906,N43,CA,,N,,,,,N43CA000000,,,261201700041C-0-0-1,NCI:225000\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WASHINGTON,UNITED STATES,,11,080160688; 080160727,US,10041230,"OMICSCRAFT, LLC",DC,20001,,15228027; ,"NEZAMI RANJBAR, MOHAMMAD ;",,9/11/2017,6/10/2018,Address; Biological; Biological Markers; cancer biomarkers; candidate marker; Computer software; computerized tools; Coupled; Data; Disease; Disease Progression; Gas Chromatography; improved; Liquid Chromatography; Mass Spectrum Analysis; metabolomics; Methods; Network-based; platform-independent; Play; Proteomics; prototype; Reproducibility; Research; Research Personnel; Role; Sampling; Software Tools; System; Systems Biology; tool; transcriptomics; Validation; ,SysMet: Integrative Systems Metabolomics,,,,,,,,,225000,
9568948,N01,DA,,N,,,,,N01DA000000,,,271201700059C-0-0-1,NIDA:888577\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LANHAM,UNITED STATES,,,58603631,US,,,MD,20706,,15228155; ,"BIZZELL, ANTON ;",,9/15/2017,9/14/2018,Adoption; Adult; career; Collaborations; Communication; Computer software; Contractor; Contracts; Development; dissemination research; E-learning; Evidence based practice; follow-up; Health Professional; interest; Learning; Logistics; Medical; meetings; Mentors; Methodology; mHealth; National Institute of Drug Abuse; new technology; Online Systems; outreach; point of care; Professional Organizations; Program Development; Research; research data dissemination; research to practice; Science; skills; Substance Use Disorder; Technology; technology training; tool; Training; Training and Education; training opportunity; ,IGF::OT::IGF: NIDA Blending Initiative: Moving Science from Research to Practice. N01DA-17-2248.,,,,,,,,,888577,
9568964,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100021-1,NCI:82758\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326892; ,"GIANNINI, ROBERT ;",,4/14/2017,10/14/2017,capsule; Clinical; Color; Contractor; Cyclic GMP; Dose; Formulation; Gelatin; Oranges; Pharmacologic Substance; seal; Testing; ,IGF::OT::IGF,,,,,,,,,82758,
9569202,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200022-1,NIAID:1116715\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15190087; ,"WALTER, EMMANUEL ;",,8/28/2017,4/30/2019,Antimicrobial Resistance; Bacterial Infections; bacterial resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Gram-Positive Bacterial Infections; Individual; named group; Phase I Clinical Trials; phase I trial; Population; programs; Resources; Therapeutic; therapeutic candidate; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS: PHASE I TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS,,,,,,,,,1116715,
9569248,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200018-1,NIAID:2440693\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,15170395; ,"CREECH, BUDDY ;",,9/15/2015,5/31/2018,antimicrobial; Antimicrobial Resistance; Child; Clinical Trials; combat; Communicable Diseases; Communities; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; phase IV trial; Pneumonia; Population; programs; Resources; Streptococcus pneumoniae; Therapeutic; Vaccines; ,Vaccine Treatment and Evaluation Units: A Phase IV Trial to Evaluate Antimicrobial Therapy for Community Acquired Pneumonia in Children,,,,,,,,,2440693,
9569759,N01,HL,,N,,,,,N01HL000000,,,268201700002I-0-26800001-1,NHLBI:824092\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,14921895; ,"CORESH, JOE ;",,11/15/2016,11/14/2021,Abdomen; Adult; African American; aged; Ancillary Study; Ankle; Atherosclerosis; Atherosclerosis Risk in Communities; base; Behavioral; Behavioral Genetics; Carotid Arteries; caucasian American; Characteristics; Clinical; clinical development; clinical predictors; cognitive function; cohort; Cohort Studies; Collaborations; Communities; Contracts; Coronary heart disease; County; Data; Data Collection; Data Set; Event; follow-up; Fostering; Funding; Genetic; Geographic Locations; Goals; Grant; Heart failure; Hemostatic Agents; indexing; Laboratories; Measurement; middle age; Monitor; mortality; Myocardial Infarction; Natural History; operation; Participant; Photography; Policies; Process; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Recruitment Activity; Research Personnel; Retinal; Risk Factors; Risk Marker; rural setting; sharing data; socioeconomics; Structure of popliteal artery; Subgroup; suburb; Testing; trend; Ultrasonography; United States National Institutes of Health; Washington; ,IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - FIELD CENTER - CORE STUDY OPERATIONS,,,,,,,,,824092,
9569768,N01,HL,,N,,,,,N01HL000000,,,268201700003I-0-26800002-1,NHLBI:60005\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,14980038; ,"FOLSOM, AARON ;",,4/1/2017,3/31/2020,"Abdomen; Adult; African American; aged; Alaska Native; American Indians; Ankle; Appointment; Atherosclerosis; Atherosclerosis Risk in Communities; Award; base; Behavioral; Behavioral Genetics; Biochemical; Biological Assay; Biomedical Research; Biometry; Blood specimen; Candidate Disease Gene; Cardiovascular Diseases; career; Carotid Arteries; Case-Control Studies; caucasian American; Characteristics; Clinical; clinical development; Clinical Nursing; cognitive function; cohort; Cohort Studies; Communities; Contracts; Coronary heart disease; County; Data; Data Set; Disabled Persons; DNA; Educational process of instructing; Eligibility Determination; Ethnic group; Event; experience; Faculty; faculty support; Family; follow-up; Funding; Genetic; Genome Scan; Geographic Locations; Grant; Heart failure; Hemostatic Agents; Hispanic Americans; Hospitalization; indexing; Individual; Injury; Investigation; Laboratories; Lymphocyte; Measurement; member; middle age; Monitor; mortality; Myocardial Infarction; National Heart, Lung, and Blood Institute; Native Hawaiian; Natural History; Pacific Island Americans; parent grant; Participant; Photography; Principal Investigator; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Qualifying; Race; Recruitment Activity; Research; Research Personnel; Research Project Grants; Research Support; residence; Retinal; Risk Factors; Risk Marker; rural setting; skills; Social Sciences; socioeconomics; Structure of popliteal artery; suburb; Support Contracts; Testing; Time; trend; Ultrasonography; Underrepresented Groups; Vital Status; Washington; ",IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES (ARIC) - FIELD CENTER; DIVERSITY SUPPLEMENT STEVE NGUYEN,,,,,,,,,60005,
9569855,N01,HD,,N,,,,,N01HD000000,,,275201300023I-0-27500013-1,NICHD:1619705\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15232721; ,"TSAI, MICHAEL ;",,9/19/2017,9/18/2019,8-hydroxy-2'-deoxyguanosine; Address; adiponectin; Affect; Anti-inflammatory; Aspirin; Biological; Biological Assay; Biological Markers; Calcium; Complex; cost; Data; Data Sources; Diet; Dietary Assessment; Dietary Component; Dietary Fiber; Dose; Double-Blind Method; double-blind placebo controlled trial; environmental chemical; environmental stressor; Exposure to; F2-Isoprostanes; Ferritin; Fertility; Fibroblast Growth Factor; Flavonoids; Folic Acid; Funding; Glycosylated hemoglobin A; healthy pregnancy; hepcidin; Hour; Hydrocortisone; improved; Inflammation; Inflammation Mediators; inflammatory marker; interest; Interleukin-1; Interleukin-10; Interleukin-6; Interleukin-8; Interleukins; Investigation; Iron; Laboratories; Length; Link; Lipid Peroxidation; Lipid Peroxides; Live Birth; male; Measurement; Measures; Medical center; Menstrual cycle; Menstruation; novel; Outcome; Ovulation; Oxidative Stress; Participant; pentosidine; Phenols; Phytoestrogens; Placental Growth Factor; Pregnancy; Pregnancy loss; pregnant; Prolactin; prospective; protein intake; Proteins; Rage; Randomized; Randomized Controlled Trials; receptor; Recording of previous events; repository; Reproduction; reproductive; reproductive hormone; Research; Role; Sampling; Seminal fluid; Serum; Serum Proteins; Site; Techniques; telomere; Testing; TFRC gene; Time; TNF gene; Transferrin; trial design; Urine; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factors; Visit; Vitamin B 12; Vitamin D; Vitamin D-Binding Protein; Woman; Work; ,MEASUREMENT OF BIOSPECIMENS IN THE EAGeR TRIAL,,,,,,,,,1619705,
9570138,N01,AI,,N,,,,,N01AI000000,,,272201700011C-0-0-1,OD:1605375\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,829971899,US,10021989,"CHRYSALIS BIOTHERAPEUTICS, INC.",TX,775501532,,14922303; ,"SOWER, LAURIE ;",,2/1/2017,1/31/2018,absorption; Acute; alpha-Thrombin; animal rule; Animals; Biological Assay; Biological Response Modifier Therapy; Clinical Trials; combat; Contracts; Data; Dermal; Dose; Drug Kinetics; Emergency Situation; Endothelial Cells; Excretory function; Family suidae; Functional disorder; Human; Injury; irradiation; Ischemia; Licensure; Metabolism; Modeling; Mus; Musculoskeletal; novel; Nuclear; Organ; Peptides; prevent; Production; Protocols documentation; Radiation; regenerative; Regimen; repaired; Signal Transduction; stem cell population; Stem cells; , A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION,,,,,,,,,1605375,
9570262,N01,AI,,N,,,,,N01AI000000,,,272201700046I-0-27200001-1,NIAID:2500000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,YEMASSEE,UNITED STATES,,,199145954,US,,ALPHA GENESIS INC,SC,299457115,,15190096; ,"WESTERGAARD, DR. GREG ;",,9/30/2017,9/29/2018,Breeding; Contractor; Contracts; cooperative study; Disease; germ free condition; Immune; Immune Tolerance; Macaca; Macaca fascicularis; Macaca mulatta; Maintenance; Mediating; Modeling; National Institute of Allergy and Infectious Disease; nonhuman primate; novel; preclinical efficacy; preclinical safety; Primates; Regimen; Research Support; Transplantation; Transplantation Tolerance; ,MAINTENANCE OF NIAID SPECIFIC PATHOGEN-FREE Macaque Breeding Colonies for Immune-mediated Diseases,,,,,,,,,2500000,
9570536,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-3,NIAID:40753\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,40753,
9570553,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-7,NIAID:40755\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Trypanosoma cruzi; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,40755,
9571110,N01,HD,,N,,,,,N01HD000000,,,275201500004C-4-0-1,NICHD:662752\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BAR HARBOR,UNITED STATES,,2,42140483,US,7096501,JACKSON LABORATORY,ME,46091500,,14278174; ,"LUTZ, CATHLEEN ;",,9/22/2017,9/21/2018,"Aneuploidy; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Communities; Contracts; Cryopreservation; Cytogenetics; Disease; Down Syndrome; Ensure; Genes; Genetic; Human; Human Chromosomes; Human Development; Intellectual functioning disability; Investments; Maintenance; Modeling; mouse model; Mouse Strains; mouse Trisomy 16; mouse Ts65Dn; Mus; National Institute of Child Health and Human Development; prevent; repository; Research; Research Personnel; Research Training; response; Study models; Support Contracts; Synteny; Time; Trisomy; ",REPOSITORY OF MOUSE MODELS FOR CYTOGENETIC DISORDERS,,,,,,,,,662752,
9571159,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200014-1,NIAID:297665\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15273092; ,"FRENCK, ROBERT ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS (VTEU): CLINICAL OPERATIONS SUPPORT,,,,,,,,,297665,
9571162,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200019-1,NIAID:1602236\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15017480; ,"WALKER, EMMANUEL ;",,9/16/2013,9/15/2023,Clostridium difficile; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase; Population; programs; Resources; Therapeutic Trials; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT:PHASE I/II THERAPEUTIC TRIAL FOR CLOSTRIDIUM DIFFICILE ,,,,,,,,,1602236,
9571278,N01,ES,,N,,,,,N01ES000000,,,273201700001C-0-0-1,NIEHS:2245642\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE PARK,UNITED STATES,,4,962071515,US,10029058,"SCIOME, LLC",NC,277093169,,14976014; ,"SHAH, RUCHIR ;",,,,Area; base; Bioinformatics; Contractor; Contracts; Data; Data Analyses; data mining; Epigenetic Process; Gene Expression; Genomics; high throughput screening; Informatics; Intramural Research Program; meetings; method development; National Institute of Environmental Health Sciences; National Toxicology Program; Preparation; programs; Publications; Research; Research Design; Research Personnel; Services; Source; Technology; Text; Toxicogenomics; Toxicology; transcriptome sequencing; transcriptomics; ,IGF::OT::IGF  BIOINFORMATICS SUPPORT FOR THE NIEHS IN DIR & DNTP,,,,,,,,,2245642,
9571325,N01,HD,,N,,,,,N01HD000000,,,275201300026I-0-27500017-1,NICHD:657738\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,15238440; ,"SHERMAN, SETH ;",,9/11/2013,9/10/2018,"Accounting; Air; Alabama; Antigens; Asthma; atopy; Autoantigens; base; Blood; Blood Pressure; Cell Separation; Cells; Chronic Disease; Clinic Visits; Clinical; clinical research site; Cohort Studies; Collection; Commuting; Contracts; Data; Data Collection; Data Coordinating Center; Data Quality; Data Set; Defect; Diet; dietary antioxidant; Dietary intake; Educational workshop; Enrollment; Environmental Exposure; Environmental Risk Factor; Exhalation; experience; Exposure to; Fetus; Flow Cytometry; follow-up; Forced expiratory volume function; FOXP3 gene; Genes; Genetic; Health; Hour; Hypersensitivity; Immune; Immune system; improved; Inflammation; inflammatory marker; interest; Knowledge; Literature; Lung Inflammation; Measurement; Measures; Mediating; Medical Records; Menstrual cycle; National Heart, Lung, and Blood Institute; Nitric Oxide; Outcome; pathogen; Patient Recruitments; Patients; peripheral blood; Pharmaceutical Preparations; Play; Population; Postpartum Period; Predictive Factor; Pregnancy; pregnancy immunology; Pregnancy Outcome; Process; Pulmonary Function Test/Forced Expiratory Volume 1; Questionnaires; Recruitment Activity; Regulation; Regulatory T-Lymphocyte; Reporting; Research Infrastructure; Respiratory physiology; Role; Sampling; Schedule; Severities; Site Visit; Specimen; Subgroup; Summary Reports; symposium; Symptoms; System; Th2 Cells; United States National Institutes of Health; Universities; Urine; Visit; web site; Woman; ",DATA COORDINATING CENTER FOR THE FOLLOW-UP AND CLOSEOUT OF THE ASTHMA PREGNANCY STUDY,,,,,,,,,657738,
9571718,N43,CA,,N,,,,,N43CA000000,,,261201700025C-0-0-1,NCI:248077\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,129852864,US,10008060,"ELECTRONIC BIOSCIENCES, INC.",CA,921214206,,15232953; ,"ERVIN, ERIC ;",,9/18/2017,6/17/2018,Adenosine; Back; base; Biological Sciences; Cells; Chemicals; Communities; Complementary DNA; Cytidine; Development; Devices; Diagnostic; Electrodes; Guanosine; Hour; Individual; infancy; innovation; Lipid Bilayers; lithography; Methodology; Methods; Microfluidics; Modification; Motion; nanofabrication; nanopore; nanoscale; new technology; Nucleotides; Phase; programs; RNA; Role; Small Business Innovation Research Grant; Supporting Cell; Testing; Therapeutic; Time; tool; transcriptome sequencing; Uridine Monophosphate; ,Nanoscale Tools for RNA Modification SequencingPOP: 9/18/17 through 6/17/18,,,,,,,,,248077,
9571728,N01,AI,,N,,,,,N01AI000000,,,272201300022I-0-27200019-2,NIAID:339469\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,15146694; ,"KOTLOFF, KAREN ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: CLINICAL OPERATIONS SUPPORT,,,,,,,,,339469,
9571899,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200017-1,NIAID:333763\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,15170392; ,"EDWARDS, KATHRYN ;",,4/7/2015,12/1/2019,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Development; Evaluation; Individual; named group; Pertussis Vaccine; Population; programs; Resources; vaccine candidate; vaccine development; Vaccines; ,Vaccine and Treatment Evaluation Unit: Pertussis Vaccine Development,,,,,,,,,333763,
9572240,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-13,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Coccidioides immitis; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572244,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-15,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Pseudomonas aeruginosa; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572628,N01,HL,,N,,,,,N01HV000000,,,268201200001I-0-26800005-1,NHLBI:825126\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WATERTOWN,UNITED STATES,,5,153914080,US,2034501,"NEW ENGLAND RESEARCH INSTITUTES, INC.",MA,24722463,,14983367; ,"SIAMI, SANDI ;",,3/31/2017,3/30/2018,Address; Cardiopulmonary; Cardiovascular Diseases; Child; Childhood; Clinical; Clinical Data; Clinical Trials; Contracts; Data; Device Approval; Device Designs; Devices; experience; Failure; Infant; neonate; novel; pre-clinical; Preparation; programs; Pump; Pumpkins; research and development; Shock; United States Food and Drug Administration; ,"IGF::OT::IGF - R&D, PUMPS FOR KIDS, INFANTS, AND NEONATES (PUMPKIN) CLINICAL TRIAL - DATA & CLINICAL COORDINATING CENTER",,,,,,,,,825126,
9572815,N01,AI,,N,,,,,N01AI000000,,,272201700010I-0-27200004-1,NIAID:2542325\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15266228; ,"MACK, FRED ;",,9/28/2017,5/31/2020,Antigens; cGMP production; Chinese Hamster Ovary Cell; Clinical Trials; Contractor; Contracts; Cyclic GMP; Databases; Development; Documentation; efficacy study; Equipment and supply inventories; Harvest; HIV vaccine; HIV-1; Human; immunogenicity; In Vitro; Investigational Drugs; Laboratories; Laboratory Animals; National Institute of Allergy and Infectious Disease; Phase; plasmid DNA; preclinical development; Preclinical Testing; Preventive vaccine; product development; Production; Proteins; Protocols documentation; prototype; quality assurance; Quality Control; research clinical testing; Running; Testing; Toxicology; Transfection; Vaccines; Viral Vector; ,NIAID Preclinical Development Support,,,,,,,,,2542325,
9572821,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-16,NIEHS:678813\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,15035369; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Chemicals; Data; Data Analyses; Evaluation; Flame Retardants; Future; Genes; Goals; hazard; Human; Liver; male; Oral; Pathology; Pattern; Phase; Rattus; Reporting; Risk; Toxic effect; Toxicity Tests; Toxicogenomics; Transcript; ,Conduct of five data toxicity and toxicogenomics studies of brominated flame retardants in male rats treated via oral gavage for the NTP,,,,,,,,,678813,
9573288,N01,HD,,N,,,,,N01HD000000,,,275201300022I-2-27500002-1,NICHD:115949\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,LOS ANGELES,UNITED STATES,,34,74121492,US,3750701,"CALIFORNIA FAMILY HEALTH COUNCIL, INC.",CA,900102610,,15236832; ,"NELSON, ANITA ;",,7/16/2013,12/31/2018,Acetates; Adherence; Adverse effects; Age; Amenorrhea; arm; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Dose; Drug Kinetics; emergency contraception; Estrogens; Hemorrhage; In Vitro; Interruption; malignant breast neoplasm; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Pharmacodynamics; pill; Population; progesterone receptor A; Progesterone Receptors; Progestins; Public Health; Randomized; Regimen; reproductive; Risk; Safety; Thromboembolism; Time; United States Food and Drug Administration; Uterine Fibroids; Venous; Woman; ,CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE,,,,,,,,,115949,
9573289,N01,AI,,N,,,,,N01AI000000,,,272201300018I-3-27200004-1,NIAID:284831\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12576821; ,"ANDERSON, LARRY ;",,9/8/2014,9/30/2019,Biological Assay; Childhood; Conduct Clinical Trials; Contracts; design; Development; Diagnostic; Evaluation; Individual; infectious disease treatment; Investigation; novel; Pediatric Research; Population; Resources; Respiratory syncytial virus; Route; System; Vaccines; ,Vaccine and Treatment Evaluation Unit: Respiratory Syncytial Virus Diagnostic and Vaccine Assays ,,,,,,,,,284831,
9573347,N01,HD,,N,,,,,N01HD000000,,,275201700003C-0-0-1,NICHD:774514\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,RIVERVIEW,UNITED STATES,,,49265333,US,,,MI,48193,,15237110; ,"KASKAR, BASHIR ;",,9/24/2017,9/23/2018,Agonist; analog; Androgens; Area; Chemical Agents; chemical synthesis; Chemicals; Clinical Research; Contraceptive Agents; Contraceptive methods; Contractor; Contracts; Cyclic GMP; Development; drug candidate; Drug Kinetics; Evaluation; Female Contraceptive Agents; Goals; Government; Human; In Vitro; in vivo; Investigation; Kilogram; Laboratories; Male Contraceptive Agents; men; metabolic abnormality assessment; milligram; Natural Products; Peptide Synthesis; Peptides; Pharmaceutical Preparations; preclinical safety; preclinical study; Preparation; Progestins; programs; Proteins; Radiolabeled; Research; Research Personnel; Research Support; Role; safety study; scale up; small molecule; stable isotope; Steroidal Estrogen; Steroids; Testing; Toxicology; unnatural amino acids; Woman; ,CHEMICAL SYNTHESIS FACILITY,,,,,,,,,774514,
9573445,N43,CA,,N,,,,,N43CA000000,,,261201700030C-0-0-1,NCI:224439\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,PALO ALTO,UNITED STATES,,18,78739184,US,10033646,"DERMTAP, INC.",CA,943012238,,15237371; ,"LONGMIRE, MICHELLE ;",,9/18/2017,6/17/2018,Advisory Committees; Architecture; Area; base; cancer care; Cancer Survivor; care giving burden; care recipients; Caregivers; caregiving; Caring; Categories; commercialization; Communication; Communication Methods; Communities; Contracts; dashboard; Data; Data Security; design; Development; digital; Education; Electronic Health Record; Ensure; Evaluation; Family; Future; Goals; Health Personnel; Healthcare; Home environment; Hospitals; informal caregiver; informal support; informant; Interview; Letters; Malignant Neoplasms; Medical Care Team; mobile application; Patient Care; Patient Monitoring; Patients; Phase; Preparation; prototype; Publishing; Reporting; Request for Proposals; Resources; Scanning; Small Business Innovation Research Grant; software systems; Structure; Technology; Testing; Validation; ,IGF::OT::IGF: Phase I SBIR Contract - FY17 - Topic 363 - Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving,,,,,,,,,224439,
9575027,N02,CA,,N,,,,,N02CA000000,,,261201600012I-0-26100002-1,NCI:66300\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WOODLAND HILLS,UNITED STATES,,,77828930,US,,,CA,913673616,,15241038; ,"GASPARIAN, ALEXANDER ;",,9/18/2017,9/17/2018,cancer imaging; Clear Cell; Clinical; clinical imaging; Clinical/Radiologic; Data; digital; Endometrial Carcinoma; follow-up; Head and Neck Cancer; Image; image archival system; Lung Adenocarcinoma; Magnetic Resonance Imaging; Medical Imaging; melanoma; Operative Surgical Procedures; Positron-Emission Tomography; Process; prospective; Proteomics; radiological imaging; Renal Cell Carcinoma; Resources; sarcoma; Ships; Site; Source; Squamous Cell Lung Carcinoma; standard of care; Tissues; tumor; Ultrasonography; ,TSS CPTAC Digital Medical Images of CPTAC Biospecimens,,,,,,,,,66300,
9575160,N01,HD,,N,,,,,N01HD000000,,,275201700002C-1-0-1,NICHD:180251\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,15239074; ,"ANAND, RAVINDER ;",,7/29/2017,7/28/2018,authority; Award; Child; Childhood; Clinical; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Design; Complement; Conduct Clinical Trials; Contractor; Contracts; Data; Data Coordinating Center; data integration; data management; Data Quality; Data Storage and Retrieval; Devices; drug development; Drug Kinetics; Drug usage; Ensure; Good Clinical Practice; Guidelines; improved; Individual; information gathering; Institutes; International; Knowledge; Label; Leadership; Monitor; National Institute of Child Health and Human Development; Obstetric pharmacology; Office for Human Research Protections; pediatric pharmacology; Pediatric Research; Pharmaceutical Preparations; Pharmacodynamics; pre-clinical; preclinical study; Preparation; Process; programs; prospective; protocol development; Protocols documentation; Quality Control; Regulation; Reporting; repository; Research; Research Infrastructure; Research Personnel; Role; Safety; sharing data; Site; Statistical Data Interpretation; statistics; Structure; Therapeutic; Therapeutic Uses; Time; Training; Treatment Efficacy; United States; United States National Institutes of Health; web site; Work; ,PEDIATRIC TRIALS NETWORK - BPCA,,,,,,,,,180251,
9575224,N02,CA,,N,,,,,N02CA000000,,,261201600005I-4-26100001-1,NCI:206400\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,POZNAN,POLAND,,,427769665,PL,10040378,INTERNAT'L INSTITUTE/MOLECULAR ONCOLOGY,,60-203,,15241425; ,"WIZNEROWICZ, MACIEJ ;",,12/30/2015,9/17/2018,actionable mutation; cancer type; Center for Translational Science Activities; Clinical; Clinical Data; clinical research site; Clinical Trials; Colorectal Cancer; Communities; Country; Data Analyses; Enrollment; Exercise; genome analysis; human subject; Informed Consent; insight; Investments; malignant breast neoplasm; Malignant neoplasm of ovary; Malignant Neoplasms; melanoma; Modification; Molecular; National Cancer Institute; Normal tissue morphology; open source; Operative Surgical Procedures; Pathway interactions; peripheral blood; Post-Translational Protein Processing; precision oncology; Proteins; proteogenomics; Proteome; Proteomics; Resected; Resistance; Resources; Source; Tissues; Toxic effect; tumor; Tumor Tissue; ,MIEDZYNARODOWY INSTYTUT ONKOLOGII MOLEKULARNEJ:1268477 [16-013238]Tissue Source Site (TSS) Clinical Proteomics Tumor Analysis Consortium (CPTAC)This modification is to add and exercise an option f,,,,,,,,,206400,
9575443,N01,ES,,N,,,,,N01ES000000,,,273201400027C-9-0-4,NIEHS:150000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15059066; ,"BURBACK, BRIAN ;",,7/25/2014,5/24/2018,Adverse effects; Animals; Chemicals; Chemistry; Contracts; cyanoginosin LR; Development; developmental toxicity; disorder prevention; Dose; drinking water; Ensure; Environmental Exposure; Evaluation; Exposure to; Formulation; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; Human; Human Cell Line; in vitro testing; Laboratories; National Toxicology Program; Outcome; Preparation; Public Health; public health research; reproductive toxicity; Research; Risk Assessment; Risk Factors; Ships; sound; Specific qualifier value; Testing; Toxic effect; Toxicity Tests; Toxicology; Validation; ,Microcystin LR ,,,,,,,,,150000,
9575739,N01,CA,,N,,,,,N01CA000000,,,261201200033I-0-26100012-1,NCI:95414\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,15242310; ,"BAILEY, HOWARD ;",,9/15/2017,9/14/2018,Dose; Human Papillomavirus; immunogenicity; Malignant Neoplasms; Phase; phase I trial; Prevention; Safety; Vaccines; Woman; ,"IGF::OT::IGF  A Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a candidate broadly protective vaccine for the prevention of HPV-associated cancer",,,,,,,,,95414,
9576329,N01,CA,,N,,,,,N01CA000000,,,261201500036I-0-26100006-1,NCI:636313\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15243293; ,"GRUBBS, CLINTON ;",,9/15/2017,3/14/2019,Adjuvant; Antigen Targeting; Antigens; antitumor effect; Autoantigens; base; Bladder; cancer diagnosis; cancer genomics; cancer immunotherapy; Cancer Vaccines; Candidate Disease Gene; Carcinoma in Situ; clinically relevant; Common Neoplasm; Country; cytokine; design; Development; Diagnosis; differential expression; Disease; Effectiveness; efficacy testing; Epitopes; ERBB2 gene; Evaluation; Gene Amplification; Genes; genomic data; Growth; Immune response; Immune system; Immunity; Immunization; immunogenic; immunogenicity; Immunotherapy; improved; In complete remission; In Vitro; in vivo; Incidence; Interleukin-10; Interleukin-6; intravesical; Lesion; Malignant - descriptor; Malignant neoplasm of urinary bladder; Malignant Neoplasms; men; Modeling; Molecular Analysis; Morale; Mutate; Mutation; Normal tissue morphology; North America; Northern Africa; novel; Oncogenic; overexpression; Patients; Pattern; peptide based vaccine; Physiological; Pre-Clinical Model; Preclinical Testing; Premalignant; prevent; Prevention; Preventive; Primary Prevention; Process; Proteins; Recurrence; Recurrent tumor; Residual Tumors; responders and non-responders; response; Role; screening; Secondary Prevention; Sex Characteristics; Signal Pathway; Southern Europe; standard of care; Th2 Cells; The Cancer Genome Atlas; Tissues; tumor; Tumor Antigens; tumorigenesis; Vaccine Antigen; vaccine candidate; Vaccines; Western Asia; Western Europe; Woman; Work; ,Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder CancerTO POP: 9/15/2017 - 3/14/2019,,,,,,,,,636313,
9576340,N01,CA,,N,,,,,N01CA000000,,,261201500037I-0-26100007-1,NCI:377537\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MILWAUKEE,UNITED STATES,,5,937639060,US,46001,MEDICAL COLLEGE OF WISCONSIN,WI,532263548,,15243318; ,"WANG, YIANG ;",,9/15/2017,11/14/2018,Accounting; Adjuvant; African American; Age; Antigen Targeting; Antigens; antitumor effect; Autoantigens; base; cancer genomics; cancer immunotherapy; Cancer Model; Cancer Patient; Cancer Vaccines; Candidate Disease Gene; Cessation of life; Clinical; clinically relevant; Common Neoplasm; cytokine; design; Development; Diagnosis; differential expression; Disease; efficacy testing; Epidermal Growth Factor Receptor; Epitopes; ERBB2 gene; Estrogen Receptors; Female; Genes; Growth; Human; Immune response; Immune system; Immunity; Immunization; immunogenic; immunogenicity; improved; In Vitro; in vivo; Interleukin-10; Interleukin-6; Lesion; Malignant - descriptor; malignant breast neoplasm; Malignant Neoplasms; Mammary Gland Parenchyma; Mammary Neoplasms; Modality; Modeling; Molecular; Molecular Analysis; Molecular Genetics; molecular subtypes; mouse model; Mutate; Normal tissue morphology; novel; novel strategies; Oncogenic; overexpression; Pathologic; Patient-Focused Outcomes; Pattern; peptide based vaccine; Peptide Vaccines; Physiological; pre-clinical; Pre-Clinical Model; Preclinical Testing; Premalignant; prevent; Prevention; Preventive; Process; Progesterone Receptors; prognostic; Proteins; Race; Recurrence; Research; response; Role; S-Phase Fraction; Scoring Method; screening; Selection for Treatments; Signal Pathway; Stage at Diagnosis; Survival Rate; Th2 Cells; The Cancer Genome Atlas; Tissue Model; Tissues; triple-negative invasive breast carcinoma; tumor; Tumor Antigens; tumorigenesis; Vaccine Antigen; vaccine candidate; Vaccines; ,"Development of a multi-antigen, multi-peptide vaccine  HHSN2612015000371 TORFP 2017-E09 PP: 9/15/17 to 11/14/18",,,,,,,,,377537,
9576445,N44,DA,,N,,,,,N44DA000000,,,271201500059C-3-0-2,NCATS:314982\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,HANOVER,UNITED STATES,,2,72021041,US,1811501,"CREARE, LLC",NH,37553116,,15243541; ,"KYNOR, DAVID ;",,9/15/2015,3/14/2018,Contractor; Contracts; cost; Crystallization; Development; drug candidate; drug discovery; experimental study; Failure; Liquid substance; Methods; Modernization; Monitor; novel therapeutics; Phase; Process; Proteins; Reagent; Running; Salts; screening; Small Business Innovation Research Grant; Speed; System; Testing; Time; wasting; ,IGF::OT::IGF Automated Droplet Monitoring System ,,,,,,,,,314982,
9576556,N44,CA,,N,,,,,N44CA000000,,,261201700035C-0-0-1,NCI:1999987\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MORGANTOWN,UNITED STATES,,0,968675244,US,10029690,"MODULATION THERAPEUTICS, INC.",WV,26505,,15327075; ,"WATERHOUSE, RIKKI ;",,9/18/2017,9/17/2019,Affinity; Animal Model; Binding; Biodistribution; Blood; Clinical Trials; commercialization; Contracts; Cutaneous Melanoma; dosage; drug candidate; drug development; Funding; Human; Ligands; Melanocortin 1 Receptor; Melanoma Cell; Metastatic Melanoma; Organ; Pathology; Performance; Phase; Phase I Clinical Trials; Radiopharmaceuticals; Rare Diseases; Risk; Small Business Innovation Research Grant; Specificity; Tissues; Toxic effect; tumor; Uveal Melanoma; ,'Targeted Ac-225-radiopharmaceutical for metastatic uveal melanoma'Period of Performance: 9/18/2017 - 9/17/2019,,,,,,,,,1999987,
9578127,N02,CA,,N,,,,,N02CA000000,,,261201700011I-0-26100001-1,NCI:1236\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,15327000; ,"WHITE, JONATHAN ;",,8/1/2017,9/30/3017,Chemicals; Contracts; cost; Formulation; Malignant Neoplasms; meetings; Teleconferences; ,"IGF::OT::IGF Administrative Costs - Contract Orientation and Kick Off Meeting -Analysis of Anti-Cancer Chemical & Pharm Formulations , HHSN261201700011I, DTP-17-040, 8/01/2017 - 09/30/2017, PRB",,,,,,,,,1236,
9579330,N01,HL,,N,,,,,N01HL000000,,,268201500003I-4-26800001-2,NHLBI:5351085\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,15177024; ,"MCCLELLAND, ROBYN ;",,8/15/2015,8/14/2018,Abdomen; aged; Ancillary Study; Ankle; Area; Behavioral; Biological; brachial artery; Cardiac; Cardiovascular Diseases; Characteristics; Clinical; clinical imaging; cohort; Contracts; Coronary Arteriosclerosis; Data; Data Set; design; Diabetic Retinopathy; digital; Disease; ethnic difference; Ethnic Origin; Event; Family; follow-up; Funding; Fundus photography; Genetic; Health Status; imaging modality; indexing; interest; Laboratories; Macular degeneration; Magnetic Resonance Imaging; Measurement; Measures; Mediating; member; men; Mentors; Microvascular Dysfunction; Multi-Ethnic Study of Atherosclerosis; Myocardial; Nutritional; Participant; Pathology; Pharmaceutical Preparations; Phenotype; Photography; Policies; population based; Population Heterogeneity; Process; psychologic; racial and ethnic; radial artery; Recruitment Activity; Research; Research Design; Research Personnel; Retinal; Risk Marker; Sampling; Severities; sex; sharing data; Signs and Symptoms; socioeconomics; Systemic disease; Time; Training; Ultrasonography; United States National Institutes of Health; Ventricular Function; Visit; Visual; Visual Acuity; Visual impairment; Woman; Work; X-Ray Computed Tomography; ,IGF::OT::IGF - MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)III- COORDINATING CENTER,,,,,,,,,5351085,
9579476,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100051-1,NCI:5342832\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266031; ,"DELBRIDGE, MATTHEW ;",,9/18/2017,2/28/2019,Floor; Research Infrastructure; ,IGF::OT::IGF  Bldg. 469 1st Floor Refurbishment & Infrastructure,,,,,,,,,5342832,
9579649,N02,CA,,N,,,,,N02CA000000,,,261201700009C-0-0-1,NCI:4250693\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,PRINCETON,UNITED STATES,,12,61814323,US,1721601,"THERADEX SYSTEMS, INC.",NJ,85405748,,15248400; ,"ANDERSON, BARRY  ;",,5/1/2017,4/30/2022,Biological Assay; Biological Markers; Biological Products; Cancer Therapy Evaluation Program; Clinical Trials; Complex; Contractor; Contracts; data management; Data Sources; Dependency; Ensure; good laboratory practice; Investigation; Laboratories; manufacturing facility; Monitor; Monitoring Clinical Trials; Process; Protocols documentation; quality assurance; Research Infrastructure; Services; Site; success; Systems Integration; Work; ,Clinical Trials Monitoring Service,,,,,,,,,4250693,
9581064,N02,DA,,N,,,,,N02DA000000,,,271201400007I-0-27100004-1,NIMH:153713\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILLOW GROVE,UNITED STATES,,,64341449,US,,,PA,190900433,,15327359; ,"MEAKER, THOMAS ;",,11/28/2016,11/27/2017,Autopsy; Award; Biological Assay; Blood; Brain; brain tissue; Contractor; Cost Savings; drug of abuse; Hair; Human; Laboratories; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; nervous system disorder; Neurodevelopmental Disorder; Performance; Pharmaceutical Preparations; programs; Psychotropic Drugs; repository; Research; Research Personnel; Resources; Sampling; screening; Services; Standardization; Testing; Therapeutic; Tissues; Toxicology; United States National Institutes of Health; Urine; ,Neurobiobank Toxicology Screening,,,,,,,,,153713,
9581084,N01,CA,,N,,,,,N01CA000000,,,261201200028I-0-26100021-1,NCI:1056561\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,; ,",  ;",,6/20/2017,6/19/2018,Data Analyses; , Global Support for BRP Data Analysis Activities,,,,,,,,,1056561,
9581108,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100064-1,NCI:106937\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,2/9/2017,5/31/2017,Logistics; ,NCI/HBRB 'Sandpit' Logistics Support,,,,,,,,,106937,
9581113,N01,CA,,N,,,,,N01CA000000,,,261201500033I-0-26100003-1,NCI:900185\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TORONTO,CANADA,,,253518997,CA,10027891,"ARTIFICIAL INTELLIGENCE IN MEDICINE, INC",ON,,,; ,",  ;",,9/26/2017,9/25/2018,Maintenance; ,IGF::OT::IGF Task Order for Year 3; ,,,,,,,,,900185,
9581156,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100038-1,NCI:3225602\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15250730; ,"OTRIDGE, JOHN ;",,9/28/2017,9/27/2020,Address; Advocate; anticancer research; Architecture; Area; base; Bioinformatics; Cancer Patient; Clinical; Communities; Computerized Medical Record; Confidentiality of Patient Information; Data; Data Analyses; Data Element; Data Linkages; data portal; Data Security; Data Sources; data visualization; Date of birth; design; Dictionary; Ecosystem; Educational workshop; encryption; Ensure; Evaluation; experience; falls; flexibility; Future; Generations; Gold; individual patient; interoperability; Link; Malignant Neoplasms; Measures; meetings; Methodology; Methods; Names; neoplasm registry; patient privacy; Patients; Phase; Recommendation; repository; Research Infrastructure; Research Personnel; Security; Services; sharing data; Source; Structure; System; Testing; Time; usability; Vendor; Work; working group; ,IGF::OT::IGF Cancer Data Ecosystem,,,,,,,,,3225602,
9581236,N01,HL,,N,,,,,N01HL000000,,,268201600011I-0-26800002-1,NHLBI:1677572\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DUARTE,UNITED STATES,,32,27176833,US,3058203,BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,910103012,,15133874; ,"GOLD, JOSEPH ;",,7/10/2017,10/9/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES,,,,,,,,,1677572,
9581247,N01,HL,,N,,,,,N01HL000000,,,268201600012I-0-26800002-1,NHLBI:381289\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CORAL GABLES,UNITED STATES,,27,52780918,US,5221250,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,FL,331462926,,15035341; ,"HARE, JOSUA ;",,5/12/2017,11/9/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES,,,,,,,,,381289,
9581256,N43,HL,,N,,,,,N43HL000000,,,268201700021C-0-0-1,NHLBI:293218\,SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SALT LAKE CITY,UNITED STATES,,2,829431076,US,10034543,"TECHNOLGY HOLDING, LLC",UT,841031470,,15327302; ,"PRICE, ROBERT ;",,9/28/2017,,"Agreement; airway hyperresponsiveness; airway inflammation; Anti-inflammatory; Anti-Inflammatory Agents; Antioxidants; Apolipoprotein A-I; Asthma; asthmatic; asthmatic patient; Attenuated; Award; Binding; Breathing; Businesses; Cells; Clinical; Clinical Research; Clinical Trials; commercialization; Contractor; Contracts; CSF3 gene; cytokine; Data; Development; Development Plans; Disclosure; Electronic Mail; Eligibility Determination; Experimental Designs; experimental study; Extrinsic asthma; Formulation; Funding; Future; Goals; Grant; High Density Lipoproteins; Human; immunoregulation; improved; Individual; Inflammation; Interferon Type II; Interleukin-17; Intramural Research; Intranasal Administration; invention; Investigational Drugs; Investigational New Drug Application; Knockout Mice; Legal patent; Licensing; Link; manufacturing process; Mediating; member; Metaplasia; Modeling; Mucous body substance; Mus; National Heart, Lung, and Blood Institute; neutrophil; novel; Obstruction; Ovalbumin; peptide drug; Peptides; peptidomimetics; Performance; Phase; Phase I Clinical Trials; Phenotype; pre-clinical; preclinical evaluation; preference; Process; programs; Property; protective effect; Proteins; Pulmonary Function Test/Forced Expiratory Volume 1; Pyroglyphidae; Regulation; Request for Proposals; Research Personnel; response; reverse cholesterol transport; Rights; Serum; Services; Site; Small Business Innovation Research Grant; Steroids; Structure; Techniques; Technology; Technology Transfer; Therapeutic; Time; TNF gene; translational study; United States Food and Drug Administration; United States National Institutes of Health; Work; ",IGF::OT::IGF,,,,,,,,,293218,
9581353,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100073-1,NCI:42412\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,5/24/2017,6/23/2017,Cancer Intervention and Surveillance Modeling Network; meetings; ,IGF::OT::IGF Task Order 73: : Cancer Intervention and Surveillance Modeling Network (CISNET) 2017 Mid-Year Meeting,,,,,,,,,42412,
9581399,N02,CA,,N,,,,,N02CA000000,,,261201700660P-0-0-1,NCI:25000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BOSTON,UNITED STATES,,7,604483045,US,894901,BOSTON UNIVERSITY MEDICAL CAMPUS,MA,21182340,,15327167; ,"LEWIS, KAZIS ;",,9/18/2017,9/21/2018,Health; Medicare; Outcome; response; Surveys; ,IGF::OT::IGF Evaluating & Correcting for Response Bias across versions of the Medicare Health Outcomes Survey.,,,,,,,,,25000,
9581408,N02,CA,,N,,,,,N02CA000000,,,261201700047A-0-0-1,NCI:70000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,,,,1963263,,,,,,,15327108; ,"ADRIAN GARCIA DE ALBENIZ, XABIER ;",,9/20/2017,9/19/2018,Address; Data; Performance; Selection Bias; ,IGF::OT::IGF OTHER FUNCTIONS. Use of Target Trial Approach for Addressing Selection Biases in SEER Treatment Assignment Data. Period of Performance 9/20/17 - 9/19/18.,,,,,,,,,70000,
9582275,N43,DA,,N,,,,,N43DA000000,,,271201700051C-0-0-1,NIDA:225000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,TALLAHASSEE,UNITED STATES,,2,80393227,US,10043218,"PEVALS, LLC",FL,323126743,,15253172; ,"ZHANG, YINFENG ;",,9/15/2017,3/14/2018,Advocacy; Agreement; Algorithms; Award; base; Bioinformatics; Biological Sciences; Contractor; Decision Making; design; Disease; Educational workshop; Effectiveness; Electronics; Engineering; essays; Evaluation; Florida; Foundations; Future; Goals; graduate student; improved; indexing; Individual; innovation; Institutes; instructor; Legal patent; Methodology; Methods; Modification; novel; novel strategies; Online Systems; Paper; Participant; Peer Review; Performance; Phase; Pilot Projects; Policy Maker; Process; programs; Reporting; Research; Science; simulation; Small Business Innovation Research Grant; Solid; Students; symposium; Testing; Universities; Work; Workload; ,"IGF::OT::IGF : An Innovative Approach for Peer-Review. Period of Performance: September 15, 2017 - March 14, 2018. N43DA-17-1214. BASE AWARD.",,,,,,,,,225000,
9583668,N01,DA,,N,,,,,N01DA000000,,,271201700034C-0-0-1,NIDA:419818\NINDS:98149\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,15124115; ,"THOMAS, BRIAN ;",,7/9/2017,7/8/2018,Contracts; Development; Equipment and supply inventories; Exercise; Institutes; Maintenance; Medical; National Institute of Drug Abuse; National Institute of Neurological Disorders and Stroke; Pharmaceutical Preparations; Program Development; Ships; Site; Source; System; Testing; Therapeutic; United States National Institutes of Health; ,"IGF::OT::IGF : OPTION (NINDS)PURITY SPECIFICATIONS, STORAGE AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT. JULY 9, 2017 - JULY 8, 2018.  N01DA-17-8934PURPOSE:   TO EXERCISE QUANTITY OPTIONS 2(A) FIVE T",,,,,,,,,517967,
9583977,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100043-1,NIAID:30337006\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266025; ,"BASELER, BETH ;",,9/14/2015,9/25/2018,Africa; clinical development; Clinical Research; Communicable Diseases; Dose; Ebola Hemorrhagic Fever; Ebola Vaccines; Ebola virus; Emerging Communicable Diseases; equipment training; Evaluation; follow-up; Future; Genetic; Guinea; Health; Human Resources; immunogenicity; Influenza; infrastructure development; Liberia; male; Participant; Placebos; research and development; Research Design; response; Safety; Seminal fluid; Survivors; Vaccination; Vaccines; ,Ebola Virus and Other Emerging & Re-emerging Infectious Diseases,,,,,,,,,30337006,
9583978,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100043-2,NIAID:6800000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266025; ,"BASELER, BETH ;",,9/14/2015,9/25/2018,Africa; Cardiovascular Diseases; Chronic Disease; Clinical Research; co-infection; Disease Progression; Epidemiology; HIV; HIV Infections; Kidney Diseases; Liberia; programs; response; Role; ,HIV CLINICAL RESEARCH IN WEST AFRICA,,,,,,,,,6800000,
9587855,N02,NS,,N,,,,,N02NS000000,,,265201700036P-0-0-1,NINDS:11650\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,BETHESDA,UNITED STATES,,,189637689,US,,,MD,208142226,,; ,",  ;",,9/28/2017,2/28/2018,Biological Markers; Charge; Genetic Transcription; meetings; Science; Services; ,IGF::CL::IGF: This Service is for Science Writer and Transcription charges for minute and meeting notes for the 2017 Biomarkers meeting,,,,,,,,,11650,
9589075,N01,AA,,N,,,,,N01AA000000,,,26320090024B28100018-0-0-1,OD:17894\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM,,HERNDON,UNITED STATES,,,789995933,US,,,VA,201703838,,; ,",  ;",,11/20/2008,2/28/2018,addiction; Adherence; adverse outcome; Affect; Age; aged; AIDS/HIV problem; alcohol abuse therapy; Alcohol consumption; Alcohol or Other Drugs use; alcohol use disorder; Alcohols; Area; Attitude; binge drinking; Birth; Candidiasis; Centers for Disease Control and Prevention (U.S.); Child; Comorbidity; Data; Data Analyses; Diagnosis; Discrimination; Disease; drinking; Drug usage; Employee Strikes; Epidemic; Epidemiology; Esophageal; Female; Fetal Alcohol Spectrum Disorder; follow-up; girls; Goals; Health; health data; Hepatitis C; high school; HIV; HIV Infections; Incidence; Investigation; Maternal and Child Health; meetings; National Institute on Alcohol Abuse and Alcoholism; Oral; Outcome; Patients; Pharmaceutical Preparations; Play; Population; Pregnancy; Prevalence; prevent; Prevention; Privatization; Provider; Publishing; Recovery; Reporting; Research; Research Personnel; response; Role; Services; sex risk; social stigma; Substance abuse problem; substance misuse; Surgeon; Surveys; symposium; transmission process; United States; Unsafe Sex; Washington; Woman; working group; ,"IGF::OT::IGF Meeting support services for the 2017 National Conference on Substance Abuse Among Women and Girls, September 22-23, 2017, Washington, D.C.",,,,,,,,,17894,
9589187,N01,OD,,N,,,,,N01OD000000,,,263201200074I-2-26300075-1,NINDS:25000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14921823; ,"WESTBROOK, DAVID ;",,9/1/2015,12/31/2017,Regenerative Medicine; ,IGF::OT::IGF: FORUM ON REGENERATIVE MEDICINE,,,,,,,,,25000,
9589199,N01,DA,,N,,,,,N01DA000000,,,271201600006I-0-27100004-1,NINDS:142909\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15266158; ,"GREEN, CAROL ;",,9/30/2017,5/31/2018,Canis familiaris; Clinical Chemistry; Drug Kinetics; International; ,IGF::OT::IGF 'Follow-On 28 Day Dog Pharmacokinetic and Clinical Chemistry Assessments'- SRI International,,,,,,,,,142909,
9591729,N01,OD,,N,,,,,N01OD000000,,,26320170082B26300005-0-0-1,NEI:97086\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,NORTHAMPTON,UNITED STATES,,,825136117,US,,,MA,10603267,,; ,",  ;",,9/13/2017,8/31/2018,Academy; Agreement; Anniversary; Area; Calendar; Communication; Communities; Contractor; Development; digital; digital media; Education; Eye; Health; Health Communication; Measures; Mission; National Eye Institute; outreach; population health; Recommendation; Reporting; Research; Research Support; Resource Sharing; Resources; Science; social media; Social Work; tool; Vision; ,IGF::OT::IGF - NEI Communications and Outreach Support Services--Social media Support,,,,,,,,,97086,
9594190,N01,AG,,N,,,,,N01AG000000,,,271201000011I-3-27100003-1,NIA:8921\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON AGING,,NORTH BETHESDA,UNITED STATES,,8,161157631,US,1968001,"JOHNSON, BASSIN AND SHAW, INC.",MD,208525032,,15040782; ,"BURTON, DAVID ;",,9/22/2011,9/21/2012,,NIA INFORMATION RESOURCE CENTER HHSN-271-2010-00011I-CAN #8469736,,,,,,,,,8921,
9594200,N01,AG,,N,,,,,N01AG000000,,,271201200001I-0-27100009-1,NIA:571397\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON AGING,,WILMINGTON,UNITED STATES,,6,19716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,18871096,,15150321; ,"FISHER, TERRY ;",,9/10/2017,9/9/2018,,IGF::OT::IGF ITEM DESCRIPTION/PROJECT TITLE: DEV. & MAINTENANCE OF A MULTIGENOTYPIC CALORIC RESTRICTED RODENT COLONYCONTRACT NUMBER:  HHSN271201200001I/TASK ORDER HHSN27100009 PERIOD OF PERFORMANCE: 9,,,,,,,,,571397,
9594209,N01,DA,,N,,,,,N01DA000000,,,271201100002I-0-27100009-1,NIA:3476255\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILMINGTON,UNITED STATES,,6,19716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,18871096,,15097611; ,"FISHER, TERRY ;",,7/15/2017,7/14/2018,,IGF::OT::IGF DEVELOPMENT AND MAINTENANCE OF THE AGING RAT COLONIES HHSN271201100002I HHSN27100009 CAN 8469730,,,,,,,,,3476255,
9594286,N01,AG,,N,,,,,N01AG000000,,,271201500003C-5-0-2,NIA:1310759\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON AGING,,CAMDEN,UNITED STATES,,1,69894707,US,7603801,CORIELL INSTITUTE FOR MEDICAL RESEARCH,NJ,81031505,,15327386; ,"REQUESENS, DEBORAH ;",,2/1/2017,1/31/2018,,IGF::OT::IGF,,,,,,,,,1310759,
9532316,N01,CA,,N,,,,,N01CA000000,,,261201300019I-0-26100011-1,NCI:50213\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HARTFORD,UNITED STATES,,1,807853791,US,1854401,CONNECTICUT STATE DEPT OF PUBLIC HEALTH,CT,61061367,,15133862; ,"PHILLIPS, CATHRYN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,Patterns of Care/Quality of Care Study: Diagnosis Year 2016 ,,,,,,,,,50213,
9532318,N01,CA,,N,,,,,N01CA000000,,,261201300005I-0-26100012-1,NCI:159811\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREMONT,UNITED STATES,,17,89958011,US,1043401,CANCER PREVENTION INSTIT OF CALIFORNIA,CA,945382334,,15140325; ,"GOMEZ, PHD, SCARLETT LIN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016 (07/31/2017 - 07/30/2018),,,,,,,,,159811,
9533348,N01,AI,,N,,,,,N01AI000000,,,272201300012I-2-27200012-1,NIAID:436930\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14754113; ,"HOOK, EDWARD ;",,9/15/2016,9/14/2018,Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; Communicable Diseases; Diagnostic; experience; Human Resources; Laboratories; Leadership; Procedures; protocol development; Research Infrastructure; sample collection; Sex Behavior; Sexually Transmitted Diseases; Therapeutic; Training; ,Sexually Transmitted Infections Clinical Trials Group ,,,,,,,,,436930,
9533413,N01,MH,,N,,,,,N01MH000000,,,271201300029C-6-0-1,NIMH:744764\NINDS:0\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,SEPULVEDA,UNITED STATES,,29,30380682,US,2857001,SEPULVEDA RESEARCH CORPORATION,CA,913432036,,12319714; ,"NAGRA, RASHED ;",,7/11/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ","NIMH, NICHD, AND NINDS BRAIN AND TISSUE REPOSITORY",,,,,,,,,744764,
9533414,N01,MH,,N,,,,,N01MH000000,,,271201300029C-6-0-2,NIMH:0\NINDS:443646\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,SEPULVEDA,UNITED STATES,,29,30380682,US,2857001,SEPULVEDA RESEARCH CORPORATION,CA,913432036,,14208369; ,"NAGRA, RASHED ;",,7/11/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ",IGF::OT::IGF,,,,,,,,,443646,
9534466,N01,DA,,N,,,,,N01DA000000,,,271201500082C-4-0-2,NIDA:7005\OD:69270\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,PITTSBURGH,UNITED STATES,,14,4514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152132303,,15253975; ,"HORVATH, ZSUZA ;",,9/10/2015,9/9/2018,Adult; Age; Anesthesiology; cancer pain; case-based; chiropracty; Collaborations; Computers; Contracts; Degenerative polyarthritis; Dementia; Dental; design; diabetic; Discipline of Nursing; Disseminated Malignant Neoplasm; E-learning; Education; Educational Curriculum; Elderly; Exercise; Faculty; fibromyalgia pain; Geriatrics; handheld mobile device; Headache; Infection; Instruction; Instructional Technology; Internal Medicine; Learning; learning materials; Learning Module; man; Medicine; middle age; Neurology; Nurses; opioid misuse; Outcome; Pain; painful neuropathy; Palliative Care; Patients; Pediatrics; Pennsylvania; Peripheral; Pharmacy facility; pre-doctoral; Primary Health Care; Provider; Psychiatry; Registries; Rheumatology; Schools; screening; Students; Teenagers; tool; Tooth Extraction; United States National Institutes of Health; Universities; virtual; web site; wisdom tooth; Woman; young adult; ,"IGF::OT::IGF: NIH Pain Consortium Centers of Excellence in Pain Education. POP: September 10, 2015 - September 9, 2018. N01DA-15-4432. To exercise Option Period 2 (Contract Year 3).",,,,,,,,,76275,
9536548,N01,CA,,N,,,,,N01CA000000,,,261201500003I-2-26100025-1,NCI:3187530\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14761413; ,"BOCIK, WILLIAM ;",,9/26/2015,9/25/2021,base; Biological Assay; Biology; Cancer Biology; Clinic; Communities; Complement; Data Set; Development; diagnostic assay; diagnostic panel; DNA sequencing; Genomics; Goals; Human; Malignant neoplasm of lung; Malignant Neoplasms; Measurement; molecular targeted therapies; multiple reaction monitoring; Mutation; next generation; Pathway interactions; Patients; precision oncology; Proteins; proteogenomics; Research Methodology; Resources; Therapeutic Intervention; treatment response; tumor; ,Lung Cancer Multiple Reaction Monitoring Project,,,,,,,,,3187530,
9537826,N01,AI,,N,,,,,N01AI000000,,,272201200003I-0-27200022-1,NIAID:363829\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15151966; ,"HORNBACK, RANDI ;",,7/28/2017,4/30/2018,Antimicrobial Resistance; assay development; Biological Response Modifier Therapy; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; nonhuman primate; novel vaccines; pathogen; Phase; product development; safety study; safety testing; Sampling; Services; Staphylococcus aureus; Testing; Toxicity Tests; Toxoids; vaccine development; Vaccines; ,TASK X22: Non-GLP Safety Study of multivalent toxoid S. aureus Vaccine (IBT-V02) in nonhuman primates for Integrated Biotherapeutics,,,,,,,,,363829,
9537838,N01,AI,,N,,,,,N01AI000000,,,272201700035I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATHENS,UNITED STATES,,10,4315578,US,676602,UNIVERSITY OF GEORGIA,GA,306021589,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537839,N01,AI,,N,,,,,N01AI000000,,,272201700026I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,100101710,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537871,N01,AI,,N,,,,,N01AI000000,,,272201700016I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BOSTON,UNITED STATES,,7,604483045,US,894901,BOSTON UNIVERSITY MEDICAL CAMPUS,MA,21182340,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537872,N01,AI,,N,,,,,N01AI000000,,,272201700037I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PITTSBURGH,UNITED STATES,,14,4514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152132303,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537877,N01,AI,,N,,,,,N01AI000000,,,272201700023I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BATON ROUGE,UNITED STATES,,6,75050765,US,577907,LOUISIANA STATE UNIV A&M COL BATON ROUGE,LA,708030001,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537888,N01,AI,,N,,,,,N01AI000000,,,272201700018I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FORT COLLINS,UNITED STATES,,2,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805231062,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9538544,N01,DA,,N,,,,,N01DA000000,,,271201300045C-9-0-2,NIDA:652655\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,,876875154,US,,IQ SOLUTIONS INC,MD,208523046,,14625393; ,"PARK, NEI-HYUN ;",,9/22/2013,9/21/2018,addiction; Address; Area; Collaborations; Consultations; Contracts; design; Development; Drug abuse; Drug Addiction; Drug usage; Fellowship; Health; House Staffs; Information Services; International; Knowledge; National Institute of Drug Abuse; Performance; Program Development; programs; Research; research and development; Research Support; Scientific Advances and Accomplishments; Scientist; Services; Training; Training Support; United States; Visit; ,"IGF::OT::IGF  INTERNATIONAL RESEARCH AND TRAINING SUPPORT . N01DA-13-1151. PERIOD OF PERFORMANCE: SEPTEMBER 22, 2013 TO SEPTEMBER 21, 2018.PURPOSE:   ",,,,,,,,,652655,
9538980,N01,HD,,N,,,,,N01HD000000,,,275201200002I-0-27500008-1,NICHD:2360737\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DURHAM,UNITED STATES,,,803902113,US,,HEALTH DECISIONS INC,NC,277132260,,15152181; ,"DART, CLINT ;",,7/18/2017,7/17/2022,androgenic; Androgens; Archives; Case Report Form; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; contraceptive efficacy; Contraceptive methods; Data; Data Analyses; Data Collection; data management; Databases; Development; diaries; Dose; Drug usage; Enrollment; Ensure; follow-up; Gel; Goals; Gonadotropins; Hormonal; Institutional Review Boards; Investigation; Logistics; Male Contraceptive Agents; man; meetings; men; Monitor; Monitoring Clinical Trials; National Institute of Child Health and Human Development; Nestorone; novel; Patients; Pharmaceutical Preparations; Preparation; Production; programs; protocol development; Protocols documentation; Recruitment Activity; Reporting; research clinical testing; Research Personnel; Safety; Services; Site; sperm cell; Spermatogenesis; System; Testosterone; Visit; Work; ,COORDINATION OF CLINICAL TRIALS OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION,,,,,,,,,2360737,
9542514,N01,AI,,N,,,,,N01AI000000,,,272201700057C-0-0-1,NIAID:153447\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,75524595,US,9340401,WISTAR INSTITUTE,PA,191044265,,15146703; ,"ERTL, HILDEGUND ;",,8/1/2017,7/31/2018,adeno-associated viral vector; Adenovirus Vector; Adenoviruses; Advanced Development; Animal Model; cGMP production; clinical development; Clinical Trials; Data; Development; Development Plans; DNA Vaccines; Formulation; Future; HIV; HIV vaccine; Human; interest; Licensure; nonhuman primate; Pan Genus; Pharmaceutical Preparations; Phase; Poxviridae; pre-clinical; Preparation; product development; Production; programs; Proteins; Recombinants; success; Update; vaccine candidate; vector; ,"CLINICAL DEVELOPMENT OF TWO REPLICATION-DEFECTIVE CHIMPANZEE ADENOVIRUS (ADC) VECTORS, TERMED ADC6 AND ADC7",,,,,,,,,153447,
9542531,N01,AI,,N,,,,,N01AI000000,,,272201700022C-0-0-1,NIAID:1690690\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,1,53785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,,15064834; ,"KAUR, AMITINDER ;",,6/1/2017,5/31/2018,AIDS Vaccines; assay development; Biological Assay; Cellular Immunology; Contractor; Contracts; cytokine; design; Development; enzyme linked immunospot assay; Flow Cytometry; HIV; Immune response; Immunize; improved; Laboratories; National Institute of Allergy and Infectious Disease; nonhuman primate; Reproducibility; research and development; Research Personnel; simian human immunodeficiency virus; Site; SIV; SIV Vaccines; Staining method; Stains; Technology; United States National Institutes of Health; vaccine development; vaccine evaluation; Vaccine Research; ,NONHUMAN PRIMATE (NHP) CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH DEVELOPMENT,,,,,,,,,1690690,
9543270,N01,AI,,N,,,,,N01AI000000,,,272201300023C-3-0-1,NIAID:3307969\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,12066646; ,"GALE, MICHAEL ;",,9/30/2017,9/29/2018,"adaptive immune response; Adjuvant; Adjuvant Study; Antigens; Avian Influenza; Avian Influenza A Virus; Bird Flu vaccine; Development; Dose; Emerging Communicable Diseases; FDA approved; Ferrets; Flavivirus; Formulation; Genes; Human; Immunologic Adjuvants; Immunologics; Infection; Influenza A Virus, H5N1 Subtype; Investigation; Investigational Drugs; Investigational New Drug Application; IRF3 gene; Lead; Licensure; Mus; National Institute of Allergy and Infectious Disease; Natural Immunity; novel; pathogen; Pathogenicity; Pathway interactions; Pharmaceutical Chemistry; Program Development; programs; response; small molecule; System; Toxicology; transcription factor; Tretinoin; Vaccine Adjuvant; vaccine candidate; Vaccines; Virus Diseases; West Nile virus; Zika virus vaccine; ","Novel Innate Immune Adjuvant for Avian Influenza. West Nile Virus, and ZIKA Vaccines",,,,,,,,,3307969,
9545124,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200010-1,NIAID:32770\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15151987; ,"SWARTZ, GLEN ;",,8/1/2017,7/31/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Biological Products; Clinical Trials; Development; HIV Infections; Licensure; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; research clinical testing; Role; sexual HIV transmission; Technology; United States Food and Drug Administration; United States National Institutes of Health; Work; ,SUPPORT FOR REGULATORY EXPERTISE IN THE DEVELOPMENT OF LIVE BIOTHERAPEUTIC AGENTS,,,,,,,,,32770,
9545129,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200004-1,NIAID:197747\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14922270; ,"SWARTZ, GLENN ;",,12/15/2016,12/14/2017,Acquired Immunodeficiency Syndrome; AIDS prevention; Clinical Trials; Development; Evaluation; HIV; HIV Infections; improved; innovation; Licensure; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; product development; research clinical testing; Resources; Role; sexual HIV transmission; Statistical Data Interpretation; Technology; United States National Institutes of Health; Work; ,STATISTICAL SUPPORT FOR HIV NONVACCINE BIOMEDICAL PREVENTION PRODUCT DEVELOPMENT,,,,,,,,,197747,
9545268,N01,AI,,N,,,,,N01AI000000,,,272201700080C-0-0-1,NIAID:299999\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROANOKE,UNITED STATES,,6,627132913,US,3604601,"LUNA INNOVATIONS, INC.",VA,240111921,,15236953; ,"TAMMY, FERGUSON ;",,8/1/2017,7/31/2018,Adjuvant; AIDS prevention; Antibodies; Antisense Oligonucleotides; aptamer; base; Biological Assay; Businesses; Carbon Nanotubes; Cell Line; Cells; Circular DNA; Clinic; clinically relevant; Contracts; cytokine; Cytoplasm; cytotoxic; cytotoxicity; Dendritic Cells; Dependovirus; Development; Dose; Double-Stranded RNA; Feasibility Studies; Genetic Transcription; Goals; HIV; HIV Antigens; HIV therapy; HIV vaccine; Immune; Immune checkpoint inhibitor; Immune response; Immune Targeting; Immunological Models; improved; In Situ; In Vitro; in vivo; Messenger RNA; Metabolism; Methods; MicroRNAs; Microscopic; Microscopy; Monitor; mouse model; neutralizing monoclonal antibodies; Nuclear; Oligonucleotides; Pathway interactions; Phase; Plasmids; programs; Property; Proteins; Reporter; Reporter Genes; Risk; RNA; RNA chemical synthesis; RNA Instability; RNA Splicing; RNA Stability; Small Interfering RNA; Subfamily lentivirinae; System; Technology; Testing; Therapeutic; Tissues; Toxic effect; Transfection; Translations; uptake; Vaccines; vector; Viral Proteins; ,CNT-VECTORED DELIVERY OF MRNA FOR HIV-VACCINES,,,,,,,,,299999,
9545273,N43,AI,,N,,,,,N43AI000000,,,272201700083C-0-0-1,NIAID:294538\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLLEGE STATION,UNITED STATES,,17,78432725,US,10031615,"AI BIOSCIENCES, INC.",TX,778455816,,15236947; ,"WONG, SEASON ;",,8/1/2017,7/31/2018,amplification detection; antiretroviral therapy; Biological Assay; Blood; Blood capillaries; capillary; CD4 Lymphocyte Count; Clinical; clinical care; Clinical Trials; Collection; cost; Devices; diabetic; Diagnosis; Drug resistance; Early Diagnosis; Early treatment; Enrollment; Fingers; glucose monitor; Guidelines; high risk; HIV; HIV Infections; Home environment; Individual; Interruption; Intervention; Lead; Molecular; Monitor; Morbidity - disease rate; mortality; Patients; Plasma; pre-exposure prophylaxis; Price; Regimen; Resistance; Resources; RNA; Sampling; Sensitivity and Specificity; Site; System; Technology; Testing; Time; transmission process; Viral Load result; viral rebound; Whole Blood; ,"A Low-cost, Automated and Rapid Home HIV Viral Load Test",,,,,,,,,294538,
9547194,N01,AI,,N,,,,,N01AI000000,,,272201400053C-5-0-1,NIAID:320000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BEDFORD PARK,AUSTRALIA,,,750421575,AS,10017775,VAXINE PTY LTD,,5042,,12441686; ,"PETROVSKY, NIKOLAI ;",,9/30/2014,9/29/2018,Adjuvant; Adjuvanticity; Animal Model; Anthrax disease; Area; Biological; Cells; Computer Simulation; Contractor; Cytotoxic T-Lymphocytes; Dendritic Cells; Disease model; Ebola virus; Emerging Communicable Diseases; Formulation; Frankfurt-Marburg Syndrome Virus; Genus staphylococcus; Helper-Inducer T-Lymphocyte; high throughput screening; Human; human disease; In Vitro; in vivo; Influenza; influenzavirus; Interleukin-12; Japanese encephalitis virus; Lead; Libraries; Ligands; Malaria; Modeling; Murray Valley Encephalitis Virus; National Institute of Allergy and Infectious Disease; novel; pathogen; Pharmaceutical Chemistry; programs; receptor; Receptor Signaling; Research; Respiratory syncytial virus; Rickettsia; Rickettsiales; Signal Pathway; Streptococcus; Structure-Activity Relationship; Study models; Testing; Vaccine Adjuvant; vaccine candidate; vaccine discovery; Vaccines; Vaccinia; Validation; West Nile virus; Work; ,High-throughput screening for novel adjuvant discovery for vaccines against influenza virus,,,,,,,,,320000,
9547195,N01,NS,,N,,,,,N01NS000000,,,N01NS62369-18-0-1,OD:775484\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,10521501; ,"GREEN, CAROL ;",,9/30/2006,4/30/2018,Basic Science; Biodistribution; Businesses; Centers of Research Excellence; Chemical Agents; chemical threat; Chemicals; Chemistry; Clinical Research; Contractor; Contracts; design; Diagnostic; drug candidate; Drug Kinetics; efficacy study; Emergency Situation; Equipment; Formulation; Goals; Government; Individual; innovation; Investigational New Drug Application; Medical; Movement; Performance at work; Pharmaceutical Preparations; preclinical development; preclinical study; prevent; Process; product development; programs; Research; Research Project Grants; Safety; Testing; Therapeutic; therapeutic candidate; Toxicology; Translational Research; treatment response; United States Food and Drug Administration; United States National Institutes of Health; Work; ,Countermeasures Against Chemical Threats ^ Preclinical Development Facility,,,,,,,,,775484,
9547684,N01,AI,,N,,,,,N01AI000000,,,272201300028C-8-0-1,NIAID:3050337\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ANN ARBOR,UNITED STATES,,12,177653487,US,10001832,NANOBIO CORPORATION,MI,481052965,,12627850; ,"FATTOM, ALI ;",,9/30/2017,9/29/2018,Adjuvant; Animals; Antigens; base; clinical toxicology; Contractor; Cyclic GMP; Development; Emerging Communicable Diseases; Engineering; Ferrets; Human; Immune response; immunogenicity; Immunologics; Infection; Influenza virus vaccine; Intramuscular; Investigation; Investigational Drugs; Lead; Licensure; manufacturing scale-up; Mus; nanoemulsion; National Institute of Allergy and Infectious Disease; novel; Oils; Oryctolagus cuniculus; pandemic influenza; pathogen; Plants; pre-clinical; Program Development; Recombinants; Research; Route; Self Administration; stability testing; Vaccine Adjuvant; vaccine candidate; vaccine development; Vaccines; Water; ,Development of a Nanoemulsion Adjuvant,,,,,,,,,3050337,
9547713,N01,OD,,N,,,,,N01OD000000,,,263201200199U-12-0-1,NEI:53106\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,,77810323,US,,HAGER SHARP,DC,200054905,,14226789; ,"CURTIS, GARY ;",,9/13/2012,11/1/2017,Adherence; Awareness; Budgets; career; Child; Clinical Research; Communication; Communities; Consultations; Contractor; Contracts; design; Development; digital; Education; Employee; Ensure; Event; Eye; Health; Health education; Health Sciences; Healthy People 2010; Hour; Institutes; interest; Internet; Interview; Investments; K-12 science education; Logistics; National Eye Institute; Newsletter; Office of Administrative Management; Ophthalmic examination and evaluation; Pamphlets; Policies; posters; Printing; programs; Publications; Reporting; Research; School-Age Population; Science; social media; Social support; technical report; United States National Institutes of Health; Vision; web site; webinar; Work; Writing; ,National Eye Institute?s Public Liaison and Education Programs,,,,,,,,,53106,
9548962,N01,DA,,N,,,,,N01DA000000,,,271201500075C-3-0-2,NINDS:94024\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BOSTON,UNITED STATES,,7,47006379,US,3212902,HARVARD MEDICAL SCHOOL,MA,21156027,,14628191; ,"SHAEFER, JEFFREY ;",,9/17/2015,9/16/2018,Analgesics; Case Based Learning; Contractor; Contracts; Dental Assistants; Dental Schools; Diagnosis; Education; educational atmosphere; Educational Curriculum; Epidemic; Exercise; Goals; improved; innovation; Learning; Medical; medical schools; Nursing Schools; Pain; Pain management; Pharmacy facility; Pharmacy Schools; repository; Resources; Students; tool; Training; United States National Institutes of Health; web site; ,IGF::OT::IGF Purpose: To exercise Option Period 1 Contract Year 2,,,,,,,,,94024,
9553425,N02,CA,,N,,,,,N02CM000000,,,261201300028I-3-26100003-1,NCI:4900509\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,14721603; ,"CELII, KATHI ;",,9/1/2017,8/31/2018,Computer software; Consult; Contracts; improved; interest; Licensing; Maintenance; Multi-Institutional Clinical Trial; operation; Secure; Services; Training; ,Medidata Rave Hosting and Maintenance,,,,,,,,,4900509,
9554731,N01,AI,,N,,,,,N01AI000000,,,272201200034C-9-0-1,NIAID:2704724\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,College Park,UNITED STATES,,5,116420691,US,10019828,CENTER FOR EXPERMENTAL SOFTWARE ENGR MD,MD,207403823,,12387815; ,"YUSIBOV, VIDADI ;",,9/27/2012,7/29/2019,Address; Anthrax Vaccines; Award; Biological Assay; Clinical Research; Cyclic GMP; Development; Dose; Formulation; Investigational Drugs; National Institute of Allergy and Infectious Disease; next generation; Pharmaceutical Preparations; Process; product development; Reagent; stability testing; Technology; Toxicology; Vaccines; Validation; ,Technologies to Advance Next Generation Anthrax Vaccines,,,,,,,,,2704724,
9555907,N01,AI,,N,,,,,N01AI000000,,,272201500015C-4-0-1,NIAID:755154\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,20,7936842,US,7666501,SOUTHWEST RESEARCH INSTITUTE,TX,782385166,,14164959; ,"BAUTA, WILLIAM ;",,7/1/2015,10/31/2018,Clinical; clinical development; Communicable Diseases; drug candidate; Ebola virus; Frankfurt-Marburg Syndrome Virus; Future; In Vitro; in vivo; infectious disease treatment; Lead; novel; Pharmaceutical Chemistry; pre-clinical; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases,,,,,,,,,755154,
9556096,N02,CA,,N,,,,,N02CA000000,,,261201400162U-5-0-2,NCI:181126\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ARLINGTON,UNITED STATES,,8,101929438,US,3085001,"FU ASSOCIATES, LTD.",VA,222013383,,14199389; ,"PIENTA, LENORE ;",,9/29/2017,9/28/2018,Cancer Patient; Contracts; Data; Data Sources; Elderly; Quality of Care; Research Project Grants; United States Centers for Medicare and Medicaid Services; ,IGF::OT::IGF OTHER FUNCTIONS - SEER LINKAGES CONTRACT,,,,,,,,,181126,
9564364,N02,HD,,N,,,,,N02HD000000,,,275201700200U-0-0-1,NIDDK:202748\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,15327851; ,"NA, NA ;",,8/14/2017,2/28/2018,Address; Americas; Area; Award; base; Biometry; Books; Caring; Characteristics; Communities; Complications of Diabetes Mellitus; computerized data processing; Contractor; Data; data management; Descriptive Epidemiology; Diabetes Mellitus; Economics; Epidemiology; Equipment; Government; Health Policy; Human Resources; Medical; named group; National Institute of Diabetes and Digestive and Kidney Diseases; Persons; Policy Maker; Publications; Publishing; Research; Resources; Services; Source; Surveys; Work; ,Diabetes in America 3rd Edition completion ,,,,,,,,,202748,
9564748,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-3,NIAID:409394\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,409394,
9564752,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-7,NIAID:181953\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Enterovirus 68; Equipment; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,181953,
9566073,N01,DA,,N,,,,,N01DA000000,,,271201500066C-3-0-1,NIDA:4136\NIDCR:125000\NINDS:3106\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,14264249; ,"HOGANS, BETH ;",,9/15/2015,9/14/2018,Caring; Clinical Research; Comprehensive Health Care; Congresses; Diagnosis; Education; experience; Health Occupations; Laws; Linguistics; literacy; medical schools; medical specialties; opioid use; Pain; Pain Clinics; Pain management; Patient Care; Pharmaceutical Preparations; Policies; programs; Regulation; Schedule; socioeconomics; Specific qualifier value; Students; United States National Institutes of Health; ,NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION,,,,,,,,,132242,
9567651,N01,LM,,N,,,,,N01LM000000,,,27620170013B27600019-0-0-1,NIAID:810000\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,; ,",  ;",,9/12/2017,,Agreement; AIDS/HIV problem; Clinical; Ensure; Government; Information Dissemination; Information Services; Institutes; Medical; Practice Guidelines; prevention clinical trial; Research; Resources; United States National Institutes of Health; United States National Library of Medicine; ,Support for Biomedical and Clinical Information Services for the National Library of Medicine and Other NIH Institutes and Centers,,,,,,,,,810000,
9594335,N01,OD,,N,,,,,N01OD000000,,,263201200074I-2-26300086-2,NIA:100000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15229182; ,"WESTBROOK, DAVID ;",,9/30/2015,9/29/2018,,IGF::OT::IGF: PARTIAL SUPPORT FOR THE COMMITTEE ON POPULATION CPOP),,,,,,,,,100000,
9594343,N01,OD,,N,,,,,N01OD000000,,,263201200074I-2-26300087-2,NIA:100000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15229185; ,"WESTBROOK, DAVID ;",,9/30/2015,9/29/2018,,"IGF::OT::IGF: SPRING MEETING OF THE BOARD ON BEHAVIORAL, COGNITIVE, AND SENSORY SCIENCES (BBCSS)",,,,,,,,,100000,
9594354,N01,DA,,N,,,,,N01DA000000,,,271201600001I-0-27100002-1,NIA:2424474\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILMINGTON,UNITED STATES,,6,19716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,18871096,,14961596; ,"FISHER, TERRENCE ;",,3/14/2017,3/13/2018,,IGF::OT::IGF DEVELOPMENT AND MAINTENANCE FOR THE BREEDING AND AGING COLONIES. HHSN271201600001I HHSN27100002 CAN 8469730,,,,,,,,,2424474,
9594379,N01,DA,,N,,,,,N01DA000000,,,271201700003C-0-0-1,NIA:323928\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,14922036; ,"TORRES, CATHERINE ;",,12/19/2016,12/18/2017,,IGF::CT::IGF,,,,,,,,,323928,
9261044,F31,GM,1,N,12/27/2016,12/27/2017,12/26/2018,859,F31GM122379,SCHOOLS OF ARTS AND SCIENCES,PA-14-148,1F31GM122379-01,NIGMS:44044\,"TRAINING, INDIVIDUAL",2017,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,,COLUMBIA,UNITED STATES,CHEMISTRY,6,41387846,US,1524302,UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA,SC,292080001,,11936486; ,"JENKINS, LAURA M;","BROWN, PATRICK",12/27/2017,12/26/2019,Address; Affinity; Anchorage-Independent Growth; angiogenesis; base; beta catenin; Binding; Biochemical; Biological; Biological Assay; Breast Epithelial Cells; cancer cell; cancer diagnosis; Cancer Model; cancer prevention; Cancerous; Carcinoma; Cause of Death; Cell Differentiation process; cell growth; Cell Line; cell motility; Cell Proliferation; Cell surface; Cellular biology; chondroitin sulfate glycosaminoglycan; Chondroitin Sulfates; Clustered Regularly Interspaced Short Palindromic Repeats; Colon Carcinoma; Complex; Coronary; crosslink; design; Development; Early Diagnosis; Embryo; Epithelial; Epithelial Cells; Equilibrium; Future; FZD1 gene; Genetic Transcription; Glycosaminoglycans; Goals; Heart Diseases; Heparitin Sulfate; Human; Hyperactive behavior; Impairment; In Vitro; in vivo; Length; Ligands; Ligation; Link; Malignant Neoplasms; Mammary Neoplasms; Mammary Tumorigenesis; Modification; mouse model; Mus; Neoplasm Metastasis; Normal Cell; novel; Patients; Play; Premature Ovarian Failure; Proteoglycan; Public Health; receptor; Research; Research Proposals; response; Role; Signal Pathway; Signal Transduction; Specific qualifier value; Techniques; Testing; TGF beta type III receptor; Time; tool; Transforming Growth Factor beta; treatment strategy; tumor; Tumor Biology; tumor growth; tumor progression; Tumor Suppressor Proteins; tumorigenesis; tumorigenic; Tumorigenicity; vasculogenesis; WNT Signaling Pathway; Woman; ,Elucidating roles for the heparan sulfate and chondroitin sulfate glycosaminoglycan chains on Betaglycan in Wnt Signaling,122379,ZRG1,Special Emphasis Panel ,,,1,44044,,44044,
9398914,IK2,VA,5,N,12/26/2017,11/1/2017,10/31/2018,999,IK2RX001512,,RFA-RX-15-009,5IK2RX001512-03,,OTHERS,2018,Veterans Affairs,,SAN DIEGO,UNITED STATES,,52,73358855,US,481156,VA SAN DIEGO HEALTHCARE SYSTEM,CA,921610002,,8403610; ,"ORFF, HENRY JOHN;",,11/1/2015,10/31/2020,Academy; addiction; Address; Adopted; Adverse effects; Afghanistan; Alcohols; American; Appointment; associated symptom; Attention; Award; Behavioral; Biometry; blind; Brain Concussion; Brain Injuries; Budgets; career; Caring; Chronic; Chronic Insomnia; Clinical; Clinical Psychology; clinically relevant; Cognitive; cognitive rehabilitation; Cognitive Therapy; comorbid depression; Complex; depressive symptoms; design; Development; Diagnosis; disability; Distal; Doctor of Philosophy; Drug abuse; Education; Educational Background; Effect Modifiers (Epidemiology); Enrollment; Ensure; Environment; Ethics; Evaluation; Evidence based practice; Evidence based treatment; experience; Feeling suicidal; Fellowship; Freedom; Funding; Goals; Health; Healthcare Systems; High Prevalence; improved; Individual; Injury; interest; Internships; Intervention; Investigation; Iraq; Israel; Lead; Letters; Literature; Manuscripts; Measures; Mediator of activation protein; Medicine; meetings; Mental Depression; Mental disorders; Mental Health; Mentors; Mentorship; mid-career faculty; mild traumatic brain injury; Minor; National Research Service Awards; negative affect; neuromuscular; Neuropsychology; Occupational; operation; Outcome; Outcome Assessment; Outcome Measure; Pain; patient population; Patients; Pharmaceutical Preparations; Philadelphia; Phonation; physical conditioning; Polysomnography; Population; Post-Concussion Syndrome; Post-Traumatic Stress Disorders; Postdoctoral Fellow; potential biomarker; pre-doctoral; primary outcome; professor; programs; Psychiatry; psychologic; Psychologist; Psychology; Publications; Publishing; Quality of life; Randomized; Randomized Clinical Trials; Randomized Controlled Trials; Recording of previous events; Recovery; Recruitment Activity; Regimen; Rehabilitation Outcome; Rehabilitation Research; Rehabilitation therapy; Reporting; Research; research and development; Research Assistant; Research Design; Research Personnel; Risk; Safety; secondary outcome; service member; skills; Sleep; Sleep Disorders; Sleep disturbances; Sleeplessness; social; Societies; sound; Staging; Statistical Data Interpretation; Stress; Supervision; symposium; Symptoms; Telephone; Testing; Therapeutic; Time; Training; Training Programs; Traumatic Brain Injury; treatment effect; Treatment outcome; treatment response; trial comparing; unhealthy lifestyle; Universities; Veterans; War; wound; Writing; ,Cognitive Behavioral Therapy for Insomnia for Veterans with History of TBI,1512,RRD9,Career Development Program - Panel II ,,,3,,,,
9425609,R01,GM,1,N,12/26/2017,12/26/2017,11/30/2018,859,R01GM126043,SCHOOLS OF MEDICINE,PA-16-160,1R01GM126043-01,NIGMS:341250\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,,PROVIDENCE,UNITED STATES,BIOCHEMISTRY,1,1785542,US,1003201,BROWN UNIVERSITY,RI,29129002,,10792458; ,"YAJIMA, MAMIKO ;","BENDER, MICHAEL T",12/26/2017,11/30/2022,Alpha Cell; Animals; base; Binding; Biological; Biological Assay; blastomere structure; Body Patterning; Cell division; Cell Fate Control; cell fate specification; cell growth regulation; Cell physiology; Cells; cellular development; chromophore; Communities; daughter cell; Defect; Detection; Development; Developmental Biology; Diffusion; egg; Embryo; embryo cell; embryo stage 2; Embryonic Development; Event; Functional disorder; Future; gain of function; Gene Proteins; Genetic Translation; Germ Lines; Imaging Techniques; Imaging technology; In Vitro; in vivo; in vivo imaging; insight; Kinetics; knock-down; Lead; Light; loss of function; Membrane; Messenger RNA; Methods; Microtubules; Mitosis; Mitotic; Mitotic spindle; Mitotic Spindle Apparatus; Molecular; optogenetics; Organism; Outcome; Process; Production; Protein Biosynthesis; Protein Dynamics; Proteins; Proteomics; Recruitment Activity; Regulation; Reporting; Research; Research Personnel; RNA Helicase; Role; Sea Urchins; Side; Site; System; Testing; Time; Translating; Translational Regulation; Translations; ,Localized mRNA translation on the spindle -an essential mechanism for embryonic cell regulation,126043,DEV2,Development - 2 Study Section ,,,1,210000,131250,341250,
9430036,N01,AI,,N,,,,,N01AI000000,,,272201000013I-4-27200004-1,NIAID:347\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SALISBURY,UNITED KINGDOM,,,233388961,UK,10007041,PUBLIC HEALTH ENGLAND,,,,12663072; ,"CARROLL, MILES ;",,10/31/2016,10/30/2017,Amoxicillin; animal model development; Anthrax disease; Bacillus anthracis; Clavulanate; Contracts; Development; efficacy testing; infectious disease model; Licensure; Modeling; nonhuman primate; Standardization; Therapeutic; ,Task C19: Efficacy of amoxicillin and amoxicillin/clavulanate in NHP model of anthrax,,,,,,,,,347,
9430037,N01,AI,,N,,,,,N01AI000000,,,272201200005I-1-27200016-1,NIAID:63306\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14096854; ,"RICHARDSON, JAMES ;",,5/22/2015,5/22/2020,Antimicrobial Resistance; Biologic Development; Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; fecal transplantation; novel vaccines; pathogen; Phase; Process; product development; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X16: Fecal Microbiota for Transplantation (FMT) Process Development,,,,,,,,,63306,
9430045,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-10,NIAID:728000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Gram-Negative Bacteria; Intervention; Lead; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Services; therapeutic development; therapy development; Translational Research; ,Task Order 2: The Interventional Agent Development Services Program,,,,,,,,,728000,
9430056,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-10,NCI:3514967\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,"Amendment; American College of Radiology Imaging Network; Annual Reports; Authorization documentation; Back; bench to bedside; Biological; Blood; Brain Neoplasms; cancer Biomedical Informatics Grid; cancer imaging; cancer therapy; Cetuximab; Clinical; Clinical Data; Clinical Research; Clinical Trials; Communities; Computer Assisted; Contracts; Contrast Media; Cyclotrons; data management; Databases; Decision Making; Deoxycytidine; Development; Diagnosis; Diagnostic; drug development; Educational workshop; Estrogen Receptors; Ferumoxtran-10; Ferumoxytol; Goals; Growth; Half-Life; Hypoxia; Image; image archival system; imaging agent; imaging informatics; imaging platform; imaging program; Informatics; infrastructure development; innovation; interest; Internet; Investigation; Investigational Drugs; Joints; Letters; Literature; lymph nodes; Magnetic Resonance Imaging; Malignant neoplasm of cervix uteri; Malignant neoplasm of lung; Malignant Neoplasms; Manufacturer Name; Medical; Medical Imaging; meetings; Metastatic breast cancer; Metastatic Neoplasm to the Bone; Metastatic Prostate Cancer; Mission; Modality; molecular imaging; Monitor; outreach; Pamphlets; patient stratification; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Positioning Attribute; preclinical study; Preparation; Procedures; Program Development; programs; Radiopharmaceuticals; Regulatory Affairs; Reporting; Research; Research Personnel; Scientific Societies; Serious Adverse Event; Site; Systems Biology; Testing; Tetrahydrouridine; Therapeutic; therapeutic development; Thymidine; tomography; Tomography, Emission-Computed, Single-Photon; tool; Tracer; Translations; treatment response; United States National Institutes of Health; virtual; Work; Writing; ",DCTD Cancer Imaging,,,,,,,,,3514967,
9430060,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-16,NCI:177466\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Area; Biological Assay; Biopsy; Cancer Patient; Clinic; Clinical; Clinical Distribution; Clinical Protocols; Clinical Research; Clinical Trials; Collection; Cryopreservation; Databases; Developmental Therapeutics Program; Drug Kinetics; Ensure; Institution; Laboratories; laboratory facility; Measures; Medical Oncology; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Pharmacodynamics; Phase; Plasma; Process; programs; quality assurance; Quality Control; Reaction; repository; Sampling; Serum; Site; Specimen; Support Groups; Time; tumor; United States National Institutes of Health; Work; ,DCTD Phase I/II CT PK/PD Studies,,,,,,,,,177466,
9430061,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-18,NCI:1423562\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Accreditation; animal care; animal efficacy; Animal Experimentation; animal facility; Animal Husbandry; Animal Model; Animals; Antibody Formation; Antineoplastic Agents; antitumor effect; Area; Autoimmune Process; Autopsy; Bacterial Toxins; Bacteriology; base; Biological; Biological Assay; Biological Testing; biosecurity; Caring; Charge; Chemistry; Clinical Trials; Communities; Consultations; Contracts; Development; Developmental Therapeutics Program; Diabetes Mellitus; Diagnostic; Diagnostic Services; Dichloroacetate; Disease; Disease Progression; Dose; drug candidate; Drug Kinetics; Early Diagnosis; efficacy study; Fluorescence; Funding; Gas Chromatography; Government Agencies; Health; Health Status; Helicobacter; High Pressure Liquid Chromatography; HIV; human disease; IACUC; Immunologics; in vivo; Individual; Infection; Institution; interest; International; Investigation; Knowledge; Laboratories; Laboratory Animal Medicine; Laboratory Animal Science; Laboratory Animals; Lead; Liquid substance; Malignant Neoplasms; Mass Spectrum Analysis; Metabolic; Metabolic Diseases; Methodology; Microbiology; Molecular; molecular diagnostics; Monitor; murine antibody; Needs Assessment; novel anticancer drug; Parasitology; pathogen; Pharmaceutical Preparations; Pharmacology; Phase; Plasma; Play; pre-clinical; preclinical study; Preclinical Testing; prevent; Production; programs; Proteomics; Quarantine; Research; Resources; response; Rodent; Role; Route; Sampling; Schedule; Sentinel; Serologic tests; Services; small molecule; Source; Spectrum Analysis; square foot; Study models; Support Groups; Testing; Time; ultraviolet; United States; United States National Institutes of Health; Urine; Viral; Virus Diseases; Weight; ,DCTD Animal Support,,,,,,,,,1423562,
9430073,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-34,NCI:4224312\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Affect; cancer epidemiology; cancer genetics; Cancer Intervention; cancer risk; case control; Case-Control Studies; cohort; Collaborations; Complex; Data; data access; Data Set; deep sequencing; Diagnostic; Disease; disorder risk; DNA; Ensure; epidemiology study; Extramural Activities; gene environment interaction; Genes; Genetic Markers; Genetic Predisposition to Disease; genetic variant; Genome Scan; genome wide association study; Genomics; Individual; Inherited; Institutes; Lead; malignant breast neoplasm; Malignant neoplasm of prostate; Malignant Neoplasms; Persons; Pilot Projects; Population Study; Predisposition; Preventive; Private Sector; programs; Research; Research Personnel; Resources; Risk; Scanning; Scientist; Series; Techniques; Therapeutic Intervention; trait; United States National Institutes of Health; Variant; ,GWAS Studies,,,,,,,,,4224312,
9430074,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-35,NCI:2623215\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,advanced system; Affect; Area; Basic Science; Bioinformatics; Biological Assay; bone marrow failure syndrome; Cancer Burden; cancer genomics; Candidate Disease Gene; Caring; case control; Chronic Lymphocytic Leukemia; clinically relevant; cohort; Colon; Communities; Complement; cost; cost effective; Custom; Data; data access; Data Analyses; Data Quality; data resource; Data Set; Data Storage and Retrieval; database of Genotypes and Phenotypes; design; digital; Disease; Disease Outcome; Division of Cancer Epidemiology and Genetics; DNA; Employment; Endometrial Carcinoma; Environmental Risk Factor; Epidemiologist; epidemiology study; Equipment and supply inventories; exome; exome sequencing; Family; follow-up; Generations; Genes; Genetic; genetic epidemiology; Genetic Markers; genetic variant; Genetic Variation; Genome Scan; genome wide association study; Genomics; Genotype; Heritability; high throughput screening; Hodgkin Disease; Human; Human Genetics; Human Genome; human genome sequencing; human genomics; Human Papillomavirus; Image; Individual; Informatics; Information Management; Inherited; Intramural Research Program; Kaposi Sarcoma; Laboratories; Laboratory Research; leukemia; Lung; malignant breast neoplasm; Malignant neoplasm of brain; Malignant neoplasm of cervix uteri; Malignant neoplasm of esophagus; Malignant neoplasm of larynx; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Malignant neoplasm of testis; Malignant neoplasm of thyroid; Malignant neoplasm of urinary bladder; Malignant Neoplasms; malignant stomach neoplasm; Management Information Systems; melanoma; Meta-Analysis; Molecular Epidemiology; molecular pathology; Multiple Myeloma; Mutation; next generation sequencing; novel; osteosarcoma; Outcome; Ovarian; Pancreatic Non-Hodgkin's Lymphoma; Phenotype; Population; Population Group; Predisposition; Preparation; Production; Prostate; Proteomics; Publications; quality assurance; Quality Control; rare variant; Rectal Cancer; Renal carcinoma; Research; research and development; Research Personnel; Research Project Grants; Resources; Sampling; Scientific Advances and Accomplishments; Scientist; screening; Skin Cancer; Staging; Statistical Methods; Surveys; Techniques; Technology; technology development; Technology Transfer; tissue processing; tool; Uterine Cancer; Work; ,Genotyping for epidemiology studies,,,,,,,,,2623215,
9430132,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-86,NCI:150000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Animal Model; Area; Basic Behavioral Science; Basic Science; Behavioral; Behavioral Research; behavioral/social science; Bioinformatics; Biological; Biology; biopsychosocial; Cancer Biology; Cancer Control; cancer prevention; Collaborations; Development; Division of Cancer Control and Population Sciences; Environment; Health; Journals; Knowledge; lens; Malignant Neoplasms; Measurement; meetings; member; Methodology; Neurosciences; novel; Outcome; Participant; Pattern; Research; Resource Sharing; Review Literature; Seeds; social; Social Functioning; Stress; Training; Travel; United States National Institutes of Health; working group; ,DCCPS Basic and Behavioral Research Network,,,,,,,,,150000,
9430172,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-140,NCI:774800\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Adjuvant; Animals; Antigens; Biological Assay; Blood; Cardiac; Cervarix; Dose; Enzyme-Linked Immunosorbent Assay; experimental study; Human Papillomavirus; Human papillomavirus 16; Immunization; Immunize; immunogenicity; In Vitro; Inbred BALB C Mice; Injection of therapeutic agent; Intramuscular; Isoflurane; Left; Mus; Muscle; paragon; particle; Peptides; pre-clinical; Preparation; Puncture procedure; Sampling; Testing; vaccine candidate; vaccine trial; Vaccines; Validation; Veins; Virus-like particle; Work; ,DCP Support- HPV16L1/RG1 Virus-Like Particle Vaccine,,,,,,,,,774800,
9430178,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-146,NCI:300000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14368683; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Cancer Surveillance Research Program; Collection; Data; Data Collection; Division of Cancer Control and Population Sciences; Ensure; Fostering; improved; Modeling; new technology; Outcome; Pharmacy facility; Process; repository; Residual state; SEER Program; Tissues; Trust; ,DCCPS - Surveillance Research Program,,,,,,,,,300000,
9430207,N01,DA,,N,,,,,N01DA000000,,,271201300043C-11-0-2,NIDA:149301\OD:128856\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,PLAINSBORO,UNITED STATES,,12,181157256,US,3632401,"XENOBIOTIC LABORATORIES, INC.",NJ,85363339,,14430984; ,"XINPING, FANG ;",,9/15/2013,9/14/2018,analytical method; Biological; Biological Assay; Clinical Research; Contractor; Contracts; Data; Drug abuse; drug of abuse; Enzymes; Evaluation; Funding; Hair; Investigational Drugs; Medical; Methods; molecular marker; National Institute of Drug Abuse; novel therapeutics; Outcome Measure; Peptides; Performance; Pharmaceutical Preparations; Pharmacotherapy; Plasma; preclinical study; Procedures; Program Development; Proteins; Publishing; Saliva; Services; small molecule; Specimen; therapy development; Tissues; Urine; ,"IGF::OT::IGF : Analytical Services Center for Medications Development Program. September 15, 2013 - September 14, 2018. N01DA-13-8920.PURPOSE:   To obligate funds to fully fund performance under T",,,,,,,,,278157,
9430224,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-1,NIAID:1918885\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,1/26/2017,1/25/2018,Categories; Contracts; Development; Intervention; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; programs; Safety; Services; therapeutic development; therapy development; Toxicology; Translational Research; ,Task 4: The Interventional Agent Development Services program ,,,,,,,,,1918885,
9430250,N02,NS,,N,,,,,N02NS000000,,,271201300224P-6-0-1,NINDS:28500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,,,,,78746965,,,,,,,12674785; ,"ANDERSON, PAUL ;",,2/28/2017,2/27/2018,Address; Biological; Biological Assay; Biology; Contracts; design; Development; Development Plans; Disease; drug development; Drug Industry; Drug Modelings; experience; Funding; Future; indexing; Industry; innovation; Institutes; Lead; Leadership; Modeling; nervous system disorder; Neurosciences; Neurosciences Research; Peer Review; Pharmaceutical Preparations; Principal Investigator; Process; Program Development; programs; Research; Research Contracts; Research Personnel; Seasons; Shapes; Therapeutic; United States National Institutes of Health; virtual; Work; ,"Anderson, Paul C:1223804",,,,,,,,,28500,
9430262,N01,AI,,N,,,,,N01AI000000,,,272201500003C-2-0-1,NIAID:1128779\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BUFFALO,UNITED STATES,,,71486518,US,,STARKS ASSOCIATES INC,NY,142131503,,12627992; ,"GIVENS, JOHN ;",,2/16/2015,2/15/2018,Acquired Immunodeficiency Syndrome; Animals; Chemicals; Clinical Research; Communicable Diseases; Contracts; Diagnosis; Diagnostic; Disease; HIV; Immune; Immunology; In Vitro; infectious disease treatment; Local Microbicides; Mediating; Medical; microbicide; Microbiology; National Institute of Allergy and Infectious Disease; Phase; Prevention; Regulation; Research; Research Support; Resources; Testing; Therapeutic; Therapeutic Agents; therapeutic development; United States Dept. of Health and Human Services; United States National Institutes of Health; vaccine development; ,Synthesis of Therapeutic Agents for Treatment of Infectious Diseases,,,,,,,,,1128779,
9430274,N01,OD,,N,,,,,N01OD000000,,,263201200074I-1-26300089-1,NCCAM:50000\NEI:50000\NIA:0\NIAAA:50000\NIDA:0\NIMH:0\NINDS:100000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14368803; ,"WESTBROOK, DAVID ;",,12/1/2015,11/30/2017,Academy; Educational workshop; Lead; meetings; nervous system disorder; Neurosciences; Paper; Policies; Reporting; Research; symposium; ,FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS,,,,,,,,,250000,
9430313,N01,AI,,N,,,,,N01AI000000,,,272201300023I-2-27200011-1,NIAID:119945\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,14767774; ,"CREECH, BUDDY ;",,9/16/2016,6/30/2019,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza virus vaccine; named group; Phase; Phase I Clinical Trials; Population; programs; Resources; vaccine candidate; Vaccine Clinical Trial; Vaccines; ,Vaccine Treatment and Evaluation Unit: Phase I Influenza Vaccine Clinical Trial,,,,,,,,,119945,
9430320,N01,AI,,N,,,,,N01AI000000,,,272201300017I-2-27200016-1,NIAID:265726\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14759378; ,"WALTER, EMMANUEL ;",,9/16/2016,12/31/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Individual; Influenza virus vaccine; named group; Phase I Clinical Trials; Population; programs; Resources; ,VTEU: Influenza Vaccine Phase I Clinical Trial ,,,,,,,,,265726,
9430340,N01,AI,,N,,,,,N01AI000000,,,272201000029C-10-0-1,OD:57893\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14190986; ,"SHANKAR, GITA ;",,9/30/2010,2/28/2017,absorption; Advanced Development; Calcium; Chelating Agents; Complex; Contracts; diethylenetriaminepentaacetate; Enhancers; Excision; Intravenous; Investigational New Drug Application; mass casualty; Metabolic Clearance Rate; National Institute of Allergy and Infectious Disease; Nebulizer; Nuclear; Oral; Pentetic Acid; Plasma; Plutonium; Radiation; Radiation exposure; Radioactive; Radioisotopes; Research Personnel; uptake; Zinc; ,Oral Radiation Nuclear Decorporation Agents,,,,,,,,,57893,
9430354,N01,MH,,N,,,,,N01MH000000,,,271201100004I-3-27100020-1,NINDS:50990\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14625385; ,"BAUGHMAN, KATHRYN ;",,6/30/2016,6/29/2017,"Animal Welfare; Award; base; bench to bedside; Chemistry; Client; Contractor; Contracts; design; Dosage Forms; Drug Kinetics; Equipment; experience; flexibility; Formulation; good laboratory practice; Heart Diseases; Hematological Disease; International; Laboratory Animals; Lung diseases; member; Modernization; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Drug Abuse; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; novel; novel therapeutics; Office for Human Research Protections; Pharmacologic Substance; Pharmacology and Toxicology; Principal Investigator; Production; programs; Regulation; Request for Proposals; research and development; Resources; response; Science; Scientist; screening; Services; small molecule; small molecule therapeutics; Testing; Toxicology; Translational Research; United States Food and Drug Administration; United States National Institutes of Health; Work; ","IGF::OT::IGF:PHARMACOKINETICS AND TOXICOLOGY STUDIES - BUCKPITT LDT,",,,,,,,,,50990,
9430373,N01,DA,,N,,,,,N01DA000000,,,271201200018C-13-0-1,NIDA:413284\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,OVERLAND PARK,UNITED STATES,,,102335952,US,,,KS,662121758,,12331038; ,"VINCE, BRADLEY ;",,9/14/2012,9/13/2017,Cannabis; Cocaine; Contractor; Development; Disease; Drug Kinetics; Methamphetamine; Opiates; Pharmaceutical Preparations; Pharmacodynamics; Pharmacology; stem; Tobacco; ,"IGF::OT::IGF Pharmacokinetic and Pharmacodynamic Studies for Medications Development; POP 9/14/12 - 9/13/17, FY12 N01DA-12-8905",,,,,,,,,413284,
9430375,N01,DA,,N,,,,,N01DA000000,,,271201600037C-2-0-2,NIDA:120097\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14761453; ,"IVER, LALITHA ;",,9/19/2016,9/18/2021,absorption; analytical method; Animals; Biological; Biological Assay; Biological Availability; Contractor; Data; Data Files; electronic data; In Vitro; Investigational Drugs; Liquid substance; Metabolism; Methods; National Institute of Drug Abuse; novel therapeutics; Pharmaceutical Preparations; Protocols documentation; Regulation; Reporting; Research Personnel; Secure; United States Food and Drug Administration; ,IGF::OT::IGF: Non-Clinical ADME Studies. N01DA-16-8931.,,,,,,,,,120097,
9430377,N01,DA,,N,,,,,N01DA000000,,,271201400059C-4-0-1,NCI:50000\NCMHD:20000\NIDA:307509\NIMH:50000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SILVER SPRING,UNITED STATES,,,961728586,US,,,MD,209103447,,12404521; ,"BRAXTON, KAREN ;",,8/27/2014,8/26/2017,Clinical Trials; Clinical Trials Network; Communication; Communities; Contractor; Contracts; Ensure; Goals; Internet; Logistics; meetings; National Institute of Drug Abuse; Outcomes Research; Research; Research Personnel; Services; symposium; Time; Travel; United States National Institutes of Health; ,IGF::OT::IGF CLINICAL TRIALS RESEARCH COORDINATION CENTER; POP: 8/30/2014-8/29/20145; N01DA-14-2241,,,,,,,,,427509,
9443549,N01,AI,,N,,,,,N01AI000000,,,272201500002C-7-0-1,NIAID:5719200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,12627908; ,"EWELL, MARIAN ;",,3/1/2015,2/28/2018,base; clinical infrastructure; Clinical Research; Communicable Diseases; Consultations; Contractor; Control Groups; Data Analyses; Data Collection; Data Coordinating Center; data management; Data Quality; electronic data; Goals; Internet; Quality Control; Randomized; Research Design; Sample Size; Specimen; statistics; Stratification; System; ,STATISTICAL AND DATA COORDINATING CENTER FOR CLINICAL RESEARCH IN INFECTIOUS DISEASES (SDCC),,,,,,,,,5719200,
9444063,R01,MH,1,N,12/26/2017,12/26/2017,10/31/2018,242,R01MH112681,SCHOOLS OF MEDICINE,PA-16-160,1R01MH112681-01A1,NIMH:703535\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF MENTAL HEALTH,,AURORA,UNITED STATES,PSYCHIATRY,6,41096314,US,1199905,UNIVERSITY OF COLORADO DENVER,CO,800452571,,8051216; ,"FRANK, GUIDO KW;","CHAVEZ, MARK",12/26/2017,10/31/2022,Affect; Affective; Age; base; Base of the Brain; Behavior; Behavioral; behavioral study; Binge Eating; Binge eating disorder; Biological; Brain; brain circuitry; Brain imaging; brain research; Brain scan; Bulimia; Calories; Categories; Characteristics; Cognition; Cognitive; cognitive control; Computer Simulation; Control Groups; Corpus striatum structure; Depressed mood; Diagnostic; Disease; Distress; Dopamine; dopamine system; Eating; Eating Disorders; Ecological momentary assessment; Emotions; Environment; Exanthema; Feeling; Food; Future; Health; healthy weight; Individual; Insula of Reil; Intervention; Knowledge; Learning; Link; Magnetic Resonance; Measures; mind control; Morbidity - disease rate; mortality; Motivation; National Institute of Mental Health; negative affect; Neurobiology; Neurosciences; Neurotransmitters; Obesity; Persons; Positive Valence; Prefrontal Cortex; Psychological reinforcement; psychopharmacologic; Quality of life; Randomized; Recurrence; Regulation; relating to nervous system; Reproducibility; Research; Research Domain Criteria; response; Rewards; Scanning; sex; Symptoms; System; Taste Perception; Testing; therapy development; Ventral Striatum; Vomiting; Weight; ,Neural Effects of Negative Affect on Food Choices and Reward In Individuals with Binge Eating Episodes,112681,APDA,Adult Psychopathology and Disorders of Aging Study Section ,,A1,1,477454,226081,703535,
9444396,N01,HL,,N,,,,,N01HL000000,,,268201600012C-1-0-1,NHLBI:1888867\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14445002; ,"ISHIKAWA, PHILLIP ;",,3/1/2016,2/28/2018,"Address; base; clinical practice; community organizations; Disease; Family health status; Fostering; Government Agencies; Health; Health Professional; Heart Diseases; Hematological Disease; Individual; Industry; Institutes; Institution; International; Leadership; Lung diseases; Mentors; National Heart, Lung, and Blood Institute; patient advocacy group; Patients; Physicians; Prevention; Privatization; Production; Professional Organizations; programs; Public Health; Research; Research Infrastructure; Research Training; Resources; Scientist; Training; Training and Education; Translations; ","IGF::OT::IGF SMARTT BIOLOGICS PRODUCTION FACILITY (PF); BASE PERIOD; FY16; AMT $2,069,079; CAN 8470205",,,,,,,,,1888867,
9444399,N01,HL,,N,,,,,N01HL000000,,,268201600013C-1-0-1,NHLBI:1275900\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14451809; ,"BAUGHMAN, KATHRYN ;",,3/1/2016,2/28/2018,"Address; base; clinical practice; community organizations; Disease; Family health status; Fostering; Government Agencies; Health; Health Professional; Heart Diseases; Hematological Disease; Individual; Industry; Institutes; Institution; International; Leadership; Lung diseases; Mentors; National Heart, Lung, and Blood Institute; patient advocacy group; Patients; Physicians; Prevention; Privatization; Professional Organizations; programs; Public Health; Research; Research Infrastructure; Research Training; Resources; Scientist; small molecule; Training; Training and Education; Translations; ","IGF::OT::IGF SMARTT NON-BIOLOGICS AND SMALL MOLECULE PF; BASE PERIOD; FY16; AMT $ 1,175,069; CAN 8470205",,,,,,,,,1275900,
9448524,R01,GM,1,N,12/26/2017,12/26/2017,11/30/2018,859,R01GM122902,SCHOOLS OF MEDICINE,PA-16-160,1R01GM122902-01A1,NIGMS:432577\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,,SAN FRANCISCO,UNITED STATES,OBSTETRICS & GYNECOLOGY,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,10129249; ,"LAIRD, DIANA J;","SALAZAR, DESIREE LYNN",12/26/2017,11/30/2021,Adult; Aneuploidy; Apoptosis; Ataxia; base; biological adaptation to stress; Birth; CGG repeat; CGG repeat expansion; Child; Congenital Abnormality; Cyst; Data; Development; Diagnosis; Disease; DNA Repair; DNA Transposable Elements; Event; Female; fetal; Fetal Development; FMR1; FMR1 Premutation; FMR1 repeat; FMR1 repeat expansion; Fragile X Syndrome; FXTAS; Genes; Genetic; Genetic Models; Genetic Transcription; genome integrity; Germ Cells; Goals; Image; image reconstruction; Imaging Techniques; Inherited; insight; Intellectual functioning disability; intergenerational; Laboratories; Light; male; Maternal Age; Mediating; Meiosis; Mothers; mouse model; Mus; Mutation; Neonatal; next generation sequencing; Oocytes; Oogonia; Ovary; Pathologic; Pathology; Pathway interactions; piRNA; postnatal; primary ovarian insufficiency; Production; protein expression; protein function; public health relevance; Quality Control; Resistance; response; Risk; RNA; Role; Schedule; sex; stressor; Testing; Testis; Three-Dimensional Imaging; transmission process; Trinucleotide Repeat Expansion; Trinucleotide Repeats; Woman; X Chromosome; ,Fmr1 Function and Repeat Expansion in the Developing Germline,122902,CMIR,"Cellular, Molecular and Integrative Reproduction Study Section ",,A1,1,275000,157577,432577,
9450444,N01,AI,,N,,,,,N01AI000000,,,272201000032I-2-27200002-1,NIAID:1682853\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,98987217,US,577703,UNIVERSITY OF ILLINOIS AT CHICAGO,IL,606127224,,12576313; ,"ZHENG, CHEN ;",,3/22/2010,3/2/2018,Contracts; Development; efficacy testing; Human poliovirus; infectious disease model; Licensure; Macaca mulatta; Modeling; nonhuman primate; oral infection; Standardization; Translational Research; Vaccine Research; ,Task C28: Rhesus Macaque Oral Infection Model for Poliovirus,,,,,,,,,1682853,
9452857,N01,AI,,N,,,,,N01AI000000,,,272201100016I-1-27200013-1,NIAID:8597\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14750998; ,"PRICHARD, MARK ;",,9/16/2016,9/15/2017,antimicrobial; Antiviral Agents; Contracts; In Vitro; meetings; programs; screening; Testing; Viral; ,Task B24: Comprehensive Viral Screening Panel,,,,,,,,,8597,
9455561,N01,ES,,N,,,,,N01ES000000,,,273201400020C-5-0-2,NIEHS:760000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,12634488; ,"ALGAIER, CLARK ;",,7/18/2014,3/17/2018,Adverse effects; Agreement; Animal Model; Animal Testing Alternatives; Biological Assay; Cell Line; Chemicals; Chemistry; Collaborations; Contracts; Databases; Dermal; Development; disorder prevention; Dose; Ensure; Environmental Exposure; Evaluation; Exposure to; Future; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; high throughput screening; Human; In Vitro; in vitro testing; Modeling; National Toxicology Program; neurotoxic; Outcome; programs; public health research; Research; Research Personnel; Risk Assessment; Risk Factors; Services; Solubility; sound; Specific qualifier value; Testing; Toxic effect; Toxicity Tests; Toxicology; water solubility; Zebrafish; ,Chemistry Support Services for the NTP: High Throughput Screening Support,,,,,,,,,760000,
9457274,N01,CA,,N,,,,,N01CA000000,,,261201500024I-2-26100002-1,NCI:174815\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,1,5447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,,14754005; ,"MCCORMICK, PH.D. DABT, DAVID ;",,9/19/2016,9/18/2018,Adverse effects; albino mouse; Biological Availability; Bone Marrow Cells; Breast Cancer therapy; cancer prevention; Cavia; Cells; Clinical; Clinical Research; Contractor; CYP2D6 gene; CYP3A4 gene; Delayed Hypersensitivity; Dependence; Dermal; Division of Cancer Prevention; Dose; Enzymes; Formulation; Gel; Gene Mutation; Impairment; In Vitro; in vivo; Liver; Mammalian Cell; Metabolic; Miniature Swine; N-desmethyltamoxifen; National Cancer Institute; Oral; Outcome; Patients; Pharmacology; Pharmacology and Toxicology; Phase; Phototoxicity; Plasma; pre-clinical; preclinical study; prevent; Rattus; Recovery; Risk; sulfation; Tamoxifen; Tissues; Toxic effect; Toxicology; Unspecified or Sulfate Ion Sulfates; ,PRECLINICAL PREVENT TOXICOLOGY AND PHARMACOLOGY,,,,,,,,,174815,
9458647,N01,AI,,N,,,,,N01AI000000,,,272201000014I-3-27200001-1,NIAID:50000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,1,5447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,,14972576; ,"HOLLAND, LOUIS ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,50000,
9459267,N02,CA,,N,,,,,N02CM000000,,,261201200028C-26-0-1,NCI:46593\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,12674637; ,"WANG, PH.D., JENNIE ;",,8/1/2012,7/31/2017,antitumor agent; antitumor drug; Chemicals; Clinical; Clinical Research; Data; drug candidate; Formulation; Investigational Drugs; Malignant Neoplasms; Pharmaceutical Preparations; Pharmacologic Substance; Quality Control; Reporting; Techniques; ,OTHER FUNCTIONS - ANALYSIS OF ANTI-CANCER CHEMICALS & PHARMACEUTICAL FORMULATION,,,,,,,,,46593,
9460282,N01,LM,,N,,,,,N01LM000000,,,276201200014C-14-0-1,NIDDK:1905064\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,12639121; ,"HIGGINS, HEATHER ;",,6/1/2012,4/30/2017,Advanced Development; Algorithms; Clinical; Clinical Research; Collaborations; Collection; Disease; Ensure; Ethics; Funding; Future; Institutes; Internal Medicine; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; novel strategies; Participant; Patients; Prognostic Marker; repository; Research; Research Personnel; Resources; Sampling; Therapeutic; United States National Institutes of Health; Work; ,NIDDK Biosample Repository,,,,,,,,,1905064,
9463728,N01,HL,,N,,,,,N01HL000000,,,268201600018C-2-0-1,NCI:0\NHLBI:10527929\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SEATTLE,UNITED STATES,,7,78200995,US,861001,FRED HUTCHINSON CANCER RESEARCH CENTER,WA,981094433,,14605357; ,"ANDERSON, GARNET ;",,4/1/2016,3/31/2018,adjudication; Biological; Clinical; Contractor; Data Analyses; data management; Development; Documentation; Government; Laboratories; Lead; Maintenance; Manuals; meetings; Monitor; Morbidity - disease rate; mortality; Observational Study; Performance Status; Procedures; protocol development; Quality Control; Security; Specimen; System; technical report; Training; Women's Health; ,WOMEN'S HEALTH INITIATIVE - CLINICAL COORDINATING CENTER,,,,,,,,,10527929,
9463731,N01,HL,,N,,,,,N01HC000000,,,268200900040C-28-0-1,NHLBI:2878369\NIA:0\NIDDK:357000\NINDS:297000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WINSTON-SALEM,UNITED STATES,,5,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,,12651285; ,"REBOUSSIN, DAVID ;",,9/14/2009,3/31/2018,acute coronary syndrome; Age-associated memory impairment; aged; arm; Blood Pressure; Cardiovascular Diseases; cardiovascular disorder risk; Cerebrum; Cessation of life; Chronic Kidney Failure; Clinic; Clinical; cognitive development; cognitive function; Dementia; Development; Disease; End stage renal failure; Goals; Heart failure; Intervention Trial; Kidney Diseases; Mortality Decline; Myocardial Infarction; Participant; Patients; primary outcome; Randomized Clinical Trials; Recruitment Activity; Renal function; research and development; Risk Factors; secondary outcome; stroke; Testing; treatment program; trial design; ,"OTHER FUNCTIONS R&D, SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL (SPRINT) COORDIN",,,,,,,,,3532369,
9471294,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-10,NIEHS:20453\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Biological; Chemicals; Epigallocatechin Gallate; Ginkgo biloba; Ginkgo biloba extract; Goals; Goldenseal; Green tea; hazard; Human; Laboratory Animals; response; Risk; Testing; Toxic effect; Toxicogenomics; ,"Conduct of studies to compare the toxicity and toxicogenomic responses of five lots of Ginkgo Biloba Extract, Goldenseal Extract and Green Tea Extract in laboratory animals for NTP",,,,,,,,,20453,
9474536,N01,AI,,N,,,,,N01AI000000,,,272201300004I-5-27200002-1,NIAID:209612\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,1,53785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,,14089058; ,"LACKNER, ANDREW ;",,5/1/2013,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Caring; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; vaccine trial; Vaccines; ,SVEU - Maintenance of NHPs,,,,,,,,,209612,
9475637,N01,DA,,N,,,,,N01DA000000,,,316201200149W-6-0-1,NIMH:102718\NINDS:133915\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,14154690; ,"BEACH, JANIS ;",,7/1/2014,6/30/2017,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Databases; Date of birth; Development; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Maintenance; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ",IGF::OT::IGFNeuroBioBank Database Development and Maintenance,,,,,,,,,236633,
9477999,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200012-1,NIAID:206368\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12577125; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Antimicrobial Resistance; Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; gonorrhea vaccine; Neisseria gonorrhoeae; novel vaccines; pathogen; Phase; product development; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X12: Development of a Gonorrhea Vaccine,,,,,,,,,206368,
9478644,N01,ES,,N,,,,,N01ES000000,,,273200900002C-15-0-1,NIEHS:1846058\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,NORTH LITTLE ROCK,UNITED STATES,,,173474107,US,,BIOTECHNICAL SERVICES INC,AR,721167057,,12254022; ,"GUNNELS, SUSAN ;",,4/30/2009,4/29/2018,base; Contractor; Data Set; Internet; Laboratories; Peer Review; Preparation; Printing; Reporting; Services; technical report; Text; Toxic effect; Toxicology; web site; Writing; ,NTP TECHNICAL REPORT PREPARATION SUPPORT SERVICES,,,,,,,,,1846058,
9478647,N01,CA,,N,,,,,N01CA000000,,,261201300016I-4-26100006-3,NCI:62048\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW ORLEANS,UNITED STATES,,2,782627814,US,577902,LSU HEALTH SCIENCES CENTER,LA,701127021,,14512949; ,"WU, XAIO-CHENG ;",,5/1/2015,4/30/2018,Centers for Disease Control and Prevention (U.S.); comparative effectiveness; cost effective; Data; effectiveness research; Ensure; Funding; Goals; Insurance; Laws; Louisiana; Malignant Neoplasms; Medical; Methods; Modification; neoplasm registry; Newly Diagnosed; oncology; Recruitment Activity; Recurrence; Registries; Research Infrastructure; SEER Program; System; Testing; ,"IGF::OT::IGF  CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)",,,,,,,,,62048,
9478658,N01,DA,,N,,,,,N01DA000000,,,271201300025C-13-0-1,NIDA:450542\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,REDMOND,UNITED STATES,,,78652667,US,,,WA,"98052,",,14782919; ,"HANSEN, KEITH ;",,8/15/2013,8/14/2018,Area; Biological; Biological Assay; Chemical Structure; Contractor; Contracts; Development; Drug abuse; drug development; Follow-Up Studies; in vitro Assay; Lead; Libraries; Ligands; National Institute of Drug Abuse; novel; Pharmacology; Process; receptor; Reporting; screening; Specific qualifier value; Specificity; Testing; Toxic effect; Toxicology; ,Receptor Profiling and Predictive Toxicology,,,,,,,,,450542,
9478660,N02,CA,,N,,,,,N02CA000000,,,261201300008I-2-26100009-1,NCI:3868033\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,14086875; ,"RILEY, TOM ;",,5/10/2015,5/9/2018,computer program; Contractor; data management; design; Development; Division of Cancer Prevention; programs; Research; Research Infrastructure; Services; System; website development; ,COMPUTING SERVICES FOR THE DIVISION OF CANCER PREVENTION,,,,,,,,,3868033,
9478814,N01,HL,,N,,,,,N01HL000000,,,268201300046C-10-0-1,NHLBI:2511676\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,JACKSON,UNITED STATES,,3,928824473,US,5390304,UNIVERSITY OF MISSISSIPPI MED CTR,MS,392164500,,14270425; ,"CORREA, ADOLFO ;",,8/16/2013,4/27/2018,African American; Age-Years; Ancillary Study; Atherosclerosis Risk in Communities; biomedical profession; Biomedical Research; career; Clinical; cohort; Cohort Studies; Communities; Community Health Education; Data; Data Analyses; Data Collection; Enrollment; Event; Geographic Locations; graduate student; Health Promotion; Hospitalization; improved; Individual; Interview; Investigation; Jackson Heart Study; Manuscripts; member; Minority; North Carolina; Outpatients; Participant; Population; Prevention; Publications; Recruitment Activity; Research Personnel; Resources; Risk; Scientist; Site; Testing; Time; Training; undergraduate student; Universities; Validation; Visit; ,IGF::OT::IGF Jackson Heart Study Renewal Coordinating Center,,,,,,,,,2511676,
9479730,N01,HD,,N,,,,,N01HD000000,,,275201300026I-0-27500015-1,NICHD:399770\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14983412; ,"GORE-LANGTON, ROBERT ;",,9/11/2013,9/10/2018,Blood; Blood Vessels; Clinical; clinical research site; Cohort Studies; Collection; Contracts; Data; Data Collection; Data Coordinating Center; data management; Data Quality; Database Management Systems; Development; Enrollment; Epidemiology; follow-up; Gestational Diabetes; Health; intergenerational; Metabolic; Molecular; Monitor; Obesity; offspring; Online Systems; Performance; Phase; population health; prospective; Quality Control; Questionnaires; Recruitment Activity; Reproductive Health; Research; Retrospective cohort study; Saliva; Seminal fluid; Site; Support Contracts; System; Urine; web site; Work; ,DATA COORDINATING CENTER FOR THE PILOT RECRUITMENT AND FOLLOW-UP FOR THE INTERGENERATIONAL HEALTH STUDY,,,,,,,,,399770,
9481780,N01,AI,,N,,,,,N01AI000000,,,272201300018I-3-27200006-1,NIAID:327462\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14173576; ,"SPEARMAN, PAUL ;",,7/1/2015,7/1/2019,Conduct Clinical Trials; Contracts; design; Ebola virus; Evaluation; Filoviridae; Filovirus; Frankfurt-Marburg Syndrome Virus; Individual; infectious disease treatment; Investigation; named group; novel; phase I trial; Population; Resources; Route; System; Vaccines; ,Vaccine and Treatment Evaluation Unit: Phase I Trial of Filovirus Vaccine  ,,,,,,,,,327462,
9483235,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-5,NIAID:1695141\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Malaria; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,1695141,
9483242,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-12,NIAID:462930\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Dengue Virus; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,462930,
9486536,N01,DA,,N,,,,,N01DA000000,,,271201600009I-1-9999-1,NINDS:44000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,FLEMINGTON,UNITED STATES,,,967680294,US,,,NJ,88227208,,; ,",  ;",,9/30/2016,9/29/2018,Achievement; Address; Agreement; Area; assay development; Attention; authority; Award; base; Behavior; Biochemical; Biological Assay; Biological Products; Brain; Cells; Chemistry; Clinical; Clinical Research; Clinical Trials; Communication; Computer software; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Data; Data Analyses; design; Development; disability; Discipline; Disclosure; Documentation; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Environment; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Health; high throughput screening; Hour; Human Resources; improved; In Vitro; in vitro Assay; Individual; Industrialization; Industry; innovation; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Knowledge; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; Maps; Mediation; Medical; Medical Research; meetings; member; Mission; Modeling; Molecular; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system development; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Phase; pre-clinical; preclinical safety; Preparation; Prevention; Principal Investigator; Process; programs; Protocols documentation; Publications; Regulation; Reporting; Research; research and development; research clinical testing; Research Contracts; Research Design; Research Personnel; Resources; Rights; Robotics; Role; Safety; Schedule; Scientific Advances and Accomplishments; screening; Security; Services; Shapes; Site Visit; skills; small molecule; Strategic Planning; stroke; symposium; Techniques; Technology; Teleconferences; Telephone; Time; Travel; United States National Institutes of Health; Validation; virtual; Work; Writing; ,IN VITRO STRATEGIES LIMITED LIABILITY COMPANY:1198212 [16-014035]IGF::CL::IGF,,,,,,,,,44000,
9487751,N01,AI,,N,,,,,N01AI000000,,,272201300022I-3-27200010-1,NIAID:1171593\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,14183768; ,"MARTIN, CAREY ;",,9/16/2013,3/15/2020,Conduct Clinical Trials; Contracts; design; enterotoxigenic Escherichia coli; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; phase I trial; Population; Resources; Route; System; Vaccines; ,Vaccine and Treatment Evaluation Unit: Phase I Trial  of an Enterotoxigenic Escherichia coli (ETEC) Vaccine ,,,,,,,,,1171593,
9491651,N02,CA,,N,,,,,N02CA000000,,,261201600002C-3-0-1,NCI:1400000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14600580; ,"VALMONTE, CLAUDINE ;",,6/1/2017,5/31/2018,Advisory Committees; cancer diagnosis; cancer therapy; Cancer Therapy Evaluation Program; Clinical Research; Clinical Trials; Contractor; Contracts; Cooperative Group Program; Data Analyses; Diagnosis Clinical Trials; drug development; Ensure; Evaluation; Extramural Activities; Grant; Group Meetings; Information Management; Investigation; meetings; molecular oncology; National Cancer Advisory Board; Program Development; programs; Recommendation; Research Personnel; Time; U-Series Cooperative Agreements; working group; , CLINICAL TRIALS AND INFORMATION MANAGEMENT SUPPORT,,,,,,,,,1400000,
9492478,N01,AI,,N,,,,,N01AI000000,,,272201400026C-8-0-1,NIAID:2256044\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GAITHERSBURG,UNITED STATES,,6,100350748,US,10007457,"DIGITAL INFUZION, INC.",MD,208781434,,12352022; ,"AIR, GILLIAN ;",,6/9/2014,6/8/2018,Basic Science; computerized data processing; Influenza; influenza surveillance; National Institute of Allergy and Infectious Disease; Research; ,CEIRS Influenza Data Processing and Coordinating Center (DPCC),,,,,,,,,2256044,
9493582,N01,AI,,N,,,,,N01AI000000,,,272201000004I-0-27200002-1,NIAID:252113\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14972570; ,"GILBERT, BRIAN ;",,3/21/2017,9/20/2018,Animal Model; animal model development; Contracts; Cotton Rats; Development; efficacy testing; Evaluation; infectious disease model; Modeling; Respiratory Syncytial Virus Vaccines; Standardization; Therapeutic; ,TASK A108: COTTON RAT MODEL FOR THE EVALUATION OF RSV VACCINES AND THERAPEUTICS,,,,,,,,,252113,
9494486,N01,ES,,N,,,,,N01ES000000,,,273201400027C-9-0-1,NIEHS:3486990\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14270591; ,"BURBACK, BRIAN ;",,7/25/2014,5/24/2018,Adverse effects; Analytical Chemistry; analytical method; Animals; base; benzotriazole; Biological; cancer risk; Carcinogenicity Tests; Chemicals; Chemistry; Contracts; Development; disorder prevention; Dose; Ensure; environmental chemical; Environmental Exposure; Evaluation; Exposure to; Formaldehyde; Formulation; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; Human; Human Cell Line; immunotoxicity; in vitro testing; Methane; Methods; National Toxicology Program; Outcome; Phenols; Plasma; programs; Public Health; public health research; Rattus; Reporting; Risk Assessment; Risk Factors; Sampling; Services; sound; Specific qualifier value; Testing; Toxic effect; Toxicity Tests; Toxicokinetics; Toxicology; ,Chemistry Services for the National Toxicology Program ? Base Subproject ,,,,,,,,,3486990,
9497680,N01,MH,,N,,,,,N01MH000000,,,271201300017C-4-0-1,NIMH:2838329\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,1884515; ,"ROTH, BRYAN L.;",,8/30/2017,8/29/2018,"Address; analog; base; Basic Science; Behavioral; Biochemical; Biological Assay; Brain imaging; Cells; Chemicals; Chemistry; Clinical Research; Code; combinatorial; Communities; Contractor; Contracts; Data; Data Files; design; Development; Drug Delivery Systems; electronic data; Enzyme Inhibitor Drugs; Functional Magnetic Resonance Imaging; Funding; gene product; Genes; Human; Individual; Lead; Libraries; Ligands; Mental disorders; National Institute of Mental Health; Natural Products; novel; Pharmacology; Positron-Emission Tomography; Preclinical Drug Evaluation; programs; Psychotropic Drugs; receptor; Research; Research Personnel; Rodent; Sampling; screening; Services; small molecule; Source; Specific qualifier value; Specificity; Testing; Therapeutic; Therapeutic Agents; Tissues; Tomography, Emission-Computed, Single-Photon; tool; United States National Institutes of Health; Vial device; ",NIMH Psychoactive Drug Screening Program ,,,,,,,,,2838329,
9503674,N01,AI,,N,,,,,N01AI000000,,,272201100022I-9-27200001-1,NIAID:219967\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,12446733; ,"MIRSALIS, JON ;",,7/31/2017,12/31/2017,Chemistry; Communicable Diseases; Contracts; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; National Institute of Allergy and Infectious Disease; Office of Administrative Management; pathogen; pre-clinical; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; therapy development; Toxicology; Toxin; ,Task Order 1: The Interventional Agent Development Services Program,,,,,,,,,219967,
9507735,N01,AI,,N,,,,,N01AI000000,,,272201500017C-4-0-1,NIAID:1678589\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,14595741; ,"PTAK, ROGER ;",,7/1/2015,6/30/2018,assay development; Biological Assay; Blood; Blood Volume; CD4 Positive T Lymphocytes; Communities; cost; Detection; Disease; Effectiveness; Highly Active Antiretroviral Therapy; HIV; HIV-1; Interphase Cell; investigator training; Laboratories; Measurement; memory CD4 T lymphocyte; National Institute of Allergy and Infectious Disease; Patients; Performance; Reproducibility; Research; Resources; Respondent; Rest; Services; Site; Standardization; Viral; ,QUANTITATIVE VIRAL OUTGROWTH ASSAY (QVOA) SERVICE RESOURCE,,,,,,,,,1678589,
9509831,N01,AI,,N,,,,,N01AI000000,,,272201000030I-0-27200007-1,NIAID:843650\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATHENS,UNITED STATES,,10,4315578,US,676602,UNIVERSITY OF GEORGIA,GA,306021589,,14972582; ,"HIENDEL, CHRISTIAN ;",,3/22/2010,2/28/2018,Animal Model; animal model development; Contracts; Development; efficacy testing; Filariasis; infectious disease model; Licensure; Reagent; Research; Standardization; Therapeutic; Vaccines; ,TASK D15: FILARIASIS RESEARCH REAGENT CENTER,,,,,,,,,843650,
9513368,N01,AI,,N,,,,,N01AI000000,,,272201300016I-5-27200006-1,NIAID:243329\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,14262962; ,"BERNSTEIN, DAVID ;",,9/15/2015,9/15/2017,antimicrobial; Antimicrobial Resistance; Child; Communities; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; phase IV trial; Pneumonia; Population; Resources; Route; System; Vaccines; ,Vaccine Treatment and Evaluation Units: Phase IV Trial to Evaluate Antimicrobial Therapy of Community Acquired Pneumonia in Children  - VTEU,,,,,,,,,243329,
9514439,N01,HL,,N,,,,,N01HL000000,,,268201600004I-0-26800002-1,NHLBI:271971\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,14949868; ,"ANDREW, LIMPER ;",,3/1/2017,2/28/2018,Chronic Obstructive Airway Disease; Clinical; Clinical Data; Contractor; Data; Enrollment; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Link; Lung diseases; Operative Surgical Procedures; Pathogenesis; Phenotype; Process; programs; Research; Research Personnel; sample collection; Specimen; Structure of parenchyma of lung; Tissues; wasting; ,IGF::OT::IGF LTRC CLINICAL CENTER - TASK ORDER 2 - 03/01/2017 - 02/28/2018 - CAN 17-8470204,,,,,,,,,271971,
9514442,N01,HL,,N,,,,,N01HL000000,,,268201600006I-0-26800002-1,NHLBI:311762\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ANN ARBOR,UNITED STATES,,12,73133571,US,1506502,UNIVERSITY OF MICHIGAN,MI,481091276,,14949874; ,"FLAHERTY, KEVIN ;",,3/1/2017,2/28/2018,Chronic Obstructive Airway Disease; Clinical; Clinical Data; Contractor; Data; Enrollment; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Link; Lung diseases; Operative Surgical Procedures; Pathogenesis; Phenotype; Process; programs; Research; Research Personnel; sample collection; Specimen; Structure of parenchyma of lung; Tissues; wasting; ,IGF::OT::IGF LTRC CLINICAL CENTER - TASK ORDER 2 - 03/01/2017 - 02/28/2018 - CAN 17-8470204,,,,,,,,,311762,
9517629,N01,HD,,N,,,,,N01HD000000,,,275201600001I-1-27500001-1,NICHD:52274\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENANDS,UNITED STATES,,20,2436061,US,5966001,"NYSDOH/HEALTH RESEARCH, INC.",NY,122042719,,14606893; ,"KANNAN, KURUNTHACHALAM ;",,6/20/2016,6/19/2018,"Acetaminophen; Acids; Adolescent Behavior; adolescent health; Adult; Aromatic Polycyclic Hydrocarbons; Benzophenones; Biological Markers; bisphenol A; Blood; Caffeine; Caring; Chemicals; Child; Child health care; Chlordan; Chlorophenols; Consultations; Contracts; Cotinine; Coumestrol; Creatinine; daidzein; Data Collection; design; Development; Dichlorodiphenyl Dichloroethylene; dichlorodiphenyltrichloroethane; Diet; Elements; enterodiol; enterolactone; Environment; environmental chemical; Environmental Exposure; epidemiology study; equol; Fluorine; Follicular Fluid; Genistein; Hair; Human; Hydrocarbons; Infant; inorganic phosphate; interest; Intervention Studies; Laboratories; Lanthanoid Series Elements; Life Style; Matrix Metalloproteinases; Melatonin; metabolomics; Metals; Mirex; Mono-S; Nail plate; National Institute of Child Health and Human Development; Newborn Infant; Nicotine; non-genetic; o,p'-DDT; Observational Study; Omentum; Organ; organochlorine pesticide; Oxidative Stress; oxychlordane; Parabens; Perchlorates; Peritoneal Fluid; Pesticides; Pharmaceutical Preparations; Phenols; phthalates; Phytoestrogens; Placenta; Plasma; Polybrominated Biphenyls; polybrominated diphenyl ether; Polychlorinated Biphenyls; Population; population health; Pregnant Women; Protocols documentation; Pyrenes; repository; Reproduction; reproductive hormone; Research; Research Project Grants; Saliva; Sampling; Scheme; Scientist; Seminal fluid; Sleep; Specific Gravity; Specimen; Spottings; Stress; Subgroup; Tissues; Tobacco smoke; Trace Elements; Triclosan; Ultraviolet Rays; Urine; Vitamins; Whole Blood; ",ENVIRONMENTAL CHEMICAL ANALYSIS OF HUMAN SPECIMENS FOR DIPHR - PROJECT TRACKING AND CONSULTATION,,,,,,,,,52274,
9517630,N01,HD,,N,,,,,N01HD000000,,,275201300022I-7-27500001-1,NICHD:26805\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,LOS ANGELES,UNITED STATES,,34,74121492,US,3750701,"CALIFORNIA FAMILY HEALTH COUNCIL, INC.",CA,900102610,,12674661; ,"NELSON, ANITA ;",,6/26/2013,6/25/2018,Clinical Trials; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; Contraceptive methods; Desogestrel; Dose; Estradiol; Female; Formulation; Injection of therapeutic agent; Intervention; Levonorgestrel; Methods; Mission; National Institute of Child Health and Human Development; Nestorone; Obesity; pill; Population; Progestins; Protocols documentation; Public Health; Risk; Risk Factors; Thromboembolism; unintended pregnancy; Vaginal Ring; Venous; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,26805,
9520813,N01,AI,,N,,,,,N01AI000000,,,272201100014I-0-27200007-1,NIAID:146762\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,14983394; ,"ANANTHAN, SUBRAMANIAM ;",,4/1/2017,7/1/2017,antimicrobial; Contracts; Custom; Data; data management; Databases; Development; In Vitro; Maintenance; Office of Administrative Management; programs; ,TASK E07: CENTRAL DATA MANAGEMENT CENTER CUSTOMIZATION AND MAINTENANCE,,,,,,,,,146762,
9521679,N01,HL,,N,,,,,N01HV000000,,,268201300027C-6-0-1,NHLBI:682765\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,12649378; ,"LLOYD-JONES, DONALD ;",,7/1/2013,6/30/2018,acquired factor; Address; Adult; Affect; Age; Ancillary Study; Atrial Fibrillation; base; Blood; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; cardiovascular risk factor; Cardiovascular system; Chicago; Clinical; cohort; Communities; Coronary artery; Coronary Artery Risk Development in Young Adults Study; Coronary heart disease; Data; Development; Disease; Education; emerging adult; Event; Evolution; follow-up; Heart Abnormalities; Heart failure; high school; Institutes; Lung; Measures; middle age; Myocardial dysfunction; novel; Participant; Phenotype; Race; racial disparity; Research Personnel; Risk; Risk Factors; Sampling; sex; sharing data; stomach cardia; stroke; Structure; Subgroup; Time; Training; Update; young adult; ,IGF::OT::IGF  Coronary Artery Risk Development in Young Adults (CARDIA) Study -,,,,,,,,,682765,
9521682,N01,HL,,N,,,,,N01HL000000,,,268201600015I-2-26800001-1,NHLBI:115447\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14658141; ,"GEE, ADRIAN ;",,8/1/2016,6/30/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities,,,,,,,,,115447,
9522292,N01,AI,,N,,,,,N01AI000000,,,272201000040I-7-27200009-2,NIAID:2953\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,14922075; ,"BEASLEY, DAVID ;",,12/1/2014,4/27/2017,Animal Model; Antiviral Agents; Communicable Diseases; Contracts; Dengue Virus; meetings; mouse model; programs; Testing; therapeutic evaluation; vaccine evaluation; ,Task A71: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus,,,,,,,,,2953,
9523033,N01,HL,,N,,,,,N01HL000000,,,268201700005C-0-0-1,NHLBI:484404\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SAN FRANCISCO,UNITED STATES,,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,14921910; ,"CONTE, MICHAEL ;",,11/15/2016,11/14/2019,Address; analog; Animals; Aortic Aneurysm; Area; Biological Availability; Bypass; Coronary Arteriosclerosis; Devices; Disease; Dissection; graft failure; Hyperplasia; interest; intracranial artery; Lymphatic Diseases; Lymphatic System; novel; Operative Surgical Procedures; Peripheral arterial disease; Preclinical Drug Development; prevent; Prevention; product development; programs; Pulmonary Hypertension; pulmonary vascular disorder; Research; Safety; Standardization; Thrombosis; Vascular Diseases; Venous; ,IGF::OT::IGF PREVENTION OF ANASTOMOTIC INTIMAL HYPERPLASIA BY A PRO-RESOLVING PERIVASCULAR DEVICE,,,,,,,,,484404,
9525658,N01,HD,,N,,,,,N01HD000000,,,275201300015I-4-27500001-1,NICHD:11155\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PROVIDENCE,UNITED STATES,,2,69851913,US,6695601,WOMEN AND INFANTS HOSPITAL-RHODE ISLAND,RI,29052499,,14270613; ,"ALLEN, REBECCA H;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,11155,
9525752,N01,AI,,N,,,,,N01AI000000,,,272201300015I-3-27200006-1,NIAID:2004304\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14369224; ,"KEITEL, WENDY ;",,12/4/2015,2/28/2020,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase; Phase I Clinical Trials; Population; programs; Resources; Schistosomiasis; vaccine candidate; Vaccine Clinical Trial; Vaccines; ,Vaccine Treatment and Evaluation Units: Phase I Schistosomiasis Vaccine Clinical Trial,,,,,,,,,2004304,
9526952,N01,AI,,N,,,,,N01AI000000,,,272201400046C-3-0-1,NIAID:1354212\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WORCESTER,UNITED STATES,,2,603847393,US,850903,UNIV OF MASSACHUSETTS MED SCH WORCESTER,MA,16550002,,12441607; ,"STERN, LAWRENCE ;",,9/30/2016,9/29/2018,Adult; aged; Award; Binding; Biochemical; Biological Assay; biophysical analysis; Bioterrorism; CD8-Positive T-Lymphocytes; Cells; Child; Chronic; Clinical; Communities; Computer software; Contractor; Contracts; cross reactivity; Data; Databases; Diagnostic; DNA Viruses; Emerging Communicable Diseases; Ensure; Epitopes; Herpesviridae; HHV-6A; Human; Human Herpesvirus 6; Immune; immunogenicity; Immunology procedure; In Vitro; in vivo; Infection; Length; microorganism; multidisciplinary; National Institute of Allergy and Infectious Disease; pathogen; Peptide/MHC Complex; Peptides; Primary Infection; programs; Proteins; Research; Sampling; seropositive; Specificity; T cell response; T-Lymphocyte; T-Lymphocyte Epitopes; Testing; tool; validation studies; Variant; volunteer; ,CD4 and CD8 T Cell Epitopes from Human Herpesvirus,,,,,,,,,1354212,
9531199,N01,AI,,N,,,,,N01AI000000,,,272200900022C-14-0-1,NIAID:4985063\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,73757627,US,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PA,191044318,,12063411; ,"ZAOUTIS, THEOKLIS ;",,8/1/2009,8/31/2017,Antibiotic Resistance; Antimicrobial Resistance; Childhood; Clinical Trials; comparative effectiveness; design; Drug Exposure; effectiveness research; Infection; Population; Probability; Regimen; safety testing; therapeutic effectiveness; Translational Research; Urinary tract infection; ,Targeted Clinical Trials for Antimicrobial Resistance ,,,,,,,,,4985063,
9532315,N01,CA,,N,,,,,N01CA000000,,,261201300020I-0-26100015-1,NCI:51875\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,15131760; ,"LYNCH, CHARLES ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,Patterns of Care/Quality of Care Study: Diagnosis Year 2016,,,,,,,,,51875,
9533120,N01,AI,,N,,,,,N01AI000000,,,272201100012I-0-27200011-1,NIAID:215690\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15138374; ,"FISHER, NATHAN ;",,8/1/2017,11/1/2017,Advanced Development; Anti-Bacterial Agents; Antibiotic Resistance; Antifungal Agents; Antimicrobial Resistance; Biological Assay; Contracts; Development; Gonorrhea; in vitro testing; Maintenance; Testing; therapeutic development; ,TASK A31: MIC Testing of GC Panel- FY17,,,,,,,,,215690,
9533350,N01,AI,,N,,,,,N01AI000000,,,272201500008C-8-0-1,NIAID:1198108\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14173580; ,"PAINTER, GEORGE ;",,6/30/2015,7/31/2018,chikungunya; Clinical; clinical development; Communicable Diseases; drug candidate; Future; In Vitro; in vivo; infectious disease treatment; Lead; novel; Pharmaceutical Chemistry; pre-clinical; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases,,,,,,,,,1198108,
9537837,N01,AI,,N,,,,,N01AI000000,,,272201700029I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537858,N01,AI,,N,,,,,N01AI000000,,,272201700042I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BLACKSBURG,UNITED STATES,,9,3137015,US,8968001,VIRGINIA POLYTECHNIC INST AND ST UNIV,VA,240616100,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537861,N01,AI,,N,,,,,N01AI000000,,,272201700040I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537868,N01,AI,,N,,,,,N01AI000000,,,272201700014I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,76137314,US,838205,BIOMEDICAL RESEARCH INSTITUTE,MD,208521707,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537869,N01,AI,,N,,,,,N01AI000000,,,272201700017I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537906,N01,AI,,N,,,,,N01AI000000,,,272201700019I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SALISBURY,UNITED KINGDOM,,,232609375,UK,10000516,DEFENCE SCIENCE & TECHNOLOGY LABORATORY,,SP4 0JQ,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9538111,N01,AI,,N,,,,,N01AI000000,,,272201200003I-2-27200019-1,NIAID:465124\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14734738; ,"HORNBACK, RANDI ;",,8/31/2016,8/31/2018,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; novel vaccines; pathogen; Phase; product development; Reagent; safety testing; Sampling; Services; Testing; Toxicity Tests; Vaccines; Zika virus vaccine; ,Task X19: Development of Assays and Reagents for Zika Virus Vaccines,,,,,,,,,465124,
9538539,N01,AI,,N,,,,,N01AI000000,,,272201100021I-1-27200026-1,NIAID:101451\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12447262; ,"LIN, NANCY ;",,9/26/2014,11/14/2020,AIDS prevention; authority; Contractor; Contracts; Development; Documentation; flexibility; Guidelines; HIV; HIV Envelope Protein gp120; HIV vaccine; HIV-1; immunogenicity; Investigational Drugs; Investigational New Drug Application; Investigator-Initiated Research; microbicide; Modality; National Institute of Allergy and Infectious Disease; Pamphlets; Phase; preclinical development; Preclinical Testing; Process; Production; Proteins; Protocols documentation; research clinical testing; Research Personnel; research study; Safety; Testing; ,NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HIV-1 gp120 PROTEIN,,,,,,,,,101451,
9542450,N01,AI,,N,,,,,N01AI000000,,,272201700014C-0-0-1,NIAID:10108724\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BETHESDA,UNITED STATES,,,57052391,US,,TECHNICAL RESOURCES INC,MD,208171197,,15001406; ,"RAFI, ASIMAH ;",,4/15/2017,4/14/2018,Acquired Immunodeficiency Syndrome; AIDS/HIV problem; Amendment; authority; Clinical Research; Clinical Trials; Collaborations; Contracts; Data; Development; Documentation; Funding; Government; Health; HIV; International; Investigational New Drug Application; Label; Link; meetings; National Institute of Allergy and Infectious Disease; programs; Publications; quality assurance; Quality Control; Records; Regulation; Reporting; Research; Research Activity; Research Personnel; Resources; Safety; System; Training; Update; web site; ,NIAID/DIVISION OF AIDS: REGULATORY SUPPORT CENTER,,,,,,,,,10108724,
9543271,N01,AI,,N,,,,,N01AI000000,,,272201300022C-4-0-1,NIAID:1546239\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,,53045477,US,,TULANE UNIVERSITY,LA,701185676,,12066629; ,"KOZAR, KATHLENN ;",,9/30/2017,9/29/2018,Adjuvant; Animal Model; Animals; Antigens; Attenuated; Collaborations; Cyclic GMP; Development; Emerging Communicable Diseases; Escherichia coli; Human; Immune; Immune response; Immunologics; Infection; Investigation; Lead; Licensure; manufacturing process; mutant; National Institute of Allergy and Infectious Disease; novel; pathogen; pre-clinical; Production; Program Development; Property; protective efficacy; Regulatory Pathway; Route; Shigella Infections; stability testing; Toxicology; Toxin; Tuberculosis; Tuberculosis Vaccines; Vaccine Adjuvant; Vaccine Antigen; vaccine candidate; vaccine delivery; vaccine development; Vaccines; ,Development of Adjuvant with Vaccines for Tuberculosis and Shigellosis,,,,,,,,,1546239,
9543272,N01,AI,,N,,,,,N01AI000000,,,272201500010C-6-0-1,NIAID:282822\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,RALEIGH,UNITED STATES,,4,828576202,US,10020406,"AGILE SCIENCES, INC.",NC,276062576,,14173584; ,"GARLAND, EVA ;",,6/30/2015,11/30/2017,Antimicrobial Resistance; bacterial resistance; Clinical; clinical development; Communicable Diseases; drug candidate; Future; Gram-Negative Bacteria; Gram-Positive Bacteria; In Vitro; in vivo; infectious disease treatment; Lead; novel; Pharmaceutical Chemistry; pre-clinical; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases,,,,,,,,,282822,
9543645,N01,AI,,N,,,,,N01AI000000,,,272201400010I-0-27200025-1,NIAID:684610\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15155826; ,"PTAK, ROGER ;",,8/1/2017,7/31/2018,Academia; base; Biochemical; Biological Assay; Cells; continuous cell line; Contracts; Data; Development; Funding; Gene Expression; high throughput screening; HIV; HIV Infections; Human; Intervention; Investigational New Drug Application; Local Microbicides; microbicide; National Institute of Allergy and Infectious Disease; novel therapeutics; Peripheral Blood Mononuclear Cell; phase I trial; preclinical development; Private Sector; product development; prospective; Public Health; public health priorities; Research Personnel; screening; service utilization; Services; Source; Testing; Therapeutic; Toxic effect; ,IDENTIFICATION OF ANTI-HIV THERAPEUTICS AND TOPICAL MICROBICIDES,,,,,,,,,684610,
9543912,N01,ES,,N,,,,,N01ES000000,,,273201400017C-5-0-1,NIEHS:3794731\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,MORRISVILLE,UNITED STATES,,,119936086,US,,,NC,275608529,,14764449; ,"JOHNSON, VICTOR ;",,8/13/2014,8/12/2018,Adult; Affect; Animals; Anthracenes; Antibody Response; Antigens; Aromatic Compounds; Autoimmune Diseases; Autoimmunity; Benzo(a)pyrene; Bone Marrow; carcinogenicity; Chemical Agents; Chemicals; Communicable Diseases; Complex; Contractor; Contracts; Cytology; Data; Dermal; Development; developmental toxicity; dietary supplements; emerging adult; environmental agent; Evaluation; Event; exposed human population; Exposure to; Flame Retardants; fluoranthene; Fluorine; Food Additives; Health; Health Hazards; Hematopoietic; Human; Hypersensitivity; immune function; immune system function; Immunologic Techniques; Immunologics; immunoregulation; immunotoxicity; Immunotoxicology; In Vitro; in vitro Assay; in vivo; Individual; Inflammatory Bowel Diseases; inorganic phosphate; Interagency Coordinating Committee on the Validation of Alternative Methods; Juvenile Hormones; Life; Measures; Methods; Modeling; Molecular; Mus; National Toxicology Program; Neoplasms; neurotoxicity; Oral; Pharmaceutical Preparations; phenanthrene; Plasticizers; Predictive Value; programs; Publishing; Pyrenes; pyridine; Rattus; Reporting; reproductive toxicity; Research; research and development; Resistance; respiratory; response; Sampling; Schedule; Skin; Structure; Testing; Therapeutic Agents; Toxic effect; Validation; Viral; Xenobiotics; ,STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY,,,,,,,,,3794731,
9546361,N01,AI,,N,,,,,N01AI000000,,,272201500007I-0-27200003-1,NIAID:126942\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HINCKLEY,UNITED STATES,,16,966783706,US,10023022,"CLINICAL RESEARCH MANAGEMENT, INC.",OH,442339801,,14922243; ,"GRIFFIS, JOHN ;",,12/15/2016,12/14/2017,Clinical; Communicable Diseases; immunoregulation; infectious disease treatment; Investigation; novel therapeutics; operation; Phase I Clinical Trials; protocol development; Therapeutic; ,PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS,,,,,,,,,126942,
9547196,N01,AI,,N,,,,,N01AI000000,,,272201400051C-6-0-1,NIAID:1577327\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,49,804355790,US,577507,UNIVERSITY OF CALIFORNIA SAN DIEGO,CA,920930934,,12441598; ,"CARSON, DENNIS ;",,9/30/2014,9/29/2018,Adjuvant; Animal Model; base; Cells; Contractor; Dendritic Cells; Emerging Communicable Diseases; Formulation; high throughput screening; Human; human disease; Immunologic Receptors; in vivo; Influenza; Interferons; Lead; Life; National Institute of Allergy and Infectious Disease; NF-kappa B; novel; pathogen; Pharmaceutical Chemistry; programs; receptor; Research; Signal Pathway; Signal Transduction; Structure-Activity Relationship; Study models; Technology; Testing; Time; Vaccine Adjuvant; vaccine candidate; vaccine discovery; Vaccines; Validation; West Nile viral infection; West Nile virus; Work; ,Adjuvant Discovery for Vaccines against West Nile Virus and Influenza ,,,,,,,,,1577327,
9547625,N01,AI,,N,,,,,N01AI000000,,,272201500006I-0-27200005-1,NIAID:40257\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14973670; ,"CAUDLE, ROB ;",,6/1/2017,12/31/2017,immunoregulation; infectious disease treatment; Investigation; Malaria; novel therapeutics; Phase I Clinical Trials; Plasmodium malariae; Therapeutic; therapeutic evaluation; ,PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS: EVALUATION OF MALARIA THERAPEUTICS,,,,,,,,,40257,
9547679,N01,HD,,N,,,,,N01HD000000,,,275201300024I-3-27500006-1,NICHD:862412\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,TORRANCE,UNITED STATES,,43,69926962,US,2543101,LA BIOMED RES INST/ HARBOR UCLA MED CTR,CA,905022006,,12447394; ,"WANG, CHRISTINA ;",,9/30/2014,6/30/2017,Admission activity; Age; base; Castor Oil; Chemicals; Clinical Research; Clinical Trials; Contraceptive Agents; Contraceptive History; demographics; Dose; Drug Delivery Systems; Drug Kinetics; Eligibility Determination; eligible participant; Enrollment; Fasting; follow-up; Formulation; human subject; Informed Consent; Institutional Review Boards; Interview; Laboratories; man; Medical History; men; Nandrolone; National Institute of Child Health and Human Development; novel therapeutics; Oral; Pharmaceutical Preparations; Pharmacodynamics; Phase; phase 1 study; Physical Examination; Powder dose form; Procedures; Protocols documentation; Randomized; Recruitment Activity; Reproductive History; research clinical testing; Research Personnel; Safety; Schedule; screening; Serum; Specific qualifier value; Specimen; Study Subject; symposium; Testing; Visit; ,CLINICAL EVALUATION OF NEW CHEMICAL CONTRACEPTIVES FOR MEN,,,,,,,,,862412,
9547706,N01,AI,,N,,,,,N01AI000000,,,272201400029C-5-0-2,NIAID:379502\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NOTRE DAME,UNITED STATES,,2,824910376,US,6169301,UNIVERSITY OF NOTRE DAME,IN,465565708,,14207859; ,"COLLINS, FRANK ;",,9/16/2014,9/15/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human; Human Resources; Invertebrates; pathogen; Pediculus; Research; Resources; Services; tool; Update; user-friendly; vector; ,Bioinformatics Resource Centers for Infectious Diseases - Invertebrate Vectors of Human Pathogens.,,,,,,,,,379502,
9547709,N01,AI,,N,,,,,N01AI000000,,,272201400029C-5-0-5,NIAID:430102\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NOTRE DAME,UNITED STATES,,2,824910376,US,6169301,UNIVERSITY OF NOTRE DAME,IN,465565708,,14207859; ,"COLLINS, FRANK ;",,9/16/2014,9/15/2018,Aedes; Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human; Human Resources; Invertebrates; pathogen; Research; Resources; Services; tool; Update; user-friendly; vector; ,Bioinformatics Resource Centers for Infectious Diseases - Invertebrate Vectors of Human Pathogens.,,,,,,,,,430102,
9547970,N01,AI,,N,,,,,N01AI000000,,,272201300002I-0-27200016-1,NIAID:368553\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15177030; ,"PAL, RANAJIT ;",,8/15/2017,2/14/2019,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Antigens; Award; base; Clinical; Complement; Contracts; Development; Evaluation; Evaluation Studies; Funding; Grant; HIV Envelope Protein gp120; HIV vaccine; Immune; Immune response; Investigator-Initiated Research; Local Microbicides; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,Evaluation of Immune Responses to a Trimerically Stabilized gp120 Immunogen,,,,,,,,,368553,
9551126,N01,AI,,N,,,,,N01AI000000,,,272201200003I-0-27200023-1,NIAID:242829\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15188454; ,"HORNBACK, RANDI ;",,7/3/2012,7/2/2022,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Control Animal; Development; Drug resistance; Ebola Vaccines; Ebola virus; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; Filoviridae; Filovirus; immunogenicity; Meta-Analysis; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; vaccine development; Vaccines; ,TASK X23: Control Animal Meta-Analysis for Ebola and Other Filoviruses,,,,,,,,,242829,
9551829,R01,AI,7,N,12/27/2017,9/1/2017,4/30/2020,855,R01AI055258,SCHOOLS OF ARTS AND SCIENCES,PA-16-285,7R01AI055258-13,NIAID:412845\,Non-SBIR/STTR RPGs,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CAMBRIDGE,UNITED STATES,CHEMISTRY,7,1425594,US,4911501,MASSACHUSETTS INSTITUTE OF TECHNOLOGY,MA,21421029,,2180106; ,"KIESSLING, LAURA L;","GONDRE-LEWIS, TIMOTHY A",9/1/2017,4/30/2020,,Synthetic Ligands for Modulating Immune Cell Responses,55258,ZRG1,Special Emphasis Panel ,,,13,276388,136457,412845,
9553427,N01,HL,,N,,,,,N01HL000000,,,268201600035C-3-0-1,NIAMS:1667949\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCKVILLE,UNITED STATES,,8,556875508,US,2768901,"KAI RESEARCH, INC",MD,208523003,,14745804; ,"DIMEO, KATHY ;",,9/1/2016,8/31/2018,Adherence; Arthritis; Biometry; Clinical Research; clinical research site; Clinical Trials; Consultations; Contracts; Data; Data Quality; Development; Ensure; Funding; Good Clinical Practice; Guidelines; Institutes; Logistics; meetings; Monitor; Musculoskeletal Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; operation; Policies; Research Personnel; research study; Safety; Services; skin disorder; Support Contracts; System; Training; , National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Studies Management and Support,,,,,,,,,1667949,
9556094,N01,HD,,N,,,,,N01HD000000,,,275201400003I-3-27500002-1,NICHD:663851\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,12447087; ,"PARSONS, CHRISTOPHER ;",,9/16/2016,9/17/2018,Acquired Immunodeficiency Syndrome; Adolescent; AIDS clinical trial group; Alcohols; Antioxidants; base; Biological; Blood; Blood specimen; brain tissue; Calcium; Caring; Child; Childhood; Chronic; Cohort Studies; Collection; Contract Services; Contractor; Contracts; Development; Dry Ice; efficacy trial; endometriosis; Ensure; Equipment and supply inventories; European; Freezing; Genetic; Government; Health; HIV; HIV Infections; House Dust; Human; Human Resources; Infection; International; Interruption; Laboratories; Liquid substance; Longitudinal Studies; Maternal-Fetal Medicine Units Network; Methods; Molds; Monitor; Mother-to-child HIV transmission; Multicenter Neonatal Research Network; National Children's Study; National Institute of Child Health and Human Development; Nitrogen; pediatric AIDS; pediatric human immunodeficiency virus; Performance; Perinatal; Phase; Pre-Eclampsia; premature; prenatal; Prevention; Program Research Project Grants; programs; repository; Research; Research Personnel; sample collection; Sampling; Services; Ships; Site; Specific qualifier value; Specimen; Spermatocidal Agents; Stillbirth; Sudden infant death syndrome; Testing; Tissue Banks; Tissues; Urine; Vagina; Women's Health; Women?s Interagency HIV Study; Work; ,HUMAN BIOSPECIMAN REPOSITORY - HISTORICAL COLLECTIONS,,,,,,,,,663851,
9563034,N02,CA,,N,,,,,N02CP000000,,,261201100017C-31-0-1,NIEHS:96000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,12619643; ,"DUNN, MARSHA ;",,9/23/2011,9/22/2018,"Address; Age; Agricultural Health Study; Award; B-Lymphocytes; Biological; Biological Markers; Blood; Businesses; Carcinogenesis Mechanism; Cessation of life; Chronic Lymphocytic Leukemia; cohort; Cohort Studies; Collection; Colorectal; Computer Systems; Contractor; Contracts; County; Data; Data Files; Databases; Eligibility Determination; Enrollment; Etiology; farmer; field study; follow-up; Funding; Future; General Population; Home environment; Incidence; indexing; Institutes; interest; Interview; Iowa; leukemia; Licensing; lifestyle factors; Link; Lung; Lymphocytosis; Malignant Neoplasms; meetings; member; Molecular Epidemiology; Monoclonal gammopathy of uncertain significance; mortality; Multiple Myeloma; neoplasm registry; Newsletter; NHANES; North Carolina; Occupational Exposure; operation; Ovarian; Participant; Pesticides; Phase; phase 1 study; phase 2 study; phase 3 study; phase 4 study; population based; Prevalence; Prevalence Study; Privatization; Prostate; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; Protocols documentation; Questionnaires; Records; Recruitment Activity; Research; Research Personnel; research study; Resources; Retrieval; Sampling; Secure; Self-Administered; Specific qualifier value; Specimen; Spouses; Study Subject; Technology; technology development; Telephone Interviews; Universities; Update; Urine; web site; Work; ",AGRICULTURAL HEALTH STUDY PHASE IV--MOD 3:,,,,,,,,,96000,
9566071,N02,CA,,N,,,,,N02CA000000,,,261201100080C-11-0-1,NCI:2095519\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MOUNTAIN VIEW,UNITED STATES,,18,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,940430816,,6305586; ,"SIGMAN, CAROLINE C;",,9/30/2011,9/29/2018,Area; Bioinformatics; Chemistry; Chemopreventive Agent; Clinic; clinical development; Clinical Trials; Contracts; Data; Decision Making; Development; Division of Cancer Prevention; Documentation; Formulation; Government Agencies; Human Resources; Information Management; Malignant Neoplasms; Management Information Systems; Medical center; molecular modeling; Molecular Models; Monitoring Clinical Trials; multidisciplinary; National Cancer Institute; neoplasm resource; Pharmacologic Substance; preclinical development; preclinical evaluation; preclinical study; Prevention program; Prevention Research; Preventive; Private Sector; Program Reviews; programs; Qualifying; Recommendation; Reporting; repository; research and development; research clinical testing; Research Contracts; Research Institute; Research Personnel; Resources; Review Committee; Scientist; Senior Scientist; Services; Site; Strategic Planning; Support Contracts; Technology; Testing; Universities; Writing; ,TECHNICAL INFORMATION RESEARCH RESOURCES FOR CANCER PREVENTIVE AGENT DEVELOPMENT,,,,,,,,,2095519,
9566388,N01,HD,,N,,,,,N01HD000000,,,275201300026I-0-27500016-1,NICHD:518623\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,15221758; ,"KATHERINE, GRANTZ ;",,9/12/2013,2/11/2019,3-Dimensional; Abdomen; Body Composition; body volume; Catalogs; cohort; Collection; Data; Data Coordinating Center; Database Management Systems; Databases; Discipline of obstetrics; Disease; Fatty acid glycerol esters; fetal; Fetal Growth; Future; Gravid; Gravidity; Handedness; Healthcare; Hospitals; Image; Left; Measurement; Measures; Names; National Institute of Child Health and Human Development; Non obese; Obesity; Online Systems; population health; Pregnancy; Pregnant Women; Published Comment; Research; research study; Scanning; Site; Specimen; subcutaneous; Technology; Thinness; Twin Multiple Birth; two-dimensional; Ultrasonography; Visceral; Woman; ,DATA COORDINATING CENTER FOR ADDITIONAL FETAL 3D STUDY MEASUREMENTS,,,,,,,,,518623,
9566457,N01,CA,,N,,,,,N01CA000000,,,261201500018I-0-26100005-1,NCI:508124\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HOUSTON,UNITED STATES,,9,800772139,US,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,770304009,,15221519; ,"BROWN, POWEL ;",,7/1/2017,6/30/2019,Apoptosis; autocrine; Behavior; beta catenin; Binding; Biological Markers; BRCA1 gene; BRCA1 Mutation; Breast Cancer cell line; Breast Cancer Model; Breast Cancer Prevention; cancer prevention; carcinogenicity; casein kinase; cell growth; Cell Line; Cell Nucleus; Complex; Disadvantaged; Dose; efficacy testing; Epithelium; ERBB2 gene; Exhibits; feeding; Gene Targeting; Genetic Transcription; Human; Hyperplasia; Immunocompromised Host; In Vitro; in vivo; Incidence; Inherited; inhibitor/antagonist; Intervention; Lesion; Ligands; malignant breast neoplasm; Malignant Neoplasms; mammary epithelium; Mammary gland; Mammary Neoplasms; Mouse Mammary Tumor Virus; mouse model; Mus; Mutation; overexpression; Pathway interactions; Patients; Pharmacologic Substance; Phosphorylation; Play; Pre-Clinical Model; Preventive treatment; Protein-Serine-Threonine Kinases; receptor; Recruitment Activity; Role; Specificity; Sum; Tail; targeted treatment; Toxic effect; TP53 gene; Transgenic Model; triple-negative invasive breast carcinoma; tumor; tumor growth; Xenograft procedure; ,IGF::OT::IGF TARGETED CASEIN KINASE INHIBITION AS A BREAST CANCER PREVENTION,,,,,,,,,508124,
9567052,N01,CA,,N,,,,,N01CA000000,,,26120140002B26100011-2-0-1,NCI:3499274\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FAIRFAX,UNITED STATES,,11,66783721,US,10030448,"ICF MACRO, INC.",VA,220316050,,; ,",  ;",,9/22/2016,9/21/2018,Intervention; mHealth; Monitor; National Cancer Institute; online resource; Performance; Population; Population Group; Services; smoking cessation; , Campaigns and Monitoring Period of Performance 09/19/2016 - 09/18/2017   ,,,,,,,,,3499274,
9567654,N01,CA,,N,,,,,N01CA000000,,,261201500036I-0-26100005-1,NCI:767562\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15224611; ,"GRUBBS, CLINTON ;",,6/19/2017,6/18/2019,Animal Model; Apoptosis; Aromatase Inhibitors; associated symptom; Biological Markers; Breast Cancer Cell; Breast Cancer Prevention; Breast Carcinogenesis; cancer prevention; Cancer Prevention Trial; cancer therapy; Carcinogens; Cell Cycle Arrest; cell growth; Cell Proliferation; Chemopreventive Agent; Clinic; Clinical; clinical efficacy; Complement; Conjugated Equine Estrogens; Cyclin D1; cytokine receptor gp130; Development; Diarrhea; Disease; Disseminated Malignant Neoplasm; Dose; Down-Regulation; drug development; efficacy study; efficacy testing; Endometrium; Epidermal Growth Factor Receptor; Estrogens; Europe; Exanthema; Exhibits; Experimental Animal Model; FDA approved; Generations; Hormones; Human; Incidence; Individual; Induction of Apoptosis; Interleukin-6; kinase inhibitor; lapatinib; Lead; malignant breast neoplasm; Mammary gland; Mammary Neoplasms; Menopause; Modeling; Osteoporosis; Patients; Pharmaceutical Preparations; Phase III Clinical Trials; preclinical study; predictive marker; prevent; Prevention; protein protein interaction; Proteins; Raloxifene; Rattus; Receptor Protein-Tyrosine Kinases; research clinical testing; Rodent Model; Selective Estrogen Receptor Modulators; Signaling Molecule; small molecule; Somatotropin; Sprague-Dawley Rats; Surrogate Markers; Tamoxifen; Testing; Tissues; Toxic effect; Translations; triple-negative invasive breast carcinoma; tumor; tumor growth; United States; Vasomotor; Work; ,IGF::OT::IGF EVALUATION OF 'CLINICAL-READY' AGENTS (BAZEDOXIFENE AND LAPATINIB) IN COMBINATION FOR THE PREVENTION OF ER+ AND ER- MAMMARY CANCERSPOP 6/19/2017 - 6/18/2019,,,,,,,,,767562,
9567727,N01,AI,,N,,,,,N01AI000000,,,272201500005I-0-27200006-1,NIAID:4083461\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,6,14130053,US,10001472,"DYNPORT VACCINE COMPANY, LLC",MD,217024734,,15217225; ,"SHUMWAY, DAVID ;",,12/15/2014,12/14/2021,Antimicrobial Resistance; biodefense; Communicable Diseases; Contracts; Disease; HIV; immunoregulation; Individual; infectious disease treatment; Investigation; National Institute of Allergy and Infectious Disease; Neisseria gonorrhoeae; novel therapeutics; Parasitic Diseases; pathogen; Phase; Phase I Clinical Trials; phase I trial; Resource Development; Therapeutic; Therapeutic Agents; therapeutic evaluation; Viral; ,PHASE 1 CLINICAL TRIALS UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES: EVALUATION OF THERAPEUTICS FOR NEISSERIA GONORRHOEAE,,,,,,,,,4083461,
9567778,N01,AI,,N,,,,,N01AI000000,,,272201300012I-2-27200012-2,NIAID:594954\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15143623; ,"HOOK, EDWARD ;",,9/15/2016,9/14/2018,Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; Diagnostic; experience; Human Resources; Laboratories; Leadership; Neisseria gonorrhoeae; Procedures; protocol development; Research; Research Infrastructure; sample collection; Sex Behavior; Sexually Transmitted Diseases; therapeutic development; Training; ,Sexually Transmitted Infections Clinical Trials Group ,,,,,,,,,594954,
9567906,N02,CA,,N,,,,,N02CA000000,,,261201000044C-14-0-1,NCI:600000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LORTON,UNITED STATES,,8,146014373,US,10027818,"ARSERVICES, LTD",VA,220791961,,12428357; ,"BRYANT-DAVIS, WANDA ;",,9/24/2017,9/23/2018,Authorization documentation; Cancer Therapy Evaluation Program; Clinical Investigator; Clinical Research; clinical research site; Clinical Trials; Communities; Community Clinical Oncology Program; Contractor; Contracts; Data Element; Databases; Descriptor; Development; Division of Cancer Prevention; Documentation; Education; Elements; Evaluation; Extramural Activities; knowledge base; Management Information Systems; Medical; meetings; Office of Administrative Management; operation; Policies; Prevention program; Prevention Protocols; Procedures; Process; programs; Protocols documentation; Reporting; Resource Allocation; Schedule; Site; System; Workload; ,"NCI, Division of Cancer Prevention Protocol Information Office Support",,,,,,,,,600000,
9568140,N01,AI,,N,,,,,N01AI000000,,,272201700077C-0-0-1,NIAID:6964520\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,2,185576639,US,10006808,"PROFECTUS BIOSCIENCES, INC.",MD,212246538,,15211125; ,"MESHULAM, JEFFREY ;",,9/1/2017,8/14/2018,Advanced Development; Contracts; Cyclic GMP; Development; Ebola virus; Filoviridae; Filovirus; Frankfurt-Marburg Syndrome Virus; Freeze Drying; Lassa Fever; pathogen; Preparation; research clinical testing; vaccine candidate; vaccine development; Vaccines; ,Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever,,,,,,,,,6964520,
9568705,N01,ES,,N,,,,,N01ES000000,,,273201600003I-1-27300002-1,NIEHS:325208\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14644169; ,"JAMES, KERRY ;",,6/30/2016,6/29/2018,Area; Attention; Budgets; Code; Collaborations; Contractor; Contracts; Data; Data Collection; Data Files; Data Storage and Retrieval; Development; Directories; Documentation; electronic data; Epidemiology; Feasibility Studies; Focus Groups; Future; Individual; Institutional Review Boards; Interview; Metadata; Names; National Institute of Environmental Health Sciences; Office Management; Periodicity; permissiveness; Pilot Projects; Procedures; Qualitative Research; Questionnaires; Research; research and development; Research Personnel; research study; sample collection; Sampling; Scientist; Services; Specimen; Structure; symposium; Time; ,IGF::OT::IGF - SUPPORT SERVICES FOR EPIDEMIOLOGY - TASK ORDER 2 - RESEARCH DEVELOPMENT,,,,,,,,,325208,
9568945,N43,AI,,N,,,,,N43AI000000,,,272201700073C-0-0-1,NIAID:223834\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROANOKE,UNITED STATES,,6,627132913,US,3604601,"LUNA INNOVATIONS, INC.",VA,240111921,,15327614; ,"TALLEY, NATHANIEL ;",,8/1/2017,7/31/2018,Antibodies; Avidity; Biological Assay; Cytomegalovirus; Detection; Development; Diagnostic; Immunoglobulin G; Immunoglobulin M; point of care; Technology; ,A Point-of-Care Cytomegalovirus Serodiagnostic and Avidity Assay,,,,,,,,,223834,
9568963,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100020-1,NCI:77283\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326889; ,"GIANNINI, ROBERT ;",,3/10/2017,6/12/2017,capsule; Clinical; Color; Excipients; Formulation; Gelatin; Label; Pharmacologic Substance; repository; seal; Testing; ,IGF::OT:IGF,,,,,,,,,77283,
9568981,N02,CA,,N,,,,,N02CA000000,,,261201500010I-0-26100005-1,NCI:9764\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SOUTH SAN FRANCISCO,UNITED STATES,,,930243360,US,,,CA,940801934,,15326907; ,"JOHNSON, CHARLES ;",,1/23/2017,3/24/2017,base; Biology; cancer diagnosis; cancer therapy; Chemicals; Collection; Contractor; Contracts; cost; Dimethyl Sulfoxide; drug development; drug discovery; Exercise; Fees; Government; high throughput screening; Informatics; Investigational Therapies; Libraries; Library Services; Maps; multidisciplinary; Names; NCI Center for Cancer Research; oncology; Pathway interactions; planetary Atmosphere; Privatization; programs; repository; Research Infrastructure; Resources; Sampling; screening; seal; Services; small molecule; Solvents; Specific qualifier value; Therapeutic; tool; ,IGF::OT::IGF Plating of Oncology Interrogation Tools Library,,,,,,,,,9764,
9569000,N44,CA,,N,,,,,N44CA000000,,,261201700002C-0-0-1,NCI:1475002\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TAMPA,UNITED STATES,,14,155500809,US,10002619,"TRANSGENEX NANOBIOTECH, INC.",FL,336133305,,15228321; ,"KENCHAPPA, RAJAPPA ;",,2/1/2017,1/31/2019,acute toxicity; atrial natriuretic factor receptor A; Biological Assay; Clinical; Computer Simulation; Contracts; Development; Documentation; Drug Kinetics; Generations; inhibitor/antagonist; Lead; Malignant neoplasm of lung; Malignant Neoplasms; Mus; novel therapeutics; Pharmacodynamics; Phase; phase 2 study; Relapse; research and development; Role; Scientist; Small Business Innovation Research Grant; small molecule libraries; Stem cells; targeted treatment; Toxic effect; tumor; tumor progression; Validation; ,"IGF::OT::IGF: SBIR Phase II, Topic 326: Development of Novel Therapeutic Agents that Target Cancer",,,,,,,,,1475002,
9569063,N01,AI,,N,,,,,N01AI000000,,,272201100022I-0-27200011-2,NIAID:2500139\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064949; ,"MIRSALIS, JON ;",,6/6/2017,6/5/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Escherichia coli; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; Pathogenicity; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; Toxicology; Toxin; ,Task 11: Interventional Agent Development Services Program,,,,,,,,,2500139,
9569234,N01,AI,,N,,,,,N01AI000000,,,272201300018I-0-27200015-1,NIAID:1282074\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15071218; ,"MULLIGAN, MARK ;",,9/16/2013,1/15/2020,Antimicrobial Resistance; Bacterial Infections; bacterial resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Gram-Negative Bacterial Infections; Individual; named group; Phase IV Clinical Trials; phase IV trial; Population; programs; Resources; Therapeutic; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS: PHASE IV TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS,,,,,,,,,1282074,
9569567,N02,HD,,N,,,,,N02HD000000,,,275201500086U-5-0-1,NICHD:219284\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,RESTON,UNITED STATES,,,926318916,US,,,VA,201915463,,14742022; ,"BOWES, KENDRAKING ;",,9/28/2015,9/27/2017,Alaskan; American; Back to Sleep; Communities; Native Americans; outreach; outreach program; Risk Reduction; Sudden infant death syndrome; ,SUDDEN INFANT DEATH SYNDROME (SIDS) RISK REDUCTION IN NORTHERN TIER AMERICAN AND ALASKAN COMMUNITIES SAFE SLEEP OUTREACH PROJECT,,,,,,,,,219284,
9569765,N01,HL,,N,,,,,N01HL000000,,,268201700001I-0-26800002-1,NHLBI:2778412\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,14921889; ,"COUPER, DAVID ;",,11/15/2016,11/14/2019,Abdomen; Address; Adult; African American; aged; Ancillary Study; Ankle; Atherosclerosis; Atherosclerosis Risk in Communities; base; Behavioral; Behavioral Genetics; Calibration; Carotid Arteries; caucasian American; Characteristics; Clinical; clinical development; clinical predictors; cognitive function; cohort; Cohort Studies; Collaborations; Communities; community center; Contracts; Coronary heart disease; County; Data; Data Collection; Data Set; Development; Disease; Electronic Health Record; Event; follow-up; Fostering; Functional disorder; Funding; Genetic; Geographic Locations; Goals; Grant; Heart failure; Hemostatic Agents; indexing; Laboratories; Measurement; middle age; Monitor; mortality; Myocardial Infarction; Natural History; Participant; Photography; Policies; Process; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Recruitment Activity; Research Personnel; Retinal; Risk Factors; Risk Marker; rural setting; Sampling; sharing data; socioeconomics; Structure of popliteal artery; Subgroup; suburb; Technology; Testing; trend; Ultrasonography; United States National Institutes of Health; Washington; ,"IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - COORDINATING CENTER - COMMUNITY SURVEILLANCE, FEASIBILITY, AND CALIBRATION STUDY",,,,,,,,,2778412,
9570332,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-14,NIAID:462930\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,15032410; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Chikungunya virus; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,462930,
9570551,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-5,NIAID:40753\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,40753,
9571001,N01,AI,,N,,,,,N01AI000000,,,272201600027C-1-0-2,NIAID:925074\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,78200995,US,861001,FRED HUTCHINSON CANCER RESEARCH CENTER,WA,981094433,,14763414; ,"GERAGHTY, DANIEL ;",,9/30/2017,9/29/2018,AIDS/HIV problem; Alleles; Animal Model; Biological; cell mediated immune response; cohort; Complex; Data; Disease; Frequencies; gene discovery; gene therapy; Genetic; Genomics; Genotype; Goals; Haplotypes; Health; Health Sciences; HIV vaccine; Human; IgG Receptors; Immune response; Immunoglobulins; Institutes; Killer Cells; Knowledge; knowledge base; Macaca; Macaca mulatta; Major Histocompatibility Complex; Major Histocompatibility Complex Gene; Methods; nonhuman primate; Oregon; Phase; Prevention strategy; Program Development; receptor; Receptor Gene; Resources; SIV; SIV Vaccines; Study models; success; technology development; Testing; Translations; Universities; vaccination strategy; vaccine evaluation; Vaccine Therapy; vaccine trial; Vaccines; ,NHP MHC COMPLEX ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT - HIV/AIDS ,,,,,,,,,925074,
9571294,N01,HD,,N,,,,,N01HD000000,,,275201300023I-0-27500014-1,NICHD:171697\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15238388; ,"TSAI, MICHAEL ;",,9/22/2017,6/21/2018,7 year old; Adult; base; Base Pairing; biobank; Biological Assay; Biomedical Research; Birth; Blood; Blood specimen; Child; Childhood; Clinical; Clinical Data; Clinics and Hospitals; cohort; Cohort Studies; Collection; Complex; Data; data archive; design; Development; Discipline of obstetrics; Disease; DNA; DNA Damage; DNA Fragmentation; DNA purification; DNA Repair; Enrollment; Environment; epidemiology study; Equipment and supply inventories; ethnic diversity; experimental study; fetal; Fetal Growth; Formalin; Future; gene environment interaction; gene interaction; Genes; Genetic; genetic epidemiology; Genetic Risk; Genetic study; genome-wide; Genomics; Genotype; Goals; Growth; Growth and Development function; health disparity; improved; Institution; Intervention; Interview; Laboratory Procedures; Link; Measures; Molecular; mortality; National Institute of Child Health and Human Development; Neurodevelopmental Disorder; Newborn Infant; offspring; Onset of illness; Paraffin Embedding; Participant; Performance; Perinatal; Perinatal Epidemiology; perinatal outcomes; Phenotype; Pilot Projects; Polymerase Chain Reaction; population health; Postpartum Period; Pregnancy; Pregnant Women; Prenatal care; Prospective cohort; Publishing; Puerto Rican; Quality Indicator; Recruitment Activity; repaired; repository; Reproducibility; Research; restoration; Sampling; Schedule; sequencing platform; Serum; Site; SNP array; SNP genotyping; Specimen; Techniques; Testing; Time; trait; Umbilical Cord Blood; United States National Institutes of Health; University Hospitals; Variant; Vial device; Visit; Whole Blood; whole genome; Woman; Work; ,GENOTYPING PERFORMANCE OF DNA FROM STORED SERUM: A PILOT STUDY IN THE COLLABORATIVE PERINATAL PROJECT,,,,,,,,,171697,
9571336,N02,HD,,N,,,,,N02HD000000,,,275201701001P-0-0-1,NICHD:80000\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,OVERLAND PARK,UNITED STATES,,3,80701337,US,10026299,"BECKLOFF ASSOCIATES, INC.",KS,662102364,,15327863; ,"NICHOLAS, SHAWN ;",,9/22/2017,9/21/2018,,'IGF::OT::IGF',,,,,,,,,80000,
9571394,N01,AI,,N,,,,,N01AI000000,,,272201300018I-0-27200016-1,NIAID:633761\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15010827; ,"MULLIGAN, ROBERT ;",,9/16/2013,9/15/2023,Clostridium difficile; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase; Population; programs; Resources; Therapeutic Trials; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: PHASE I/II THERAPEUTIC TRIAL FOR CLOSTRIDIUM DIFFICILE ,,,,,,,,,633761,
9571422,N01,AI,,N,,,,,N01AI000000,,,272201300020I-0-27200016-1,NIAID:157456\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,15193803; ,"WINOKUR, PATRICIA ;",,9/16/2013,9/15/2023,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Drug Kinetics; Evaluation; Gram-Negative Bacteria; Gram-Positive Bacteria; Individual; named group; Population; programs; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: POPULATION PHARMACOKINETICS STUDY,,,,,,,,,157456,
9571847,N43,CA,,N,,,,,N43CA000000,,,261201700044C-0-0-1,NCI:249642\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,Brooklyn,UNITED STATES,,13,961919508,US,10025995,"LUCERNA, INC.",NY,11226,,15233162; ,"SOMALINGA, BALAJEE ;",,9/18/2017,6/18/2018,aptamer; Basal cell carcinoma; base; Biochemical; Biological Assay; cancer type; Cells; circular RNA; design; diagnostic biomarker; drug discovery; Exhibits; Fluorescence; Generations; Glioma; Individual; interest; Length; Ligation; Link; Malignant neoplasm of pancreas; Mediating; Messenger RNA; MicroRNAs; Nature; novel; Oncogenic; Performance; Phase; Porifera; portability; Proteins; receptor; Regulation; Research; RNA; RNA Ligase (ATP); RNA-Binding Proteins; Role; Sampling; Scaffolding Protein; sensor; Signal Transduction; Small Business Innovation Research Grant; Specificity; Testing; tool; Translations; Tumor Suppressor Proteins; Untranslated RNA; ,IGF::OT::IGF SBIR Phase I Topic 356 Flourogenic assay platform for circular RNA detectionPoP 9/18/2017 - 6/18/2018.,,,,,,,,,249642,
9572110,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200013-1,NIAID:310219\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,14922213; ,"CREECH, BUDDY ;",,11/7/2016,1/6/2021,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Drug Kinetics; Evaluation; Gram-Positive Bacteria; Individual; named group; Population; programs; Resources; therapeutic development; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: POPULATION PHARMACOKINETIC ANALYSES ,,,,,,,,,310219,
9572234,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-9,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Bartonella henselae; Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572239,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-12,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Burkholderia mallei; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572778,N01,CA,,N,,,,,N01CA000000,,,261201600015I-0-26100003-1,NCI:479694\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,1,5447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,,15235135; ,"MCCORMICK, DAVID ;",,9/8/2017,12/31/2018,anti-cancer therapeutic; anticancer activity; Award; Cancer Patient; Cells; Contracts; Development; Evaluation; In Vitro; Investigation; Malignant Neoplasms; Organ; Pharmaceutical Preparations; Pharmacology and Toxicology; pre-clinical; Process; research clinical testing; Source; Testing; Tissues; Toxic effect; ,"IGF::OT::IGF NExT Preclinical Toxicology & Pharmacology of Drugs Developed for Cancer Patients, TO#3, Exploratory Studies of CCR4 CART Cells",,,,,,,,,479694,
9572814,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-14,NIEHS:201598\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,15035369; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Chemicals; Complex Mixtures; Data; Development; Gene Targeting; Genetic Transcription; Human; Human Development; Individual; Legal patent; programs; Reporter; Signal Transduction; small molecule libraries; Technology; Toxic effect; toxicant; transcription factor; ,Multiplexed transcription factor profiling of complex mixtures and developmental toxicants for the NTP,,,,,,,,,201598,
9572903,N01,AI,,N,,,,,N01AI000000,,,272201300018I-0-27200017-1,NIAID:611678\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15131769; ,"MULLIGAN, MARK ;",,6/1/2017,3/31/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Norovirus; Phase; Population; programs; Resources; vaccine candidate; vaccine trial; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: PHASE I NOROVIRUS VACCINE TRIAL,,,,,,,,,611678,
9573086,N01,HD,,N,,,,,N01HD000000,,,275201700005C-0-0-1,NIDDK:367158\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15266317; ,"GRZYWACZ, BARTOSZ ;",,9/29/2017,6/28/2018,Americas; Animal Experimentation; cell type; Cells; Contracts; Disease; Excision; Freezing; Hepatic; Hepatic Tissue; Hepatocyte; Human; in vitro Model; Liver; liver transplantation; Metabolism; Operating Rooms; Pathologic; Research; Research Personnel; Slide; System; Time; Tissues; United States; United States National Institutes of Health; ,Liver Tissue and Cell Distribution System (LTCDS),,,,,,,,,367158,
9573325,N01,ES,,N,,,,,N01ES000000,,,273201300010C-8-0-1,NIEHS:2400000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15043498; ,"HEBERT, CHARLES ;",,9/23/2013,5/19/2018,Acquired Immunodeficiency Syndrome; Adult; Adverse effects; AIDS therapy; AIDS/HIV problem; Animals; Biological Markers; Birth; Bone Development; Chemicals; Clinical; Communities; Compliance behavior; Congenital Abnormality; critical period; design; Developing Countries; Development; dietary supplements; disorder prevention; Dose; Drug Combinations; Drug usage; early life exposure; efavirenz; emtricitabine; Environmental Pollution; Exhibits; Exposure to; FDA approved; fetal; Fetal Development; Fetal Weight; Flame Retardants; Generations; Goals; Hazard Identification; Hazardous Chemicals; Health; HIV Seropositivity; Human; in utero; Individual; Industrialization; Infertility; Investigation; Laboratory Animals; Laboratory mice; Laboratory Rat; Life; Materials Testing; Medical; Monitor; mortality; National Toxicology Program; Neural tube; neurodevelopment; offspring; Ovary; Patients; personal care products; Pharmaceutical Preparations; postnatal; pregnant; prenatal exposure; Primates; programs; Puberty; public health research; Rattus; reproductive organ; reproductive toxicity; Rodent; Safety; Stavudine; Tenofovir; Testis; Therapeutic; Toxic effect; Toxicity Tests; tumor; Weight Gain; Woman; World Health Organization; Zidovudine; ,AIDS Tricombination Therapies Subproject 1,,,,,,,,,2400000,
9573428,N43,CA,,N,,,,,N43CA000000,,,261201700028C-0-0-1,NCI:224984\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BUFFALO GROVE,UNITED STATES,,8,141256797,US,10001032,BRIGHTOUTCOME INC.,IL,600891944,,15237351; ,"HAAS, NIINA ;",,9/18/2017,6/17/2018,Address; base; cancer care; Cancer Patient; Caregiver support; Caregivers; caregiving; Caring; Communication; Communities; Contracts; design; Development; digital; Education; Electronic Health Record; Emotional; Evaluation; experience; Failure; Feedback; Focus Groups; Goals; high risk; Home environment; informal support; Malignant Neoplasms; Patients; peer; Phase; Process; prototype; Provider; Psyche structure; Reporting; Self Care; Small Business Innovation Research Grant; social; success; Support System; Symptoms; System; Testing; United States; usability; Work; ,IGF::OT::IGF: Phase I SBIR Contract - FY17 - Topic 363 - Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving,,,,,,,,,224984,
9573608,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200018-2,NIAID:220601\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14922168; ,"WALTER, EMMANUEL ;",,11/1/2016,11/2/2018,Bacterial Vaginosis; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase; Population; programs; Resources; Therapeutic Trials; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: PHASE II THERAPEUTIC TRIAL FOR BACTERIAL VAGINOSIS ,,,,,,,,,220601,
9573707,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-3,NIAID:344050\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Biological; Biomedical Research; Campylobacter jejuni; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,344050,
9573709,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-5,NIAID:172025\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Ebola virus; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,172025,
9573712,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-8,NIAID:344040\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; Salmonella typhi; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,344040,
9573714,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-10,NIAID:172025\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Toxoplasma; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,172025,
9573763,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-19,NIAID:64094\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,64094,
9574396,N44,CA,,N,,,,,N44CA000000,,,261201700050C-0-0-1,NCI:1499895\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BELLEFONTE,UNITED STATES,,5,791379030,US,10013439,"ACTUATED MEDICAL, INC.",PA,168238445,,15239914; ,"SNOOK, KEVIN ;",,9/19/2017,9/18/2019,Acceptance Process; Air; Animals; Area; Biological Markers; Biopsy; Biopsy Specimen; Birds; cancer cell; cancer diagnosis; Canis familiaris; Classification; Clinical; Clinical Research; Collection; commercialization; Contractor; Contracts; Core Biopsy; Data; design; Development; Device Designs; Diagnosis; Diagnostic; Disease; Documentation; Excision biopsy; Frequencies; Health; Histologic; Human; improved; in vivo Model; Lasers; Lateral; Lighting; Low Prevalence; manufacturing process; Measures; Methods; Modeling; Molecular Profiling; Mutation; Needles; Ovarian; Pathologic; Patients; Performance; Phase; Physicians; pre-clinical; Production; prototype; Recurrence; Reporting; Resolution; Risk; Safety; Sampling; Signal Transduction; Small Business Innovation Research Grant; Specimen; System; Techniques; Technology; Therapeutic; Tissues; tool; tumor; United States National Institutes of Health; Vertebrates; ,Photoacoustic Needle for Identifying Tumor Content and Margins to Improve Sampling During Core Needle Biopsy,,,,,,,,,1499895,
9574580,N01,CA,,N,,,,,N01CA000000,,,261201500038I-0-26100011-2,NCI:522064\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,OKLAHOMA CITY,UNITED STATES,,5,878648294,US,1524003,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,73104,,15240263; ,"RAO, CHINTHALAPALLY ;",,9/15/2017,9/14/2019,Aberrant crypt foci; Angiotensin Receptor; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animal Model; Anti-inflammatory; Anti-Inflammatory Agents; Aspirin; Biological Markers; Cancer Etiology; cancer type; Captopril; Cardiovascular system; Case-Control Studies; cell growth; Cell Survival; Chemoprevention; Clinic; clinical efficacy; Colorectal Cancer; colorectal cancer prevention; cyclooxygenase 2; Diagnosis; Dose; Drug usage; gastrointestinal; Generations; hypertension treatment; Inflammation; inhibitor/antagonist; mortality; olmesartan; Pharmaceutical Preparations; pre-clinical; prevent; Property; PTGS2 gene; Risk; Safety; Signal Transduction; telmisartan; Toxic effect; ,IGF::OT::IGF PREVENT Efficacy Task Order: Chemoprevention of Colorectal Cancer with Olmesartan Medoxomil,,,,,,,,,522064,
9574802,N43,CA,,N,,,,,N43CA000000,,,261201700024C-0-0-1,NCI:1908933\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,EAST AMHERST,UNITED STATES,,27,57763991,US,10030988,"PHOTOLITEC, LLC",NY,140512076,,15240619; ,"MARKO, AIMEE ;",,9/12/2017,9/11/2019,Adjuvant; analog; base; Biological Markers; bone; Breast Cancer Model; Cancer Patient; Canis familiaris; Cells; chemotherapy; Clinic; Clinical; Comorbidity; Couples Therapy; Detection; Diagnosis; dimer; Dimerization; Disease; Distant; Dose; Drug Kinetics; Excision; Fluorescence; fluorescence-guided surgery; image guided; imaging agent; improved; improved outcome; Lesion; Light; Lung; lung imaging; Lung Neoplasms; lung xenograft; lymph nodes; Mus; Neoplasm Metastasis; neoplastic cell; Non-Small-Cell Lung Carcinoma; novel; Operative Surgical Procedures; Patients; Pharmacodynamics; Phase; Positron-Emission Tomography; Primary Neoplasm; PUVA Photochemotherapy; Radioactive; Rattus; Reaction; Small Business Innovation Research Grant; Specificity; Stromal Cells; System; three dimensional cell culture; Tissues; Toxic effect; Translating; tumor; ,IGF::OT::IGF SBIR Phase II Topic 357; POP: 09/12/2017 - 09/11/2019,,,,,,,,,1908933,
9574969,N02,CA,,N,,,,,N02CA000000,,,261201400004I-0-26100007-1,NCI:239654\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SPRINGFIELD,UNITED STATES,,18,831496661,US,4155401,NORTH AMERICAN ASSN/CENTRAL CANCER REG,IL,627047412,,15240925; ,"KOHLER, BETSY ;",,9/19/2017,9/18/2018,American; Cancer Patient; Cessation of life; Clinical Trials; Cohort Studies; Data Set; Databases; follow-up; indexing; interest; Marketing; Methods; neoplasm registry; Patients; Process; Registries; Research; Research Personnel; Resources; Standardization; Time; United States; virtual; Work; ,"North American Association of Central Registries INC. (NAACR): Virtual Pooled Registry Project. September 19, 2017 through September 18, 2018 ",,,,,,,,,239654,
9575202,N02,CA,,N,,,,,N02CA000000,,,261201600005I-0-26100002-1,NCI:71250\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,POZNAN,POLAND,,,427769665,PL,10040378,INTERNAT'L INSTITUTE/MOLECULAR ONCOLOGY,,60-203,,15241389; ,"WIZNEROWICZ, MACIEJ ;",,9/18/2017,9/17/2018,cancer imaging; clinical imaging; Collection; Data; Diagnostic Procedure; Enrollment; follow-up; Glioblastoma; Hospitals; human subject; Image; image archival system; Imaging Techniques; Magnetic Resonance Imaging; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Medical Imaging; melanoma; MRI Scans; oncology; Operative Surgical Procedures; Patients; Positron-Emission Tomography; radiological imaging; Renal Cell Carcinoma; Technology; tumor; Ultrasonography; X-Ray Computed Tomography; ,"Medical Images for BiospecimensThe Task Order is in the amount of $71,250.00",,,,,,,,,71250,
9575404,N01,HL,,N,,,,,N01HL000000,,,268201500001I-0-26800004-1,NHLBI:950269\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BOSTON,UNITED STATES,,7,604483045,US,894901,BOSTON UNIVERSITY MEDICAL CAMPUS,MA,21182340,,15241777; ,"RAMACHANDRAN, VASAN ;",,4/1/2017,3/31/2018,Abdomen; adipokines; African American; Age; American Indians; Area; Asians; Atherosclerosis; base; Behavior; Biochemical; Bioinformatics; Biological Markers; Blood; Boston; Bronchodilator Agents; calcification; Calcified; Calcium; Cell Line; Clinical; Coagulation Process; cognitive function; cohort; Communities; Complement; Complex; Contracts; Coronary; Data; detector; Development; Disease; DNA; DNA Resequencing; Environment; Environmental Risk Factor; Family; Fatty acid glycerol esters; follow-up; Framingham Heart Study; Funding; Generations; Genes; Genetic; genetic analysis; Genetic study; Genome; Genotype; Grant; Heart; Hispanics; Hormonal; Imaging Techniques; immortalized cell; inflammatory marker; innovation; Insulin Resistance; Knowledge; Laboratories; Lipids; Lipoproteins; Longitudinal cohort study; Lung; Measurement; Measures; Minority; Obesity; offspring; Participant; Persons; Phenotype; phenotypic data; Physical activity; Physical Function; Privacy; Process; pulmonary function; Recruitment Activity; Renal function; Research Personnel; Resources; Rest; Risk Factors; Scanning; Sleep; Spirometry; Structure of parenchyma of lung; Techniques; Time; United States National Institutes of Health; Universities; Visceral; X-Ray Computed Tomography; ,IGF::OT::IGF FRAMINGHAM HEART STUDY (FHS) - TASK ORDER 04,,,,,,,,,950269,
9575649,N01,CA,,N,,,,,N01CA000000,,,261201200042I-0-26100014-1,NCI:243804\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,15201012; ,"LIMBURG, PAUL ;",,9/15/2017,9/14/2018,base; Biopsy Specimen; Colorectal; Cyclic GMP; Dose; double-blind placebo controlled trial; healthy volunteer; Pharmacology; Phase; Placebos; post intervention; randomized trial; Rectum; ,"IGF::OT::IGF PHASE I DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL OF 0.3MG LINACLOTIDE DELAYED-RELEASE (DR1) TO DEMONSTRATE COLORECTAL BIOACTIVITY IN HEALTHY VOLUNTEERS",,,,,,,,,243804,
9575705,N01,CA,,N,,,,,N01CA000000,,,261201200031I-0-26100011-1,NCI:405600\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TUCSON,UNITED STATES,,3,806345617,US,490201,UNIVERSITY OF ARIZONA,AZ,857210158,,15242259; ,"CHOW, SHERRY ;",,9/15/2017,12/14/2019,aged; Biopsy; Cervical; Fluorouracil; Imiquimod; intraepithelial; Lesion; Phase I Clinical Trials; Safety; Self-Administered; Vaginal Route of Drug Administration; Woman; ,IGF::OT::IGF  Topical Therapies for Treatment of CIN 2-3,,,,,,,,,405600,
9576432,N44,CA,,N,,,,,N44CA000000,,,261201700034C-0-0-1,NCI:1999999\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MENLO PARK,UNITED STATES,,3,26823768,US,10028662,"MIRA DX, INC.",CA,94026,,15327072; ,"SALZMAN, DAVID ;",,9/19/2017,9/18/2019,3' Untranslated Regions; base; Biological Markers; biomarker panel; Cancer Patient; Clinical; cohort; Collection; Contracts; diagnostic assay; Distant; DNA; Failure; Genetic; Germ-Line Mutation; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Health; Human; Immune; Immune response; improved; individual patient; Inherited; Malignant neoplasm of lung; Malignant Neoplasms; Medical; MicroRNAs; Non-Small-Cell Lung Carcinoma; Normal tissue morphology; patient population; Patients; PDCD1LG1 gene; Phase; prospective; Radiation; radiation response; Radiation therapy; Radiation Therapy Oncology Group; Radiation Tolerance; radiosensitive; Randomized; response; Sampling; Small Business Innovation Research Grant; Statistical Data Interpretation; Techniques; Technology; Testing; tissue biomarkers; Toxic effect; tumor; Tumor Markers; ,IGF::OT::IGF SBIR Phase II: Topic 338 - Defining Normal Tissue and Tumor Biomarkers of Radiosensitivity to Best Direct Treatment,,,,,,,,,1999999,
9576580,N02,CA,,N,,,,,N02CA000000,,,261201600024I-0-26100003-1,NCI:16715\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,15326961; ,"REID, JOEL ;",,8/7/2017,6/30/2021,base; Biological Availability; Cancer Patient; Data; Drug Kinetics; Mus; Plasma; small molecule; ,"NExT NX232-107-158-006 TO#3 Milestone 3 (base) - PK & Bioavail Stud w/Selected Anticancer Compounds in Mice, PK & Pharm Evals of Agents Being Developed for Cancer Patients, HHSN261201600024I/HHSN26100",,,,,,,,,16715,
9576625,N43,DA,,N,,,,,N43DA000000,,,271201700030C-1-0-1,NCATS:219687\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,HANOVER,UNITED STATES,,2,72021041,US,1811501,"CREARE, LLC",NH,37553116,,15243881; ,"KYNOR, DAVID ;",,6/15/2017,3/14/2018,Algorithms; Architecture; arm; base; Computer software; Contractor; cost effective; design; Environment; flexibility; grasp; Laboratories; Methods; Monitor; novel; open source; Performance; Phase; prototype; Route; System; ,IGF::OT::IGF Automated Plate Transport System,,,,,,,,,219687,
9578132,N02,CA,,N,,,,,N02CA000000,,,261201700013I-0-26100001-1,NCI:638\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,15327006; ,"THOMAS, BRIAN ;",,8/1/2017,9/30/2017,Contracts; cost; Formulation; Malignant Neoplasms; meetings; Teleconferences; ,"IGF::OT::IGF Administrative Cost - Contract Orientation & Kick Off Mtg, HHSN261201700013I, DTP-17-038, 08/01/17 - 09/30/17,  Analysis of Anti-Cancer Chem & Pharm Formulations, PRB.",,,,,,,,,638,
9578336,N44,DA,,N,,,,,N44DA000000,,,271201700060C-0-0-1,NIDA:999904\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,Owings Mills,UNITED STATES,,7,943185496,US,3070101,"MEDICAL DECISION LOGIC, INC.",MD,21117,,15246544; ,"TIEN, ALLEN ;",,9/25/2017,9/24/2019,Address; Area; Award; base; behavioral health; Belief; career; Caring; Client; Collaborations; Communities; Computer software; Contractor; cost; Data Analytics; Ecosystem; Evolution; experience; Health; Healthcare; Healthcare Systems; Human; improved; Information Technology; innovation; Internet; Knowledge; Life Cycle Stages; Link; Logic; Medical Care Costs; medical schools; Mental Health; National Institute of Drug Abuse; Outcome; Patient Self-Report; Phase; Prevention; Problem Solving; Process; Productivity; Provider; Public Health; Quality of life; Research; school health; Science; screening; Services; Small Business Innovation Research Grant; Software Tools; Substance abuse problem; System; tool; Triage; Trust; Validation; Variant; web services; Work; ,IGF::OT::IGF FY17 Web Platform to Integrate Behavioral Health NIDA Ref. No. N44DA-17-5679; POP: 09/25/2017 - 09/24/2019. Base Award.,,,,,,,,,999904,
9578565,N43,CA,,N,,,,,N43CA000000,,,261201700023C-0-0-1,NCI:299999\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BETHESDA,UNITED STATES,,8,78788097,US,10033999,"OTOMAGNETICS, LLC",MD,208141450,,15246860; ,"SHIMOJI, MIKA ;",,9/19/2017,6/18/2018,3D Print; Adverse effects; Anatomy; Animals; Carboplatin; chemotherapy; Chemotherapy-Oncologic Procedure; Child; Childhood; Cisplatin; Cochlea; cognitive development; Control Groups; Devices; Dose; Dose-Limiting; Drug Delivery Systems; Ear; Hearing; hearing impairment; Label; Lead; Learning; Magnetism; middle ear; mouse model; nanoparticle; ototoxicity; Patients; pediatric patients; Prevention; Regimen; Speech Development; Steroids; System; Technology; Teenagers; Testing; Topical application; Toxic effect; tumor; ,Drug Delivery System to Save Hearing During Pediatric Chemotherapy Regimens.  POP 09/19/17 - 06/18/18.,,,,,,,,,299999,
9579364,N01,HL,,N,,,,,N01HL000000,,,268201500003I-0-26800005-2,NHLBI:30152\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,14975959; ,"JOHNSON, CRAIG ;",,3/23/2017,6/22/2017,Address; African American; aged; Behavioral; Biochemical; Biological Assay; Blood specimen; Candidate Disease Gene; Cardiovascular Diseases; Case-Control Studies; Caucasians; Characteristics; Chinese People; Clinical; clinical development; clinical predictors; cognitive function; cohort; Coronary Arteriosclerosis; Data; Disease; DNA; Event; follow-up; Functional disorder; Genetic; Genome Scan; Goals; Hispanics; Investigation; Laboratories; Lymphocyte; member; men; Participant; population based; Population Heterogeneity; psychologic; Recruitment Activity; Risk Factors; Risk Marker; Sampling; socioeconomics; Subgroup; Testing; Woman; ,"IGF::OT::IGF MESA - TASK ORDER 0005 - TOPMED - MARCH 23, 2017 -  JUNE 22, 2017",,,,,,,,,30152,
9579844,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-157,NCI:762640\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,Cancer Model; Human; Modeling; ,OCG HCMI Additional Models,,,,,,,,,762640,
9580665,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100053-1,NCI:18408319\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266034; ,"PARCHMENT, RALPH ;",,9/21/2017,9/20/2022,analog; base; Benchmarking; Biological; Biological Assay; Biological Markers; Biopsy; Canis familiaris; Clinical; Collaborations; Contractor; cross reactivity; CTLA4 gene; Cyclic GMP; Cytotoxic T-Lymphocyte-Associated Protein 4; Development; Diagnostic Reagent; Evaluation; experience; Growth; High-Frequency Microsatellite Instability; Human; Immunooncology; Immunotherapy; Malignant Neoplasms; Measures; molecular marker; Monoclonal Antibodies; pharmacodynamic biomarker; Pharmacodynamics; Phase; Property; Reagent; Regimen; research clinical testing; response; Role; success; Therapeutic; Therapeutic Monoclonal Antibodies; tumor; ,Canine Immuno-Oncology ,,,,,,,,,18408319,
9581110,N01,CA,,N,,,,,N01CA000000,,,26120160004B26100002-0-0-1,NCI:125716\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,; ,",  ;",,2/15/2017,2/14/2018,Cancer Control; Population Research; ,"Professional Support for Cancer Control and Population Based Research, NCI - Call Order No.2",,,,,,,,,125716,
9581129,N01,CA,,N,,,,,N01CA000000,,,26120170003B26100001-0-0-1,NCI:1780969\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,; ,",  ;",,9/22/2017,,Communication; Division of Cancer Control and Population Sciences; Services; ,"Communication Services for NCI/DCCPS; POP September 30, 2017-September 29, 2018.",,,,,,,,,1780969,
9581238,N01,HL,,N,,,,,N01HB000000,,,268201100002I-0-26800004-1,NHLBI:3154514\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,15266076; ,"UPTON, BLAKE ;",,9/30/2017,3/31/2019,Address; Adult; Affect; Area; Basic Science; Biometry; Blood; Clinical Research; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; data management; Data Set; Databases; Development; Documentation; Ensure; Epidemic; Epidemiology; expiration; HIV; improved; International; international center; Laboratories; Laboratory Study; Link; Manuals; Medical; Medicine; member; Monitor; Observational Study; Online Systems; operation; Patient Education; Patients; Phase; Privatization; Procedures; programs; protocol development; Protocols documentation; Public Health; Publications; Research; Research Activity; Research Personnel; Resources; Retrieval; Risk; Safety; Secure; Site; Site Visit; Surveys; System; Training; Training and Education; Transfusion; Translational Research; transmission process; web site; ,REDS III - Phase 3 - Data Coordinating Center,,,,,,,,,3154514,
9581358,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100074-1,NCI:32081\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,6/20/2017,9/11/2017,behavioral/social science; Cancer Control Research; cancer prevention; career; Development; Educational workshop; meetings; Research Personnel; ,IGF::OT::IGF Task Order 74: 2017 Behavioral and Social Sciences (BSS) Early Career/Junior Investigator Meeting: A Workshop on Professional Development in Cancer Prevention and Control Research,,,,,,,,,32081,
9581371,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100058-1,NCI:9923\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,11/4/2016,2/3/2017,meetings; Natural Language Processing; ,"IGF::OT::IGF  Natural Language Processing Meeting, December 8-9, 2016; POP November 4, 2016 - February 3, 2017. Labor for NLP",,,,,,,,,9923,
9581378,N01,CA,,N,,,,,N01CA000000,,,261201200010I-0-26100027-1,NCI:137545\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FAIRFAX,UNITED STATES,,11,66783721,US,10030448,"ICF MACRO, INC.",VA,220316050,,; ,",  ;",,2/1/2017,,Communication; Division of Cancer Control and Population Sciences; National Cancer Institute; ,"IGF::OT::IGF ICF - HHSN261201200010I, Task Oder 27 - NCI Workforce Analysis Communication Products for the National Cancer Institute Division of Cancer Control and Population Sciences; Period of perfo",,,,,,,,,137545,
9581388,N02,CA,,N,,,,,N02CA000000,,,261201700064A-0-0-1,NCI:48000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALEXANDRIA,UNITED STATES,,8,175355734,US,3641001,NATIONAL CANCER REGISTRAR'S ASSOCIATION,VA,223141693,,15327127; ,"ALLEN, NANCY ;",,9/1/2017,8/31/2018,cancer registrars; Computer software; Contractor; Evaluation; Methodology; ,IGF::OT::IGF OTHER FUNCTIONS.  Technical Assistance for Cancer Registrar Tasks. POP 9/1/17 - 8/31/18.  Please see attached SOW.,,,,,,,,,48000,
9581405,N02,CA,,N,,,,,N02CA000000,,,261201700689P-0-0-1,NCI:16550\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BERKELEY,UNITED STATES,,,139027663,US,,AMERICAN NONSMOKERS  RIGH,CA,947022000,,15327173; ,"HALLETT, CYNTHIA ;",,9/22/2017,9/21/2018,Databases; Health Services Accessibility; ,IGF::OT::IGF services to access to the Smokefree Ordinance Database ,,,,,,,,,16550,
9582795,N01,DA,,N,,,,,N01DA000000,,,271201700008C-0-0-1,NIDA:856466\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,RICHMOND,UNITED STATES,,3,105300446,US,353201,VIRGINIA COMMONWEALTH UNIVERSITY,VA,232980568,,14949883; ,"BEARDSLEY, PATRICK ;",,2/22/2017,2/21/2018,addiction; Animal Model; Behavior; Collaborations; Contracts; Data; Disease; Drug abuse; Drug Addiction; Evaluation; Food; in vivo; International; Laws; Modeling; National Institute of Drug Abuse; novel; Opioid; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Physical Dependence; pre-clinical; prevent; Primates; programs; Psychological reinforcement; receptor; Reporting; Research; Rodent; Schedule; Self Stimulation; Street Drugs; symposium; Testing; Treaty; ,IGF::OT::IGF: PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.,,,,,,,,,856466,
9587850,N01,NS,,N,,,,,N01NS000000,,,26320100141B26500001-0-0-1,NINDS:52484\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,WASHINGTON,UNITED STATES,,,42441001,US,,MDB INC,DC,200364382,,; ,",  ;",,6/12/2017,12/31/2017,American; meetings; Neurologic; Services; ,IGF::CL::IGF: This service is for Meeting planning and administration for the American neurological association (ANA) meeting,,,,,,,,,52484,
9587870,N01,NS,,N,,,,,N01NS000000,,,265201700016P-0-0-1,NINDS:24999\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,ARLINGTON,UNITED STATES,,,79691359,US,,,VA,222023505,,; ,",  ;",,8/24/2017,8/23/2018,meetings; symposium; ,"IGF::CL::IGF: This order is for Meeting Room, Breakout room for 3 conference dates with a POP:7/25/2017-01/31/2018",,,,,,,,,24999,
9591732,N01,OD,,N,,,,,N01OD000000,,,26320170082B26300003-0-0-1,NEI:75163\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,NORTHAMPTON,UNITED STATES,,,825136117,US,,,MA,10603267,,; ,",  ;",,9/13/2017,8/31/2018,Academy; Agreement; Anniversary; Area; Calendar; Communication; Communities; Contractor; digital; digital media; Education; Eye; Health; Health Communication; Hispanics; Language; Latino; Measures; Mission; National Eye Institute; news; outreach; population health; programs; Reporting; Research; Research Support; Resource Sharing; Resources; Science; Services; social media; tool; Translating; Translations; United States National Institutes of Health; Update; Vision; ,IGF::OT::IGF NEI Communications and Outreach Support Services- Spanish-language support ,,,,,,,,,75163,
9594197,N02,DA,,N,,,,,N02DA000000,,,271201400119C-3-0-2,NIA:329280\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15327383; ,"WONG, DEAN ;",,9/29/2014,9/28/2018,,IGF::OT::IGF PET Tau Imaging in the BLSA for the NIA,,,,,,,,,329280,
9594237,N01,OD,,N,,,,,N01OD000000,,,263201200074I-2-26300066-2,NIA:20000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15134078; ,"WESTBROOK, DAVID ;",,6/29/2015,6/28/2018,,IGF::OT::IGF: ROUNDTABLE ON GENOMICS AND PRECISION HEALTH,,,,,,,,,20000,
9594259,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300114-1,NIA:30000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14921829; ,"WESTBROOK, DAVID ;",,1/30/2017,1/29/2018,,"IGF::OT::IGF: FORUM ON AGING, DISABILITY, AND INDEPENDENCE",,,,,,,,,30000,
9594334,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300134-1,NIA:50000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15266067; ,"MOLYE, ELIZABETH ;",,9/15/2017,2/27/2019,,IGF::OT::IGF: PARTIAL SUPPORT FOR ACTIVITIES ON THE DEMOGRAPHY OF SEXUAL AND GENDER MINORITIES,,,,,,,,,50000,
9607211,R01,AI,3,N,12/26/2017,12/26/2017,11/30/2018,855,R01AI123323,,PA-13-302,3R01AI123323-02S1,NIAID:98542\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,78200995,US,861001,FRED HUTCHINSON CANCER RESEARCH CENTER,WA,981094433,,9239370; ,"PRLIC, MARTIN ;","KELLY, HALONNA R",12/1/2016,11/30/2021,adaptive immune response; Address; Affect; Age; Antigen Presentation; Antigen-Presenting Cells; Antigens; B-Lymphocytes; Biological Models; CD8-Positive T-Lymphocytes; Cell Compartmentation; cell killing; Cell physiology; Cells; Cellular Immunology; Communicable Diseases; Cues; cytokine; cytotoxic; Data; Dendritic Cells; design; Elderly; Engineering; Ensure; experimental study; Goals; Granzyme; Health; Human; Immune response; Immunity; Immunization; improved; Infection; Inflammation; Inflammatory; inhibitor/antagonist; innovation; Interleukin-12; Interleukin-15; Interleukin-18; Killings; Lead; Ligands; Measures; Mediating; Memory; Memory B-Lymphocyte; Morbidity - disease rate; mortality; mouse model; Mus; Nature; novel; Outcome; pathogen; perforin; Phenotype; Play; Population; Populations at Risk; Process; Receptor Signaling; Reporting; Research; response; Role; Signal Transduction; T cell response; T memory cell; T-Cell Receptor; T-Lymphocyte; Testing; Therapeutic; Time; Vaccination; vaccine development; vaccine efficacy; vaccine response; Vaccines; Vulnerable Populations; ,Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity,123323,ZRG1,Special Emphasis Panel ,,S1,2,55990,42552,98542,
9349747,H79,HH,1,N,9/19/2016,9/30/2016,9/29/2017,239,H79AE000103,,RFA-HS-16-001,1H79AE000103-01,,OTHERS,2016,DEPARTMENT OF HEALTH & HUMAN SERVICES,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,7255653; ,"BERGER, LAWRENCE M;",,9/30/2016,9/29/2021,,Poverty Research Center,103,ZAE1,Special Emphasis Panel ,,,1,,,,
9392924,R01,HL,5,N,12/27/2017,12/1/2017,11/30/2018,837,R01HL122323,SCHOOLS OF MEDICINE,PA-13-302,5R01HL122323-04,NHLBI:641447\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,PHYSIOLOGY,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,1866720; ,"METZGER, JOSEPH MARK;","WONG, RENEE P",12/1/2014,11/30/2018,Adult; amphiphilicity; base; Cardiac; Cardiac Myocytes; Cardiomyopathies; Cell Death; Cell model; Cell physiology; Cell surface; Cell Survival; Cellular Membrane; Cessation of life; Chemical Engineering; Chemicals; Clinical; clinically relevant; Complex; copolymer; Coupled; Dissection; Event; Family suidae; Functional disorder; Health; Heart; Human; improved; In Vitro; in vivo; in vivo Model; induced pluripotent stem cell; Inherited; insight; Ischemia; Mediating; Membrane; Mitochondria; mitochondrial membrane; Modeling; Muscle Cells; Muscular Dystrophies; Myocardial; Myocardial dysfunction; Myocardial Ischemia; Myocardium; novel therapeutics; Pathogenesis; Pathway interactions; Patients; Performance; Physiology; Poloxamers; Production; public health relevance; Pump; Reactive Oxygen Species; Reperfusion Injury; Reperfusion Therapy; Rodent; Role; Sarcolemma; Stress; Structure; Surface; Testing; Therapeutic; Time; tool; Translating; Translations; Work; ,Targeted membrane integrity in cardiac ischemia and reperfusion,122323,MIM,Myocardial Ischemia and Metabolism Study Section ,,,4,422005,219442,641447,
9403207,R01,HD,5,N,12/27/2017,12/1/2017,11/30/2018,865,R01HD058730,SCHOOLS OF ARTS AND SCIENCES,PA-13-302,5R01HD058730-08,NICHD:282946\,Non-SBIR/STTR RPGs,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PHILADELPHIA,UNITED STATES,BIOLOGY,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,8827715; 8854381 (contact); ,"BLACK, BEN E.; LAMPSON, MICHAEL ALTERMAN (contact);","TAYMANS, SUSAN",8/1/2008,11/30/2020,Address; Age; Aneuploidy; Animals; Assisted Reproductive Technology; base; Biophysics; Cell Cycle; Cell Cycle Arrest; Cell Cycle Progression; Cells; Centromere; centromere protein A; Childbirth; Chromosome Segregation; Chromosomes; cohesin; cohesion; Complex; Coupled; Data; Defect; design; Deuterium; Development; DNA; DNA biosynthesis; DNA Methylation; DNA Sequence; Embryo; Epigenetic Process; experimental study; Female; Fertility; G1 Phase; Genetic; Genome; Germ Cells; Goals; Health; Histone H3; Histones; Hormonal; Human; Hydrogen; In Vitro; in vivo; Infertility; insight; interdisciplinary approach; Kinetochores; Knock-out; knockin animal; Knockout Mice; Longevity; Maintenance; Mass Spectrum Analysis; Maternal Age; Meiosis; Meiotic Prophase I; Molecular; Mus; mutant; Nucleosomes; oocyte maturation; Oocytes; Point Mutation; Primordial Follicle; programs; Prophase; protein structure; Proteins; reconstitution; reproductive; Reproductive Biology; reproductive fitness; Research; Resolution; response; Rest; sex; Sister Chromatid; Somatic Cell; stability testing; Stimulus; structural biology; Structure; Testing; Time; Variant; Woman; Work; ,Age and molecular mechanisms contributing to aneuploidy in oocytes,58730,CMIR,"Cellular, Molecular and Integrative Reproduction Study Section ",,,8,179100,103846,282946,
9414204,R21,CA,1,N,12/25/2017,12/26/2017,11/30/2018,395,R21CA221683,,PAR-16-176,1R21CA221683-01,NCI:229576\,Non-SBIR/STTR RPGs,2018,NATIONAL CANCER INSTITUTE,,BOSTON,UNITED STATES,,7,76580745,US,1464901,DANA-FARBER CANCER INST,MA,22155450,,6410805; ,"CARRASCO, RUBEN D;","ARYA, SURESH",12/26/2017,11/30/2019,Active Sites; Address; angiogenesis; anticancer activity; Apoptosis; Automobile Driving; base; BCL9 gene; beta catenin; Binding; Biochemical; Biological; Biological Assay; Bioluminescence; Biophysics; Calorimetry; Cancer Model; Cancer Patient; cancer therapy; Cell Proliferation; Cells; Cellular Assay; Chemicals; Clinical; Colorectal Cancer; Complex; Crystallization; Data; design; Development; DNA; Drosophila genus; drug discovery; Electron Transport Complex III; Ensure; enthalpy; Epithelial; Evaluation; Event; Exhibits; Future; Gastric Adenocarcinoma; Gene Expression; Genes; Genetic Transcription; Goals; high throughput screening; Homeostasis; Homologous Gene; Human; Immunoprecipitation; improved; In Vitro; in vitro activity; in vivo; in vivo Model; inhibitor/antagonist; innovation; Intervention; Libraries; Lung Adenocarcinoma; Lymphoma; Malignant Neoplasms; malignant stomach neoplasm; Measurement; Mediating; Medicine; Methods; migration; Molecular; Molecular Probes; Monitor; Morphologic artifacts; Multiple Myeloma; next generation; Normal tissue morphology; novel; novel therapeutic intervention; Nuclear; Oncogenic; overexpression; Pathogenesis; Pathway interactions; Patient-Focused Outcomes; Patients; peptidomimetics; Pharmaceutical Preparations; Pharmacology; Play; pluripotency; Poisons; Porcupines; Pre-Clinical Model; Preclinical Testing; Proteins; Public Health; Reporter; research clinical testing; Role; screening; self-renewal; Signal Pathway; Signal Transduction; Site; small molecule; small molecule inhibitor; Source; Specificity; Stem cells; Stomach Carcinoma; Structure; Structure-Activity Relationship; Surface; Synthesis Chemistry; T cell factor 4; targeted cancer therapy; targeted treatment; TCF7L2 gene; Testing; Therapeutic; Time; Tissues; Titrations; tool; Toxic effect; Transcription Coactivator; Transgenic Mice; Translating; Treatment Cost; tumor; Tumor Cell Biology; Work; X-Ray Crystallography; Xenograft procedure; ,Development of molecular probes to investigate and drug the oncogenic Wnt/?-catenin/BCL9/B9L transcriptional complex,221683,ZCA1,Special Emphasis Panel ,,,1,130500,99076,229576,
9415744,R01,DK,1,N,12/25/2017,12/25/2017,7/31/2018,847,R01DK115366,SCHOOLS OF MEDICINE,PA-16-160,1R01DK115366-01,NIDDK:369000\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,,VALHALLA,UNITED STATES,PHARMACOLOGY,17,41907486,US,5948901,NEW YORK MEDICAL COLLEGE,NY,105951524,,10417771; ,"LIN, DAO-HONG ;","KETCHUM, CHRISTIAN J",12/25/2017,8/31/2020,absorption; Alanine; Alkalosis; Apical; base; basolateral membrane; Binding; Binding Sites; Chronic Kidney Failure; Co-Immunoprecipitations; Data; Development; Diet; Disease; Distal; Distal convoluted renal tubule structure; Excretory function; experimental study; Goals; Heart failure; hyperkalemia; Hypertension; Hypokalemia; Hypomagnesemia; Intake; inward rectifier potassium channel; Kidney; Knock-out; Knockout Mice; Knowledge; Lead; loss of function mutation; Mediating; Membrane; Membrane Potentials; Metabolic; mouse model; Mus; Mutation; Nephrons; novel; novel strategies; Phenotype; Phosphoric Monoester Hydrolases; Play; Potassium Channel; Protein Sequence Analysis; Regulation; Reporting; Role; Sesame - dietary; Syndrome; Testing; Threonine; Transmembrane Transport; ubiquitin-protein ligase; Ubiquitination; Up-Regulation; Urine; wasting; ,Kir5.1 regulates Kir4.1 ubiquitination by Nedd4-2 in DCT,115366,ZRG1,Special Emphasis Panel ,,,1,225000,144000,369000,
9420122,R01,MH,1,N,12/26/2017,12/27/2017,10/31/2018,242,R01MH114877,SCHOOLS OF ARTS AND SCIENCES,PA-16-160,1R01MH114877-01,NIMH:411666\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF MENTAL HEALTH,,BOSTON,UNITED STATES,PSYCHOLOGY,7,49435266,US,10001093,BOSTON UNIVERSITY (CHARLES RIVER CAMPUS),MA,22151390,,11595325; ,"REINHART, ROBERT ;","BUHRING, BETTINA D",12/27/2017,10/31/2022,Adaptive Behaviors; adaptive learning; addiction; Anodes; Architecture; Area; Attention deficit hyperactivity disorder; Autistic Disorder; Avoidance Learning; base; Basic Science; Behavior; Behavior Control; behavior measurement; Behavioral; Behavioral Mechanisms; Beta Rhythm; Boston; Brain; Brain Diseases; Cathodes; Clinical; Cognition; Cognitive; Communication; Computer Simulation; Data; Data Collection; density; Development; Double-Blind Method; Electric Stimulation; Electroencephalography; Electrophysiology (science); Ensure; Environment; executive function; experimental study; Failure; Feedback; flexibility; Frequencies; frontal lobe; Gilles de la Tourette syndrome; Goals; Hour; Human; Impairment; improved; indexing; Individual; information processing; insight; interest; Intervention; Knowledge; Laboratories; Lateral; learned behavior; Learning; Maintenance; Measurement; Measures; Medial; Methodology; Methods; Modality; Modeling; Motor; Motor Cortex; neuroimaging; neuromechanism; neurophysiology; neuropsychiatric disorder; neuroregulation; Neurosciences; Neurosciences Research; neurotransmission; next generation; novel; Parkinson Disease; patient population; Performance; Periodicity; Pharmaceutical Preparations; Phase; Physiological; power analysis; Prefrontal Cortex; Procedures; programs; Punishment; reconstruction; relating to nervous system; Reproducibility; Research; Research Personnel; response; Rewards; Sample Size; Schizophrenia; Sensory; sensory cortex; Signal Transduction; Source; success; support network; System; Techniques; Technology; Testing; Theta Rhythm; tool; Universities; ,Causal Restructuring of Neural Rhythms Improves Adaptive Behavior,114877,CP,Cognition and Perception Study Section ,,,1,250000,161666,411666,
9424240,R01,HD,1,N,12/27/2017,12/27/2017,11/30/2018,865,R01HD093780,SCHOOLS OF PUBLIC HEALTH,PA-16-160,1R01HD093780-01,NICHD:546475\,Non-SBIR/STTR RPGs,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CHICAGO,UNITED STATES,PUBLIC HEALTH & PREV MEDICINE,7,98987217,US,577703,UNIVERSITY OF ILLINOIS AT CHICAGO,IL,606127224,,9017073; ,"MEHTA, SUPRIYA DINESH;","CHAKHTOURA, NAHIDA ABDO",12/27/2017,11/30/2021,14 year old; 16 year old; 18 year old; 19 year old; Adolescent; Adult; Affect; Africa South of the Sahara; Age; aged; Anaerobic Bacteria; Area; arm; Award; Bacterial Vaginosis; base; Behavior; Chlamydia trachomatis; Clinical; Coercion; Communities; cost; cost effective; Counseling; County; Couples; Detection; Development; Disease; Drops; Epidemic; Escherichia coli; Evolution; Feasibility Studies; Female Adolescents; Funding; General Population; girls; global health; Health; High Risk Woman; HIV; HIV Infections; HIV risk; HIV Seropositivity; HIV/STD; Human Herpesvirus 2; Hygiene; Incidence; Infection; International; Intervention; Investigation; Kenya; Knowledge; Lactobacillus; Life; low and middle-income countries; male; Male Circumcision; Marketing; Measures; Medical Research; microbial community; microbiome; Neisseria gonorrhoeae; Nested Case-Control Study; novel; Organism; Outcome; pandemic disease; Participant; Prevalence; Prevention; Preventive Intervention; Randomized; Randomized Controlled Trials; reproductive; Reproductive Health; Research; Research Personnel; Resources; Risk; Risk Reduction; rRNA Genes; Safety; Sampling; scale up; Schools; Secondary Schools; Selection Bias; sex; Sex Behavior; sexual debut; Sexual Partners; Soaps; Structure; Student Dropouts; Swab; systematic review; Testing; Therapeutic Intervention; Time; tool; transmission process; Trichomonas vaginalis; Trust; uptake; Vagina; vaginal microbiome; Visit; Woman; ,"Menstrual cups, maturation of the adolescent vaginal microbiome, and STI/HIV risk",93780,IRAP,"Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section ",,,1,395548,150927,546475,
9430046,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-11,NIAID:109803\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Categories; Chemistry; Development; Intervention; Lead; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; programs; Services; Therapeutic; therapy development; Translational Research; ,Task Order 2: The Interventional Agent Development Services Program,,,,,,,,,109803,
9430127,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-99,NCI:4401768\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Antibodies; Clinical; Communities; cost; Intellectual Property; Laboratories; Malignant Neoplasms; Monoclonal Antibodies; programs; Proteomics; Research; ,Antibody Characterization ,,,,,,,,,4401768,
9430191,N01,AI,,N,,,,,N01AI000000,,,272201300003C-6-0-1,NIAID:1039277\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,67180786,US,1301901,FAMILY HEALTH INTERNATIONAL,NC,277012478,,12674697; ,"CHEN, MARIO ;",,12/31/2012,12/30/2017,Africa; Asia; Clinical Research; Clinical Sciences; Communicable Diseases; design; Developing Countries; International; Latin American; Research; Research Personnel; Research Project Grants; Research Support; South American; ,International Clinical Sciences Support (ICSS) ,,,,,,,,,1039277,
9430275,N01,HL,,N,,,,,N01HL000000,,,268201600002C-2-0-1,NCI:0\NHLBI:1077667\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,COLUMBUS,UNITED STATES,,3,832127323,US,6218701,OHIO STATE UNIVERSITY,OH,432101016,,14368947; ,"KOCH, ELLEN ;",,10/15/2015,10/14/2017,Cardiovascular Diseases; Communities; Contracts; follow-up; Knowledge; Mentors; older women; Research Personnel; Resources; Women's Health; ,IGF::CT::IGF WOMEN HEALTH INITIATIVE - REGIONAL CENTER,,,,,,,,,1077667,
9430288,N01,AI,,N,,,,,N01AI000000,,,272201200010C-15-0-4,NIAID:663880\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,52,603880287,US,2465301,LA JOLLA INST FOR ALLERGY & IMMUNOLGY,CA,920371387,,12576841; ,"SETTE, ALESSANDRO ;",,12/15/2012,12/14/2017,Algorithms; Alleles; Allergens; Alloantigen; Amino Acids; analytical tool; Animals; Antibodies; Antigens; Attention; Autoantigens; Autoimmune Diseases; Binding; Biological; Bioterrorism; Categories; Communities; Computer software; Contractor; Databases; Development; Disease; Documentation; Epitope Mapping; Epitopes; Frequencies; Graves' Disease; Human; Imagery; Immune; immunogenicity; improved; Insulin-Dependent Diabetes Mellitus; Ligands; Link; Literature; Lupus; Methods; MHC Class I Genes; Modeling; Molecular; Molecular Conformation; Multiple Sclerosis; Myasthenia Gravis; National Institute of Allergy and Infectious Disease; nonhuman primate; Online Systems; pathogen; Peptides; Population; prediction algorithm; programs; protein structure; Proteins; Publications; Publishing; relational database; Research; Resources; Rheumatoid Arthritis; Series; Source; Source Code; Systemic Lupus Erythematosus; T-Lymphocyte Epitopes; three dimensional structure; tool; Toxin; Validation; web site; ,"IEDB for Multiple sclerosis,  Rheumatoid Arthritis, Lupus, and Type 1 Diabetes",,,,,,,,,663880,
9430300,N01,HL,,N,,,,,N01HL000000,,,268201300028U-10-0-2,NIA:12500\NIAMS:727512\NICHD:50000\NIDCR:50000\NIDDK:50000\OD:50000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCKVILLE,UNITED STATES,,,876875154,US,,IQ SOLUTIONS INC,MD,208523046,,12576543; ,"HOLMES, KIM ;",,2/15/2013,1/14/2018,Asians; Awareness; Bone Diseases; bone health; Early Diagnosis; Early treatment; Education; General Population; Health Professional; Hispanics; Hyperparathyroidism; Individual; Information Dissemination; Knowledge; Language; Link; Low Literacy Population; men; Metabolic Bone Diseases; Osteitis Deformans; Osteogenesis Imperfecta; Osteoporosis; outreach; Pamphlets; Patients; Physicians; Populations at Risk; Prevention; Resources; United States Dept. of Health and Human Services; United States National Institutes of Health; Visual impairment; Woman; young man; ,NIH Osteoporosis and Related Bone Diseases~National Resource Center (NRC),,,,,,,,,940012,
9430305,N02,CA,,N,,,,,N02CO000000,,,261201300009C-15-0-1,NCI:3223761\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14770995; ,"MEHRINFAR, MAHZAD ;",,3/8/2013,1/31/2018,Cancer Center; cancer clinical trial; cancer diagnosis; cancer therapy; Clinical; Clinical Distribution; clinical investigation; Clinical Trials; computerized; Contractor; Contracts; Controlled Clinical Trials; Double-Blind Method; Equipment and supply inventories; Fire - disasters; Funding; Institution; Label; Monitor; National Cancer Institute; New Agents; open label; Patients; Pharmacologic Substance; Physicians; Placebo Control; Preclinical Drug Development; Process; programs; Records; Regulation; repository; research and development; Secure; Services; Specific qualifier value; System; Temperature; ,STORAGE AND DISTRIBUTION OF CLINICAL AGENTS ,,,,,,,,,3223761,
9430307,N01,AI,,N,,,,,N01AI000000,,,272201100018I-4-27200009-1,NIAID:1486\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,14396714; ,"PATTERSON, THOMAS ;",,2/1/2016,1/31/2017,Antifungal Agents; Biological Assay; Coccidioides posadasii; Contracts; Development; in vitro testing; Maintenance; pathogen; therapeutic development; Translational Research; ,Task A21: In vitro testing against fungal pathogens,,,,,,,,,1486,
9430333,N01,DA,,N,,,,,N01DA000000,,,271201400054C-7-0-2,NIDA:678958\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,15253548; ,"THOMAS, BRIAN ;",,11/21/2016,8/3/2017,Analytical Chemistry; analytical method; Chemicals; Databases; Detection; Documentation; Dosage Forms; drug testing; Ensure; Equipment and supply inventories; Excipients; Formulation; Government; Guidelines; improved; International; Methods; National Institute of Drug Abuse; Pharmaceutical Preparations; Pharmacologic Substance; potency testing; Quality Control; Recovery; Research Personnel; Sampling; Secure; Ships; Site; Specificity; stability testing; Stress Tests; Substance Use Disorder; symposium; Testing; ,"IGF::OT::IGF : Analytical Chemistry and Stability Testing of Treatment Drugs for Substance Use Disorders. August 4, 2014 - August 3, 2018. N01DA-14-8918. ",,,,,,,,,678958,
9430335,N02,DA,,N,,,,,N02DA000000,,,271201500009C-4-0-1,NINDS:1057759\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,,876875154,US,,IQ SOLUTIONS INC,MD,208523046,,12651344; ,"ANNE, GARRET ;",,1/1/2017,12/31/2017,Academy; American; Archives; Brain; Clinical Research; Contractor; Contracts; Data Analyses; Data Storage and Retrieval; Databases; Development; Electronic Mail; Ensure; Equipment and supply inventories; Exhibits; Institutes; interest; Internet; Language; Letters; Literature; Location; Maintenance; Maryland; meetings; Mission; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Neurology; Neurosciences; Pamphlets; Photocopying; post stroke; Preparation; Procedures; Professional Organizations; programs; Publications; Research; Research Support; response; Services; Site; Societies; System; Telephone; United States National Institutes of Health; United States Public Health Service; Work; Writing; ,IGF::OT::IGFIQ SOLUTIONS INC:1108271 [15-003267],,,,,,,,,1057759,
9430342,N01,AI,,N,,,,,N01AI000000,,,272201300018I-2-27200012-1,NIAID:520509\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14605367; ,"MULLIGAN, MARK ;",,6/15/2016,3/15/2019,Antimicrobial Resistance; Bacterial Drug Resistance; Clinical Research; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Diagnostics Research; Individual; Lower Respiratory Tract Infection; named group; pathogen; Population; programs; Resources; Therapeutic Human Experimentation; Translational Research; ,VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI),,,,,,,,,520509,
9430345,N01,DA,,N,,,,,N01DA000000,,,271201600002C-2-0-1,NIMH:1509519\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SEATTLE,UNITED STATES,,7,78198520,US,3080503,KAISER FOUNDATION HEALTH PLAN OF WASHINGTON,WA,981011466,,14786557; ,"UNKNOWN, UNKNOWN ;",,4/25/2016,12/24/2017,Address; Adolescent; Algorithms; Antipsychotic Agents; Behavioral; Child; Community of Practice; Community Practice; Development; disturbance in affect; Emotional; Guidelines; Pharmaceutical Preparations; predicting response; Problem behavior; Psychotic Disorders; Research; Testing; tool; Youth; ,A Targeted Approach To A Safter Antipsychotic In Youth,,,,,,,,,1509519,
9430346,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300003-1,NIEHS:618549\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14595749; ,"WAGNER, DAVID ;",,6/18/2016,6/17/2017,Clinical Research; Clinical Trials; Consent Forms; Contractor; Contracts; Development; Institutional Review Boards; Intervention; National Institute of Environmental Health Sciences; operation; Principal Investigator; Procedures; protocol development; Protocols documentation; quality assurance; Quality Control; Recruitment Activity; Reporting; Research; Research Support; Resources; Services; Statistical Data Interpretation; Work; ,Clinical Research Support Services for NIEHS Contract Task Order 3 - Protocol Development and Support,,,,,,,,,618549,
9430350,N01,AI,,N,,,,,N01AI000000,,,272201300016I-1-27200010-1,NIAID:176071\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,14708075; ,"WOODALL, AMY ;",,11/14/2016,6/29/2018,Clinical; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Respiratory Syncytial Virus Vaccines; Vaccines; ,Vaccine Treatment and Evaluation Unit: Concept and Protocol Development,,,,,,,,,176071,
9430365,N01,AI,,N,,,,,N01AI000000,,,272201100007I-4-27200001-1,NIAID:269229\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FORT COLLINS,UNITED STATES,,2,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805231062,,11173683; ,"KENNETH, OLSON ;",,7/5/2016,7/31/2017,Arboviruses; Biological Assay; Contracts; Culicidae; Development; Fever; in vitro testing; Insecticides; Maintenance; Parasites; Prevention; Research; Testing; vector; Zika Virus; ,Task C3: Testing an insecticidal agent against mosquitos harboring arboviruses (Zika fever),,,,,,,,,269229,
9437646,N01,AI,,N,,,,,N01AI000000,,,272201300006C-9-0-1,NIAID:675305\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12582711; ,"ALTMAN, JOHN ;",,3/21/2013,3/20/2020,Alleles; Antigens; Custom; Disease; Human; Immune; Immunology; improved; Major Histocompatibility Complex; Mediating; microbial; Mus; Neoplasm Metastasis; new technology; nonhuman primate; pathogen; Peptides; Production; Reagent; Research; T-Lymphocyte; tumor; United States National Institutes of Health; ,Tetramers for Immune-mediated Diseases Research,,,,,,,,,675305,
9437647,N01,AI,,N,,,,,N01AI000000,,,272201300006C-9-0-2,NIAID:322000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12582709; ,"ALTMAN, JOHN ;",,3/21/2013,3/20/2020,Acquired Immunodeficiency Syndrome; Alleles; Antigens; Custom; Disease; Human; Immune; Immunology; improved; Major Histocompatibility Complex; Mediating; microbial; Mus; Neoplasm Metastasis; new technology; nonhuman primate; pathogen; Peptides; Production; Reagent; Research; T-Lymphocyte; tumor; United States National Institutes of Health; ,Tetramers for AIDS Research And AIDS-related Research,,,,,,,,,322000,
9441644,N01,AI,,N,,,,,N01AI000000,,,272201400004I-2-27200001-1,NIAID:976\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HIGHLAND HEIGHTS,UNITED STATES,,,184227809,US,,,KY,410769167,,14369272; ,"HENDERSON, CICILY ;",,10/30/2015,3/31/2017,Clinical; Clinical Research; Communicable Diseases; Laboratories; National Institute of Allergy and Infectious Disease; research study; Research Support; Services; ,CLINICAL CENTRAL LABORATORY SERVICES,,,,,,,,,976,
9443553,N01,ES,,N,,,,,N01ES000000,,,273201400022C-7-0-2,NIEHS:64581\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,12627954; ,"FERNANDO, RESHAN ;",,7/30/2014,2/28/2018,Adverse effects; Biological; Chemicals; Chemistry; Contracts; data modeling; Development; disorder prevention; Dose; efavirenz; emtricitabine; Ensure; Environmental Exposure; Evaluation; Exposure to; Formulation; Goals; Hazard Identification; Hazardous Chemicals; Health; Heightened Cancer Risk; HIV; Human; Mono-S; Mus; National Toxicology Program; Outcome; Performance; public health research; Risk Assessment; Risk Factors; Sampling; Services; sound; Specific qualifier value; Tenofovir; Teratology; Testing; Therapeutic; Toxic effect; Toxicity Tests; Toxicokinetics; Toxicology; ,"Chemistry Services for the National Toxicology Program, Sub 2",,,,,,,,,64581,
9446098,U19,AI,1,N,12/28/2017,12/1/2017,11/30/2018,,U19AI135817,,RFA-AI-16-027,1U19AI135817-01,NIAID:86134\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,76647908,US,8961401,BENAROYA RESEARCH INST AT VIRGINIA MASON,WA,981012795,,2061597; ,"LINSLEY, PETER S.;",,,,Allergens; Allergic Disease; Allergy to peanuts; analytical tool; Antigens; Automobile Driving; Biological Markers; CD4 Positive T Lymphocytes; Cell Differentiation process; Cells; Cluster Analysis; Color; Complement; Cytometry; Data; Databases; design; Epitopes; experience; experimental study; Flow Cytometry; Gene Expression; Gene Expression Profiling; Genes; Heterogeneity; Histocompatibility Antigens Class II; Immune; Immune Tolerance; Immunology; Immunotherapy; improved; Individual; Knowledge; Laboratories; new technology; novel; oral immunotherapy; Pathway interactions; Patient Selection; Peptides; Phenotype; Play; Population; Process; Property; protein expression; repository; Role; single cell analysis; Statistical Data Interpretation; Supervision; Surface; System; Systems Biology; T-Cell Receptor; T-Lymphocyte Epitopes; Techniques; Technology; transcriptome; transcriptome sequencing; Work; ,Allergen T cell epitopes during the management of peanut allergic disease,135817,ZAI1,Special Emphasis Panel ,8608,,1,50667,35467,,86134
9446868,N01,AI,,N,,,,,N01AI000000,,,272200800005C-25-0-5,NIAID:194950\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12245161; ,"MULLIGAN, MARK ;",,11/1/2007,6/30/2017,Clinical Trials; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; Norovirus; novel; Phase I Clinical Trials; Population; Resources; Route; System; vaccine candidate; Vaccines; ,VACCINE AND EVALUTION TREATMENT UNITS:PHASE I CLINICAL TRIAL OF A NOROVIRUS VACCINE CANDIDATE,,,,,,,,,194950,
9446875,N01,AI,,N,,,,,N01AI000000,,,272201300017I-1-27200015-1,NIAID:157232\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14652686; ,"WARD, MARIANNE ;",,7/12/2016,10/26/2017,Antimicrobial Resistance; Biological Assay; Clinical; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Gram-Positive Bacteria; Individual; named group; operation; Population; programs; protocol development; Resources; therapeutic development; Vaccines; ,Vaccine and Treatment Evaluation Unit - Clinical Operations Support,,,,,,,,,157232,
9458645,N01,AI,,N,,,,,N01AI000000,,,272201000039I-1-27200018-1,NIAID:47538\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14670016; ,"MORREY, JOHN ;",,3/21/2017,7/20/2017,Animal Model; Contracts; Development; efficacy testing; Flavivirus; infectious disease model; Research; Standardization; Therapeutic; Vaccines; Zika Virus; ,Task A103: Small animal models for Zika and other flaviviruses,,,,,,,,,47538,
9533347,N01,HD,,N,,,,,N01HD000000,,,275201400003I-4-27500003-1,NICHD:32772\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,12447078; ,"PARSONS, CHRISTOPHER ;",,9/23/2016,9/22/2017,Air Pollution; Asthma; base; Blood; Blood specimen; Contract Services; Contractor; Dry Ice; Ensure; Equipment and supply inventories; Feces; Freezing; Government; Human; Human Resources; Laboratories; Liquid substance; Lung Inflammation; Methods; microbiome; Monitor; National Institute of Child Health and Human Development; Nitrogen; Performance; Perinatal; pregnancy immunology; Pregnancy Outcome; Pregnant Women; Program Research Project Grants; programs; repository; Research Personnel; Respiratory physiology; Sampling; Serum; Services; Ships; Specific qualifier value; Specimen; Testing; Tissues; Umbilical Cord Blood; Urine; ,HUMAN BIOSPECIMEN REPOSITORY - ASTHMA STUDY,,,,,,,,,32772,
9535021,N01,MH,,N,,,,,N01MH000000,,,271201300031C-7-0-1,NIMH:633198\NINDS:169681\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,NEW YORK,UNITED STATES,,13,78861598,US,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NY,100296574,,12321766; ,"HAROUTUNIAN, VAHRAM ;",,9/1/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ","NIMH, NICHD, AND NINDS BRAIN AND TISSUE REPOSITORY",,,,,,,,,802879,
9536537,N01,HL,,N,,,,,N01HB000000,,,268201200017C-11-0-1,NHLBI:42550\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,11301122; ,"FRANTZ, JOANNE ;",,1/10/2012,4/30/2018,"2 year old; Age; Applied Research; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; cohort; Collaborations; Collection; Contracts; design; Development; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Medical; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; research and development; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT),,,,,,,,,42550,
9536538,N01,HL,,N,,,,,N01HB000000,,,268201200014C-11-0-1,NHLBI:30327\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHARLESTON,UNITED STATES,,6,183710748,US,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,SC,294035120,,11301128; ,"JACKSON, SHERRON ;",,1/10/2012,4/30/2018,"2 year old; Age; Award; Best Pharmaceuticals for Children Act; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; clinical research site; cohort; Collaborations; Collection; Contracts; design; Diagnostic radiologic examination; double-blind placebo controlled trial; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Label; Laboratories; Life; Long-Term Effects; Lung; Monitor; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Natural History; Neuropsychology; Organ; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sickle Cell Anemia; standard of care; Structure; Testing; Toxic effect; United States Food and Drug Administration; ",AWARD OF BABY HUG FOLLOW UP STUDY II CLINICAL SITE.,,,,,,,,,30327,
9537856,N01,AI,,N,,,,,N01AI000000,,,272201700022I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,EDMONTON,CANADA,,,202499542,CA,,KMT HEPATECH INC,AB,T6G 2M9,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537904,N01,AI,,N,,,,,N01AI000000,,,272201700012I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9538113,N01,AI,,N,,,,,N01AI000000,,,272201400010I-4-27200001-1,NIAID:130657\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,10690505; ,"PTAK, ROGER ;",,8/1/2014,7/31/2018,Academia; base; Biochemical; Biological Assay; Cells; Contracts; Data; Development; Funding; high throughput screening; HIV; Investigational New Drug Application; Local Microbicides; Maintenance; National Institute of Allergy and Infectious Disease; novel therapeutics; phase I trial; preclinical development; Private Sector; product development; prospective; Public Health; public health priorities; quality assurance; Quality Control; Reporting; Research Personnel; service utilization; Services; Source; Test Result; Therapeutic; ,Administration and Data Coordination,,,,,,,,,130657,
9539090,N44,CA,,N,,,,,N44CA000000,,,261201700005C-0-0-1,NCI:1494124\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW YORK,UNITED STATES,,13,79212608,US,10039545,"YOUV LABS, INC.",NY,100276458,,15326988; ,"DUMONT, EMMANUEL ;",,1/20/2017,1/19/2019,Actinic keratosis; Anxiety; Basal cell carcinoma; Biological Markers; Cancer Etiology; cancer prevention; Car Phone; Characteristics; Clinical; Clinical Research; Coagulation Process; Computers; Contracts; Dermatologist; Devices; Diagnosis; DNA Damage; Education; Enrollment; Enzyme-Linked Immunosorbent Assay; experience; Goals; Health; High Prevalence; high risk; Histology; Individual; Information Systems; keratinocyte; Kidney; Lesion; Measurement; Measures; Mental Depression; Mental Health; Minor; mobile application; mobile computing; Monitor; Outcome; Patient Outcomes Assessments; patient population; Patients; Pharmaceutical Preparations; Population; portability; Premalignant; Public Health; Pyrimidine Dimers; Quality of life; Recruitment Activity; Research Design; Role; sensor; Skin; skin cancer prevention; Skin Carcinoma; skin squamous cell carcinoma; social; Squamous cell carcinoma; Sunscreening Agents; Surveys; Symptoms; System; Technology; Testing; Therapeutic immunosuppression; Time; tool; Transplant Recipients; ultraviolet; UV induced; UV Radiation Exposure; Validation; Work; ,TOPIC 342 - PHASE II CONTRACT - VALIDATION OF SHADE A MOBILE TECHNOLOGY FOR MONITORING OF ULTRAVIOLET EXPOSUREPOP - 1/20/2017 - 1/19/2019,,,,,,,,,1494124,
9539145,N01,AI,,N,,,,,N01AI000000,,,272201600045C-1-0-1,NIAID:6412369\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,,,,,220514820,,,,,,,14922276; ,"TRANTER, HOWARD ;",,9/27/2012,12/31/2017,Anthrax Vaccines; Biological Assay; Clinical Research; Cyclic GMP; Development; Formulation; Investigational Drugs; next generation; Process; product development; Reagent; stability testing; Support Contracts; Technology; Toxicology; Vaccines; Validation; ,VACCINE TECHNOLOGIES TO ADVANCE NEXT GENERATION ANTHRAX VACCINES,,,,,,,,,6412369,
9539152,N01,AI,,N,,,,,N01AI000000,,,272201700007C-1-0-1,NIAID:19855811\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BETHESDA,UNITED STATES,,,57052391,US,,TECHNICAL RESOURCES INC,MD,208171197,,14922297; ,"HOLMES, MELYNDA ;",,4/17/2017,4/16/2018,Clinical Research; clinical research site; Clinical Trials; Communicable Diseases; Logistics; Maintenance; Management Information Systems; Monitor; Operations Research; programs; Safety; Services; Support Contracts; ,DMID CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT,,,,,,,,,19855811,
9542479,N01,AI,,N,,,,,N01AI000000,,,272201300004I-0-27200006-1,NIAID:1593039\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,1,53785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,,15271218; ,"AYE, PYONE ;",,12/7/2016,2/6/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Attenuated; Award; base; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Macaca nemestrina; Modality; Modeling; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; Virus; ,Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine,,,,,,,,,1593039,
9542540,N01,AI,,N,,,,,N01AI000000,,,272201700004C-0-0-1,NIAID:16030454\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WILMINGTON,UNITED STATES,,7,362574527,US,4079901,"PPD, INC.",NC,284013331,,14961732; ,"VARGAS, MICHELLE ;",,2/1/2017,1/31/2018,Accelerometer; Acquired Immunodeficiency Syndrome; Address; Adherence; AIDS/HIV problem; Clinical; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contractor; Contracts; Country; Data; Development; Ensure; Grant; Guidelines; HIV Infections; HIV therapy; HIV vaccine; Investigation; Modality; Monitor; National Institute of Allergy and Infectious Disease; operation; Performance; Pharmacy facility; Phase; Prevention Measures; Preventive; Procedures; Process; Protocols documentation; public health emergency; quality assurance; Quality Control; Recommendation; Records; Reporting; Research; Research Project Grants; Research Support; response; Safety; Services; Site; Site Visit; System; Treatment Efficacy; vaccine efficacy; Visit; ,NIAID CLINICAL SITE MONITORING,,,,,,,,,16030454,
9542675,N01,DA,,N,,,,,N01DA000000,,,271201400045C-5-0-1,NICHD:1350000\NIMH:587854\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,12412304; ,"ZIELKE, H RONALD ;",,8/8/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ","THE NIMH, NICHD, AND NINDS BRAIN AND TISSUE REPOSITORY",,,,,,,,,1937854,
9543862,N01,AI,,N,,,,,N01AI000000,,,272201300003I-1-27200010-1,NIAID:465058\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,14498623; ,"LEWIS, MARK ;",,4/15/2016,7/14/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Development; DNA; Evaluation Studies; Funding; Grant; HIV; HIV envelope protein; HIV vaccine; Immune; immunogenicity; Investigator-Initiated Research; Local Microbicides; Modality; Modeling; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Regimen; Research Personnel; Research Project Grants; Resources; simian human immunodeficiency virus; Vaccination; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,"Study to investigate the immunogenicity and efficacy of a rVSV-HIVenv Prime, HIV envelope protein boost vaccination regimen and DNA-HIV Prime, rVSV-HIVenv boost vaccination regimen",,,,,,,,,465058,
9543914,N01,AI,,N,,,,,N01AI000000,,,272201400056C-7-0-2,NIAID:300000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LAWRENCE,UNITED STATES,,2,76248616,US,1484302,UNIVERSITY OF KANSAS LAWRENCE,KS,660457568,,14496474; ,"DAVID, SUNIL ;",,9/30/2014,9/29/2018,Adjuvant; Animal Model; Cells; Formulation; high throughput screening; Human; in vivo; Lead; novel; Pharmaceutical Chemistry; programs; receptor; Research; Signal Pathway; Structure-Activity Relationship; Vaccine Adjuvant; vaccine candidate; Validation; Work; Zika Virus; ,Adjuvant discovery: Zika,,,,,,,,,300000,
9544404,N01,AI,,N,,,,,N01AI000000,,,272201400006I-0-27200007-1,NIAID:1439619\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15017486; ,"MIRSALIS, JON ;",,5/1/2017,4/30/2018,Acquired Immunodeficiency Syndrome; Amikacin; Arts; Biological Assay; clinical investigation; co-infection; Contracts; Development; Development Plans; drug development; Formulation; HIV; HIV Infections; HIV therapy; Intervention; microbicide; Mitochondria; National Institute of Allergy and Infectious Disease; Pharmacologic Substance; Pharmacology and Toxicology; prevent; Research Personnel; Services; sexual HIV transmission; Therapeutic Agents; Toxic effect; transmission process; United States Dept. of Health and Human Services; United States National Institutes of Health; ,"PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN, TLC-ART-101, NDB-COMPOUNDS, SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF MITOCHONDRIAL TOXICITY ASSAYS",,,,,,,,,1439619,
9550882,N02,CA,,N,,,,,N02CM000000,,,261201400023C-6-0-1,NCI:6260330\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,12404448; ,"VALMONTE, CLAUDINE ;",,9/1/2014,8/31/2018,Institutional Review Boards; , CENTRAL INSTITUTIONAL REVIEW BOARD (CIRB),,,,,,,,,6260330,
9551395,N01,DA,,N,,,,,N01DA000000,,,271201500056C-3-0-1,NCCAM:47127\NICHD:5371\NIDA:21408\NINR:47293\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,EDWARDSVILLE,UNITED STATES,,15,6331342,US,1194503,SOUTHERN ILLINOIS UNIV AT EDWARDSVILLE,IL,620260001,,14264831; ,"HERNDON, CHRISTOPHER ;",,9/18/2015,9/17/2018,Dental Assistants; Diagnosis; Education; Educational Curriculum; Goals; Health Occupations; Medical; Mental Health; Pain; Pain management; Pharmacy facility; Physical therapy; repository; Resources; Training; United States National Institutes of Health; web site; ,NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION,,,,,,,,,121199,
9555905,N01,AI,,N,,,,,N01AI000000,,,272201500032C-2-0-1,NIAID:10790360\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,10626351,US,4494401,"MACROGENICS, INC.",MD,208503368,,14261273; ,"NORDSTROM, JEFFREY ;",,9/15/2015,8/23/2019,Address; Affinity; AIDS prevention; AIDS/HIV problem; Anti-Retroviral Agents; Antibodies; antiretroviral therapy; attenuation; base; Binding; Biological Products; Biological Response Modifier Therapy; Bone Marrow Transplantation; Cell Line; Clinical Research; Clinical Trials; Complement; Contractor; Cyclic GMP; Development; Disease remission; Drug Combinations; Engineering; Epidemic; HIV; HIV Antibodies; HIV vaccine; HIV-1; Human; Immune; Immunotherapeutic agent; improved; Infection; innovation; interest; Mediating; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; neutralizing antibody; Newborn Infant; novel; Outcome; Patients; Persons; Phase I Clinical Trials; programs; Property; Research; research clinical testing; Safety; Specificity; Technology; Testing; Therapeutic; Therapeutic Agents; Treatment Efficacy; Vaccine Design; Vaccines; Viral Load result; Virus; Work; ,DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION,,,,,,,,,10790360,
9556092,N01,ES,,N,,,,,N01ES000000,,,N01ES45525-27-0-1,NIEHS:7098237\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,605370733,US,10028392,"CODA RESEARCH, INC.",MD,209103737,,14782877; ,"SANDRA, HALVERSON ;",,8/23/2004,8/22/2018,Address; Affect; Age; aged; Back; base; Biological; Blood Banks; Blood specimen; Breast Cancer Risk Factor; cancer risk; case control; Case-Control Studies; Cessation of life; Clinical Course of Disease; cohort; Cohort Analysis; Cohort Studies; Collection; Complex; Data; data structure; design; Development; Diagnosis; Diet; Disease; disease diagnosis; disorder risk; DNA; Enrollment; Environmental and Occupational Exposure; Environmental Exposure; Environmental Risk Factor; Etiology; Exposure to; Family; follow-up; Future; gene environment interaction; General Population; Genes; Genetic; genetic risk factor; Health; House Dust; Joints; Life Style; lifestyle factors; malignant breast neoplasm; Malignant Neoplasms; Medical History; Medicine; non-genetic; novel; Nuclear Family; Occupational; Parents; Participant; Play; population based; prospective; Questionnaires; Recording of previous events; Reproductive History; Resources; Risk; Risk Factors; Role; Saliva; Sampling; Sister; Structure; Structure of nail of toe; Testing; Time; United States; Update; Urine; Woman; ,Environmental and Genetic Risk Factors for Breast Cancer,,,,,,,,,7098237,
9557704,N01,ES,,N,,,,,N01ES000000,,,316201200054W-3-0-1,NIEHS:4905765\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESTON,UNITED STATES,,,786520767,US,,VISTRONIX INC,VA,201915423,,; ,",  ;",,12/11/2015,12/10/2017,Collection; Contractor; Contracts; Data; data acquisition; data integration; Decision Making; Ensure; Environment; Environmental Exposure; experience; Exposure to; flexibility; Generations; Goals; Government; Government Agencies; hazard; Health; Human; Imagery; Knowledge; Logistics; Metadata; Methods; National Toxicology Program; Probability; Recommendation; Reporting; Research Design; Scientific Advances and Accomplishments; Scientist; sound; success; Technology; Toxic Environmental Substances; Toxicology; Work; ,IGF::OT::IGF 'Support for Toxicological Data for the National Toxicology Program',,,,,,,,,4905765,
9562943,N01,DA,,N,,,,,N01DA000000,,,271201600048C-1-0-1,NINDS:3722750\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,14769114; ,"WILCOX, KAREN ;",,9/30/2016,9/29/2018,Epilepsy; National Institute of Neurological Disorders and Stroke; programs; screening; ,IGF::OT::IGF OTHER FUNCTIONS NINDS EPILEPSY THERAPY SCREENING PROGRAM,,,,,,,,,3722750,
9564742,N02,CA,,N,,,,,N02CA000000,,,261201500010I-2-26100001-1,NCI:267367\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SOUTH SAN FRANCISCO,UNITED STATES,,,930243360,US,,,CA,940801934,,14270005; ,"JOHNSON, CHARLES ;",,9/30/2015,9/29/2018,Archives; base; Biology; Businesses; Characteristics; Charge; Chemical Structure; Chemicals; China; Collection; Contractor; Contracts; cost; cost effective; Custom; Data; Databases; Descriptor; design; Dimethyl Sulfoxide; Distributional Activity; Diversity Library; Documentation; Dry Ice; Ensure; Equipment; Equipment and supply inventories; falls; Film; flexibility; Government; High Pressure Liquid Chromatography; high throughput analysis; India; Individual; Informatics; Institutes; instrument; International; Ions; Libraries; Life; liquid chromatography mass spectrometry; Maintenance; Mass Fragmentography; member; Methods; Molecular; Monitor; planetary Atmosphere; Powder dose form; Property; quality assurance; Quality Control; Recording of previous events; Regulation; Research Infrastructure; Research Personnel; sample collection; Sampling; screening; Shipping; Ships; Solid; solid solution; Solvents; Specific qualifier value; Structure; Tube; Update; Vial device; ,"CBCSLC TASK ORDER FOR THE NCI CHEMICAL BIOLOGY CONSORTIUM, TO# 1 12 MONTH TASK ORDER BASE",,,,,,,,,267367,
9564755,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-10,NIAID:409394\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Coronaviridae; Coronavirus; Data; Equipment; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,409394,
9564756,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-11,NIAID:818791\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Dengue Virus; Equipment; Flavivirus; Human Resources; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; Zika Virus; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,818791,
9565464,N01,HD,,N,,,,,N01HD000000,,,275201300021I-4-27500001-1,NICHD:14654\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DAVIS,UNITED STATES,,3,47120084,US,577503,UNIVERSITY OF CALIFORNIA AT DAVIS,CA,956186153,,12445540; ,"CREININ, MITCHELL ;",,6/26/2017,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,14654,
9566072,N01,CA,,N,,,,,N01CA000000,,,261201200034I-2-26100010-1,NCI:1130914\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HOUSTON,UNITED STATES,,9,800772139,US,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,770304009,,14262602; ,"BROWN, POWEL ;",,9/24/2015,9/23/2018,cancer prevention; Clinical; Clinical Chemoprevention; Clinical Trials; clinically relevant; Conduct Clinical Trials; Contractor; Data; data management; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; interest; laboratory experiment; Maintenance; Malignant Neoplasms; meetings; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; prevention clinical trial; Preventive; programs; protocol development; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; , CORE INFRASTRUCTURE SUPPORT,,,,,,,,,1130914,
9567372,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500026-1,NICHD:5794\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15223728; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,Collection; Funding; Goals; Human; Institutes; interest; National Institute of Child Health and Human Development; Pilot Projects; repository; Research; Research Project Grants; Services; Ships; Specimen; ,REPOSITORY SERVICES FOR PULLS AND SHIPMENTS FOR PILOT STUDIES,,,,,,,,,5794,
9568704,N01,ES,,N,,,,,N01ES000000,,,273201600003I-1-27300001-1,NIEHS:563468\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14644165; ,"BARKER-CUMMINGS, CHRISTIE ;",,6/30/2016,6/29/2018,Adherence; Budgets; Contracts; Ensure; Epidemiology; falls; Modification; Monitor; Office of Administrative Management; Research Personnel; Resources; Services; Supervision; Support Contracts; TimeLine; Vendor; ,IGF::OT::IGF SUPPORT SERVICES FOR EPIDEMIOLOGY - TASK ORDER 1 - 'ADMINISTRATIVE MANAGEMENT AND SUPPORT',,,,,,,,,563468,
9568943,N43,AI,,N,,,,,N43AI000000,,,272201700069C-0-0-1,NIAID:224314\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BOSTON,UNITED STATES,,8,831908996,US,10024698,"SAMPLE6 TECHNOLOGIES, INC.",MA,22102377,,15327608; ,"KOERIS, MICHAEL ;",,8/1/2017,8/31/2018,Antibiotic susceptibility; Antibiotics; Antimicrobial Resistance; Bacterial Infections; Bacteriophages; base; Blood Tests; Communicable Diseases; Coupled; Development; Diagnostic; pathogen; Physicians; point of care; System; Testing; ,Phage-Based Blood Test to Detect Bacterial Infections at the Point of Care,,,,,,,,,224314,
9569066,N01,AI,,N,,,,,N01AI000000,,,272201100022I-0-27200011-4,NIAID:284619\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064949; ,"MIRSALIS, JON ;",,6/6/2017,6/5/2018,Antimicrobial Resistance; Chemistry; Clostridium difficile; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; Toxicology; Toxin; ,Task 11: Interventional Agent Development Services Program,,,,,,,,,284619,
9569211,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200023-1,NIAID:621114\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15195798; ,"WALTER, EMMANUEL ;",,9/16/2013,9/15/2023,Address; Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Drug Kinetics; Evaluation; Gram-Negative Bacterial Infections; Individual; named group; Population; programs; Protocols documentation; Resources; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS (VTEU): POPULATION PHARMACOKINETICS STUDY ,,,,,,,,,621114,
9569761,N01,HL,,N,,,,,N01HL000000,,,268201700004I-0-26800001-1,NHLBI:741784\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,JACKSON,UNITED STATES,,3,928824473,US,5390304,UNIVERSITY OF MISSISSIPPI MED CTR,MS,392164500,,6969315; ,"MOSLEY, THOMAS H;",,11/15/2016,11/14/2021,Abdomen; Adult; African American; aged; Ancillary Study; Ankle; Atherosclerosis; Atherosclerosis Risk in Communities; base; Behavioral; Behavioral Genetics; Carotid Arteries; caucasian American; Characteristics; Clinical; clinical development; clinical predictors; cognitive function; cohort; Cohort Studies; Collaborations; Communities; Contracts; Coronary heart disease; County; Data; Data Collection; Data Set; Event; follow-up; Fostering; Funding; Genetic; Geographic Locations; Goals; Grant; Heart failure; Hemostatic Agents; indexing; Laboratories; Measurement; middle age; Monitor; mortality; Myocardial Infarction; Natural History; operation; Participant; Photography; Policies; Process; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Recruitment Activity; Research Personnel; Retinal; Risk Factors; Risk Marker; rural setting; sharing data; socioeconomics; Structure of popliteal artery; Subgroup; suburb; Testing; trend; Ultrasonography; United States National Institutes of Health; Washington; ,IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - FIELD CENTER - CORE STUDY OPERATIONS,,,,,,,,,741784,
9569837,N01,OD,,N,,,,,N01OD000000,,,263201200074I-1-26300104-1,NICHD:10000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15227356; ,"WESTBROOK, DAVID ;",,9/26/2016,9/25/2018,,CONTRIBUTION TO THE NAS STANDING COMMITTEE,,,,,,,,,10000,
9570107,N01,AI,,N,,,,,N01AI000000,,,272201700008C-0-0-1,OD:1649153\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GAINESVILLE,UNITED STATES,,,2236250,US,,,FL,326110110,,14922300; ,"PRINDLE, BRIAN ;",,2/1/2017,1/31/2018,Acute; animal rule; Bacterial Translocation; Bone Marrow; Cells; Chronic; Contractor; Contracts; Dose; Drug Kinetics; FGF2 gene; Fibroblast Growth Factor; Gastrointestinal Agents; Granulocyte Colony-Stimulating Factor; improved; irradiation; Licensure; Modeling; Mucous Membrane; Mus; Peptides; Pharmacodynamics; Radiation; Rattus; Small Intestines; Syndrome; Toxic effect; ,A MULTIPOTENTIAL MITIGATION AGENT FOR GASTROINTESTINAL SYNDROME,,,,,,,,,1649153,
9571108,N01,HD,,N,,,,,N01HD000000,,,275201300010I-2-27500002-1,NICHD:391798\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,NEW YORK,UNITED STATES,,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323702,,12062832; ,"ALLEN, ERIN ;",,7/16/2013,12/31/2018,Acetates; Adherence; Adverse effects; Age; Amenorrhea; arm; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Dose; Drug Kinetics; emergency contraception; Estrogens; Hemorrhage; In Vitro; Interruption; malignant breast neoplasm; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Pharmacodynamics; pill; Population; progesterone receptor A; Progesterone Receptors; Progestins; Public Health; Randomized; Regimen; reproductive; Risk; Safety; Thromboembolism; Time; United States Food and Drug Administration; Uterine Fibroids; Venous; Woman; ,CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE,,,,,,,,,391798,
9571157,N01,AI,,N,,,,,N01AI000000,,,272201300015I-0-27200014-1,NIAID:273387\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,15146691; ,"KEITEL, WENDY ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; , VACCINE AND TREATMENT EVALUATION UNITS (VTEU),,,,,,,,,273387,
9459265,N01,AI,,N,,,,,N01AI000000,,,272201000033I-1-27200005-1,NIAID:508703\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOUISVILLE,UNITED STATES,,3,57588857,US,4679701,UNIVERSITY OF LOUISVILLE,KY,402081838,,14614836; ,"JONATHON, WARAWA ;",,5/26/2016,5/25/2018,Animal Model; animal model development; Burkholderia pseudomallei; Contracts; Development; infectious disease model; Melioidosis; mouse model; Standardization; subcutaneous; Testing; Translational Research; vaccine evaluation; ,Task A91: Development of a Murine Model of Subcutaneous (SC) Melioidosis for Use in Vaccine Evaluation,,,,,,,,,508703,
9461446,N01,AI,,N,,,,,N01AI000000,,,272201100022C-10-0-1,NIAID:736840\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12645624; ,"PAL, RANAJIT ;",,3/30/2011,3/29/2018,AIDS Vaccines; assay development; Biological Assay; Contracts; design; Detection; HIV; improved; Laboratories; Lymphoid Tissue; Mucous Membrane; National Institute of Allergy and Infectious Disease; nonhuman primate; Plasma; Reproducibility; research and development; Research Personnel; RNA; simian human immunodeficiency virus; Site; SIV; Specimen; Technology; United States National Institutes of Health; vaccine evaluation; viral RNA; ,NONHUMAN PRIMATE CORE QUANT IRAL RNA LABORATORY FOR AIDS VACCINE R&D,,,,,,,,,736840,
9463734,N01,AI,,N,,,,,N01AI000000,,,272201400006C-10-0-3,NIAID:1474608\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MEMPHIS,UNITED STATES,,9,67717892,US,7893501,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,TN,381053678,,14443113; ,"WEBBY, RICHARD ;",,4/1/2014,3/31/2021,Animals; Area; Avian Influenza; base; Biological; Birds; Control Animal; Development; Disease; Domestic Animals; Effectiveness; Epidemiology; Human; Influenza; Influenza A virus; Influenza Therapeutic; influenzavirus; interest; International; Maintenance; Measures; migratory bird; Molecular; pandemic disease; Pathogenicity; Research; Role; Serological; Surveillance Program; virology; wild bird; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,1474608,
9463736,N01,AI,,N,,,,,N01AI000000,,,272201400008C-12-0-1,NIAID:7195513\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,13,78861598,US,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NY,100296574,,2104524; ,"GARCIA-SASTRE, ADOLFO ;",,4/1/2014,3/31/2021,Animals; Avian Influenza; Basic Science; Environmental Risk Factor; Evolution; Immune; Immune response; improved; Influenza; influenzavirus; Molecular; pandemic disease; Pathogenicity; Research; transmission process; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,7195513,
9467403,N01,AI,,N,,,,,N01AI000000,,,272201100023C-13-0-1,NIAID:1871237\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GAITHERSBURG,UNITED STATES,,6,103926911,US,2017101,"QUALITY BIOLOGICAL, INC.",MD,208795412,,12660795; ,"BROWN, RONALD ;",,4/8/2017,4/7/2018,AIDS Vaccine Development; AIDS Vaccines; Biological Assay; Clinical; Cloning; Contracts; cytokine; Equipment and supply inventories; Genetic; immunogenicity; Local Microbicides; Maintenance; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Peptides; polyclonal antibody; pre-clinical; programs; quality assurance; Quality Control; Reagent; reagent testing; Resources; Services; Ships; Vaccine Adjuvant; Vaccine Research; vaccine safety; vector vaccine; Viral Proteins; Virus; ,Reagent Resource Support Program for AIDS Vaccine Development,,,,,,,,,1871237,
9471291,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-7,NIEHS:7535\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Evaluation; experimental study; Goals; Modeling; Procedures; Protocols documentation; response; Standardization; Testing; Toxic effect; Toxicity Tests; Toxicology; Zebrafish; ,Systematic Evaluation of the Application of Zebrafish in Toxicology (SEAZIT),,,,,,,,,7535,
9471292,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-8,NIEHS:54022\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; benzotriazole; Chemicals; Exposure to; Gene Expression Profiling; Goals; hazard; Human; Laboratory Animals; Life; member; National Toxicology Program; Pathology; Phase; Phenols; Reporting; Risk; Toxic effect; Toxicity Tests; ,Conduct of studies to evaluate the toxicity phenolic benzotriazoles (PBZTs) in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,54022,
9474077,N01,AI,,N,,,,,N01AI000000,,,272201300002I-5-27200001-1,NIAID:533784\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14089026; ,"RANAJIT, PAL ;",,5/1/2013,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Data; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; Occupational activity of managing finances; pre-clinical; preclinical evaluation; preclinical study; Preparation; Prevention; Prevention strategy; programs; Reporting; Research Personnel; Research Project Grants; Resources; Ships; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,,,,,,,,,533784,
9476859,N01,ES,,N,,,,,N01ES000000,,,273201600011C-1-0-2,NIEHS:1755668\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14511303; ,"WAGNER, DAVID ;",,4/25/2016,4/24/2018,analytical method; Area; Biological Assay; Chemicals; computer program; Contracts; Data; Data Analyses; Development; Experimental Designs; high throughput screening; laboratory experiment; mathematical model; method development; Modeling; National Institute of Environmental Health Sciences; National Toxicology Program; Reporting; Research; Research Personnel; Rodent; Sample Size; Services; Statistical Methods; Statistical Models; Surveys; Toxicokinetics; Writing; ,"Statistical Support Services for NIEHS within DIR and DNTP, Subproject: Support for DNTP",,,,,,,,,1755668,
9478811,N01,HL,,N,,,,,N01HL000000,,,268201300048C-9-0-1,NCMHD:750000\NHLBI:857071\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,TOUGALOO,UNITED STATES,,2,72618572,US,8363801,TOUGALOO COLLEGE,MS,391749700,,12255154; ,"MELVIN, CYNTHIA ;",,8/16/2013,8/12/2018,Abdomen; African American; Ancillary Study; Aorta; Area; Back; Biochemical; Biological; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; career; Clinical; cohort; Cohort Studies; Collection; Communities; Community Health Education; Community Outreach; Contracts; Data; Data Analyses; Disease; disorder risk; Echocardiography; Epidemiology; Event; follow-up; Funding; graduate student; Health Professional; Health Promotion; healthy lifestyle; heart imaging; High School Student; Hospitalization; improved; Institution; interest; Interview; Investigation; Jackson Heart Study; Magnetic Resonance Imaging; Manuscripts; Measures; Minority; minority student; Mississippi; Morbidity - disease rate; mortality; Outpatients; Participant; Prevention; Public Health; public health research; Publications; Recruitment Activity; Research Personnel; Resources; Risk; Risk Factors; Sampling; Services; Site; socioeconomics; Testing; Time; Training; Training and Education; Training Programs; undergraduate student; Validation; Visit; X-Ray Computed Tomography; ,IGF::OT::IGF Jackson Heart Study Renewal Undergraduate Training and Education Cen,,,,,,,,,1607071,
9480025,N01,AI,,N,,,,,N01AI000000,,,272201200005I-1-27200017-1,NIAID:72562\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14199652; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Freeze Drying; novel vaccines; pathogen; Phase; product development; Rabies Vaccines; Rabies virus; Services; Toxicology; United States Food and Drug Administration; vaccine candidate; vaccine development; Vaccines; ,Task X17: OPTIMIZATION OF LYOPHILIZATION AND THERMAL STABILITY OF A RABIES VACCINE CANDIDATE,,,,,,,,,72562,
9483231,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-1,NIAID:3240511\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; Zika Virus; , MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR) - ZIKA RESOURCES,,,,,,,,,3240511,
9483240,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-10,NIAID:1157325\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,1157325,
9484131,N01,DA,,N,,,,,N01DA000000,,,271201400056C-9-0-1,NIDA:561900\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BEL AIR,UNITED STATES,,,2833684,US,,,MD,210143654,,15243969; ,"HOWELL, EMILY  ;",,9/8/2014,9/7/2018,Communication; Data; design; Development; National Institute of Drug Abuse; Publications; Services; ,'Communications Support' POP ,,,,,,,,,561900,
9491650,N01,HD,,N,,,,,N01HD000000,,,275201300008I-3-27500004-1,NICHD:14125\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PORTLAND,UNITED STATES,,3,96997515,US,6297007,OREGON HEALTH & SCIENCE UNIVERSITY,OR,972393098,,12445721; ,"JENSEN, JEFFREY ;",,11/25/2013,9/30/2017,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Male Contraceptive Agents; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE ,,,,,,,,,14125,
9492479,N01,HD,,N,,,,,N01HD000000,,,275201200001I-2-27500012-1,NICHD:193139\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BETHESDA,UNITED STATES,,8,177159456,US,3020801,"CDM GROUP, INC.",MD,208146133,,14524145; ,"HERRON-VENANCIO, KATHRYN ;",,4/6/2016,11/24/2017,Accelerometer; actigraphy; adolescent health; Adult; African American; Behavior; Biological Markers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; cardiovascular disorder risk; cohort; Communities; Data Collection; Data Set; Diet; Environment; Fasting; Health; Health behavior; Health Status; Intake; Longitudinal Studies; Measures; Mental Health; next generation; Obesity; Participant; Physical activity; Recruitment Activity; Research Personnel; Schools; Sleep; social; Substance abuse problem; Support Contracts; Surveys; Youth; ,NEXT GENERATION STUDY - DATA COLLECTION AND PUBLIC ACCESS DATASETS ,,,,,,,,,193139,
9503675,N01,AI,,N,,,,,N01AI000000,,,272201300020I-1-27200006-1,NIAID:27551\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14369240; ,"WINAKUR, PATRICIA ;",,10/19/2015,4/15/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza virus vaccine; named group; Phase I Clinical Trials; Population; programs; Resources; Vaccines; ,Vaccine Treatment and Evaluation Unit: Phase I Clinical Trial of an Influenza Vaccine,,,,,,,,,27551,
9509789,N01,AI,,N,,,,,N01AI000000,,,272201000026I-0-27200002-1,NIAID:150000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,,53045477,US,,TULANE UNIVERSITY,LA,701185676,,14973652; ,"ROY, CHAD ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Licensure; nonhuman primate; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,150000,
9509795,N01,AI,,N,,,,,N01AI000000,,,272201000036I-0-27200002-1,NIAID:50000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,14973667; ,"SKERRETT, SHAWN ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,50000,
9509856,N01,AI,,N,,,,,N01AI000000,,,272201000033I-0-27200006-1,NIAID:729174\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOUISVILLE,UNITED STATES,,3,57588857,US,4679701,UNIVERSITY OF LOUISVILLE,KY,402081838,,14973661; ,"WARAWA, JONATHAN ;",,3/21/2017,11/20/2018,Animal Model; animal model development; Antimicrobial Resistance; Contracts; Development; efficacy testing; Infection; infectious disease model; Lung; mouse model; Multi-Drug Resistance; Pseudomonas aeruginosa; Standardization; Therapeutic; therapeutic evaluation; ,TASK A111: THERAPEUTICS TESTING IN A MURINE MODEL OF MULTIPLE DRUG RESISTANT (MDR) PSEUDOMONAS AERUGINOSA LUNG INFECTION,,,,,,,,,729174,
9511679,N01,CA,,N,,,,,N01CA000000,,,261201200035I-2-26100008-1,NCI:1575715\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,14262606; ,"KHAN, SEEMA ;",,9/24/2015,9/23/2017,cancer prevention; Clinical; Clinical Chemoprevention; Clinical Trials; clinically relevant; Conduct Clinical Trials; Contractor; Data; data management; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; interest; laboratory experiment; Maintenance; Malignant Neoplasms; meetings; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; prevention clinical trial; Preventive; programs; protocol development; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; ,CORE INFRASTRUCTURE SUPPORT,,,,,,,,,1575715,
9513975,N01,AI,,N,,,,,N01AI000000,,,272200800002C-28-0-3,NIAID:5590\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,6323835; ,"KEITEL, WENDY A;",,11/1/2007,12/31/2017,"Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Influenza; Influenza A virus; Influenza A Virus, H5N1 Subtype; Investigation; named group; novel; Phase I Clinical Trials; Population; Resources; Route; System; vaccine candidate; Vaccines; ",Vaccine and Treatment Evaluation Units ,,,,,,,,,5590,
9513981,N01,AI,,N,,,,,N01AI000000,,,272201400039C-9-0-1,NIAID:4599143\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PRINCETON,UNITED STATES,,12,153880778,US,3868901,"SOLIGENIX, INC.",NJ,85405919,,12428371; ,"BREY, ROBERT ;",,8/18/2014,9/30/2018,Advanced Development; Categories; Cold Chains; Communicable Diseases; Development; Disease Outbreaks; Event; Formulation; National Institute of Allergy and Infectious Disease; pathogen; response; Ricin Vaccine; Technology; vaccine development; Vaccines; ,DEVELOPMENT OF RICIN VACCINE FORMULATION,,,,,,,,,4599143,
9514438,N01,HL,,N,,,,,N01HL000000,,,268201600003I-0-26800002-1,NHLBI:205723\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,14949865; ,"BARTHOLMAI, BRIAN ;",,3/1/2017,2/28/2018,Archives; Chronic Obstructive Airway Disease; Clinical; Clinical Data; Collection; Contractor; Data; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Image; Link; Lung diseases; Pathogenesis; Process; programs; Radiology Specialty; Research; Research Personnel; sample collection; Specimen; Structure of parenchyma of lung; X-Ray Computed Tomography; ,IGF::OT::IGF LTRC RADIOLOGY CENTER - TASK ORDER 2 - 03/01/2017 - 02/28/2018 - CAN 17-8470204,,,,,,,,,205723,
9514443,N01,HL,,N,,,,,N01HL000000,,,268201600007I-0-26800002-1,NHLBI:220102\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,PITTSBURGH,UNITED STATES,,14,4514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152132303,,14949877; ,"SCIURBA, FRANK ;",,3/1/2017,2/28/2018,Chronic Obstructive Airway Disease; Clinical; Clinical Data; Contractor; Data; Enrollment; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Link; Lung diseases; Operative Surgical Procedures; Pathogenesis; Phenotype; Process; programs; Research; Research Personnel; sample collection; Specimen; Structure of parenchyma of lung; Tissues; wasting; ,IGF::OT::IGF LTRC CLINICAL CENTER - TASK ORDER 2 - 03/01/2017 - 02/28/2018 - CAN 17-8470204,,,,,,,,,220102,
9518510,N01,LM,,N,,,,,N01LM000000,,,276201200017C-10-0-1,NIDDK:100935\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,12321912; ,"GOURLEY, GLENN ;",,6/29/2012,6/28/2017,Americas; Animal Experimentation; cell type; Cells; Contracts; Disease; Excision; Freezing; Hepatic; Hepatic Tissue; Hepatocyte; Human; in vitro Model; Liver; liver transplantation; Metabolism; Operating Rooms; Pathologic; Research; Research Personnel; Slide; System; Time; Tissues; United States; United States National Institutes of Health; ,Liver Tissue and Cell Distribution System,,,,,,,,,100935,
9518511,N01,AI,,N,,,,,N01AI000000,,,272201600011I-1-27200001-1,NIAID:742765\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,10,20790895,US,10019434,INTERNATIONAL AIDS VACCINE INITIATIVE,NY,100042400,,14658157; ,"HASSELL, THOMAS ;",,7/15/2017,7/14/2018,assay development; Basic Science; Chemistry; Clinic; Clinical Trials; Contracts; Data; Development; Development Plans; Documentation; HIV; HIV Infections; HIV vaccine; Immunology; Investigational New Drug Application; manufacturing process development; Molecular Biology; National Institute of Allergy and Infectious Disease; novel vaccines; Phase; prevent; Process; product development; Proteins; Quality Control; Reporting; vaccine development; Vaccines; ,COORDINATION AND TECHNICAL SUPPORT,,,,,,,,,742765,
9520982,N01,AI,,N,,,,,N01AI000000,,,272201100018I-0-27200012-2,NIAID:48978\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,14936010; ,"PATTERSON, THOMAS ;",,3/1/2017,2/28/2018,Advanced Development; Anti-Bacterial Agents; Antifungal Agents; Biological Assay; Development; In Vitro; in vitro testing; Maintenance; screening; Support Contracts; therapeutic development; ,TASK A28: In Vitro Screening for Antifungal Activity,,,,,,,,,48978,
9521686,N01,HL,,N,,,,,N01HV000000,,,268201300024C-4-0-1,NHLBI:0\NIDDK:423634\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BOSTON,UNITED STATES,,7,30811269,US,1080401,BRIGHAM AND WOMEN'S HOSPITAL,MA,21156110,,10222899; ,"SOLOMON, SCOTT DAVID;",,7/1/2013,6/30/2018,Acculturation; Asthma; Blood; Cardiovascular Diseases; Chronic Obstructive Airway Disease; cultural values; Diabetes Mellitus; Disease; Echocardiography; Gestational Diabetes; Health; Health Services Accessibility; Heart; Hispanic Community Health Study; Hispanic Community Health Study/Study of Latinos; Hispanics; Left Ventricular Hypertrophy; Length; Lung; Lung diseases; Measures; Medical; migration; mortality; Prevalence; Reading; Risk; Risk Behaviors; Risk Factors; Socioeconomic Factors; socioeconomics; Time; United States National Institutes of Health; Visit; ,IGF::OT::IGF Hispanic Community Health Study - Study of Latinos HCHS-SOL) Ech,,,,,,,,,423634,
9523031,N01,HL,,N,,,,,N01HL000000,,,268201700004C-0-0-1,NHLBI:658400\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ANN ARBOR,UNITED STATES,,12,73133571,US,1506502,UNIVERSITY OF MICHIGAN,MI,481091276,,14921904; ,"LARKIN, TRACEY ;",,11/15/2016,11/14/2019,Acute; Animal Model; Anticoagulants; Aortic Aneurysm; Area; Competence; Controlled Study; Coronary Arteriosclerosis; Deep Vein Thrombosis; Disease; Dissection; E-Selectin; effective therapy; Hemorrhage; Human; improved; Incidence; inhibitor/antagonist; interest; intracranial artery; Lead; Low-Molecular-Weight Heparin; Lymphatic Diseases; Lymphatic System; Michigan; Peripheral arterial disease; Postphlebitic Syndrome; product development; programs; Pulmonary Hypertension; pulmonary vascular disorder; Quality of life; Resolution; Risk; Thrombosis; Thrombus; Universities; Vascular Diseases; Venous; Venous Thrombosis; ,IGF::OT::IGF GMI-1271 AND ITS COMBINATION WITH LMWH PROMOTES SAFER & MORE EFFECTIVE TREATMENT OF VENOUS THROMBOSIS,,,,,,,,,658400,
9523044,N01,HL,,N,,,,,N01HL000000,,,268201700007C-0-0-1,NHLBI:322865\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHICAGO,UNITED STATES,,7,98987217,US,577703,UNIVERSITY OF ILLINOIS AT CHICAGO,IL,606127224,,14921922; ,"DUTTA, MITRA ;",,11/15/2016,11/14/2019,Adult Respiratory Distress Syndrome; Aortic Aneurysm; Area; base; Blood Vessels; Coronary Arteriosclerosis; Disease; Dissection; Extravasation; Goals; interest; intracranial artery; Lymphatic Diseases; Lymphatic System; novel therapeutics; Pathogenesis; Peripheral arterial disease; Pharmaceutical Preparations; product development; programs; Pulmonary Edema; Pulmonary Hypertension; pulmonary vascular disorder; Research; Thrombosis; Vascular Diseases; Venous; ,IGF::OT::IGF NOVEL DRUG-BASED THERAPY FOR TREATMENT OF VASCULAR LEAKAGE,,,,,,,,,322865,
9523045,N01,HL,,N,,,,,N01HL000000,,,268201700008C-0-0-1,NHLBI:303922\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CORAL GABLES,UNITED STATES,,27,52780918,US,5221250,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,FL,331462926,,14921925; ,"TINCHER, JILL ;",,11/15/2016,11/14/2019,Aortic Aneurysm; Area; base; Bone Marrow; Cell Adhesion Molecules; Cells; Coronary Arteriosclerosis; Disease; Dissection; E-Selectin; extracellular; Gangrene; improved; interest; intracranial artery; Ischemia; Limb structure; Lymphatic Diseases; Lymphatic System; medical schools; Modeling; Mus; Peripheral arterial disease; product development; programs; Pulmonary Hypertension; pulmonary vascular disorder; repaired; stem; Stem cells; Testing; Therapeutic; Thrombosis; tissue repair; Tissues; Universities; Vascular Diseases; Venous; ,IGF::OT::IGF E-SELECTIN/AAV FOR THERAPEUTIC REVERSAL OF LIMB ISCHEMIA,,,,,,,,,303922,
9525754,N01,HD,,N,,,,,N01HD000000,,,275201300001I-5-27500001-1,NICHD:14552\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PITTSBURGH,UNITED STATES,,14,119132785,US,3840801,MAGEE-WOMEN'S RES INST AND FOUNDATION,PA,152134430,,12445625; ,"CHEN, BEATRICE ;",,6/26/2013,6/25/2017,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Male Contraceptive Agents; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,14552,
9526059,N01,CA,,N,,,,,N01CA000000,,,261201300011I-0-26100011-1,NCI:104606\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,DETROIT,UNITED STATES,,13,1962224,US,9110501,WAYNE STATE UNIVERSITY,MI,482024050,,15111714; ,"DAVIS, KERRY ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016 (SEER) PERIOD OF PERFORMANCE:  07/31/2017 - 07/30/2018,,,,,,,,,104606,
9531996,N01,AI,,N,,,,,N01AI000000,,,272201200003I-1-27200018-1,NIAID:183769\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14636701; ,"HORNBACK, RANDI ;",,7/6/2016,7/5/2018,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; Ebola Vaccines; efficacy testing; Emerging Communicable Diseases; Evaluation; evaluation/testing; Feasibility Studies; Filoviridae; Filovirus; immunogenicity; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; Vaccines; ,Task X18: Evaluation of Filovirus Vaccines ,,,,,,,,,183769,
9533343,N01,HD,,N,,,,,N01HD000000,,,275201500002I-1-27500007-1,NICHD:393572\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14769126; ,"BAUGHMAN, KATHRYN ;",,9/26/2016,9/25/2018,Animals; Biological Testing; Contraceptive Agents; contraceptive efficacy; design; Documentation; Dose; Effectiveness; efficacy study; Formulation; good laboratory practice; Human; Implant; In Vitro; in vitro Model; in vivo; Injectable; Modeling; Nature; Oral; Phase; pre-clinical; preclinical development; Property; Protocols documentation; Reporting; research clinical testing; Research Design; Route; Safety; safety study; Testing; Toxic effect; ,BIOLOGICAL TESTING FACILITY - PRECLINICAL DEVELOPMENT OF CONTRACEPTIVES,,,,,,,,,393572,
9571158,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200012-1,NIAID:1278322\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15097620; ,"BERNSTEIN, DAVID ;",,6/12/2017,3/28/2020,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Hantavirus; Individual; named group; Phase; Population; programs; Resources; Vaccine Clinical Trial; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS: HANTAVIRUS VACCINE CLINICAL TRIAL,,,,,,,,,1278322,
9571163,N01,AI,,N,,,,,N01AI000000,,,272201300018I-0-27200018-1,NIAID:369743\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15273096; ,"MULLIGAN, MARK ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: CLINICAL OPERATIONS SUPPORT,,,,,,,,,369743,
9571292,N01,HL,,N,,,,,N01HL000000,,,268201700006I-0-26800011-1,NICHD:99940\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15244440; ,"NA, NA ;",,9/21/2017,9/20/2019,Disease; DNA sequencing; Genetic study; Genotype; Health; Human; Neural Tube Defects; screening; ,GLOBAL SCREENING ARRAY (GSA) - GENETIC STUDY OF NEURAL TUBE DEFECTS ,,,,,,,,,99940,
9571345,N01,HD,,N,,,,,N01HD000000,,,275201000003I-0-27500050-1,NICHD:307332\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15244608; ,"MELLONI, CHIARA ;",,9/22/2017,9/21/2019,authority; Best Pharmaceuticals for Children Act; Child; Drug Kinetics; National Institute of Child Health and Human Development; Pharmaceutical Preparations; pharmacodynamic biomarker; standard of care; ,BIOANALYTICAL ANALYSIS FOR PHARMACOKINETICS OF UNDERSTUDIED DRUGS ADMINISTERED TO CHILDREN PER STANDARD OF CARE (POPS) IV and V,,,,,,,,,307332,
9571411,N01,AI,,N,,,,,N01AI000000,,,272201300019I-0-27200008-1,NIAID:343142\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,78198520,US,3080503,KAISER FOUNDATION HEALTH PLAN OF WASHINGTON,WA,981011466,,15143639; ,"JACKSON, LISA ;",,7/12/2017,7/11/2018,Clinical; Clinical Trials; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNITS (VTEU):CLINICAL OPERATIONS SUPPORT,,,,,,,,,343142,
9571681,N43,CA,,N,,,,,N43CA000000,,,261201700021C-0-0-1,NCI:248357\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAINT LOUIS,UNITED STATES,,2,100512883,US,4494601,"MEDIOMICS, LLC",MO,631242041,,15232894; ,"TIAN, LIAN ;",,9/19/2017,6/18/2018,Affinity; Antibodies; Antibody Affinity; Antigens; Biological; Biological Assay; Carrier Proteins; Chickens; cost; cost effective; Coupled; deep sequencing; Detection; Development; Enzyme-Linked Immunosorbent Assay; Goals; IgY; Immunize; improved; Keyhole Limpet Hemocyanin; Liquid Chromatography; Malignant Neoplasms; Mass Spectrum Analysis; Methods; Modification; next generation sequencing; novel; Nucleosides; Performance; Phase; polyclonal antibody; Research; Research Personnel; RNA; RNA analysis; Sampling; Schedule; Scientist; Series; Site; Site-Directed Mutagenesis; Specificity; Technology; Testing; Time; tool; ,"IGF::OT::IGF Developing Novel Tools for Site-Specific Quantitative Analysis of RNA ModificationsPeriod Performance: September 19, 2017 through June 16, 2018",,,,,,,,,248357,
9571682,N01,AI,,N,,,,,N01AI000000,,,272201300021I-0-27200017-1,NIAID:219240\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,14974797; ,"HOFT, DANIEL ;",,3/7/2017,12/31/2017,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Multiple drug resistant Mycobacteria Tuberculosis; named group; Phase; Population; programs; Resources; Therapeutic Trials; Tuberculosis; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: Phase 4 Tuberculosis Therapeutics Trial,,,,,,,,,219240,
9572237,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-10,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572241,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-14,NIAID:330101\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Ebola virus; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,330101,
9572629,N01,HL,,N,,,,,N01HV000000,,,268201200001I-0-26800006-1,NHLBI:1420558\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WATERTOWN,UNITED STATES,,5,153914080,US,2034501,"NEW ENGLAND RESEARCH INSTITUTES, INC.",MA,24722463,,14983370; ,"SIAMI, SANDI ;",,3/31/2017,3/31/2018,5 year old; Berlin; Child; Childhood; Clinical Data; Clinical Trials; Contractor; Contracts; Development; Devices; Extracorporeal Membrane Oxygenation; Heart; Heart Diseases; Infant; Investigation; neonate; pre-clinical; Pump; Pumpkins; research and development; Testing; ventricular assist device; ,"IGF::OT::IGF - R&D, PUMPS FOR KIDS, INFANTS, AND NEONATES (PUMPKIN) CLINICAL TRIAL - DATA & CLINICAL COORDINATING CENTER",,,,,,,,,1420558,
9572715,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200013-2,NIAID:231807\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15170389; ,"BERNSTEIN, DAVID ;",,9/16/2013,12/31/2018,Bacterial Vaginosis; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; phase II trial; Population; programs; Resources; Therapeutic; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: PHASE II TRIAL FOR BACTERIAL VAGINOSIS,,,,,,,,,231807,
9572895,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200020-2,NIAID:439277\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15143632; ,"WALKER, EMMANUEL ;",,7/12/2017,7/11/2018,Bacterial Vaginosis; Clinical Research; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Population; programs; protocol development; Resources; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,439277,
9572897,N01,AI,,N,,,,,N01AI000000,,,272201300017I-0-27200018-1,NIAID:439277\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14922168; ,"WALTER, EMMANUEL ;",,11/1/2016,11/2/2018,Clinical; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,Vaccine and Treatment Evaluation Unit - Clinical Operations Support,,,,,,,,,439277,
9572911,N43,AI,,N,,,,,N43AI000000,,,272201700075C-0-0-1,NIAID:223323\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,20,154088710,US,1310501,OPERATIONAL TECHNOLOGIES CORPORATION,TX,78229,,15327620; ,"BRUNO, JOHN ;",,8/1/2017,7/31/2018,Antibodies; Cytomegalovirus; Development; Diagnostic; Human; Human Herpesvirus 2; Investigation; Monitor; Patients; Serum; tool; Viral; ,Proof of concept investigation to detect exposure of patients to Cytomegalovirus (CMV) and Herpes Simplex Virus-2 (HSV-2),,,,,,,,,223323,
9573079,N01,AI,,N,,,,,N01AI000000,,,272201100022I-2-27200009-3,NIAID:284966\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14922096; ,"MIRSALIS, JON ;",,12/16/2016,10/5/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Ebola virus; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; public health relevance; reagent testing; Services; Staphylococcus aureus; therapeutic development; Toxicology; Toxin; Translational Research; ,TO X9: OPTIMIZATION PK STUDIES ,,,,,,,,,284966,
9573285,N01,HD,,N,,,,,N01HD000000,,,275200900099U-5-0-1,NICHD:21528\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,NEW YORK,UNITED STATES,,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323702,,15236823; ,"WESTHOFF, CAROLYN ;",,9/30/2009,12/31/2012,Age; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Contractor; Contracts; efficacy evaluation; Female Condoms; Female Contraceptive Agents; Gynecologic; Gynecology; Male Contraceptive Agents; National Institute of Child Health and Human Development; Phase; pregnancy prevention; Protocols documentation; reproductive; Research; Safety; treatment trial; Woman; ,CONTRACEPTIVE EFFICACY EVALUATION OF THE PATH FEMALE CONDOM,,,,,,,,,21528,
9573349,N02,CA,,N,,,,,N02CP000000,,,261201400010I-0-26100010-1,OD:20061\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,15237124; ,"ARCHER, JANET ;",,9/19/2017,9/18/2018,Area; base; Data; Feasibility Studies; Logistics; Preparation; Radiometry; sample collection; Sampling; Services; Work; ,REB Core Support Services - Task Area 2,,,,,,,,,20061,
9573705,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-2,NIAID:344050\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Bacillus anthracis; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,344050,
9573713,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-9,NIAID:344050\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; Staphylococcus aureus; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,344050,
9573719,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-13,NIAID:516085\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Vibrio cholerae; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,516085,
9573751,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-18,NIAID:106821\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Pseudomonas aeruginosa; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,106821,
9574271,N01,HD,,N,,,,,N01HD000000,,,275201000003I-4-27500034-1,NICHD:483733\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15239065; ,"BENJAMIN, DANNY ;",,8/3/2017,8/2/2018,Adult; Adverse reactions; Animals; Area; Asthma; Authorization documentation; Awareness; Best Pharmaceuticals for Children Act; biodefense; Cardiovascular Diseases; Child; Childhood; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Communicable Diseases; Complex; Contractor; Contracts; Data; Device or Instrument Development; Devices; Diagnostic; Disease; Dose; drug development; drug testing; Effectiveness; Ensure; Environment; Ethical Issues; Face; Funding; Gastroenterology; Gastroesophageal reflux disease; Goals; Growth and Development function; Health; hypertension treatment; Incentives; Individual; Infant; Life; Lung diseases; Maternal and Child Health; methicillin resistant Staphylococcus aureus; National Institute of Child Health and Human Development; Nature; Neonatal; neonate; Obesity; operation; Pediatric Oncology; pediatric pharmacology; permissiveness; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; programs; Public Health; Research; Research Infrastructure; Research Personnel; response; Technology; Therapeutic; Work; ,PEDIATRIC TRIALS NETWORK - PROGRAM MANAGEMENT SUPPORT,,,,,,,,,483733,
9574343,N43,AI,,N,,,,,N43AI000000,,,272201700018C-0-0-1,NIAID:224563\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MIAMI,UNITED STATES,,24,35354070,US,4474801,"INFOTECH SOFT, INC.",FL,331313207,,15239791; ,"KABUKA, MANSUR ;",,8/1/2017,7/31/2018,base; Contractor; Data; data modeling; Data Reporting; Data Sources; Data Storage and Retrieval; Descriptor; Evaluation; Galaxy; Immunology; indexing; Knowledge; Metadata; Modeling; Ontology; prototype; repository; Retrieval; tool; virtual; Web Ontology Language; Work; ,Immunology Information Integration,,,,,,,,,224563,
9574356,N43,AI,,N,,,,,N43AI000000,,,272201700066C-0-0-1,NIAID:223002\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,12,831676247,US,10024422,"ADJUVANCE TECHNOLOGIES, INC.",NY,10010,,15327602; ,"LIVINGSTON, PHILIP ;",,8/1/2017,7/31/2018,Adjuvant; analog; Chemicals; Contractor; Fluvirin; Fluzone; Hemagglutinin; Immune response; Immunization; immunogenicity; Immunologic Adjuvants; Immunologics; improved; Influenza virus vaccine; Mus; Proteins; QS21; response; Saponins; Science; Vaccines; , Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 on Influenza Vaccine Immunogenicity and Stability  ,,,,,,,,,223002,
9574776,N43,CA,,N,,,,,N43CA000000,,,261201700014C-0-0-1,NCI:300000\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,COLUMBIA,UNITED STATES,,2,80369038,US,10043116,"DELPHI GENOMICS, LLC",SC,292092306,,15240568; ,"BANNISTER, CAROLYN ;",,9/19/2017,6/18/2018,3-Dimensional; African; African American; American; biobank; cancer health disparity; Colon; Colon Carcinoma; Colonic Neoplasms; Colorectal Cancer; Dependence; EGF gene; European; FDA approved; Gene Mutation; Measures; mutant; Mutation; Oncogenes; oncology; Operative Surgical Procedures; Organoids; patient population; Patients; Pharmaceutical Preparations; Preclinical Drug Evaluation; Small Business Innovation Research Grant; Somatic Mutation; Specimen; Stem cells; TGFB1 gene; TP53 gene; tumor; Work; ,IGF::OT::IGF SBIR Topic 355: An Organoid Avatar Biobank for Cancer Disparities. To establish a colorectal cancer organoid avatar bio-bank from an ethnically and genetically diverse patient populatio,,,,,,,,,300000,
9574808,N43,CA,,N,,,,,N43CA000000,,,261201700019C-0-0-1,NCI:304961\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TORRANCE,UNITED STATES,,33,33449757,US,3841801,"INTELLIGENT OPTICAL SYSTEMS, INC.",CA,905055217,,15240628; ,"DELGADO, JESUS ;",,9/11/2017,6/10/2018,analog; base; Budgets; Chemistry; Clinical; Data; Data Set; design; Diagnosis; digital; drug discovery; Drug Targeting; effective therapy; Fiber Optics; Goals; Image; Implantation procedure; implanted sensor; improved; in vivo; instrument; Ions; Measures; microsensor; Molecular Target; Monitor; Office Management; Optics; outcome forecast; Oxygen; Partial Pressure; Patients; Periodicity; Pharmaceutical Preparations; Phase; Physicians; response; Seeds; sensor; Signal Transduction; Small Business Innovation Research Grant; System; Technology; Time; tumor growth; tumor microenvironment; ,IGF::OT::IGF SBIR Phase I Topic 357; POP: 09/11/2017 - 06/10/2018 The Office of Management and Budget has issued Memorandum M-11-32 and M-12-16.  These memoranda establish a goal of 15-day accelerated,,,,,,,,,304961,
9574970,N02,CA,,N,,,,,N02CA000000,,,261201400004I-0-26100008-1,NCI:99278\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SPRINGFIELD,UNITED STATES,,18,831496661,US,4155401,NORTH AMERICAN ASSN/CENTRAL CANCER REG,IL,627047412,,15240936; ,"KOHLER, BETSY ;",,9/26/2017,9/25/2018,Communication; Country; Information Systems; interest; Knowledge; Malignant Neoplasms; member; neoplasm registry; Performance; Politics; population based; Professional Organizations; Public Health; Resources; Technical Expertise; Training; ,IGF::OT::IGF Enhancing Global Cancer Registry-Centered Surveillance (Global CR-CS) Project Period of Performance 9/26/2017 - 9/25/2018.,,,,,,,,,99278,
9575442,N01,ES,,N,,,,,N01ES000000,,,273201400027C-9-0-3,NIEHS:558242\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15059066; ,"BURBACK, BRIAN ;",,7/25/2014,5/24/2018,Adverse effects; Animals; Botanical dietary supplements; Chemicals; Chemistry; Complex; Contracts; Development; Dose; Ensure; Evaluation; Formulation; Ginkgo biloba; Goals; Human Cell Line; in vitro testing; Laboratories; Link; National Toxicology Program; Outcome; Preparation; programs; Public Health; Research; Risk Assessment; Ships; sound; Specific qualifier value; Testing; Toxic effect; Toxicity Tests; Toxicokinetics; ,Botanical Dietary Supplements,,,,,,,,,558242,
9575795,N01,CA,,N,,,,,N01CA000000,,,261201200035I-0-26100013-1,NCI:450103\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15242410; ,"KHAN, SEEMA ;",,9/15/2017,9/14/2019,Age; arm; Biological Markers; Cirrhosis; Diagnosis; Hepatocarcinogenesis; Incidence; Liver; Malignant neoplasm of pancreas; Malignant Neoplasms; men; Patients; Phase; Pilot Projects; Polyphenon E; Primary carcinoma of the liver cells; Survival Rate; Testing; Woman; ,"OT::IGF::OT A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis",,,,,,,,,450103,
9576321,N02,CA,,N,,,,,N02CA000000,,,261201600022I-0-26100002-1,NCI:143135\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,PITTSBURGH,UNITED STATES,,14,4514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152132303,,15326949; ,"EISEMAN, JULIE ;",,4/10/2017,4/9/2018,analog; Clinic; Clinical Trials; Developmental Therapeutics Program; Evaluation; Human; phase I trial; Plasma; Sampling; Series; Site; Topoisomerase-I Inhibitor; Urine; ,"Title: Determination of LMP744 (NSC 706744) Levels in Human Plasma and Urine Samples from an NCI Phase I Trial.POP: 04/10/2017 - 04/09/2018 	",,,,,,,,,143135,
9578288,N43,CA,,N,,,,,N43CA000000,,,261201700037C-0-0-2,NCI:299989\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WEST CHESTER,UNITED STATES,,6,928315084,US,3327601,"MOLECULAR TARGETING TECHNOLOGIES, INC.",PA,193804471,,15246547; ,"GRAY, BRIAN D. ;",,9/18/2017,6/17/2018,Address; Back; beta-Glucosidase Stimulating Protein; Biological Response Modifier Therapy; Blood; Brain Neoplasms; cancer cell; chemotherapy; Coupled; Data; Drug Delivery Systems; Exhibits; extracellular; Glioblastoma; Goals; Label; Lead; Lipid Binding; Lipids; lipophilicity; Malignant neoplasm of brain; Malignant Neoplasms; Modeling; mouse model; nanovesicle; neoplastic cell; novel; Orphan Drugs; Phase I Clinical Trials; Phosphatidylserines; pre-clinical; Property; Publishing; Radiation; Radiation exposure; Radiation therapy; Radiolabeled; Radionuclide therapy; Reporter; Research Proposals; System; Testing; Therapeutic; tumor; Tumor Markers; ,BIOTHERAPY OF BRAIN TUMORS BY RADIOIODINATED SAPC-DOPS NANOVESICLES,,,,,,,,,299989,
9579435,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100041-1,NCI:15241462\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266019; ,"AGARWAL, RACHANA ;",,9/28/2017,9/27/2020,Academic Medical Centers; Address; Adult; Antibodies; Architecture; Atlases; base; Biocompatible Materials; Cells; Childhood Glioma; childhood sarcoma; Chimeric Proteins; Clinical; clinical research site; cloud platform; Collaborations; Colon Carcinoma; Communities; Data; Data Collection; Data Coordinating Center; data format; Development; Dictionary; Ecosystem; Event; Experimental Designs; experimental study; Foundations; Funding; Future; Generations; genomic data; Genomics; Government; Guidelines; Heterogeneity; Human; Image; Immune; In Situ Hybridization; Individual; Institution; interest; Knowledge; Lesion; Malignant Childhood Neoplasm; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant Neoplasms; Mentors; Metadata; Metastatic breast cancer; Metastatic to; Microscopy; molecular dynamics; Neoplasm Metastasis; neoplastic cell; Neuroblastoma; non-genomic; Normal tissue morphology; Oncogenic; patient population; Pediatric Neoplasm; Physiological; Pilot Projects; Policies; Predictive Cancer Model; preference; Primary Lesion; Procedures; programs; Proteomics; protocol development; Quality Control; Recommendation; Research; Research Personnel; response; Role; Sampling; sarcoma; sharing data; single cell analysis; Site; Spatial Distribution; Techniques; Tissue Banks; Tissue Procurements; Tissues; transcriptomics; tumor; Tumor Tissue; United States National Institutes of Health; Validation; ,IGF::OT::IGF Human Tumor Atlas Pilot Program,,,,,,,,,15241462,
9581114,N02,CA,,N,,,,,N02CA000000,,,261201700656P-0-0-1,NCI:49950\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MILANO,ITALY,,,437616480,IT,10030081,FDN NATIONAL CANCER INSTITUTE (IRCCS),,20133,,15327164; ,"ASIOLI, MARCO ;",,9/15/2017,9/14/2018,Malignant Neoplasms; ,IGF::OT::IGF Surveillance of Rare Cancers in SEER,,,,,,,,,49950,
9581237,N01,HL,,N,,,,,N01HL000000,,,268201600011I-0-26800003-1,NHLBI:607581\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DUARTE,UNITED STATES,,32,27176833,US,3058203,BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,CA,910103012,,15266100; ,"GOLD, JOSEPH ;",,9/28/2017,9/27/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - Production Assistance For Cellular Therapies (PACT)- Cell Processing Facilities,,,,,,,,,607581,
9581366,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100063-1,NCI:41161\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,12/23/2016,6/30/2017,Support Groups; working group; ,IGF::OT::IGF NCORP CCDR COORDINATING COMMITTEE AND WORKING GROUP SUPPORT (2017).,,,,,,,,,41161,
9581379,N02,CA,,N,,,,,N02CA000000,,,261201700078P-0-0-1,NCI:24987\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,15327133; ,"THOMPSON, KRISTIE ;",,1/4/2017,9/30/2017,Attention; cancer genetics; Communication; consumer product; Contracts; Genomics; Health Communication; Literature; Malignant Neoplasms; Marketing; Patients; precision genomic medicine; precision medicine; Publishing; Research; Science; systematic review; Testing; ,IGF::OT::IGF HEALTH COMMUNICATION IN THE ERA OF GENOMICS AND PRECISION MEDICINE,,,,,,,,,24987,
9581407,N02,CA,,N,,,,,N02CA000000,,,261201700679P-0-0-1,NCI:30000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,DAVIS,UNITED STATES,,,79401641,US,,,CA,95616,,15327170; ,"JIANG, JIMING ;",,9/19/2017,9/18/2018,Age; Sampling Errors; ,"IGF::OT::IGF  JIANG, JIMING: Variance and interval estimators of age-adjusted rates with sampling errors in the denominators",,,,,,,,,30000,
9581730,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-159,NCI:4052011\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,anticancer research; Cancer Biology; Collaborations; Communities; Computational Science; Computer Simulation; Data; data modeling; Data Science; Databases; Department of Energy; Diagnosis; frontier; high end computer; improved; individual patient; knowledge base; Low Dose Radiation; Malignant Neoplasms; Mission; Molecular; National Cancer Institute; next generation; novel diagnostics; oncology; Outcome; Patients; population based; Pre-Clinical Model; Precision Medicine Initiative; precision oncology; predictive modeling; Radiobiology; Research Infrastructure; Resources; Systems Biology; Technology; Testing; ,MS DOE Coordination Support,,,,,,,,,4052011,
9582533,N02,DA,,N,,,,,N02DA000000,,,271201400076C-6-0-2,NIA:4958752\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,NORTH BETHESDA,UNITED STATES,,8,161157631,US,1968001,"JOHNSON, BASSIN AND SHAW, INC.",MD,208525032,,15253581; ,"UNKNOWN, UNKNOWN ;",,9/1/2014,8/31/2017,Aging; Alzheimer's Disease; biomedical referral center; Brain Diseases; Communication Research; Contracts; Databases; Dementia; design; Development; Education; Equipment and supply inventories; Impaired cognition; Information Centers; Information Management; Information Resources; Maintenance; meetings; Nerve Degeneration; Neurosciences; operation; outreach; product development; Quality Control; Services; symposium; Training; web site; ,NIA Information Resource Center Clearinghouse and The Alzheimer's Disease Education and Referral Center (ADEAR),,,,,,,,,4958752,
9587854,N01,NS,,N,,,,,N01NS000000,,,265201700092M-0-0-1,NINDS:3420\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,HERNDON,UNITED STATES,,,36632328,US,,,VA,"20,170,256",,; ,",  ;",,9/13/2017,9/30/2017,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,IGF::CL::IGF: This service is for Toxicology consulting service,,,,,,,,,3420,
9587913,N02,DA,,N,,,,,N02DA000000,,,271201500014I-0-27100003-1,NINDS:19500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CHESTERFIELD,UNITED STATES,,,804242449,US,,,MO,630054230,,15327395; ,"ROMERO, DONNA ;",,6/20/2017,6/19/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"ROMERO, DONNA L:1198213 [17-002156] IGF::CL::IGF",,,,,,,,,19500,
9587957,N02,DA,,N,,,,,N02DA000000,,,271201400012I-0-27100004-1,NINDS:19500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,GLENCOE,UNITED STATES,,,64650392,US,,,MO,630381607,,15327371; ,"LAWSON, JON ;",,9/28/2014,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,IGF::CL::IGF JP LAWSON CONSULTING:1238760 [17-004923],,,,,,,,,19500,
9594192,N01,AG,,N,,,,,N01AG000000,,,271201000011I-2-27100002-1,NIA:54284\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON AGING,,NORTH BETHESDA,UNITED STATES,,8,161157631,US,1968001,"JOHNSON, BASSIN AND SHAW, INC.",MD,208525032,,15040779; ,"BASSIN, GAIL ;",,9/22/2010,9/21/2011,,TAS::75 0843::TAS NIA INFORMATION RESOURCE CENTER,,,,,,,,,54284,
9594219,N02,DA,,N,,,,,N02DA000000,,,271201500131U-3-0-2,NIA:323478\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BURLINGAME,UNITED STATES,,14,83778964,US,10001134,"ACUMEN, LLC",CA,940101936,,15327410; ,"KELLY, MARTHA ;",,9/28/2015,9/27/2018,,IGF::OT::IGF LINKING CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) DATA ,,,,,,,,,323478,
9594253,N01,OD,,N,,,,,N01OD000000,,,263201200074I-2-26300085-2,NIA:100000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15236808; ,"WESTBROOK, DAVID ;",,9/30/2015,9/29/2018,,IGF::OT::IGF: PARTIAL SUPPORT FOR THE CORE ACTIVITIES OF THE CNSTAT,,,,,,,,,100000,
9594384,N02,LM,,N,,,,,N02LM000000,,,276201500251U-6-0-1,NIA:538100\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,ARLINGTON,UNITED STATES,,,611823738,US,,,VA,222012909,,15327887; ,"ANTORI, DENISE ;",,8/24/2015,8/23/2018,,IGF::OT::IGF,,,,,,,,,538100,
9594410,N01,HL,,N,,,,,N01HV000000,,,268201300029C-8-0-2,NIA:18497\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,OAKLAND,UNITED STATES,,13,150829349,US,3497005,KAISER FOUNDATION RESEARCH INSTITUTE,CA,946123466,,14921847; ,"SIDNEY, STEVE ;",,7/1/2013,6/30/2017,,IGF::OT::IGF CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) - FIELD CENTER. ADMINISTRATIVE MODIFICATION,,,,,,,,,18497,
8929926,H79,HH,5,N,9/14/2015,9/30/2015,9/29/2017,239,H79AE000101,,RFA-HS-11-023,5H79AE000101-05,,OTHERS,2015,DEPARTMENT OF HEALTH & HUMAN SERVICES,,STANFORD,UNITED STATES,,18,9214214,US,8046501,STANFORD UNIVERSITY,CA,943041222,,11105072; ,"GRUSKY, DAVID ;",,9/30/2011,9/29/2017,,Establishing a Poverty Research Center Program at Stanford University,101,SRC,Special Emphasis Panel ,,,5,,,,
9238947,R01,MH,2,N,12/27/2017,12/27/2017,10/31/2018,242,R01MH082017,SCHOOLS OF MEDICINE,PA-13-302,2R01MH082017-11,NIMH:777587\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF MENTAL HEALTH,,NEW YORK,UNITED STATES,NEUROSCIENCES,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323702,,1897398; ,"SALZMAN, C DANIEL;","BUHRING, BETTINA D",4/10/2008,10/31/2022,addiction; Amygdaloid structure; Anterior; Anxiety Disorders; Area; Autistic Disorder; Behavioral; Biological Neural Networks; Brain; Cognitive; cognitive control; cognitive process; cognitive reappraisal; Cues; Development; Electrophysiology (science); emotion regulation; Emotional; emotional experience; Emotions; Event; executive function; expectation; experimental study; Feeling; flexibility; Grant; Health; Hippocampus (Brain); Impaired cognition; insight; Knowledge; Lead; Learning; Life; Maintenance; Mediating; Memory; memory process; Mental disorders; Methods; Monkeys; Mood Disorders; neural circuit; neurophysiology; operation; optogenetics; Outcome; Perception; Performance; Physiological; Play; Prefrontal Cortex; prevent; Primates; Process; Psychological reinforcement; relating to nervous system; Research; response; Response to stimulus physiology; Reversal Learning; Rewards; Role; Schizophrenia; sensory stimulus; Short-Term Memory; Signal Transduction; statistics; Stimulus; Structure; Supervision; Task Performances; Testing; Time; Update; Work; ,Neurophysiology underlying neural representations of value,82017,SPC,"Mechanisms of Sensory, Perceptual, and Cognitive Processes Study Section ",,,11,485992,291595,777587,
9327389,F31,AI,1,N,8/18/2017,9/1/2017,8/31/2018,855,F31AI126673,SCHOOLS OF MEDICINE,PA-16-309,1F31AI126673-01A1,NIAID:44044\,"TRAINING, INDIVIDUAL",2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,NONE,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,14110021; ,"GOLDSTEIN, STEPHEN ;","STEMMY, ERIK J",9/1/2017,8/31/2020,A549; Amino Acids; Antiviral Agents; Antiviral Response; arm; base; Biological; Biological Assay; Biology; career; Cell Death; Cell Line; Cell Nucleus; Cells; Cessation of life; Cleaved cell; Co-Immunoprecipitations; Conflict (Psychology); Confocal Microscopy; Coronaviridae; Coronavirus; CRISPR/Cas technology; Cytoplasm; Data; Dipeptidyl-Peptidase IV; Distributional Activity; Ectopic Expression; Employee Strikes; Engineering; Ensure; Enzyme-Linked Immunosorbent Assay; Enzymes; Epithelial; Exhibits; Exons; experimental study; Family; Gene Expression; Genetic Transcription; Genome; heterokaryon; Histidine; Homologous Gene; Human; Immune response; Importins; Infection; Interferon-beta; Interferons; Introns; IRF3 gene; Kinetics; Knock-out; Label; leptomycin B; Link; Literature; Liver; Mediating; Mediator of activation protein; Messenger RNA; Middle East Respiratory Syndrome Coronavirus; Molecular Biology Techniques; Murine hepatitis virus; Mus; mutant; Mutate; Myeloid Cells; novel; Nuclear; Nuclear Import; Nuclear Translocation; pathogen; Pathogenesis; Pathway interactions; phosphodiester; phosphodiesterase V; Physiological; Play; Process; promoter; Proteins; Public Health; receptor; Recombinants; Reporter; Reporting; Research; Research Personnel; reverse genetics; Ribonucleases; RNA; Role; SARS coronavirus; Sequence Homology; Severe Acute Respiratory Syndrome; Staining method; Stains; Structural Models; success; Testing; therapeutic target; Time; Training; Transcript; Transcription Process; transcriptome sequencing; transmission process; Viral; Viral Proteins; Virulent; Virus; Virus Replication; Western Blotting; Work; Zoonoses; ,Investigating MERS-CoV NS4b as a modulator of the host antiviral response in the nucleus,126673,ZRG1,Special Emphasis Panel ,,A1,1,44044,,44044,
9424863,R01,ES,1,N,12/26/2017,1/1/2017,12/31/2018,113,R01ES028712,,PA-16-160,1R01ES028712-01,NIEHS:721528\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,BOSTON,UNITED STATES,,7,30811269,US,1080401,BRIGHAM AND WOMEN'S HOSPITAL,MA,21156110,,9167594; ,"HART, JAIME ELIZABETH;","BOYLES, ABEE",1/1/2017,12/31/2022,Address; Affect; Air Pollution; Animals; Aromatic Polycyclic Hydrocarbons; base; cell motility; cell type; Cellular Phone; Chemicals; Clinical; cohort; Couples; Development; DNA Methylation; early childhood; Endocrine Disruptors; Environmental Exposure; Environmental Impact; Environmental Risk Factor; epidemiologic data; Epigenetic Process; epigenome; epigenomics; Exposure to; Female; Fertility; Flame Retardants; General Population; Generations; Genetic; genome-wide; Health; Home environment; Human; improved; Individual; Indoor Air Pollution; Infertility; Laboratories; Lead; lifestyle factors; Link; Literature; male; Male Infertility; Measurement; Measures; men; Meta-Analysis; Methods; methylation pattern; modifiable risk; Monitor; monitoring device; Morphology; Nitrogen Dioxide; novel; Outcome; Particulate Matter; Pathway interactions; Pattern; Pesticides; phthalates; Play; pollutant; Population; Prevalence; Prevention; prospective; Research; Risk Factors; Role; Sampling; Seminal fluid; Source; sperm cell; sperm morphology; Sperm Motility; sperm quality; Spermatogenesis; Techniques; Technology; temporal measurement; Time; United States; volatile organic compound; young adult; ,The effects of environmental exposures on semen quality and the sperm epigenome,28712,IRAP,"Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section ",,,1,531332,190196,721528,
9430030,N01,AI,,N,,,,,N01AI000000,,,272201000014I-3-27200002-1,NIAID:100000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,1,5447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,,14922060; ,"HOLLAND, LOUIS ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Licensure; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,100000,
9430039,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-4,NIAID:104024\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Categories; Chemistry; Communicable Diseases; Development; Intervention; Lead; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; programs; Services; Therapeutic; therapy development; Translational Research; ,Task Order 2: Interventional Agent Development Services Program ,,,,,,,,,104024,
9430040,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-5,NIAID:254281\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Chemistry; Communicable Diseases; Development; Influenza Therapeutic; Intervention; Lead; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Services; therapeutic development; therapy development; Translational Research; ,Task Order 2: The Interventional Agent Development Services Program,,,,,,,,,254281,
9430048,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-2,NCI:976485\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Acute; Adenovirus Vector; Adenoviruses; Adopted; Adverse drug effect; Adverse effects; Affect; analog; Anesthesia procedures; Animal Model; Animals; Apoptosis; aqueous; Area; assay development; Assessment tool; base; Biological Assay; Biological Markers; Biological Models; Biological Testing; Biopsy; body system; Bone Marrow; cancer cell; Cancer Model; cancer therapy; Canis familiaris; Cardiotoxicity; Carrier Proteins; CCR; Cell Culture Techniques; cell type; Cells; Characteristics; Chemicals; chemotherapeutic agent; chemotherapy; Chronic; Clinic; Clinical; Clinical assessments; clinical development; clinical predictors; Clinical Trials; clinically relevant; Collaborations; Combined Modality Therapy; Companions; Contractor; Custom; cytotoxic; Data; Dependency; design; Development; Developmental Therapeutics Program; Dosage Forms; Dose; Dose-Limiting; drug candidate; drug development; drug discovery; Drug effect disorder; Drug Evaluation; Drug Exposure; Drug Formulations; Drug Kinetics; Drug Modelings; Drug Monitoring; Drug Targeting; Drug Tolerance; Drug toxicity; Effectiveness; efficacy evaluation; efficacy study; Emulsions; Engineering; Equilibrium; Evaluable Disease; Evaluation; Excision biopsy; Exhibits; Exposure to; Failure; Formulation; Foundations; functional status; Future; gastrointestinal; Goals; Grant; Guidelines; Hepatocyte; Hepatotoxicity; Human; human disease; human tissue; improved; In Vitro; in vitro Assay; in vitro Model; in vitro testing; in vivo; in vivo imaging; in vivo Model; Injection of therapeutic agent; innovation; interest; intravenous administration; intravenous injection; Investigation; keratinocyte; Knowledge; Laboratories; Lead; Learning; Lesion; Liquid substance; Liver; Lung; Malignant Neoplasms; man; Maximum Tolerated Dose; Measles; Mediating; Medical; melanoma; Men's Role; Methodology; Methods; Mission; Modality; Modeling; Modernization; Molecular; Molecular Target; Monitor; mouse model; multidisciplinary; Mus; Myeloid Progenitor Cells; nanoparticle; Needle biopsy procedure; Nerve Tissue; Neutropenia; new technology; Normal tissue morphology; novel; novel therapeutics; oncology; oncolysis; Oncolytic; operation; Operative Surgical Procedures; Oral Administration; Oral mucous membrane structure; Organ; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacodynamics; Pharmacology and Toxicology; Pharmacotherapy; Phase; Physiological; Plasma; Play; Poliomyelitis; pre-clinical; Pre-Clinical Model; preclinical development; preclinical efficacy; preclinical evaluation; preclinical study; predict clinical outcome; Procedures; Program Development; programs; Proximal Kidney Tubules; Radiation; Radiology Specialty; Readiness; Recombinants; Reovirus 3; Reporter; Reporting; Research; research clinical testing; Research Design; response; Rodent; Role; Route; Safety; safety engineering; Saliva; Sampling; Schedule; screening; Signal Transduction; Skin; small molecule; Solubility; Specimen; Structure of parenchyma of lung; Supervision; Symptoms; System; Technology; Testing; Therapeutic; Therapeutic Agents; Tissue Banks; tissue culture; tissue processing; Tissue Sample; Tissues; Toxic effect; toxicant; Toxicity Tests; Toxicology; Training; Translational Research; Translations; Treatment Protocols; tumor; Tumor Cell Line; Tumor Markers; Tumor Tissue; Uncertainty; United States National Institutes of Health; Validation; vector; Viral; Viral Load result; Viral Vector; Virus; Virus Replication; Work; Xenograft Model; Xenograft procedure; ,DCTD Human Toxicology and Pharmacology,,,,,,,,,976485,
9430076,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-36,NCI:1380084\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Area; Biliary Tract Diseases; Biological; Bladder Diseases; Bone Diseases; cold temperature; Collection; computerized; Epidemiology; epidemiology study; Equipment; Equipment and supply inventories; Eye diseases; Hodgkin Disease; Human; Kaposi Sarcoma; leukemia; Maintenance; malignant breast neoplasm; malignant mouth neoplasm; Malignant neoplasm of brain; Malignant neoplasm of cervix uteri; Malignant neoplasm of esophagus; Malignant neoplasm of larynx; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pharynx; Malignant neoplasm of prostate; Malignant neoplasm of testis; Malignant neoplasm of thyroid; Malignant neoplasm of urinary bladder; malignant stomach neoplasm; Malignant Vaginal Neoplasm; melanoma; Molecular Epidemiology; Multiple Myeloma; Pancreatic Non-Hodgkin's Lymphoma; Procedures; Program Development; Rectal Cancer; Renal carcinoma; repository; Sampling; Services; Skin Cancer; Specimen; Transportation; Urologic Cancer; Uterine Cancer; Vaginal Diseases; ,Repository Services for epidemiology studies,,,,,,,,,1380084,
9430087,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-49,NCI:418691\NIA:508\NIAID:0\NIDDK:0\NIEHS:40000\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Computers; Contract Services; Contractor; Contracts; data management; Development; Information Services; International; Libraries; National Cancer Institute; operation; programs; Science; Services; statistical service; Support Contracts; ,NCI-Frederick Operations and Technical Support,,,,,,,,,459199,
9430114,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-77,NCI:22930714\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,cancer Biomedical Informatics Grid; Communities; Engineering; Funding; International; outreach; quality assurance; ,Support of NCIP activities,,,,,,,,,22930714,
9430133,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-100,NIGMS:153639\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Databases; Detection; Gene Expression Profile; Human; information display; Literature; Methods; Online Systems; protein biomarkers; Research; Variant; ,Biospecimen Research Database Support ,,,,,,,,,153639,
9430135,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-102,NCI:6467562\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Adherence; Blood; Collection; Colon Carcinoma; design; Malignant neoplasm of ovary; Malignant Neoplasms; Morphologic artifacts; Normal tissue morphology; Proteomics; Standardization; The Cancer Genome Atlas; tumor; ,Biospecimen Collection Proteomic ,,,,,,,,,6467562,
9430151,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-117,NCI:9734000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,anticancer research; Capital; Core Facility; Development; Equipment; Expenditure; Funding; Gene Mutation; Institution; Intramural Research Program; Laboratories; Laboratory Research; Malignant Neoplasms; Modeling; programs; ras Genes; Research; research and development; Research Personnel; Signal Transduction; Technology; Therapeutic; United States Dept. of Health and Human Services; ,RAS Program at FNL ,,,,,,,,,9734000,
9430158,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-125,NCI:200000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,,DCP - Support to NSRG,,,,,,,,,200000,
9430205,N01,HD,,N,,,,,N01HD000000,,,275201500002I-3-27500004-1,NICHD:170002\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14264448; ,"BAUGHMAN, KATHRYN ;",,9/21/2015,9/20/2017,absorption; Animals; Area; Award; Biological Assay; Biological Testing; chemical synthesis; Chemicals; Clinical; clinical lot; clinical material; Clinical Trials; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; Contraceptive Devices; contraceptive effectiveness; design; Development; drug candidate; Drug Formulations; Drug Kinetics; Endocrine; Enrollment; Evaluation; Excretory function; Formulation; In Vitro; in vitro Assay; in vivo; Intramuscular; Investigational Drugs; Investigational New Drug Application; lot production; men; Metabolism; National Institute of Child Health and Human Development; Oral; Ovulation; Pharmaceutical Preparations; Pharmacologic Substance; Phase; pre-clinical; preclinical development; Process; product development; Production; Protocols documentation; Recruitment Activity; research clinical testing; Research Personnel; Research Support; Route; Safety; Site; sperm cell; sperm function; stability testing; System; Testing; Time; Toxic effect; Toxicology; Woman; ,BIOLOGICAL TESTING FACILITY - PRECLINICAL DEVELOPMENT OF CONTRACEPTIVES,,,,,,,,,170002,
9430219,N02,LM,,N,,,,,N02LM000000,,,276201200161U-12-0-1,NCCAM:9904\NIDCD:9936\NIDDK:296958\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,12246388; ,"BYRD-CLARK, DANITA ;",,4/17/2012,4/16/2017,Administrator; Americas; Area; Biometry; Committee Members; Complementary and alternative medicine; Complex; computer program; computerized data processing; Consultations; Contracts; Data; Data Analyses; Data Files; data management; Diabetes Mellitus; Digestive System Disorders; Disease; Documentation; editorial; Endocrinology; Ensure; Epidemiologist; Epidemiology; epidemiology study; Hematological Disease; Kidney; Metabolic Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Deafness and Other Communication Disorders; nutrition; Nutritional Study; Obesity; Publications; Reporting; Research; Research Support; Resources; Scientist; Services; Source; Surveys; United States National Center for Health Statistics; urologic; Work; Writing; ,Support services for the NIDDK Epidemiology Coordinating Committee,,,,,,,,,316798,
9430227,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-4,NIAID:427400\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,1/26/2017,1/25/2018,Antimicrobial Resistance; Communicable Diseases; Contracts; Development; Intervention; Microbiology; National Institute of Allergy and Infectious Disease; Neisseria gonorrhoeae; pre-clinical; programs; Safety; Services; therapeutic development; therapy development; Toxicology; Translational Research; ,Task 4: The Interventional Agent Development Services program ,,,,,,,,,427400,
9430234,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-11,NIAID:381000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14369140; ,"MIRSALIS, JON ;",,1/26/2017,1/25/2018,Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; Taenia solium; therapeutic development; Toxicology; Toxin; Translational Research; Trypanosoma cruzi; ,Task 4: The Interventional Agent Development Services Program ,,,,,,,,,381000,
9430243,N01,HL,,N,,,,,N01HL000000,,,268201300028C-9-0-1,NHLBI:528955\NIA:0\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,12577007; ,"SHREINER, PAMELA ;",,7/1/2013,6/30/2017,acquired factor; Address; Adult; Affect; Age; Ancillary Study; Arteries; Atrial Fibrillation; base; Blood; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; cardiovascular risk factor; Cardiovascular system; Chicago; Clinical; cohort; Communities; Coronary Artery Risk Development in Young Adults Study; Coronary heart disease; Data; Development; Disease; Education; emerging adult; Event; Evolution; follow-up; Heart Abnormalities; Heart failure; high school; Institutes; Lung; Measures; middle age; Myocardial dysfunction; novel; Participant; Phenotype; Race; racial disparity; Research Personnel; Risk; Risk Factors; Sampling; sex; sharing data; stomach cardia; stroke; Structure; Subgroup; Time; Training; Update; young adult; ,IGF::OT::IGF RD  CORONERY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) UMN FI,,,,,,,,,528955,
9430247,N01,DA,,N,,,,,N01DA000000,,,271201300001C-6-0-1,NIDA:854872\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,FORT WORTH,UNITED STATES,,12,110091808,US,6108502,UNIVERSITY OF NORTH TEXAS HLTH SCI CTR,TX,761072699,,12576983; ,"FORSTER, MICHAEL ;",,1/4/2013,1/3/2018,Abstinence; addiction; Address; Animals; Biological Assay; Chemicals; Chemosensitization; clinical predictors; Cocaine; Dependence; Development; Disease; Drug abuse; drug discrimination; Drug Industry; efficacy testing; in vivo; in vivo Model; Individual; Lead; Medical; Methamphetamine; Modeling; Motor Activity; Mus; National Institute of Drug Abuse; Neuraxis; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Physiological; pre-clinical; preclinical evaluation; preference; prevent; Primates; programs; Public Health; Rattus; Relapse; Rodent; Self Administration; Stress; Substance abuse problem; Substance Addiction; Support Contracts; Testing; Tetrahydrocannabinol; Therapeutic; Therapeutic Effect; Work; , FY 13 Rodent Testing to Identify Pharma. for Substance Dependence,,,,,,,,,854872,
9430252,N01,AI,,N,,,,,N01AI000000,,,272201400041C-2-0-1,NIAID:2748153\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,809846819,US,3125901,INFECTIOUS DISEASE RESEARCH INSTITUTE,WA,981023788,,12441852; ,"FOX, CHRIS ;",,9/30/2014,3/14/2021,Advanced Development; Categories; Cold Chains; Communicable Diseases; Development; Disease Outbreaks; Event; Formulation; National Institute of Allergy and Infectious Disease; pathogen; response; Technology; Tuberculosis Vaccines; vaccine development; Vaccines; ,DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS ,,,,,,,,,2748153,
9430253,N01,HD,,N,,,,,N01HD000000,,,275201300013C-7-0-1,NICHD:1105009\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,EVANSTON,UNITED STATES,,9,160079455,US,6144601,NORTHWESTERN UNIVERSITY,IL,602013149,,12440408; ,"LYNCH, DAVID ;",,9/26/2013,9/25/2023,"Accounting; Air; Antigens; Asthma; atopy; Autoantigens; base; Blood; Blood Pressure; Cells; Chronic Disease; Clinic; Clinic Visits; Clinical; Cohort Studies; Commuting; Contractor; Data; Defect; Diet; dietary antioxidant; Dietary intake; Educational workshop; Enrollment; Environmental Exposure; Environmental Risk Factor; Exhalation; experience; Exposure to; Fetus; Flow Cytometry; follow-up; Forced expiratory volume function; FOXP3 gene; Genes; Genetic; Health; Hour; Hypersensitivity; Immune; Immune system; improved; Inflammation; inflammatory marker; interest; Knowledge; Literature; Lung Inflammation; Measures; Mediating; Medical Records; Menstrual cycle; National Heart, Lung, and Blood Institute; Nitric Oxide; Outcome; pathogen; Patients; peripheral blood; Pharmaceutical Preparations; Play; Population; Postpartum Period; Predictive Factor; Pregnancy; pregnancy immunology; Pregnancy Outcome; Process; Questionnaires; Recruitment Activity; Regulation; Regulatory T-Lymphocyte; Reporting; research study; Respiratory physiology; Role; Sampling; Severities; Specimen; Subgroup; Symptoms; United States National Institutes of Health; Urine; Visit; Woman; ",ASTHMA CONTROL VARIABILITY DURING PREGNANCY,,,,,,,,,1105009,
9430259,N01,AI,,N,,,,,N01AI000000,,,272201000009I-1-27200006-1,NIAID:1509378\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FORT COLLINS,UNITED STATES,,2,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805231062,,14376832; ,"IZZO, ANGELO ;",,1/11/2016,6/30/2018,Animal Model; Contracts; Development; efficacy testing; Genus Mycobacterium; infectious disease model; Intervention; Mycobacterium tuberculosis; Standardization; Testing; Translational Research; vaccine development; ,Task A80: Advanced Small Animal Models for the Testing of Candidate Interventions against Mycobacteria,,,,,,,,,1509378,
9430261,N02,DA,,N,,,,,N02DA000000,,,271201500014A-4-0-1,NIMH:307370\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILMINGTON,UNITED STATES,,,109359435,US,,"PPD DEVELOPMENT, LP",NC,284013331,,12627860; ,"EZZELLE, JASON ;",,1/9/2017,1/8/2018,Adherence; Clinical; Clinical Research; clinical research site; Clinical Trials; Contractor; Country; Data; Effectiveness; Ensure; Guidelines; International; Measures; meetings; Mental Health; Monitor; National Institute of Mental Health; Outcome; Performance; Preparation; Procedures; Process; Protocols documentation; Quality Control; Recommendation; Records; Reporting; Research; Services; Site; Site Visit; Teleconferences; Training; Visit; ,IGF::OT::IGF  COLLABORATIVE HUBS FOR INTERNATIONAL RESEARCH ON MENTAL HEALTH (CHIRMH),,,,,,,,,307370,
9478656,N01,CA,,N,,,,,N01CA000000,,,261201300014I-3-26100005-2,NCI:3132161\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,OAKLAND,UNITED STATES,,13,128663390,US,1618201,PUBLIC HEALTH INSTITUTE,CA,946074046,,14505838; ,"CRESS, ROSEMARY ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER); PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017.",,,,,,,,,3132161,
9478657,N02,DA,,N,,,,,N02DA000000,,,271201500084C-3-0-1,NINDS:6494\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MOUNTAIN VIEW,UNITED STATES,,18,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,940430816,,14256101; ,"HANSEN, KAREN ;",,9/14/2017,9/13/2018,Biological Assay; Chemistry; Clinical Pharmacology; Contracts; Development; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; experience; Funding; Industry; Institutes; Lead; Leadership; Maps; Medical; National Institute of Neurological Disorders and Stroke; Neurosciences; Neurosciences Research; Pharmaceutical Chemistry; Pharmacologic Substance; Phase; Phase I Clinical Trials; Principal Investigator; Program Development; programs; Regulatory Affairs; Research; Research Contracts; Research Personnel; Services; Toxicology; United States National Institutes of Health; Writing; ,NINDS BPN MEDICAL WRITING CONSULTANT IGF::CL::IGF,,,,,,,,,6494,
9478818,N01,HL,,N,,,,,N01HL000000,,,268201300050C-7-0-1,NHLBI:637871\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,JACKSON,UNITED STATES,,2,44507085,US,692401,JACKSON STATE UNIVERSITY,MS,39217,,12255144; ,"GATES, MICHAEL ;",,8/16/2013,8/12/2018,Abdomen; African American; Ancillary Study; Aorta; Area; Back; Biochemical; Biological; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; career; Clinical; cohort; Cohort Studies; Collection; Communities; Community Health Education; Community Outreach; Contracts; Data; Data Analyses; Disease; disorder risk; Echocardiography; Epidemiology; Event; follow-up; Funding; graduate student; Health Professional; Health Promotion; healthy lifestyle; heart imaging; High School Student; Hospitalization; improved; Institution; interest; Interview; Investigation; Jackson Heart Study; Magnetic Resonance Imaging; Manuscripts; Measures; Minority; minority student; Mississippi; Morbidity - disease rate; mortality; Outpatients; Participant; Prevention; Public Health; public health research; Publications; Recruitment Activity; Research Personnel; Resources; Risk; Risk Factors; Sampling; Services; Site; socioeconomics; Testing; Time; Training; Training Programs; undergraduate student; Validation; Visit; X-Ray Computed Tomography; ,IGF::OT::IGF Jackson Heart Study Renewal Community Outreach Center activities inc,,,,,,,,,637871,
9478820,N01,MH,,N,,,,,N01MH000000,,,271201200007I-9-27100003-2,NIMH:258713\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,NEW YORK,UNITED STATES,,13,167204994,US,1590919,NEW YORK STATE PSYCHIATRIC INSTITUTE,NY,100321007,,12576919; ,"LIEBERMAN, JEFFREY ;",,8/29/2013,4/28/2018,Agonist; Anhedonia; Biological Markers; Certificate of Confidentiality; Clinical; clinical development; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; cognitive function; Communication; Communities; Contracts; Development; Dimensions; Disease; Enrollment; Feasibility Studies; Future; Goals; Human; Information Dissemination; Information Systems; Informed Consent; Intervention; Manuscripts; Measurement; Measures; Medicine; Modality; Molecular; National Institute of Mental Health; novel; Phase; Physiological; Pilot Projects; Preparation; protocol development; Protocols documentation; Psychopathology; Publications; receptor; Recruitment Activity; Registries; Reporting; Research Infrastructure; Schedule; Site; social engagement; Support Contracts; Teleconferences; Testing; tool; Training; United States National Institutes of Health; United States National Library of Medicine; ,New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum,,,,,,,,,258713,
9478821,N01,AI,,N,,,,,N01AI000000,,,272201100021I-1-27200035-1,NIAID:137181\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14726104; ,"VANCOTT, THOMAS ;",,9/1/2016,8/31/2020,AIDS prevention; authority; Contracts; Development; DNA; Documentation; flexibility; Guidelines; HIV vaccine; immunogenicity; Investigational Drugs; Investigational New Drug Application; Investigator-Initiated Research; microbicide; Modality; National Institute of Allergy and Infectious Disease; Pamphlets; Pharmaceutical Preparations; Phase; preclinical development; Preclinical Testing; Process; Production; Protocols documentation; Recombinant DNA; research clinical testing; Research Personnel; research study; Safety; Testing; ,NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF GEO-D02 DNA DRUG PRODUCT,,,,,,,,,137181,
9483232,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-2,NIAID:462930\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; Yellow fever virus; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,462930,
9487081,N01,AI,,N,,,,,N01AI000000,,,272201500011C-5-0-1,NIAID:239961\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,809832558,US,10018550,"KINETA, INC.",WA,981095230,,14164947; ,"IADONATO, SHAWN ;",,6/30/2015,7/31/2017,Clinical; clinical development; Communicable Diseases; drug candidate; Future; In Vitro; in vivo; infectious disease treatment; Influenza A virus; Lead; novel; Pharmaceutical Chemistry; pre-clinical; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases,,,,,,,,,239961,
9487084,N02,DA,,N,,,,,N02DA000000,,,271201500089C-2-0-1,NINDS:18000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,NORRISTOWN,UNITED STATES,,,79830109,US,,,PA,194031376,,14256109; ,"WINCHELL, GREGORY ;",,9/14/2015,9/13/2018,Biological Assay; Chemistry; Clinical Pharmacology; Contracts; Development; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; experience; Funding; Industry; Institutes; Lead; Leadership; Maps; Medical; National Institute of Neurological Disorders and Stroke; Neurosciences; Neurosciences Research; Pharmaceutical Chemistry; Pharmacologic Substance; Phase; Phase I Clinical Trials; Principal Investigator; Program Development; programs; Regulatory Affairs; Research; Research Contracts; Research Personnel; Services; Toxicology; United States National Institutes of Health; Writing; ,NINDS GREG WINCHELL BPN CLINICAL PHASE 1 CONSULTING IGF::CL::IGF,,,,,,,,,18000,
9487752,N01,AI,,N,,,,,N01AI000000,,,272201000003I-3-27200004-1,NIAID:9322\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,11173807; ,"BRUCE, MARY ;",,3/22/2010,3/21/2017,Antibiotic Therapy; Contracts; Development; efficacy testing; infectious disease model; Licensure; Modeling; nonhuman primate; Plague; Standardization; therapeutic evaluation; Yersinia pestis; ,Task C07: Plague Antibiotic Treatment Models,,,,,,,,,9322,
9492477,N02,CA,,N,,,,,N02CA000000,,,261201600003C-1-0-1,NCI:1275000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,,,,806502816,,,,,,,14600584; ,"KIERNAN, SHERYL ;",,6/16/2016,5/31/2018,Cancer Center; Cancer Therapy Evaluation Program; Clinical Trials; Communities; Contractor; Data Element; Databases; Decision Making; Descriptor; Development; Drug Industry; Ensure; Extramural Activities; Goals; Mission; Monitor; operation; Policies; Process; programs; Protocols documentation; Reporting; Research Personnel; Resource Allocation; Schedule; Support Contracts; System; Time; TimeLine; working group; ,IGF::OT::IGF OPERATION & SUPPORT OF THE CTEP PROTOCOL AND INFORMATION OFFICE (PIO),,,,,,,,,1275000,
9493588,N01,AI,,N,,,,,N01AI000000,,,272201000006I-0-27200013-1,NIAID:1781563\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,14969773; ,"PATTON, DOROTHY ;",,3/20/2017,8/31/2018,animal model development; Antimicrobial Resistance; Chlamydia trachomatis; co-infection; Contracts; Development; efficacy testing; Family suidae; Infection; infectious disease model; Licensure; Macaca; Modeling; Neisseria gonorrhoeae; nonhuman primate; Standardization; Tail; Therapeutic; Vaccines; ,TASK C34: PILOT INFECTION MODEL IN PIG-TAILED MACAQUES: ASSESSMENT OF NEISSERIA GONORRHEA (GC) AND CHLAMYDIA TRACHOMATIS (CT) CO-INFECTION,,,,,,,,,1781563,
9507736,N01,CA,,N,,,,,N01CA000000,,,261201200042I-2-26100007-1,NCI:96186\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,6721205; ,"LIMBURG, PAUL J;",,9/5/2014,9/23/2019,Adverse event; Animal Model; Cirrhosis; Clinic; Clinical Trials; Contractor; design; Dose; Epidermal Growth Factor; Epidermal Growth Factor Receptor; Erlotinib; Excision; Gene Expression Profile; Hepatitis C; Intervention; Liver; Measurable; Organ; outcome forecast; overexpression; Participant; Patients; Pilot Projects; Plasma; prevent; Primary Carcinoma; Primary carcinoma of the liver cells; Receptor Inhibition; Receptor Signaling; response; Schedule; Staining method; Stains; Tissues; Viral Load result; ,CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26,,,,,,,,,96186,
9509785,N01,AI,,N,,,,,N01AI000000,,,272201000025I-0-27200004-1,NIAID:25000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BOSTON,UNITED STATES,,7,39318308,US,8422704,TUFTS UNIVERSITY BOSTON,MA,21111901,,14973649; ,"TZIPORI, SAUL ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,25000,
9513980,N01,AI,,N,,,,,N01AI000000,,,272201200023C-7-0-1,NIAID:3278581\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,68610245,US,6644301,RUSH UNIVERSITY MEDICAL CENTER,IL,606123833,,12401444; ,"BREMER, JAMES ;",,9/21/2012,9/20/2017,AIDS/HIV problem; Anti-HIV Therapy; Biological Assay; Clinical; Clinical Trials Network; Clinical Virology; co-infection; Communicable Diseases; Contracts; cost; Country; data management; Development; Ensure; Epidemiology; Evaluation; Evaluation Studies; FDA approved; Funding; Grant; HIV drug resistance; International; Investigation; Laboratories; Methodology; Methods; Mission; Modification; Monitor; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; new technology; point of care; pre-clinical; programs; quality assurance; reagent standard; Reproducibility; Research Personnel; Resources; Sensitivity and Specificity; Site; Standardization; Statistical Data Interpretation; Testing; Therapeutic; Vaccines; Validation; virology; ,NIAID VIROLOGY QUALITY ASSURANCE,,,,,,,,,3278581,
9514429,N01,HL,,N,,,,,N01HL000000,,,268201600002I-0-26800002-1,NHLBI:513267\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14921871; ,"BRANDT, DIANE ;",,12/1/2016,11/30/2017,Chronic Obstructive Airway Disease; Clinical; Clinical Data; Data; Data Coordinating Center; Data Quality; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Human Resources; Link; Lung diseases; meetings; Pathogenesis; Process; Quality Control; repository; Research; Research Personnel; sample collection; Site Visit; Specimen; Structure of parenchyma of lung; Training; ,"IGF::OT::IGF LUNG TISSUE RESEARCH CONSORTIUM RENEWAL, DATA COORDINATING CENTER, TASK ORDER 02, DECEMBER 1, 2016-NOVEMBER 30, 2017",,,,,,,,,513267,
9515630,N01,HD,,N,,,,,N01HD000000,,,275201300019I-4-27500001-1,NICHD:9609\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,NORFOLK,UNITED STATES,,3,58625146,US,471501,EASTERN VIRGINIA MEDICAL SCHOOL,VA,235011980,,12445776; ,"ARCHER, DAVID F ;",,6/26/2013,6/25/2018,Acetates; Adverse effects; Age; arm; Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Contracts; Data; Development; Devices; Dose; drug candidate; Drug Kinetics; emergency contraception; endometriosis; Estrogens; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Hemorrhage; Interruption; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; Non obese; novel therapeutics; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; Pharmaceutical Preparations; Pharmacodynamics; Pharmacotherapy; Phase; Phase IV Clinical Trials; pill; Population Research; pre-clinical; progesterone receptor A; Progestins; protocol development; Randomized; Regimen; reproductive; Reproductive Health; research and development; Risk; Safety; Site; Social Welfare; synthetic peptide; Testing; Thromboembolism; Time; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Uterine Fibroids; Venous; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,9609,
9515632,N01,HD,,N,,,,,N01HD000000,,,275201300014I-4-27500001-1,NICHD:10597\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CINCINNATI,UNITED STATES,,1,41064767,US,1523902,UNIVERSITY OF CINCINNATI,OH,452210001,,12446636; ,"KUES, KIM ;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Male Contraceptive Agents; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,10597,
9515724,N01,HD,,N,,,,,N01HD000000,,,275201300004I-5-27500001-1,NICHD:8141\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,12445627; ,"BURKE, ANNE ;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,8141,
9519200,UH2,NS,3,N,12/27/2017,8/1/2017,7/31/2018,856,UH2NS100588,SCHOOLS OF MEDICINE,PA-16-287,3UH2NS100588-02S1,NIA:21585\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,BALTIMORE,UNITED STATES,RADIATION-DIAGNOSTIC/ONCOLOGY,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,1866096; 8097658 (contact); ,"ALBERT, MARILYN S.; LU, HANZHANG  (contact);","MCGAVERN, LINDA",9/30/2016,7/31/2018,AD pathology; Age; Alzheimer's Disease; Amyloid beta-Protein; anatomic imaging; base; Biochemical; Biological Markers; Blood Vessels; Brain; candidate marker; Cardiovascular Diseases; cardiovascular risk factor; cerebrovascular; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinical; clinical research site; Clinical Trials; Cognition; Cognitive; cognitive function; cognitive testing; cohort; Complement; Coupling; Cross-Sectional Studies; Dementia; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Disease; driving force; Elderly; Funding; Goals; Health; Homeostasis; hypercholesterolemia; Hypertension; Image; imaging biomarker; imaging modality; Impaired cognition; indexing; Individual; Institution; Lacunar Infarctions; Lesion; Liquid substance; Longitudinal cohort; Magnetic Resonance Imaging; Measures; Microvascular Dysfunction; neurovascular unit; novel marker; novel therapeutics; Participant; Pathologic; Pathology; Patients; Perfusion; Phase; Physiological; Preparation; Process; processing speed; prognostic; Readiness; Records; Recruitment Activity; Regression Analysis; Reproducibility; Research Infrastructure; Research Personnel; Rest; Risk Factors; Scanning; Site; Spinal Puncture; targeted biomarker; tau Proteins; Techniques; Time; Universities; validation studies; vascular contributions; White Matter Hyperintensity; Work; ,Development of MRI microvascular biomarkers in cognitive impairment and dementia,100588,ZNS1,Special Emphasis Panel ,,S1,2,13200,8385,21585,
9521483,N02,CA,,N,,,,,N02CA000000,,,261201400004I-3-26100002-1,NCI:849032\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SPRINGFIELD,UNITED STATES,,18,831496661,US,4155401,NORTH AMERICAN ASSN/CENTRAL CANCER REG,IL,627047412,,14165167; ,"KOHLER, BETSY ;",,7/1/2015,6/30/2018,American; Area; Cancer Surveillance Research; Collaborations; Contracts; data registry; improved; Institutes; Malignant Neoplasms; Methods; neoplasm registry; operation; Registries; Surveillance Program; Time; ,"IGF::OT::IGF 402 - NORTH AMERICAN ASSOCIATION OF CENTRAL CANCER REGISTRIES, INC. (NAACCR); TECHNICAL SUPPORT FOR CANCER SURVEILLANCE; POP 07/01/2015 -06/30/2016",,,,,,,,,849032,
9521684,N02,CA,,N,,,,,N02CA000000,,,261201500006C-7-0-1,NCI:7298456\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BETHESDA,UNITED STATES,,,57052391,US,,TECHNICAL RESOURCES INC,MD,208171197,,12062814; ,"SAUNDERS, JOAN ;",,7/1/2015,6/30/2018,Cancer Therapy Evaluation Program; drug development; Reporting; , DRUG DEVELOPMENT SUPPORT FOR THE CANCER THERAPY EVALUATION PROGRAM (CTEP),,,,,,,,,7298456,
9522286,N01,AI,,N,,,,,N01AI000000,,,272201000040I-2-27200011-2,NIAID:2854\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,14944512; ,"BEASLEY, DAVID ;",,4/28/2016,6/23/2017,Animal Model; Antiviral Agents; Communicable Diseases; Contracts; Ebola virus; meetings; mouse model; programs; Testing; therapeutic evaluation; ,TASK A94: Mouse Models for Therapeutics Testing Against Ebola Virus,,,,,,,,,2854,
9525755,N02,DA,,N,,,,,N02DA000000,,,271201600039C-1-0-1,NINDS:4125\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BOSTON,UNITED STATES,,,64226999,US,,,MA,2127,,14772082; ,"MACKIN, BILL ;",,9/21/2017,9/20/2018,Academia; Achievement; Address; Affect; Agreement; analytical method; Area; authority; Award; base; Basic Science; Behavior; Biochemistry; Biologic Development; Biological Assay; Biological Products; Biological Sciences; Biotechnology; Brain; Businesses; Cell Therapy; Cells; Characteristics; Chemicals; Client; Clinical; clinical development; clinical investigation; Clinical Protocols; Clinical Research; Clinical Trials; Code; Collaborations; Color; Communities; Complex; Comprehension; Computers; Confidential Information; Consent; Consult; Contractor; Contracts; cost; Data; Data Analyses; Data Files; Decision Making; design; Development; Development Plans; Disabled Persons; Disclosure; Disease; Doctor of Philosophy; Documentation; Educational workshop; Electronic Mail; Elements; Employee; encryption; Evaluation; experience; experimental study; Extramural Activities; federal policy; Feedback; Food; Formulation; Funding; gene therapy; Government; Grant; Guidelines; Health; health data; Home environment; Hour; Human; Human Resources; indexing; Individual; Industry; Information Technology; Institutes; Institution; Internet; Intramural Research Program; Investigational Drugs; Joints; Knowledge; Lead; Licensing; Life; Liposomes; Mediation; member; method development; Methods; Mission; Modality; Monitor; multidisciplinary; Multimedia; Names; nanoparticle; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; novel therapeutic intervention; Oligonucleotides; Oral; Ownership; Participant; Peptide antibodies; Performance; Performance at work; Personnel Management; Persons; Phase; Polymers; Preparation; Prevention; Price; Principal Investigator; Privacy; Privacy Act; Process; Production; programs; Progress Reports; Property; Published Comment; Recombinant Proteins; Recommendation; Regulation; Rehabilitation therapy; Reporting; Research; Research Activity; Research Design; Research Personnel; Research Project Grants; Resolution; Resources; response; Rights; Risk; Role; scale up; Scanning; Schedule; Security; Services; Site; Site Visit; skills; Specific qualifier value; Speech; stability testing; stroke; Supervision; symposium; Telephone; Testing; Theft; Therapeutic; therapy development; Time; Time Management; Training; Training Programs; Translational Research; Translations; Travel; U-Series Cooperative Agreements; United States; United States National Institutes of Health; Viral; Virus; Visit; Visual; web site; webinar; Weight; Work; Writing; ,NINDS W MACKIN & ASSOCIATES CMC CONSULTING IGF::CL::IGF,,,,,,,,,4125,
9526100,N01,CA,,N,,,,,N01CA000000,,,261201300015I-0-26100009-1,NCI:53572\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15082066; ,"WARD, KEVIN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016.,,,,,,,,,53572,
9528357,N01,AI,,N,,,,,N01AI000000,,,272201400021C-7-0-1,NIAID:1507804\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENANDS,UNITED STATES,,20,153695478,US,5966012,WADSWORTH CENTER,NY,122042726,,12441477; ,"COLOMB, JOLIE ;",,9/30/2017,9/29/2018,Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; Bioterrorism; Computer software; Contracts; Data; Databases; Emerging Communicable Diseases; Epitopes; Evaluation; Goals; Human; Humoral Immunities; Immune; In Vitro; in vivo; multidisciplinary; neutralizing antibody; novel; Pathogenesis; programs; Resources; Ricin; Sampling; Toxin; Validation; ,Identification and validation of B-cell epitopes on ricin toxin,,,,,,,,,1507804,
9528358,N01,AI,,N,,,,,N01AI000000,,,272201400030C-7-0-1,NIAID:1064685\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,12424678; ,"ROOS, DAVID ;",,9/30/2017,9/29/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human Resources; Malaria; pathogen; Research; Resources; Services; tool; Update; user-friendly; ,BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,1064685,
9529453,N01,AI,,N,,,,,N01AI000000,,,272201400058C-7-0-1,NIAID:674441\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,34055645,US,4419201,INTEGRAL MOLECULAR,PA,191045504,,12441480; ,"DORANZ, BENJAMIN ;",,9/30/2014,9/29/2019,Alanine; Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; B-Lymphocytes; Binding Sites; Biochemical; Biological Assay; Bioterrorism; Clinical; Clone Cells; Computer software; Contracts; cross reactivity; Data; Databases; Ebola virus; Emerging Communicable Diseases; Epitope Mapping; Epitopes; Evaluation; Goals; GP2 gene; GTPBP1 gene; Hepatitis C; Human; Humoral Immunities; Immune; In Vitro; Maps; Monoclonal Antibodies; multidisciplinary; Mutagenesis; novel; pathogen; Pathogenesis; Patients; Phage Display; programs; Property; Resources; Sampling; Scanning; Shotguns; Structure; Surface; Technology; Toxin; Vaccinated; Validation; Viral; Viral Pathogenesis; ,Discovery and Characterization of B-Cell Epitopes for Hepatitis C Virus and Ebola Virus,,,,,,,,,674441,
9531622,N01,CA,,N,,,,,N01CA000000,,,261201300017I-0-26100014-1,NCI:56361\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,15124289; ,"SWEENEY, CAROL ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016,,,,,,,,,56361,
9531997,N02,LM,,N,,,,,N02LM000000,,,276201300171U-5-0-1,NIDDK:260634\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,12326301; ,"DURAKO, STEVE ;",,7/1/2016,6/30/2018,Attention; Brain Diseases; Centers for Disease Control and Prevention (U.S.); Cessation of life; Child; cohort; Contractor; Creutzfeldt-Jakob Syndrome; Development; Disease; Failure; follow-up; Growth; Individual; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Neurological Disorders and Stroke; Physicians; Pituitary Hormones; programs; Research; Services; Somatropin; United States; United States Public Health Service; ,CREUTZFELDT-JAKOB DISEASE SURVEILLANCE IN RECIPIENTS OF HUMAN GROWTH HORMONE,,,,,,,,,260634,
9531999,N01,AI,,N,,,,,N01AI000000,,,272201300023I-1-27200012-1,NIAID:131810\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,14763901; ,"CREECH, BUDDY ;",,9/22/2016,5/15/2021,Antimicrobial Resistance; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Drug Kinetics; Gram-Negative Bacteria; Individual; named group; Population; programs; protocol development; Resources; Therapeutic Studies; ,VTEU: POPULATION PHARMACOKINETIC ANALYSES ,,,,,,,,,131810,
9532319,N01,CA,,N,,,,,N01CA000000,,,261201300013I-0-26100012-1,NCI:125492\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LEXINGTON,UNITED STATES,,6,939017877,US,2793601,UNIVERSITY OF KENTUCKY,KY,405260001,,15138368; ,"NEE, JACLYN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016 POP 7/31/2017-7/30/2018,,,,,,,,,125492,
9532320,N01,CA,,N,,,,,N01CA000000,,,261201300009I-0-26100009-1,NCI:56697\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HONOLULU,UNITED STATES,,,9438664,US,,HAWAII UNIV,HI,968222205,,15138365; ,"HERNANDEZ, BRENDA ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016 POP 7/31/2017-7/30/2018.,,,,,,,,,56697,
9533344,N01,HD,,N,,,,,N01HD000000,,,276201500204U-4-0-1,NIDDK:450495\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14199660; ,"DRUCKENMILLER, JIM ;",,7/29/2015,7/28/2018,Americas; Clinical Practice Patterns; Contractor; Data; data access; Data Analyses; Data Sources; demographics; design; Economics; Ensure; Epidemiology; Government; Health Care Costs; Health Professional; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Malignant; outreach; patient oriented; Periodicity; Privatization; Procedures; Services; Update; Urologic Diseases; web page; webinar; ,Suppport Services for Urologic Diseases in America,,,,,,,,,450495,
9533346,N01,HD,,N,,,,,N01HD000000,,,275201400003I-1-27500016-1,NICHD:40431\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14678076; ,"MANDACI, OGUZ ;",,7/22/2016,7/19/2017,6 year old; Assisted Reproductive Technology; Blood Pressure; cardiometabolic risk; Child; Clinic; Clinic Visits; cohort; Data; Epigenetic Process; follow-up; health difference; Home environment; In Vitro; Infant Development; Infertility; infertility treatment; Lipids; Measurement; Measures; New York; Obesity; Ovarian; Ovulation; Ovulation Induction; Participant; Process; programs; Recruitment Activity; repository; screening; Services; Specimen; Subgroup; Testing; Time; Training; treatment effect; Twin Multiple Birth; Visit; ,REPOSITORY SERVICES FOR UPSTATE KIDS FOLLOW UP SPECIMENS ,,,,,,,,,40431,
9534467,N01,AI,,N,,,,,N01AI000000,,,272201600001G-1-0-1,NIAID:966176\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,RESTON,UNITED STATES,,11,43690788,US,10022495,"EDJ ASSOCIATES, INC.",VA,201911244,,14644230; ,"JUBILEE, JAMES ;",,7/21/2016,7/20/2018,Acquired Immunodeficiency Syndrome; AIDS/HIV problem; Area; Biomedical Research; Communicable Diseases; Community Health; Contracts; Development; Evaluation; Global Change; Goals; meetings; member; Mission; Monitor; National Institute of Allergy and Infectious Disease; outreach; Private Sector; Process; Professional Organizations; programs; Research; Research Personnel; research study; Research Support; Resources; Scientist; Services; Surveys; symposium; Training; United States National Institutes of Health; Work; ,RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME,,,,,,,,,966176,
9535023,N02,HL,,N,,,,,N02HL000000,,,268201500061U-4-0-1,NHLBI:193446\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,14092500; ,"WOOTEN, LINDA ;",,5/1/2015,8/31/2017,"Area; commercialization; innovation; International; National Heart, Lung, and Blood Institute; Performance; Services; ","IGF::OT::IGF - RTI INTERNATIONAL TO PROVIDE SUPPORT SERVICES FOR FUNCTIONAL AREA TWO (2) OF THE NHLBI INNOVATION AND COMMERCIALIZATION COORDINATING CENTER (NIC3) FOR A PERIOD OF PERFORMANCE OF MAY 1, ",,,,,,,,,193446,
9430286,N01,AI,,N,,,,,N01AI000000,,,272201200010C-15-0-2,NIAID:324723\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,52,603880287,US,2465301,LA JOLLA INST FOR ALLERGY & IMMUNOLGY,CA,920371387,,12576845; ,"SETTE, ALESSANDRO ;",,12/15/2012,12/14/2017,Algorithms; Alleles; Allergens; Allergic rhinitis; Alloantigen; Amino Acids; analytical tool; Animals; Antibodies; Antigens; Attention; Autoantigens; Binding; Biological; Bioterrorism; Categories; Communities; Computer software; Contractor; Databases; Development; Disease; Documentation; Epitope Mapping; Epitopes; Food Hypersensitivity; Frequencies; Human; Imagery; Immune; immunogenicity; improved; Ligands; Link; Literature; Methods; MHC Class I Genes; Modeling; Molecular; Molecular Conformation; National Institute of Allergy and Infectious Disease; nonhuman primate; Online Systems; pathogen; Peptides; Population; prediction algorithm; programs; protein structure; Proteins; Publications; Publishing; relational database; Research; Resources; Series; Source; Source Code; T-Lymphocyte Epitopes; three dimensional structure; tool; Toxin; Validation; web site; ,Immune Epitope Database: Allergic rhinitis and food allergy,,,,,,,,,324723,
9430287,N01,AI,,N,,,,,N01AI000000,,,272201200010C-15-0-3,NIAID:93808\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,52,603880287,US,2465301,LA JOLLA INST FOR ALLERGY & IMMUNOLGY,CA,920371387,,12576843; ,"SETTE, ALESSANDRO ;",,12/15/2012,12/14/2017,Algorithms; Alleles; Allergens; Alloantigen; Amino Acids; analytical tool; Animals; Antibodies; Antigens; Attention; Autoantigens; Binding; Biological; Bioterrorism; Categories; Cell Transplantation; Communities; Computer software; Contractor; Databases; Development; Disease; Documentation; Epitope Mapping; Epitopes; Frequencies; Human; Imagery; Immune; immunogenicity; improved; Ligands; Link; Literature; Methods; MHC Class I Genes; Modeling; Molecular; Molecular Conformation; National Institute of Allergy and Infectious Disease; nonhuman primate; Online Systems; Organ Transplantation; pathogen; Peptides; Population; prediction algorithm; programs; protein structure; Proteins; Publications; Publishing; relational database; Research; Resources; Series; Source; Source Code; T-Lymphocyte Epitopes; three dimensional structure; Tissue Transplantation; tool; Toxin; Transplantation; Validation; web site; ,"Immune Epitope Database:  Transplantation of organs, tissues, and cells",,,,,,,,,93808,
9430297,N01,NS,,N,,,,,N01NS000000,,,271201500005I-4-27100001-1,NINDS:28163\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,ALBANY,UNITED STATES,,20,787793900,US,3294801,"ALBANY MOLECULAR RESEARCH, INC.",NY,122035121,,12576605; ,"REILLY, JOHN ;",,1/15/2015,1/14/2025,analytical method; Clinical Trials; Contractor; Contracts; Data; Development; Documentation; Dosage Forms; drug candidate; drug development; drug distribution; efficacy study; Formulation; good laboratory practice; Grant; Investigational Drugs; Investigational New Drug Application; Label; method development; novel therapeutics; Pharmaceutical Preparations; Pharmacologic Substance; preclinical efficacy; Preparation; Process; programs; Regulation; small molecule; support network; United States Food and Drug Administration; United States National Institutes of Health; Validation; Work; ,IGF::OT::IGF DRUG MANUFACTURING AND FORMULATION PROGRAM (DMFP) TASK ORDER #01:  PERFORMANCE ACTIVITY 1 TECHNICAL SUPPORT (1/15/15 / 1/14/16),,,,,,,,,28163,
9430322,N01,AI,,N,,,,,N01AI000000,,,272201300022I-2-27200013-2,NIAID:526082\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,14652706; ,"DERR, NICOLE ;",,7/12/2016,5/14/2018,Bird Flu vaccine; Clinical; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza A virus; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,526082,
9430337,N01,AI,,N,,,,,N01AI000000,,,272201300020I-4-27200004-1,NIAID:311677\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,9417388; ,"WINOKUR, PATRICIA ;",,7/1/2015,7/16/2018,Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; Phase I Clinical Trials; phase I trial; Population; Resources; Route; System; vaccine candidate; Vaccines; Yellow fever virus; ,Vaccine and Treatment Evaluation Unit: Phase I Trial of a Yellow Fever Virus Vaccine,,,,,,,,,311677,
9430339,N01,AI,,N,,,,,N01AI000000,,,272201400048C-6-0-1,NIAID:1442378\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,49,781613492,US,7375802,SCRIPPS RESEARCH INSTITUTE,CA,920371000,,12441846; ,"OLDSTONE, MICHAEL B.A. ;",,9/29/2016,9/30/2017,Adult; Africa; aged; Alleles; Award; Binding; Biological Assay; Bioterrorism; CD4 Positive T Lymphocytes; CD8B1 gene; Child; Communities; Computer software; Contracts; Data; Databases; Diagnostic; Emerging Communicable Diseases; enzyme linked immunospot assay; Epitopes; Glycoproteins; Goals; Human; Human Volunteers; Immune; immunogenicity; In Vitro; Lassa Fever; Lassa virus; microorganism; multidisciplinary; neonate; novel; Nucleoproteins; Patients; Peptides; programs; protein expression; Research; seropositive; Sierra Leone; T-Cell Proliferation; T-Lymphocyte; T-Lymphocyte Epitopes; tool; Validation; validation studies; ,Identification and Validation of Novel Human T cell Epitopes in Lassa Fever,,,,,,,,,1442378,
9430352,N02,HL,,N,,,,,N02HL000000,,,268201500062U-4-0-1,NHLBI:497303\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ALEXANDRIA,UNITED STATES,,8,19121586,US,10037609,"DELOITTE CONSULTING, LLP",VA,223143456,,14092504; ,"HOSEA, KIRSTY ;",,5/1/2015,8/31/2017,"Area; commercialization; Consult; innovation; National Heart, Lung, and Blood Institute; Performance; Services; ",IGF::OT::IGF - DELOITTE CONSULTING TO PROVIDE SUPPORT SERVICES FOR FUNCTIONAL AREA TWO (2) OF THE NHLBI INNOVATION AND COMMERCIALIZATION COORDINATING CENTER (NIC3) FOR A PERIOD OF PERFORMANCE OF MAY 1,,,,,,,,,497303,
9435059,N01,AI,,N,,,,,N01AI000000,,,272201000040I-6-27200008-1,NIAID:197699\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,14478316; ,"BEASLEY, DAVID ;",,9/1/2014,6/16/2017,Animal Model; animal model development; Biological Assay; Contracts; Development; Ebola virus; efficacy testing; Filoviridae; Filovirus; Frankfurt-Marburg Syndrome Virus; infectious disease model; Standardization; Therapeutic Human Experimentation; Vaccine Research; ,Task A68: Refinement of small animal model potency assays for Filovirus challenge material,,,,,,,,,197699,
9440306,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300007-1,NIEHS:193494\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14634893; ,"WAGNER, DAVID ;",,7/11/2016,7/10/2017,Accelerometer; base; Clinical; Clinical Research; Clinical Research Associate; Collaborations; Communication; Contractor; Contracts; data integrity; Ensure; expectation; Expenditure; Frequencies; Good Clinical Practice; Human Resources; International; Monitor; National Institute of Environmental Health Sciences; Participant; Persons; Practice Guidelines; Procedures; Protocol Compliance; Regulation; Reporting; research study; Research Support; Resources; Schedule; Secure; Services; Site; Specific qualifier value; Structure; symposium; TimeLine; tool; Training; Visit; Workplace; ,Clinical Research Support Services for NIEHS Contract Task Order 7 - Clinical Monitoring Activities,,,,,,,,,193494,
9442646,N02,OD,,N,,,,,N02OD000000,,,263201200029I-2-27200003-1,NIAID:547069\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,FAIRFAX,UNITED STATES,,,183818145,US,,CAPITAL CONSULTING CORP,VA,220314376,,12627834; ,"SINGER, BARBARA ;",,3/1/2015,11/14/2017,Acquired Immunodeficiency Syndrome; Adverse event; clinical research site; Clinical Trials; Clinical Trials Data Monitoring Committees; Data; Funding; Geographic Locations; Individual; Institutes; Institutional Review Boards; Light; meetings; Monitor; National Institute of Allergy and Infectious Disease; operation; Outcome; Phase; Phase I/II Trial; phase II trial; phase III trial; Policies; Prevention; Protocols documentation; Randomized Clinical Trials; Regulation; Reporting; Research Personnel; Safety; Specific qualifier value; Therapeutic; U-Series Cooperative Agreements; United States National Institutes of Health; Vaccines; ,NIAID/DIVISION OF AIDS (DAIDS) DATA AND SAFETY MONITORING BOARD (DSMB) MEETING SUPPORT,,,,,,,,,547069,
9445924,R01,HL,1,N,12/23/2017,12/25/2017,11/30/2018,838,R01HL136377,SCHOOLS OF MEDICINE,PA-16-160,1R01HL136377-01A1,NHLBI:460262\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SAN FRANCISCO,UNITED STATES,INTERNAL MEDICINE/MEDICINE,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,7250901; ,"ATABAI, KAMRAN ;","CRAIG, MATT",12/25/2017,11/30/2021,Architecture; Behavior; Biological; Bleomycin; Candidate Disease Gene; CDC7 gene; Cell Cycle; Cell division; Cell surface; Cells; Characteristics; Cicatrix; Collagen; Coupled; Data; Degradation Pathway; Development; Diagnosis; disability; Disease; Drosophila genus; Endo180; Endocytosis; Equilibrium; extracellular; Fatty Acids; Fatty-acid synthase; Feedback; Fibrillar Collagen; Fibrosis; flotillin; Gases; Gene Silencing; Genes; Genetic; Goals; Health; high throughput screening; Human; Impairment; in vivo; innovation; insight; Investigation; Knowledge; KRP protein; Laboratories; Life; lipid mediator; macrophage; Mammalian Cell; Mediating; Mediator of activation protein; Medical; Metabolism; Mission; Modality; Molecular; mortality; mouse model; Mus; Nature; new therapeutic target; novel therapeutics; Organism; Orthologous Gene; Outcome; palmitoylation; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacological Treatment; prevent; Process; Production; Public Health; Publishing; Pulmonary Fibrosis; receptor; Regulation; Research; Resolution; RNA Interference; RNA interference screen; Role; Severities; Testing; Therapeutic; therapeutic development; therapeutic target; Time; Tissues; Transgenic Organisms; translational impact; United States National Institutes of Health; uptake; Vesicular Protein Transport; Vesicular Transport Proteins; Work; ,Investigating the role of cell-mediated collagen turnover in regulating tissue fibrosis,136377,LIRR,"Lung Injury, Repair, and Remodeling Study Section ",,A1,1,290386,169876,460262,
9446096,U19,AI,1,N,12/28/2017,12/1/2017,11/30/2018,,U19AI135817,,RFA-AI-16-027,1U19AI135817-01,NIAID:39288\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,76647908,US,8961401,BENAROYA RESEARCH INST AT VIRGINIA MASON,WA,981012795,,1883597; ,"KWOK, WILLIAM W.;",,,,Allergens; Allergic Disease; Allergy to peanuts; Budgets; Clinical Data; cohesion; Collaborations; Communication; Communities; Data; data integration; Databases; dissemination research; Ensure; Goals; human subject protection; Immunotherapy; Individual; innovation; Leadership; Link; member; Phenotype; Preparation; programs; Progress Reports; Regulation; research data dissemination; Research Project Grants; sharing data; success; T-Lymphocyte Epitopes; United States National Institutes of Health; Work; ,Allergen T cell epitopes during the management of peanut allergic disease,135817,ZAI1,Special Emphasis Panel ,8607,,1,23111,16177,,39288
9446099,U19,AI,1,N,12/28/2017,12/1/2017,11/30/2018,,U19AI135817,,RFA-AI-16-027,1U19AI135817-01,NIAID:478378\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,76647908,US,8961401,BENAROYA RESEARCH INST AT VIRGINIA MASON,WA,981012795,,1883597; ,"KWOK, WILLIAM W.;",,,,Allergens; Allergic; Allergic Disease; Allergy to peanuts; Anaphylaxis; Antigens; Biological Assay; Biological Markers; CCR6 gene; CD4 Positive T Lymphocytes; Cells; Clinical; Cytometry; Data Analyses; Development; Disease; disease heterogeneity; Elements; Epitopes; Eragrostis; Flow Cytometry; Food Hypersensitivity; Frequencies; functional disability; Functional disorder; Gene Expression; Gene Expression Profile; Helper-Inducer T-Lymphocyte; Heterogeneity; Hypersensitivity; IgE; Immunology; Immunotherapy; Individual; Knowledge; Link; Mediating; Molecular Profiling; Monitor; Pathogenesis; Phenotype; Play; Regulatory T-Lymphocyte; response; Role; Specificity; Staining method; Stains; Stratification; Subgroup; System; T cell response; T-Lymphocyte; T-Lymphocyte Epitopes; Technology; Testing; Time; TNFSF5 gene; transcriptome sequencing; transcriptomics; Up-Regulation; ,Allergen T cell epitopes and phenotypes in peanut allergy,135817,ZAI1,Special Emphasis Panel ,8609,,1,283375,195003,,478378
9451983,N01,AI,,N,,,,,N01AI000000,,,272201000028C-9-0-1,NIAID:767208\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BOSTON,UNITED STATES,,7,71723621,US,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,MA,22155400,,7705082; ,"SANTRA, SAMPA ;",,8/1/2010,7/31/2017,Acquired Immunodeficiency Syndrome; AIDS Vaccines; assay development; Biological Assay; Cell Count; Cellular Immunology; clinical candidate; Clinical Trials; Contractor; Contracts; cytokine; design; enzyme linked immunospot assay; Flow Cytometry; HIV; Human; Immune response; Immunize; improved; Laboratories; Mucous Membrane; National Institute of Allergy and Infectious Disease; nonhuman primate; Process; Research Personnel; response; simian human immunodeficiency virus; Site; SIV; SIV Vaccines; Staining method; Stains; Technology; United States National Institutes of Health; Vaccines; Virus; ,NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS ,,,,,,,,,767208,
9452779,N01,AI,,N,,,,,N01AI000000,,,272201100022I-9-27200003-3,NIAID:61882\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,4/17/2017,4/16/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Contracts; Development; Diagnostic; Gram-Negative Bacteria; Hypersensitivity skin testing; Image; in vivo; Intervention; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; preclinical development; programs; reagent testing; Services; Staphylococcus aureus; therapeutic development; therapy development; Toxin; Translational Research; ,Task Order 3: Interventional Agent Development Services Program,,,,,,,,,61882,
9457205,N02,CA,,N,,,,,N02CA000000,,,261201400193P-3-0-2,NCI:29820\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,6,796826423,US,10032812,"STATNET CONSULTING, LLC",MD,208794000,,14462331; ,"WILLIAMS PICKLE, LINDA ;",,4/1/2017,3/31/2018,Cancer Cluster; Computer software; Data; Future; Geography; Incidence; Malignant Neoplasms; mortality; Pattern; Recommendation; Statistical Data Interpretation; Statistical Methods; ,IGF::OT::IGF STATISTICAL METHODS FOR THE ANALYSIS OF SPATIAL AND TEMPORAL PATTERNS IN CANCER DATA.,,,,,,,,,29820,
9458642,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200018-3,NIAID:100000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14369184; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Falciparum Malaria; novel vaccines; pathogen; Phase; Process; product development; Reagent; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X18: Process Development and Early Reagent Manufacturing for Vaccines and Other Biologics ,,,,,,,,,100000,
9459270,N01,ES,,N,,,,,N01ES000000,,,273201600015U-2-0-3,NIEHS:791829\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,14505712; ,"BURCH, DAVID ;",,4/21/2016,4/20/2017,Address; base; Communication; Contractor; Data; Educational workshop; Epidemiology; Evaluation; Event; Exhibits; Health Hazards; Information Management; International; Literature; Logistics; Malignant Neoplasms; meetings; National Toxicology Program; Peer Review; Policies; Public Health; Research; response; Science Policy; Source; systematic review; Technical Expertise; Toxicology; ,"Scientific Information Management and Literature-Based Evaluations for the National Toxicology Program (NTP) ? Support for the DNTP Office of the Office of Liaison, Policy, and Review",,,,,,,,,791829,
9459801,N01,AI,,N,,,,,N01AI000000,,,272201400004C-9-0-1,NIAID:3547646\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12651364; ,"ORENS, WALTER A. ;",,4/1/2014,3/31/2021,Animals; Basic Science; Environmental Risk Factor; Evolution; Immune; Immune response; improved; Influenza; influenzavirus; Molecular; pandemic disease; Pathogenicity; Research; transmission process; Vaccination; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,3547646,
9463403,N01,AI,,N,,,,,N01AI000000,,,272201100016C-10-0-1,NIAID:1987141\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,6210215; ,"MONTEFIORI, DAVID C;",,3/30/2011,3/29/2018,AIDS Vaccines; Animals; Antibodies; Antibody -dependent cell cytotoxicity; Antiviral Agents; assay development; Biological Assay; Cells; clinical candidate; Contracts; design; GMP lots; HIV; Human; Immune response; Immunize; Immunology; improved; Instruction; Laboratories; Measures; Mediating; National Institute of Allergy and Infectious Disease; neutralizing antibody; nonhuman primate; Process; protective effect; research and development; Research Personnel; simian human immunodeficiency virus; Site; SIV; SIV Vaccines; Technology; Training; Vaccines; Virus; ,NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LAB AIDS VACCINE R&D,,,,,,,,,1987141,
9467406,N01,AI,,N,,,,,N01AI000000,,,272201600014C-1-0-1,NIAID:1903837\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PHILADELPHIA,UNITED STATES,,2,73757627,US,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PA,191044318,,14620138; ,"FISHER, BRIAN ;",,7/1/2016,6/30/2021,Address; Adenoviruses; Advanced Development; Childhood; Clinical Course of Disease; Clinical Research; Medical; patient population; therapeutic development; Transplant Recipients; Virus Diseases; ,TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS,,,,,,,,,1903837,
9469395,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200011-2,NIAID:431854\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12577129; ,"RICHARDSON, JAMES ;",,11/6/2014,5/1/2020,Antimicrobial Resistance; APBA1 gene; Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; Lassa fever virus; novel vaccines; pathogen; Phase; product development; Services; Staphylococcus aureus; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; Zika Virus; ,Task X11: Product Development Plans and Feasibility Assessments,,,,,,,,,431854,
9471285,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-1,NIEHS:503088\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; carcinogenicity; Chemicals; Chronic; Data; design; Development; drinking water; Goals; hazard; Human; Laboratory Animals; National Toxicology Program; reproductive; Risk; Sodium; Toxic effect; Toxicity Tests; Vanadium; Vanadium Compounds; vanadyl sulfate; ,Conduct of studies to evaluate the toxic and potential of vanadyl sulfate and sodium metavanadate in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,503088,
9471288,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-4,NIEHS:86187\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Asbestos; Breathing; carcinogenicity; Chemicals; Data; design; Dose; Fiber; Goals; hazard; Histopathology; Human; Inhalation Exposure; Laboratory Animals; method development; Methodology; Methods; National Toxicology Program; Preparation; response; Risk; Tissues; Toxic effect; Toxicity Tests; Work; ,Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,86187,
9471295,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-11,NIEHS:12262\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Animals; Chemicals; Data; drinking water; Goals; hazard; Human; Laboratory Animals; National Toxicology Program; Nicotine; Palate; Pathology Report; Phase; Risk; Toxic effect; Toxicity Tests; ,Conduct of studies to evaluate the toxic potential of nicotine in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,12262,
9471750,N01,AI,,N,,,,,N01AI000000,,,272200800006C-24-0-8,NIAID:312232\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,12245063; ,"BERNSTIEN, DAVID ;",,11/1/2007,9/30/2017,Conduct Clinical Trials; Contracts; design; Escherichia coli Vaccines; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; Phase I Clinical Trials; Population; Resources; Route; System; vaccine candidate; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNITS: Phase I Clinical Trial to Evaluate an E. Coli Vaccine,,,,,,,,,312232,
9474532,N01,AI,,N,,,,,N01AI000000,,,272201300003I-6-27200002-1,NIAID:255699\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,12445025; ,"LEWIS, MARK ;",,5/1/2013,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Caring; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; vaccine trial; Vaccines; ,SVEU - Maintenance of Nonhuman Primates,,,,,,,,,255699,
9474534,N01,AI,,N,,,,,N01AI000000,,,272201300003I-1-27200012-1,NIAID:233204\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,14595733; ,"WEISS, DEBORAH ;",,5/1/2016,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Animals; Award; base; Caring; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,SIMIAN VACCINE EVALUATION UNITS - Animal Maintenance and Care,,,,,,,,,233204,
9474535,N01,AI,,N,,,,,N01AI000000,,,272201100040C-9-0-1,NIAID:8707\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALBUQUERQUE,UNITED STATES,,1,45911138,US,679302,LOVELACE BIOMEDICAL & ENVIRONMENTAL RES,NM,871085129,,11143816; ,"KAJON, ADRIANA ;",,9/26/2011,9/25/2016,Address; Adenoviruses; Basic Science; Clinical Research; Natural History; patient population; programs; therapy development; Virus Diseases; ,Targeted Clinical Research Program to Address Selected Viral Infections ,,,,,,,,,8707,
9474539,N01,CA,,N,,,,,N01CA000000,,,261201300020I-3-26100006-2,NCI:4348100\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14511291; ,"LYNCH, CHARLES ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,4348100,
9475636,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300005-1,NIEHS:822848\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14628398; ,"WAGNER, DAVID ;",,7/1/2016,6/30/2017,Advertising; age group; Amendment; Archives; Back; Blood; Clinical Research; Collection; Consent; Contractor; Contracts; cost; Data; data registry; Databases; demographics; Development; Electronic Mail; Ensure; Equipment and Supplies; Equipment and supply inventories; Financial compensation; follow-up; Follow-Up Studies; Future; gender minority; Genetic Polymorphism; genome sequencing; Genotype; Government; Hand; Human Resources; Internet; Intervention Studies; Interview; Laboratories; Link; Maintenance; Manuscripts; Monitor; National Institute of Environmental Health Sciences; Newsletter; Online Systems; Paper; Participant; Phenotype; Phonation; posters; Preparation; Privacy; Process; Progress Reports; prospective; protocol violation; Protocols documentation; Questionnaires; Recruitment Activity; Registries; Reporting; Research; Research Infrastructure; Research Support; response; Risk Assessment; Scientist; Services; Site; social media; Specific qualifier value; Specimen; Study Subject; Surveys; Telephone; Testing; Toxic effect; Training; Travel; web interface; whole genome; ,Clinical Research Support Services for NIEHS Contract Task Order 5 - Environmental Polymorphisms Registry,,,,,,,,,822848,
9475642,N02,DA,,N,,,,,N02DA000000,,,271201600012C-1-0-1,NINDS:330384\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BURLINGAME,UNITED STATES,,14,149823846,US,10004761,"COLLABORATIVE DRUG DISCOVERY, INC.",CA,940101515,,14569755; ,"ERNST, SYLVIA ;",,6/1/2016,5/31/2017,Databases; drug discovery; National Institute of Neurological Disorders and Stroke; ,NINDS/COLLABORATIVE DRUG DISCOVERY DATABASE IGF::OT::IGF,,,,,,,,,330384,
9478646,N01,CA,,N,,,,,N01CA000000,,,261201300016I-4-26100006-2,NCI:1730927\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW ORLEANS,UNITED STATES,,2,782627814,US,577902,LSU HEALTH SCIENCES CENTER,LA,701127021,,14512949; ,"WU, XAIO-CHENG ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF  CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)",,,,,,,,,1730927,
9478651,N01,CA,,N,,,,,N01CA000000,,,261201300005I-4-26100007-2,NCI:4139643\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREMONT,UNITED STATES,,17,89958011,US,1043401,CANCER PREVENTION INSTIT OF CALIFORNIA,CA,945382334,,14505692; ,"GLASER, SALLY ;",,5/1/2016,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ," CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY,AND END RESULTS (SEER);",,,,,,,,,4139643,
9565463,N02,CA,,N,,,,,N02CA000000,,,261201100064C-10-0-1,NCI:2338262\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MOUNTAIN VIEW,UNITED STATES,,18,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,940430816,,6305586; ,"SIGMAN, CAROLINE C;",,9/30/2011,9/29/2018,Adverse event; Agreement; Amendment; Area; cancer prevention; Chemoprevention; Clinical; Clinical Data; Clinical Research; Clinical Trials; Contractor; Contracts; Cooperative Research and Development Agreement; Data; Development; Disclosure; Division of Cancer Prevention; Documentation; Information Management; Investigation; Laws; Maintenance; Malignant Neoplasms; Management Information Systems; material transfer agreement; meetings; National Cancer Institute; Paper; Pharmacologic Substance; pre-clinical; Prevention program; Prevention Protocols; Preventive; Procedures; Process; programs; Protocols documentation; Records; Regulation; Regulatory Affairs; Reporting; Research; research and development; Research Personnel; Safety; Schedule; Services; United States Food and Drug Administration; ,Regulatory Support for Cancer Prevention Agent Development,,,,,,,,,2338262,
9566958,N02,CA,,N,,,,,N02CA000000,,,261201600696P-1-0-1,NCI:45600\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,,,,831402115,,,,,,,14752373; ,"RIES, LYNN ;",,9/15/2017,9/14/2018,Area; Code; Contracts; Development; Diagnostic Neoplasm Staging; International; Malignant Neoplasms; National Cancer Institute; Recommendation; Reporting; SEER Program; Staging System; System; Technical Expertise; ,DEVELOPMENT OF RECOMMENDATIONS FOR CODING ACROSS CANCER REPORTING SYSTEMS FOR SEER,,,,,,,,,45600,
9567719,N02,AI,,N,,,,,N02AI000000,,,272201700084C-0-0-1,NIAID:715130\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FORT WORTH,UNITED STATES,,12,110091808,US,6108502,UNIVERSITY OF NORTH TEXAS HLTH SCI CTR,TX,761072699,,15327632; ,"WEISS, WILLIAM ;",,9/8/2017,9/7/2018,Anti-Bacterial Agents; Antimicrobial Resistance; Bacterial Infections; Bacterial Model; bacterial resistance; Contracts; Gram-Positive Bacterial Infections; Infection; Lung; mouse model; Research; therapeutic development; therapeutic evaluation; Thigh structure; ,Therapeutics Testing In Murine Models of Bacterial Thigh & Lung Infections,,,,,,,,,715130,
9568933,N43,AI,,N,,,,,N43AI000000,,,272201700063C-0-0-1,NIAID:224978\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,6,154704444,US,10002911,"AKONNI BIOSYSTEMS, INC.",MD,217016052,,15327593; ,"HOLMBERG, REBECCA ;",,7/31/2017,7/30/2018,Child; Childhood; Clinical; Development; Diagnostic; Influenza; Lung diseases; Preparation; Process; rapid diagnosis; Respiratory Tract Infections; Sampling; screening; Specimen; Technology; ,Sample Preparation and Screening of Non-invasive Pediatric Specimens for Lower Respiratory Disease,,,,,,,,,224978,
9568967,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100022-1,NCI:17542\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326895; ,"GIANNINI, ROBERT ;",,6/19/2017,6/18/2018,Argon; Biological Assay; capsule; Control Groups; Evaluation; Experimental Designs; Gases; Gossypium; Label; Life; Methods; Oxygen; Production; Publishing; purge; seal; Temperature; Testing; Time; ,Production and Evaluation of the stability of Tetrathiomolibdate Capsules (Non GMP study),,,,,,,,,17542,
9569062,N01,AI,,N,,,,,N01AI000000,,,272201100022I-0-27200011-1,NIAID:949290\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064949; ,"MIRSALIS, JON ;",,6/6/2017,6/5/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; Toxicology; Toxin; ,Task 11: Interventional Agent Development Services Program,,,,,,,,,949290,
9569564,N01,ES,,N,,,,,N01ES000000,,,273200800005C-28-0-1,NIEHS:4242215\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,STERLING,UNITED STATES,,10,66769217,US,9648301,EXPERIMENTAL PATHOLOGY LABORATORIES,VA,201664302,,12239688; ,"HAMLIN, MELVIN ;",,9/30/2008,9/29/2018,Archives; Contractor; Contracts; Data; Data Science; Equipment; Freezing; Government; Human Resources; Intramural Research; National Institute of Environmental Health Sciences; National Toxicology Program; Practice Management; repository; research study; Services; Specimen; Tissue Banks; Work; ,NTP Archives & Frozen Tissue Bank and NIEHS Data and Specimen Repository,,,,,,,,,4242215,
9570142,N01,AI,,N,,,,,N01AI000000,,,272201700012C-0-0-1,OD:1822601\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MONROVIA,UNITED STATES,,32,168312028,US,10005243,"CHROMOLOGIC, LLC",CA,910164244,,14947857; ,"MENON, NARESH ;",,3/1/2017,2/28/2018,Affect; base; biodosimeter; biodosimetry; Biological Assay; Caring; circulating biomarkers; circulating microRNA; Clinical Research; Communities; Contractor; Devices; Diagnostic; Dose; emergency service/first responder; Event; Funding; instrument; Ionizing radiation; Licensure; Modeling; Mus; National Institute of Allergy and Infectious Disease; National Security; Nuclear Radiology; Patients; point of care; Population; Probability; Quantitative Reverse Transcriptase PCR; Radiation; Radiation induced damage; response; Risk; System; Tissues; Triage; Whole Blood; ,POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.,,,,,,,,,1822601,
9570366,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-16,NIAID:1157325\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,15032410; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Avian Influenza; Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Influenza; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,1157325,
9570532,N43,CA,,N,,,,,N43CA000000,,,261201700043C-0-0-1,NCI:299980\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MONROVIA,UNITED STATES,,32,168312028,US,10005243,"CHROMOLOGIC, LLC",CA,910164244,,15230994; ,"JOHNSON, DONALD  ;",,9/15/2017,6/14/2018,cancer cell; Cell Line; cell type; Cells; Coupled; Development; Disease; Encapsulated; exosome; Inflammatory; Integral Membrane Protein; interest; Ion Exchange; Liquid substance; Methods; Peptides; Phase; Plant Resins; Population; Process; protein profiling; Signal Transduction; Small Business Innovation Research Grant; Therapeutic; transcriptome; ,SBIR Topic 359 Phase I: Highly-Efficient Isolation and Fidelity Differentiation of Exosomes (HIFiDE) from Bodily Fluids Kit,,,,,,,,,299980,
9570534,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-1,NIAID:163012\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,163012,
9571161,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200017-1,NIAID:124847\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15266192; ,"FRENCK, ROBERT ;",,9/22/2017,4/30/2019,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase; Population; programs; Resources; Respiratory syncytial virus; Respiratory Syncytial Virus Vaccines; Vaccine Clinical Trial; vaccine trial; Vaccines; ,VACCINE AND TREATMENT EVALUATION UNIT: PHASE 1 VACCINE TRIAL FOR RSV ,,,,,,,,,124847,
9571357,N01,HD,,N,,,,,N01HD000000,,,263201500037I-1-27500001-1,NICHD:2200000\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MCLEAN,UNITED STATES,,11,79529872,US,10046975,"PRICEWATERHOUSECOOPERS PUBLIC SECTOR, LLP",VA,221024257,,; ,",  ;",,9/26/2016,9/25/2019,,'IGF::OT::IGF',,,,,,,,,2200000,
9572248,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-17,NIAID:165050\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,165050,
9572675,N01,AI,,N,,,,,N01AI000000,,,272201200003I-0-27200026-1,NIAID:675049\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15266186; ,"HORNBACK, RANDI ;",,7/3/2012,7/2/2022,Animal Model; assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; vaccine candidate; vaccine development; Vaccines; Zika virus vaccine; ,TASK X26: Immunogenicity and Efficacy Testing of Zika Vaccine Candidates in Animal Models,,,,,,,,,675049,
9572820,N01,AI,,N,,,,,N01AI000000,,,272201700010I-0-27200006-1,NIAID:180198\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15266231; ,"MACK, FRED ;",,9/28/2017,9/27/2022,Adjuvant; Antigens; Clinical Trials; Contractor; Contracts; Cyclic GMP; Databases; Development; Documentation; efficacy study; Equipment and supply inventories; HIV vaccine; HIV-1; Human; immunogenicity; In Vitro; Investigational Drugs; Laboratories; Laboratory Animals; National Institute of Allergy and Infectious Disease; Phase; plasmid DNA; preclinical development; Preclinical Testing; Preventive vaccine; product development; Production; Proteins; Protocols documentation; prototype; quality assurance; Quality Control; research clinical testing; Testing; Toxicology; Vaccines; Viral Vector; ,Production of Adjuvants,,,,,,,,,180198,
9572825,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-17,NIEHS:385687\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,15035369; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Adult; Apical; Benchmarking; Chemicals; Dose; Exposure to; Genetic Transcription; Liver; Oral; Rattus; response; Toxic effect; transcriptomics; ,Conduct of five day high throughput transcriptomic dose response studies of selected chemicals for the NTP  ,,,,,,,,,385687,
9573286,N01,HD,,N,,,,,N01HD000000,,,275201100002I-6-27500002-1,NICHD:9958\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,,22488345,US,,MINNESOTA UNIV,MN,554550149,,11173963; ,"TSAI, MICHAEL ;",,9/22/2011,9/21/2016,Androgens; Anus; Bioavailable; Biological Assay; Caffeine; Chromatography; comparative; design; Electrospray Ionization; Enzyme-Linked Immunosorbent Assay; Folic Acid; Hormones; Immunoassay; improved; inhibin B; Leptin; liquid chromatography mass spectrometry; Measures; Methodology; Methods; Modification; Oxidative Stress; Participant; Performance; reproductive hormone; Sampling; selected ion monitoring; Serum; Site; Specimen; tandem mass spectrometry; Techniques; Testing; Testosterone; Theobromine; Theophylline; Tissues; Woman; ,BIOCYCLE STUDYT,,,,,,,,,9958,
9573287,N01,HD,,N,,,,,N01HD000000,,,275201300008I-2-27500002-2,NICHD:67041\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PORTLAND,UNITED STATES,,3,96997515,US,6297007,OREGON HEALTH & SCIENCE UNIVERSITY,OR,972393098,,12062832; ,"ALLEN, ERIN ;",,7/16/2013,12/31/2018,Acetates; Adherence; Adverse effects; Age; Amenorrhea; arm; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Data; Dose; Drug Kinetics; emergency contraception; Estrogens; Hemorrhage; In Vitro; Interruption; malignant breast neoplasm; Menstrual cycle; Methods; Mission; National Institute of Child Health and Human Development; Non obese; Obesity; Oral; Oral Contraceptives; Ovulation; Pattern; pill; Population; progesterone receptor A; Progesterone Receptors; Progestins; Public Health; Randomized; Regimen; reproductive; Risk; Safety; Thromboembolism; Time; United States Food and Drug Administration; Uterine Fibroids; Venous; Woman; ,CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE,,,,,,,,,67041,
9573607,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200014-2,NIAID:1324403\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15273092; ,"FRENCK, ROBERT ;",,7/12/2017,7/11/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Population; programs; protocol development; Resources; Respiratory Syncytial Virus Vaccines; Vaccines; , VACCINE AND TREATMENT EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,1324403,
9573699,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-1,NIAID:610079\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Influenza; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,610079,
9573708,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-4,NIAID:172025\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dengue Virus; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,172025,
9573740,N01,HD,,N,,,,,N01HD000000,,,275201500002I-0-27500009-1,NICHD:1471728\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15243222; ,"PARMAN, TOUFAN ;",,9/27/2017,9/26/2019,absorption; Animals; Area; Biological Assay; Biological Testing; chemical synthesis; Chemicals; Clinical; clinical lot; clinical material; Clinical Research; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive Devices; Contraceptive methods; Contractor; design; Development; Documentation; drug candidate; drug development; Drug Formulations; Drug Kinetics; Endocrine; Enrollment; Evaluation; Excretory function; Formulation; Implant; In Vitro; in vitro Assay; in vivo; Injectable; Investigational Drugs; Investigational New Drug Application; lot production; men; Metabolism; Methods; Mission; National Institute of Child Health and Human Development; novel therapeutics; Oral; Ovulation; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Phase; Plasma; Play; pre-clinical; preclinical development; Process; product development; Production; Program Development; programs; Protocols documentation; Recruitment Activity; Reporting; research clinical testing; Research Personnel; Research Support; Role; Route; Safety; sperm cell; sperm function; stability testing; System; Testing; Therapeutic Agents; Time; Toxic effect; Toxicology; Woman; ,BIOLOGICAL TESTING FACILITY - PRECLINICAL DEVELOPMENT OF CONTRACEPTIVES,,,,,,,,,1471728,
9573750,N01,HD,,N,,,,,N01HD000000,,,263201500040I-0-27500002-1,NICHD:710742\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MC LEAN,UNITED STATES,,11,6928857,US,682902,BOOZ ALLEN HAMILTON,VA,221023830,,; ,",  ;",,9/22/2017,9/14/2018,,'IGF::OT::IGF',,,,,,,,,710742,
9574346,N43,AI,,N,,,,,N43AI000000,,,272201700065C-0-0-1,NIAID:224992\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LAWRENCE,UNITED STATES,,2,80412808,US,10044975,"HAFION, LLC",KS,660471620,,15327599; ,"CAI, SHUANG ;",,8/1/2017,7/31/2018,Adjuvant; Bordetella pertussis Bacterium; Contractor; Enterotoxins; Escherichia coli; Hyaluronan; Immunologics; Molecular Weight; Pertussis; Proteins; synergism; ,Generating Synergy Between Protein and Non-Protein Macromolecular Adjuvants,,,,,,,,,224992,
9574500,N43,CA,,N,,,,,N43CA000000,,,261201700031C-0-0-1,NCI:224910\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LEXINGTON,UNITED STATES,,5,80388289,US,10043321,"PRECISION IMAGING METRICS, INC.",MA,24218014,,15240054; ,"URBAN, TRINITY  ;",,9/18/2017,6/17/2018,Address; Area; base; Cancer Center; cancer imaging; Cell Nucleus; Clinical Trials; cloud based; Communication; Computer software; Contracts; Data; Development; Documentation; Evaluation; Goals; Image; Informatics; Instruction; Internet; Malignant Neoplasms; Measurement; Metric System; Monitor; NCI-Designated Cancer Center; Online Systems; Performance; Phase; Process; Protocols documentation; prototype; radiologist; Recommendation; response; Retrieval; Site; software systems; Surrogate Endpoint; System; Therapeutic; Time; tool; Training; transmission process; Vendor; volunteer; ,Cloud-hosted Clinical Trial Imaging Assessment and Workflow Management System,,,,,,,,,224910,
9574781,N43,CA,,N,,,,,N43CA000000,,,261201700015C-0-0-1,NCI:297962\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,79170146,US,10038016,"MIMETAS US, INC.",MD,208504146,,15240580; ,"SALEH, ANTHONY  ;",,9/19/2017,6/18/2018,African American; angiogenesis; Antineoplastic Agents; Biological Assay; Biological Factors; cancer health disparity; Cancer Patient; Caucasians; Cell Culture Techniques; Clinical; Clinical Data; clinically relevant; Coculture Techniques; Communities; Data; Diffusion; drug candidate; Extracellular Matrix; Failure; Fibroblasts; Growth; Hispanics; improved; in vitro Model; in vivo; Incidence; Malignant neoplasm of prostate; Malignant Neoplasms; men; Modeling; neoplastic cell; Output; patient population; Patients; Perfusion; Pharmaceutical Preparations; Phase; Phenotype; Preclinical Drug Evaluation; prostate cancer cell line; racial and ethnic; racial diversity; Reproducibility; Research; response; Rice; screening; Small Business Innovation Research Grant; Source; Specimen; Stromal Cells; success; Testing; Therapeutic; three dimensional cell culture; Time; Translating; tumor; tumor microenvironment; two-dimensional; Universities; Variant; Xenograft procedure; ,IGF::OT::IGF SBIR Topic 355: A 3D Perfusable Platform for HTS Across Diverse Racial/Ethnic Cancer Specimens To generate racially diverse patient-derived xenograft (PDX)-derived prostate cancer culture,,,,,,,,,297962,
9575726,N01,CA,,N,,,,,N01CA000000,,,261201200033I-0-26100013-1,NCI:45458\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,15242296; ,"BAILEY, HOWARD ;",,9/18/2017,9/17/2018,Adult; Biopsy; Cervical; Cervical Intraepithelial Neoplasia; Clinical Trials; Cytology; DNA Vaccines; Dose; Electroporation; Female; Human Papillomavirus; Human papillomavirus 16; Injection of therapeutic agent; intraepithelial; Intramuscular; open label; Patients; Phase; Safety; System; ,"IGF::OT::IGF A Phase I Open Label, Dose Escalation Clinical Trial assessing the Safety, Tolerability, and Feasibility of pNGLV4aCRTE6E7L2 HPV DNA vaccine administration via Intramuscular TriGridTM Ele",,,,,,,,,45458,
9575770,N01,CA,,N,,,,,N01CA000000,,,261201200034I-0-26100013-1,NCI:524438\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HOUSTON,UNITED STATES,,9,800772139,US,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,770304009,,15242368; ,"BROWN, POWEL ;",,9/21/2017,9/20/2019,arm; BRCA1 gene; Contractor; Dose; Epithelial Cells; Mammalian Oviducts; Mutation; mutation carrier; Operative Surgical Procedures; Pilot Projects; Premenopause; Risk; Salpingo-Oophorectomy; Schedule; Woman; ,Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oopherectomy,,,,,,,,,524438,
9576382,N43,DA,,N,,,,,N43DA000000,,,271201700028C-1-0-1,NCATS:229872\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ANDOVER,UNITED STATES,,3,73800062,US,1925101,"PHYSICAL SCIENCES, INC",MA,18101022,,15243404; ,"LADERER, MATTHEW  ;",,6/15/2017,3/14/2018,arm; Back; base; Computer software; Contractor; cost; design; Documentation; Drops; Economics; Engineering; Feedback; fly; Goals; Government; grasp; high throughput screening; Industry; Influenza; innovation; Laboratories; Location; Modeling; novel; operation; Outcome; Performance; performance tests; Phase; Progress Reports; prototype; Public Health; repaired; Report (document); Reporting; Research; research and development; Research Infrastructure; Robotics; Running; Safety; Sampling; simulation; Solid; Speed; System; Testing; tool; United States National Institutes of Health; Work; ,IGF::OT::IGF LabHand Payload for InstantEye sUAS Platform for Continuous Autonomous Indoor Transport of Laboratory Consumables ,,,,,,,,,229872,
9576665,N43,DA,,N,,,,,N43DA000000,,,271201700053C-0-0-1,NIDA:225000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MC LEAN,UNITED STATES,,11,10639917,US,10030446,NET ESOLUTIONS CORPORATION (NETE),VA,221024929,,15243949; ,"CHACKO, GEORGE ;",,9/15/2017,3/14/2018,Address; analytical tool; Award; Benchmarking; Case Study; cloud based; Collaborations; Communication; Data; Device or Instrument Development; Devices; Diagnostic; Dimensions; drug development; Evaluation; Event; experience; Funding; Goals; Influentials; Informatics; Knowledge; Libraries; Link; Methods; Performance; Pharmaceutical Preparations; Phase; Policy Maker; programs; repository; Research; Role; Testing; United States National Institutes of Health; ,"IGF::OT::IGF Enhanced Research Network Informatics Exploration (ERNIE) (Period of Performance: September 15, 2017 - March 14, 2018). N43DA-17-1216. BASE AWARD",,,,,,,,,225000,
9577524,N01,MH,,N,,,,,N01MH000000,,,271201400001I-0-27100012-1,NIMH:220572\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,15059060; ,"JEFFREY, ODOM ;",,6/1/2017,5/31/2018,Advocacy; Award; Biological; brain tissue; chemical synthesis; Collection; Communities; Contracts; Disease; disorder control; Fetal Tissues; Goals; Grant; Human; human disease; Institutes; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; Patients; Pharmaceutical Preparations; Process; programs; repository; Research; Research Personnel; Sampling; Services; Site; Source; Specimen; stroke; Tissues; United States National Institutes of Health; ,NIMH Chemical Synthesis and Drug Supply Program (CDSP),,,,,,,,,220572,
9578264,N01,CA,,N,,,,,N01CA000000,,,261201600016I-0-26100003-1,NCI:116039\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,15246442; ,"LYNCH, MARYELLEN ;",,8/11/2017,12/31/2018,anti-cancer therapeutic; anticancer activity; Award; Canis familiaris; Contracts; Development; Disease; inhibitor/antagonist; Investigation; Malignant Neoplasms; Oral; Organ; Pharmaceutical Preparations; Process; research clinical testing; Testing; Toxic effect; ,"IGF::OT::IGF NExT Mcl-1 NX232-108-172-001 TO#3 Exploratory Tox Study in Dogs Admin Mcl-1 Inhibitor Orally, 8/11/17-12/31/18, Pre-clin Tox & Pharm Study of Drug Dev for Cancer & Other Diseases,  HHSN26",,,,,,,,,116039,
9578710,N43,CA,,N,,,,,N43CA000000,,,261201700046C-0-0-1,NCI:298822\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BRANFORD,UNITED STATES,,3,79364420,US,10037539,"PACT AND HEALTH, LLC",CT,64052546,,15247072; ,"PAPINENI, RAO ;",,9/19/2017,6/18/2018,3-Dimensional; Adopted; Antineoplastic Agents; Automation; Biological Assay; Biopsy; Cell Culture Techniques; Cell Line; Cell Survival; Cells; commercialization; design; Dose; dosimetry; drug use screening; Engineering; Environment; Gases; Image; Image Analysis; in vivo; irradiation; Malignant Neoplasms; Microfluidics; Microscopy; miniaturize; Modeling; Monitor; Patients; Phase; precision medicine; Preclinical Drug Evaluation; Radiation; Roentgen Rays; Sampling; screening; Small Business Innovation Research Grant; Speed; System; Therapeutic; three dimensional cell culture; Time; tissue/cell culture; Tissues; tumor; Validation; ,I-PARTS Integrated Platform for Anti-Cancer Radiation Therapeutics Screening,,,,,,,,,298822,
9579421,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100042-1,NCI:39999252\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266022; ,"ROCHE, NANCY ;",,9/28/2017,9/27/2022,Adult; Aftercare; biobank; Biological Assay; Biopsy; Blood; cancer care; Cancer Model; Catalogs; CLIA certified; Clinical; Clinical Data; Clinical Distribution; cohort; Collaborations; Collection; Community Physician; Consent; Custom; Data; Data Collection; Databases; Deposition; Development; Diagnosis; Disease; Drug resistance; Educational workshop; Funding; Future; Hematologic Neoplasms; Immunotherapy; laboratory facility; Malignant Neoplasms; meetings; Modeling; Molecular; National Cancer Institute; Participant; Pathology; Patients; Physicians; Preparation; programs; quality assurance; Quality Control; Radiation therapy; Recommendation; Research; Research Personnel; Research Project Grants; Resistance; Resources; response; Sampling; Site; socioeconomics; Solid Neoplasm; Source; standard of care; Structure; symposium; Systemic Therapy; Therapeutic; therapy resistant; Time; Total Quality Management; Translational Research; tumor; young adult; ,IGF::OT::IGF Biobank,,,,,,,,,39999252,
9579803,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-156,NCI:125000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,programs; ,OCG PM Support,,,,,,,,,125000,
9579884,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100054-1,NCI:38534220\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266037; ,"KARLOVICH, CHRIS ;",,9/21/2017,9/20/2022,Accountability; Archives; arm; base; biobank; Biological Assay; Biological Markers; Biopsy; Blood specimen; Childhood; Clinical; Clinical Investigator; Clinical Protocols; clinical research site; Clinical Trials; clinically relevant; clinically significant; Data Storage and Retrieval; Development; Diagnostic; diagnostic assay; Drug Targeting; Early Therapeutic-Clinical Trials Network; Eligibility Determination; Environment; Equipment and supply inventories; Evaluation; Failure; flexibility; follow-up; Immunoassay; In Situ Hybridization; Investigation; Laboratories; Location; Modeling; Molecular; Molecular Abnormality; Molecular Mechanisms of Action; Molecular Profiling; Monitor; next generation; novel therapeutics; operation; Patients; Performance; performance site; Periodicity; Pharmaceutical Preparations; pharmacodynamic biomarker; Pharmacodynamics; Plant Roots; precision oncology; Proteins; protocol development; quality assurance; Quality Control; Readiness; Reagent; Records; Reporting; repository; Reproducibility; sample collection; Sampling; Schedule; Secure; Services; Shipping; Site; Site Visit; Specimen; success; System; targeted agent; targeted treatment; Technology; Testing; Time; Training; transcriptome sequencing; trend; tumor; Validation; Variant; Work; ,IGF::OT::IGF A National Clinical Laboratory Network for NCI Precision Oncology IGF::OT::IGF ,,,,,,,,,38534220,
9579995,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100037-1,NCI:1079417\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15200702; ,"KHALSA, AMAR ;",,9/1/2017,8/30/2020,Accounting; animal facility; Animals; Breeding; Censuses; Computer software; Computers; Contractor; cost; Elements; Equipment and supply inventories; Health; Health Status; Human Resources; IACUC; Laboratory Animal Science; Maintenance; Monitor; nonhuman primate; Policies; programs; Protocols documentation; Regulation; Reporting; Research; Research Personnel; Rodent; Security; software systems; statistical service; System; Testing; Topaz; United States National Institutes of Health; Work; ,"IGF::OT::IGF REPLACEMENT OF THE ANIMAL FACILITY COLONY MANAGEMENT SYSTEM, YT 17-064",,,,,,,,,1079417,
9581063,N02,DA,,N,,,,,N02DA000000,,,271201400007I-0-27100005-1,NIMH:42516\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILLOW GROVE,UNITED STATES,,,64341449,US,,,PA,190900433,,15327362; ,"MEAKER, THOMAS ;",,9/22/2017,12/21/2017,Autopsy; Award; Biological Assay; Blood; Brain; brain tissue; Contractor; Cost Savings; drug of abuse; Hair; Human; Laboratories; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; nervous system disorder; Neurodevelopmental Disorder; Performance; Pharmaceutical Preparations; programs; Psychotropic Drugs; repository; Research; Research Personnel; Resources; Sampling; Services; Standardization; Testing; Therapeutic; Tissues; Toxicology; United States National Institutes of Health; Urine; ,Neurobiobank: Toxicology Testing services ,,,,,,,,,42516,
9581069,N02,DA,,N,,,,,N02DA000000,,,271201700007A-0-0-1,NIMH:276805\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILMINGTON,UNITED STATES,,7,362574527,US,4079901,"PPD, INC.",NC,284013331,,15327438; ,"KIRBY, MATTHEW ;",,5/26/2017,5/25/2018,Adherence; Clinical; Clinical Research; clinical research site; Clinical Trials; Contractor; Country; Data; Effectiveness; Ensure; Guidelines; Measures; meetings; Monitor; National Institute of Mental Health; Outcome; Performance; Preparation; Procedures; Process; Protocols documentation; Quality Control; Recommendation; Records; Reporting; Services; Site; Site Visit; Teleconferences; Training; Visit; ,IGF::OT::IGF   PPD DEVELOPMENT Site & Study Monitoring,,,,,,,,,276805,
9581093,N02,CA,,N,,,,,N02CA000000,,,261201700069U-0-0-1,NCI:385920\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SILVER SPRING,UNITED STATES,,,828939132,US,,HUMANITAS INC,MD,209103819,,15327130; ,"LINN, ADAM ;",,4/4/2017,,Cancer Therapy Evaluation Program; Performance; Software Tools; web site; ,CTEP software tools and websitesmanagement,,,,,,,,,385920,
9581109,N01,CA,,N,,,,,N01CA000000,,,26120160004B26100003-0-0-1,NCI:1049924\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,; ,",  ;",,9/16/2017,9/15/2018,Cancer Control; Population Research; Signal Recognition Particle; ,SRP Professional Support for Cancer Control and Population Based Research,,,,,,,,,1049924,
9581243,N01,HL,,N,,,,,N01HL000000,,,268201600014I-0-26800002-1,NHLBI:242087\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15078145; ,"MCKENNA, DAVID ;",,6/6/2017,3/5/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT III)- CELL PROCESSING FACILITIES,,,,,,,,,242087,
9581244,N01,HL,,N,,,,,N01HB000000,,,268201100003I-0-26800003-1,NHLBI:720000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MILWAUKEE,UNITED STATES,,4,57163172,US,5304801,"BLOODCENTER OF WISCONSIN, INC.",WI,532332121,,15266079; ,"MAST, ALAN ;",,9/30/2017,3/31/2019,"Adult; Affect; Allogenic; Amendment; Area; base; Basic Science; Biological Sciences; Blood; Blood Donations; Blood Transfusion; Cancer Center; Cardiac Surgery procedures; Clinical Research; Clinical Sciences; Collection; Community Hospitals; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; data hub; data management; Data Security; Development; dopamine D5 receptor; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; evidence base; evidence based guidelines; Grant; Health Insurance Portability and Accountability Act; Health Personnel; HIV; Hospitals; improved; Institutional Review Boards; Intensive Care Units; International; K-Series Research Career Programs; Knowledge; Laboratories; Laboratory Study; Leadership; Manuals; Medical; Medicine; meetings; member; Mentors; National Heart, Lung, and Blood Institute; oncology; operation; Orthopedic Surgery procedures; Outpatients; Participant; Pathologic; Patient Care; Patient Education; Patients; Performance; Phase; Policy Developments; Population; population based; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; Risk; Safety; Series; Services; Ships; Site; Surveys; symposium; System; tertiary care; Training; Training and Education; Transfusion; Translational Research; Trauma; Voting; Work; ",IGF::OT::IGF  DBDR REDS-III Domestic Site Phase 3,,,,,,,,,720000,
9581250,N01,HL,,N,,,,,N01HB000000,,,268201100007I-0-26800003-1,NHLBI:726032\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SAN FRANCISCO,UNITED STATES,,12,6902498,US,10004326,BLOOD SYSTEMS RESEARCH INSTITUTE,CA,941184417,,15266091; ,"CUSTER, BRIAN ;",,9/30/2017,3/31/2019,"Acquired Immunodeficiency Syndrome; Address; Adult; Affect; AIDS/HIV problem; Alloimmunization; Amendment; Area; base; Basic Science; Behavior; Biological; Biological Sciences; Blood; Blood Banks; Blood Donations; Blood donor; Blood donor screening; Blood Transfusion; Books; Budgets; Catalogs; Characteristics; Clinical Research; Clinical Sciences; Code; Collaborations; Collection; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; Data Set; Databases; Development; dopamine D5 receptor; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; evidence base; evidence based guidelines; Geography; Goals; Government; Health Insurance Portability and Accountability Act; Health Personnel; HIV; HIV-1; HIV-2; improved; Incidence; Income; Infection; Infectious Agent; Informed Consent; Institution; Institutional Review Boards; interest; International; Knowledge; Laboratories; Laboratory Study; Language; Leadership; Location; Manuals; Medical; Medicine; meetings; member; Methodology; Monitor; National Heart, Lung, and Blood Institute; Office Management; operation; Participant; Pathologic; Patient Care; Patient Education; Performance; Phase; Policy Developments; population based; Prevalence; prevent; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; Questionnaires; Reporting; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; response; Risk; Risk Factors; Safety; sample collection; Sampling; Ships; Site; Specimen; Surveys; symposium; Technical Expertise; Test Result; Testing; Training; Training and Education; Transfusion; Translating; Translational Research; transmission process; Vascular blood supply; work-study; Writing; ",IGF::OT::IGF DBDR REDS-III International Sites Phase 3,,,,,,,,,726032,
9581349,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100072-1,NCI:53224\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,5/24/2017,8/30/2017,Health; meetings; Research; ,IGF::OT::IGF Task Order 72: Building Capacity for Health Econ Research,,,,,,,,,53224,
9581360,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100075-1,NCI:74813\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,8/11/2017,12/29/2017,Educational workshop; meetings; ,"IGF::OT::IGF SCG - Labor: Meeting Support for New Grantee Workshop; POP August 11, 2017 - December 30, 2017",,,,,,,,,74813,
9581361,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100079-1,NCI:34567\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,8/7/2017,12/31/2017,cohort; meetings; ,IGF::OT::IGF 2017 NCI Cohort Consortium Meeting,,,,,,,,,34567,
9581362,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100078-1,NCI:38107\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,7/19/2017,10/31/2017,meetings; United States National Institutes of Health; ,IGF::OT::IGF Trans-NIH Consortium Meeting,,,,,,,,,38107,
9581377,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100076-1,NCI:34082\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,7/14/2017,10/30/2017,Body Composition; Cancer Prognosis; cancer risk; Cancer Survivor; meetings; Muscle; Role; ,Task Order No.HHSN26100076 Understanding the Role of Muscle and Body Composition on Cancer Risk and Prognosis in Cancer Survivors - Meeting Support,,,,,,,,,34082,
9581385,N02,CA,,N,,,,,N02CA000000,,,261201700057A-0-0-1,NCI:24562\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WESTBURY,UNITED STATES,,,13375885,US,,,NY,115905034,,15327124; ,"MOELLER, TIMOTHY ;",,9/1/2017,2/28/2018,Collection; metabolomics; Sampling; Urine; ,IGF::OT::IGF BioreclamationIVT The effect of pre-analytical conditions on metabolite stability in urine Metabolomics Reference Sample Set Collection of 60 samples,,,,,,,,,24562,
9581401,N02,CA,,N,,,,,N02CA000000,,,261201700690P-0-0-1,NCI:99932\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW HAVEN,UNITED STATES,,3,43207562,US,9420201,YALE UNIVERSITY,CT,65208327,,15327176; ,"DAVIDOFF, AMY ;",,9/18/2017,11/21/2018,Adult; cancer diagnosis; Elderly; functional status; Malignant Neoplasms; Measures; Mental Depression; Pain; Patient Outcomes Assessments; Pattern; Pharmaceutical Preparations; Reporting; ,IGF::OT::IGF Exploring Part D Claims in SEER-MHOS. ,,,,,,,,,99932,
9583616,N43,DA,,N,,,,,N43DA000000,,,271201700041C-0-0-1,NIDA:225000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BERWYN,UNITED STATES,,6,827407243,US,10019442,"SCITECH STRATEGIES, INC.",PA,193122151,,15327465; ,"BOYACK, KEVIN ;",,9/1/2017,2/28/2018,Advocacy; Award; base; Biological Sciences; Complement; Contractor; Data; Databases; Decision Making; Disease; economic impact; Evaluation; Foundations; Machine Learning; Manuals; Measures; Methods; Modeling; novel; Policy Maker; PubMed; Quality Indicator; Records; Reproducibility; Research; Structure; Testing; Text; tool; Translations; ,IGF::OT::IGF Base Award. Creation of an Accurate Model of the Topical Structure of PubMed and Associated Indicators. POP: 09/01/17 - 02/28/18. N43DA-17-1215.,,,,,,,,,225000,
9583975,N01,CA,,N,,,,,N01CA000000,,,261201500003I-2-26100015-2,NIAID:23310140\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15225539; ,"BEIGEL, JOHN ;",,9/26/2015,9/25/2020,Area; Biometry; Clinical; Clinical Research; data management; Disease; Geographic Locations; Geography; Goals; improved; Influenza; Leadership; Lung diseases; Medical; Methodology; Middle East Respiratory Syndrome Coronavirus; Modeling; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; Natural History; Patient-Focused Outcomes; programs; Protocols documentation; Reporting; Research; Resources; respiratory virus; Severe Acute Respiratory Syndrome; Severity of illness; Therapeutic; ,RESPIRATORY VIRUSES RESEARCH,,,,,,,,,23310140,
9587934,N02,DA,,N,,,,,N02DA000000,,,271201400011I-0-27100004-1,NINDS:55500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,EAST SETAUKET,UNITED STATES,,,79235699,US,,,NY,11733,,15327368; ,"ARALDI, GIAN ;",,9/28/2014,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,IGF::CL::IGF,,,,,,,,,55500,
9588818,N01,DA,,N,,,,,N01DA000000,,,271201600007I-0-27100002-1,NINDS:253062\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15266161; ,"HEBERT, CHARLES ;",,9/30/2017,9/29/2018,Award; Canis familiaris; Contracts; Drug Kinetics; Funding; Pharmacology and Toxicology; programs; Rattus; Rodent; Therapeutic; United States National Institutes of Health; ,IGF::OT::IGF Task Order #2 for 'Continuous Rodent and Non-Rodent Pharmacokinetic Assessments' ,,,,,,,,,253062,
9589169,N02,DA,,N,,,,,N02DA000000,,,271201700014C-0-0-1,NINDS:37500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CRANBURY,UNITED STATES,,,57738543,US,,WHITE GLOBAL PHARMA CONSU,NJ,85122130,,15327444; ,"WHITE, RON ;",,6/8/2017,6/7/2018,Achievement; Address; Agreement; Area; assay development; Attention; Award; Back; base; Behavior; Biological Products; Board Certification; Brain; Businesses; Capital; Chemistry; Clinic; Clinical Research; Clinical Trials; Communication; Complex; Computer software; Computer Systems; Computers; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Data; Data Analyses; Data Files; design; Development; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; Education; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; Event; experience; Experimental Designs; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; health data; Hour; Human Resources; improved; Individual; Industry; innovation; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Knowledge; Laws; Lead; Leadership; Legal patent; Letters; Life; literacy; Maps; Measures; Mediation; Medical; Medical Research; meetings; member; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system development; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Participant; Peer Review; Performance; Performance at work; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; physical science; portability; preclinical safety; Preparation; Prevention; Price; Principal Investigator; Privacy; Procedures; Process; programs; Property; Protocols documentation; Publications; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resources; Rights; Risk Assessment; Role; Running; Security; Services; Shapes; Site; Site Visit; skills; small molecule; Strategic Planning; stroke; success; symposium; Teleconferences; Telephone; Theft; Time; Training; Travel; United States National Institutes of Health; Update; virtual; Virus; Work; Writing; ,NINDS BPN DMPK Consulting - White Global Pharma Consultants LLC  IGF::CL::IGF,,,,,,,,,37500,
9589170,N01,OD,,N,,,,,N01OD000000,,,263201600278U-3-0-1,NINDS:28000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,,,,,88365767,,,,,,,; ,",  ;",,9/19/2017,,,Part no. 29-ACE-BAS-1Acquia Cloud Enterprise Basic (1 Codebase) IGF::OT::IGF,,,,,,,,,28000,
9589186,N01,DA,,N,,,,,N01DA000000,,,271201400009I-0-27100004-1,NINDS:37500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CARY,UNITED STATES,,,36513535,US,,,NC,275191564,,; ,",  ;",,9/28/2016,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"IGF::OT::IGF JM SISCO PHARMA CONSULTING, LLC:1238758 [17-004967]",,,,,,,,,37500,
9591720,N01,OD,,N,,,,,N01OD000000,,,316201300006W-1-0-1,NEI:329075\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,ROCKVILLE,UNITED STATES,,8,24775638,US,10029439,"MEDICAL SCIENCE & COMPUTING, INC.",MD,208521631,,; ,",  ;",,3/1/2017,2/28/2018,Contracts; Medical; Science; ,IGF::OT::IGF,,,,,,,,,329075,
9594323,N01,AG,,N,,,,,N01AG000000,,,271201300018C-9-0-2,NIA:106611\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON AGING,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,15133877; ,"KEMNITZ, JOSEPH ;",,9/30/2013,9/29/2018,,`IGF::OT::IGF NHP TISSUE BANK,,,,,,,,,106611,
9595701,N01,DA,,N,,,,,N01DA000000,,,271201700002C-0-0-1,NIA:1244135\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WINSTON-SALEM,UNITED STATES,,5,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,,14922033; ,"RAPP, STEPHEN ;",,11/4/2016,11/3/2017,,"IGF::CT::IGF THE PURPOSE OF THIS CONTRACT IS TO PERFORM PROSPECTIVE FOLLOW-UPS, INCLUDING ADJUDICATED DIAGNOSTIC ASSESSMENTS AND COGNITIVE EVALUATIONS, OF OLDER WOMEN IN THE WHIMS STUDIES, TO PROVIDE ",,,,,,,,,1244135,
9610232,OT2,TR,1,N,12/29/2017,12/29/2017,1/31/2018,350,OT2TR002517,SCHOOLS OF MEDICINE,,1OT2TR002517-01,NCATS:74250\,OTHERS,2018,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,,BIRMINGHAM,UNITED STATES,INTERNAL MEDICINE/MEDICINE,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14299082; ,"MIGHT, MATTHEW BRENDON;","COLVIS, CHRISTINE",12/29/2017,1/31/2018,,Biomedical Data Translator Technical Feasibility Assessment of Reasoning Tool: University of Alabama at Birmingham,2517,ZTR1,Special Emphasis Panel ,,,1,50000,24250,74250,
9613383,OT2,TR,1,N,12/29/2017,12/29/2017,1/31/2018,350,OT2TR002520,SCHOOLS OF PUBLIC HEALTH,,1OT2TR002520-01,NCATS:73500\,OTHERS,2018,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,,CORVALLIS,UNITED STATES,NONE,4,53599908,US,6297004,OREGON STATE UNIVERSITY,OR,973318517,,8235712; 12042364; 8434665 (contact); ,"DEUTSCH, ERIC ; NANDI, ARNAB ; RAMSEY, STEPHEN A. (contact);","COLVIS, CHRISTINE",12/29/2017,1/31/2018,,Biomedical Data Translator Technical Feasibility Assessment of Reasoning Tool: Oregon State University,2520,ZTR1,Special Emphasis Panel ,,,1,50000,23500,73500,
9360003,I01,VA,5,N,12/26/2017,11/1/2017,10/31/2018,999,I01RX001859,,RFA-RX-16-007,5I01RX001859-02,,Non-SBIR/STTR RPGs,2018,Veterans Affairs,,GAINESVILLE,UNITED STATES,,3,97378632,US,481152,VETERANS HEALTH ADMINISTRATION,FL,326081135,,7599009; ,"WANG, KEVIN KA WANG;",,11/1/2016,10/31/2020,Address; Affect; Aggressive behavior; Aging; Anxiety; Autopsy; base; Behavior; Biochemical; Biological Assay; Biological Markers; Brain; Brain region; brain tissue; Chronic; Chronic Phase; chronic traumatic encephalopathy; Clinical Research; Closed head injuries; Cognitive; Cognitive deficits; combat; Confusion; Craniocerebral Trauma; Data; Dementia; Deposition; depressive symptoms; Development; Diagnosis; DNA-Binding Proteins; Enzyme-Linked Immunosorbent Assay; experience; extracellular; Human; human subject; Immunization; Immunoassay; Immunotherapeutic agent; Immunotherapy; Impaired cognition; Impairment; improved; Injury; Knowledge; Lead; Learning; Link; link protein; MAPT gene; Memory Loss; Mental Depression; mild traumatic brain injury; Military Personnel; Mission; Modeling; mouse model; Mus; Nerve Degeneration; Nervous System Trauma; neurobehavioral; neurobehavioral test; Neurologic; neuropathology; novel; overexpression; oxidation; Pathologic; Patient Care; Patients; Phase; Phosphorylation; Prevention; protein aggregate; protein biomarkers; Protein Fragment; protein TDP-43; Proteins; Research; Risk; Rodent; Serum; Symptoms; tau Proteins; Testing; Time; tool; Transgenic Mice; Transgenic Organisms; Translating; Veterans; Wild Type Mouse; Work; ,Repetitive mTBI-induced neurobehavioral changes and CTE-like proteinopathy,1859,RRD1,Brain Injury: TBI & Stroke  ,,,2,,,,
9394007,R01,DK,5,N,12/26/2017,12/1/2017,11/30/2018,847,R01DK107716,,PAS-13-031,5R01DK107716-03,NIDDK:358425\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,,BOSTON,UNITED STATES,,7,76593722,US,1504801,BOSTON CHILDREN'S HOSPITAL,MA,21155724,,1941436; ,"AGARWAL, SUNEET ;","BISHOP, TERRY ROGERS",12/1/2015,11/30/2020,Alpha Cell; Aplastic Anemia; base; Binding; Biogenesis; blood treatment; Cardiovascular Diseases; cell type; Cells; chromatin modification; Chromatin Structure; Cirrhosis; cis acting element; Complex; curative treatments; Data; Defect; Degenerative Disorder; Disease; DNA Sequence Alteration; Dyskeratosis Congenita; Dysmyelopoietic Syndromes; Enzymes; Equilibrium; Functional disorder; Gene Expression; Genes; Genetic; Genetic Transcription; genome editing; Goals; Hand; Health; Hematological Disease; Hematopoiesis; Hematopoietic; Hematopoietic stem cells; Hematopoietic System; Human; human stem cells; Impairment; induced pluripotent stem cell; innovation; insight; Investigation; Knowledge; Lesion; leukemia; Longevity; Lung diseases; Malignant Neoplasms; Mutation; Nature; novel; novel strategies; novel therapeutic intervention; Outcome; Pancytopenia; Patients; Poly(A)-specific ribonuclease; Pulmonary Fibrosis; Regulation; Research; Ribonucleases; Ribonucleoproteins; RNA; RNA Processing; Role; self-renewal; Solid Neoplasm; stem cell biology; Stem cells; Techniques; Telomerase; Telomerase RNA Component; telomere; TERC gene; Testing; Therapeutic; therapy development; Tissues; tool; Trans-Activators; Transcript; transcription factor; Untranslated RNA; Work; ,Regulation of the telomerase RNA component in hematopoiesis,107716,MCH,Molecular and Cellular Hematology Study Section ,,,3,202500,155925,358425,
9424721,R01,DK,1,N,12/22/2017,12/26/2017,11/30/2018,847,R01DK115844,SCHOOLS OF MEDICINE,PA-16-160,1R01DK115844-01,NIDDK:529860\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,,ANN ARBOR,UNITED STATES,INTERNAL MEDICINE/MEDICINE,12,73133571,US,1506502,UNIVERSITY OF MICHIGAN,MI,481091276,,11167875; ,"WRIGHT, JULIE ANNE;","NARVA, ANDREW",12/26/2017,11/30/2022,Address; Adoption; Adult; advanced disease; Affect; Age; American; Behavior; behavior change; Blood Pressure; blood pressure reduction; blood pressure regulation; Cardiovascular system; Caring; Cessation of life; Chronic; chronic care model; Chronic Kidney Failure; Clinic; Clinical; Communities; Community of Practice; Community Practice; community setting; Continuity of Patient Care; Control Groups; disease diagnosis; Disease Progression; Education; Educational Intervention; End stage renal failure; Epidemic; Event; evidence base; Evidence based program; experience; follow-up; Future; Glomerular Filtration Rate; Goals; group intervention; Health; Health behavior; Health behavior outcomes; high risk; improved; improved outcome; innovation; Intervention; Kidney Diseases; Kidney Failure; Knowledge; Lead; Life; medication compliance; Methodology; Methods; Mission; Modeling; Morbidity - disease rate; mortality; Motivation; multidisciplinary; Nature; Organism; Outcome; Patient Education; Patient Outcomes Assessments; Patient Self-Report; Patients; practice-based research network; primary care setting; Primary Health Care; primary outcome; Process; process optimization; programs; Proteins; Provider; Public Health; Randomized Controlled Trials; Research; Resources; satisfaction; secondary outcome; Self Efficacy; skills; success; System; Technology; Testing; theories; Time; tool; Translations; United States National Institutes of Health; uptake; Urine; ,Improving Outcomes in Kidney Disease Using Systems-Driven Education and Coaching,115844,ZDK1,Special Emphasis Panel ,,,1,346735,183125,529860,
9430038,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200002-3,NIAID:109803\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,12/22/2016,12/21/2017,Categories; Chemistry; Communicable Diseases; Development; Intervention; Lead; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; programs; Services; Therapeutic; therapy development; Translational Research; ,Task Order 2: Interventional Agent Development Services Program ,,,,,,,,,109803,
9430051,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-5,NCI:3487154\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Address; ALCAM gene; Algorithms; Alpha Cell; analog; Antineoplastic Agents; Automation; base; Binding; Binding Sites; Biological; Biological Assay; Calcium; Cancer cell line; cancer diagnosis; Cancer Patient; cancer stem cell; cancer therapy; CCAAT-Enhancer-Binding Proteins; CCNE1 gene; CD44 gene; Cell Cycle; Cell Cycle Progression; cell growth; cell killing; Cell Line; Cell Separation; Cells; Characteristics; CHEK2 gene; Chemicals; Cleaved cell; Collaborations; college; Colon Carcinoma; Complement; Crude Extracts; Culture Media; Cultured Cells; Cyclic AMP-Dependent Protein Kinases; cytotoxicity; Data; Databases; design; Development; Developmental Therapeutics Program; Dimethyl Sulfoxide; Disease; DNA Binding; Dose; Drug Controls; drug development; drug discovery; drug distribution; drug testing; Endopeptidases; Enzyme Inhibitor Drugs; Enzymes; Equipment and Supplies; established cell line; Evaluation; experience; Family; Flow Cytometry; Fluorescence Polarization; Fluorescence Resonance Energy Transfer; Gene Targeting; Glioblastoma; Goals; Growth; high throughput screening; Human; Human Resources; hypoxia inducible factor 1; improved; In Vitro; Individual; Information Technology; inhibitor/antagonist; instrumentation; interest; kinase inhibitor; Label; Laboratories; Lead; leukemia; Libraries; malignant breast neoplasm; Malignant neoplasm of brain; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Malignant Neoplasms; MDA-MB-468; Measures; medical schools; Medicine; melanoma; member; Methodology; Methods; Molecular Biology; molecular marker; Molecular Target; National Institute of Neurological Disorders and Stroke; Natural Products; Neoplasm Metastasis; neoplastic cell; neuro-oncology; Nonmuscle Myosin Type IIA; Oncogenes; operation; Pattern; Pattern Recognition; Peptide Hydrolases; Peptides; Pharmaceutical Preparations; Pharmacologic Substance; Phosphotransferases; Play; Population; pre-clinical; Preclinical Drug Development; Procedures; Process; Program Development; programs; Protease Inhibitor; Proteins; Protocols documentation; prototype; Reagent; Recombinant Proteins; Renal carcinoma; Reproducibility; Research Infrastructure; Research Personnel; Resources; response; Role; S100A4 gene; Sampling; scaffold; screening; Screening Result; Services; small molecule inhibitor; small molecule libraries; Solubility; Stem cells; System; Technology; Testing; TFE3 gene; Therapeutic; thiazole orange; Threonine; Time; tissue culture; Titrations; Training; transcription factor; Transfection; Trifluoperazine; tumor; Tumor Cell Line; Tumor Stem Cells; Universities; Washington; Work; ,DCTD Screening Technologies,,,,,,,,,3487154,
9430130,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-98,NCI:5603999\NIA:0\NIAID:0\NIDDK:2140\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Adverse effects; animal imaging; Animal Model; Animals; Biodistribution; Biological; Biological Assay; Clinical Data; Clinical Trials; Diagnostic; Dose; Drug Delivery Systems; Funding; Image; imaging agent; imaging program; In Vitro; in vivo; Laboratories; Malignant Neoplasms; nanoparticle; Nanotechnology; nanotherapeutic; novel therapeutics; Performance; Phase; pre-clinical; Property; Research; Rodent; Therapeutic; Translations; ,Office of Cancer Nanotechnology Research ,,,,,,,,,5606139,
9430186,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-154,NCI:3303051\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14368683; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Address; anticancer research; Data Collection; Goals; Image; interest; Laboratories; Macromolecular Complexes; Malignant Neoplasms; Microscope; National Cancer Institute; Resolution; Structural Biologist; United States National Institutes of Health; ,Cryo-EM,,,,,,,,,3303051,
9430189,N01,AI,,N,,,,,N01AI000000,,,272201200001C-11-0-1,NIAID:627477\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,,13872747,US,,,MD,217039401,,12577165; ,"THADIKONDA, PAUL ;",,1/1/2012,12/31/2016,Clinical; Clinical Research; Clinical Trials; Conduct Clinical Trials; Contracts; Equipment and supply inventories; Immune Tolerance; Investigation; Label; Placebos; Preparation; Regulation; Research Personnel; research study; Services; ,Clinical Products Center,,,,,,,,,627477,
9430199,N01,ES,,N,,,,,N01ES000000,,,273201500010C-10-0-2,NIEHS:2998270\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,RESEARCH TRIANGLE PARK,UNITED STATES,,4,130427701,US,1933801,"INTEGRATED LABORATORY SYSTEMS, INC.",NC,277093501,,14082068; ,"ALLEN, DAVID ;",,5/5/2015,5/4/2017,adverse outcome; Animals; Authorization documentation; base; Characteristics; Chemicals; Computer Simulation; Contractor; Contracts; Data; Databases; Development; Documentation; Drug Kinetics; Economics; Educational workshop; Ensure; Evaluation; Exposure to; Guidelines; Hazard Identification; Health; high throughput screening; Human; In Vitro; in vivo; Interagency Coordinating Committee on the Validation of Alternative Methods; interest; Knowledge; Literature; meetings; Methods; Mission; Modeling; National Toxicology Program; novel; operation; Pathway interactions; Peer Review; Performance; pharmacodynamic model; Physiological; Production; Published Comment; Publishing; Quantitative Structure-Activity Relationship; Reporting; research and development; Research Methodology; Research Support; Risk Assessment; safety testing; screening; Support Contracts; System; Testing; Toxicokinetics; Toxicology; Validation; Work; ,NICEATM Support Contract: Base Contract,,,,,,,,,2998270,
9535670,R21,AI,1,N,12/25/2017,12/25/2017,11/30/2018,855,R21AI136472,SCHOOLS OF MEDICINE,PA-16-161,1R21AI136472-01A1,NIAID:208500\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GRAND FORKS,UNITED STATES,OTHER BASIC SCIENCES,0,102280781,US,6093301,UNIVERSITY OF NORTH DAKOTA,ND,582026059,,9481949; ,"SHARMA, JYOTIKA ;","MINNICOZZI, MICHAEL",12/25/2017,11/30/2019,Acute; Alveolar Macrophages; Anti-inflammatory; Anti-Inflammatory Agents; Antibiotic Resistance; Antigen-Antibody Complex; antimicrobial; Apoptotic; Bacteria; base; Biological Response Modifiers; C Type Lectin Receptors; care burden; Cells; Characteristics; Chronic; Chronic lung disease; Clinical; Complex; CSF3 gene; Data; Defect; Development; Disease; Drug resistance; effective therapy; Equilibrium; Event; Excision; Exhibits; extracellular; Feedback; Future; Goals; Gram-Negative Bacteria; Grant; Granulopoiesis; Health; Healthcare; Homeostasis; Hospitalization; Immune; immune activation; Immune response; Immune system; Immune System Diseases; improved; In Vitro; in vivo; Infection; Infection Control; Inflammation; Inflammatory; inflammatory lung disease; Inflammatory Response; Injury; Interleukin-17; interleukin-23; Klebsiella pneumonia bacterium; Lead; lipid mediator; Lung; Lung Inflammation; lung injury; macrophage; Measures; Mediating; Mediator of activation protein; Microbe; Modeling; Molecular; Morbidity - disease rate; mortality; Multi-Drug Resistance; Mus; neutrophil; Neutrophilia; Nosocomial Infections; novel; overexpression; pathogen; Pathologic; Phagocytes; Phagocytosis; Phenotype; Plant Roots; Play; Pneumonia; prevent; Prevention strategy; Process; Production; Property; public health relevance; Publishing; Pulmonary Pathology; Regulation; Reporting; Research; Resolution; response; restoration; Role; Sepsis; Sterility; System; Therapeutic; tissue repair; Tissues; Treatment Efficacy; treatment strategy; United States; Up-Regulation; uptake; ,Efferocytosis and neutrophil homeostasis in pneumonic sepsis,136472,SAT,"Surgery, Anesthesiology and Trauma Study Section ",,A1,1,150000,58500,208500,
9535806,N01,HD,,N,,,,,N01HD000000,,,275201300005I-4-27500001-1,NICHD:5152\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CLEVELAND,UNITED STATES,,11,77758407,US,218601,CASE WESTERN RESERVE UNIVERSITY,OH,441061712,,12445707; ,"LIU, JAMES ;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,5152,
9536615,N01,HL,,N,,,,,N01HB000000,,,268201200019C-13-0-1,NHLBI:156698\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DALLAS,UNITED STATES,,30,800771545,US,578404,UT SOUTHWESTERN MEDICAL CENTER,TX,753909105,,12246670; ,"ZORA, ROGERS ;",,1/10/2012,4/30/2018,"2 year old; Abdomen; Age; Award; Benefits and Risks; Blood; Brain; Cardiac; Child; Child Care; Childhood; Chronic; Clinical; Clinical Data; clinical research site; cohort; Collection; Contractor; Contracts; Data Analyses; Data Collection; Development; double-blind placebo controlled trial; drug distribution; Early treatment; Enrollment; Evaluation; follow-up; Follow-Up Studies; Growth and Development function; hydroxyurea; improved; Kidney; Laboratories; Life; Long-Term Effects; Lung; Medical; Monitor; National Heart, Lung, and Blood Institute; Natural History; Neuropsychology; Organ; Patients; Performance; Pharmaceutical Preparations; Phase III Clinical Trials; prevent; Randomized; Recruitment Activity; Risk; Sampling; Scanning; Sickle Cell Anemia; Site Visit; Spleen; standard of care; Structure; Surrogate Markers; Testing; Toxic effect; Urine; ",BABY HUG FOLLOW-UP STUDY II ,,,,,,,,,156698,
9537828,N01,AI,,N,,,,,N01AI000000,,,272201700039I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537831,N01,AI,,N,,,,,N01AI000000,,,272201700036I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537832,N01,AI,,N,,,,,N01AI000000,,,272201700038I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SASKATOON,CANADA,,,207413170,CA,7328301,UNIVERSITY OF SASKATCHEWAN,SK,S7N 5C9,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537842,N01,AI,,N,,,,,N01AI000000,,,272201700024I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALBUQUERQUE,UNITED STATES,,1,45911138,US,679302,LOVELACE BIOMEDICAL & ENVIRONMENTAL RES,NM,871085129,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537862,N01,AI,,N,,,,,N01AI000000,,,272201700040I-0-27200003-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537865,N01,AI,,N,,,,,N01AI000000,,,272201700015I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537908,N01,AI,,N,,,,,N01AI000000,,,272201700020I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,,,,,658873501,,,,,,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9539223,N01,NS,,N,,,,,N01NS000000,,,271201100013C-41-0-1,NIA:1121000\NIDA:1121000\NINDS:765880\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,ALBANY,UNITED STATES,,20,787793900,US,3294801,"ALBANY MOLECULAR RESEARCH, INC.",NY,122035121,,12246362; ,"BARNES, KEITH ;",,8/17/2011,2/16/2018,analog; Basic Science; Biological Assay; Chemical Structure; Chemicals; Collaborations; Contractor; Contracts; Country; Data; high throughput screening; Human; improved; Individual; Information Systems; Instruction; Modeling; Modification; nervous system disorder; Participant; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Pharmacology and Toxicology; programs; Property; Research Personnel; research study; Services; small molecule; Time; United States National Institutes of Health; Work; ,TAS::75 0886::TAS MEDICINAL CHEMISTRY FOR NEUROTHERAPEUTICS PROGRAM (MCNP),,,,,,,,,3007880,
9539927,N02,NS,,N,,,,,N02NS000000,,,271201200158U-6-0-1,NINDS:754200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,WASHINGTON,UNITED STATES,,,116191875,US,,,DC,200363506,,12379826; ,"SONG, JEAN ;",,9/1/2017,2/28/2018,aging population; Autistic Disorder; Brain; Communication; Congresses; Contractor; Development; Diagnosis; digital; Education and Outreach; Educational Activities; Epilepsy; Evaluation; General Population; Health; Health Professional; Healthcare; improved; Institutes; Laws; Lead; Medical; Mission; National Institute of Neurological Disorders and Stroke; nervous system disorder; Neurologic; Neurology; Neurosciences Research; Pain; Parkinson Disease; Program Development; programs; public education; Quality of life; Research; Research Support; Services; social media; standard care; stroke; Translating; United States National Institutes of Health; web site; Writing; ,EDUCATION AND OUTREACH ACTIVITIES FOR NINDS; SUPPORT- PROFESSIONAL: OTHER,,,,,,,,,754200,
9542526,N01,AI,,N,,,,,N01AI000000,,,272201700001C-0-0-1,NIAID:1337240\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KANSAS CITY,UNITED STATES,,5,7173453,US,5282001,MIDWEST RESEARCH INSTITUTE,MO,641102241,,14922279; ,"COFFIN, JEANETTE ;",,1/1/2017,12/31/2023,Adult; AIDS clinical trial group; Bacterial DNA; base; Bedside Testings; Biological Assay; Blood; Brazil; Centers for Disease Control and Prevention (U.S.); Childhood; Clinical; clinical investigation; Clinical Trials; Clinical Trials Network; cohort; Collection; Contracts; design; Diagnosis; Disease Progression; DNA sequencing; drug development; Drug-sensitive; Evaluation; Evaluation Studies; Generations; Genetic Variation; Geography; HIV; HIV Infections; HIV Vaccine Trials Network; India; Individual; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Laboratories; Liquid substance; Lung; Methodology; Methods; Military Personnel; Monitor; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; next generation; Non-Commercial Sources; novel; Observational Study; Performance; performance tests; Preparation; Procedures; programs; prospective; Quality Control; Reagent; Reporting; Research; resistant strain; Resources; Saliva; sample collection; Sampling; Shipping; Solid; Source; Specific qualifier value; Sputum; Standardization; Statistical Data Interpretation; Test Result; Testing; Time; Training; transcriptome sequencing; treatment response; Tuberculosis; tuberculosis drugs; United States; Urine; vaccine efficacy; ,MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA),,,,,,,,,1337240,
9543648,N01,AI,,N,,,,,N01AI000000,,,272201400010I-0-27200027-1,NIAID:146836\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15155832; ,"PTAK, ROGER ;",,8/1/2017,7/31/2018,Academia; assay development; base; Biochemical; Biological Assay; Cells; Contracts; Data; Development; Funding; high throughput screening; HIV; Intervention; Investigational New Drug Application; Local Microbicides; National Institute of Allergy and Infectious Disease; novel therapeutics; phase I trial; preclinical development; Private Sector; product development; prospective; Public Health; public health priorities; Research Personnel; service utilization; Services; Source; Therapeutic; Validation; ,NEW ASSAY DEVELOPMENT,,,,,,,,,146836,
9543861,N01,HD,,N,,,,,N01HD000000,,,275201300025I-3-27500005-1,NICHD:500765\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,15170319; ,"PAGE, STEPHANIE ;",,9/30/2014,6/30/2017,Chemicals; Clinical Trials Network; Contraceptive Agents; Development; Gonadotropins; Male Contraceptive Agents; men; Nandrolone; Phase I Clinical Trials; research clinical testing; Testing; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK,,,,,,,,,500765,
9545126,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200009-1,NIAID:131138\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15151984; ,"SWARTZ, GLEN ;",,8/1/2017,7/31/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Clinical Trials; collaborative trial; Data Analyses; Development; Future; high risk; HIV; HIV Infections; HIV prevention trial; Licensure; medication compliance; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; Research Activity; research clinical testing; research study; Research Support; Resources; Role; sexual HIV transmission; Target Populations; Technology; United States National Institutes of Health; uptake; Work; ,SUPPORT FOR ENHANCING STUDY DRUG ADHERENCE IN HIV PREVENTION TRIALS,,,,,,,,,131138,
9545265,N43,AI,,N,,,,,N43AI000000,,,272201700079C-0-0-1,NIAID:299591\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WOBURN,UNITED STATES,,5,194643722,US,2256601,APHIOS CORPORATION,MA,18011720,,15236950; ,"CASTOR, TREVOR ;",,8/1/2017,7/31/2018,Adjuvant; AIDS prevention; Antisense Oligonucleotides; aptamer; base; Businesses; Cell Culture Techniques; Cells; chemical property; Circular DNA; Clinic; clinically relevant; Contracts; cytokine; Cytoplasm; Dependovirus; design; Development; Double-Stranded RNA; Feasibility Studies; Genetic Transcription; Goals; HIV; HIV therapy; HIV vaccine; Immune checkpoint inhibitor; improved; In Vitro; in vivo; Liquid substance; Messenger RNA; Methods; MicroRNAs; Modification; neutralizing monoclonal antibodies; Nuclear; Oligonucleotides; Particle Size; Pathway interactions; Phase; physical property; Plasmids; Process; RANTES; Recovery; Risk; RNA; RNA chemical synthesis; RNA Instability; RNA Splicing; RNA Stability; Small Interfering RNA; Subfamily lentivirinae; System; targeted delivery; Technology; Testing; Therapeutic; Tissues; Transfection; Vaccines; vector; ,Critical Fluid Nanosomes for Effective Targeted Delivery and Manufacture of siRNA-based Therapeutics,,,,,,,,,299591,
9547571,N01,AI,,N,,,,,N01AI000000,,,272201600006I-0-27200002-1,NIAID:565110\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALACHUA,UNITED STATES,,3,73438462,US,4146401,"NANOTHERAPEUTICS, INC.",FL,326159403,,15165421; ,"HOUSE, ROBERT ;",,8/14/2017,8/13/2018,Bontoxilysin; Botulism; Contracts; stability testing; Therapeutic; therapeutic development; therapeutic evaluation; ,TASK B1: STABILITY TESTING OF THERAPEUTICS FOR BOTULISM,,,,,,,,,565110,
9547618,N01,AI,,N,,,,,N01AI000000,,,272201500005I-0-27200004-1,NIAID:99299\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,6,14130053,US,10001472,"DYNPORT VACCINE COMPANY, LLC",MD,217024734,,14922237; ,"SHUMWAY, DAVID ;",,12/15/2016,12/14/2017,clinical infrastructure; Communicable Diseases; immunoregulation; infectious disease treatment; Investigation; novel therapeutics; Phase I Clinical Trials; Therapeutic; ,PHASE I CLINICAL TRIAL UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES,,,,,,,,,99299,
9547620,N01,AI,,N,,,,,N01AI000000,,,272201500005I-0-27200005-1,NIAID:222661\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,6,14130053,US,10001472,"DYNPORT VACCINE COMPANY, LLC",MD,217024734,,14923892; ,"SHUMWAY, DAVID ;",,2/3/2014,5/15/2021,Communicable Diseases; immunoregulation; infectious disease treatment; Investigation; Mycobacterium tuberculosis; novel therapeutics; Phase I Clinical Trials; Therapeutic; therapeutic evaluation; Tuberculosis; ,PHASE 1 CLINICAL TRIALS UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES: EVALUATION OF THERAPEUTICS FOR TUBERCULOSIS ,,,,,,,,,222661,
9547623,N01,AI,,N,,,,,N01AI000000,,,272201500006I-0-27200004-1,NIAID:128440\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14922240; ,"COHENWOLKOWIEZ, MICHAEL ;",,12/15/2016,12/14/2017,Clinical; Development; immunoregulation; infectious disease treatment; Investigation; novel therapeutics; operation; Phase I Clinical Trials; Therapeutic; ,PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS,,,,,,,,,128440,
9547705,N01,AI,,N,,,,,N01AI000000,,,272201400029C-5-0-1,NIAID:885500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NOTRE DAME,UNITED STATES,,2,824910376,US,6169301,UNIVERSITY OF NOTRE DAME,IN,465565708,,12426195; ,"COLLINS, FRANK ;",,9/16/2014,9/15/2018,Anopheles Genus; Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human; Human Resources; Invertebrates; pathogen; Research; Resources; Services; tool; Update; user-friendly; vector; ,BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES - INVERTEBRATE VECTORS OF HUMAN PATHOGENS,,,,,,,,,885500,
9547710,N01,MH,,N,,,,,N01MH000000,,,271201300030C-6-0-1,NIMH:922784\NINDS:621877\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,BELMONT,UNITED STATES,,5,46514535,US,1876801,MCLEAN HOSPITAL,MA,24781064,,14270469; ,"WOO, TSUNG-UNG W. ;",,8/8/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ",Brain Bank,,,,,,,,,1544661,
9551392,N01,ES,,N,,,,,N01ES000000,,,273201600003I-1-27300010-1,NIEHS:2398293\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14763642; ,"CURRY, MATTHEW ;",,9/26/2016,9/25/2018,cohort; Cohort Studies; Communication; Data; Development; follow-up; laboratory experiment; Maintenance; meetings; Telephone Interviews; web site; ,IGF::OT::IGF EPI SUPPORT TO 10 - GULF COHORT MAINTENANCE,,,,,,,,,2398293,
9553424,N01,AI,,N,,,,,N01AI000000,,,272201100021I-3-27200012-1,NIAID:181774\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14270531; ,"ISHIKAWA, PHILLIP ;",,8/29/2013,8/31/2019,AIDS prevention; authority; cGMP production; Clinical Trials; Contracts; Development; Documentation; env Gene Products; flexibility; Guidelines; HIV vaccine; HIV-1; Human; immunogenicity; Investigational Drugs; Investigational New Drug Application; Investigator-Initiated Research; microbicide; Modality; National Institute of Allergy and Infectious Disease; Pamphlets; Phase; preclinical development; Preclinical Testing; Process; Production; Protocols documentation; research clinical testing; Research Personnel; research study; Safety; Testing; ,NIAID Preclinical Development Support -  HIV-1 Envelope Protein Production,,,,,,,,,181774,
9554733,N01,CA,,N,,,,,N01CA000000,,,261201200031I-2-26100010-1,NCI:738224\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TUCSON,UNITED STATES,,3,806345617,US,490201,UNIVERSITY OF ARIZONA,AZ,857210158,,14264138; ,"CHOW, SHERRY ;",,9/24/2017,9/23/2018,cancer prevention; Clinical; Clinical Chemoprevention; Clinical Trials; clinically relevant; Conduct Clinical Trials; Contractor; Data; data management; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; interest; laboratory experiment; Maintenance; Malignant Neoplasms; meetings; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; prevention clinical trial; Preventive; programs; protocol development; Protocols documentation; Request for Proposals; research and development; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; ,IGF::OT::IGF R&D- CORE INFRASTRUCTURE SUPPORT,,,,,,,,,738224,
9554735,N01,CA,,N,,,,,N01CA000000,,,261201200042I-3-26100009-1,NCI:855261\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,6721205; ,"LIMBURG, PAUL J;",,9/24/2015,9/23/2018,cancer prevention; Clinical; Clinical Chemoprevention; Clinical Trials; clinically relevant; Conduct Clinical Trials; Contractor; Data; data management; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; interest; laboratory experiment; Maintenance; Malignant Neoplasms; meetings; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; prevention clinical trial; Preventive; programs; protocol development; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; ,CORE INFRASTRUCTURE SUPPORT,,,,,,,,,855261,
9555908,N01,AI,,N,,,,,N01AI000000,,,272201200003I-4-27200014-1,NIAID:89265\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14256209; ,"BRUCE, MARY ;",,9/10/2015,7/31/2018,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; Ebola Vaccines; efficacy testing; Emerging Communicable Diseases; Evaluation; evaluation/testing; Feasibility Studies; immunogenicity; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; vaccine development; Vaccines; Virus; ,Task X14:  Evaluation of Ebola Vaccines ,,,,,,,,,89265,
9555910,N01,ES,,N,,,,,N01ES000000,,,273201600002I-1-27300009-1,NIEHS:50000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14770507; ,"WAGNER, DAVID ;",,9/27/2016,9/26/2018,Acute; Administrative Coordination; Adverse event; Breathing; Chronic Obstructive Airway Disease; Clinical Data; Clinical Research; Clinical Trials Data Monitoring Committees; clinically relevant; Contractor; Contracts; Data; Data Collection; data management; Documentation; Enrollment; Environmental air flow; follow-up; Funding; Graph; Hyaluronan; Information Dissemination; Italy; Manuscripts; Molecular Weight; Monitor; National Institute of Environmental Health Sciences; Outcome; Participant; Patients; posters; Progress Reports; Protocols documentation; Reporting; Research Personnel; Research Support; Rome; Safety; Services; Site; symposium; ,Clinical Research Support Services for NIEHS Contract Task Order 9 - Inhaled Hyaluronan in acute COPD Exacerbation,,,,,,,,,50000,
9555912,N02,CA,,N,,,,,N02CA000000,,,261201600638P-1-0-1,NCI:38294\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WASHINGTON,UNITED STATES,,98,804535342,US,1638101,ACADEMYHEALTH,DC,200364647,,14734679; ,"KANANI, NISHA ;",,9/1/2017,8/31/2018,Affect; anticancer research; Attention; Cancer Burden; cancer care; care delivery; career; Caring; Communities; Contracts; data resource; design; Development; Division of Cancer Control and Population Sciences; evidence base; Extramural Activities; Family; Fellowship Program; Funding; Grant; Health; health care delivery; improved; Individual; Intervention; Knowledge; Malignant Neoplasms; Manuscripts; Outcome; patient oriented; programs; Publishing Peer Reviews; Research; Research Personnel; Resources; Talents; Testing; Time; tool; Training; Work; ,IGF::OT::IGF PILOT TESTING A HEALTHCARE DELIVERY RESEARCH FELLOWSHIP PROGRAM,,,,,,,,,38294,
9559805,N01,AI,,N,,,,,N01AI000000,,,272201300004I-0-27200007-1,NIAID:303353\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,1,53785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,,15195795; ,"VEAZEY, RONALD ;",,9/1/2017,11/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Antibodies; Antigens; Award; base; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Macaca mulatta; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,Elicitation of ?4?7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen,,,,,,,,,303353,
9559819,N01,AI,,N,,,,,N01AI000000,,,272201700061C-0-0-1,NIAID:4433477\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,15200736; ,"WARD, MARIANNE ;",,9/30/2017,9/29/2018,Acquired Immunodeficiency Syndrome; Antibodies; Antigens; assay development; Biological Assay; cell bank; Collection; Contracts; cytokine; Data; Data Quality; Databases; design; Development; Flow Cytometry; HIV; HIV Infections; HIV vaccine; Immune response; Immunologic Factors; Individual; Interferon Type II; Internet; Knowledge; Laboratories; Laboratory Research; Measures; microbiota; Mission; Monitor; National Institute of Allergy and Infectious Disease; pathogen; Pathogenesis; Performance; Peripheral Blood Mononuclear Cell; Prevention strategy; Procedures; programs; quality assurance; Reagent; reagent standard; repository; Reproducibility; research clinical testing; Research Support; Specimen; Staining method; Stains; Testing; therapy development; transmission process; United States National Institutes of Health; vaccine candidate; vaccine development; Vaccines; Validation; ,EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL),,,,,,,,,4433477,
9560665,N02,CA,,N,,,,,N02CA000000,,,261201300008I-1-26100014-1,NCI:200000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,14752337; ,"RILEY, THOMAS ;",,9/14/2016,9/13/2018,Data; data access; Malignant Neoplasms; System; , IDATA STUDY DATA CLEANING AND ANALYSIS AND CANCER DATA ACCESS SYSTEM ENHANCEMENTS FOR PUBLIC USE,,,,,,,,,200000,
9560667,N01,DA,,N,,,,,N01DA000000,,,271201500055C-4-0-1,NICHD:14630\NIDA:37520\NINR:77707\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,14264245; ,"SAHLER, OLLE JANE ;",,9/21/2015,9/20/2018,Analgesics; Case Based Learning; Contractor; Dental Assistants; Dental Schools; Diagnosis; Education; educational atmosphere; Educational Curriculum; Epidemic; Goals; improved; innovation; Learning; Medical; medical schools; Nursing Schools; Pain; Pain management; Pharmacy facility; Pharmacy Schools; repository; Resources; Students; tool; Training; United States National Institutes of Health; web site; ,NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION,,,,,,,,,129857,
9562945,N01,AI,,N,,,,,N01AI000000,,,272201500001G-2-0-1,NIAID:590866\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,TAKOMA PARK,UNITED STATES,,8,361283638; 800210077,US,10007104,"GRYPHON SCIENTIFIC, LLC",MD,209124481,,14273194; ,"CASAGRANDE, ROCCO ;",,9/30/2017,9/29/2018,biological standardization; Chemical Structure; Chemicals; computerized; Contracts; Data; Databases; Hepatitis; HIV; HIV/TB; In Vitro; in vivo; Literature; microbicide; New Agents; novel therapeutics; Research Personnel; Resources; Review Literature; screening; Testing; Therapeutic; Tuberculosis; ,ANALYSIS OF CHEMICAL STRUCTURES AND THERAPEUTIC ACTIVITY OF AGENTS FOR HIV AND TUBERCULOSIS (CHEMDB),,,,,,,,,590866,
9563036,N02,CA,,N,,,,,N02CA000000,,,261201600066C-3-0-1,NCI:535826\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALACHUA,UNITED STATES,,3,12852344,US,10020711,ALCHEM LABORATORIES CORPORATION,FL,326156687,,14759310; ,"RUDCHENKO, VLADIMIR ;",,9/20/2016,9/19/2018,analog; Biological; chemical synthesis; Contracts; drug development; Evaluation; Investigational Therapies; Malignant Neoplasms; Methodology; Mission; Pharmaceutical Preparations; programs; Recommendation; ,IGF::OT::IGF NON-GMP SYNTHESIS OF COMPOUNDS FOR DRUG DEVELOPMENT,,,,,,,,,535826,
9563041,N01,CA,,N,,,,,N01CA000000,,,261201200042I-1-26100012-1,NCI:15681\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,14782585; ,"PAUL, LIMBURG ;",,9/15/2016,9/14/2018,Adenomatous Polyposis Coli; Adverse effects; Adverse event; Aggressive Fibromatosis; American Medical Association; Anastomosis - action; Anus; clinical efficacy; Clinical Trials; cohort; Data; differential expression; Dose; Duodenal Adenoma; Duodenum; Epidermal Growth Factor Receptor; Erlotinib; Esophagogastroduodenoscopy; Exanthema; follow-up; Gastrointestinal Polyp; Gene Expression; Gene Targeting; Genes; Ileal Reservoirs; Immune response; Journals; Molecular Profiling; Neoplasms; oral mucositis; Participant; Phase; phase II trial; Polyps; Population; post intervention; pre-clinical; Publishing; rectal; Sampling; Signal Transduction; standard of care; statistics; success; Time; Tissues; week trial; ,IGF::OT::IGF PHASE II TRIAL OF WEEKLY ERLOTINIB DOSING TO REDUCE DUADENAL POLYP BURDEN ASSOCIATED WITH FAMILIAL ADENOMATOUS POLYPOSIS,,,,,,,,,15681,
9430230,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-7,NIAID:658780\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,1/26/2017,1/25/2018,Antimicrobial Resistance; Communicable Diseases; Contracts; Development; Gram-Negative Bacteria; Intervention; Microbiology; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Safety; Services; therapeutic development; therapy development; Toxicology; Translational Research; ,Task 4: The Interventional Agent Development Services Program ,,,,,,,,,658780,
9430233,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-10,NIAID:91300\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14369140; ,"MIRSALIS, JON ;",,1/26/2017,1/25/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; Staphylococcus aureus; therapeutic development; Toxicology; Toxin; Translational Research; ,Task 4: The Interventional Agent Development Services Program ,,,,,,,,,91300,
9430251,N01,LM,,N,,,,,N01LM000000,,,276201400001C-11-0-1,NIDDK:2323017\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,ANN ARBOR,UNITED STATES,,12,73133571,US,1506502,UNIVERSITY OF MICHIGAN,MI,481091276,,7600559; ,"SARAN, RAJIV ;",,2/8/2014,2/7/2018,Area; Biomedical Research; Categories; Chronic Kidney Failure; Communities; Contracts; cost effectiveness; Data; Data Collection; Data Set; Databases; design; Dialysis procedure; disability; Disease; Economics; End stage renal failure; Etiology; Expenditure; follow-up; Genetic; Geographic Distribution; Health; Hospitalization; Immune; Incidence; Information Systems; interest; Investigation; Investigator-Initiated Research; Kidney; Kidney Diseases; Kidney Failure; Kidney Transplantation; Lead; Metabolic; Modality; Morbidity - disease rate; mortality; National Institute of Diabetes and Digestive and Kidney Diseases; patient population; Patients; Persons; Population; Prevalence; Registries; research study; Sampling; Time; United States; ,UNITED STATES RENAL DATA SYSTEM COORDINATING,,,,,,,,,2323017,
9430256,N01,AI,,N,,,,,N01AI000000,,,272201100022I-2-27200009-1,NIAID:193766\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14433388; ,"MIRSALIS, JON ;",,12/16/2016,10/5/2018,Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Ebola virus; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; Toxicology; Toxin; Translational Research; ,TO X9: OPTIMIZATION PK STUDIES,,,,,,,,,193766,
9430257,N01,AI,,N,,,,,N01AI000000,,,272201100022I-2-27200009-2,NIAID:697838\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14433388; ,"MIRSALIS, JON ;",,12/16/2016,10/5/2018,Bacterial Drug Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Gram-Negative Bacteria; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; Toxicology; Toxin; ,TO X9: OPTIMIZATION PK STUDIES,,,,,,,,,697838,
9430263,N01,AI,,N,,,,,N01AI000000,,,272201300021C-10-0-1,OD:205528\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,JOHNSON CITY,UNITED STATES,,1,185698334,US,10008475,"RXBIO, INC.",TN,376043619,,12348478; ,"MCCOOL, SHANNON ;",,9/30/2013,4/30/2017,Advanced Development; Advisory Committees; Animal Model; animal model development; Award; Caring; Contracts; Development; Dose; Elements; Evaluation; gastrointestinal; Goals; granulocyte; Granulocyte Colony-Stimulating Factor; Growth Factor; irradiation; Lead; Leukocytes; Medical; meetings; Modeling; nonhuman primate; Radiation Syndromes; Radiation Toxicity; Regimen; Safety; ,Development of Medical Countermeasures to Mitigate or Treat GI-ARS,,,,,,,,,205528,
9430278,N01,AI,,N,,,,,N01AI000000,,,272201200005C-17-0-1,NIAID:1534338\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,12627974; ,"TOPHAM, DAVID ;",,12/13/2011,12/12/2018,Basic Science; Clinical Research; Development; Measures; pathogen; Pediatric Research; Research; respiratory; Respiratory syncytial virus; Translational Research; Viral; ,Respiratory Pathogens Research Center (RPRC),,,,,,,,,1534338,
9430279,N01,AI,,N,,,,,N01AI000000,,,272201200005C-17-0-2,NIAID:460301\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCHESTER,UNITED STATES,,25,41294109,US,7047101,UNIVERSITY OF ROCHESTER,NY,146270140,,12627972; ,"TOPHAM, DAVID ;",,12/13/2011,12/12/2018,Basic Science; Clinical Research; Development; Measures; microbiome; pathogen; Research; respiratory; Translational Research; Viral; ,Respiratory Pathogens Research Center (RPRC),,,,,,,,,460301,
9430285,N01,AI,,N,,,,,N01AI000000,,,272201200010C-15-0-1,NIAID:2525625\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,52,603880287,US,2465301,LA JOLLA INST FOR ALLERGY & IMMUNOLGY,CA,920371387,,12576847; ,"SETTE, ALESSANDRO ;",,12/15/2012,12/14/2017,Algorithms; Alleles; Allergens; Alloantigen; Amino Acids; analytical tool; Animals; Antibodies; Antigens; Attention; Autoantigens; Binding; Biological; Bioterrorism; Categories; Communicable Diseases; Communities; Computer software; Contractor; Databases; Development; Disease; Documentation; Ebola virus; Epitope Mapping; Epitopes; Frankfurt-Marburg Syndrome Virus; Frequencies; Hantavirus; Human; Imagery; Immune; immunogenicity; improved; Lassa fever virus; Ligands; Link; Literature; Methods; MHC Class I Genes; Modeling; Molecular; Molecular Conformation; National Institute of Allergy and Infectious Disease; nonhuman primate; Online Systems; pathogen; Peptides; Population; prediction algorithm; programs; protein structure; Proteins; Publications; Publishing; relational database; Research; Resources; Ricin; Series; Source; Source Code; T-Lymphocyte Epitopes; three dimensional structure; tool; Toxin; Validation; web site; ,Immune  Epitope Database: Infectious diseases,,,,,,,,,2525625,
9430292,N01,HL,,N,,,,,N01HL000000,,,268201300026C-9-0-1,NHLBI:600026\NIA:15513\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,9479316; ,"LEWIS, CORA E ;",,7/1/2013,6/30/2017,acquired factor; Address; Adult; Affect; Age; Ancillary Study; Arteries; Atrial Fibrillation; base; Blood; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; cardiovascular risk factor; Cardiovascular system; Chicago; Clinical; cohort; Communities; Coronary Artery Risk Development in Young Adults Study; Coronary heart disease; Data; Development; Disease; Education; emerging adult; Event; Evolution; follow-up; Heart Abnormalities; Heart failure; high school; Institutes; Lung; Measures; middle age; Myocardial dysfunction; novel; Participant; Phenotype; Race; racial disparity; Research Personnel; Risk; Risk Factors; Sampling; sex; sharing data; stomach cardia; stroke; Structure; Subgroup; Time; Training; Update; young adult; ,IGF::OT::IGF RD  CORONERY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) FIELD ,,,,,,,,,615539,
9430331,N02,DA,,N,,,,,N02DA000000,,,271201400011I-1-27100003-1,NINDS:38700\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,EAST SETAUKET,UNITED STATES,,,79235699,US,,,NY,11733,,14763393; ,"ARALDI, GIAN LUCA ;",,9/28/2014,9/27/2017,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"IGF::OT::IGF ARALDI, GIAN LUCA:1238759 [16-005379]",,,,,,,,,38700,
9430356,N01,CA,,N,,,,,N01CA000000,,,261201200026I-9-26100002-1,NCI:15468\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,12446926; ,"IYER, LALITHA ;",,9/19/2014,7/31/2017,Amino Acids; Antibodies; antitumor effect; base; Biological Availability; calreticulin; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; cell bank; Cellular Immunity; Cervarix; Cervical Intraepithelial Neoplasia; Clinical; clinical development; Clinical Trials; Codon Nucleotides; Contractor; Contracts; Data; Devices; DNA; DNA Vaccines; Dose; Electroporation; Evaluation; Future; Gardasil; gene gun; Genes; genital infection; Genotype; Goals; head-to-head comparison; HIV; Human; Human papilloma virus infection; Human Papilloma Virus Vaccine; Human Papillomavirus; Human papillomavirus 16; Immune; Immune response; Immunocompromised Host; Intramuscular; Intramuscular Injections; L2 viral capsid protein; Lesion; Link; Malignant neoplasm of cervix uteri; Malignant Neoplasms; Manufacturer Name; Mediating; Medical; Methods; Mus; Mutation; Needles; Neoplasms; neoplastic cell; Oncogenic; particle; Patients; Persons; Phase; phase 1 study; pre-clinical; Pre-Clinical Model; Prevention; programs; Proteins; Safety; safety and feasibility; Splenocyte; System; Testing; Therapeutic Effect; therapeutic vaccine; Toxicology; Translating; tumor; Vaccinated; Vaccination; vaccine delivery; Vaccines; Virion; Virus-like particle; Work; ,Preclinical Toxicology: Safety Evaluation of pNGVL4a-CRT-E6E7L2 (detox) Recombinant DNA Vaccine in Mice,,,,,,,,,15468,
9430360,N01,ES,,N,,,,,N01ES000000,,,273201500077U-2-0-1,NIEHS:171243\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,FAIRFAX,UNITED STATES,,11,97779698,US,4095501,"SRA INTERNATIONAL, INC.",VA,220334232,,14505708; ,"MURRAY, MATT ;",,9/24/2015,11/23/2016,Bioinformatics; cheminformatics; Contracts; Data; data mining; Experimental Designs; experimental study; Genomics; Intramural Research; Literature; metabolomics; Methods; National Institute of Environmental Health Sciences; National Toxicology Program; Proteomics; Research; Research Design; Research Personnel; Sample Size; Services; text searching; ,"Statistical Support Services for the NIEHS, Subproject: Bioinformatics support for optional contract periods",,,,,,,,,171243,
9430361,N01,AI,,N,,,,,N01AI000000,,,272201000006I-5-27200012-1,NIAID:768645\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,14256117; ,"ELYARD, HANNE ;",,5/1/2016,4/30/2017,Chlamydia trachomatis; Contracts; Development; efficacy testing; Family suidae; infectious disease model; Licensure; Macaca; Modeling; nonhuman primate; Standardization; Tail; Translational Research; vaccine development; ,Task C32: Model Refinement in Pig-Tailed Macaques to AssessTherapeutics for Chlamydia trachomatis ,,,,,,,,,768645,
9430363,N02,CA,,N,,,,,N02CM000000,,,261201200014C-11-0-1,NCI:28900\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BUFFALO,UNITED STATES,,,71486518,US,,STARKS ASSOCIATES INC,NY,142131503,,12067281; ,"KANE, CHARLES ;",,5/21/2012,5/20/2017,Funding; Modification; ,"OTHER FUNCTIONS THIS MODIFICATION PROVIDES FUNDING FOR WA'S 2, 3, AND 4; AND REV",,,,,,,,,28900,
9430366,N01,AI,,N,,,,,N01AI000000,,,272201000011I-1-27200004-1,NIAID:751682\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WASHINGTON,UNITED STATES,,98,49515844,US,2869001,GEORGETOWN UNIVERSITY,DC,200570001,,14494627; ,"MENNE, STEPHEN ;",,4/12/2016,2/28/2018,Animal Model; Contracts; Development; efficacy testing; Hepatitis B; infectious disease model; Licensure; Standardization; Testing; Therapeutic; Therapeutic Human Experimentation; Translational Research; Woodchuck; ,Task D13: Woodchuck animal model for testing hepatitis B virus therapeutics,,,,,,,,,751682,
9431091,N02,CA,,N,,,,,N02CA000000,,,261201600007I-1-26100001-1,NCI:1045358\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,14443057; ,"MATHEW, SUNITHA ;",,3/1/2016,2/28/2018,Cessation of life; Clinical Data; Code; Colorectal Cancer; Contracts; Data; Data Collection; Elderly; follow-up; Incidence; indexing; Link; Long-Term Effects; Lung; Malignant neoplasm of lung; Malignant neoplasm of prostate; Malignant Neoplasms; Medicare claim; mortality; neoplasm registry; Participant; Resources; screening; Screening for Ovarian Cancer; Services; Update; ,"IGF::OT::IGF HHSN261201600007I/HHSN26100001, POP 03/01/2016 - 02/28/2017, PRIMARY PRODUCT/SERVICE CODE TO:  B537, DESCRIPTION: CENTRAL DATA COLLECTION CENTER (CDCC), WESTAT",,,,,,,,,1045358,
9438404,N01,AI,,N,,,,,N01AI000000,,,272201300014I-3-27200007-1,NIAID:1811664\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14256229; ,"COHEN, CRAIG ;",,8/28/2015,11/30/2017,Bacterial Vaginosis; Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; experience; Human Resources; Laboratories; Leadership; Phase; prevent; protocol development; Recurrence; Research Infrastructure; sample collection; Sexually Transmitted Diseases; therapeutic development; Training; Vaginitis; ,PHASE II-B CLINICAL TRIAL TO PREVENT THE RECURRENCE OF BACTERIAL VAGINOSIS,,,,,,,,,1811664,
9442648,N01,DA,,N,,,,,N01DA000000,,,271201400012C-6-0-2,NIDA:187185\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SALT LAKE CITY,UNITED STATES,,2,9095365,US,514002,UNIVERSITY OF UTAH,UT,841128930,,14438312; ,"MOODY, PH.D., DAVID ;",,2/27/2014,2/26/2018,Biological; Biological Assay; Communities; Contracts; Drug abuse; drug of abuse; Liquid substance; method development; Methods; Pharmaceutical Preparations; Reporting; Research; Review Literature; Sampling; Specimen; Tissues; Validation; ,"IGF::OT::IGF: Quantification of Drugs of Abuse and Related Substances in Biological Specimens. February 27, 2014 - February 26, 2017. N01DA-14-7788.",,,,,,,,,187185,
9442649,N01,AI,,N,,,,,N01AI000000,,,272201000040I-2-27200011-1,NIAID:267475\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,14516089; ,"BEASLEY, DAVID ;",,4/28/2016,6/23/2017,Animal Model; Contracts; Development; Ebola virus; efficacy testing; infectious disease model; mouse model; Standardization; therapeutic development; therapeutic evaluation; Translational Research; ,TASK A94: Mouse Models for Therapeutics Testing Against Ebola Virus,,,,,,,,,267475,
9443857,R01,HL,1,N,12/19/2017,12/24/2017,11/30/2018,839,R01HL136363,SCHOOLS OF MEDICINE,PA-16-160,1R01HL136363-01A1,NHLBI:475839\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BOSTON,UNITED STATES,INTERNAL MEDICINE/MEDICINE,7,604483045,US,894901,BOSTON UNIVERSITY MEDICAL CAMPUS,MA,21182340,,1869870; ,"RAVID, KATYA ;","CHANG, HENRY",12/24/2017,11/30/2021,Acute; Adhesions; Affect; Aldehydes; Alpha Cell; Binding; Blood Platelets; Bone Marrow; calreticulin; Cardiovascular system; Carotid Arteries; Cell surface; Cells; Chronic; Chronic Kidney Failure; Cicatrix; cohort; Collaborations; Collagen; Collagen Receptors; Collagen Type I; Complement; crosslink; Data; Deposition; Disease; drug development; Dyes; Elastin; Engineering; Enzymes; Event; extracellular; Extracellular Matrix; ferric chloride; Flowmeters; Future; Gene Mutation; Genes; Human; human disease; Image; in vivo; Incidence; inhibitor/antagonist; innovation; Integrin alpha2; Integrins; intravital microscopy; Investigation; Kidney; knock-down; Knockout Mice; Laboratories; Lasers; Lead; Light; Link; loss of function; LOX gene; Lysine; Malignant Neoplasms; Measurement; Mediating; Megakaryocytes; Membrane Proteins; mouse model; Mus; Mutagenesis; Myelofibrosis; Myeloproliferative disease; Nitrogen; novel; overexpression; Oxidases; oxidation; Oxides; Pathologic; Pathology; Pathway interactions; Patients; Pharmacology; Physiologic pulse; Platelet Activation; Platelet-Derived Growth Factor Receptor; Primary Myelofibrosis; Property; Protein-Lysine 6-Oxidase; Proteins; Proteomics; Publishing; receptor; Receptor Activation; Research; response; Risk; Role; Sampling; Serum; Shapes; Stenosis; Structure; Tensile Strength; Testing; Thrombosis; Thrombus; Tissues; Transgenic Mice; Up-Regulation; Western Blotting; Work; ,A path to thrombosis in primary myelofibrosis,136363,HT,Hemostasis and Thrombosis Study Section ,,A1,1,288898,186941,475839,
9445044,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500021-1,NICHD:1067\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14949301; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,Affect; Aspirin; Biological; Child health care; Childhood; Collection; Communicable Diseases; Contracts; Coupled; DNA Methylation; Dose; Double-Blind Method; Environment; epigenome-wide association studies; Equipment and supply inventories; Erythrocytes; Human; Human Development; implantation; Inflammation; Intramural Research; maternal obesity; methylation pattern; Monitor; National Institute of Child Health and Human Development; Newborn Infant; Perinatology; population health; Pregnancy; Pregnancy Outcome; prospective; randomized trial; repository; Research; Research Activity; Sampling; Services; Shipping; Ships; Site; Specimen; System; Testing; trial design; ,REPOSITORY SERVICES FOR REPLACEMENT SAMPLES IN THE EAGeR TRIAL,,,,,,,,,1067,
9445369,N01,DA,,N,,,,,N01DA000000,,,271201400006I-2-27100006-1,NCCAM:180013\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14256053; ,"NG, HANNA ;",,9/3/2015,9/2/2017,Biological Assay; Canis familiaris; Cardiovascular system; Chromosome abnormality; cytisine; Data; Dose; good laboratory practice; Human; In Vitro; in vivo; Investigational Drugs; Investigational New Drug Application; Laboratory Study; Lung; Lymphocyte; Maximum Tolerated Dose; micronucleus; No-Observed-Adverse-Effect Level; Pharmacology Study; Rattus; Safety; Toxic effect; Toxicology; United States Food and Drug Administration; United States National Institutes of Health; ,IGF::OT::IGF IND DIRECTED SAFETY AND TOXICOLOGY STUDIES FOR CYTISINE,,,,,,,,,180013,
9448901,R01,DK,1,N,12/22/2017,12/26/2017,11/30/2018,847,R01DK111930,SCHOOLS OF MEDICINE,PA-16-160,1R01DK111930-01A1,NIDDK:351828\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,,SAINT LOUIS,UNITED STATES,INTERNAL MEDICINE/MEDICINE,1,68552207,US,9083901,WASHINGTON UNIVERSITY,MO,631304862,,1952844; ,"HENDERSON, JEFFREY P;","BAVENDAM, TAMARA G",12/26/2017,11/30/2021,Affinity; Agreement; Anti-Bacterial Agents; Antibiotic Resistance; Antibiotics; antimicrobial; Bacteria; Bacterial Infections; base; Behavior; Bioavailable; Biochemical; Bladder; Chemicals; Clinical; clinical practice; Complex; Data Science; Diet; Enterobactin; Environment; Escherichia coli; Evaluation; experimental study; Genetic; Growth; Human; Immune; Immunity; Individual; Individual Differences; Infection; Influentials; Intestines; Iron; Iron Chelation; LCN2 gene; Learning; Ligands; Link; Mass Spectrum Analysis; Mediating; Metabolism; metabolome; metabolomics; microbial; Modeling; novel strategies; Nutritional; pathogen; Pathogenesis; Patient Care; Phenotype; Physiological; Play; Predisposition; pressure; prevent; prophylactic; Proteins; Resistance; Resistance to infection; Role; Siderophores; targeted treatment; Testing; Therapeutic; Translating; Translations; urinary; Urinary tract; Urinary tract infection; Urine; Uropathogen; Uropathogenic E. coli; ,Metabolomic Mechanisms of Nutritional Immunity in the Urinary Tract,111930,HIBP,Host Interactions with Bacterial Pathogens Study Section ,,A1,1,251762,100066,351828,
9452777,N01,AI,,N,,,,,N01AI000000,,,272201100022I-9-27200003-1,NIAID:472376\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,4/17/2017,4/16/2018,Chemistry; Contracts; Development; Intervention; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Services; Taenia solium; therapeutic development; therapy development; ,Task Order 3:Interventional Agent Development Services Program ,,,,,,,,,472376,
9456569,N01,AI,,N,,,,,N01AI000000,,,272201400038C-5-0-1,NIAID:8677955\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GAITHERSBURG,UNITED STATES,,6,189488554,US,3191901,EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR,MD,208793419,,12664348; ,"LEMIALE, LAURENCE ;",,8/28/2014,1/30/2019,Advanced Development; Anthrax Vaccines; Categories; Cold Chains; Communicable Diseases; Development; Disease Outbreaks; Event; Formulation; National Institute of Allergy and Infectious Disease; pathogen; response; Technology; Vaccines; ,DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N,,,,,,,,,8677955,
9459268,N01,ES,,N,,,,,N01ES000000,,,273201600015U-2-0-1,NIEHS:791829\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,FAIRFAX,UNITED STATES,,11,72648579,US,1644201,"ICF, INC., LLC",VA,220316050,,14505712; ,"BURCH, DAVID ;",,4/21/2016,4/20/2017,Address; Adverse effects; base; Contractor; Data; Educational workshop; Environmental Health; Epidemiology; Evaluation; exposed human population; Health; Health Hazards; Health Resources; Human; Information Management; Lead; Literature; Logistics; Malignant Neoplasms; meetings; National Toxicology Program; Public Health; Research; Science; Source; systematic review; Technical Expertise; Toxicology; Translations; ,Scientific Information Management and Literature-Based Evaluations for the National Toxicology Program (NTP) ? Support for the DNTP Office of Health Assessment and Translation,,,,,,,,,791829,
9459803,N01,DA,,N,,,,,N01DA000000,,,271201200027C-7-0-1,NIDA:42075\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,GAITHERSBURG,UNITED STATES,,,143526247,US,,FAST TRACK DRUGS AND BIOL,MD,208784276,,12387805; ,"RICKMAN, WILLIAM ;",,8/22/2012,8/21/2017,Clinical Trials; Contract Services; Contractor; Contracts; Development; Drug abuse; Ensure; Good Clinical Practice; Guidelines; International; National Institute of Drug Abuse; Pharmaceutical Preparations; Practice Guidelines; Regulation; Regulatory Affairs; symposium; United States Food and Drug Administration; United States National Institutes of Health; ,"OTHER FUNCTIONS: REGULATORY FILING SUPPORT FOR THE DEVELOPMENT OF MEDICATIONS, N",,,,,,,,,42075,
9462600,N01,AI,,N,,,,,N01AI000000,,,272201200003I-6-27200001-1,NIAID:190878\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,12445211; ,"BRUCE, MARY ;",,7/3/2012,7/2/2022,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; Infectious Diseases Research; novel vaccines; Office of Administrative Management; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; Vaccines; ,Task X1: Evaluation and Testing Services (ETS) for Vaccines and Other Biologics,,,,,,,,,190878,
9467404,N01,AI,,N,,,,,N01AI000000,,,272201600017C-1-0-1,NIAID:2608666\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14620064; ,"KIMBERLIN, DAVID ;",,7/1/2016,6/30/2021,Address; Advanced Development; Childhood; Clinical Course of Disease; Clinical Research; Cytomegalovirus Infections; Emerging Communicable Diseases; Medical; patient population; Population; Research; Therapeutic; therapeutic development; Virus Diseases; ,TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS,,,,,,,,,2608666,
9467405,N01,HD,,N,,,,,N01HD000000,,,275201300015C-5-0-1,NICHD:192588\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,12649366; ,"FAITH, MYLES ;",,3/27/2017,9/26/2018,Address; Adherence; adiponectin; Age; Alcohol abuse; Appetite Regulation; base; Basic Science; Behavioral; biobank; Blood; Body Composition; Body Image; Body mass index; Body Weight; Body Weight Changes; Brain; C-reactive protein; Carotenoids; Categories; Characteristics; Child; Chronic; Chronic Disease; Clinic; clinical development; Collection; Consumption; craving; Data; Diet; Dietary Assessment; Dietary intake; Discipline of obstetrics; discount; discounting; Disinhibition; Drug abuse; drug of abuse; Eating; Eating Behavior; Eating Disorders; eating in absence of hunger; Elements; Eligibility Determination; emotional eating; Energy Intake; Enrollment; Environmental Risk Factor; experience; experimental study; Fasting; fasting glucose; Fatty acid glycerol esters; Feces; First Pregnancy Trimester; Focus Groups; Food; food environment; Food Preferences; Food Processing; Frequencies; General Population; Genetic; genetic variant; Gestational Diabetes; gestational weight gain; Guidelines; Gynecology; Hair; Health; Health behavior; health economics; Health Status; hedonic; Hour; Hydrocortisone; Hyperphagia; Hypertension; Illicit Drugs; Impulsivity; Individual; Infant; Infant Food; Informed Consent; innovation; Institute of Medicine (U.S.); Insulin; Intake; Interleukin-6; Intervention Studies; Laboratories; Link; Lipids; Maternal and Child Health; Measures; Mental disorders; Mothers; National Institute of Child Health and Human Development; Nausea; Neurologic; Neurosciences; non-smoking; Nutritional; Obesity; Observational Study; Outcome; Outcome Measure; Overweight; Palate; Participant; Perception; Perinatal; Phenotype; Physical activity; Placenta; Population; Population Research; Postpartum Period; Predisposition; Pregnancy; pregnant; Pregnant Women; Prevalence; primary outcome; Procedures; prospective; Protocols documentation; Psychological reinforcement; Public Health; public health intervention; Questionnaires; racial and ethnic; Randomized; Recording of previous events; Recruitment Activity; reproductive; Reproductive History; Research; response; restraint; Rewards; Risk; Role; Saliva; Sampling; Satiation; Self-Administered; Self-control as a personality trait; Ships; Sleep; Sodium; Source; Specimen; Stress; Substance abuse problem; sugar; System; Taste Perception; Testing; Time; TNF gene; Umbilical Cord Blood; United States; Urine; Weight; Weight Gain; weight loss intervention; Woman; ,"DIET, OBESITY AND WEIGHT CHANGE IN PREGNANCY",,,,,,,,,192588,
9470481,R01,DK,1,N,12/27/2017,12/27/2017,11/30/2018,847,R01DK114224,SCHOOLS OF MEDICINE,PA-16-160,1R01DK114224-01A1,NIDDK:351333\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES,,WINSTON-SALEM,UNITED STATES,MICROBIOLOGY/IMMUN/VIROLOGY,5,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,,11972013; ,"SUBASHCHANDRABOSE, SARGURUNATHAN ;","MULLINS, CHRISTOPHER V",12/27/2017,11/30/2022,Affect; alcohol abuse prevention; Animal Model; Antibiotic Resistance; Antibiotics; Bacteremia; Bacterial Infections; base; Biological; Biological Availability; Bladder; Catheters; Ceruloplasmin; Child; Clinical; Communicable Diseases; Copper; Data; Diabetes Mellitus; Diet; Direct Costs; Disease; Disulfiram; efflux pump; Elderly; Etiology; FDA approved; Goals; Health; Health Benefit; Host Defense; Human; Immune response; in vivo; Individual; Infection; innovation; Intervention; Iron; kidney infection; Killings; macrophage; Mediating; Menkes Kinky Hair Syndrome; Mission; Modeling; Molecular; Mus; neutrophil; nonhuman primate; novel; novel strategies; Outcome Study; Pain; pathogen; Patients; Phagocytes; Pharmaceutical Preparations; Pharmacology; Physicians; Prevalence; Primates; protective effect; Proteins; Public Health; Publishing; Recurrence; Reporting; Research; Resolution; response; Role; Sepsis; Signal Transduction; Site; targeted treatment; Testing; Therapeutic; therapeutic development; Toxic effect; United States; United States National Institutes of Health; urinary; Urinary Calculi; Urinary tract; Urinary tract infection; Urine; Uropathogenic E. coli; Urothelium; Virulence; Visit; Woman; Work; ,Copper is a Host Effector in Protection Against Urinary Tract Infection,114224,ZRG1,Special Emphasis Panel ,,A1,1,228640,122693,351333,
9470507,F31,MH,1,N,8/23/2017,9/1/2017,8/31/2018,242,F31MH115611,SCHOOLS OF MEDICINE,PA-16-309,1F31MH115611-01,NIMH:44044\,"TRAINING, INDIVIDUAL",2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,NEW YORK,UNITED STATES,NEUROLOGY,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,100101710,,14459589; ,"SUN, SIMON D;","DRISCOLL, JAMIE",9/1/2017,8/31/2020,Action Potentials; Address; Affect; Alternative Splicing; Animal Model; Animals; area striata; autism spectrum disorder; Axon; Behavior; Behavioral; Biological Assay; Biological Neural Networks; Brain; Calcium; Calcium Channel; chemical stability; Chronic; Consequentialism; cost; dark rearing; Darkness; detector; disorder subtype; Electrophysiology (science); Excitatory Postsynaptic Potentials; Excitatory Synapse; Exhibits; experience; experimental study; Exposure to; Feedback; Frequencies; Functional disorder; Future; Genes; Genetic; genetic analysis; Genetic Models; Genetic study; Homeostasis; Image; Impaired cognition; In Vitro; in vivo; Individual; informant; Investigation; Ion Channel; Learning; Link; Measures; Mediating; Mediator of activation protein; Messenger RNA; Modeling; Molecular; Molecular Biology; Mutation; Neurodevelopmental Disorder; Neurons; Nucleotides; Pattern; Permeability; Pharmacology; Phenotype; Phosphorylation; Play; Preparation; Process; Property; receptor; Regulation; Research; response; Role; Sensory; Series; Shapes; Societies; Synapses; Syndrome; Testing; Tetrodotoxin; Timothy syndrome; Transfection; United States; Viral; Weight; Western Blotting; Work; ,Characterizing Maladaptive Homeostatic Plasticity In An Animal Model Of ASD,115611,ZRG1,Special Emphasis Panel ,,,1,44044,,44044,
9471289,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-5,NIEHS:130789\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,14498461; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Acute; acute toxicity; Animals; Breathing; Chemicals; Diazomethane; Goals; hazard; Human; Laboratories; Laboratory Animals; Lung; National Toxicology Program; Pathology Report; Pulmonary Edema; Risk; Synthesis Chemistry; Toxic effect; Toxicity Tests; ,Conduct of studies to evaluate the toxicity of trimethylsilyldiazomethane in laboratory animals for the National Toxicology Program (NTP),,,,,,,,,130789,
9474537,N01,AI,,N,,,,,N01AI000000,,,272201300004I-5-27200001-1,NIAID:259942\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW ORLEANS,UNITED STATES,,1,53785812,US,8424601,TULANE UNIVERSITY OF LOUISIANA,LA,701185665,,14089052; ,"LACKNER, ANDREW ;",,5/1/2013,4/30/2018,Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Data; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Maintenance; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; Occupational activity of managing finances; pre-clinical; preclinical evaluation; preclinical study; Preparation; Prevention; Prevention strategy; programs; Reporting; Research Personnel; Research Project Grants; Resources; Ships; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,SVEU - Core Activities - Administrative and Technical Support,,,,,,,,,259942,
9475638,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200005-1,NIAID:87207\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,4/21/2017,11/30/2017,biodefense; Categories; Communicable Diseases; Contracts; Development; Intervention; National Institute of Allergy and Infectious Disease; Organism; pre-clinical; programs; Services; therapeutic evaluation; therapy development; Translational Research; , Task Order 5: The Interventional Agent Development Services Program,,,,,,,,,87207,
9475639,N01,AI,,N,,,,,N01AI000000,,,272201100022I-8-27200005-2,NIAID:87207\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,4/21/2017,11/30/2017,Categories; Communicable Diseases; Contracts; Development; Intervention; National Institute of Allergy and Infectious Disease; Organism; pre-clinical; programs; Services; therapeutic evaluation; therapy development; Translational Research; ,Task Order 5: The Interventional Agent Development Services Program,,,,,,,,,87207,
9476856,N01,AI,,N,,,,,N01AI000000,,,272201200019C-13-0-1,NIAID:75287\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,Tacoma,UNITED STATES,,6,959131194,US,4276901,GENEVA FOUNDATION,WA,984024446,,14256217; ,"MARJORIE, OSMER ;",,7/16/2012,9/30/2018,Address; Advanced Development; Award; Biological Assay; Clinical Research; Contractor; Contracts; Cyclic GMP; design; Development; DNA Vaccines; Dose; Electroporation; Formulation; Goals; Hantavirus; Hemorrhagic Fever with Renal Syndrome; Immune response; improved; Investigational Drugs; National Institute of Allergy and Infectious Disease; Preclinical Testing; Process; product development; programs; Reagent; research clinical testing; seroconversion; stability testing; System; Technology; technology development; Toxicology; Vaccines; Validation; ,Development of Technologies that Accelerate the Immune Response to Vaccines,,,,,,,,,75287,
9476857,N01,AI,,N,,,,,N01AI000000,,,272201500004C-7-0-1,OD:1828001\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PASADENA,UNITED STATES,,27,788136880,US,10016969,"BCN BIOSCIENCES, LLC",CA,911073658,,14083441; ,"NORRIS, ANDREW ;",,6/1/2015,5/31/2018,animal rule; Benefits and Risks; Biological Markers; Chemistry; Contracts; Coupled; Data; design; Development; Drug Kinetics; Drug usage; efficacy study; Exposure to; Goals; Hour; Injury; Ionizing radiation; Lead; Lung; lung injury; Medical; Metabolism; model development; Modeling; Morbidity - disease rate; Nuclear; Nuclear Radiology; Pharmaceutical Preparations; Pharmacodynamics; Pharmacology and Toxicology; programs; Radiation; Radiation exposure; radiation mitigator; Radiology Specialty; Research; Research Support; subcutaneous; Testing; Therapeutic; Work; ,DEVELOPMENT OF MEDICAL COUNTERMEASURES TO MITIGATE AND/OR TREAT RADIATION-INDUCED LUNG INJURY AFTER A RADIOLOGICAL/NUCLEAR INCIDENT),,,,,,,,,1828001,
9477998,N01,CA,,N,,,,,N01CA000000,,,261201300012I-6-26100005-2,NCI:4288675\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SEATTLE,UNITED STATES,,7,78200995,US,861001,FRED HUTCHINSON CANCER RESEARCH CENTER,WA,981094433,,14505834; ,"SCHWARTZ, STEPHEN ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT TASK ORDER FOR SURVEILLANCE, EPIDEMIOLOGY,AND END RESULTS (SEER).",,,,,,,,,4288675,
9478001,N01,CA,,N,,,,,N01CA000000,,,261201300004I-3-26100005-2,NCI:3532033\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LOS ANGELES,UNITED STATES,,37,72933393,US,7636101,UNIVERSITY OF SOUTHERN CALIFORNIA,CA,900339263,,14503033; ,"DEAPEN, DENNIS ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)POP: 5/1/15-4/30/17",,,,,,,,,3532033,
9478003,N01,AI,,N,,,,,N01AI000000,,,272201400006I-3-27200001-1,NIAID:243556\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,12445325; ,"BAUGHMAN, KATHRYN ;",,5/31/2014,5/30/2018,Acquired Immunodeficiency Syndrome; clinical investigation; co-infection; Contractor; Contracts; Development; Development Plans; drug development; Formulation; Future; good laboratory practice; HIV; HIV Infections; HIV therapy; Intervention; meetings; microbicide; National Institute of Allergy and Infectious Disease; Pharmacologic Substance; Pharmacology and Toxicology; Practice Guidelines; prevent; quality assurance; Quality Control; Reporting; Research Personnel; Services; sexual HIV transmission; Teleconferences; Therapeutic Agents; transmission process; United States Dept. of Health and Human Services; United States National Institutes of Health; ,GENERAL ADMINISTRATIVE AND TECHNICAL SUPPORT,,,,,,,,,243556,
9478640,N01,CA,,N,,,,,N01CA000000,,,261201300015I-4-26100006-1,NCI:514000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12684309; ,"WARD, KEVIN ;",,5/1/2015,4/30/2018,anticancer research; clinical practice; Complement; Data; Data Element; Data Linkages; Databases; Development; improved; Manuals; oncology; Pharmacy facility; Pilot Projects; Population Research; Process; Registries; Research Infrastructure; SEER Program; Vendor; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)  POP 05/01/2015 - 04/30/2016",,,,,,,,,514000,
9478649,N01,CA,,N,,,,,N01CA000000,,,261201300009I-3-26100005-2,NCI:1357831\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HONOLULU,UNITED STATES,,,9438664,US,,HAWAII UNIV,HI,968222205,,14511279; ,"HERNANDEZ, BRENDA ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER)PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,1357831,
9478654,N01,CA,,N,,,,,N01CA000000,,,261201300021I-4-26100005-3,NCI:30500\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW BRUNSWICK,UNITED STATES,,6,78728091,US,10034166,RBHS -CANCER INSTITUTE OF NEW JERSEY,NJ,89011914,,14509885; ,"STROUP, ANTOINETTE ;",,5/1/2015,4/30/2018,cost effective; Data; Ensure; Goals; Insurance; Laws; Malignant Neoplasms; Medical; Modification; Newly Diagnosed; oncology; Recruitment Activity; SEER Program; System; Testing; ,"IGF::OT::IGF CORE INFRASTURCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER)PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,30500,
9483234,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-4,NIAID:142963\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,14600472; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; Trypanosoma; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,142963,
9502224,N02,CA,,N,,,,,N02CM000000,,,261201200021C-13-0-1,NCI:42581\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BUFFALO,UNITED STATES,,,71486518,US,,STARKS ASSOCIATES INC,NY,142131503,,14368723; ,"STARKS, DAVID ;",,9/1/2016,7/31/2017,Chemicals; preclinical study; ,IGF::OT::IGF OTHER,,,,,,,,,42581,
9507737,N01,CA,,N,,,,,N01CA000000,,,261201200042I-4-26100006-1,NCI:86842\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,6721205; ,"LIMBURG, PAUL J;",,9/9/2014,9/23/2019,Adjuvant; Antibody Response; base; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; CD8B1 gene; Chronic Hepatitis C; Clinic; Contractor; DNA Vaccines; Dose; Electroporation; Enrollment; Evaluable Disease; Genotype; Hepatitis C; Hepatitis C Therapy; Immune response; immunogenicity; Interferon Type II; Interleukin-12; Participant; Patients; Phase I Clinical Trials; phase I trial; plasmid DNA; Production; response; Safety; screening; Testing; therapeutic DNA; Time; trial design; vaccine candidate; Vaccines; Viral Antigens; viral DNA; Viral Load result; viral RNA; virology; ,CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PHASEI/II TRIAL OF A THERAPEUTIC DNA VACCINE FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION;HHSN261201200042I; TASK ORDER HHSN26100006; 09/09/2014 09/08/2016,,,,,,,,,86842,
9509317,N43,CA,,N,,,,,N43CA000000,,,261201600024C-2-0-1,NCI:1499991\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HUNTERSVILLE,UNITED STATES,,9,15685211,US,10030470,"VIRIDIAN TECHNOLOGIES, INC.",NC,280784463,,14759250; ,"JUNG, DUANE ;",,9/19/2016,12/18/2019,Architecture; Attention; base; Clinical Research; Cognitive; cognitive change; cognitive neuroscience; Cognitive Science; cognitive testing; Computer software; Contracts; cost; Data; Data Analyses; data visualization; database structure; design; Development; Disease; Educational workshop; Environment; Evaluation; executive function; experience; Impaired cognition; Injury; Institutional Review Boards; Legal; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Methods; Monitor; Motor; Neurocognitive; Neuropsychological Tests; Neurosciences Research; Paper; Participant; Phase; Privacy; processing speed; prototype; Recovery; Recruitment Activity; Reporting; Research Design; Research Infrastructure; Secure; Sensitivity and Specificity; Short-Term Memory; Small Business Innovation Research Grant; Specificity; Standardization; Testing; theories; Training; Treatment-Related Cancer; usability; Visuospatial; ,IGF::OT::IGF PLATFORM FOR NEUROCOGNITIVE EVALUATION AND MONITORING,,,,,,,,,1499991,
9509807,N01,AI,,N,,,,,N01AI000000,,,272201000029I-0-27200004-1,NIAID:219205\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,41064767,US,1523902,UNIVERSITY OF CINCINNATI,OH,452210001,,14972579; ,"CUSHION, MELANIE ;",,3/22/2010,8/20/2017,Animal Model; animal model development; Contracts; Development; efficacy testing; infectious disease model; mouse model; Mycoses; Pneumocystis; Pneumocystis Infections; Standardization; Therapeutic; ,TASK A106: MURINE MODELS OF FUNGAL INFECTIONS - PNEUMOCYSTIS,,,,,,,,,219205,
9509891,N01,AI,,N,,,,,N01AI000000,,,272201000038I-0-27200009-1,NIAID:71353\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,14964323; ,"PATTERSON, THOMAS ;",,3/16/2017,8/15/2017,Animal Model; animal model development; Aspergillosis; Candidiasis; Contracts; Development; efficacy testing; infectious disease model; mouse model; Standardization; Therapeutic; ,TASK A107: MURINE MODEL EFFICACY TESTING - ASPERGILLOSIS AND CANDIDIASIS,,,,,,,,,71353,
9509975,N01,AI,,N,,,,,N01AI000000,,,272201000039I-0-27200021-1,NIAID:266000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LOGAN,UNITED STATES,,1,72983455,US,514003,UTAH STATE UNIVERSITY,UT,843221415,,14969782; ,"MORREY, JOHN ;",,3/17/2017,3/16/2018,Animal Model; animal model development; Contracts; Development; efficacy testing; infectious disease model; Influenza; Influenza virus vaccine; influenzavirus; mouse model; Standardization; Testing; vaccination strategy; vaccine candidate; Virus Diseases; ,TASK A109: MOUSE MODEL FOR TESTING OF INFLUENZA VACCINE CANDIDATES AND VACCINATION STRATEGIES AGAINST INFLUENZA VIRUS INFECTION,,,,,,,,,266000,
9513974,N01,AI,,N,,,,,N01AI000000,,,272200800002C-28-0-2,NIAID:82586\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,6323835; ,"KEITEL, WENDY A;",,11/1/2007,12/31/2017,Clinical Trials; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; Phase; Pneumococcal vaccine; Population; Resources; Route; System; vaccine candidate; Vaccines; ,Vaccine Treatment and Evaluation Unit,,,,,,,,,82586,
9513979,N01,OD,,N,,,,,N01OD000000,,,263201500012C-3-0-1,NEI:559780\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,,,,,47481528,,,,,,,14285530; ,"BORDELON, NANCY ;",,9/30/2015,3/1/2018,Age related macular degeneration; Animals; Area; Autologous; base; Biological Assay; Cell Differentiation process; Cell Line; Cell Therapy; Cells; Clinical Research; Contractor; Contracts; Control Animal; Control Groups; Controlled Study; Data; Data Analyses; Data Collection; design; Detection; Documentation; Drug usage; Elderly; Equipment; Evaluation; experience; Eye; Feedback; follow-up; good laboratory practice; Histopathology; Human; Human Resources; Immunohistochemistry; induced pluripotent stem cell; Injection of therapeutic agent; Investigation; Life; Longitudinal Studies; Maintenance; Measures; meetings; Methods; monolayer; novel therapeutics; Operative Surgical Procedures; Outcome; Patients; Performance; Phase; phase 1 study; Phase I Clinical Trials; Pilot Projects; preclinical study; preclinical toxicity; Preparation; Procedures; Protocols documentation; Published Comment; Rattus; Records; Regulation; Reporting; Research Design; Rodent; safety study; sample collection; Sampling; scaffold; segregation; Site; Specimen; Staining method; Stains; Sterility; Structure of retinal pigment epithelium; subretinal injection; Surgeon; System; systemic toxicity; Teratoma; Testing; Tissue Fixation; tissue preparation; Tissue Transplantation; Toxic effect; Training; Transplantation; Tumorigenicity; Validation; Work; ,NEI Toxicity Studies to Support an IND Filing for Conducting Phase I Study of induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium on Scaffold,,,,,,,,,559780,
9514435,N01,HL,,N,,,,,N01HL000000,,,268201600001I-0-26800002-1,NHLBI:632037\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DENVER,UNITED STATES,,1,76443019,US,5720901,NATIONAL JEWISH HEALTH,CO,802062761,,14921865; ,"BROWN, KEVIN ;",,1/1/2017,12/31/2017,Chronic Obstructive Airway Disease; Clinical; Clinical Data; Collection; Contractor; Etiology; genomic data; Hamman-Rich syndrome; Harvest; Link; Lung diseases; Pathogenesis; Process; programs; repository; Research; Research Personnel; sample collection; Specimen; Structure of parenchyma of lung; Tissues; ,"IGF::OT::IGF LUNG TISSUE RESEARCH CONSORTIUM RENEWAL, TISSUE REPOSITORY, TASK ORDER 02, JANUARY 1, 2017 - DECEMBER 31, 2017",,,,,,,,,632037,
9520981,N01,AI,,N,,,,,N01AI000000,,,272201100018I-0-27200012-1,NIAID:5442\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN ANTONIO,UNITED STATES,,21,800772162,US,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,TX,782293901,,14936010; ,"PATTERSON, THOMAS ;",,3/1/2017,2/28/2018,Advanced Development; Anti-Bacterial Agents; Antifungal Agents; Biological Assay; Coccidioides posadasii; Development; In Vitro; in vitro testing; Maintenance; screening; Support Contracts; therapeutic development; ,TASK A28: In Vitro Screening for Antifungal Activity,,,,,,,,,5442,
9521676,N02,DA,,N,,,,,N02DA000000,,,271201600041C-1-0-1,NINDS:7360\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ALEXANDRIA,UNITED STATES,,,33068821,US,,,VA,22314,,14772090; ,"PRICE, PAUL ;",,9/21/2017,9/20/2018,Academia; Achievement; Address; Affect; Agreement; analytical method; Area; authority; Award; base; Basic Science; Behavior; Biochemistry; Biologic Development; Biological Assay; Biological Products; Biological Sciences; Biotechnology; Brain; Businesses; Cell Therapy; Cells; Characteristics; chemical group; Chemicals; Client; Clinical; clinical development; clinical investigation; Clinical Protocols; Clinical Research; Clinical Trials; Code; Collaborations; Color; Communities; Complex; Comprehension; Computers; Confidential Information; Consent; Consult; Contractor; Contracts; cost; Data; Data Analyses; Data Files; Decision Making; design; Development; Development Plans; Disabled Persons; Disclosure; Disease; Doctor of Philosophy; Documentation; Educational workshop; Electronic Mail; Elements; Employee; encryption; Evaluation; experience; experimental study; Extramural Activities; federal policy; Feedback; Food; Formulation; Funding; gene therapy; Government; Grant; Guidelines; Health; health data; Home environment; Hour; Human; Human Resources; indexing; Individual; Industry; Information Technology; Institutes; Institution; Internet; Intramural Research Program; Investigational Drugs; Joints; Knowledge; Lead; Licensing; Life; Liposomes; Mediation; member; method development; Methods; Mission; Modality; Monitor; multidisciplinary; Multimedia; Names; nanoparticle; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; novel therapeutic intervention; Oligonucleotides; Oral; Ownership; Participant; Peptide antibodies; Performance; Performance at work; Personnel Management; Persons; Phase; Polymers; Preparation; Prevention; Price; Principal Investigator; Privacy; Privacy Act; Process; Production; programs; Progress Reports; Property; Published Comment; Recombinant Proteins; Recommendation; Regulation; Rehabilitation therapy; Reporting; Research; Research Activity; Research Design; Research Personnel; Research Project Grants; Resolution; Resources; response; Rights; Risk; Role; scale up; Scanning; Schedule; Security; Services; Site; Site Visit; skills; Specific qualifier value; Speech; stability testing; stroke; Supervision; symposium; Telephone; Testing; Theft; Therapeutic; therapy development; Time; Time Management; Training; Training Programs; Translational Research; Translations; Travel; U-Series Cooperative Agreements; United States; United States National Institutes of Health; Viral; Virus; Visit; Visual; web site; webinar; Weight; Work; Writing; ,NINDS BIOLOGICS CONSULTING GROUP CMC CONSULTING IGF::CL::IGF,,,,,,,,,7360,
9521688,N01,HD,,N,,,,,N01HD000000,,,275201500006I-1-27500002-1,NIAAA:24333\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,LA JOLLA,UNITED STATES,,49,781613492,US,7375802,SCRIPPS RESEARCH INSTITUTE,CA,920371000,,14754149; ,"JANDA, KIM ;",,9/21/2016,9/20/2017,Alcohols; ghrelin; Investigation; Production; Rattus; Research Institute; Vaccines; ,IGF::OT::IGF:THE SCRIPPS RESEARCH INSTITUTE. TASK ORDER 2 (HHSN275201500006I/HHSN27500002).'PRODUCTION AND DISTRIBUTION OF INVESTIGATIONAL GHRELIN VACCINES--GHRELIN VACCINE AGAINST RAT HORMONE. 09/21/,,,,,,,,,24333,
9523029,N01,HL,,N,,,,,N01HL000000,,,268201700003C-0-0-1,NHLBI:383867\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CLEVELAND,UNITED STATES,,11,79709941,US,10038360,"SUJANA BIOTECH, LLC",OH,441225344,,14921898; ,"GAUGHAN, GLEN ;",,11/15/2016,8/14/2019,Aortic Aneurysm; Area; Biology; Biotechnology; Coronary Arteriosclerosis; Disease; Dissection; Foundations; improved; Inflammation; insight; interest; intracranial artery; Link; Lymphatic Diseases; Lymphatic System; Molecular; Monoclonal Antibodies; Peripheral arterial disease; Pharmaceutical Preparations; product development; programs; Pulmonary Hypertension; pulmonary vascular disorder; Safety; System; Thrombosis; Vascular Diseases; Venous; ,IGF::OT::IGF VITA 2 - DEVELOPING AN ANTI-THROMBOTIC MONOCLONAL ANTIBODY (MAB) WITH IMPROVED SAFETY AND EFFICACY,,,,,,,,,383867,
9525758,N01,HD,,N,,,,,N01HD000000,,,275201300010I-4-27500001-1,NICHD:11958\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,NEW YORK,UNITED STATES,,13,621889815,US,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NY,100323702,,12445620; ,"WESTHOFF, CAROLYN ;",,6/26/2017,6/25/2018,Basic Science; Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,11958,
9526061,N01,CA,,N,,,,,N01CA000000,,,261201300014I-0-26100009-1,NCI:182086\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,OAKLAND,UNITED STATES,,13,128663390,US,1618201,PUBLIC HEALTH INSTITUTE,CA,946074046,,15122610; ,"CRESS, ROSEMARY ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY DIAGNOSIS YEAR 2016,,,,,,,,,182086,
9526951,N01,AI,,N,,,,,N01AI000000,,,272201400049C-5-0-1,NIAID:1161977\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,12441547; ,"MHYRE, TIM ;",,9/30/2016,9/29/2018,Adult; aged; Amino Acid Sequence; Award; Binding; biosecurity; Bioterrorism; Categories; CD4 Positive T Lymphocytes; Chickenpox; Clinical; Communities; Computer software; Contractor; Contracts; Data; Databases; Diagnostic; Emerging Communicable Diseases; Epitopes; Etiology; Geriatrics; Herpes zoster disease; Herpesvirus Type 3; Human; Immune; Immunity; immunogenicity; In Vitro; Memory; microorganism; Military Personnel; multidisciplinary; National Institute of Allergy and Infectious Disease; pathogen; programs; Research; Smallpox; T-Lymphocyte; T-Lymphocyte Epitopes; tool; Vaccines; Vaccinia virus; validation studies; Viral; volunteer; ,Immunodominant Viral Memory CD4 Epitopes of Biosecurity and Geriatric Medicine Concern,,,,,,,,,1161977,
9528362,N01,CA,,N,,,,,N01CP000000,,,261201400009C-5-0-1,NCI:157967\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HIROSHIMA,JAPAN,,,704549278,JA,,RADIATION EFFECTS RESEARC,,732-0815,,12366463; ,"OZASA, KOTARO ;",,8/1/2014,7/31/2018,cancer risk; Cohort Studies; Contractor; Contracts; Dose; Epidemiology; epidemiology study; Foundations; Investigation; Longevity; Malignant Neoplasms; member; multidisciplinary; Radiation; radiation effect; Research; Survivors; ,IGF::OT::IGF SUPPORT FOR EPIDEMIOLOGICAL STUDIES OF CANCER AMONG ATOMIC BOMB SURVIVORS,,,,,,,,,157967,
9529454,N01,AI,,N,,,,,N01AI000000,,,272201400019C-7-0-1,NIAID:1277038\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,12,121911077,US,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NY,100101710,,12441601; ,"SILVERMAN, GREGG ;",,9/30/2014,9/29/2018,Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; Biological Models; Bioterrorism; Clinical; Computer software; Contracts; Data; Databases; Emerging Communicable Diseases; Epitopes; Evaluation; Experimental Models; Goals; Human; Humoral Immunities; Immune; Immunity; In Vitro; multidisciplinary; Mus; novel; Pathogenesis; programs; Resources; Sampling; Staphylococcus aureus; Toxin; Validation; ,Identification of B Cell Epitopes Fundamental to Immune Defenses against Staphylococcus Aureus ,,,,,,,,,1277038,
9529792,N01,AI,,N,,,,,N01AI000000,,,272201600049C-0-0-1,NIAID:8509190\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ANN ARBOR,UNITED STATES,,12,73133571,US,1506502,UNIVERSITY OF MICHIGAN,MI,481091276,,15040788; ,"KAYE, KEITH ;",,9/1/2016,2/29/2020,Antibiotic Resistance; Antimicrobial Resistance; Clinical Trials; Drug Exposure; Gram-Negative Bacteria; Multidrug-resistant Acinetobacter; Probability; Regimen; Risk; safety testing; therapeutic effectiveness; therapeutic evaluation; ,TARGETED CLINICAL TRIALS TO REDUCE THE RISK OF ANTIMICROBIAL RESISTANCE,,,,,,,,,8509190,
9531520,N44,CA,,N,,,,,N44CA000000,,,261201700003C-0-0-1,NCI:1499971\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FAIRFAX,UNITED STATES,,10,832866201,US,10030393,"VIGNET, INC.",VA,22030,,15139028; ,"JAIN, PRADUMAN ;",,1/20/2017,1/19/2019,Adherence; Anxiety; Awareness; base; Biopsy; Caring; Cellular Phone; Cessation of life; Clinical assessments; Cognitive; Communication; Compliance behavior; Consultations; Contractor; cost; Cutaneous Melanoma; Dermatologist; diaries; Direct Costs; Disease; Early Diagnosis; Education; Facilities and Administrative Costs; Family; First Degree Relative; Friends; Health Care Costs; Healthcare Systems; Home environment; Immunotherapy; improved; Intervention; Learning; Lesion; lost work time; melanoma; mobile computing; Mole the mammal; molecular targeted therapies; mortality; neoplasm registry; Participant; Pathologic; Patient Self-Report; Patients; Performance; Phase; Physicians; Pigments; prevent; Randomized Clinical Trials; Randomized Controlled Trials; Reporting; Risk; screening; Self-Examination; skills; Skin; Small Business Innovation Research Grant; Social support; System; Testing; tool; Travel; Validation; Visit; ,"SBIR TOPIC 342 - Direct to Phase II: Melanoma Early Detection RCT With Smartphones, Cognitive Computing & Family Social Support",,,,,,,,,1499971,
9532317,N01,CA,,N,,,,,N01CA000000,,,261201300016I-0-26100016-1,NCI:71709\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW ORLEANS,UNITED STATES,,2,782627814,US,577902,LSU HEALTH SCIENCES CENTER,LA,701127021,,15140328; ,"MANISCALCO, LAUREN ;",,7/31/2017,7/30/2018,Adjuvant Therapy; Adopted; Age; Beds; Biological Markers; Body of uterus; Cancer Patient; cancer site; cancer therapy; Characteristics; chemotherapy; clinical practice; Clinical Trials; Communities; Community of Practice; Community Practice; Comorbidity; Data; Diagnosis; Diagnostic tests; Division of Cancer Control and Population Sciences; Educational process of instructing; Ethnic Origin; Geographic Locations; Head and neck structure; hormone therapy; Hospitals; Immunoglobulin Variable Region; Immunotherapy; Insurance Coverage; Laws; Link; Malignant Neoplasms; Medicare; National Cancer Institute; Operative Surgical Procedures; Outcome; Pancreas; Patients; Pattern; Patterns of Care; Physicians; Quality of Care; Race; Radiation therapy; Reporting; sex; Time; United States; ,IGF::OT::IGF PATTERNS OF CARE/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2016 PERIOD OF,,,,,,,,,71709,
9533345,N01,AI,,N,,,,,N01AI000000,,,272201100022I-9-27200006-1,NIAID:683747\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,8/31/2017,8/30/2018,Antimicrobial Resistance; Contracts; National Institute of Allergy and Infectious Disease; pre-clinical; programs; Resistance; Services; Therapeutic; therapeutic development; therapy development; Translational Research; Tuberculosis; ,Task 6: Technical Support for Tuberculosis Therapeutics,,,,,,,,,683747,
9535018,N01,MH,,N,,,,,N01MH000000,,,271201300032C-6-0-1,NIMH:1390519\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,PITTSBURGH,UNITED STATES,,14,4514360,US,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PA,152132303,,12321771; ,"LEWIS, DAVID ;",,9/1/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ","NIMH, NICHD, AND NINDS BRAIN AND TISSUE REPOSITORY",,,,,,,,,1390519,
9537836,N01,AI,,N,,,,,N01AI000000,,,272201700029I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9569840,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500029-1,NICHD:10486\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15232026; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,adverse pregnancy outcome; Age; Aspirin; base; Biological Assay; Biological Markers; Blood specimen; Conceptions; Data; Data Sources; double-blind placebo controlled trial; Eligibility Determination; Endocrine disruption; environmental chemical; Exposure to; Fertility; follow-up; Funding; Gestational Age; Impairment; Measurement; Measures; Medical center; Menstrual cycle; novel; Ovulation; Participant; Placebos; Pregnancy; Pregnancy loss; pregnant; Property; Randomized; randomized trial; repository; Research; Risk; sample collection; Sampling; Serum; Spontaneous abortion; Spottings; Time; Urine; Visit; Woman; ,REPOSITORY PULL FOR THE MEASUREMENT OF ENVIRONMENTAL CHEMICALS FROM THE EAGeR TRIAL 2017,,,,,,,,,10486,
9570387,N01,AI,,N,,,,,N01AI000000,,,272201600013C-3-0-17,NIAID:462865\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MANASSAS,UNITED STATES,,1,57954067,US,397101,AMERICAN TYPE CULTURE COLLECTION,VA,201102204,,15032410; ,"STEDMAN, TIMOTHY ;",,5/5/2016,5/4/2018,Basic Science; Biological Preservation; biological research; Categories; Communicable Diseases; Communities; Contracts; Emerging Communicable Diseases; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; product development; Production; Reagent; repository; Research; research and development; Resources; West Nile virus; ,MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR),,,,,,,,,462865,
9570537,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-4,NIAID:40753\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,40753,
9571111,N01,HD,,N,,,,,N01HD000000,,,275201300024I-6-27500001-1,NICHD:51003\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,TORRANCE,UNITED STATES,,43,69926962,US,2543101,LA BIOMED RES INST/ HARBOR UCLA MED CTR,CA,905022006,,12447064; ,"WANG, CHRISTINA ;",,9/27/2013,9/26/2018,Adverse effects; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; Contraceptive methods; Development; Future; Goals; male; Medical; men; Methods; Mission; National Institute of Child Health and Human Development; product development; protocol development; Protocols documentation; Risk; Services; unintended pregnancy; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - MALE,,,,,,,,,51003,
9571164,N01,AI,,N,,,,,N01AI000000,,,272201300018I-0-27200018-2,NIAID:79065\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,15273096; ,"MULLIGAN, MARK ;",,7/12/2017,7/11/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Population; programs; protocol development; Rabies Vaccines; Resources; Vaccine Clinical Trial; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,79065,
9571360,N01,HD,,N,,,,,N01HD000000,,,263201500040I-1-27500001-1,NICHD:848427\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MC LEAN,UNITED STATES,,11,6928857,US,682902,BOOZ ALLEN HAMILTON,VA,221023830,,; ,",  ;",,9/27/2016,9/26/2019,,'IGF::OT::IGF',,,,,,,,,848427,
9571874,N01,AI,,N,,,,,N01AI000000,,,272201300023I-0-27200014-1,NIAID:485489\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NASHVILLE,UNITED STATES,,,4413456,US,,,TN,37235,,15019564; ,"CREECH, BUDDY ;",,5/1/2017,7/31/2021,Antimicrobial Resistance; Clostridium difficile; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase; Population; programs; Resources; Therapeutic Trials; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: PHASE I/II THERAPEUTIC TRIAL FOR CLOSTRIDIUM DIFFICILE,,,,,,,,,485489,
9571992,N43,CA,,N,,,,,N43CA000000,,,261201700051C-0-0-1,NCI:300000\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,49,78518178,US,10032068,"DIAGNOLOGIX, LLC",CA,921273717,,15233387; ,"SHI, GUIXIN ;",,9/19/2017,6/18/2018,Blood Transfusion; cancer type; Cell Separation; Cell Therapy; cell type; Cells; chemotherapy; Clinical; cost effective; cost efficient; Devices; Disseminated Malignant Neoplasm; Immunotherapy; innovation; interest; Leukocytes; Manuals; Metastatic Melanoma; Microbubbles; Modernization; Phase; Procedures; Property; Small Business Innovation Research Grant; System; Technology; ,IGF::OT::IGF  SBIR Topic 360: A Simple End-to-end System for Serial Cell Sorting and Manipulation Using a Single ContainerSBIR Phase I Topic 360POP: 9/19/17  6/18/18,,,,,,,,,300000,
9572054,N01,AI,,N,,,,,N01AI000000,,,272201600011I-0-27200006-1,NIAID:135934\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,10,20790895,US,10019434,INTERNATIONAL AIDS VACCINE INITIATIVE,NY,100042400,,15266219; ,"DEY, ANTU ;",,9/20/2017,9/19/2018,assay development; Basic Science; Chemistry; Clinic; clinical development; Clinical Trials; Contracts; Development; Development Plans; HIV; HIV Infections; HIV vaccine; Immunology; Investigational New Drug Application; manufacturing process development; Molecular Biology; National Institute of Allergy and Infectious Disease; novel vaccines; Phase; Preparation; prevent; Process; product development; Proteins; Technology Transfer; vaccine development; Vaccines; ,Product Development Plans to Support HIV Vaccine Manufacturing Efforts,,,,,,,,,135934,
9572711,N01,AI,,N,,,,,N01AI000000,,,272201300016I-0-27200013-1,NIAID:2620417\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,71284913,US,615001,CINCINNATI CHILDRENS HOSP MED CTR,OH,452293039,,15170389; ,"BERNSTEIN, DAVID ;",,9/16/2013,12/31/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Escherichia coli Vaccines; Evaluation; Individual; named group; Phase; Population; programs; Resources; Vaccine Clinical Trial; vaccine trial; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNIT: PHASE I E.COLI VACCINE TRIAL,,,,,,,,,2620417,
9572813,N01,AI,,N,,,,,N01AI000000,,,272201700010I-0-27200003-1,NIAID:1752200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15266225; ,"MACK, FRED ;",,9/22/2017,11/30/2022,Adjuvant; Aluminum; Aluminum Hydroxide; Antigens; base; cGMP production; Clinical Trials; Contractor; Contracts; Databases; Development; Documentation; efficacy study; Equipment and supply inventories; HIV vaccine; HIV-1; Human; immunogenicity; In Vitro; Investigational Drugs; Laboratories; Laboratory Animals; National Institute of Allergy and Infectious Disease; Phase; plasmid DNA; preclinical development; Preclinical Testing; Preventive vaccine; product development; Production; Proteins; Protocols documentation; prototype; quality assurance; Quality Control; research clinical testing; Testing; Toxicology; Vaccines; Viral Vector; ,Production of Aluminum Based Adjuvants,,,,,,,,,1752200,
9572816,N01,ES,,N,,,,,N01ES000000,,,273201400015C-7-0-15,NIEHS:587051\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,COLUMBUS,UNITED STATES,,,926695685,US,,BATTELLE MEMORIAL INSTITU,OH,432012681,,15035369; ,"SPARROW, BARNEY ;",,4/15/2014,4/14/2018,Chemical Exposure; Chemicals; Gene Expression; Genes; high throughput analysis; high throughput screening; In Vitro; Measurement; Technology; Toxic effect; Transcript; transcriptomics; ,Analysis of high throughput transcroptomics via S1500,,,,,,,,,587051,
9573291,N01,AI,,N,,,,,N01AI000000,,,272201300021I-2-27200006-1,NIAID:767273\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,14256245; ,"HOFT, DANIEL ;",,9/15/2015,10/14/2018,Biological Assay; Clinical; Conduct Clinical Trials; Consultations; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; Malaria Vaccines; named group; novel; Population; Resources; Route; Sampling; System; Testing; vaccine development; Vaccines; Work; ,Vaccine and Treatment Evaluation Unit: Malaria Vaccine Development,,,,,,,,,767273,
9573710,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-6,NIAID:172025\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Escherichia coli; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; Pathogenicity; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,172025,
9573711,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-7,NIAID:344050\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Francisella; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,344050,
9573715,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-11,NIAID:172025\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; Yersinia pestis; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,172025,
9573743,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-14,NIAID:64092\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Bacteroides; Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,64092,
9573744,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-15,NIAID:42728\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Legionella; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,42728,
9573746,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-16,NIAID:42728\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,42728,
9574345,N43,AI,,N,,,,,N43AI000000,,,272201700062C-0-0-1,NIAID:230270\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,967732384,US,10028885,METACLIPSE THERAPEUTICS CORPORATION,GA,303164713,,15327590; ,"PACK, CHRISTOPHER ;",,8/1/2017,1/31/2019,Adjuvant; Contractor; cytokine; Development; Elderly; Engineering; Glycosylphosphatidylinositols; Granulocyte-Macrophage Colony-Stimulating Factor; Immunologics; In Vitro; in vivo; Influenza; Interleukin-12; Lipid Bilayers; Membrane; novel vaccines; particle; Population; Vaccine Adjuvant; Viral; ,Development of membrane anchored cytokines as novel vaccine adjuvants for the elderly ,,,,,,,,,230270,
9574422,N43,CA,,N,,,,,N43CA000000,,,261201700032C-0-0-1,NCI:225000\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ST. LOUIS,UNITED STATES,,2,829964316,US,10021627,"RADIOLOGICS, INC.",MO,631226309,,15239956; ,"OLSEN, TIMOTHY ;",,9/18/2017,6/17/2018,anticancer research; Back; base; Cancer Diagnostics; Cancer Research Project; Clinical; Clinical Trials; cloud platform; Code; Computer software; Custom; Data; data management; Data Set; Data Sources; design; Development; Diagnostic; Funding; genomic data; Grant; Human Resources; Image; imaging informatics; Industry; Informatics; interoperability; Manuals; Maps; Measurement; Measures; medical schools; Monitor; National Cancer Institute; Occupations; open source; operation; Patient Care; Patients; Performance; Phase; phenotypic data; programs; Protocols documentation; prototype; quantitative imaging; Radiology Specialty; Readiness; Reporting; Research Infrastructure; Research Personnel; response; Running; Sampling; Security; Services; Small Business Innovation Research Grant; Software Validation; System; systems research; Technology; Testing; tool; Universities; Validation; Washington; web interface; Work; ,FDA Compliant Imaging Informatics for Cancer Research,,,,,,,,,225000,
9574551,N01,CA,,N,,,,,N01CA000000,,,261201500018I-0-26100006-1,NCI:681028\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HOUSTON,UNITED STATES,,9,800772139,US,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,770304009,,15240197; ,"BROWN, POWEL ;",,9/15/2017,3/14/2020,AKT1 gene; Anatomy; Animal Model; Animals; Apoptosis; Biological Markers; Blood; BRCA1 gene; BRCA1 Mutation; Breast Cancer Model; Breast Cancer Patient; Breast Cancer Prevention; Breast Carcinogenesis; breast tumorigenesis; cancer therapy; CASP3 gene; Cell Proliferation; Cessation of life; Chemoprevention; Chemopreventive Agent; chemotherapy; Clinical; clinical development; clinical translation; Clinical Treatment; Clinical Trials; clinically relevant; Data; Disease; Dose; drug development; Early Diagnosis; effective therapy; efficacy study; Enzymes; ERBB2 gene; Estrogen Antagonists; Estrogen receptor negative; Estrogen receptor positive; Estrogen Receptors; Estrogen Therapy; Evaluation; Family history of; FRAP1 gene; Gene Mutation; Generations; Goals; Health; Histologic; Hormone Receptor; improved; in vivo; Intervention; Kidney; Liver; Long-Term Effects; malignant breast neoplasm; Malignant Neoplasms; Mammary gland; Mammary Neoplasms; Measures; Mediator of activation protein; Modeling; mortality; Mouse Mammary Tumor Virus; mTOR Inhibitor; mTOR Signaling Pathway; Mus; mutant; Mutant Strains Mice; Natural immunosuppression; New Agents; novel; outcome forecast; Pathway interactions; Pharmaceutical Preparations; Phosphorylation; Phosphotransferases; Postmenopause; Pre-Clinical Model; predictive marker; prevent; Prevention; Preventive; Progesterone Receptors; Regimen; Renal function; Resistance; Rodent Model; Schedule; SDZ RAD; Signal Transduction; Skin; Spleen; targeted treatment; Testing; tissue biomarkers; Toxic effect; TP53 gene; Transplantation; treatment effect; triple-negative invasive breast carcinoma; tumor; tumor progression; Tumor Tissue; United States Food and Drug Administration; Weight Gain; Woman; ,IGF::OT::IGF Targeting the mTOR Pathway for the Prevention of Breast Cancer,,,,,,,,,681028,
9574791,N43,CA,,N,,,,,N43CA000000,,,261201700016C-0-0-1,NCI:284341\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MOBILE,UNITED STATES,,1,79992109,US,10040414,"TATVA BIOSCIENCES, LLC",AL,366191734,,15240589; ,"BHARDWAJ, ARUN ;",,9/19/2017,6/18/2018,Advanced Malignant Neoplasm; advanced system; African American; Animals; Applications Grants; Architecture; Area; base; Biological Models; Breast Cancer Patient; cancer health disparity; caucasian American; Cells; Characteristics; Development; Dimensions; Foundations; Generations; Genetic; Goals; Human Resources; human tissue; innovation; Logistics; malignant breast neoplasm; Mammary Neoplasms; Mass in breast; Modeling; Molecular; molecular subtypes; novel; Outcome; Patients; Phase; Phenotype; Protocols documentation; racial and ethnic; racial disparity; racial health disparity; Research; Small Business Innovation Research Grant; Standardization; three dimensional cell culture; three-dimensional modeling; tissue culture; Training; tumor; Validation; Woman; ,IGF::OT::IGF SBIR TOPIC 355: Cell and Animal-Based Models to Advance Cancer Health Disparity Research. Project Title: Establishment of 3D human tissue culture model system for advancing breast cancer ,,,,,,,,,284341,
9575156,N01,HD,,N,,,,,N01HD000000,,,275201300023I-0-27500015-1,NICHD:291977\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15241572; ,"TSAI, MICHAEL ;",,9/29/2017,9/28/2019,8-hydroxy-2'-deoxyguanosine; Address; adiponectin; Affect; Anti-inflammatory; Aspirin; Biological; Biological Assay; Biological Markers; Calcium; Complex; cost; Data; Data Sources; Diet; Dietary Assessment; Dietary Component; Dietary Fiber; Dose; Double-Blind Method; double-blind placebo controlled trial; environmental chemical; environmental stressor; Exposure to; F2-Isoprostanes; Ferritin; Fertility; Fibroblast Growth Factor; Flavonoids; Folic Acid; Funding; Glycosylated hemoglobin A; healthy pregnancy; hepcidin; Hour; Hydrocortisone; improved; Inflammation; Inflammation Mediators; inflammatory marker; interest; Interleukin-1; Interleukin-10; Interleukin-6; Interleukin-8; Interleukins; Investigation; Iron; Laboratories; Length; Link; Lipid Peroxidation; Lipid Peroxides; Live Birth; male; Measurement; Measures; Medical center; Menstrual cycle; Menstruation; novel; Outcome; Ovulation; Oxidative Stress; Participant; pentosidine; Phenols; Phytoestrogens; Placental Growth Factor; Pregnancy; Pregnancy loss; pregnant; Prolactin; prospective; protein intake; Proteins; Rage; Randomized; Randomized Controlled Trials; receptor; Recording of previous events; repository; Reproduction; reproductive; reproductive hormone; Research; Role; Sampling; Seminal fluid; Serum; Serum Proteins; Site; Techniques; telomere; Testing; TFRC gene; Time; TNF gene; Transferrin; trial design; Urine; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factors; Visit; Vitamin B 12; Vitamin D; Vitamin D-Binding Protein; Woman; Work; ,MEASUREMENT OF DIETARY BIOMAKERS IN EAGeR TRIAL,,,,,,,,,291977,
9575161,N02,HD,,N,,,,,N02HD000000,,,275201700295U-0-0-1,NICHD:1157766\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,RESTON,UNITED STATES,,,967488987,US,,,VA,20190,,15244424; ,"NA, NA ;",,9/30/2017,9/29/2018,Contracts; crowdsourcing; Down Syndrome; Environment; Internet; Maintenance; patient registry; Pregnancy; Registries; Resources; Secure; ,DOWN SYNDROME CONNECT AND PREGSOURCE SUPPORT,,,,,,,,,1157766,
9575691,N01,CA,,N,,,,,N01CA000000,,,261201200031I-0-26100012-1,NCI:487895\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TUCSON,UNITED STATES,,3,806345617,US,490201,UNIVERSITY OF ARIZONA,AZ,857210158,,15242235; ,"CHOW, SHERRY ;",,9/15/2017,9/14/2019,Acids; Address; Benzene; Broccoli - dietary; Carcinogen Metabolism; Carcinogens; Clinical Research; Clinical Trials; Collection; dietary supplements; Drug Metabolic Detoxication; Excretory function; Goals; Head Cancer; healthy volunteer; Hour; Liquid Chromatography; Malignant neoplasm of lung; Malignant Neoplasms; Measures; Neck Cancer; Smoker; Sulforaphane; Tablets; tandem mass spectrometry; Tobacco; tobacco prevention; Tobacco-Associated Carcinogen; urinary; Urine; ,IGF::OT::IGF Clinical Study of Avmacol for Detoxification of Tobacco Carcinogens in Heavy Smokers,,,,,,,,,487895,
9576354,N02,CA,,N,,,,,N02CA000000,,,261201700004I-0-26100001-1,NCI:1200000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LANHAM,UNITED STATES,,,58603631,US,,,MD,20706,,15326985; ,"BIZZELL, ANTON ;",,9/1/2017,8/31/2018,Behavior; Behavioral Research; Communication; Contractor; data management; Development; Division of Cancer Control and Population Sciences; editorial; evidence base; Extramural Activities; Interdisciplinary Study; International; Intervention; Logistics; meetings; Monograph; National Cancer Institute; prevent; Production; programs; Publications; Research; Series; Services; symposium; Tobacco; tobacco control; Tobacco Control Research; tobacco prevention; tobacco regulatory science; Tobacco use; United States National Institutes of Health; Writing; ,"IGF::OT::IGF Core Support Activities: Scientific writing, technical and logistical support services",,,,,,,,,1200000,
9576448,N44,CA,,N,,,,,N44CA000000,,,261201700033C-0-0-1,NCI:1996011\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW HAVEN,UNITED STATES,,3,142406110,US,3970901,"L2 DIAGNOSTICS, LLC",CT,65300175,,15327069; ,"PETERSON-ROTH, ELIZABETH ;",,9/19/2017,9/18/2019,Advanced Development; Adverse effects; adverse outcome; Adverse reactions; Biological Assay; Biological Markers; Cancer Patient; cancer radiation therapy; Clinical; cohort; Data; genetic information; Goals; Injury; Malignant neoplasm of prostate; Morbidity - disease rate; Outcome; Patients; Phase; predictive marker; preference; Prostate; prototype; Provider; Radiation therapy; Radiation Tolerance; radiosensitive; rectal; Risk; Small Business Innovation Research Grant; Testing; treatment planning; urinary; ,IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy,,,,,,,,,1996011,
9576449,N02,CA,,N,,,,,N02CA000000,,,261201700007I-0-26100001-1,NCI:1000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALACHUA,UNITED STATES,,3,12852344,US,10020711,ALCHEM LABORATORIES CORPORATION,FL,326156687,,15243560; ,"ZHANG, MIANJI  ;",,9/18/2017,10/17/2017,Confidential Information; Contractor; Contracts; cost effective; cost effectiveness; drug synthesis; expectation; Goals; meetings; Methods; Modification; Procedures; Science; small molecule; Specific qualifier value; targeted delivery; Time; Work; ,IGF::OT::IGF Task Order #1 'Kickoff Meeting with NCI Staff' POP: 9/18/17-10/17/17 ,,,,,,,,,1000,
9576537,N44,CA,,N,,,,,N44CA000000,,,261201700036C-0-0-1,NCI:1944651\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,IOWA CITY,UNITED STATES,,2,830356262,US,10023067,"VIEWPOINT MOLECULAR TARGETING, LLC",IA,522468707,,15327078; ,"JOHNSON, FRANCES ;",,9/18/2017,9/17/2019,Adverse effects; Clinical; Data; design; Disease; Human; Incidence; innovation; Life; Malignant Neoplasms; meetings; melanoma; Metastatic Melanoma; Mus; Operative Surgical Procedures; Performance; Phase; Published Comment; Radiation therapy; Radionuclide therapy; receptor; Regimen; research and development; Resistance development; response; Small Business Innovation Research Grant; therapeutic candidate; Toxicology; tumor; Work; ,'Systemic Targeted Radionuclide Therapy for Metastatic Melanoma'Period of Performance: 9/18/2017 - 9/17/2019,,,,,,,,,1944651,
9577560,N01,DA,,N,,,,,N01DA000000,,,271201400006I-0-27100010-1,NIMH:57445\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15167019; ,"NG, HANNA ;",,9/1/2017,8/31/2018,"Binding; Biochemical; Biological Assay; Brain imaging; Clinical Research; Complement; Consultations; Contracts; cost effective; data management; Development; Evaluation; Human; Image; Ligands; Mental disorders; National Institute of Mental Health; Neuraxis; novel; Pharmacology; Positron-Emission Tomography; Preclinical Drug Evaluation; programs; Psychotropic Drugs; receptor; Resources; Support Contracts; Therapeutic Agents; Tomography, Emission-Computed, Single-Photon; Toxicology; ","IGF::OT::IGF PURPOSE: THE FOURTH ADMINISTRATIVE TASK ORDER WILL PROVIDE CONTRACT ADMINISTRATION, INCLUDING AN EFFORT NEEDED TO SUPPORT CONTRACT MANAGEMENT, DATA MANAGEMENT, CONSULTATION, AND COMMUNICA",,,,,,,,,57445,
9578212,N44,DA,,N,,,,,N44DA000000,,,271201700065C-0-0-1,NIDA:998926\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,CAMBRIDGE,UNITED STATES,,7,131092079,US,10007176,"DIMAGI, INC.",MA,21394075,,15246376; ,"JACKSON, JONATHAN ;",,9/25/2017,9/24/2019,Address; Area; Award; Awareness; base; Boston; Childhood; Clinical; Collaborations; commercialization; Contracts; design; Educational Curriculum; Effectiveness; Exhibits; Goals; Health Information System; Hospitals; improved; Infant; innovation; Knowledge; mobile computing; multidisciplinary; Multimedia; National Institute of Drug Abuse; Neonatal; Neonatal Abstinence Syndrome; neonatal care; Neonatal Intensive Care Units; neonatal outcome; Nurseries; open source; Outcome; Phase; Provider; Research Design; skills; Small Business Innovation Research Grant; Specialist; symptom treatment; Symptoms; System; Testing; tool; Withdrawal Symptom; Work; ,IGF::OT::IGF FY17 NASCare: Mobile Tool for Neonatal Abstinence Syndrome. NIDA Ref. No. N44DA-17-1211; POP: 09/25/2017 - 09/24/2019. Base Award.,,,,,,,,,998926,
9581101,N43,DA,,N,,,,,N43DA000000,,,271201700057C-0-0-1,NIDA:149514\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BOSTON,UNITED STATES,,7,79705123,US,10039131,"PEAR THERAPEUTICS, INC.",MA,21112735,,15250565; ,"MCFARLAND, IAN ;",,9/22/2017,3/21/2018,Adverse effects; Award; base; Communities; Computer software; design; Development; Education; Environment; experience; Feedback; Fees; Foundations; Health Personnel; Health Professional; Healthcare; Measures; meetings; mentoring community; Modeling; opioid use disorder; Patients; Pear; peer; peer coaching; peer support; Perception; prototype; Research; Social support; Support Groups; Testing; Therapeutic; Translating; Treatment outcome; usability; virtual reality; ,"IGF::OT::IGF: Developing a Virtual Environment to Enhance Patient Engagement in Peer Support in Opioid Use Disorder. September 22, 2017 - March 21, 2018. N43DA-17-5586. Base Award",,,,,,,,,149514,
9581128,N01,CA,,N,,,,,N01CA000000,,,26120150002B26100012-0-0-1,NCI:490798\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,15250741; ,"GIFFEN, CAROL ;",,9/18/2017,6/17/2020,Academia; Address; Biological Products; Cancer Center; cancer genomics; cancer initiation; Cancer Model; Cancer Patient; Cells; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Data; clinical research site; Communities; Consent; Contractor; Data; Data Collection; Development; Enrollment; Formulation; Genome; Genomic Data Commons; Genomics; Goals; Human; human subject; In Vitro; indexing; Industry; Institution; Intellectual Property; International; Libraries; Medical; Methods; model development; Modeling; Molecular; National Cancer Institute; next generation; novel; Office of Cancer Genomics; Organoids; Protocols documentation; Research Personnel; Resources; response; Services; Site; System; Techniques; Tissues; tool; tumor; ,IGF::OT::IGF Clinical Data Center Services for Cancer Models Development Centers (CMDCs),,,,,,,,,490798,
9581233,N01,HL,,N,,,,,N01HB000000,,,268201100009I-0-26800003-1,NHLBI:790008\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SAN FRANCISCO,UNITED STATES,,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,15266097; ,"MURPHY, EDWARD ;",,9/30/2017,3/31/2019,"Acquired Immunodeficiency Syndrome; Address; Adult; Affect; AIDS/HIV problem; Alloimmunization; Amendment; Area; base; Basic Science; Behavior; Biological; Biological Sciences; Blood; Blood Banks; Blood Donations; Blood donor; Blood donor screening; Blood Transfusion; Books; Budgets; Catalogs; Characteristics; Clinical Research; Clinical Sciences; Code; Collaborations; Collection; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; Data Set; Databases; Development; dopamine D5 receptor; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; evidence base; evidence based guidelines; Geography; Goals; Government; Health Insurance Portability and Accountability Act; Health Personnel; HIV; HIV-1; HIV-2; improved; Incidence; Income; Infection; Infectious Agent; Informed Consent; Institution; Institutional Review Boards; interest; International; Knowledge; Laboratories; Laboratory Study; Language; Leadership; Location; Manuals; Medical; Medicine; meetings; member; Methodology; Monitor; National Heart, Lung, and Blood Institute; Office Management; operation; Participant; Pathologic; Patient Care; Patient Education; Performance; Phase; Policy Developments; population based; Prevalence; prevent; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; Questionnaires; Reporting; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; response; Risk; Risk Factors; Safety; sample collection; Sampling; Ships; Site; Specimen; Surveys; symposium; Technical Expertise; Test Result; Testing; Training; Training and Education; Transfusion; Translating; Translational Research; transmission process; Vascular blood supply; work-study; Writing; ",IGF::OT::IGF DBDR REDS-III International Sites Phase 3,,,,,,,,,790008,
9537847,N01,AI,,N,,,,,N01AI000000,,,272201700031I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLLEGE STATION,UNITED STATES,,17,835607441,US,8266910,TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR,TX,778454375,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537878,N01,AI,,N,,,,,N01AI000000,,,272201700027I-0-27200002-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SALISBURY,UNITED KINGDOM,,,233388961,UK,10007041,PUBLIC HEALTH ENGLAND,,,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537905,N01,AI,,N,,,,,N01AI000000,,,272201700013I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9539928,N01,DA,,N,,,,,N01DA000000,,,271201600006I-1-27100001-1,NINDS:77941\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14754089; ,"GREEN, CAROL ;",,9/13/2017,9/12/2018,"Animal Welfare; Award; base; bench to bedside; Chemistry; Client; Contractor; Contracts; design; Dosage Forms; Equipment; experience; flexibility; Formulation; good laboratory practice; Heart Diseases; Hematological Disease; International; Laboratory Animals; Lung diseases; member; Modernization; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Drug Abuse; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; novel; novel therapeutics; Office for Human Research Protections; operation; Pharmacologic Substance; Pharmacology and Toxicology; Principal Investigator; Production; programs; Regulation; Request for Proposals; research and development; Resources; response; Science; Scientist; screening; Services; small molecule; small molecule therapeutics; Testing; Translational Research; United States Food and Drug Administration; United States National Institutes of Health; Work; ",IGF::OT::IGF TASK ORDER #001  PERFORMANCE AREA 1  MANAGEMENT AND OPERATIONS SUPPORT,,,,,,,,,77941,
9542155,N01,DA,,N,,,,,N01DA000000,,,271201600007I-1-27100001-1,NINDS:97279\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,14754093; ,"HEBERT, CHARLES ;",,9/13/2017,9/12/2018,Brain; Drug Kinetics; operation; Rodent; ,IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT,,,,,,,,,97279,
9542156,N01,AI,,N,,,,,N01AI000000,,,272201400052C-7-0-1,NIAID:1843527\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BOSTON,UNITED STATES,,7,76593722,US,1504801,BOSTON CHILDREN'S HOSPITAL,MA,21155724,,12441483; ,"LEVY, OFER ;",,9/30/2014,9/29/2018,Adjuvant; Adult; Animal Model; base; Cells; Computer Simulation; Contractor; Dendritic Cells; Elderly; Emerging Communicable Diseases; Formulation; high throughput screening; Human; human disease; human tissue; immunogenicity; In Vitro; in vivo; Individual; Influenza virus vaccine; influenzavirus; Lead; Modeling; Mononuclear; National Institute of Allergy and Infectious Disease; Newborn Infant; novel; pathogen; Pharmaceutical Chemistry; programs; receptor; Research; Signal Pathway; small molecule libraries; Structure-Activity Relationship; Study models; System; Testing; transcriptome; Vaccine Adjuvant; vaccine candidate; vaccine discovery; Vaccines; Validation; Work; ,Adjuvant Discovery for Vaccines against Influenza Virus,,,,,,,,,1843527,
9543652,N01,AI,,N,,,,,N01AI000000,,,272201400010I-0-27200026-1,NIAID:386510\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15155829; ,"PTAK, ROGER ;",,8/1/2017,7/31/2018,Academia; base; Biochemical; Biological Assay; Cells; Chemicals; Contracts; Data; Development; Funding; Gene Expression; high throughput screening; HIV; HIV Infections; inhibitor/antagonist; Intervention; Investigational New Drug Application; Libraries; Local Microbicides; National Institute of Allergy and Infectious Disease; novel therapeutics; phase I trial; preclinical development; Private Sector; product development; prospective; Public Health; public health priorities; Research Personnel; service utilization; Services; Source; Testing; Therapeutic; ,HIGH THROUGHPUT SCREENING TO IDENTIFY HIV INHIBITORS,,,,,,,,,386510,
9545127,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200005-1,NIAID:80999\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14922273; ,"SWARTZ, GLENN ;",,2/1/2017,1/31/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Clinical Trials; Development; Devices; Drug Kinetics; Evaluation; HIV; HIV Infections; Investigation; Investigational Drugs; Licensure; microbicide; Modeling; National Institute of Allergy and Infectious Disease; novel therapeutics; Pathway interactions; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; product development; research clinical testing; Resources; Role; Safety; Services; sexual HIV transmission; Technology; United States Food and Drug Administration; United States National Institutes of Health; vaginal microbiome; Work; ,OVINE MODEL AND VAGINAL MICROBIOME SUPPORT FOR HIV NONVACCINE BIOMEDICAL PREVENTION PRODUCT DEVELOPMENT.,,,,,,,,,80999,
9545133,N01,AI,,N,,,,,N01AI000000,,,272201600009I-0-27200001-1,NIAID:23657\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALBUQUERQUE,UNITED STATES,,1,45911138,US,679302,LOVELACE BIOMEDICAL & ENVIRONMENTAL RES,NM,871085129,,15059063; ,"REED, MATHEW ;",,6/1/2017,5/31/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Area; Clinical Trials; Development; HIV; HIV Infections; Licensure; method development; Methods; microbicide; National Institute of Allergy and Infectious Disease; Performance; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; quality assurance; Quality Control; research clinical testing; Resources; Role; Services; sexual HIV transmission; Technology; United States Food and Drug Administration; United States National Institutes of Health; Validation; Work; ,DEVELOP A QUALITY ASSURANCE/QUALITY CONTROL (QA/QC) PLAN FOR ACTIVITIES CONDUCTED UNDER TASK AREA C.,,,,,,,,,23657,
9547063,N01,AI,,N,,,,,N01AI000000,,,272201700078C-0-0-1,NIAID:8644838\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WILMINGTON,UNITED STATES,,7,362574527,US,4079901,"PPD, INC.",NC,284013331,,15174817; ,"STROKES, BAMBRA ;",,8/15/2017,8/14/2018,Acquired Immunodeficiency Syndrome; AIDS/HIV problem; Area; Biometry; Clinical; Clinical Research; clinical research site; Clinical Trials; Communicable Diseases; Contracts; Country; data management; design; Diagnosis; Diagnostic; Disease; flexibility; good laboratory practice; HIV; HIV Infections; Immune; Immunology; Laboratories; Mediating; Medical; Microbiology; National Institute of Allergy and Infectious Disease; Policies; Populations at Risk; Preparation; Prevention; product development; Research; Research Support; Resources; Services; Site; Therapeutic; therapeutic development; Training; Translations; United States Dept. of Health and Human Services; United States National Institutes of Health; vaccine development; Vaccines; Work; ,NIAID HIV AND OTHER INFECTIOUS DISEASES CLINICAL RESEARCH SUPPORT SERVICES (CRSS),,,,,,,,,8644838,
9547683,N01,DA,,N,,,,,N01DA000000,,,271201500067C-5-0-1,OD:77860\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,PHILADELPHIA,UNITED STATES,,2,42250712,US,6463801,UNIVERSITY OF PENNSYLVANIA,PA,191046205,,14256085; ,"FARRAR, JOHN ;",,9/1/2015,8/31/2018,Award; Case Based Learning; Contractor; Dental Assistants; Diagnosis; Education; educational atmosphere; Educational Curriculum; Goals; Health Occupations; improved; innovation; Learning; Medical; Mental Health; Pain; Pain management; Pharmacy facility; Physical therapy; repository; Resources; Students; tool; Training; United States National Institutes of Health; web site; ,"IGF::OT::IGF: NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION. POP SEPTEMBER 1, 2015 - AUGUST 31, 2016. N01DA-15-4429. BASE AWARD.",,,,,,,,,77860,
9548532,N02,CA,,N,,,,,N02CA000000,,,261201300008I-2-26100010-1,NCI:894589\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CALVERTON,UNITED STATES,,8,83656892,US,1069201,"INFORMATION MANAGEMENT SERVICES, INC.",MD,207053407,,14086875; ,"RILEY, TOM ;",,8/24/2015,8/23/2018,Colorectal Cancer; Etiology; Internet; Logistics; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Monitor; Peer Review; programs; Sampling; Services; System; , SUPPORT SERVICES FOR THE PLCO ETIOLOGIC & EARLY MARKER STUDIES(PLCO EEMS),,,,,,,,,894589,
9548957,N01,AI,,N,,,,,N01AI000000,,,272201600028C-2-0-1,NIAID:4676851\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BETHESDA,UNITED STATES,,8,79454826,US,10036940,"ABVIRO, LLC",MD,208142934,,14759398; ,"RAMSTEDT, URBAN ;",,9/23/2016,3/21/2019,Advanced Development; Categories; Communicable Diseases; Dengue Virus; Disease Outbreaks; Event; Flavivirus; Flavivirus Infections; National Institute of Allergy and Infectious Disease; pathogen; product development; response; Therapeutic antibodies; therapeutic development; ,A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.,,,,,,,,,4676851,
9550881,N01,HD,,N,,,,,N01HD000000,,,275201500006C-3-0-1,NICHD:59943\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MOUNTAIN VIEW,UNITED STATES,,18,123543399,US,1738001,SOCIOMETRICS CORPORATION,CA,940402462,,14264267; ,"CARD, JOSEFINA ;",,9/15/2017,9/14/2018,Address; Adolescence; adolescent sexual health; Agreement; Archives; Area; Award; Behavioral; Centers for Disease Control and Prevention (U.S.); computerized; Contractor; Contracts; cost; Data; data archive; Data Collection; Data Files; Data Science; Data Set; design; Development; Documentation; Family Planning; Funding; Guidelines; Health; Incidence; instrument; Internet; Intervention; intervention program; learning materials; Maintenance; Names; National Institute of Child Health and Human Development; Population; Pregnancy; Pregnancy in Adolescence; pregnancy prevention; Preparation; Prevalence; Prevention program; Prevention Research; program dissemination; Program Effectiveness; programs; repository; Research; Research Project Grants; Resources; Services; Sex Behavior; Sexuality; Sexually Transmitted Diseases; Social Sciences; teenage fertility; Training; Update; user-friendly; ,DATA  ARCHIVE ON ADOLESCENT PREGNANCY AND PREGNANCY PREVENTION ,,,,,,,,,59943,
9554730,N01,DA,,N,,,,,N01DA000000,,,271201300013C-7-0-1,NIDA:373710\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15253319; ,"JAYASINGHE, DUDLEY ;",,9/29/2013,9/28/2018,analytical method; Chemicals; drug of abuse; Methodology; Monitor; National Institute of Drug Abuse; Optics; Peptides; Reproducibility; Resources; stability testing; synthetic peptide; Variant; Work; ,"IGF::OT::IGF Synthetic Peptides and Other Drugs of Abuse - Purity Determination, ",,,,,,,,,373710,
9555914,N43,CA,,N,,,,,N43CA000000,,,261201600034C-3-0-1,NCI:1915127\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BALTIMORE,UNITED STATES,,7,79670802,US,10038134,"PAPGENE, INC.",MD,212112840,,14754029; ,"KINDE, ISAAC ;",,9/2/2017,9/1/2019,base; Biological Assay; Cancer Etiology; Clinical; Cytology; Detection; Development; DNA; DNA Sequence Alteration; Genetic; innovation; Malignant neoplasm of urinary bladder; Massive Parallel Sequencing; Recurrence; Sampling; Sensitivity and Specificity; Specimen; Techniques; Testing; Urine; Validation; ,IGF::OT::IGF GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER,,,,,,,,,1915127,
9556090,N01,HD,,N,,,,,N01HD000000,,,275201300025I-7-27500001-1,NICHD:57386\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,12445915; ,"BREMNER, WILLIAM ;",,9/27/2013,9/26/2018,Adverse effects; Clinical Trials; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; Contraceptive methods; Development; Future; Goals; male; Male Contraceptive Agents; Medical; men; Methods; Mission; National Institute of Child Health and Human Development; product development; protocol development; Protocols documentation; Risk; Services; unintended pregnancy; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - MALE,,,,,,,,,57386,
9557712,N02,ES,,N,,,,,N02ES000000,,,273201300004C-11-0-2,NIEHS:1028333\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,CONSHOHOCKEN,UNITED STATES,,13,188124564,US,10029415,INSTEM LSS (NORTH AMERICA) LIMITED,PA,194282047,,15327672; ,"WHEELER, DAVID ;",,3/1/2013,2/28/2018,Back; base; Contracts; Data; Data Collection; data management; Databases; environmental agent; Housing; Human Resources; Information Systems; Internet; Laboratories; Laboratory Study; Licensing; Life; Location; Mission; Performance; Research; Research Design; Scientist; Secure; System; Testing; usability; ,IGF::OT::IGF Hosted Commercial In Life Data Collection and Management System for DNTP ,,,,,,,,,1028333,
9563577,N02,HD,,N,,,,,N02HD000000,,,275201700004C-0-0-1,NIDDK:128196\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,139133230,US,10012716,"RIPPLE EFFECT COMMUNICATIONS, INC.",MD,208506528,,15327842; ,"BIELSKI, AMY ;",,9/1/2017,8/31/2018,cohort; Communication; design; Ensure; Evaluation; experience; Funding; Future Generations; hands on research; Individual; Internships; Mission; Monitor; National Institute of Diabetes and Digestive and Kidney Diseases; Outcome; Participant; Persons; Program Evaluation; programs; Research; Research Personnel; Science; Structure; summer research; Time; tool; ,NIDDK Short Term Research Experience for Underrepresented Persons Program (Step - Up),,,,,,,,,128196,
9564741,N01,CA,,N,,,,,N01CA000000,,,261201200042I-2-26100010-1,NCI:24042\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,14652670; ,"LIMBURG, PAUL ;",,8/1/2016,7/31/2018,absorption; Africa; American Cancer Society; Antioxidants; Arachidonic Acids; Asia; Asians; Atrophic Gastritis; Bioflavonoid; Cancer Burden; Cancer Etiology; cancer type; carcinogenesis; Central America; Cessation of life; chemokine; Chemoprevention; Chemopreventive Agent; Country; Curcumin; CXCL10 gene; cytokine; Developing Countries; Diagnosis; Diet; disability-adjusted life years; Disease; DNA Damage; double-blind placebo controlled trial; Eastern Europe; Encapsulated; Europe; Far East; Flow Cytometry; Formulation; Genotype; Histology; Human; IL8 gene; immunoregulation; Incidence; Indium-111; Individual; inflammatory marker; inhibitor/antagonist; Interleukin-1 beta; Intestinal Metaplasia; Intestinal Mucosa; Investigation; Japan; Lecithin; Legal patent; Liposomes; Lipoxygenase; magnetic beads; Malignant Neoplasms; malignant stomach neoplasm; men; Metabolism; Methods; Molecular; mortality; Multifocal Lesion; North America; Outcome; Participant; Pathway interactions; Persons; Phenols; Placebos; Plants; Populations at Risk; Premalignant; Prostaglandin-Endoperoxide Synthase; Randomized; Reporting; Research Personnel; Resources; Rhizome; Risk; Safety; screening; South America; Southern Europe; soy; Stomach; Survival Rate; Technology; TNF gene; Tumeric; Woman; ,"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS",,,,,,,,,24042,
9564746,N01,AI,,N,,,,,N01AI000000,,,272201400028C-8-0-1,NIAID:136465\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,14270585; ,"WALDEN, AIMEE ;",,9/15/2015,9/14/2018,Archives; Basic Science; Bioinformatics; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human Resources; Paramyxoviridae; Paramyxovirus; pathogen; Research; Resources; Services; tool; Update; user-friendly; Viral; ,THE VIRAL BIOINFORMATICS RESOURCE CENTER,,,,,,,,,136465,
9566070,N01,CA,,N,,,,,N01CA000000,,,26120140002B26100008-4-0-1,NCI:496268\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,BETHESDA,UNITED STATES,,8,,US,2079401,QUANTUM RESEARCH CORPORATION,MD,208143224,,; ,",  ;",,9/15/2015,9/14/2018,Cancer Control; Contractor; Data; Databases; design; Development; Emerging Technologies; evidence base; Guidelines; Health; Health behavior; Health Communication; Information Technology; Performance; Physical activity; Recommendation; Reporting; Resources; Source; System; web site; , Physical Activity Guidelines ProjectPeriod of Performance: 09/15/2015 - 09/14/2016,,,,,,,,,496268,
9566075,N01,DA,,N,,,,,N01DA000000,,,271201500070C-5-0-2,NIDA:14790\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SILVER SPRING,UNITED STATES,,,79515853,US,,,MD,209103750,,14644153; ,"WESTON, JOANNA ;",,9/18/2015,10/17/2017,Award; Categories; Clinical; Clinical Research; Collaborations; Communication; Contracts; Development; dissemination research; Drug abuse; Exercise; Goals; meetings; Mentors; Mentorship; Mission; National Institute of Drug Abuse; outreach; Professional Organizations; program dissemination; Research; research data dissemination; research to practice; Science; Technology; Training; United States Substance Abuse and Mental Health Services Administration; ,"IGF::OT::IGF: NIDA Blending Initiative: Moving Science from Research to Practice. POP: September 18, 2015 - October 17, 2017. N01DA-15-2244. Exercise of Option 4.",,,,,,,,,14790,
9566454,N01,CA,,N,,,,,N01CA000000,,,261201500038I-0-26100008-1,NCI:713988\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,OKLAHOMA CITY,UNITED STATES,,5,878648294,US,1524003,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OK,73104,,15082072; ,"RAO, C V ;",,6/15/2017,6/14/2019,Apoptosis; Bioavailable; Biopsy; Cell Cycle Arrest; cell transformation; Chronic; Client; Complex; Complex Endometrial Hyperplasia with Atypia; Cyclin D1; Development; Endometrial; Endometrial Carcinoma; Endometrial Hyperplasia; Endometrial Hyperplasia without Atypia; Endometrioid Carcinoma; Endometrium; Estrogens; Future; Gland; GRP75; Histologic; hormone therapy; Human; Hyperplasia; Hysterectomy; migration; Mitochondria; Molecular Chaperones; Mus; neoplastic cell; Oral; Pharmaceutical Preparations; Precancerous Conditions; Prevention; Process; Progesterone; Proteins; Risk; Rodent Model; SHetA2; Tissues; Vagina; Vaginal Suppository; ,IGF::OT::IGF PREVENTION OF ENDOMETRIAL HYPERPLASIA AND ITS TRANSITION TO ENDOMETRIAL CANCER WITH SHETA2 POP 6/1/2017 - 5/31/2019,,,,,,,,,713988,
9566531,N01,AI,,N,,,,,N01AI000000,,,272201100006I-0-27200003-1,NIAID:81622\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FORT COLLINS,UNITED STATES,,2,785979618,US,1725201,COLORADO STATE UNIVERSITY,CO,805231062,,15266179; ,"SLAYDEN, RICHARD ;",,9/13/2017,9/12/2018,Advanced Development; Anti-Bacterial Agents; Antifungal Agents; biodefense; Biological Assay; Contracts; Development; Emerging Communicable Diseases; In Vitro; in vitro testing; Maintenance; pathogen; screening; Therapeutic; ,TASK A30: In vitro screening for antibacterial activity against biodefense and emerging infectious disease pathogens ,,,,,,,,,81622,
9567334,N01,HD,,N,,,,,N01HD000000,,,275201400003I-0-27500028-1,NICHD:626990\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,15266284; ,"MANDACI, OGUZ ;",,9/23/2014,9/22/2024,Adrenal Cortex Hormones; antenatal; Aspirin; Clinical Trials Unit; Collection; Data; Data Coordinating Center; Dose; Factor V; Factor V Leiden mutation; High Risk Woman; Human; Label; Maternal-Fetal Medicine Units Network; National Institute of Child Health and Human Development; Observational Study; Omega-3 Fatty Acids; Perinatology; phenotypic data; Pre-Eclampsia; Pregnancy; Premature Birth; prevent; Progesterone; prospective; repository; Research Project Grants; sample collection; Sampling; Scheme; Specimen; Supplementation; Triplet Multiple Birth; Twin Multiple Birth; Woman; Work; ,NICHD REPOSITORY CONSOLIDATION EFFORTS -  MFMU - FISHER BIOSERVICES,,,,,,,,,626990,
9567366,N01,AI,,N,,,,,N01AI000000,,,272201600011I-0-27200004-1,NIAID:450419\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,10,20790895,US,10019434,INTERNATIONAL AIDS VACCINE INITIATIVE,NY,100042400,,15266213; ,"DEY, ANTU ;",,9/18/2017,9/17/2018,Antigens; assay development; Basic Science; Chemistry; Clinic; Clinical Trials; Contracts; Development; env Gene Products; HIV; HIV Infections; HIV vaccine; Immunology; Investigational New Drug Application; manufacturing process development; Molecular Biology; National Institute of Allergy and Infectious Disease; novel vaccines; Phase; prevent; Process; product development; Proteins; vaccine development; Vaccines; ,Feasibility Assessment of HIV Env Protein Antigens,,,,,,,,,450419,
9567488,N01,AI,,N,,,,,N01AI000000,,,272201400007C-7-0-2,NIAID:601278\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,14974806; ,"ROTHMAN, RICHARD ;",,4/1/2014,3/31/2021,Basic Science; Clinical; Development; Government; improved; Influenza; influenza outbreak; influenza surveillance; Institution; Link; Medical; pandemic disease; pandemic influenza; Pathway interactions; Public Health; Public Health Practice; Research; seasonal influenza; Vaccine Research; Virus; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,601278,
9568935,N43,AI,,N,,,,,N43AI000000,,,272201700064C-0-0-1,NIAID:224999\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,PASADENA,UNITED STATES,,27,830844523,US,10023560,DETON CORPORATION,CA,911073658,,15327596; ,"CHAPMAN, STEPHEN ;",,7/15/2017,7/14/2018,Bacteria; Childhood; Coughing; design; Development; Devices; Diagnostic; Infection; Lower Respiratory Tract Infection; Population; Pseudomonas aeruginosa; rapid diagnosis; Staphylococcus aureus; ,"Cough Collector, a Non-invasive Device for Lower Respiratory Tract Infections",,,,,,,,,224999,
9568941,N43,AI,,N,,,,,N43AI000000,,,272201700068C-0-0-1,NIAID:223024\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DUBLIN,UNITED STATES,,12,1004258,US,1698201,"GUILD ASSOCIATES, INC.",OH,430161234,,15327605; ,"DAVID, SCHOFIELD ;",,8/1/2017,8/31/2018,Antimicrobial Resistance; Bacteria; Detection; Development; Diagnostic; Pharmaceutical Preparations; Predisposition; Urinary tract infection; ,LumiPhage direct ID/AST of Urinary Tract Infections,,,,,,,,,223024,
9568962,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100018-1,NCI:179379\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326883; ,"GIANNINI, ROBERT ;",,2/10/2017,8/10/2017,Aluminum; Amber; Ascorbic Acid; Citric Acid; Clinical; Contractor; Contracts; Development; Ethanol; Formulation; Injection of therapeutic agent; Life; Polyethylene Glycols; Polytetrafluoroethylene; Procedures; Product Labeling; repository; Rubber; seal; Ships; Silicon; Solubility; Sterility; Triapine; Vial device; Work; ,IGF::OT::IGF,,,,,,,,,179379,
9568975,N02,CA,,N,,,,,N02CA000000,,,261201500009I-0-26100016-1,NCI:82758\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,SAN DIEGO,UNITED STATES,,52,79682716,US,3452401,"IRISYS, INC.",CA,92121,,15326880; ,"GIANNINI, ROBERT ;",,1/30/2017,7/30/2017,Award; base; capsule; Clinical; Color; Contractor; Cyclic GMP; Dose; Formulation; Gelatin; Label; Oranges; Pharmacologic Substance; repository; seal; Testing; ,BASE AWARD,,,,,,,,,82758,
9568984,N02,CA,,N,,,,,N02CA000000,,,261201700020C-0-0-1,NCI:125000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ALACHUA,UNITED STATES,,3,12852344,US,10020711,ALCHEM LABORATORIES CORPORATION,FL,326156687,,15327030; ,"DENYSENKO, SERGIY ;",,8/1/2017,7/31/2018,Chemicals; Clinical; Clinical Research; Clinical Trials; Developmental Therapeutics Program; drug discovery; Human; Investigational Therapies; Malignant Neoplasms; Manufactured Supplies; National Cancer Institute; novel therapeutics; Pharmaceutical Preparations; Pharmacologic Substance; preclinical study; programs; Research Personnel; Therapeutic Agents; ,IGF::OT::IGF Manufacture of Bulk Chemicals and Bulk Pharmaceutical Ingredients for Preclinical and Clinical Studies,,,,,,,,,125000,
9569064,N01,AI,,N,,,,,N01AI000000,,,272201100022I-0-27200011-3,NIAID:1580085\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064949; ,"MIRSALIS, JON ;",,6/6/2017,6/5/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; therapeutic development; Toxicology; Toxin; ,Task 11: Interventional Agent Development Services Program,,,,,,,,,1580085,
9569562,N01,AI,,N,,,,,N01AI000000,,,272201300020I-2-27200007-1,NIAID:293012\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14369244; ,"WINAKUR, PATRICIA ;",,11/2/2015,1/15/2020,chikungunya; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Phase I Clinical Trials; Population; programs; Resources; Vaccines; ,Vaccine and Treatment Evaluation Unit: Phase I Clinical Trial of a Chikungunya Vaccine,,,,,,,,,293012,
9569762,N01,HL,,N,,,,,N01HL000000,,,268201700005I-0-26800001-1,NHLBI:742658\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,14921913; ,"HEISS, GERARDO ;",,11/15/2016,11/14/2021,Abdomen; Adult; African American; aged; Ancillary Study; Ankle; Atherosclerosis; Atherosclerosis Risk in Communities; base; Behavioral; Behavioral Genetics; Carotid Arteries; caucasian American; Characteristics; Clinical; clinical development; clinical predictors; cognitive function; cohort; Cohort Studies; Collaborations; Communities; Contracts; Coronary heart disease; County; Data; Data Collection; Data Set; Event; follow-up; Fostering; Funding; Genetic; Geographic Locations; Goals; Grant; Heart failure; Hemostatic Agents; indexing; Laboratories; Measurement; middle age; Monitor; mortality; Myocardial Infarction; Natural History; operation; Participant; Photography; Policies; Process; Prospective cohort study; psychologic; Psychosocial Factor; Publications; Recruitment Activity; Research Personnel; Retinal; Risk Factors; Risk Marker; rural setting; sharing data; socioeconomics; Structure of popliteal artery; Subgroup; suburb; Testing; trend; Ultrasonography; United States National Institutes of Health; Washington; ,IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - FIELD CENTER - CORE STUDY OPERATIONS,,,,,,,,,742658,
9581239,N01,HL,,N,,,,,N01HL000000,,,268201600015I-0-26800002-1,NHLBI:275333\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,15195783; ,"ROONEY, CLIONA ;",,8/22/2017,2/21/2019,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; manufacturing process development; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL MANUFACTURING AND PROCESS DEVELOPMENT SERVICES FOR RSA PCT0005-01: DEVELOPMENT OF AN EFFICIENT T CE,,,,,,,,,275333,
9581252,N44,HL,,N,,,,,N44HL000000,,,268201700015C-0-0-1,NHLBI:1999623\,SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,ALISO VIEJO,UNITED STATES,,,63148304,US,,,CA,926564131,,15327296; ,"LUBOCK, PAUL ;",,7/3/2017,7/2/2019,"Animal Experiments; Animal Model; Animals; base; biomaterial compatibility; Caring; Case Report Form; Catheters; Chronic; Clinical; clinical development; clinical material; Clinical Protocols; Clinical Trials; Collaborations; cost; design; Development Plans; Device or Instrument Development; Devices; Documentation; Ductus Arteriosus; Elements; Equipment Malfunction; Failure; Fatigue; Freezing; Geometry; Goals; hemodynamics; Human; Implant; in vivo; Informed Consent; Intramural Research; Investigation; Laboratories; Laboratory Research; Licensing; Marketing; Maryland; Mechanics; meetings; minimally invasive; Modeling; Morbidity - disease rate; mortality; National Heart, Lung, and Blood Institute; Patent Ductus Arteriosus; payment; Peripheral; Phase; Premature Infant; Preparation; prototype; Reporting; research and development; research clinical testing; Research Design; Risk; safety testing; Specific qualifier value; Sterility; System; Testing; Travel; treatment strategy; United States National Institutes of Health; ","IGF::OT::IGF Topic 090, Phase II, Devices to Close Ductus Arteriosus in Premature Infants IGF::OT::IGF",,,,,,,,,1999623,
9581253,N44,HL,,N,,,,,N44HL000000,,,268201700010C-0-0-1,NHLBI:999969\,SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,DURHAM,UNITED STATES,,4,23317253,US,4529501,"INNOVATION RESEARCH AND TRAINING, INC.",NC,277136628,,15327281; ,"KUPERSMIDT, JANIS ;",,12/1/2016,11/30/2018,"Address; Adherence; Adolescent; Age; Asthma; Award; Awareness; base; Books; bullying; Child; Childhood; Clinical Research; Clinical Trials; Collaborations; commercialization; crowdsourcing; Development; Disease; Educational Materials; Empathy; Enrollment; Ensure; Ethnic Origin; Evaluation; experience; Fostering; Goals; Health Benefit; Health Status; Hearing; Human Subject Research; innovation; interest; Knowledge; Learning; learning strategy; Modification; National Heart, Lung, and Blood Institute; open source; Participant; Pediatric Research; Phase; Population; Public Health; Race; Reading; Regulation; Research; Resources; Sickle Cell Anemia; Small Business Innovation Research Grant; Suicide prevention; Target Populations; Technology; Teenagers; Testing; TimeLine; tool; web site; Youth; ",IGF::OT::IGF SBIR Phase II Topic 86: Tools for Educating Children about Clinical Research,,,,,,,,,999969,
9581257,N43,HL,,N,,,,,N43HL000000,,,268201700022C-0-0-1,NHLBI:225000\,SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,PHILADELPHIA,UNITED STATES,,2,962502287,US,10026770,"LONGEVITY BIOTECH, INC.",PA,191043352,,15327305; ,"SHANDLER, SCOTT ;",,9/28/2017,,"Agreement; airway hyperresponsiveness; airway inflammation; Anti-inflammatory; Anti-Inflammatory Agents; Antioxidants; Apolipoprotein A-I; Asthma; asthmatic; asthmatic patient; Attenuated; Award; Binding; Breathing; Businesses; Cells; Clinical; Clinical Research; Clinical Trials; commercialization; Contractor; Contracts; CSF3 gene; cytokine; Data; Development; Development Plans; Disclosure; Electronic Mail; Eligibility Determination; Experimental Designs; experimental study; Extrinsic asthma; Formulation; Funding; Future; Goals; Grant; High Density Lipoproteins; Human; immunoregulation; improved; Individual; Inflammation; Interferon Type II; Interleukin-17; Intramural Research; Intranasal Administration; invention; Investigational Drugs; Investigational New Drug Application; Knockout Mice; Legal patent; Licensing; Link; manufacturing process; Mediating; member; Metaplasia; Modeling; Mucous body substance; Mus; National Heart, Lung, and Blood Institute; neutrophil; novel; Obstruction; Ovalbumin; peptide drug; Peptides; peptidomimetics; Performance; Phase; Phase I Clinical Trials; Phenotype; pre-clinical; preclinical evaluation; preference; Process; programs; Property; protective effect; Proteins; Pulmonary Function Test/Forced Expiratory Volume 1; Pyroglyphidae; Regulation; Request for Proposals; Research Personnel; response; reverse cholesterol transport; Rights; Serum; Services; Site; Small Business Innovation Research Grant; Steroids; Structure; Techniques; Technology; Technology Transfer; Therapeutic; Time; TNF gene; translational study; United States Food and Drug Administration; United States National Institutes of Health; Work; ",IGF::OT::IGF,,,,,,,,,225000,
9581351,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100071-1,NCI:18770\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,5/17/2017,1/31/2018,dissemination research; Health; implementation research; Institutes; meetings; research data dissemination; Training; Training Support; ,Task Order No. 71: 'Training Institute for Dissemination and Implementation Research in Health 2017 (TIDIRH)',,,,,,,,,18770,
9581359,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100084-1,NCI:28116\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,8/15/2017,8/14/2018,Applied Research; meetings; programs; Support Groups; working group; ,"IGF::OT::IGF Applied Research Program (ARP) Meeting and Working Group Support-Option Period 3CISNET 2017 Annual Meeting- October 30th-3rd POP September 14th, 2017 through Nov 30, 2017",,,,,,,,,28116,
9581374,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100062-1,NCI:27823\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,12/29/2016,12/28/2017,Cancer Intervention and Surveillance Modeling Network; meetings; ,Task Order No.62 - Pre-Meeting Planning Activities for Cancer Intervention and Surveillance Modeling Network (CISNET),,,,,,,,,27823,
9581387,N02,CA,,N,,,,,N02CA000000,,,261201700458P-0-0-1,NCI:25000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,PENSACOLA,UNITED STATES,,,80749040,US,,,FL,32503,,15327149; ,"AMIN, RAID ;",,9/1/2017,8/31/2018,Data; Databases; Malignant Neoplasms; Pollution; ,IGF::OT::IGF Adding Enviromental Pollution Data to Cancer Surveillance Databases,,,,,,,,,25000,
9581394,N02,CA,,N,,,,,N02CA000000,,,261201700604P-0-0-1,NCI:25000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WESTLAKE VILLAGE,UNITED STATES,,,14731052,US,,,CA,913627038,,15327161; ,"DANESE, MARK ;",,9/11/2017,3/10/2018,Data; data modeling; insight; Outcome; ,"OUTCOMES INSIGHTS, INC: SEER Data into Common Data Model",,,,,,,,,25000,
9581406,N02,CA,,N,,,,,N02CA000000,,,261201700087A-0-0-1,NCI:140692\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15327140; ,"SACHI, KAREN ;",,9/20/2017,9/19/2018,Data; Division of Cancer Control and Population Sciences; health care delivery; Healthcare; Medicare; National Cancer Institute; programs; Research; Services; ,"IGF::OT::IGF SEER-Medicare Technical Support Services in Support of the National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), Healthcare Delivery Research Progra",,,,,,,,,140692,
9581839,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-161,NCI:397361\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,Address; Advocate; American; anticancer research; Bilateral; Biotechnology; Cancer Burden; Cancer Control; cancer prevention; Cessation of life; Collaborations; Congresses; Contractor; Country; Data; Data Analyses; Development; Devices; Diagnostic; Documentation; Evaluation; experience; fight against; global health; Goals; Government; Government Agencies; Grant; Individual; investigator training; Knowledge; Leadership; Logistics; Malignant Neoplasms; Manuscripts; meetings; Mission; New Agents; Outcome; Pharmacologic Substance; Program Evaluation; programs; Publications; Reporting; Research; Resources; response; Scientist; screening; Site; symptom management; technical writing; Training; Training Activity; Travel; United States; web site; Work; ,"CGH - Center for Global Health Dialogues, Data Analysis, and Technical Support",,,,,,,,,397361,
9581888,N01,HL,,N,,,,,N01HL000000,,,268201700006I-0-26800002-1,NIDCR:143766\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15200705; ,"DOHENY, KIMBERLY ;",,8/30/2017,8/29/2019,Affect; Animals; base; Behavior Therapy; Candidate Disease Gene; Cleft lip with or without cleft palate; Cleft Palate; Congenital Abnormality; Defect; Dental; Disease; DNA sequencing; Etiology; exome sequencing; Family; follow-up; Funding; Genes; Genetic study; genetic variant; genome wide association study; Genotype; Goals; Health; health economics; Human; Individual; Lead; Live Birth; Medical; Nutritional; Operative Surgical Procedures; orofacial cleft; Palate; Phenotype; Population; Protocols documentation; Public Health; Research; Risk; Speech; Study Subject; ,IGF::OT::IGF HIGH THROUGHPUT GENOTYPING AND DNA SEQUENCING FOR STUDYING THE GENETIC CONTRIBUTIONS TO HUMAN HEALTH AND DISEASE,,,,,,,,,143766,
9583285,N43,DA,,N,,,,,N43DA000000,,,271201700035C-0-0-1,NIDA:150000\,SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LOS ANGELES,UNITED STATES,,,80429668,US,,,CA,900674305,,15254797; ,"RUTCHICK, ABE ;",,9/25/2017,3/24/2018,addiction; Adolescent; billing data; Comorbidity; Data; Data Security; design; Development; Dialectical behavior therapy; Disease; dual diagnosis; Health Insurance Portability and Accountability Act; Insurance; Mental disorders; Patients; Phase; Privacy; Reaction; Risk; substance abuse treatment; Substance Use Disorder; task analysis; Testing; usability; virtual reality; Work; ,IGF::OT::IGF: Development and Testing of Virtual Reality Enhanced Dialectic Behavior Therapy (DBT) for Adolescents with Dual Diagnosis. PoP: 9/25/2017-3/24/2018. N43DA-17-5585.,,,,,,,,,150000,
9584015,N01,DA,,N,,,,,N01DA000000,,,271201700070C-0-0-1,NIDA:97233\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MOUNTAIN VIEW,UNITED STATES,,18,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,940430816,,15255714; ,"DOODY, LINDA ;",,9/22/2017,9/21/2022,Amendment; Annual Reports; Clinical Trials; Contract Services; Contracts; Ensure; Good Clinical Practice; Guidelines; International; Investigational New Drug Application; Medical; National Institute of Drug Abuse; novel therapeutics; Practice Guidelines; Regulation; Regulatory Affairs; research study; Research Support; Resources; symposium; Therapeutic; United States Food and Drug Administration; United States National Institutes of Health; ,"IGF::OT::IGF : Regulatory Affairs Support. September 22, 2017 - September 21, 2022. N01DA-17-8933.",,,,,,,,,97233,
9587866,N01,NS,,N,,,,,N01NS000000,,,26320160123B26500005-0-0-1,NINDS:43122\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,BETHESDA,UNITED STATES,,8,802894832,US,3978501,"BETAH ASSOCIATES, INC.",MD,208143064,,; ,",  ;",,7/24/2017,4/20/2018,Educational workshop; meetings; Services; Traumatic Brain Injury; Woman; ,"IGF::CL::IGF:THIS SERVICE IS FOR THE MEETING PLANNING AND ADMINISTRATION: WOMEN'S TRAUMATIC BRAIN INJURY WORKSHOP DECEMBER 18-19, 2017 POP JULY 24, 2017 TO APRIL 20, 2018.",,,,,,,,,43122,
9587871,N01,NS,,N,,,,,N01NS000000,,,26320090024B26500011-0-0-1,NINDS:56652\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,HERNDON,UNITED STATES,,,789995933,US,,,VA,201703838,,; ,",  ;",,8/28/2017,1/31/2018,Educational workshop; meetings; Services; ,IGF::CL::IGF: This service is for Administrative and Planning for meeting support for up coming workshop.,,,,,,,,,56652,
9587909,N01,DA,,N,,,,,N01DA000000,,,271201400016I-0-27100004-1,NINDS:19500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SANBORNTON,UNITED STATES,,,968353594,US,,,NH,32692813,,; ,",  ;",,9/28/2014,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,"IGF::OT::IGF JOHNSON, GRAHAM:1200592 [17-008613]",,,,,,,,,19500,
9587915,N01,DA,,N,,,,,N01DA000000,,,271201400013I-0-27100004-1,NINDS:55500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ANN ARBOR,UNITED STATES,,,16763403,US,,INTEGRATED NONCLINICAL DE,MI,481032122,,; ,",  ;",,9/28/2014,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,IGF::CL::IGF,,,,,,,,,55500,
9587919,N01,DA,,N,,,,,N01DA000000,,,271201400014I-0-27100004-1,NINDS:19500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,HERNDON,UNITED STATES,,,36632328,US,,,VA,"20,170,256",,; ,",  ;",,9/14/2017,9/27/2018,Achievement; Address; Agreement; Amendment; analytical method; Annual Reports; Area; assay development; Attention; authority; Award; base; Behavior; behavior test; Biological Assay; Biological Products; Board Certification; Brain; candidate selection; Chemical Structure; Chemicals; Chemistry; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; cognitive testing; Communication; Complex; Computer software; Conduct Clinical Trials; Confidential Information; Consult; Consultations; Contractor; Contracts; cost; cost effective; Critical Thinking; Data; Data Analyses; Decision Making; design; Development; Development Plans; disability; Discipline; Disclosure; Doctor of Philosophy; Documentation; Dose; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; experience; Experimental Designs; experimental study; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; Hour; improved; in vivo; Individual; Industrialization; Industry; innovation; innovative technologies; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Investigational New Drug Application; Knowledge; Label; Laws; Lead; Leadership; Legal patent; Life; literacy; Logistics; manufacturing process; manufacturing scale-up; Maps; Marketing; Measures; Mediation; Medical; Medical Device; Medical Research; meetings; member; method development; Methods; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Outsourcing; Participant; Peer Review; Performance; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmaceutical Technology; Pharmacologic Substance; Pharmacology; Pharmacology and Toxicology; Pharmacology Study; Phase; phase 1 study; physical science; Plants; pre-clinical; Preparation; Prevention; Principal Investigator; Process; product development; Program Development; programs; Protocols documentation; Provider; Publications; Regulation; Regulatory Affairs; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resolution; Resources; Rights; Risk; Risk Assessment; Robotics; Role; scale up; Science; Security; self organization; Self-Direction; Services; Shapes; Site; Site Visit; skills; small molecule; sound; Strategic Planning; stroke; success; symposium; Techniques; Technology; technology development; Technology Transfer; Teleconferences; Telephone; Testing; Time; TimeLine; Toxicology; Travel; trend; United States National Institutes of Health; Validation; Visit; Work; Writing; ,IGF::OT::IGF GRAHAM T JOHNSON:NN00063121 [17-004909],,,,,,,,,19500,
9587924,N02,OD,,N,,,,,N02OD000000,,,263201200031I-0-27100001-1,NINDS:83257\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,MCLEAN,UNITED STATES,,,48298954,US,,CIRCLE SOLUTIONS INC,VA,221023807,,15327185; ,"LEWIS, KRISTINA ;",,7/13/2017,1/13/2018,meetings; National Institute of Neurological Disorders and Stroke; Services; ,NINDS 19th Udall Centers Meeting Support Services IGF::OT::IGF,,,,,,,,,83257,
9587931,N02,DA,,N,,,,,N02DA000000,,,271201700013C-0-0-1,NINDS:41500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LANCASTER,UNITED STATES,,,80192207,US,,,VA,225033700,,15327441; ,"BURNSIDE, BETH ;",,5/23/2017,5/22/2018,Achievement; Address; Agreement; analytical method; Attention; authority; Award; Back; base; Behavior; Biological Products; Board Certification; Brain; Businesses; Capital; Chemicals; Chemistry; Clinic; Clinical; Clinical Trials; Communication; Complex; Computer software; Computer Systems; Computers; Conduct Clinical Trials; Confidential Information; Consult; Contractor; Contracts; cost; cost effective; Data; Data Analyses; Data Files; Development; disability; Discipline; Disclosure; Documentation; Dose; drug development; drug discovery; Drug Industry; Education; efficacy study; Electronic Mail; Ensure; Environment; Evaluation; Event; experience; Feedback; Food; Formulation; Funding; Future; Government; Guidelines; Health; health data; Hour; Human Resources; improved; Individual; Industry; innovation; Institutes; Institution; Intellectual Property; interest; Investigational Drugs; Knowledge; Laws; Lead; Leadership; Legal patent; Letters; Life; literacy; Logistics; manufacturing process; Maps; Marketing; Measures; Mediation; Medical; Medical Research; meetings; member; method development; Mission; Modeling; multidisciplinary; Names; National Institute of Neurological Disorders and Stroke; Nature; nervous system development; nervous system disorder; Nervous system structure; Neurosciences; Neurosciences Research; Organism; Participant; Peer Review; Performance; Performance at work; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacy (field); Phase; portability; pre-clinical; preclinical safety; Preparation; Prevention; Price; Principal Investigator; Privacy; Procedures; Process; product development; programs; Property; Publications; Regulation; Reporting; Research; research clinical testing; Research Contracts; Research Design; Research Personnel; Resources; Rights; Risk; Risk Assessment; Role; Running; Science; Security; Services; Shapes; Site; Site Visit; skills; small molecule; stroke; success; symposium; Teleconferences; Telephone; Theft; Time; Training; Travel; United States National Institutes of Health; Update; virtual; Virus; Visit; Work; Writing; ,NINDS BPN/ Lowery Creek /CMC Consulting Services IGF::CL::IGF,,,,,,,,,41500,
9589163,N02,DA,,N,,,,,N02DA000000,,,271201700692P-0-0-1,NINDS:46976\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,HERNDON,UNITED STATES,,,789995933,US,,,VA,201703838,,15327501; ,"ALBERTSON, DOREEN ;",,9/20/2017,4/12/2018,Address; Australia; Award; Back; Brain; Budgets; Calendar; Clinical; Clinical Research; Code; Common Data Element; Communication; Congresses; Consultations; Contractor; Contracts; cost; Data; Data Analytics; Data Collection; data management; Data Reporting; Data Security; Data Set; Data Sources; Databases; Department of Defense; design; disability; Education; Electronic Mail; Employee; Ensure; Equipment; Equipment and Supplies; European; Evaluation; Event; Expenditure; experience; Floor; follow-up; Funding; Genetic Transcription; Goals; Government; Guidelines; Health; Healthcare; Human; Human Resources; improved; Individual; information processing; Information Services; Information Technology; Injury; Institutes; Instruction; International; Language; Laws; Length; Logistics; Maryland; meetings; member; Midwestern United States; Mind-Body Method; Monitor; National Institute of Neurological Disorders and Stroke; neuroimaging; Neurosciences; Occupations; Office Management; Ontario; Outcome Measure; Participant; Performance; Performance at work; Persons; Policies; posters; Price; Printing; Privatization; Procedures; programs; Property; Publishing; Regulation; Rehabilitation therapy; Report (document); Reporting; Research; Research Activity; Reservations; Rights; Schedule; Science; Security; Services; sharing data; Statistical Data Interpretation; Subway; symposium; Task Performances; Taxes; Technology; Time; TimeLine; Training; Transportation; Traumatic Brain Injury; Travel; United States Dept. of Health and Human Services; United States National Institutes of Health; Update; web site; Work; working group; Writing; ,IGF::OT::IGF INFINITY CONFERENCE GROUP INC: 1108883,,,,,,,,,46976,
9589175,N01,DA,,N,,,,,N01DA000000,,,271201700064C-0-0-1,NINDS:1148994\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,15266170; ,"CLEMONS, TRACI ;",,9/30/2017,9/29/2018,Clinical Research; Clinical Trials; National Institute of Neurological Disorders and Stroke; Research; Resources; ,IGF::OT::IGF OTHER FUNCTION NINDS CENTER FOR CLINICAL RESEARCH RESOURCES,,,,,,,,,1148994,
9589226,N02,DA,,N,,,,,N02DA000000,,,271201600025C-2-0-1,NIMH:0\OD:40448\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MANASSAS,UNITED STATES,,,123230570,US,,,VA,201128850,,14922024; ,"GIBSON, KAREN ;",,12/23/2016,12/22/2017,Acquired Immunodeficiency Syndrome; Address; Affect; Chronic; cognitive reserve; Comorbidity; Diagnosis; Disease; Encephalitis; Etiology; Europe; Functional disorder; HIV; HIV Seropositivity; HIV-1; Impairment; Infection; Location; low and middle-income countries; meetings; Mission; National Institute of Child Health and Human Development; National Institute of Drug Abuse; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; neuroAIDS; neuron loss; Neurosciences; Pathogenesis; Pathologic; Patients; Phenotype; Population; Publications; Research; Research Personnel; Research Priority; Role; Therapeutic Human Experimentation; United States National Institutes of Health; Viral; ,IGF::OT::IGF,,,,,,,,,40448,
9591730,N01,OD,,N,,,,,N01OD000000,,,26320170082B26300004-0-0-1,NEI:2173469\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,NORTHAMPTON,UNITED STATES,,,825136117,US,,,MA,10603267,,; ,",  ;",,9/13/2017,8/31/2018,Academy; African American; Agreement; American; Anniversary; Area; Awareness; Books; Calendar; Communication; Communities; Contractor; design; Development; diabetic; digital; digital media; Education; Eye; Eye diseases; General Population; Glaucoma; Health; Health Communication; Health education; Health Sciences; Hispanics; Measures; meetings; Methods; Mission; National Eye Institute; Native Americans; Ophthalmology; outreach; Pamphlets; population health; Populations at Risk; posters; Printing; programs; Publications; Recommendation; Recording of previous events; Reporting; Research; Research Support; Resource Sharing; Resources; Science; Services; Special Event; Testing; Text; tool; Vision; vision science; ,IGF::OT::IGF - NEI Communications and Outreach Support Services- Development and dissemination of eye health and vision science messaging and resources ,,,,,,,,,2173469,
9592637,F32,GM,7,N,12/25/2017,11/1/2017,7/31/2018,859,F32GM119202,SCHOOLS OF MEDICINE,PA-14-149,7F32GM119202-03,NIGMS:43986\,"TRAINING, INDIVIDUAL",2017,NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES,,CHARLOTTESVILLE,UNITED STATES,ANATOMY/CELL BIOLOGY,5,65391526,US,1526402,UNIVERSITY OF VIRGINIA,VA,229044195,,10656459; ,"MCCLUSKEY, BRAEDAN MARSHALL;","MAAS, STEFAN",8/1/2016,7/31/2019,Address; Adolescent; Adult; Affect; Animal Model; Automobile Driving; base; Cell Differentiation process; cell motility; Cell physiology; cell type; Cells; Chimera organism; Chromatophore; Cis Tests; Complex; Development; Developmental Biology; Developmental Process; Disease; disorder risk; Elements; Embryo; Embryonic Development; Environment; Event; Evolution; experimental study; Fishes; Gene Expression; Genetic; Genetic Variation; genome editing; genome wide association study; Genomics; Genotype; Human; Learning; Link; Macrophage Colony-Stimulating Factor; Malignant Neoplasms; Mediating; melanoma; Melanophores; migration; Modeling; Modification; Morphogenesis; Morphology; Mutagenesis; Mutation; Neural Crest; novel; Onset of illness; Organism; Outcome; Pathology; Pathway interactions; Pattern; Phenotype; Pigmentation physiologic function; Pigments; prevent; Process; Public Health; public health relevance; Quantitative Reverse Transcriptase PCR; Regulation; Regulatory Element; Role; Sister; species difference; System; Testing; Tissues; Training; Transgenic Organisms; Translating; Variant; Zebrafish; ,Morphogenesis of Pigmentation Patterns in Zebrafish and its Relatives: Testing the Genetic and Developmental Basis of Diverse Adult Phenotypes across Evolution,119202,ZRG1,Special Emphasis Panel ,,,3,43986,,43986,
9594203,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300128-1,NIA:158008\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15211110; ,"MOLYE, ELIZABETH ;",,9/6/2017,9/5/2018,,IGF::OT::IGF: BEHAVIORAL ECONOMICS AND THE PROMOTION OF HEALTH AMONG AGING POPULATIONS,,,,,,,,,158008,
9594231,N02,LM,,N,,,,,N02LM000000,,,276201500329U-2-0-2,NIA:51577\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,COMPTCHE,UNITED STATES,,,103932240,US,,,CA,95427,,15327893; ,"KAPLAN, NORTON ;",,9/28/2017,9/27/2018,,"IGF::OT::IGF - MODIFICATION 04:  The purpose of this modification is to fund support NICHE Assessment Program for NIH SBIR Phase I (Under option year 2).  The period of performance is September 28, 20",,,,,,,,,51577,
9594255,N01,DA,,N,,,,,N01DA000000,,,271201700004I-0-27100001-1,NIA:297774\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WILMINGTON,UNITED STATES,,6,19716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,18871096,,14922042; ,"FISHER, TERRENCE ;",,12/20/2016,12/19/2017,,IGF::OT::IGF DEVELOPMENT AND MAINTENANCE OF A MULTIGENOTYPIC AGED RAT COLONY  ,,,,,,,,,297774,
9594257,N01,OD,,N,,,,,N01OD000000,,,263201200074I-1-26300089-2,NIA:50000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14921826; ,"WESTBROOK, DAVID ;",,12/1/2015,11/30/2017,,IGF::OT::IGF:  FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS,,,,,,,,,50000,
9594359,N01,DA,,N,,,,,N01DA000000,,,271201500001I-0-27100003-1,NIA:167068\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WESTBROOK,UNITED STATES,,,784226511,US,,,ME,40922040,,14921982; ,"BESCH-WILLIFORD, CYNTHIA ;",,3/1/2017,2/28/2018,,IGF::OT::IGF PATHOLOGY MONITORING OF AGED RODENT COLONIES,,,,,,,,,167068,
9594407,N01,HL,,N,,,,,N01HV000000,,,268201300025C-9-0-2,NIA:159778\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14921835; ,"SHIKANY, JAMES ;",,7/1/2013,6/30/2017,,IGF::OT::IGF CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - COORDINATING CENTER,,,,,,,,,159778,
9609037,OT2,TR,1,N,12/29/2017,12/29/2017,1/31/2018,350,OT2TR002515,BIOMED ENGR/COL ENGR/ENGR STA,,1OT2TR002515-01,NCATS:78500\,OTHERS,2018,NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES,,STANFORD,UNITED STATES,BIOMEDICAL ENGINEERING,18,9214214,US,8046501,STANFORD UNIVERSITY,CA,943041222,,6620309; ,"ALTMAN, RUSS BIAGIO;","COLVIS, CHRISTINE",12/29/2017,1/31/2018,,Biomedical Data Translator Technical Feasibility Assessment of Reasoning Tool: Stanford University,2515,ZTR1,Special Emphasis Panel ,,,1,50000,28500,78500,
9618294,R01,HD,3,N,12/26/2017,8/1/2015,7/31/2017,865,R01HD069175,,RFA-HD-09-015,3R01HD069175-05S1,NICHD:36396\,Non-SBIR/STTR RPGs,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,RONDEBOSCH,SOUTH AFRICA,,,568227214,SF,1147601,UNIVERSITY OF CAPE TOWN,,7700,,10561748; ,"MCILLERON, HELEN ;","RUSSO, DENISE",8/22/2011,7/31/2017,12 year old; 2 year old; absorption; Adult; Africa; Africa South of the Sahara; Age; Anti-Retroviral Agents; Antitubercular Agents; base; Child; Childhood; co-infection; cohort; Data; Development; Dose; drug clearance; Drug Combinations; Drug Interactions; Drug Kinetics; Drug toxicity; Ethambutol; evidence based guidelines; Formulation; Guidelines; high risk; HIV; HIV Infections; Hour; improved; isoniazid; Knowledge; Life; Lopinavir; Lopinavir/Ritonavir; Malawi; Modeling; Nevirapine; Nutritional status; Oral; Overdose; Pharmaceutical Preparations; Population; Process; Protease Inhibitor; Public Health; Pyrazinamide; Regimen; Research; Rifampin; Risk; Ritonavir; South Africa; Standardization; Therapeutic; Tuberculosis; tuberculosis drugs; tuberculosis treatment; Uncertainty; Weight; World Health Organization; ,Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children,69175,ZHD1,Special Emphasis Panel ,,S1,5,33700,2696,36396,
8929927,H79,HH,5,N,9/14/2015,9/30/2015,9/29/2017,239,H79AE000102,,RFA-HS-11-023,5H79AE000102-05,,OTHERS,2015,DEPARTMENT OF HEALTH & HUMAN SERVICES,,MADISON,UNITED STATES,,2,,US,578501,UNIVERSITY OF WISCONSIN SYSTEM,WI,537061525,,7255653; ,"BERGER, LAWRENCE M;",,9/30/2011,9/29/2017,,Poverty Research Center Program,102,SRC,Special Emphasis Panel ,,,5,,,,
9389498,R01,EY,5,N,12/26/2017,12/1/2017,11/30/2018,867,R01EY025358,BIOMED ENGR/COL ENGR/ENGR STA,PA-13-302,5R01EY025358-03,NEI:333587\,Non-SBIR/STTR RPGs,2018,NATIONAL EYE INSTITUTE,,COLUMBUS,UNITED STATES,ENGINEERING (ALL TYPES),3,832127323,US,6218701,OHIO STATE UNIVERSITY,OH,432101016,,8094752; ,"LIU, JUN ;","MCKIE, GEORGE ANN",12/1/2015,11/30/2020,Address; Age; Aging; AIDS diagnosis; base; bench to bedside; Biomechanics; Cardiac; Clinic; Clinical; clinically relevant; Collagen; Cornea; crosslink; Custom; Data; Data Analyses; Decision Making; Development; Diagnosis; Diastolic blood pressure; Disease; disease diagnosis; Dose; Economic Inflation; elastography; Evaluation; Eye; Eye diseases; Frequencies; Functional disorder; Health; Heart Rate; Human; human subject; Image; improved; in vivo; in vivo imaging; indexing; innovation; insight; Intervention; Keratoconus; Knowledge; Lead; Maps; Measurable; Measurement; Measures; mechanical force; mechanical properties; Mechanics; Methods; Modeling; Monitor; Operative Surgical Procedures; Pathological Dilatation; Patients; Periodicity; Physicians; Physiologic Intraocular Pressure; Physiologic pulse; Physiological; Play; Property; Protocols documentation; public health relevance; Quantitative Evaluations; radiofrequency; Regression Analysis; Research; Resolution; response; Riboflavin; Risk; Role; Science; Secondary to; simulation; Solubility; Spatial Distribution; Staging; Structure; Techniques; Testing; Therapeutic; Thick; Tissues; tool; translational impact; treatment response; trend; Ultrasonics; Ultrasonography; Variant; volunteer; ,Ocular Pulse Elastography,25358,BNVT,"Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section ",,,3,225000,108587,333587,
9390063,R01,HL,5,N,12/28/2017,12/1/2017,11/30/2018,839,R01HL122216,SCHOOLS OF MEDICINE,PA-13-302,5R01HL122216-04,NHLBI:374415\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MINNEAPOLIS,UNITED STATES,INTERNAL MEDICINE/MEDICINE,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,1882744; ,"MILLER, JEFFREY S.;","EL KASSAR, NAHED",12/1/2014,11/30/2018,Acute Myelocytic Leukemia; Adoptive Transfer; Affect; Allogenic; Alpha Cell; Antibody Affinity; Antigens; Basic Science; Biology; cancer cell; Cancer Control; Cancer Relapse; cancer therapy; CD8-Positive T-Lymphocytes; Cell Differentiation process; cell killing; Cell physiology; Cell Survival; Cell Transplants; Cells; chemotherapy; Clinical; Clinical Research; Clonal Expansion; cohort; Cohort Studies; Complex; cytokine; Cytomegalovirus; Data; deep sequencing; Development; Diamond; Disease; Disease remission; DNA; DNA Methylation; Education; effective therapy; Employee Strikes; Ensure; Epigenetic Process; Exhibits; experience; FCGR3B gene; fighting; Frequencies; Genes; Genetic Transcription; genome-wide; Goals; Grant; Hematopoietic; hematopoietic cell transplantation; Homing; Human; Immune; Immunologist; Immunology; Immunotherapy; in vitro Assay; in vivo; Individual; Infection; Inflammatory; Innate Immune System; interest; Killings; leukemia; leukemia treatment; Leukocytes; Longevity; lymphoid enhancer-binding factor 1; Malignant - descriptor; Malignant Neoplasms; Mediating; Memory; Methods; MicroRNAs; Modeling; Molecular; mRNA Expression; Murid herpesvirus 1; Mus; Natural Killer Cells; notch protein; novel; Pathway interactions; Patients; Phenotype; Population; Positioning Attribute; Process; Production; programs; Property; protein complex; public health relevance; reactivation from latency; receptor; reconstitution; Refractory; relapse risk; response; Role; Self Tolerance; seropositive; Signal Transduction; Signaling Molecule; Solid Neoplasm; success; SYK gene; Testing; Therapeutic; transcription factor; Transcription Initiation Site; transcriptome; Translating; Transplant Recipients; Transplantation; tumor; Viral; virology; Virus; Virus Diseases; WNT Signaling Pathway; ,Inducing NK cells to remember and fight cancer,122216,ZRG1,Special Emphasis Panel ,,,4,253570,120845,374415,
9392934,R01,HL,5,N,12/29/2017,12/1/2017,11/30/2018,838,R01HL095797,,PA-13-302,5R01HL095797-09,NHLBI:484857\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,NASHVILLE,UNITED STATES,,5,79917897,US,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,TN,372320011,,6625587; ,"WEST, JAMES D;","XIAO, LEI",3/31/2009,11/30/2018,Acetylation; Avidity; BMPR2 gene; Case Study; Cell Culture Techniques; cell growth; Cell Survival; Cells; Citric Acid Cycle; Clinical; Clinical Research; Data; Defect; Dependence; Development; Diagnostic; Disease; Drops; Energy Metabolism; Enzymes; Etiology; fatty acid oxidation; Gene Expression; Glucose; Glutamates; Glutamine; Growth; hemodynamics; Heritability; High Fat Diet; Hour; Human; Intervention; Isocitrate Dehydrogenase; Knockout Mice; Label; Link; Lung; Lysine; Malignant Neoplasms; Measures; Metabolic; Metabolic Pathway; Metabolism; metabolomics; Mitochondria; Molecular; mouse model; Mus; mutant; Mutant Strains Mice; Mutation; Neoplastic Processes; Non-Essential Amino Acid; noninvasive diagnosis; Organ; overexpression; Oxidative Stress; Oxygen; Pathogenesis; Patients; Penetrance; Positron-Emission Tomography; prevent; Process; Progress Reports; Protein Acetylation; public health relevance; pulmonary arterial hypertension; Pulmonary Hypertension; Pulmonary Vascular Resistance; Regulation; Serum; Sirtuins; Source; stable isotope; success; Testing; therapeutic target; Tissues; tool; Tracer; treatment response; uptake; ,Interventions Against the Molecular Etiology of BMPR2-induced PAH,95797,RIBT,Respiratory Integrative Biology and Translational Research Study Section ,,,9,310548,174309,484857,
9430035,N01,HD,,N,,,,,N01HD000000,,,275201300025I-2-27500004-1,NICHD:406972\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SEATTLE,UNITED STATES,,7,605799469,US,9087701,UNIVERSITY OF WASHINGTON,WA,981959472,,14967827; ,"PAGE, STEPHANIE ;",,9/30/2014,6/30/2017,Androgens; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Contraceptive Usage; Drug Combinations; Drug Formulations; Drug Kinetics; Formulation; Gel; Gonadotropins; male; men; Methods; National Institute of Child Health and Human Development; Nestorone; Pharmacodynamics; Phase; Preparation; Production; Progestins; Property; Regimen; Safety; sperm cell; Steroids; Testing; Testosterone; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE,,,,,,,,,406972,
9430049,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-3,NCI:3591094\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,"ABCC1 gene; Affect; Agreement; Amination; Amines; Animals; Anthrax disease; anthrax lethal factor; anthrax protective factor; Antibodies; anticancer research; antimicrobial; Area; Bacillus anthracis; base; Binding; Biochemical; Bioinformatics; Biological; biothreat; Bontoxilysin; Boston; botulinum; Caliber; cancer cell; cancer diagnosis; cancer therapy; Certification; chemical genetics; Chemical Structure; chemical synthesis; Chemicals; Clinical Trials; Colchicine; Collaborations; Colon Carcinoma; Communities; Computer Analysis; computer center; Computer Simulation; Computer software; computerized tools; Computers; Computing Methodologies; Critical Pathways; Data; data acquisition; Data Base Management; Data Compromising; Data Reporting; Data Set; Database Management Systems; Databases; design; Development; Developmental Therapeutics Program; Dimensions; Dose; drug candidate; Drug Design; drug development; drug discovery; Ebola virus; encryption; Evaluation; Exercise; experimental analysis; experimental study; Filoviridae; Filovirus; Fingerprint; flexibility; Frankfurt-Marburg Syndrome Virus; Frequencies; Funding; Generations; genetic approach; GTP-Binding Protein alpha Subunits, Gs; heuristics; improved; in vivo; Information Systems; Information Technology; inhibitor/antagonist; interest; Internet; Investigation; Java; Joints; kinase inhibitor; Laboratories; laptop; Lead; Legal; Libraries; Ligands; Light; Linux; Maintenance; Malignant neoplasm of lung; Malignant Neoplasms; Metalloproteases; method development; Methods; Microtubules; Mining; Modeling; molecular modeling; Molecular Models; Molecular Target; Molecular Weight; Monitor; Monkeypox virus; mortality; mouse model; Mus; National Cancer Institute; National Institute of Allergy and Infectious Disease; Natural Products; Neurons; novel; novel therapeutics; Online Systems; operation; Pathogenesis; Performance; pharmacophore; Play; Policies; Positioning Attribute; prevent; Prodrugs; Program Evaluation; programs; Proteins; Protocols documentation; Publications; Published Comment; Publishing; Rapid Access to Intervention Development; remediation; Reporting; repository; research and development; Research Infrastructure; Research Personnel; Research Project Grants; Research Proposals; Resources; response; Review Committee; Ribosomal Protein S6 Kinase; Ribosomes; Ricin; Ricinus communis; Rift Valley fever virus; Role; Savings; Schedule; Scientist; screening; Secure; Security; Security Measures; Series; Serotyping; Services; Shapes; Site; small molecule; small molecule inhibitor; small molecule therapeutics; Smallpox Viruses; software development; Source; Specific qualifier value; staphylococcal enterotoxin; Statistical Data Interpretation; Structure; Support Groups; Survival Rate; System; Systems Analysis; Techniques; tertiary amine; Testing; Therapeutic; therapeutic development; Time; tool; Topoisomerase; Toxic effect; Toxin; Translational Research; transmission process; Tubulin; United States National Institutes of Health; Universities; Update; vector; Virginia; Virus; weapons; web app; web page; web site; Work; Zinc; ",DCTD Computer Support,,,,,,,,,3591094,
9430057,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-12,NCI:749777\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,American; Archives; Area; bcr-abl Fusion Proteins; Biological Assay; biomarker evaluation; Breast Carcinoma; Calibration; cancer diagnosis; Cancer Research Network; Chronic Myeloid Leukemia; CLIA certified; Clinical; Clinical Data; clinical decision-making; clinical practice; Clinics and Hospitals; Collection; Communities; Community Healthcare; community setting; Complex; computer program; Computerized Medical Records Systems; cost; Data; Databases; design; Development; Diagnosis; diagnostic biomarker; Disease; Evaluation; follow-up; Funding; Genes; Geographic Locations; Health Maintenance Organizations; Histologic; Human Resources; improved; Informatics; Inpatients; Laboratories; Laboratory Procedures; Link; malignant breast neoplasm; Manuals; member; molecular diagnostics; molecular marker; Noninfiltrating Intraductal Carcinoma; open source; Outcome; Outpatients; Pathologic; Pathologist; Pathology; Pathology Report; patient population; Patients; peer; Performance; prognostic; programs; Protocols documentation; Records; Recurrence; Research; Research Personnel; Retrieval; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sampling; Site; Slide; Specimen; Standardization; System; Testing; Time; Tissue Microarray; Tissues; tumor; tumor registry; Vital Status; Work; ,DCTD Cancer Diagnosis,,,,,,,,,749777,
9430063,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-20,NCI:3494460\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Animals; Antineoplastic Agents; antitumor effect; Biological Assay; Biological Testing; Cancer Model; Cell Line; chemotherapeutic agent; Clinical; Clinical Trials; Collaborations; Collection; Data; density; Development; Dichloroacetate; Dose; drug development; drug efficacy; efficacy evaluation; efficacy study; Equipment and supply inventories; Evaluation; Fiber; Floxuridine; Formulation; Generations; Human; Immunodeficient Mouse; In Vitro; in vivo; Intravenous infusion procedures; Label; Laboratories; Luciferases; Malignant neoplasm of lung; Materials Testing; Methods; Modeling; mouse model; Mus; neoplastic cell; New Agents; novel drug combination; Nude Rats; Pathway interactions; pharmacodynamic biomarker; Pharmacodynamics; Phase; pre-clinical; Preclinical Drug Evaluation; Preclinical Testing; Preparation; Publishing; Rattus; Residual Neoplasm; Residual Tumors; Rodent; Route; Sampling; Schedule; screening; Solubility; success; Support Groups; technique development; Techniques; Testing; Tetrahydrouridine; Time; Transgenic Mice; tumor; Tumor Tissue; tumor xenograft; Validation; Xenograft procedure; ,DCTD In Vivo Preclinical Testing,,,,,,,,,3494460,
9430077,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-37,NCI:1493361\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,anticancer research; Area; Biliary Tract Diseases; biobank; Biological; Biological Assay; Biological Process; bioprocess; Bladder Diseases; blood fractionation; Blood specimen; Bone Diseases; cancer epidemiology; cell immortalization; Cell Line; Cells; Cervical; CLIA certified; Clinical Research; cold temperature; Cryopreservation; Cytology; Detection; Diagnostics Research; Division of Cancer Epidemiology and Genetics; DNA; Epidemiology; epidemiology study; Erythrocytes; established cell line; Eye diseases; Feces; Fibroblasts; Flow Cytometry; Fluorescence-Activated Cell Sorting; Freeze Drying; Freezing; Hodgkin Disease; Hormones; Human; Human Herpesvirus 4; immortalized cell; Immunologic Monitoring; Immunologic Tests; Immunologics; In Vitro; instrumentation; Kaposi Sarcoma; Laboratories; leukemia; Liquid substance; malignant breast neoplasm; malignant mouth neoplasm; Malignant neoplasm of brain; Malignant neoplasm of cervix uteri; Malignant neoplasm of esophagus; Malignant neoplasm of larynx; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pharynx; Malignant neoplasm of prostate; Malignant neoplasm of testis; Malignant neoplasm of thyroid; Malignant neoplasm of urinary bladder; malignant stomach neoplasm; Malignant Vaginal Neoplasm; Mass Spectrum Analysis; Measurement; melanoma; Molecular; molecular diagnostics; Molecular Epidemiology; Multiple Myeloma; Mutation Detection; Nitrogen; Nucleic Acids; Pancreatic Non-Hodgkin's Lymphoma; Paraffin Embedding; Pathogen detection; Pathogenesis; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Polymorphism Analysis; Preparation; Prevention; Process; programs; Proteins; quality assurance; Quality Control; Rectal Cancer; Renal carcinoma; Reporting; repository; Research Infrastructure; Research Personnel; RNA; Scientist; Serum; Services; Single Nucleotide Polymorphism; Skin Cancer; small molecule; Specimen; Specimen Handling; Spectrophotometry; Structure; Techniques; Technology; Tissue Embedding; Tissues; tumor; Urine; Urologic Cancer; Uterine Cancer; Vaginal Diseases; Virus; Whole Blood; ,Molecular Assays for epidemiology studies,,,,,,,,,1493361,
9430091,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-51,NCI:5855121\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,academic program; Adenovirus Vector; Adjuvant; Advisory Committees; aluminum sulfate; Amyloid; amyloid imaging; Amyloidosis; Angiogenesis Inhibitors; Antibodies; Antibody Formation; Antigens; Area; base; Biological; Biological Assay; Biological Products; Biological Response Modifiers; Budgets; cancer clinical trial; cancer diagnosis; cancer immunotherapy; cancer therapy; Cancer Therapy Evaluation Program; Cancer Vaccines; CCR; Certification; chaperonin; chemokine; Childhood; chimeric antibody; Chimeric Proteins; Clinical; Clinical Investigator; clinical lot; Clinical Research; clinical toxicology; Clinical Trials; Collaborations; Communities; cost; Country; Cyclic GMP; cytokine; Data; Dendritic Cells; Deposition; Development; Developmental Therapeutics Program; Disease; DNA Vaccines; Documentation; Drug Discovery Groups; Educational workshop; Endotoxins; Escherichia coli; Evaluation; experience; Extramural Activities; Facility Designs; Faculty; Familiarity; Fermentation; flexibility; Formulation; Funding; gene therapy; Gene-Modified; Glioma; Government; Government Agencies; Government Programs; Head and Neck Cancer; Herpesviridae; Human Resources; humanized monoclonal antibodies; IL2 gene; imaging study; Immune; Immunologic Adjuvants; Immunotherapy; Immunotoxins; improved; In Vitro; Income; innovation; Institutes; Institution; Insulin-Dependent Diabetes Mellitus; Intellectual Property; Interleukin-12; Interleukin-15; Interleukin-2; International; Intravenous; Investigation; large scale production; Liquid substance; lot production; Lymphoma; Malaria Vaccines; Malignant neoplasm of cervix uteri; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Malignant Neoplasms; Mammalian Cell; Manufacturer Name; manufacturing facility; manufacturing process; Measles; meetings; melanoma; member; Metastatic Neoplasm to the Liver; Mission; Monoclonal Antibodies; Multiple Myeloma; Mus; National Cancer Institute; National Institute of Allergy and Infectious Disease; Neuroblastoma; New Agents; Non-Hodgkin's Lymphoma; novel vaccines; Oligonucleotides; oncology; Oncolytic viruses; Pathway interactions; Patients; Peptide Vaccines; Pharmacology; Phase; Phase I Clinical Trials; phase I trial; Phase III Clinical Trials; Plasmids; Plasticizers; Primary carcinoma of the liver cells; Process; Production; Program Development; Program Evaluation; programs; Proteins; Protocols documentation; Recombinant Proteins; Recombinants; Recommendation; Regulation; Research; Research Contracts; Research Personnel; Research Project Grants; Residual Neoplasm; Resources; response; Safety; scale up; Schedule; Ships; SILV gene; Source; STAT3 gene; System; Technology; technology development; Technology Transfer; Testing; Therapeutic; Time; Toxicology; Training; Translating; Tropism; vaccine trial; Vaccines; Vial device; Viral; Virus; Work; working group; ,DCTD Biopharmaceutical Development,,,,,,,,,5855121,
9430098,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-61,NCI:5275409\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,,Clinical Pharmacodynamics,,,,,,,,,5275409,
9430112,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-79,NCI:5657124\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,Cancer Center; Clinical Research; Clinical Trials; Communities; Funding; Goals; Institutes; National Cancer Institute; programs; Research Infrastructure; systems research; translational research program; ,Support for NCI CCCT ,,,,,,,,,5657124,
9430157,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-124,NCI:1000000\NIA:0\NIAID:0\NIDDK:0\NIEHS:0\NIGMS:0\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,14267998; ,"HEIMBROOK, DAVID ;",,9/26/2008,9/25/2018,,DCP - COPTRG - SELECT/PCPT,,,,,,,,,1000000,
9430188,N01,AI,,N,,,,,N01AI000000,,,272201400002C-5-0-1,NIAID:1953904\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAN FRANCISCO,UNITED STATES,,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,1872890; ,"STODDART, CHERYL ;",,12/6/2013,12/5/2017,Animal Model; Clinical Research; Complement; Contracts; cost; Data; drug discovery; Drug Evaluation; HIV; humanized mouse; In Vitro; in vitro activity; in vivo; mouse model; National Institute of Allergy and Infectious Disease; nonhuman primate; Pharmaceutical Preparations; Phase; Prevention strategy; Process; Program Evaluation; Research Personnel; Research Support; Resources; Therapeutic; therapeutic development; Time; tool development; Translations; ,'HUMANIZED MOUSE MODELS FOR HIV THERAPEUTICS DEVELOPMENT',,,,,,,,,1953904,
9430194,N01,HD,,N,,,,,N01HD000000,,,275201400003I-1-27500012-1,NICHD:80635\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14369392; ,"MANDACI, OGUZ ;",,10/28/2015,10/27/2017,brain tissue; Clinical; DNA; Enrollment; Equipment and supply inventories; Freezing; Human; Infant; Meconium; Monitor; National Institute of Child Health and Human Development; Paraffin; Pregnant Women; repository; Saliva; Services; Ships; Specimen; System; Temperature; Tissues; Umbilical Cord Blood; ,REPOSITORY SERVICES FOR THE SAFE PASSAGE STUDY (PASS),,,,,,,,,80635,
9430195,N01,HD,,N,,,,,N01HD000000,,,275201400003I-2-27500004-1,NICHD:27422\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14369380; ,"MANDACI, OGUZ ;",,1/12/2015,1/11/2018,Clinical; Eating; Equipment and supply inventories; Feces; Freezing; Human; microbiome; Monitor; National Institute of Child Health and Human Development; North Carolina; Plasma; Pregnancy; repository; Serum; Services; Ships; Specimen; System; Temperature; Umbilical Cord Blood; Urine; ,HUMAN BIOSPECIMEN REPOSITORY -  PREGNANCY EATING ATTRIBUTES STUDY,,,,,,,,,27422,
9430196,N01,HD,,N,,,,,N01HD000000,,,275201400003I-1-27500011-1,NICHD:180863\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14369388; ,"MANDACI, OGUZ ;",,10/28/2015,10/27/2017,Cervical; Clinical; Data Coordinating Center; Equipment and supply inventories; Freezing; Human; maternal serum; Monitor; Mothers; National Institute of Child Health and Human Development; Nulliparity; Outcome Study; Placenta; Plasma; Pregnancy Outcome; repository; sample collection; Sampling; Services; Ships; Specimen; System; Temperature; United States; Urine; Vagina; ,REPOSITORY SERVICES FOR NULLIPAROUS PREGNANCY OUTCOMES STUDY: MONITORING MOTHERS-TO-BE (NuMom2b),,,,,,,,,180863,
9430220,N01,HL,,N,,,,,N01HV000000,,,268201300025C-9-0-1,NHLBI:1696562\NIA:0\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,12577001; ,"SHIKANY, JAMES ;",,7/1/2013,6/30/2017,acquired factor; Address; Adult; Affect; Age; Ancillary Study; Atrial Fibrillation; base; Blood; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; cardiovascular risk factor; Cardiovascular system; Chicago; Clinical; cohort; Communities; Coronary artery; Coronary Artery Risk Development in Young Adults Study; Coronary heart disease; Data; Development; Disease; Education; emerging adult; Event; Evolution; follow-up; Heart Abnormalities; Heart failure; high school; Institutes; Lung; Measures; middle age; Myocardial dysfunction; novel; Participant; Phenotype; Race; racial disparity; Research Personnel; Risk; Risk Factors; Sampling; sex; sharing data; stomach cardia; stroke; Structure; Subgroup; Time; Training; Update; young adult; ,IGF::OT::IGF,,,,,,,,,1696562,
9430221,N01,HL,,N,,,,,N01HL000000,,,268201600004C-2-0-1,NCI:0\NHLBI:1000000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WINSTON-SALEM,UNITED STATES,,5,937727907,US,9021205,WAKE FOREST UNIVERSITY HEALTH SCIENCES,NC,271570001,,14368959; ,"FAVREAU, RYAN ;",,10/15/2015,10/14/2017,Cardiovascular Diseases; Communities; Contracts; follow-up; Knowledge; Mentors; older women; Research Personnel; Resources; Women's Health; ,IGF::CT::IGF WOMEN HEALTH INITIATIVE - REGIONAL CENTER,,,,,,,,,1000000,
9430225,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-2,NIAID:1232162\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,1/26/2017,1/25/2018,Categories; Communicable Diseases; Contracts; Development; Intervention; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; programs; Safety; Services; therapeutic development; therapy development; Toxicology; Translational Research; ,Task 4: The Interventional Agent Development Services program,,,,,,,,,1232162,
9430226,N01,AI,,N,,,,,N01AI000000,,,272201100022I-10-27200004-3,NIAID:1884484\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,1/26/2017,1/25/2018,Categories; Communicable Diseases; Contracts; Development; Intervention; Microbiology; National Institute of Allergy and Infectious Disease; pathogen; pre-clinical; programs; Safety; Services; therapeutic development; therapy development; Toxicology; Translational Research; ,Task 4: The Interventional Agent Development Services program,,,,,,,,,1884484,
9430235,N01,HD,,N,,,,,N01HD000000,,,275201300003C-20-0-1,NICHD:29139313\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,49508120,US,9611701,"WESTAT, INC.",MD,208503129,,12576529; ,"DRIVER, BARBARA ;",,9/1/2013,5/31/2017,Academic Medical Centers; Acquired Immunodeficiency Syndrome; Address; Adolescent; Adolescent Medicine; Adolescent Medicine Trials Network; Adult; Affect; AIDS clinical trial group; AIDS prevention; AIDS/HIV problem; Alabama; Anti-Retroviral Agents; Area; Argentina; Bacterial Infections; Baltimore; base; Biological; Boston; Brazil; Breast Feeding; California; Centers for Disease Control and Prevention (U.S.); Child; Childhood; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; co-infection; Code; Collaborations; Colorado; communicable disease diagnosis; Communicable Diseases; Comorbidity; Conduct Clinical Trials; Contractor; Contracts; cooking; Country; County Hospitals; Data Coordinating Center; demographics; design; Development; Diagnosis; Diagnostic; Diagnostic Procedure; Discipline of obstetrics; Disease; disorder prevention; drug abuse prevention; Drug Kinetics; Drug usage; Epidemic; Epidemiology; Equipment; European; Evaluation; Evaluation Research; Exposure to; fetal; flexibility; Florida; Funding; Future; General Hospitals; Goals; Gynecology; Health Sciences; HIV; HIV Infections; Hospitals; Human Resources; Infant; Infection; Infection prevention; infrastructure development; Institutes; interest; International; International AIDS; international center; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Intervention; Intravenous Immunoglobulins; Investigation; Investigational Therapies; Lactation; Latin America; Logistics; Long-Term Effects; Los Angeles; Maryland; Maternal Health; Medical center; medical schools; Michigan; Modality; Morbidity - disease rate; Mother-to-child HIV transmission; Mothers; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; Natural History; Nature; New York; Newborn Infant; Opportunistic Infections; Pathogenesis; patient population; pediatric AIDS; Pediatric Hospitals; pediatric human immunodeficiency virus; Perinatal; Perinatal Infection; Pharmaceutical Preparations; Pharmacotherapy; Population; Pregnancy; pregnant; Pregnant Women; prevent; Prevention; Prevention strategy; programs; Prophylactic treatment; Protocols documentation; repository; Research; Research Activity; Research Design; Research Personnel; Resources; response; Safety; San Francisco; Services; Site; Specific qualifier value; Specimen; State Hospitals; targeted treatment; Therapeutic Agents; Time; Training Support; transmission process; treatment center; Tuberculosis; United States National Institutes of Health; Universities; University Hospitals; Urban Hospitals; vaccine evaluation; Vaccines; virtual; Washington; Woman; Work; young woman; ,NICHD INTERNATIONAL &  DOMESTIC PEDIATRIC & MATERNAL HIV STUDIES DATA COORDINATING CENTER,,,,,,,,,29139313,
9430236,N01,DA,,N,,,,,N01DA000000,,,271201400002C-4-0-1,NIDA:821495\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BELMONT,UNITED STATES,,5,46514535,US,1876801,MCLEAN HOSPITAL,MA,24781064,,12576745; ,"BERGMAN, JACK ;",,12/16/2013,12/15/2017,Award; base; Catheters; Cocaine; Code; Dose; drug discrimination; Follow-Up Studies; Food; Intramuscular Injections; Macaca mulatta; male; nonhuman primate; Pharmaceutical Preparations; Protocols documentation; response; Saline; Self Administration; Self-Administered; Stimulus; Testing; Training; ,FY14.  BASE AWARD; ASSESSMENT OF POTENTIAL COCAINE TREATMENT MEDICATIONS IN NON-HUMAN PRIMATES; POP 12/16/2013-12/15/2014; N01DA-14-8913,,,,,,,,,821495,
9430242,N02,CA,,N,,,,,N02PC000000,,,261201300002I-2-26100004-1,NCI:280102\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LYNDEN,UNITED STATES,,1,19827539,US,10027811,"CORNERSTONE SYSTEMS NORTHWEST, INC.",WA,982649714,,14368731; ,"CLARKE, LAUREN ;",,1/1/2016,12/31/2017,base; Cancer Model; cohort; comparative; Data; flexibility; Information Resources Management; Logistics; Malignant Neoplasms; Modeling; models and simulation; Natural History; Online Systems; Structure; System; ,Technical and Logistical Support for Cancer Surveillance,,,,,,,,,280102,
9430246,N01,AI,,N,,,,,N01AI000000,,,272201100025C-16-0-1,NIAID:338999\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,12576477; ,"SULLIVAN, KEITH ;",,11/1/2016,10/31/2017,Antithymoglobulin; Autologous; Autologous Transplantation; Blood; CD34 gene; Clinical Trials; Contractor; Cyclophosphamide; Data; Disease-Free Survival; Dose; Enrollment; Intravenous; Multicenter Studies; open label; Phase; Physiologic pulse; Protocols documentation; Randomized; Scleroderma; Stem cell transplant; Systemic Scleroderma; Testing; Therapeutic immunosuppression; Transplantation; Whole-Body Irradiation; ,SCLERODERMA CYCLOPHOSPHAMIDE OR TRANSPLANTION STUDY (SCOT),,,,,,,,,338999,
9430248,N01,AI,,N,,,,,N01AI000000,,,272201300018I-2-27200009-1,NIAID:1360130\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14256237; ,"MULLIGAN, MARK ;",,9/15/2015,9/5/2017,Biological Assay; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; Population; Resources; Route; System; Vaccines; Work; Yellow Fever Vaccine; ,Vaccine and Treatment Evaluation Unit: Assay Work for Yellow Fever Vaccines ,,,,,,,,,1360130,
9430254,N01,DA,,N,,,,,N01DA000000,,,271201400009C-17-0-1,NIDA:168717\OD:162858\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BETHESDA,UNITED STATES,,,57052391,US,,TECHNICAL RESOURCES INC,MD,208171197,,12638912; ,"MOLINA, DANIEL ;",,3/19/2014,3/18/2019,Clinical; Clinical Pharmacology; Clinical Research; Cocaine; Contractor; Contracts; Data; Data Reporting; Development; Drug Kinetics; drug of abuse; Laboratory Study; Monitor; Pharmaceutical Preparations; Pharmacodynamics; Phase; Process; Protocols documentation; Regulation; Reporting; Research Design; Resources; Specific qualifier value; Statistical Data Interpretation; United States Food and Drug Administration; ,IGF::OT::IGF Task Order 4 for Clinical Support for a phase 1 clinical interaction study between lorcaserin and cocaine POP: 08/18/2014 -08/17/2015.,,,,,,,,,331575,
9430258,N01,CA,,N,,,,,N01CP000000,,,261201200006C-12-0-1,NCI:2638379\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,,COSTA RICA,,,853088008,CS,10011285,FUNDACION INCIENSA,,,,14436604; ,"GONZALEZ, PAULA ;",,11/1/2016,4/30/2017,Age; Antibodies; Anus; base; Cervical; Cervix Neoplasms; Cervix Uteri; Clinical; Collaborations; Colposcopy; Communities; Costa Rica; Cytology; DNA; Dose; Effectiveness; efficacy evaluation; Enrollment; Evaluation; follow-up; Funding; high risk; Human papilloma virus infection; Human Papilloma Virus Vaccination; Human Papilloma Virus Vaccine; Human Papillomavirus; Human papillomavirus 16; Immune response; immunogenic; Immunologics; Individual; Infection; Lesion; Malignant neoplasm of cervix uteri; Medical; Methodology; Molecular Conformation; Natural History; Oncogenic; Oral cavity; Participant; particle; Phase; Phase III Clinical Trials; Phylogenetic Analysis; Population; Pregnancy; Pregnancy Rate; Premalignant; prevent; programs; prophylactic; Randomized; Randomized Controlled Trials; Research; Safety; screening; Series; Site; Structural Protein; System; United States National Institutes of Health; Vaccinated; Vaccination; vaccine development; vaccine trial; Vaccines; Virion; virtual; Virus-like particle; Vulva; Woman; Women's Health; young adult; ,HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 VACCINE TRIAL IN COSTA RICA,,,,,,,,,2638379,
9430309,N01,DA,,N,,,,,N01DA000000,,,271201500074C-5-0-2,NIDA:429383\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,NEW YORK,UNITED STATES,,,1503580,US,,SCHOLASTIC INC,NY,100123999,,14381400; ,"MUELLER, MICHAEL ;",,7/31/2015,6/30/2018,addiction; Age; Alcohol or Other Drugs use; Americas; Area; Contracts; Development; Education; experience; Funding; high risk; High School Student; Journals; junior high school; Marketing; Mental Health; National Institute of Drug Abuse; news; outreach; Perception; Pharmaceutical Preparations; physical conditioning; Population; Research; Source; Students; success; Trust; twelfth grade; web site; Youth; ,"IGF::OT::IGF, Educational Outreach to Middle and High School Students, POP: October 1, 2016 to September 30, 2017, Quantity Option 5, N01DA-15-1154.Purpose: To modify Sections B, C, F, and G, and ",,,,,,,,,429383,
9430316,N01,AI,,N,,,,,N01AI000000,,,272201300021I-4-27200004-1,NIAID:485555\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,14165214; ,"HOFT, DANIEL ;",,7/1/2015,5/31/2018,Conduct Clinical Trials; Contracts; design; Evaluation; Individual; infectious disease treatment; Investigation; named group; novel; phase I trial; Population; Resources; Route; System; vaccine candidate; Vaccines; Yellow fever virus; ,Vaccine and Treatment Evaluation Unit: Phase I Trial of a Yellow Fever Virus Vaccine,,,,,,,,,485555,
9430319,N01,DA,,N,,,,,N01DA000000,,,271201600028C-3-0-2,NIDA:697612\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LEXINGTON,UNITED STATES,,6,943117366,US,3514301,"MURTY PHARMACEUTICALS, INC.",KY,405091016,,14759366; ,"MURTY, RAM ;",,9/18/2016,9/17/2021,Clinical; Clinical Research; Communities; Contractor; Cyclic GMP; design; Development; Documentation; Dosage Forms; Drug Incompatibility; Ensure; Excipients; experience; Formulation; insight; Investigation; Investigational Drugs; Investigational New Drug Application; Label; National Institute of Drug Abuse; novel therapeutics; Pharmaceutical Preparations; Pharmacologic Substance; Phase; pre-clinical; Production; Quality Control; Regulation; Research; substance abuse treatment; Testing; United States Food and Drug Administration; Validation; ,IGF::OT::IGF Development & Manufacture of Pharmaceutical Products for the Treatment of Substance Abuse Disorcer. NIDA Ref. No. N01DA-16-8926; POP: 09/18/2016 - 09/17/2021.,,,,,,,,,697612,
9430323,N01,AI,,N,,,,,N01AI000000,,,272201300020I-2-27200009-1,NIAID:92192\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,IOWA CITY,UNITED STATES,,2,62761671,US,3972901,UNIVERSITY OF IOWA,IA,522463111,,14652698; ,"BUSH, DAVID ;",,7/12/2016,7/1/2019,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; named group; Population; programs; protocol development; Resources; Taenia solium; Therapeutic; Trichocephalus trichiura; Vaccines; ,Vaccine and Treatment Evaluation Unit: Concept and Protocol Development,,,,,,,,,92192,
9430326,N01,AI,,N,,,,,N01AI000000,,,272201300021I-2-27200015-2,NIAID:105135\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,14652702; ,"SILER, WILLIAM ;",,7/12/2016,3/31/2018,combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza virus vaccine; named group; Population; programs; protocol development; Resources; Vaccine Clinical Trial; Vaccines; ,Vaccine and Treatment Evaluation Unit - Concept and Protocol Development,,,,,,,,,105135,
9430328,N01,ES,,N,,,,,N01ES000000,,,273201600002I-2-27300008-1,NIEHS:1687816\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,14636713; ,"WAGNER, DAVID ;",,7/11/2016,7/10/2017,Accelerometer; Accreditation; Adverse event; Area; base; Caring; Clinical; clinical care; Clinical Research; Clinical Trials; Contractor; Contracts; Data; data management; Employee; Ensure; experience; federal policy; follow-up; Government; Guidelines; Healthcare; Human Resources; Human Subject Research; Individual; Intervention; Investigation; Joint Commission on Accreditation of Healthcare Organizations; Measures; Medical; Medical Research; Monitor; National Institute of Environmental Health Sciences; Nursing Research; operation; Patient Care; Preventive therapy; Procedures; programs; Protocols documentation; Regulation; Reporting; research study; Research Support; Resources; Risk Reduction; Services; Site; Specimen; Training; Training Programs; ,Clinical Research Support Services for NIEHS Contract Task Order 8 - Staffing,,,,,,,,,1687816,
9430343,N01,AI,,N,,,,,N01AI000000,,,272201300017I-2-27200014-1,NIAID:619820\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,DURHAM,UNITED STATES,,1,44387793,US,2221101,DUKE UNIVERSITY,NC,277054673,,14605363; ,"WALTER, EMMANUEL ;",,6/15/2016,3/15/2019,Antimicrobial Resistance; Bacterial Drug Resistance; Clinical Research; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Diagnostics Research; Individual; Lower Respiratory Tract Infection; named group; pathogen; Population; programs; Resources; Therapeutic Human Experimentation; Translational Research; ,VTEU: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI),,,,,,,,,619820,
9430344,N01,DA,,N,,,,,N01DA000000,,,271201300035C-16-0-1,NIDA:1119379\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,12576691; ,"STOCK, HOWARD ;",,8/23/2013,8/22/2018,Acute; Award; Basic Science; Canis familiaris; Contracts; Data; Development; Dose; Drug Interactions; good laboratory practice; Guidelines; Human; International; Investigational Drugs; Investigational New Drug Application; Laboratory Study; Mission; Monkeys; National Institute of Drug Abuse; novel therapeutics; Oryctolagus cuniculus; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology Study; Pharmacotherapy; pre-clinical; preclinical development; preclinical study; Regulation; research and development; Resource Development; Rodent; Safety; Substance Use Disorder; symposium; Testing; Toxicology; Translations; United States Food and Drug Administration; ,13-8911 award; Other functions,,,,,,,,,1119379,
9430357,N01,HL,,N,,,,,N01HC000000,,,268201400018C-4-0-1,NHLBI:347610\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,12246285; ,"LIMA, JOAO ;",,7/1/2013,6/30/2017,"acquired factor; Address; Adult; Affect; Age; Ancillary Study; Atrial Fibrillation; base; Cardiac; Cardiovascular Diseases; cardiovascular disorder risk; cardiovascular risk factor; Cardiovascular system; Chicago; Clinical; cohort; Communities; Coronary artery; Coronary Artery Risk Development in Young Adults Study; Coronary heart disease; Data; Development; Disease; Echocardiography; Education; emerging adult; Event; Evolution; follow-up; Funding; Heart Abnormalities; Heart failure; high school; Measures; middle age; Myocardial dysfunction; National Heart, Lung, and Blood Institute; novel; Participant; Phenotype; Race; racial disparity; Reading; Research Personnel; Risk; Risk Factors; Sampling; sex; sharing data; stomach cardia; stroke; Structure; Subgroup; Time; Training; Update; young adult; ",IGF::OT::IGF - CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) - ECHOCARDIOGRAPHY READING CENTER,,,,,,,,,347610,
9430370,N01,MH,,N,,,,,N01MH000000,,,271201100005I-1-27100016-1,NEI:80947\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,14569749; ,"THOMPSON, NANCY ;",,6/1/2016,5/31/2017,Brain; Drug Kinetics; Rodent; ,IGF::OT::IGF HHSN27120110005I/HHSN27100016,,,,,,,,,80947,
9521677,N01,HL,,N,,,,,N01HV000000,,,268201300001I-1-26800004-1,NHLBI:60521\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,14576247; ,"CAI, JIANWEN ;",,6/1/2016,12/31/2017,"Acculturation; aged; Area; Cardiovascular Diseases; Central American; Chicago; Chronic Disease; college; Communities; Cuban; cultural values; design; Diabetes Mellitus; Digestive System Disorders; Disease; Dominican; Echocardiography; Enrollment; epidemiology study; Event; Funding; Gestational Diabetes; Health; Health Services Accessibility; Hispanic Community Health Study; Hispanic Community Health Study/Study of Latinos; Hispanics; Hospitals; Illinois; Incidence; Institutes; interest; Journals; Kidney Diseases; Laboratories; Latino; Left Ventricular Hypertrophy; Length; Logistics; Lung diseases; Medical; Medicine; Mexican; migration; mortality; National Heart, Lung, and Blood Institute; New York; North Carolina; Outcome; Participant; Prevalence; Publications; Puerto Rican; Reading; Recruitment Activity; Research; Risk; Risk Behaviors; Role; Services; Socioeconomic Factors; South American; Time; Universities; Woman; ",Hispanic Community Health Study - Study of Latinos,,,,,,,,,60521,
9521678,N01,HL,,N,,,,,N01HL000000,,,268201600013I-2-26800001-1,NHLBI:134987\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,TAMPA,UNITED STATES,,15,139301956,US,3736101,H. LEE MOFFITT CANCER CTR & RES INST,FL,336129497,,14658133; ,"KELLEY, LINDA ;",,8/1/2016,6/30/2018,"Academia; Adverse event; Alpha Cell; Animal Welfare; Antibodies; Archives; Area; authority; base; Biocompatible Materials; Biological; Blood; Cell Therapy; Cells; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consult; Contractor; Contracts; cytokine; Data; Databases; design; Development; Educational Activities; Educational workshop; Ensure; Evaluation; Event; Funding; Geography; Heart; Industry; Infusion procedures; Institution; Institutional Review Boards; interest; Investigational Drugs; Laboratories; Laboratory Animals; Lung; Maintenance; Manuals; Manufacturer Name; manufacturing facility; Manuscripts; material transfer agreement; member; Monitor; National Heart, Lung, and Blood Institute; novel; Office for Human Research Protections; operation; Performance; Phase; preclinical study; Procedures; Process; Production; Professional Organizations; programs; Protocols documentation; Publications; quality assurance; Quality Control; Reagent; Recombinant Proteins; Regulation; Reporting; Research Design; Research Personnel; Sampling; Services; Ships; Site Visit; Testing; Therapeutic Studies; TimeLine; Training; Translational Research; translational study; United States National Institutes of Health; Work; Writing; ",IGF::OT::IGF - Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities,,,,,,,,,134987,
9521681,N01,HD,,N,,,,,N01HD000000,,,275201300009I-4-27500001-1,NICHD:6307\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,CHICAGO,UNITED STATES,,1,5421136,US,1413601,UNIVERSITY OF CHICAGO,IL,606372612,,12445772; ,"GILLIAM, MELISSA ;",,6/26/2015,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Male Contraceptive Agents; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,6307,
9521683,N01,HD,,N,,,,,N01HD000000,,,275201300017I-7-27500001-1,NICHD:9413\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BOSTON,UNITED STATES,,7,5492160,US,3617301,BOSTON MEDICAL CENTER,MA,21182908,,12445778; ,"BORGATTA, LYNN ;",,6/26/2013,6/25/2018,Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Contraceptive Agents; Contraceptive methods; Contracts; Development; Devices; drug candidate; endometriosis; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Gynecologic; Gynecology; Health education; Lead; Leiomyoma; Methods; National Institute of Child Health and Human Development; novel therapeutics; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Reproductive Health; research and development; Safety; Site; Social Welfare; synthetic peptide; Testing; treatment trial; United States Food and Drug Administration; United States National Institutes of Health; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,9413,
9526954,N01,AI,,N,,,,,N01AI000000,,,272201100021I-7-27200005-1,NIAID:479765\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14270529; ,"ISHIKAWA, PHILLIP ;",,9/27/2012,12/31/2018,AIDS prevention; authority; Contracts; Development; Documentation; flexibility; Guidelines; HIV; HIV vaccine; immunogenicity; Investigational Drugs; Investigational New Drug Application; Investigator-Initiated Research; microbicide; Modality; National Institute of Allergy and Infectious Disease; Pamphlets; Phase; preclinical development; Preclinical Testing; Process; Production; Protocols documentation; research clinical testing; Research Personnel; research study; Safety; Testing; Vaccines; ,NIAID Preclinical Development Support - Development of clade C Vaccine,,,,,,,,,479765,
9527705,N01,MH,,N,,,,,N01MH000000,,,271201300028C-9-0-2,NIMH:0\NINDS:463155\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,,,,,4146619,,,,,,,14658145; ,"MASH, DEBORAH ;",,7/5/2017,8/31/2018,"Advocacy; advocacy organizations; Award; base; Biological; Biopsy; Birth; Blood; Brain; brain tissue; Catchment Area; Cause of Death; Centers for Disease Control and Prevention (U.S.); Cephalic; Cessation of life; Classification Scheme; Clinical; Clinical Data; Code; Collaborations; Collection; Common Data Element; Communities; Comorbidity; Contractor; Contracts; Date of birth; Diagnosis; Diagnostic; Disease; disorder control; Documentation; Educational Background; Ethnic Origin; Evaluation; experience; Family; Fetal Tissues; Fibroblasts; First Degree Relative; Future; Genetic screening method; Geography; Gestational Age; Goals; Grant; Hereditary Disease; Hospitalization; Human; human disease; Image; Institutes; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); Judgment; Liver; Magnetic Resonance Imaging; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; Neonatal; nervous system disorder; Neuraxis; Neurodevelopmental Disorder; neuropsychiatric disorder; Onset of illness; outreach; Patients; Pharmaceutical Preparations; Phenotype; phenotypic data; Population; prenatal; Process; Radiology Specialty; Recording of previous events; Recruitment Activity; Reporting; repository; Research; Research Personnel; Sampling; Services; Site; Skin; Source; Specialist; Specimen; stroke; Substance abuse problem; Time; Tissue Banks; Tissues; United States National Institutes of Health; Urine; ",IGF::OT::IGF,,,,,,,,,463155,
9529455,N01,OD,,N,,,,,N01OD000000,,,263201200074I-2-26300066-1,NCI:145000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,14162348; ,"WESTBROOK, DAVID ;",,6/29/2015,6/28/2018,Academia; Address; Area; base; Communities; ethical legal social implication; Family; Family member; Foundations; genetic information; Genomics; Government; Health; Health Professional; Individual; Industry; Institution; interest; Medical; Medicine; Patient Representative; Process; Public Health; Research; Rights; Translating; Translation Process; Translations; ,ROUNDTABLE ON TRANSLATING GENOMIC-BASED RESEARCH FOR HEALTH,,,,,,,,,145000,
9536540,N01,DA,,N,,,,,N01DA000000,,,271201500088C-4-0-1,NICHD:52499\OD:77870\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14264851; ,"KVALE, ELIZABETH ;",,9/18/2015,9/17/2018,case-based; Development; Education; Elements; Evaluation; Funding; medical schools; Methods; Online Systems; Pain; Pain management; Pain Measurement; School Nursing; United States National Institutes of Health; ,NIH PAIN CONSORTIUM CENTERS OF EXCELLENCE IN PAIN EDUCATION,,,,,,,,,130369,
9536544,N01,HD,,N,,,,,N01HD000000,,,275201400003I-2-27500007-1,NICHD:431324\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14256329; ,"PARSONS, CHRISTOPHER ;",,9/9/2016,9/8/2017,Acquired Immunodeficiency Syndrome; Adipose tissue; Adolescent; AIDS/HIV problem; Amniotic Fluid; antiretroviral therapy; base; Blood; blood lipid; Candida; Cell Extracts; Cells; Cervical; Child; Childhood; Clinical; Clinical Trials; Cohort Studies; combat; Communicable Diseases; Contracts; Cryopreserved Cell; cytokine; Data; data management; Dental Plaque; DNA; Dose; Drug Kinetics; Endometrial; Equipment and supply inventories; Erythrocytes; Foundations; Freezing; frontier; Funding; Future; Goals; HIV; HIV Infections; HIV therapy; HIV-exposed uninfected infant; Human; IMPAACT; Infant; Infection; International Maternal Pediatric Adolescent AIDS Clinical Trials; Intervention; Liquid substance; Meconium; Monitor; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; neutrophil; operation; Participant; pediatric human immunodeficiency virus; Perinatal; Pharyngeal structure; Placenta; Plasma; Population; Pregnant Women; Prevention; programs; Protocols documentation; Public Health Schools; repository; Research; Safety; Saliva; Science; Serum; Services; Ships; Site; Specimen; Spottings; support network; Swab; Symptoms; System; Technology; Temperature; Tissues; Umbilical Cord Blood; United States; Urine; Vagina; Vertical Disease Transmission; young woman; Youth; ,REPOSITORY SERVICES FOR THE MATERNAL AND PEDIATRIC INFECTIOUS DISEASES BRANCH SPECIMENS,,,,,,,,,431324,
9537846,N01,AI,,N,,,,,N01AI000000,,,272201700034I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CINCINNATI,UNITED STATES,,1,41064767,US,1523902,UNIVERSITY OF CINCINNATI,OH,452210001,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537860,N01,AI,,N,,,,,N01AI000000,,,272201700040I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,15213147; ,"BEASLEY, DAVID ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537866,N01,AI,,N,,,,,N01AI000000,,,272201700015I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,12043055,US,1965903,"BIOQUAL, INC.",MD,208503336,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537874,N01,AI,,N,,,,,N01AI000000,,,272201700028I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,6,965180610,US,10028042,"SIGMOVIR BIOSYSTEMS, INC.",MD,208506330,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9537879,N01,AI,,N,,,,,N01AI000000,,,272201700027I-0-27200001-1,NIAID:3500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SALISBURY,UNITED KINGDOM,,,233388961,UK,10007041,PUBLIC HEALTH ENGLAND,,,,; ,",  ;",,7/14/2017,7/13/2024,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,3500,
9538110,N01,AI,,N,,,,,N01AI000000,,,272201200003I-1-27200020-1,NIAID:80581\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14734742; ,"HORNBACK, RANDI ;",,8/31/2016,3/15/2018,assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; efficacy testing; Emerging Communicable Diseases; evaluation/testing; Feasibility Studies; immunogenicity; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; Vaccines; Zika virus vaccine; ,Task X20: Clinical Sample Testing for Zika Virus Vaccines ,,,,,,,,,80581,
9538984,N01,HD,,N,,,,,N01HD000000,,,275201200002I-0-27500007-1,NICHD:2849760\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,DURHAM,UNITED STATES,,,803902113,US,,HEALTH DECISIONS INC,NC,277132260,,15151996; ,"DART, CLINT ;",,7/20/2017,7/19/2021,Adverse event; Androgens; Clinical; Clinical Research; Clinical Trials; Contraceptive Agents; contraceptive efficacy; Contraceptive methods; Data; Data Analyses; Data Collection; Databases; Devices; diaries; Drug Approval; drug development; Drug usage; Elements; Enrollment; Evaluation; follow-up; Goals; Guidelines; Logistics; meetings; men; Monitor; Monitoring Clinical Trials; novel therapeutics; Patients; Pharmaceutical Preparations; Preparation; product development; protocol development; Protocols documentation; Recruitment Activity; Regulation; Reporting; research clinical testing; Research Personnel; Safety; Services; Site; Specific qualifier value; Spermatogenesis; Statistical Data Interpretation; System; Task Performances; Visit; Work; ,STATISTICAL AND CLINICAL COORDINATING CENTER FOR CCTN,,,,,,,,,2849760,
9539222,N02,OD,,N,,,,,N02OD000000,,,276201400012C-17-0-1,NIGMS:250000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,,,,,833063253,,,,,,,14270651; ,"BOSAK, ROBERT ;",,8/11/2016,8/10/2018,Computer software; Data; Development; Funding; Services; System; ,"IGF::OT::IGF FOR OTHER FUNCTIONS - PURPOSE OF MODIFICATION 8:  TO ADD FUNDS FOR ERA SOFTWARE SUPPORT SERVICES IN THE AMOUNT OF $1,699,687.00.",,,,,,,,,250000,
9545119,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200008-1,NIAID:158210\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15115085; ,"SWARTZ, GLEN ;",,7/1/2017,6/30/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Animal Model; Biological Markers; Clinical Trials; Communities; Development; Future; Health; HIV; HIV Infections; Inflammation; Licensure; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; research clinical testing; Resources; Role; Services; sexual HIV transmission; Sheep; Study models; Technology; United States National Institutes of Health; Vagina; vaginal microbiome; Work; ,STUDIES TO ASSESS SHEEP VAGINAL MICROBIOME COMMUNITY PROFILES AND VAGINAL HEALTH,,,,,,,,,158210,
9545120,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200007-1,NIAID:1657672\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15115082; ,"PAL, RANAJIT ;",,7/1/2017,6/30/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; animal care; Caring; Clinical Trials; Development; HIV; HIV Infections; Housing; Licensure; Maintenance; microbicide; National Institute of Allergy and Infectious Disease; nonhuman primate; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; product development; Quarantine; research clinical testing; Resources; Role; sexual HIV transmission; Ships; Technology; United States National Institutes of Health; Work; ,NONHUMAN PRIMATE PURCHASE AND HOLDING,,,,,,,,,1657672,
9545270,N01,AI,,N,,,,,N01AI000000,,,272201700081C-0-0-1,NIAID:296286\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,RANCHO DOMINGUEZ,UNITED STATES,,44,58878682,US,3719901,"MOLECULAR EXPRESS, INC.",CA,902205610,,15160663; ,"FUJII, GARY ;",,8/1/2017,7/31/2018,Adjuvant; AIDS prevention; Amino Acid Sequence; Antibodies; Antisense Oligonucleotides; aptamer; base; Businesses; Capsid Proteins; Cell Line; Cells; Circular DNA; Clinic; clinically relevant; Code; Contracts; cytokine; Cytoplasm; Dendritic Cells; Dependovirus; design; Development; Double-Stranded RNA; env Gene Products; Feasibility Studies; Genes; Genetic Engineering; Genetic Transcription; Goals; HIV; HIV Antigens; HIV therapy; HIV vaccine; Human; Immune checkpoint inhibitor; Immune response; improved; In Vitro; in vivo; Incubated; men's group; Messenger RNA; Methods; MicroRNAs; Mus; neutralizing monoclonal antibodies; novel; Nuclear; Oligonucleotides; Pathway interactions; Plasmids; Production; reconstitution; Risk; RNA; RNA chemical synthesis; RNA Instability; RNA Splicing; Series; Small Interfering RNA; Subfamily lentivirinae; System; Technology; Therapeutic; Tissues; Transfection; uptake; Vaccinated; Vaccines; Variant; vector; Virus; Virus-like particle; Women's Group; ,DELIVERY OF SELF-REPLICATING HIV VACCINES USING IN VITRO RECONSTITUTED VIRUS-LIKE PARTICLES,,,,,,,,,296286,
9547708,N01,AI,,N,,,,,N01AI000000,,,272201400029C-5-0-4,NIAID:417450\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NOTRE DAME,UNITED STATES,,2,824910376,US,6169301,UNIVERSITY OF NOTRE DAME,IN,465565708,,14207859; ,"COLLINS, FRANK ;",,9/16/2014,9/15/2018,Archives; Basic Science; Bioinformatics; Black-legged Tick; Communicable Diseases; Communities; Computer Analysis; Data; Equipment; Human; Human Resources; Invertebrates; pathogen; Research; Resources; Services; tool; Update; user-friendly; vector; , Bioinformatics Resource Centers for Infectious Diseases - Invertebrate Vectors of Human Pathogens.,,,,,,,,,417450,
9547976,N01,AI,,N,,,,,N01AI000000,,,272201400010I-0-27200029-1,NIAID:271236\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,15178924; ,"PTAK, ROGER ;",,8/15/2017,8/14/2018,Academia; base; Biochemical; Biological Assay; Biotechnology; Cells; Contracts; Data; Databases; Development; Funding; high throughput screening; HIV; HIV-1; Human; Investigational New Drug Application; Literature; Local Microbicides; National Institute of Allergy and Infectious Disease; novel therapeutics; phase I trial; preclinical development; Private Sector; product development; prospective; Proteins; Public Health; public health priorities; Publishing; Regulatory Element; Research Personnel; service utilization; Services; Source; Therapeutic; Update; ,ANNUAL UPDATE OF THE NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION (NCBI) DATABASE,,,,,,,,,271236,
9549180,N01,AI,,N,,,,,N01AI000000,,,272201100008I-0-27200008-1,NIAID:244200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,WASHINGTON,UNITED STATES,,98,49515844,US,2869001,GEORGETOWN UNIVERSITY,DC,200570001,,15185395; ,"KORBA, BRENT ;",,9/16/2017,9/15/2018,Advanced Development; Biological Assay; Cell Line; Contracts; in vitro testing; Maintenance; screening; Therapeutic; Viral; virus development; ,TASK B27: COMPREHENSIVE VIRAL SCREENING PANEL,,,,,,,,,244200,
9549182,N01,AI,,N,,,,,N01AI000000,,,272201100016I-0-27200014-1,NIAID:670950\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,15185398; ,"PRICHARD, MARK ;",,9/16/2017,9/15/2018,Advanced Development; Biological Assay; Cell Line; Contracts; in vitro testing; Maintenance; screening; Therapeutic; Viral; virus development; ,TASK B27: COMPREHENSIVE VIRAL SCREENING PANEL,,,,,,,,,670950,
9550880,N01,AI,,N,,,,,N01AI000000,,,272201300015I-3-27200005-1,NIAID:359166\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HOUSTON,UNITED STATES,,9,51113330,US,481201,BAYLOR COLLEGE OF MEDICINE,TX,770303411,,14369220; ,"KEITEL, WENDY ;",,11/2/2015,10/14/2018,chikungunya; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Individual; named group; Phase; Phase I Clinical Trials; Population; programs; Resources; vaccine candidate; Vaccine Clinical Trial; ,VTEU: Phase I Chikungunya Vaccine Clinical Trial,,,,,,,,,359166,
9551393,N01,ES,,N,,,,,N01ES000000,,,273201500012C-2-0-1,NIEHS:2915267\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,,WILMINGTON,UNITED STATES,,6,19716729,US,1336801,"CHARLES RIVER LABORATORIES INTNTL, INC.",MA,18871096,,14234575; ,"MORRISON, JAMES ;",,8/24/2015,8/23/2018,Adverse effects; Apoptosis; Autopsy; Award; base; Cancer Etiology; carcinogenicity; Cell Proliferation; Chemicals; Consult; Contracts; Data; Development; developmental toxicity; disorder prevention; DNA; DNA sequencing; Electron Microscopy; Ensure; Environmental Exposure; Evaluation; Exposure to; Funding; Genotype; Goals; Government; Hazard Identification; Histology; Immunohistochemistry; immunotoxicity; In Situ; In Situ Hybridization; Journals; Laboratories; Laboratory Animal Medicine; Laboratory Animals; Manuscripts; Molecular and Cellular Biology; Molecular Biology; molecular pathology; Morphology; National Institute of Environmental Health Sciences; National Toxicology Program; Pathologic; Pathology; Peer Review; Persons; posters; Preparation; Procedures; Public Health; Publications; Reporting; reproductive toxicity; Research Design; Research Personnel; research study; Rivers; RNA; Services; Site; Slide; Specimen; Staining method; Stains; Support Contracts; Techniques; Time; Tissues; Toxic effect; Training; Work; working group; ,Charles River Laboratories (CRL); Contract:HHSN273201500012C ; FY15 funding to fund the base contract award; CAN 8010787; IGF::OT::IGF:: Pathology Peer Review & Pathology Support for DNTP & DIR at NIE,,,,,,,,,2915267,
9553428,N01,CA,,N,,,,,N01CA000000,,,261201200033I-2-26100008-1,NCI:816237\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,14262594; ,"BAILEY, HOWARD ;",,9/24/2017,9/23/2018,cancer prevention; Clinical; Clinical Chemoprevention; Clinical Trials; clinically relevant; Conduct Clinical Trials; Contractor; Data; data management; Development; Division of Cancer Prevention; Drug Industry; Funding; Guidelines; Individual; interest; laboratory experiment; Maintenance; Malignant Neoplasms; meetings; Molecular Target; Monitor; National Cancer Institute; Outcome; Performance; Phase; Prevention; prevention clinical trial; Preventive; programs; protocol development; Protocols documentation; Request for Proposals; Research Infrastructure; Safety; Site; Specific qualifier value; Time; Visit; ,IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT,,,,,,,,,816237,
9553429,N02,LM,,N,,,,,N02LM000000,,,276201500304U-7-0-1,NCI:0\NHLBI:95000\NICHD:100000\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,DURHAM,UNITED STATES,,1,67180786,US,1301901,FAMILY HEALTH INTERNATIONAL,NC,277012478,,14275333; ,"PHILLIPS, TODD ;",,9/29/2015,9/28/2018,Address; Agriculture; Area; Body Weight; built environment; Centers for Disease Control and Prevention (U.S.); Child; Collaborations; Communication; Data; Data Coordinating Center; Diet; disorder prevention; Economics; Educational workshop; effective intervention; effectiveness research; energy balance; Energy Metabolism; Ensure; Environmental Policy; Epidemic; Evaluation; Food; Foundations; Health; Health Food; Health Personnel; Healthcare Systems; Incentives; Individual; Measures; meetings; member; obesity in children; obesity prevention; Physical activity; Policies; Population; Prevention; public-private partnership; Registries; Research; Research Activity; S-nitro-N-acetylpenicillamine; Sales; Science; tool; Translations; United States National Institutes of Health; Update; Wood material; working group; Youth; ,NATIONAL COLLABORATIVE ON CHILDHOOD OBESITY RESEARCH (NCCOR) DATA COORDINATING CENTER,,,,,,,,,195000,
9553992,N01,AI,,N,,,,,N01AI000000,,,272201300014I-0-27200010-1,NIAID:3309642\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SILVER SPRING,UNITED STATES,,8,91340943,US,10007277,"SOCIAL AND SCIENTIFIC SYSTEMS,  INC.",MD,209103737,,15133886; ,"KLAUSNER, JEFFREY ;",,7/14/2017,3/13/2019,Antimicrobial Resistance; Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; Development; Devices; Evaluation; experience; Human Resources; Laboratories; Leadership; Neisseria gonorrhoeae; point-of-care diagnostics; protocol development; Research Infrastructure; sample collection; Sexually Transmitted Diseases; Training; ,Sexually Transmitted Infections Clinical Trial Group: Clinical Study of Point-of-Care Diagnostics   ,,,,,,,,,3309642,
9555906,N01,CA,,N,,,,,N01CA000000,,,261201200031I-2-26100008-1,NCI:109227\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,TUCSON,UNITED STATES,,3,806345617,US,490201,UNIVERSITY OF ARIZONA,AZ,857210158,,14255881; ,"CHOW, SHERRY ;",,9/1/2017,8/31/2018,Address; Arizona; base; Biological Markers; Blood; British Columbia; C-Peptide; California; cancer biomarkers; Cancer Center; cancer risk; Clinical; Clinical Trials; cytokine; DNA; Epidermal Growth Factor Receptor; Erythroplasia; Genes; Glucose; Glycosylated hemoglobin A; Goals; Growth; Histologic; IL8 gene; Individual; Inflammatory; Intervention; Lesion; malignant mouth neoplasm; Malignant Neoplasms; Metabolic; Metformin; Minnesota; Molecular; Molecular Target; Monitor; Oncogenes; Oral; oral cancer prevention; Oral Leukoplakia; Organic Cation Transporter; Phase; polypeptide C; Premalignant; prevent; PTEN gene; response; Saliva; Serum; Tissues; TP53 gene; Universities; Vascular Endothelial Growth Factors; , M4OC-PREVENT:  METFORMIN FOR ORAL CANCER PREVENTION,,,,,,,,,109227,
9556091,N01,HD,,N,,,,,N01HD000000,,,275201500002I-3-27500002-1,NICHD:890602\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14256341; ,"BAUGHMAN, KATHRYN ;",,9/4/2015,9/3/2018,Biological Testing; Contraceptive Agents; Contraceptive methods; Interruption; Maintenance; men; Mission; National Institute of Child Health and Human Development; new product development; nonhuman primate; preclinical development; Primates; programs; Woman; ,BIOLOGICAL TESTING FACILITY - MAINTENANCE OF EXISTING NON-HUMAN PRIMATE COLONY,,,,,,,,,890602,
9559799,N01,AI,,N,,,,,N01AI000000,,,272201300002I-0-27200017-1,NIAID:715267\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15200714; ,"PAL, RANAJIT ;",,9/1/2017,8/15/2018,Adjuvant; Advanced Development; AIDS Vaccine Development; AIDS Vaccines; Award; base; Clinical; Complement; Contracts; Development; DNA; Evaluation; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; immunogenicity; Inulin; Investigator-Initiated Research; Local Microbicides; Modality; National Institute of Allergy and Infectious Disease; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; Prevention; Prevention strategy; programs; Proteins; Research Personnel; Research Project Grants; Resources; vaccine candidate; Vaccine Design; vaccine evaluation; Vaccine Research; Vaccines; ,Evaluation of the Immunogenicity and Efficacy of a DNA Prime/Protein Boost Vaccine,,,,,,,,,715267,
9559811,N01,AI,,N,,,,,N01AI000000,,,272201600008I-0-27200011-1,NIAID:394121\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15190093; ,"PAL, RANAJIT ;",,9/1/2017,8/31/2018,Acquired Immunodeficiency Syndrome; AIDS prevention; Clinical Trials; Development; HIV; HIV Infections; Licensure; microbicide; National Institute of Allergy and Infectious Disease; Play; pre-clinical; pre-exposure prophylaxis; prevent; Prevention; Prevention strategy; Preventive vaccine; product development; research clinical testing; Resources; Role; sexual HIV transmission; Technology; United States National Institutes of Health; Work; ,COMPREHENSIVE RESOURCES FOR HIV MICROBICIDES AND BIOMEDICAL PREVENTION,,,,,,,,,394121,
9562944,N01,HD,,N,,,,,N01HD000000,,,275201400003I-6-27500001-1,NICHD:56539\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,12447089; ,"PARSONS, CHRISTOPHER ;",,9/23/2016,9/22/2017,Acquired Immunodeficiency Syndrome; Adolescent; AIDS clinical trial group; Alcohols; Antioxidants; base; Biological; Blood; Blood specimen; brain tissue; Calcium; Caring; Child; Childhood; Chronic; Cohort Studies; Collection; Contract Services; Contractor; Contracts; Development; Dry Ice; efficacy trial; endometriosis; Ensure; Equipment and supply inventories; European; Freezing; Genetic; Government; Health; HIV; HIV Infections; House Dust; Human; Human Resources; Infection; International; Interruption; Laboratories; Liquid substance; Longitudinal Studies; Maternal-Fetal Medicine Units Network; Methods; Molds; Monitor; Mother-to-child HIV transmission; Multicenter Neonatal Research Network; National Children's Study; National Institute of Child Health and Human Development; Nitrogen; pediatric AIDS; pediatric human immunodeficiency virus; Performance; Perinatal; Phase; Pre-Eclampsia; premature; prenatal; Prevention; Program Research Project Grants; programs; repository; Research; Research Personnel; sample collection; Sampling; Services; Ships; Site; Specific qualifier value; Specimen; Spermatocidal Agents; Stillbirth; Sudden infant death syndrome; Testing; Tissue Banks; Tissues; Urine; Vagina; Women's Health; Women?s Interagency HIV Study; Work; ,HUMAN BIOSPECIMEN REPOSITORY  ,,,,,,,,,56539,
9563035,N01,CA,,N,,,,,N01CA000000,,,261201500039I-1-26100004-1,NCI:476619\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW YORK,UNITED STATES,,12,60217502,US,1514803,WEILL MEDICAL COLL OF CORNELL UNIV,NY,100654805,,1873540; ,"LIPKIN, STEVEN M;",,9/19/2016,9/18/2019,adenoma; Adenomatous Polyposis Coli; African American; Age; Anaerobic Bacteria; Antigen-Presenting Cells; Antigens; APC gene; ApcMin/+ mice; Bacterial Adhesins; base; Binding; Biological; cancer cell; Cancer Etiology; cancer risk; Cell physiology; Cell Proliferation; Cell-Mediated Cytolysis; cigarette smoking; Clinical; Codon Nucleotides; cohort; Colon Carcinoma; Colonic Adenoma; Colorectal; Colorectal Adenoma; Colorectal Cancer; Colorectal Neoplasms; Colorectal Polyp; Containment; Data; Dental Plaque; design; Development; Diagnosis; Disease; Distant; Distant Metastasis; DNA; Dysplasia; E-Cadherin; Endothelial Cells; Engineering; Enhancers; Epithelial Cells; Family history of; Feces; Fusobacteria; Fusobacterium nucleatum; gene repair; Genetic; Germ-Line Mutation; Gram-Negative Bacteria; Hepatitis B; Hereditary Nonpolyposis Colorectal Neoplasms; high risk; Human; Human Papilloma Virus Vaccine; Immune; Immune Evasion; Immunity; immunogenic; immunogenicity; Immunoglobulins; improved; In Vitro; in vivo; Incidence; Individual; Infection; Infection prevention; Infectious Agent; Inflammatory Bowel Diseases; Inherited; Intestinal Neoplasms; Intestines; ITIM; Lead; Ligands; lymph nodes; Malignant neoplasm of cervix uteri; Malignant neoplasm of gastrointestinal tract; Malignant Neoplasms; Measures; Mediating; Membrane; Membrane Lipids; Microsatellite Instability; Mismatch Repair; Modeling; Morbidity - disease rate; mortality; mouse model; Nanostructures; Natural Killer Cells; neoplastic cell; Non-Insulin-Dependent Diabetes Mellitus; Nonsense Mutation; Obesity; Oncogenic; Oral; Organ; pathogen; Patients; Peptides; Play; Population; Prevalence; Preventive; Preventive vaccine; Primary carcinoma of the liver cells; Proteins; Race; receptor; Recording of previous events; Regulatory T-Lymphocyte; Risk; Risk Factors; Role; Signal Pathway; Signal Transduction; Surface; Survival Rate; Syndrome; System; T-Lymphocyte; Time; Tissues; tumor; tumor growth; tumor microenvironment; tumorigenesis; tumorigenic; Tumorigenicity; Vaccines; Vesicle; Virulence Factors; Wild Type Mouse; ,IGF::OT::IGF ANTI FUSOBACTERIUM NUCLEATUM VACCINE FOR COLORECTAL CANCER IMMUNOPREVENTION,,,,,,,,,476619,
9564745,N02,OD,,N,,,,,N02OD000000,,,316201200028W-2-0-1,NIDDK:90000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,ROCKVILLE,UNITED STATES,,,829601645,US,,,MD,208521631,,14091088; ,"WHITLEY, MARY ;",,9/22/2016,9/21/2018,AIDS/HIV problem; Biomedical Research; Clinical Research; Communications Media; Companions; Complementary and alternative medicine; Conduct Clinical Trials; Contractor; Contracts; Databases; Development; Environmental Health; environmental toxicology; evidence base; General Population; Genetic; Goals; Health; health knowledge; Health Personnel; Health Resources; Home environment; improved; Information Services; Internet; Language; Literature; Medical; Mission; multidisciplinary; named group; National Center for Complementary and Alternative Medicine; Online Systems; Patients; Practice Guidelines; Prevention; programs; Public Health; Publishing; Registries; Research; Research Personnel; Resources; Services; social media; Toxicology; United States; United States National Institutes of Health; web site; Women's Health; ,AIDSinfo Service,,,,,,,,,90000,
9430371,N01,AI,,N,,,,,N01AI000000,,,272201100012I-1-27200010-1,NIAID:970\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,6900526,US,7657001,SOUTHERN RESEARCH INSTITUTE,AL,352052708,,14634881; ,"RICHTER, STEFAN ;",,7/16/2016,7/15/2017,Advanced Development; Anthrax disease; Anti-Bacterial Agents; Antifungal Agents; Antimicrobial Resistance; biodefense; Biological Assay; Contracts; Development; Emerging Communicable Diseases; In Vitro; in vitro testing; Maintenance; pathogen; Pseudomonas aeruginosa; screening; therapeutic development; ,Task A25: In vitro screening for antibacterial activity against biodefense and emerging infectious disease pathogens,,,,,,,,,970,
9430372,N01,AI,,N,,,,,N01AI000000,,,272201500014C-5-0-1,NIAID:2015511\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,,,,,218591088,,,,,,,14164955; ,"DAWSON, MICHAEL J. ;",,7/1/2015,12/12/2017,Acinetobacter baumannii; Antimicrobial Resistance; bacterial resistance; carbapenem-resistant Enterobacteriaceae; Clinical; clinical development; Communicable Diseases; drug candidate; Future; In Vitro; in vivo; infectious disease treatment; Klebsiella pneumonia bacterium; Lead; novel; pathogen; Pharmaceutical Chemistry; pre-clinical; Pseudomonas aeruginosa; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases,,,,,,,,,2015511,
9430376,N01,HD,,N,,,,,N01HD000000,,,275201300024I-3-27500005-1,NICHD:537175\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,TORRANCE,UNITED STATES,,43,69926962,US,2543101,LA BIOMED RES INST/ HARBOR UCLA MED CTR,CA,905022006,,12447390; ,"WANG, CHRISTINA ;",,9/30/2014,6/30/2017,Admission activity; Androgens; Attitude; Blood specimen; Chemistry; Clinical Trials; Clinical Trials Network; Contraceptive Agents; contraceptive efficacy; Contraceptive History; Contraceptive methods; Contraceptive Usage; demographics; diaries; Drug Kinetics; Eligibility Determination; eligible participant; Enrollment; Evaluation; Formulation; Future; Gel; Gonadotropins; Informed Consent; Instruction; Interview; Laboratories; man; Medical History; men; Methods; Moods; National Institute of Child Health and Human Development; Nestorone; Pharmaceutical Preparations; Pharmacodynamics; Phase; Physical Examination; Pregnancy; Preparation; Procedures; Production; Progestins; Property; Prostate; Protocols documentation; Randomized; Recruitment Activity; Regimen; Reproductive History; reversible contraceptive; Sampling; Schedule; screening; Seminal fluid; Sex Functioning; Specimen; sperm cell; Spermatogenesis; Steroids; Study Subject; Symptoms; Testing; Testosterone; Urinalysis; Urine; Visit; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - MALE 28 DAY NES TES,,,,,,,,,537175,
9433586,N02,CA,,N,,,,,N02CA000000,,,261201600006I-1-26100001-2,NCI:2136305\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCKVILLE,UNITED STATES,,8,161157953,US,3601801,"FISHER BIOSERVICES, INC.",MD,208505312,,14438381; ,"SMALLWOOD, DOUG ;",,3/1/2017,2/28/2018,Archives; Biological; cancer diagnosis; cancer therapy; Chemicals; chemotherapeutic agent; Contractor; Contracts; Data; Databases; Development; Developmental Therapeutics Program; drug synthesis; Equipment and supply inventories; Evaluation; Extramural Activities; flexibility; Goals; National Cancer Institute; National Institute of Allergy and Infectious Disease; Natural Products; Pharmaceutical Preparations; pre-clinical; Preclinical Drug Evaluation; Program Evaluation; programs; repository; Research; Research Personnel; Sampling; Screening for cancer; Services; Shipping; small molecule; small molecule therapeutics; Therapeutic Agents; Therapeutics for Rare and Neglected Diseases; United States National Institutes of Health; Update; ,"Title: Registration, Storage and Distribution of Chemicals and Drugs for Pre-Clinical Discovery, Evaluation and Development",,,,,,,,,2136305,
9434110,R21,HL,1,N,12/26/2017,12/22/2017,11/30/2018,839,R21HL135285,,PAR-16-441,1R21HL135285-01A1,NHLBI:250500\,Non-SBIR/STTR RPGs,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,MILWAUKEE,UNITED STATES,,4,57163172,US,5304801,"BLOODCENTER OF WISCONSIN, INC.",WI,532332121,,9954214; ,"BOUGIE, DANIEL ;","ZOU, SHIMIAN",12/22/2017,11/30/2019,"Acute; Adverse reactions; Alloantigen; Amino Acids; Animal Model; Antibodies; Antibody titer measurement; Antigen-Antibody Complex; Antigens; Autoantibodies; Autoimmune Diseases; Autoimmunity; Autologous; autoreactive B cell; autoreactivity; B-Cell Activation; B-Lymphocytes; Bacteria; Binding; Blood Cells; Blood Circulation; Blood Platelets; Blood Transfusion; Complementarity Determining Regions; Disease; Epitopes; Evolution; experience; Exposure to; Fatal Outcome; Future; Genetic; Genetic Polymorphism; Germ Lines; Glycoproteins; Grant; Human; Human Platelet Antigens; Immune; Immune response; Immune system; Immune Tolerance; Immunity; Immunization; immunogenic; Immunoglobulin G; Immunoglobulin Somatic Hypermutation; Individual; Injectable; Integrins; Isoantibodies; isoimmunity; Lead; Membrane Glycoproteins; Modeling; Molecular; mouse model; Mouse Strains; Mus; Pathogenesis; Patients; Pharmaceutical Preparations; Pregnancy; Process; Production; Public Health; Purpura; Reaction; Receptors, Antigen, B-Cell; Recombinants; Recovery; Reporting; response; Serological; Serum; Specificity; System; T-Lymphocyte; Thrombocytopenia; Time; Tissues; Transfusion; Virus; ",Molecular basis of transfusion-induced auto-immunity,135285,ZRG1,Special Emphasis Panel ,,A1,1,150000,100500,250500,
9437648,N01,AI,,N,,,,,N01AI000000,,,272201300006C-9-0-3,NIAID:1140113\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,12582707; ,"ALTMAN, JOHN ;",,3/21/2013,3/20/2020,Alleles; Antigens; biodefense; Custom; Disease; Human; Immune; Immunology; improved; Major Histocompatibility Complex; Mediating; microbial; Mus; Neoplasm Metastasis; new technology; nonhuman primate; pathogen; Peptides; Production; Reagent; Research; T-Lymphocyte; tumor; United States National Institutes of Health; ,Tetramers for Biodefense Research,,,,,,,,,1140113,
9438756,R25,HL,2,N,12/21/2017,12/24/2017,11/30/2018,838,R25HL084762,SCHOOLS OF MEDICINE,RFA-HL-16-008,2R25HL084762-11,NHLBI:117059\,OTHER RESEARCH-RELATED,2018,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,INTERNAL MEDICINE/MEDICINE,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,8807727; 1882904 (contact); ,"DAMARLA, MAHENDRA ; SHIMODA, LARISSA A. (contact);","TIGNO, XENIA",5/1/2006,11/30/2022,"Admission activity; Advisory Committees; Area; Award; base; Behavioral Sciences; Biomedical Research; Blood; Breathing; career; Clinical Research; cohort; Communication; Complement; Complex; Critical Care; design; Development; Disadvantaged; Education Projects; Enrollment; Environment; Exhibits; experience; Exposure to; Faculty; Fellowship; Foundations; Functional disorder; Funding; Goals; Health; Heart; Individual; Institution; Interview; Journals; Length; Lung; Medical; medical schools; Medicine; member; Mentors; National Heart, Lung, and Blood Institute; Participant; Play; Positioning Attribute; posters; Process; programs; Publications; Recruitment Activity; Research; Research Personnel; Research Training; Review Literature; Role; Running; Scholarship; Schools; Science; skills; student mentoring; Students; success; summer research; Talents; Time; Training; Training Programs; undergraduate student; Underrepresented Students; young man; young woman; ",Short-Term Training Program to Increase Diversity in Health-Related Research,84762,ZHL1,Special Emphasis Panel ,,,11,108388,8671,117059,
9441645,N01,AI,,N,,,,,N01AI000000,,,272201000040I-1-27200012-1,NIAID:643620\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,GALVESTON,UNITED STATES,,14,800771149,US,578406,UNIVERSITY OF TEXAS MED BR GALVESTON,TX,775555302,,14721623; ,"BARTON, CONNIE ;",,8/31/2016,3/16/2018,Animal Model; antimicrobial; Antimicrobial Resistance; Contracts; Development; diabetic; efficacy testing; Escherichia coli; infectious disease model; Modeling; Mus; Standardization; Testing; therapeutic evaluation; Translational Research; vaccine evaluation; ,Task A104: Refining the Model of diabetic murine UTI for testing antimicrobial therapies for E. coli,,,,,,,,,643620,
9445370,N02,CA,,N,,,,,N02CA000000,,,261201600195P-2-0-1,NCI:159000\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MELVILLE,UNITED STATES,,,192736499,US,,,NY,117473515,,14660047; ,"LEVERICH, WALDEN ;",,3/1/2017,2/28/2018,Computer software; Institutional Review Boards; ,IRB Manager Software,,,,,,,,,159000,
9447089,N02,DA,,N,,,,,N02DA000000,,,271201500086C-3-0-1,NINDS:14961\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MOUNTAIN VIEW,UNITED STATES,,18,602744732,US,2083701,"CCS ASSOCIATES, INC.",CA,940430816,,14256105; ,"HANSEN, KAREN ;",,9/14/2017,9/13/2018,Biological Assay; Chemistry; Clinical Pharmacology; Contracts; Development; drug development; drug discovery; Drug Industry; Drug Kinetics; drug metabolism; experience; Funding; Industry; Institutes; Lead; Leadership; Maps; Medical; National Institute of Neurological Disorders and Stroke; Neurosciences; Neurosciences Research; Pharmaceutical Chemistry; Pharmacologic Substance; Phase; Phase I Clinical Trials; Principal Investigator; Program Development; programs; Regulatory Affairs; Research; Research Contracts; Research Personnel; Services; Toxicology; United States National Institutes of Health; Writing; ,NINDS BPN REGULATORY AFFAIRS CONSULTANT CCS ASSOCIATES IGF::CL::IGF,,,,,,,,,14961,
9452780,N01,AI,,N,,,,,N01AI000000,,,272201100022I-9-27200003-4,NIAID:511740\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,1934548; ,"MIRSALIS, JON C;",,4/17/2017,4/16/2018,Chemistry; Contracts; Development; Intervention; National Institute of Allergy and Infectious Disease; Plasmodium falciparum; pre-clinical; programs; Services; Therapeutic Human Experimentation; therapy development; Translational Research; ,Task Order 3: Interventional Agent Development Services Program,,,,,,,,,511740,
9455945,R21,HD,1,N,12/30/2017,12/30/2017,11/30/2018,865,R21HD091974,,PA-16-161,1R21HD091974-01A1,NICHD:251376\,Non-SBIR/STTR RPGs,2018,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,BOSTON,UNITED STATES,,7,71723084,US,2133701,JOSLIN DIABETES CENTER,MA,22155306,,9959863; 2084822 (contact); ,"ISGANAITIS, ELVIRA MARIE; PATTI, MARY E (contact);","MOSS, STUART B",12/30/2017,11/30/2019,Adult; Bariatrics; Bioinformatics; Body Weight decreased; cost effective; Data; Development; diabetes control; diabetes management; Diabetes Mellitus; Diet; Disease; disease phenotype; disorder risk; DNA Methylation; DNA Sequence; Embryo; Environmental Exposure; Epidemic; Epigenetic Process; epigenome; Exercise; Experimental Models; fasting glucose; Fathers; Female; Foundations; Future; Gene Expression; Generations; Genes; Genetic Transcription; Genetic Variation; Glucose; Glucose Intolerance; glycemic control; Glycosylated hemoglobin A; Goals; Health; high risk; histone modification; Human; improved; in utero; Individual; Insulin; Insulin Resistance; intergenerational; Interruption; Intervention; lipid metabolism; Lipids; Long-Term Effects; male; male health; Malnutrition; man; Maternal Health; Mediating; Medical; men; Metabolic; Metabolic Diseases; Metabolic syndrome; Metabolism; methylation pattern; Mitotic; Modeling; mouse model; Mus; Non-Insulin-Dependent Diabetes Mellitus; novel; nutrition; Obesity; obesity risk; offspring; Outpatients; Pattern; Phenotype; Physiological; Pregnancy; programs; Recording of previous events; response; Risk; RNA; RNA methylation; Rodent; Sampling; Seminal fluid; Shapes; sperm cell; stem; Stimulus; Supplementation; targeted treatment; Testing; Tissue-Specific Gene Expression; translational study; transmission process; Untranslated RNA; Variant; Vitamins; Weight maintenance regimen; ,Impact of Metabolic Health in Type 2 Diabetes on Sperm Epigenetic Marks in Humans: A Novel Intergenerational Mechanism for Metabolic Disease Risk Transmission,91974,CIDO,Clinical and Integrative Diabetes and Obesity Study Section ,,A1,1,150000,101376,251376,
9457206,N01,HL,,N,,,,,N01HB000000,,,268201100002I-9-26800003-1,NHLBI:437639\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,RESEARCH TRIANGLE,UNITED STATES,,4,4868105,US,6939101,RESEARCH TRIANGLE INSTITUTE,NC,277092194,,12446065; ,"BRAMBILLA, DONALD ;",,3/15/2013,3/14/2019,Address; Adult; Affect; Area; Basic Science; Biometry; Blood; Clinical Research; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; data management; Data Set; Databases; Development; Documentation; Ensure; Epidemic; Epidemiology; Evaluation Studies; expiration; HIV; improved; International; international center; Laboratories; Laboratory Study; Link; Manuals; Medical; Medicine; member; Monitor; Observational Study; Online Systems; operation; Patient Education; Patients; Privatization; Procedures; programs; protocol development; Protocols documentation; Public Health; Publications; Research; Research Activity; Research Personnel; Resources; Retrieval; Risk; Safety; Secure; Site; Site Visit; Surveys; System; Training; Training and Education; Transfusion; Translational Research; transmission process; web site; ,Recipient Epidemiology and Donor Evaluation Study III (REDS-III) DCC,,,,,,,,,437639,
9457210,N01,AI,,N,,,,,N01AI000000,,,272201300012I-3-27200008-1,NIAID:204317\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BIRMINGHAM,UNITED STATES,,7,63690705,US,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,AL,352940001,,14244132; ,"HOOK, EDWARD W. ;",,9/8/2015,5/31/2017,Biological; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Cooperative Group; efficacy study; experience; Human Resources; Laboratories; Leadership; Phase; Phase II Clinical Trials; protocol development; Research Infrastructure; safety study; sample collection; Sexually Transmitted Diseases; Therapeutic; Training; Vaginitis; ,PHASE II SAFETY AND EFFICACY STUDY OF A TREATMENT FOR VAGINITIS,,,,,,,,,204317,
9458641,N01,AI,,N,,,,,N01AI000000,,,272201200005I-3-27200018-2,NIAID:250000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,14190994; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; novel vaccines; pathogen; Phase; Process; product development; Reagent; Services; Toxicology; United States Food and Drug Administration; vaccine development; Vaccines; Virus; Yellow Fever Vaccine; ,Task X18: Process Development and Early Reagent Manufacturing for Vaccines and Other Biologics,,,,,,,,,250000,
9458643,N01,DA,,N,,,,,N01DA000000,,,271201400033C-10-0-1,NIDA:500000\OD:169291\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ANN ARBOR,UNITED STATES,,12,73133571,US,1506502,UNIVERSITY OF MICHIGAN,MI,481091276,,12627814; ,"PIENTA, AMY ;",,8/1/2014,3/31/2018,addiction; Archives; Contracts; Data; data archive; Drug abuse; HIV; Services; Social Sciences; ,IGF::OT::IGF Drug Abuse and HIV Data Archive; POP 8/1/2014 - 3/31/2018; FY14 N01DA-14-5576,,,,,,,,,669291,
9459266,N01,AI,,N,,,,,N01AI000000,,,272201000017I-3-27200001-1,NIAID:50000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ALBUQUERQUE,UNITED STATES,,1,45911138,US,679302,LOVELACE BIOMEDICAL & ENVIRONMENTAL RES,NM,871085129,,14973646; ,"HARROD, KEVIN ;",,3/22/2010,3/21/2017,Animal Model; animal model development; Communicable Diseases; Contracts; Development; efficacy testing; infectious disease model; Research Infrastructure; Standardization; ,ANIMAL MODELS OF INFECTIOUS DISEASES SUPPORT,,,,,,,,,50000,
9459802,N01,AI,,N,,,,,N01AI000000,,,272201400004C-9-0-2,NIAID:1679200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ATLANTA,UNITED STATES,,5,66469933,US,2384501,EMORY UNIVERSITY,GA,303224250,,14467894; ,"ORENS, WALTER A. ;",,4/1/2014,3/31/2021,Animals; Birds; Environmental Risk Factor; Evolution; Immune; Immune response; improved; Influenza; influenzavirus; Molecular; pandemic disease; Pathogenicity; Research; transmission process; Vaccination; Vaccine Research; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,1679200,
9460280,N01,HD,,N,,,,,N01HD000000,,,275201300026I-4-27500003-1,NICHD:302912\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,12649372; ,"CLEMONS, TRACI ;",,2/6/2014,5/31/2018,cell motility; Clinical; Couples; Data Collection; Data Coordinating Center; Diet; DNA; DNA Fragmentation; Embryo; Enrollment; Fertilization; Fertilization in Vitro; Folic Acid; folic acid supplementation; Goals; Human Chorionic Gonadotropin; implantation; improved; Incidence; infertility treatment; Intervention; Intracytoplasmic Sperm Injections; men; Morphology; Placebos; Pregnancy; Procedures; Public Health; Recruitment Activity; Reproductive Health; Research; Seminal fluid; sperm cell; Supplementation; System; Treatment outcome; Zinc Sulfate; Zinc supplementation; ,DATA COORDINATING CENTER - FASST,,,,,,,,,302912,
9462599,N01,HL,,N,,,,,N01HL000000,,,268201500001I-4-26800001-1,NHLBI:4730595\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BOSTON,UNITED STATES,,7,604483045,US,894901,BOSTON UNIVERSITY MEDICAL CAMPUS,MA,21182340,,14099624; ,"RAMACHANDRAN, VASAN ;",,5/18/2015,3/31/2017,Abdomen; adipokines; African American; Age; American Indians; Area; Asians; Atherosclerosis; base; Behavior; Biochemical; Bioinformatics; Biological Markers; Blood; Boston; Bronchodilator Agents; calcification; Calcified; Calcium; Cell Line; Clinical; Coagulation Process; cognitive function; cohort; Communities; Complement; Complex; Contracts; Coronary; Data; detector; Development; Disease; DNA; DNA Resequencing; Environment; Environmental Risk Factor; Family; Fatty acid glycerol esters; follow-up; Framingham Heart Study; Funding; Generations; Genes; Genetic; genetic analysis; Genetic study; Genome; Genotype; Grant; Heart; Hispanics; Hormonal; Imaging Techniques; immortalized cell; inflammatory marker; innovation; Insulin Resistance; Knowledge; Laboratories; Lipids; Lipoproteins; Longitudinal cohort study; Lung; Measurement; Measures; Minority; Obesity; offspring; Participant; Persons; Phenotype; phenotypic data; Physical activity; Physical Function; Privacy; Process; pulmonary function; Recruitment Activity; Renal function; Research Personnel; Resources; Rest; Risk Factors; Scanning; Sleep; Spirometry; Structure of parenchyma of lung; Techniques; Time; United States National Institutes of Health; Universities; Visceral; X-Ray Computed Tomography; ,IGF::OT::IGF FRAMINGHAM HEART STUDY (FHS) - TASK ORDER 01,,,,,,,,,4730595,
9463727,N01,NS,,N,,,,,N01NS000000,,,271201500005I-5-27100002-1,NEI:388443\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,ALBANY,UNITED STATES,,20,787793900,US,3294801,"ALBANY MOLECULAR RESEARCH, INC.",NY,122035121,,12651328; ,"REILLY, JOHN ;",,1/15/2015,3/31/2019,Age related macular degeneration; All-Trans-Retinol; analytical method; Animal Model; Atrophic; Binding; Binding Sites; Biological Assay; Blood Circulation; Chemicals; clinical efficacy; Clinical Trials; Complex; Contractor; Contracts; counterscreen; Cytoplasmic Granules; cytotoxic; Data; Development; Documentation; Dosage Forms; drug candidate; drug development; drug distribution; Drug Kinetics; efficacy study; Formulation; glomerular filtration; Goals; good laboratory practice; Grant; inhibitor/antagonist; Investigational Drugs; Investigational New Drug Application; Label; Legal Blindness; Lipofuscin; macula; Mediating; method development; Neurodegenerative Disorders; Neurons; novel therapeutics; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Phase I Clinical Trials; Photoreceptors; pre-clinical; Prealbumin; preclinical efficacy; Preparation; Process; Production; programs; RBP4 gene; Regulation; Retina; Retinal Cone; Retinal Degeneration; retinal rods; Safety; Serum; small molecule; Specificity; Structure of retinal pigment epithelium; support network; Testing; United States Food and Drug Administration; United States National Institutes of Health; uptake; Validation; Vision; visual cycle; Wallerian Degeneration; Work; ,IGF::OT::IGF DMFP - TASK ORDER NO. 2 PETRUKHIN BPN-14967,,,,,,,,,388443,
9463732,N01,AI,,N,,,,,N01AI000000,,,272201400006C-10-0-1,NIAID:11796860\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MEMPHIS,UNITED STATES,,9,67717892,US,7893501,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,TN,381053678,,12651370; ,"WEBBY, RICHARD ;",,4/1/2014,3/31/2021,Animals; Area; Avian Influenza; base; Basic Science; Biological; Birds; Control Animal; Development; Disease; Domestic Animals; Effectiveness; Epidemiology; Human; Influenza; Influenza A virus; influenzavirus; interest; International; Maintenance; Measures; migratory bird; Molecular; pandemic disease; Pathogenicity; Research; Role; Serological; Surveillance Program; virology; wild bird; ,CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS),,,,,,,,,11796860,
9471284,N01,AI,,N,,,,,N01AI000000,,,272201200005I-4-27200005-1,NIAID:229955\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,12643073; ,"RICHARDSON, JAMES ;",,7/20/2012,7/19/2022,Bioterrorism; cell bank; Chemistry; Chlamydia; Chlamydia trachomatis; Clinical Research; Communicable Diseases; Contracts; Cyclic GMP; Development; Development Plans; Drug resistance; Emerging Communicable Diseases; National Institute of Allergy and Infectious Disease; novel vaccines; pathogen; Phase; pre-clinical; product development; programs; Reporting; Services; Toxicology; trachoma vaccine; United States Food and Drug Administration; vaccine development; Vaccines; ,Task X5: Master Cell Bank for Chlamydia Trachoma Vaccine,,,,,,,,,229955,
9471755,N01,AI,,N,,,,,N01AI000000,,,272201200003I-2-27200015-1,NIAID:45643\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLUMBUS,UNITED STATES,,3,7901598,US,685902,BATTELLE CENTERS/PUB HLTH RES & EVALUATN,OH,432012693,,14475082; ,"HORNBACK, RANDI ;",,10/13/2015,6/30/2017,Animal Model; assay development; Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; Ebola Vaccines; efficacy testing; Emerging Communicable Diseases; Evaluation; evaluation/testing; Feasibility Studies; Filoviridae; Filovirus; immunogenicity; novel; novel vaccines; pathogen; Phase; product development; safety testing; Sampling; Services; Testing; Toxicity Tests; vaccine development; Vaccines; ,Task X15:  Evaluation of Ebolavirus and Other Filovirus Vaccines in a Novel Animal Model,,,,,,,,,45643,
9478005,N01,CA,,N,,,,,N01CA000000,,,261201300013I-4-26100005-2,NCI:1732798\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LEXINGTON,UNITED STATES,,6,939017877,US,2793601,UNIVERSITY OF KENTUCKY,KY,405260001,,14511283; ,"TUCKER, THOMAS ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,1732798,
9478653,N01,CA,,N,,,,,N01CA000000,,,261201300021I-4-26100005-2,NCI:1030922\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,NEW BRUNSWICK,UNITED STATES,,6,78728091,US,10034166,RBHS -CANCER INSTITUTE OF NEW JERSEY,NJ,89011914,,14509885; ,"STROUP, ANTOINETTE ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTURCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER)PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,1030922,
9478662,N01,CA,,N,,,,,N01CA000000,,,261201300011I-3-26100005-2,NCI:4317134\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,DETROIT,UNITED STATES,,13,1962224,US,9110501,WAYNE STATE UNIVERSITY,MI,482024050,,14509881; ,"SCHWARTZ, ANN ;",,5/1/2015,4/30/2018,Cancer Burden; Cancer Control; Cancer Etiology; Cancer Patient; cancer risk; cancer therapy; Diagnosis; Disease; Geography; Incidence; Malignant Neoplasms; Monitor; National Cancer Institute; National Cancer Program; operation; Patients; Periodicity; Population; Reporting; Research Infrastructure; Resources; response; SEER Program; Social Characteristics; Subgroup; Time; Treatment-Related Cancer; trend; United States; ,"IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2017",,,,,,,,,4317134,
9478813,N01,AI,,N,,,,,N01AI000000,,,272201500009C-3-0-1,NIAID:882497\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SOUTH SAN FRANCISCO,UNITED STATES,,14,167293153,US,10005405,"ACHAOGEN, INC.",CA,940801945,,14164943; ,"HILLAN, KENNETH ;",,7/1/2015,1/15/2018,Bacterial Drug Resistance; Burkholderia pseudomallei; Clinical; clinical development; Communicable Diseases; drug candidate; Future; Gram-Negative Bacteria; In Vitro; in vivo; infectious disease treatment; Lead; Multi-Drug Resistance; novel; Pharmaceutical Chemistry; pre-clinical; Pseudomonas aeruginosa; Series; small molecule; Testing; Therapeutic; therapeutic development; Toxic effect; ,Optimizing Lead Therapeutic Compounds Against Infectious Diseases,,,,,,,,,882497,
9483436,N01,HD,,N,,,,,N01HD000000,,,275201300023I-0-27500011-1,NICHD:791278\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MINNEAPOLIS,UNITED STATES,,5,555917996,US,1450402,UNIVERSITY OF MINNESOTA,MN,554552070,,15032413; ,"TSAI, MICHAEL ;",,9/9/2013,5/9/2019,Area; base; Birth; Blood; Child; Chromosomes; Code; Congenital Abnormality; Copy Number Polymorphism; cost; Data; design; DNA; Etiology; exome; exome sequencing; Family; Genetic; Genome; genome sequencing; genome-wide analysis; Genomics; Health; Investigation; Paper; Pathway interactions; Prevalence; Process; Recurrence; Research; Sampling; Sex Characteristics; Single Nucleotide Polymorphism; Spottings; Technology; Testing; Variant; whole genome; ,GENETIC FACTORS IN BIRTH DEFECTS-GENOMIC TESTING ,,,,,,,,,791278,
9486535,N01,DA,,N,,,,,N01DA000000,,,271201600008I-1-9999-1,NINDS:41500\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,WESTLAKE VILLAGE,UNITED STATES,,,14266581,US,,,CA,913626420,,; ,",  ;",,9/30/2016,9/29/2018,Achievement; Address; Area; assay development; base; Biochemical; Biological Assay; Cells; Chemistry; Clinical; Clinical Research; Clinical Trials; Consult; Consultations; Contractor; Contracts; Data; Data Analyses; design; Development; drug development; drug discovery; Drug Kinetics; drug metabolism; Electronic Mail; Experimental Designs; experimental study; Feedback; Formulation; Future; in vitro Assay; Individual; innovation; Investigational Drugs; Lead; Logistics; member; Modeling; Peer Review; Pharmaceutical Chemistry; pre-clinical; preclinical safety; Process; programs; Protocols documentation; Research Design; Resources; Role; Services; Shapes; small molecule; Strategic Planning; symposium; Time; United States National Institutes of Health; Validation; Work; ,PEARSON PHARMA PARTNERS:1198214 [16-013035]IGF::CL::IGF,,,,,,,,,41500,
9509318,N01,DA,,N,,,,,N01DA000000,,,271201500065C-6-0-1,NIDA:4069336\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14223651; ,"LINDBLAD, ROBERT ;",,8/14/2015,8/13/2018,Area; Award; base; Behavioral; Clinical; Clinical Research; Clinical Trials Network; Consultations; Contracts; drug testing; Goals; Laboratories; meetings; Monitor; National Institute of Drug Abuse; Pharmaceutical Services; protocol development; Protocols documentation; Research; research and development; Research Support; Services; Specific qualifier value; symposium; Training; Work; ,IGF::OT::IGF  PURPOSE: TO AWARD THE BASE PERIOD FOR CLINICAL RESEARCH COORDINATING CENTER FOR THE NIDA CTN POP: 08/14/2015-08/13/2016.,,,,,,,,,4069336,
9511958,N01,HL,,N,,,,,N01HL000000,,,268201700002C-0-0-1,NHLBI:792047\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,WILLOWBROOK,UNITED STATES,,1,79748462,US,10038531,"DUPAGE MEDICAL TECHNOLOGY, INC.",IL,605271896,,14921892; ,"GU, MINYI ;",,11/15/2016,11/14/2019,Animals; Aortic Aneurysm; Area; Clinical Trials; Coronary Arteriosclerosis; Development; Disease; Dissection; drug production; Fibrinolytic Agents; Generations; inhibitor/antagonist; Integrins; interest; intracranial artery; Lymphatic Diseases; Lymphatic System; Medical Technology; Methods; novel; Peripheral arterial disease; Pharmaceutical Preparations; product development; programs; Pulmonary Hypertension; pulmonary vascular disorder; scale up; Signal Transduction; Testing; Thrombosis; Vascular Diseases; Venous; Work; ,IGF::OT::IGF DEVELOPING AN INHIBITOR OF INTEGRIN OUTSIDE-IN SIGNALING AS A NEW GENERATION OF ANTI-THROMBOTIC DRUG,,,,,,,,,792047,
9517631,N01,HD,,N,,,,,N01HD000000,,,275201300008I-4-27500001-1,NICHD:11592\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,PORTLAND,UNITED STATES,,3,96997515,US,6297007,OREGON HEALTH & SCIENCE UNIVERSITY,OR,972393098,,12445660; ,"JENSEN, JEFFREY ;",,6/26/2013,6/25/2018,Adverse effects; Biological Assay; Chemicals; Clinical Research; clinical research site; Clinical Trials; Clinical Trials Network; Conduct Clinical Trials; Contraceptive Agents; contraceptive effectiveness; Contraceptive methods; Contracts; Data; Development; Devices; drug candidate; Drug Kinetics; Female; Female Contraceptive Agents; Formulation; Goals; Grant; Health education; Hemorrhage; Hormones; Laboratories; Lead; Measures; Methods; Mission; National Institute of Child Health and Human Development; novel; novel therapeutics; Obesity; Pattern; Pharmaceutical Preparations; Phase; Phase IV Clinical Trials; Population Research; pre-clinical; protocol development; Protocols documentation; Reproductive Health; research and development; Risk; Safety; Site; Social Welfare; synthetic peptide; Testing; Thromboembolism; unintended pregnancy; United States Food and Drug Administration; United States National Institutes of Health; Venous; Woman; ,CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE,,,,,,,,,11592,
9519626,N01,AI,,N,,,,,N01AI000000,,,272201600011I-1-27200002-1,NIAID:897313\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,NEW YORK,UNITED STATES,,10,20790895,US,10019434,INTERNATIONAL AIDS VACCINE INITIATIVE,NY,100042400,,14759394; ,"DEY, ANTU ;",,9/21/2017,9/20/2018,assay development; base; Basic Science; Chemistry; Clinic; Clinical Trials; Contracts; Development; env Gene Products; HIV; HIV Infections; HIV vaccine; Immunology; Investigational New Drug Application; manufacturing process development; Molecular Biology; National Institute of Allergy and Infectious Disease; novel vaccines; Phase; prevent; Process; product development; Proteins; Recombinants; vaccine development; Vaccines; ,PURIFICATION OF HIV ENV PROTEINS WITH AN IMMUNOAFFINITY BASED PROCESS,,,,,,,,,897313,
9521482,N01,AI,,N,,,,,N01AI000000,,,272201400037C-5-0-1,NIAID:3451231\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,6,78706021,US,10034768,"PRECISION BIOSERVICES, INC.",MD,217014765,,14619993; ,"PHIPPARD, DEBORAH ;",,9/30/2017,9/29/2018,Adult; AIDS clinical trial group; AIDS Treatment Research; AIDS Vaccines; Aliquot; Biological; Catalogs; Clinical; Cohort Studies; computerized; Cryopreservation; Database Management Systems; Ensure; Epidemiology; Equipment and supply inventories; Freezing; Future; Heterosexuals; HIV; HIV prevention trials network; HIV Vaccine Trials Network; Human; Human Resources; National Institute of Allergy and Infectious Disease; novel; operation; pediatric AIDS; Procedures; Process; programs; quality assurance; Quality Control; repository; Secure; Services; Shipping; Ships; Specimen; Support System; Technology; The Multicenter AIDS Cohort Study; transmission process; vaccine evaluation; Women?s Interagency HIV Study; ,NIAID SPECIMEN REPOSITORY,,,,,,,,,3451231,
9566448,N01,CA,,N,,,,,N01CA000000,,,261201500018I-0-26100004-1,NCI:775035\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HOUSTON,UNITED STATES,,9,800772139,US,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,770304009,,15221481; ,"BROWN, POWEL ;",,6/15/2017,6/14/2019,adenoma; Adenomatous Polyposis Coli; Age; Animals; Clinical; Clinical Trials; Colonic Neoplasms; Colorectal Cancer; colorectal cancer prevention; Coupled; Diet; Dose; Duodenum; Erlotinib; Ethnic Origin; Etiology; Gastrointestinal tract structure; Gender; Genetic; Geographic Locations; Growth; improved; Individual; Inherited; Intestines; lifestyle factors; Long-Term Effects; Modeling; mortality; Non-Steroidal Anti-Inflammatory Agents; Operative Surgical Procedures; Patients; Pharmaceutical Preparations; pharmacodynamic biomarker; polyposis; Polyps; pre-clinical; predictive marker; Prevention; Prevention strategy; Reducing Agents; Regimen; Resistance development; Risk; Schedule; standard of care; Sulindac; Syndrome; Toxic effect; Treatment Efficacy; Treatment Protocols; tumor; ,IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/2019,,,,,,,,,775035,
9566534,N01,AI,,N,,,,,N01AI000000,,,272201600004I-0-27200002-1,NIAID:101642\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15211119; ,"ZIV, SANDALON ;",,9/11/2017,2/10/2018,assay development; Attenuated; base; Biological Products; Biotechnology; Cholera; Development; Development Plans; Documentation; Evaluation; Formulation; Infectious Diseases Research; Monoclonal Antibodies; Peptide Nucleic Acids; Plasmids; preclinical development; Process; product development; programs; Recombinant Proteins; Services; Small Interfering RNA; therapeutic development; Translational Research; vector; Vibrio cholerae; ,TASK A1: Product Development Plan for Cholera Product,,,,,,,,,101642,
9568148,N01,AI,,N,,,,,N01AI000000,,,272201400004I-0-27200006-1,NIAID:140370\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HIGHLAND HEIGHTS,UNITED STATES,,,184227809,US,,,KY,410769167,,15183697; ,"KIRKBY, MATTHEW ;",,8/18/2017,11/30/2019,Clinical; Clinical Research; Communicable Diseases; Laboratories; National Institute of Allergy and Infectious Disease; research study; Research Support; Services; ,CLINICAL CENTRAL LABORATORY SERVICES ,,,,,,,,,140370,
9568702,N01,EY,,N,,,,,N01EY000000,,,263201300005C-10-0-1,NEI:256644\OD:100000\,Non SBIR/STTR Contracts,2017,NATIONAL EYE INSTITUTE,,ROCKVILLE,UNITED STATES,,8,96360284,US,1381101,EMMES CORPORATION,MD,208501737,,14255937; ,"CLEMONS, TRACI ;",,9/26/2013,9/25/2018,age related; aged; Ancillary Study; Archives; Ascorbic Acid; Authorization documentation; Back; base; Beta Carotene; Biometry; Calendar; Cataract; Cataract Extraction; Certification; Cessation of life; clinical research site; cohort; Collaborations; Communication; Consent Forms; Consultations; Contractor; Contracts; Data; Data Analyses; Data Collection; data management; Data Set; Databases; Development; Diagnosis; Diagnostic; Disease; Documentation; Dose; electronic data; Electronic Mail; Enrollment; Ensure; Event; experience; Eye diseases; follow-up; Follow-Up Studies; Formulation; Health; Health Insurance Portability and Accountability Act; indexing; Individual; Information Technology; Informed Consent; lens; Life Style; Link; Lutein; Malignant neoplasm of lung; Malignant Neoplasms; Manuals; Medical; Medical Records; meetings; Methods; Modification; Monitor; mortality; Nutritional Study; Oral; Outcome; Paper; Participant; Pathology; Performance; Physicians; Policies; Press Releases; Procedures; Process; Protocols documentation; Publications; Randomized Controlled Clinical Trials; randomized trial; Recording of previous events; Reporting; Resources; Retinal; Risk; Safety; Schedule; Secure; Security; Services; Site; Slide; Source; Standardization; Surveys; System; Telephone Interviews; Testing; Training; Translational Research; Update; Validation; Visit; Vitamins; web site; Writing; zeaxanthin; Zinc; ,Age Related Eye Disease Study 2 - Follow-on Study,,,,,,,,,356644,
9568920,N43,CA,,N,,,,,N43CA000000,,,261201700040C-0-0-2,NCI:223808\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,MIAMI,UNITED STATES,,24,35354070,US,4474801,"INFOTECH SOFT, INC.",FL,331313207,,15228049; ,"BUENDIA, PATRICIA ;",,9/11/2017,6/10/2018,base; Bioinformatics; Biological; Biology; Biometry; cancer imaging; Catalogs; Classification; Communities; Complex; Computer software; Computers; Controlled Vocabulary; Correlation Studies; Data; Data Analyses; data format; data integration; Data Set; Data Sources; Data Storage and Retrieval; data visualization; database schema; design; Detection; Dimensions; Documentation; Ensure; experimental study; Feedback; Gene Chips; genetic signature; genome sequencing; Glioblastoma; Goals; Graph; graphical user interface; high throughput analysis; Image; imaging modality; improved; in vivo imaging; Individual; Ingestion; innovative technologies; insight; knowledge base; Malignant Neoplasms; Measurement; Medical Imaging; metabolome; metabolomics; Metadata; Methods; Modeling; Molecular; multiple omics; next generation sequencing; Ontology; Pathway interactions; Phase; Phenotype; precision medicine; Process; product development; Proteome; Proteomics; Protocols documentation; prototype; public health research; Quality Control; radiomics; Reporting; repository; Research; Retrieval; Sampling; Slice; Software Engineering; Source; Structure; System; Systems Analysis; Techniques; Technology; Testing; The Cancer Genome Atlas; tool; transcriptome; transcriptomics; tumor; user centered design; Vocabulary; ,Platform for High-Throughput Analysis of Integrated Cancer Imaging and Multi-Omics Data,,,,,,,,,223808,
9569067,N01,AI,,N,,,,,N01AI000000,,,272201100022I-0-27200011-5,NIAID:284619\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064949; ,"MIRSALIS, JON ;",,6/6/2017,6/5/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; reagent testing; Services; Staphylococcus aureus; therapeutic development; Toxicology; Toxin; ,Task 11: Interventional Agent Development Services Program,,,,,,,,,284619,
9569069,N01,AI,,N,,,,,N01AI000000,,,272201100022I-0-27200011-6,NIAID:3017090\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064949; ,"MIRSALIS, JON ;",,6/6/2017,6/5/2018,Antimicrobial Resistance; Chemistry; Communicable Diseases; Development; Development Plans; Diagnostic; Evaluation; Hypersensitivity skin testing; Image; In Vitro; in vivo; Intervention; Lead; pathogen; preclinical development; preclinical safety; programs; Pseudomonas aeruginosa; reagent testing; Services; therapeutic development; Toxicology; Toxin; ,Task 11: Interventional Agent Development Services Program,,,,,,,,,3017090,
9569529,N01,AI,,N,,,,,N01AI000000,,,272201500007I-0-27200004-1,NIAID:1472261\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,HINCKLEY,UNITED STATES,,16,966783706,US,10023022,"CLINICAL RESEARCH MANAGEMENT, INC.",OH,442339801,,15266207; ,"GRIFFISS, J. MCLEOD ;",,9/14/2017,9/20/2019,Communicable Diseases; Dengue Virus; immunoregulation; infectious disease treatment; Investigation; novel therapeutics; Phase I Clinical Trials; Therapeutic; therapeutic evaluation; ,Phase 1 Clinical Trial Units for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for Dengue Virus ,,,,,,,,,1472261,
9569763,N01,HL,,N,,,,,N01HL000000,,,268201700005I-0-26800002-1,NHLBI:41761\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,CHAPEL HILL,UNITED STATES,,4,608195277,US,578206,UNIV OF NORTH CAROLINA CHAPEL HILL,NC,275990001,,14921916; ,"HEISS, GERARDO ;",,12/19/2016,8/31/2017,"African American; Age; aged; Alaska Native; American Indians; Appointment; Atherosclerosis Risk in Communities; Award; Behavioral; Biological Markers; Biomedical Research; Biometry; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; career; Caring; Cessation of life; Clinic; Clinical; Clinical Nursing; cohort; Cohort Studies; Communities; Contracts; Coronary heart disease; County; demographics; design; Dietary intake; Disabled Persons; Educational process of instructing; Eligibility Determination; Environmental Risk Factor; epidemiology study; Ethnic group; Etiology; Event; experience; Faculty; faculty support; Family; Funding; Genetic; Genetic Markers; Grant; Health; Health Status; Heart failure; Hispanic Americans; Incidence; Individual; Inpatients; Longitudinal trends; Measurement; Medical; member; men; Monitor; mortality; Myocardial Infarction; National Heart, Lung, and Blood Institute; Native Hawaiian; Natural History; Outcome; Outcomes Research; Outpatients; Pacific Island Americans; parent grant; Participant; Performance; Principal Investigator; Probability Samples; programs; prospective; psychosocial; pulmonary function; Qualifying; Race; Recruitment Activity; Research; Research Personnel; Research Project Grants; Research Support; Risk Factors; skills; Social Sciences; stroke; Support Contracts; Telephone; Time; trend; Underrepresented Groups; Ventricular Dysfunction; Washington; Woman; ","IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - FIELD CENTER; DIVERSITY SUPPLEMENT PERIOD OF PERFORMANCE: DECEMBER 19, 2016 - AUGUST 31, 2017",,,,,,,,,41761,
9570331,N01,AI,,N,,,,,N01AI000000,,,272201700013C-0-0-1,OD:1958323\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,ROCKVILLE,UNITED STATES,,8,113033224,US,10000826,"MESO SCALE DIAGNOSTICS, LLC",MD,208503126,,14966613; ,"SIGAL, GEORGE ;",,3/15/2017,3/14/2018,Algorithms; base; biodosimetry; Biological Assay; Biological Markers; biomarker panel; Blood; Data; Devices; Emergency Situation; Goals; Immunoassay; mass casualty; Nuclear Radiology; Patients; Performance; Plasma; Population; programs; Radiation; radiation absorbed dose; Sampling; Testing; Triage; Validation; ,HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY,,,,,,,,,1958323,
9570997,N01,AI,,N,,,,,N01AI000000,,,272201400045C-2-0-1,NIAID:300000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,LA JOLLA,UNITED STATES,,52,603880287,US,2465301,LA JOLLA INST FOR ALLERGY & IMMUNOLGY,CA,920371387,,15275085; ,"SETTE, ALEX ;",,4/27/2016,9/29/2018,Acute; Address; Adult; Affect; aged; Area; Attenuated Live Virus Vaccine; Award; Binding; Bioterrorism; Child; Clinical; clinical development; Communities; Computer software; Contractor; Contracts; Data; Databases; Dengue; Dengue Hemorrhagic Fever; Dengue Virus; Diagnostic; Disease; Emerging Communicable Diseases; Epitopes; General Population; Hospitalization; Hospitals; Human; Immune; immunogenicity; In Vitro; Individual; Infection; microorganism; multidisciplinary; Peripheral Blood Mononuclear Cell; Phase; Population; programs; Research; Severities; Sri Lanka; T-Lymphocyte; T-Lymphocyte Epitopes; tool; Vaccination; Vaccines; Validation; validation studies; Virus; Virus Diseases; volunteer; ,"Global Identification of Dengue Virus Epitopes Following Exposure, Vaccination, and Acute Infection",,,,,,,,,300000,
9571355,N02,HD,,N,,,,,N02HD000000,,,275201700994P-0-0-1,NICHD:23000\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,SAN DIEGO,UNITED STATES,,52,621516145,US,10027826,POLYPEPTIDE LABORATORIES SAN DIEGO,CA,921264310,,15327860; ,"NA, NA ;",,8/1/2017,7/31/2018,analog; Androgens; Animals; Area; Cattle; chemical synthesis; Chemicals; Clinical Research; Contraceptive Agents; Contraceptive methods; Contractor; Contracts; Development; Drug Kinetics; Estrogens; Generations; Government; Haptens; Heterocyclic Compounds; Histamine; Investigation; Laboratories; Link; metabolic abnormality assessment; Nandrolone; National Institute of Child Health and Human Development; novel; Optics; Oral; Peptide Synthesis; Peptides; Pharmaceutical Preparations; preclinical study; Progesterone Receptors; programs; Radioimmunoassay; Radiolabeled; Reproductive Health; Serum; Services; Steroids; Testing; Testosterone; Tracer; unnatural amino acids; ,PEPTIDE SYNTHESIS FACILITY,,,,,,,,,23000,
9571717,N01,AI,,N,,,,,N01AI000000,,,272201300022I-0-27200019-1,NIAID:595200\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,BALTIMORE,UNITED STATES,,7,188435911,US,820104,UNIVERSITY OF MARYLAND BALTIMORE,MD,212011508,,15146694; ,"KOTLOFF, KAREN ;",,7/12/2017,7/11/2018,Clinical; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Malaria Vaccines; named group; operation; Population; programs; protocol development; Resources; Vaccines; ,VACCINE TREATMENT AND EVALUATION UNITS: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,595200,
9572249,N01,AI,,N,,,,,N01AI000000,,,272201700059C-0-0-18,NIAID:495151\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SEATTLE,UNITED STATES,,7,70967955,US,1116301,SEATTLE BIOMEDICAL RESEARCH INSTITUTE,WA,981095240,,15152078; ,"MYLER, PETER ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Organism; pathogen; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES,,,,,,,,,495151,
9572807,N01,AI,,N,,,,,N01AI000000,,,272201700010I-0-27200002-1,NIAID:2302002\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,KENSINGTON,UNITED STATES,,8,94888294,US,319502,"ADVANCED BIOSCIENCE LABORATORIES, INC.",MD,208951042,,15266222; ,"MACK, FRED ;",,9/28/2017,9/27/2022,Antigens; Clinical Trials; Contractor; Contracts; Cyclic GMP; Databases; Development; Documentation; efficacy study; Equipment and supply inventories; Formulation; HIV Envelope Protein gp120; HIV vaccine; HIV-1; Human; immunogenicity; In Vitro; Investigational Drugs; Laboratories; Laboratory Animals; National Institute of Allergy and Infectious Disease; Pharmaceutical Preparations; Phase; plasmid DNA; preclinical development; Preclinical Testing; Preventive vaccine; product development; Production; Proteins; Protocols documentation; prototype; quality assurance; Quality Control; research clinical testing; Shipping; stability testing; Testing; Toxicology; Vaccines; Viral Vector; ,"Fill-Finish, Release, and Stability Testing of HIV-1 gp120 Proteins",,,,,,,,,2302002,
9573395,N43,CA,,N,,,,,N43CA000000,,,261201700026C-0-0-1,NCI:224631\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GLENDALE,UNITED STATES,,,189055101,US,,,CA,91203,,15237250; ,"BELGAUM, JAGDISH ;",,9/18/2017,6/17/2018,Address; Adoption; Architecture; cancer care; care delivery; Caring; Clinical; Complex; Computer software; Data; Data Collection; Data Sources; Decision Making; design; Goals; Health; Health Planning; improved; Informatics; Information Systems; interoperability; Malignant Neoplasms; Measures; medical specialties; member; oncology; Patients; prototype; Provider; Reporting; Research; Site; Software Design; System; Testing; tool; usability; webinar; ,IGF::OT::IGF Informatics Tools to Measure Cancer Care CoordinationPOP:  09/18/2017-06/17/2018,,,,,,,,,224631,
9573739,N01,HD,,N,,,,,N01HD000000,,,275201500002I-0-27500008-1,NICHD:383726\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15242219; ,"PARMAN, TOUFAN ;",,9/27/2017,9/26/2018,Acetates; Adrenal Cortex Hormones; Adrenal Glands; Androgen Antagonists; Androgens; animal care; Animal Welfare Act; Animals; Anti-inflammatory; Anti-Inflammatory Agents; Antibodies; Area; base; Bioinformatics; Biological Assay; Biological Testing; Caring; Clinical; Clinical Chemistry; Clinical Trials; Collaborations; Contraceptive Agents; Contraceptive Availability; Contraceptive Devices; contraceptive target; Contract Services; Contractor; Data; Databases; design; Development; Devices; Discipline; Dose; drug discovery; Drug Formulations; drug testing; efficacy evaluation; Endocrine; Estradiol; Estrogen Antagonists; Estrogens; Estrone; Ethinyl Estradiol; Evaluation; Excretory function; Female; Female Contraceptive Agents; Fertility; Fertilization; Fetal Growth; Follicle Stimulating Hormone; Glucocorticoids; Government; Grant; Growth and Development function; Guidelines; Hematology; Hormones; Housing; Human; Hydrocortisone; implantation; In Vitro; in vivo; inhibin; Internet; Investigational Drugs; Investigational New Drug Application; irritation; Knowledge; Laboratory Animals; Levonorgestrel; leydig interstitial cell; Literature; male; Male Contraceptive Agents; Mining; Monkeys; National Institute of Child Health and Human Development; next generation; nonhuman primate; Norethindrone; novel; novel strategies; Oryctolagus cuniculus; Pathology; Pharmaceutical Preparations; Pharmacology; Phase; Policies; pre-clinical; preclinical evaluation; preclinical safety; Pregnancy Maintenance; Preparation; Process; Progesterone; Progestins; programs; Protocols documentation; receptor binding; Regulation; reproductive; Research Personnel; Rodent; Safety; sertoli cell; Services; Site; Specific qualifier value; Sperm Maturation; sperm morphology; Sperm Motility; Sperm Transport; Spermatogenesis; stability testing; Stanolone; System; Testing; Testosterone; therapeutic candidate; Thyrotropin; Toxic effect; Toxicology; Tracer; United States Public Health Service; Urinalysis; user-friendly; Vagina; web app; web page; web site; Work; zygote; ,BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET WEB APPLICATION,,,,,,,,,383726,
9573748,N01,AI,,N,,,,,N01AI000000,,,272201700060C-0-0-17,NIAID:106821\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,CHICAGO,UNITED STATES,,7,5436803,US,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,IL,606113152,,15151990; ,"SATCHELL, KARLA ;",,9/1/2017,8/31/2018,Basic Science; Biological; Biomedical Research; Categories; Communicable Diseases; Dimensions; Emerging Communicable Diseases; Goals; Molecular; National Institute of Allergy and Infectious Disease; Organism; pathogen; Plasmodium vivax; programs; Proteins; Research Project Grants; Research Support; Role; structural biology; structural genomics; Structure; Technology; three dimensional structure; ,Structural Genomics Centers for Infectious Diseases,,,,,,,,,106821,
9573813,N01,AI,,N,,,,,N01AI000000,,,272201300021I-0-27200019-2,NIAID:106026\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,SAINT LOUIS,UNITED STATES,,1,50220722,US,7915401,SAINT LOUIS UNIVERSITY,MO,631032006,,15151975; ,"HOFT, DANIEL ;",,7/12/2017,7/11/2018,"Birds; combat; Communicable Diseases; Conduct Clinical Trials; Contracts; design; Evaluation; Individual; Influenza A virus; Influenza A Virus, H5N1 Subtype; named group; Population; programs; protocol development; Protocols documentation; Resources; vaccine trial; Vaccines; ",VACCINE TREATMENT AND EVALUATION UNITS: CONCEPT AND PROTOCOL DEVELOPMENT,,,,,,,,,106026,
9574378,N01,AI,,N,,,,,N01AI000000,,,272201200001C-11-0-2,NIAID:484926\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,FREDERICK,UNITED STATES,,,13872747,US,,,MD,217039401,,14922102; ,"THADIKONDA, PAUL ;",,1/1/2012,12/31/2016,biodefense; Clinical; Clinical Research; Clinical Trials; Conduct Clinical Trials; Contracts; Equipment and supply inventories; Immune Tolerance; Investigation; Label; Placebos; Preparation; Regulation; Research Personnel; research study; Services; ,CLINICAL PRODUCTS CENTER for Biodefense,,,,,,,,,484926,
9574404,N01,AI,,N,,,,,N01AI000000,,,316201200036W-0-0-2,NIAID:1383666\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MCLEAN,UNITED STATES,,,962048695,US,,NORTHROP GRUMMAN SYSTEMS,VA,221027508,,; ,",  ;",,9/30/2017,9/29/2022,analytical tool; Bioinformatics; Clinical Data; Contracts; data access; Data Collection; data integration; Data Storage and Retrieval; Databases; Development; Disease; Environment; Funding; Immune; Immunology; Information Technology; interoperability; Mediating; Methods; novel; Production; quality assurance; Research; Research Infrastructure; Services; tool; ,The Immunology Database and Analysis Portal (ImmPort) for Immune-Mediated Diseases,,,,,,,,,1383666,
9574469,N01,AI,,N,,,,,N01AI000000,,,272201500013I-0-27200007-1,NIAID:3160619\OD:9920588\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15266210; ,"CHANG, POLLY ;",,9/1/2015,8/31/2020,animal efficacy; authority; Award; Clinical; Contract Services; Contracts; Documentation; efficacy study; Evaluation; Formulation; good laboratory practice; Human; Medical; Medical Licensure; National Institute of Allergy and Infectious Disease; Nuclear; Pharmacology Study; product development; Radiation; Radiation Injuries; Radiology Specialty; Research; research and development; Safety; Services; stability testing; Strategic Planning; United States Dept. of Health and Human Services; United States Food and Drug Administration; United States National Institutes of Health; ,Radiation/Nuclear Medical Countermeasure (MCM) Product Development Support Services,,,,,,,,,13081207,
9574543,N01,AI,,N,,,,,N01AI000000,,,272201600007C-3-0-2,NIAID:606111\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,MADISON,UNITED STATES,,2,161202122,US,578503,UNIVERSITY OF WISCONSIN-MADISON,WI,537151218,,15019570; ,"KULOW, RACHEL ;",,6/1/2017,9/30/2018,AIDS/HIV problem; Alleles; Communities; Development; exome sequencing; Frequencies; gene discovery; Genes; Genetic; Genome; genomic profiles; Genomics; Genotype; Goals; Haplotypes; HIV; HIV/SIV vaccine; Immune; Immunoglobulins; improved; Killer Cells; killer immunoglobulin-like receptor; knowledge base; Macaca; Major Histocompatibility Complex; Major Histocompatibility Complex Gene; Methods; nonhuman primate; Program Development; Proteins; receptor; Receptor Gene; reference genome; Reproducibility; Research; Technology; technology development; vaccine trial; Variant; ,NON-HUMAN PRIMATE MAJOR HISTOCOMPATIBILITY COMPLEX ALLELE DISCOVERY AND TYPING TECHNOLOGY AND DEVELOPMENT - HIV/AIDS,,,,,,,,,606111,
9574794,N43,CA,,N,,,,,N43CA000000,,,261201700017C-0-0-1,NCI:293728\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,LEXINGTON,UNITED STATES,,6,79703270,US,10038664,"HERA TESTING LABORATORIES, INC.",KY,40505,,15240605; ,"YESHI, TSETEN ;",,9/19/2017,6/18/2018,Advanced Malignant Neoplasm; Adverse effects; African; Animals; Appalachian Region; Asians; base; Cancer Etiology; cancer health disparity; Cancer Model; Cancer Patient; Cancer Survivorship; Cell Line; Cells; Cessation of life; chemotherapeutic agent; chemotherapy; Chemotherapy-Oncologic Procedure; clinical predictors; Comorbidity; comparative; Cryopreservation; Disease Progression; Drug resistance; Economics; Engraftment; Epidermal Growth Factor Receptor; exome; Generations; Genes; Genotype; Growth; Hot Spot; implantation; individualized medicine; KRAS2 gene; Malignant neoplasm of lung; Minority; Modeling; Mutation Analysis; NOD/SCID mouse; Non-Small-Cell Lung Carcinoma; Patients; Phenotype; Population; preclinical study; Rattus; Research; response; Rodent; Sampling; SCID Mice; Serial Passage; Small Business Innovation Research Grant; Specimen; Survival Rate; targeted treatment; Therapeutic; Toxic effect; Transplantation; tumor; Tumor-Derived; Xenograft Model; Xenograft procedure; ,IGF::OT::IGF SBIR TOPIC 355: Cell and Animal-Based Models to Advance Cancer Health Disparity Research. To contribute to studies of cancer health disparities by generating several patient-derived xenog,,,,,,,,,293728,
9575641,N01,CA,,N,,,,,N01CA000000,,,261201200042I-0-26100013-1,NCI:390096\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,ROCHESTER,UNITED STATES,,1,6471700,US,4976101,MAYO CLINIC ROCHESTER,MN,559050001,,15200699; ,"LIMBURG, PAUL ;",,9/1/2017,8/31/2018,anti-IgG; Antibody titer measurement; base; Colon Carcinoma; high risk; immunogenic; immunogenicity; Individual; Malignant neoplasm of lung; Mucin 1 protein; Pilot Projects; Risk; Safety; Smoker; Vaccination; Vaccines; ,IGF::OT::IGF A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER,,,,,,,,,390096,
9575775,N01,CA,,N,,,,,N01CA000000,,,261201200034I-0-26100012-1,NCI:382036\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,HOUSTON,UNITED STATES,,9,800772139,US,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,TX,770304009,,15213255; ,"BROWN, POWEL ;",,9/1/2017,9/23/2017,Bexarotene; Breast; Clinical Trials; Dose; Evaluation; Gel; High Risk Woman; Intervention; malignant breast neoplasm; Mammary Gland Parenchyma; Maximum Tolerated Dose; Phase; Safety; Testing; Toxic effect; Woman; ,IGF::OT::IGF A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER,,,,,,,,,382036,
9577083,N01,CA,,N,,,,,N01CA000000,,,261201500024I-0-26100004-1,NCI:2597086\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,CHICAGO,UNITED STATES,,1,5447826,US,962701,IIT RESEARCH INSTITUTE,IL,606163717,,15266046; ,"MCCORMACK, DAVID ;",,9/18/2017,9/17/2019,Adverse effects; Aerosols; Animals; base; Bexarotene; Blood; Cancer Etiology; Cessation of life; chemotherapy; Clinical; Clinical Trials; clinically relevant; Cutaneous; Cyclic GMP; Development; Disease; Dose; Drug Kinetics; Formulation; hypercholesterolemia; Hypertriglyceridemia; Lung; Malignant neoplasm of lung; Non-Small-Cell Lung Carcinoma; Oral; outcome forecast; Patients; Pharmaceutical Preparations; Procedures; Process; Rattus; Recovery; Site; Survival Rate; T-Cell Lymphoma; Toxic effect; ,IGF::OT::IGF Support for the Aerosol Development of Bexarotene HHSN2612015000240 TO: HHSN26100004 PoP: 9/18/2017 to 9/17/2019,,,,,,,,,2597086,
9578584,N43,CA,,N,,,,,N43CA000000,,,261201700052C-0-0-1,NCI:289443\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GALDSTONE,UNITED STATES,,7,78271970,US,10043309,"HS-DESIGN, INC.",NJ,79342155,,15246900; ,"QUINN, MICHAEL ;",,9/21/2017,6/20/2018,Acids; Affect; Antineoplastic Agents; Benchmarking; cancer therapy; Caregivers; Child; cost; design; Dose; Drug Delivery Systems; Formulation; Humidity; liquid formulation; Liquid substance; Malignant Childhood Neoplasm; Measures; Microspheres; Oral; Patients; Pharmaceutical Preparations; Phase; prototype; reconstitution; Refrigeration; Resistance; Risk; Saliva; Skin; Small Business Innovation Research Grant; Stomach; Syringes; System; Systems Development; systems research; Testing; Texture; Toxic effect; usability; Vial device; ,SBIR PHS-2017-1 Topic 369 : Pediatric Cancer Drug Delivery System Research and Development. POP 09/21/2017 to 6/20/2018.,,,,,,,,,289443,
9581045,N02,HL,,N,,,,,N02HL000000,,,268201700287U-1-0-1,NHLBI:186445\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SILVER SPRING,UNITED STATES,,8,166611132,US,10006018,SOCIAL SOLUTIONS INTERNATIONAL,MD,209104973,,15327338; ,"WHITE, KATHERINE ;",,9/27/2017,9/26/2018,advocacy organizations; Affect; Aortic Aneurysm; bicuspid aortic valve; Biological; Blood Vessels; Cardiovascular system; Cessation of life; clinical imaging; Clinical Management; Clinical Research; cohort; Communities; Connective Tissue Diseases; cost; Data; Data Collection; Databases; Daughter; Diagnosis; Eligibility Determination; Enrollment; fundamental research; Genes; Genetic study; Goals; Heart Diseases; Hereditary Disease; improved; Individual; Link; Logistics; Medical; Morbidity - disease rate; Patient advocacy; patient registry; Patient Representative; Patients; Persons; Physicians; premature; programs; Registries; repository; Research; Research Personnel; Resources; Sampling; Services; Specimen; Support Contracts; Syndrome; Thoracic Aortic Aneurysm; Turner's Syndrome; ,IGF::OT::IGF GenTAC Alliance Management Support Services,,,,,,,,,186445,
9581049,N43,CA,,N,,,,,N43CA000000,,,261201700049C-0-0-1,NCI:300000\,SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,WOBURN,UNITED STATES,,,788238363,US,,,MA,18016200,,15250384; ,"LEE, HARRY ;",,9/19/2017,6/18/2018,Aliquot; Autologous; base; Biological Assay; Bioreactors; cancer immunotherapy; CD3 Antigens; Cell Culture Techniques; Cell Density; Cell Therapy; Cells; Characteristics; cost; design; Development; Device Designs; Devices; experimental study; improved; Individual; Legal patent; magnetic beads; Magnetism; Microfluidics; next generation; Performance; personalized medicine; Preparation; Process; process optimization; Production; Quality Control; Reporting; Running; Sampling; System; T-Lymphocyte; Testing; transduction efficiency; Update; ,IGF::OT::IGF Microbioreactors for Manufacturing Autologous Cell-Based Cancer Immunotherapies,,,,,,,,,300000,
9581065,N01,MH,,N,,,,,N01MH000000,,,278201700023P-0-0-1,NIMH:8000\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,WILLOW GROVE,UNITED STATES,,,64341449,US,,,PA,190900433,,; ,",  ;",,7/21/2017,9/29/2017,Autopsy; Award; Biological Assay; Blood; Brain; brain tissue; Contractor; Cost Savings; Data; drug of abuse; Hair; Human; Laboratories; Medical; Mental disorders; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; nervous system disorder; Neurodevelopmental Disorder; Performance; Pharmaceutical Preparations; programs; Psychotropic Drugs; repository; Research; Research Personnel; Resources; Sampling; Services; Standardization; Testing; Therapeutic; Tissues; Toxicology; United States National Institutes of Health; Urine; ,Reconfigure and legacy data transfer of toxicological results. (for OTDC). National Medical Service (NMS) (Toxicology Testing) [17-004996],,,,,,,,,8000,
9581133,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100040-1,NCI:6779027\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266016; ,"PHUNG, QUY ;",,9/28/2017,9/27/2020,Academia; Address; anticancer research; Biological Products; Cancer Center; cancer genome; cancer genomics; cancer initiation; Cancer Model; Catalogs; Cells; Clinical; clinical diagnostics; Communities; Data; data integration; data modeling; Data Sources; Databases; Development; effective therapy; Formulation; Genome; Genomic Data Commons; Genomics; Genotype; Goals; Human; In Vitro; indexing; Industry; Inherited; Institution; Intellectual Property; interest; International; Libraries; member; Methods; Modeling; Molecular; National Cancer Institute; next generation; novel; Office of Cancer Genomics; Online Systems; Organoids; Parents; precision medicine; programs; Protocols documentation; Research; Research Personnel; Resources; response; Sampling; sharing data; small molecule; Source; The Cancer Genome Atlas; Therapeutic; Time; Tissue Donors; tool; transcriptome; tumor; ,HCMI/CMDC Sequencing and HCMI Searchable Catalog (Moonshot),,,,,,,,,6779027,
9581193,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100068-1,NCI:14902\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,3/30/2017,6/30/2017,Division of Cancer Control and Population Sciences; Engineering; Medicine; meetings; United States National Academy of Sciences; ,"Task Order No. 68 - National Academies of Science, Engineering and Medicine(NASEM)- Meeting",,,,,,,,,14902,
9581245,N01,HL,,N,,,,,N01HL000000,,,268201600010I-0-26800004-1,NHLBI:818605\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,FREDERICK,UNITED STATES,,6,78706021,US,10034768,"PRECISION BIOSERVICES, INC.",MD,217014765,,15165409; ,"PHIPPARD, DEB ;",,8/7/2017,8/6/2018,"Aliquot; biobank; Biocompatible Materials; Collection; Contractor; Contracts; Databases; Equipment and supply inventories; Guidelines; National Heart, Lung, and Blood Institute; programs; quality assurance; Quality Control; repository; Research; Resources; Retrieval; Sampling; Site; Specimen; ",IGF::OT::IGF,,,,,,,,,818605,
9581249,N01,HL,,N,,,,,N01HB000000,,,268201100005I-0-26800003-1,NHLBI:640412\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SAN FRANCISCO,UNITED STATES,,12,94878337,US,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",CA,941186215,,15266085; ,"MURPHY, EDWARD ;",,9/30/2017,3/31/2019,"Adult; Affect; Allogenic; Amendment; Area; base; Basic Science; Biological Sciences; Blood; Blood Donations; Blood Transfusion; Cancer Center; Cardiac Surgery procedures; Clinical Research; Clinical Sciences; Collection; Community Hospitals; Contractor; Contracts; Country; Data; Data Collection; Data Coordinating Center; Data Element; data hub; data management; Data Security; Development; dopamine D5 receptor; Education; Educational Activities; Ensure; Epidemic; Epidemiology; epidemiology study; evidence base; evidence based guidelines; Grant; Health Insurance Portability and Accountability Act; Health Personnel; HIV; Hospitals; improved; Institutional Review Boards; Intensive Care Units; International; K-Series Research Career Programs; Knowledge; Laboratories; Laboratory Study; Leadership; Manuals; Medical; Medicine; meetings; member; Mentors; National Heart, Lung, and Blood Institute; oncology; operation; Orthopedic Surgery procedures; Outpatients; Participant; Pathologic; Patient Care; Patient Education; Patients; Performance; Phase; Policy Developments; Population; population based; Principal Investigator; Procedures; Process; programs; Protocols documentation; Public Health; Publications; repository; Research; Research Activity; Research Methodology; Research Personnel; research study; Risk; Safety; Series; Services; Ships; Site; Surveys; symposium; System; tertiary care; Training; Training and Education; Transfusion; Translational Research; Trauma; Voting; Work; ",IGF::OT::IGF  DBDR REDS-III Domestic Site Phase 3,,,,,,,,,640412,
9581255,N01,OD,,N,,,,,N01OD000000,,,263201200074I-0-26300136-1,NHLBI:125000\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,WASHINGTON,UNITED STATES,,98,41964057,US,5624001,NATIONAL ACADEMY OF SCIENCES,DC,200012721,,15266070; ,"DAY, ROBERT ;",,8/28/2017,2/27/2019,Addendum; Address; Affect; Age; Antacids; base; Beverages; Blood Pressure; Canada; Chronic Disease; Chronic Kidney Failure; Counseling; Data; Databases; design; Development; Diabetes Mellitus; Diet; Dietary intake; Engineering; Ethnic Origin; Evaluation Research; evidence base; Exclusion Criteria; Food; Gender; good diet; Guidelines; Health; Hypertension; inclusion criteria; Individual; Institute of Medicine (U.S.); Intake; Intervention; Life; Longevity; Medicine; Methods; Military Personnel; Nutrient; Nutrition Monitoring; Nutritional status; Obesity; Outcome Measure; Participant; Patients; Play; Population; Potassium; Procedures; Process; programs; Public Health; Publishing; Race; Recommendation; Reference Values; Reporting; Research; Research Design; Research Personnel; research study; Review Literature; Risk; Risk Assessment; Role; Sample Size; Sodium; Sodium Chloride; Source; Specific qualifier value; Statistical Data Interpretation; Subgroup; systematic review; Toxic effect; Uncertainty; United States Agency for Healthcare Research and Quality; United States National Academy of Sciences; Unspecified or Sulfate Ion Sulfates; Update; Water; Water consumption; Work; ,IGF::OT::IGF: Review of DRI's for Sodium and Potassium,,,,,,,,,125000,
9581311,N02,LM,,N,,,,,N02LM000000,,,276201500329U-2-0-1,NCATS:0\NCCAM:0\NCI:0\NCMHD:7456\NEI:17403\NHGRI:10861\NHLBI:0\NIA:0\NIAAA:10933\NIAID:0\NIAMS:0\NIBIB:0\NICHD:0\NIDA:0\NIDCD:10277\NIDCR:9129\NIDDK:48239\NIEHS:0\NIGMS:0\NIMH:0\NINDS:42732\NINR:0\OD:0\,Non SBIR/STTR Contracts,2017,NATIONAL LIBRARY OF MEDICINE,,COMPTCHE,UNITED STATES,,,103932240,US,,,CA,95427,,15327893; ,"KAPLAN, NORTON ;",,9/28/2017,9/27/2018,Data; Funding; Future; Modification; Performance; Phase; programs; Small Business Innovation Research Grant; United States National Institutes of Health; ,"IGF::OT::IGF - MODIFICATION 04:  The purpose of this modification is to fund support NICHE Assessment Program for NIH SBIR Phase I (Under option year 2).  The period of performance is September 28, 20",,,,,,,,,157030,
9581367,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100082-1,NCI:5407\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,8/15/2017,8/14/2018,Science; symposium; ,IGF::OT::IGF SCG Labor for Audiovisual support for 10th Annual Conference on the Science of Dissemination and Implementation,,,,,,,,,5407,
9581376,N01,CA,,N,,,,,N01CA000000,,,261201400011I-0-26100066-1,NCI:42767\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,GAITHERSBURG,UNITED STATES,,,779951912,US,,SCIENTIFIC CONSULTING GRO,MD,208781409,,; ,",  ;",,3/10/2017,3/9/2018,Consult; Support Groups; working group; ,The Scientific Consulting Group NCORP DISPARITIES WORKING GROUP SUPPORT (2017)HHSN261201400011I/HHSN26100066 ,,,,,,,,,42767,
9581565,N01,CA,,N,,,,,N01CA000000,,,261201500003I-0-26100055-1,NCI:25266647\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15266040; ,"PARCHMENT, RALPH ;",,9/21/2017,9/20/2022,Affect; Algorithmic Analysis; Antibodies; Apoptosis; Biochemical; Biological Assay; Biological Markers; biological systems; Biological Tumor Markers; Biopsy; cancer cell; Cell Death; Cell Survival; Clinical; Clinical Trials; Complex; design; Detection; Development; DNA Repair; drug development; Drug Evaluation; endoplasmic reticulum stress; Epithelial; fitness; Functional Imaging; Histology; Human; Humor; Image Analysis; Imaging Techniques; Laboratories; Link; Measures; Medical Imaging; Meiosis; Membrane; Mesenchymal; Mismatch Repair; Modeling; molecular imaging; Necrosis; Needles; neoplastic cell; Oxidases; oxidative DNA damage; Patients; Pharmaceutical Preparations; pharmacodynamic biomarker; Pharmacodynamics; repaired; Reproducibility; response; Sampling; stemness; Stress; System; targeted cancer therapy; Technology; Technology Transfer; Testing; tumor; Tumor Immunity; United States National Institutes of Health; Validation; ,IGF::OT::IGF High-plex Pharmacodynamic Biomarker Assay,,,,,,,,,25266647,
9582130,N01,CA,,N,,,,,N01CO000000,,,261200800001E-111-0-162,NCI:310643\,Non SBIR/STTR Contracts,2017,NATIONAL CANCER INSTITUTE,,FREDERICK,UNITED STATES,,8,159990456,US,10008928,"LEIDOS BIOMEDICAL RESEARCH, INC.",MD,217029242,,15326781; ,"DMITROVSKY, ETHAN ;",,9/26/2008,9/25/2018,Cancer Therapy Evaluation Program; Clinical Trials; Collaborations; Contract Services; Cooperative Research and Development Agreement; cost; Development; Fostering; Funding; Investigation; meetings; Protocols documentation; Transportation; ,DCTD/CTEP Protocol Support,,,,,,,,,310643,
9584283,N01,DA,,N,,,,,N01DA000000,,,271201700007C-0-0-1,NIDA:541229\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,SAN DIEGO,UNITED STATES,,52,621516145,US,10027826,POLYPEPTIDE LABORATORIES SAN DIEGO,CA,921264310,,14934473; ,"PASCAL, JEANICK ;",,2/15/2017,2/14/2022,Authorization documentation; base; Contracts; Data; Development; Equipment and supply inventories; Mission; Monitor; National Institute of Drug Abuse; Opioid; Opioid Peptide; Peptides; Pharmaceutical Preparations; Publications; Radiolabeled; Records; Research; Research Personnel; Review Literature; Ships; Summary Reports; System; United States National Institutes of Health; Update; ,IGF::OT::IGF : SYNTHESIS AND DISTRIBUTION OF OPIOID AND RELATED PEPTIDES. PERIOD OF PERFORMANCE: 02/15/2017-02/14/2022. N01DA-17-7795.,,,,,,,,,541229,
9584429,N01,HL,,N,,,,,N01HL000000,,,316201200116W-0-0-1,NIDCR:128000\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,SILVER SPRING,UNITED STATES,,,788299782,US,,,MD,209106331,,; ,",  ;",,6/23/2017,6/22/2018,Biological Sciences; Catalogs; Communities; Data; Data Sources; Deposition; Development; High Performance Computing; Human; Informatics; Intramural Research; Maintenance; National Institute of Dental and Craniofacial Research; Online Systems; Process; programs; Proteome; Proteomics; Research; Salivary; Schedule; System; wiki; ,"IGF::OT::IGF - Human Salivary Proteome Wiki, ITAC-Project Scheduling, Process, and Program Management Support for IT Programs and Projects",,,,,,,,,128000,
9587867,N01,NS,,N,,,,,N01NS000000,,,26320090024B26500009-0-0-1,NINDS:93367\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE,,HERNDON,UNITED STATES,,,789995933,US,,,VA,201703838,,; ,",  ;",,2/13/2017,11/30/2017,meetings; Pain; symposium; ,IGF::CL::IGF:INFINITY CONFERENCE GROUP INC:1108883 [17-004800] Conference meeting administration and planning for the 12th Annual Pain Consortium,,,,,,,,,93367,
9589197,N01,DA,,N,,,,,N01DA000000,,,271201600006I-0-27100002-1,NINDS:179557\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,15064828; ,"GREEN, CAROL ;",,6/1/2017,9/30/2017,Canis familiaris; Dose; Toxic effect; ,IGF::OT::IGF DOG DOSE RANGE FINDING (DRF) TOXICITY STUDY - BUCKPITT- LDT-EC5026,,,,,,,,,179557,
9591102,R33,AI,4,N,12/28/2017,12/28/2017,11/30/2018,855,R33AI121689,EARTH SCIENCES/RESOURCES,RFA-AI-14-066,4R33AI121689-03,NIAID:466873\,Non-SBIR/STTR RPGs,2018,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES,,COLLEGE STATION,UNITED STATES,VETERINARY SCIENCES,17,847205713,US,8266920,TEXAS A&M AGRILIFE RESEARCH,TX,778430001,,11692768 (contact); 10795725; ,"GILL, JASON J. (contact); WALSH, THOMAS ;","XU, ZUOYU",12/22/2015,11/30/2020,Alleles; Animal Model; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; antimicrobial; antimicrobial drug; Bacteremia; Bacteria; Bacterial Infections; bacterial resistance; bactericide; Bacteriophages; base; Biological; Burkholderia; carbapenemase; Cessation of life; Characteristics; Chemicals; Clinical; clinically relevant; Collection; combat; Communities; Conduct Clinical Trials; Critical Illness; design; Development; direct application; Drug resistance; effective therapy; Enterobacteriaceae; Environment; experience; Food; gastrointestinal; Gastrointestinal tract structure; Goals; Gram-Negative Bacteria; Growth; Human; Immunocompromised Host; in vivo; Individual; Infection; Intravenous; Killings; Klebsiella pneumonia bacterium; Lead; Libraries; Life Cycle Stages; Lytic; Medical; Medicine; member; Modeling; mouse model; Mus; National Institute of Allergy and Infectious Disease; Oral; Organism; Oryctolagus cuniculus; Outcome; pathogen; Patients; Performance; Personal Communication; prevent; Pseudomonas aeruginosa; Public Health; public health relevance; receptor; Research; Resistance; Resistance profile; resistant strain; Risk; Sepsis; Site; small molecule; Soil; Study models; Surface; Testing; Therapeutic; therapeutic development; Treatment Efficacy; treatment strategy; United States National Institutes of Health; Uropathogenic E. coli; Virulent; Virus; Water; Work; ,Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae,121689,ZAI1,Special Emphasis Panel ,,,3,395320,71553,466873,
9591473,N02,HD,,N,,,,,N02HD000000,,,275201600122U-1-0-1,NICHD:6092614\,Non SBIR/STTR Contracts,2017,EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT,,MC LEAN,UNITED STATES,,11,6928857,US,682902,BOOZ ALLEN HAMILTON,VA,221023830,,15327817; ,"SAMAVEDAM, RAJNI ;",,6/1/2016,5/31/2020,,IGF::OT::IGF,,,,,,,,,6092614,
9591663,N01,EY,,N,,,,,N01EY000000,,,4837581-0-0-1,NEI:90000\,Non SBIR/STTR Contracts,2017,NATIONAL EYE INSTITUTE,,,,,,,,,,,,,; ,",  ;",,,,3-Dimensional; Address; Adult; Affect; Alpha Cell; Amacrine Cells; Area; Biological; Biological Models; Biological Process; Biology; Biomedical Engineering; bioprinting; blind; Blindness; Categories; Cell Survival; cell type; Cells; Diagnosis; Disease; Disease model; drug testing; embryonic stem cell; Ensure; Evaluation; Eye; Eye Development; ganglion cell; Goals; horizontal cell; Human; ideation; improved; In Vitro; in vitro Model; induced pluripotent stem cell; innovation; interest; Intervention; Laboratories; Methods; Microfluidics; model development; Modeling; Morphology; multipotent cell; National Eye Institute; Neurons; novel; Organoids; Perfusion; Photoreceptors; Physicians; Physiological; Process; Protocols documentation; prototype; Regenerative Medicine; Reproducibility; Research; Research Personnel; Resources; Retina; Retinal; Retinal Diseases; scaffold; screening; self organization; Source; Speed; Structure; System; Systems Development; Technology; Testing; Time; Tissues; Toxic effect; transdifferentiation; Transplantation; Vision research; Visually Impaired Persons; Weight; ,NEI 3D ROC CHALLENGE AWARD Part 1: Ideation,,,,,,,,,90000,
9591707,N01,HL,,N,,,,,N01HL000000,,,268201700006I-0-26800007-1,NEI:93800\,Non SBIR/STTR Contracts,2017,"NATIONAL HEART, LUNG, AND BLOOD INSTITUTE",,BALTIMORE,UNITED STATES,,7,1910777,US,4134401,JOHNS HOPKINS UNIVERSITY,MD,212051832,,15266112; ,"DOHENY, KIM ;",,9/14/2017,9/13/2019,Blindness; Clinical Research; Communities; Custom; Data; Development; Disease; Disease susceptibility; disorder risk; Eating; Eye; Future; gene discovery; Genes; Genetic; Genetic Predisposition to Disease; Genetic Research; genetic variant; Genomics; Genotype; good diet; Image; improved; Individual; Inherited; insight; Laboratories; Lead; lifestyle factors; Macular degeneration; Mission; Modeling; new technology; new therapeutic target; next generation sequencing; Patient Care; Peer Review; personalized medicine; Phenotype; predictive modeling; Principal Investigator; Production; Publications; Quality Control; Research; Research Design; Research Personnel; research study; Resources; response; Risk; Risk Factors; Sampling; Services; Site; SNP array; Technology; Translating; Universities; ,"IGF::OT::IGF ISELECT INFINIUM CUSTOM SNP ARRAY, 700,000 BEADTYPES FOR NEI (SEDDON) FY 2017 CAN 8469334",,,,,,,,,93800,
9591731,N01,OD,,N,,,,,N01OD000000,,,26320170082B26300002-0-0-1,NEI:786082\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,NORTHAMPTON,UNITED STATES,,,825136117,US,,,MA,10603267,,; ,",  ;",,9/12/2017,8/31/2018,Academy; Agreement; Anniversary; Area; Brain; Calendar; Central Nervous System Diseases; Color Visions; Communication; Communities; Contractor; digital; digital media; Disease; Education; Emotions; Eye; Health; Health Communication; Measures; Mission; Multimedia; National Eye Institute; outreach; Persons; Photography; population health; Recording of previous events; Reporting; Research; Research Support; Resource Sharing; Resources; Running; Science; Services; symposium; tool; virtual reality; Vision; Vision research; Work; ,"IGF::OT::IGF NEI Communications and Outreach Support Services-	Multimedia support ",,,,,,,,,786082,
9594188,N01,DA,,N,,,,,N01DA000000,,,271201600005C-1-0-2,NIA:860971\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE ON DRUG ABUSE,,LANUSEI,ITALY,,,437306274,IT,10047456,ISTITUTO DI RICERCA GENETICA E BIOMEDICA IRGB CNR,,,,15002930; ,"CUCCA, FRANCESCO ;",,6/1/2016,5/31/2018,,IGF::OT::IGF,,,,,,,,,860971,
9594218,N01,OD,,N,,,,,N01OD000000,,,263201600268U-3-0-2,NIA:79201\,Non SBIR/STTR Contracts,2017,"OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH",,ROCKVILLE,UNITED STATES,,,949275804,US,,,MD,208552604,,; ,",  ;",,6/16/2017,,,AlzPED Website and Database - Phase 2 IGF::OT::IGF,,,,,,,,,79201,
9594389,N01,MH,,N,,,,,N01MH000000,,,271201100004I-2-27100021-2,NIA:194124\,Non SBIR/STTR Contracts,2017,NATIONAL INSTITUTE OF MENTAL HEALTH,,MENLO PARK,UNITED STATES,,18,9232752,US,8042701,SRI INTERNATIONAL,CA,940253493,,14921934; ,"BAUGHMAN, KATHRYN ;",,8/31/2016,12/31/2017,,IGF::OT::IGF:PHARMACOKINETICS AND TOXICOLOGY STUDIES:IND - ENABLING STUDIES - WAGNER LTD 9/15/16-9/14/17,,,,,,,,,194124,
